<SEC-DOCUMENT>0000105770-23-000023.txt : 20230427
<SEC-HEADER>0000105770-23-000023.hdr.sgml : 20230427
<ACCEPTANCE-DATETIME>20230427161011
ACCESSION NUMBER:		0000105770-23-000023
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		87
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230427
DATE AS OF CHANGE:		20230427

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			WEST PHARMACEUTICAL SERVICES INC
		CENTRAL INDEX KEY:			0000105770
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				231210010
		STATE OF INCORPORATION:			PA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-08036
		FILM NUMBER:		23856928

	BUSINESS ADDRESS:	
		STREET 1:		530 HERMAN O. WEST DRIVE
		CITY:			EXTON
		STATE:			PA
		ZIP:			19341
		BUSINESS PHONE:		6105942900

	MAIL ADDRESS:	
		STREET 1:		530 HERMAN O. WEST DRIVE
		CITY:			EXTON
		STATE:			PA
		ZIP:			19341

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	WEST CO INC
		DATE OF NAME CHANGE:	19990405
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>wst-20230331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:a34422fb-98f0-4bfc-83b0-7c0b1b7c96bb,g:fe42bdb5-3507-4fad-98a2-d4b1f779591c,d:7bf87d07bb544f48851c48374130181b--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:wst="http://www.westpharma.com/20230331" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>wst-20230331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80L2ZyYWc6YzIyMDgxZTYzYWE4NDY1Yjk0ZTFmNDEyYjc5ODM3YmIvdGFibGU6M2E1MmU1YmE2YjBkNDczYmFhOTU5Y2QzYmFkNTU2YmEvdGFibGVyYW5nZTozYTUyZTViYTZiMGQ0NzNiYWE5NTljZDNiYWQ1NTZiYV8yLTEtMS0xLTgyNzgy_be108184-0a70-49d6-b7de-b267537e1b35">0000105770</ix:nonNumeric><ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80L2ZyYWc6YzIyMDgxZTYzYWE4NDY1Yjk0ZTFmNDEyYjc5ODM3YmIvdGFibGU6M2E1MmU1YmE2YjBkNDczYmFhOTU5Y2QzYmFkNTU2YmEvdGFibGVyYW5nZTozYTUyZTViYTZiMGQ0NzNiYWE5NTljZDNiYWQ1NTZiYV8zLTItMS0xLTgyNzgy_4e0a1c7f-9abe-4909-a067-5cd0c92d70a9">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80L2ZyYWc6YzIyMDgxZTYzYWE4NDY1Yjk0ZTFmNDEyYjc5ODM3YmIvdGFibGU6M2E1MmU1YmE2YjBkNDczYmFhOTU5Y2QzYmFkNTU2YmEvdGFibGVyYW5nZTozYTUyZTViYTZiMGQ0NzNiYWE5NTljZDNiYWQ1NTZiYV80LTEtMS0xLTgyNzgy_3a34db12-e630-41a1-a1be-b131e5914414">2023</ix:nonNumeric><ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80L2ZyYWc6YzIyMDgxZTYzYWE4NDY1Yjk0ZTFmNDEyYjc5ODM3YmIvdGFibGU6M2E1MmU1YmE2YjBkNDczYmFhOTU5Y2QzYmFkNTU2YmEvdGFibGVyYW5nZTozYTUyZTViYTZiMGQ0NzNiYWE5NTljZDNiYWQ1NTZiYV81LTEtMS0xLTgyNzgy_3f0d5e8d-3539-4cee-bc64-b60bb4b9967c">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80L2ZyYWc6YzIyMDgxZTYzYWE4NDY1Yjk0ZTFmNDEyYjc5ODM3YmIvdGFibGU6M2E1MmU1YmE2YjBkNDczYmFhOTU5Y2QzYmFkNTU2YmEvdGFibGVyYW5nZTozYTUyZTViYTZiMGQ0NzNiYWE5NTljZDNiYWQ1NTZiYV82LTEtMS0xLTgyNzgy_8b2faeb3-8b47-4b76-9ac0-01af7e35f583">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="wst-20230331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id65f0e55c9ce468dab69a4cf20c6ce02_I20230412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-04-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i2af6ba55593d446686e312e0578684c6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5583fe9d33064523a217abe67f6f392d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00c9b6f38a304d5190000b6168ba7dce_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3cc75f001344ce095d702cd95b46078_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae34400f53bb478b90a83802a119f9f9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">wst:BiologicsCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="icda5c4d11f62428a95249de65f0fefd2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">wst:BiologicsCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie37ebad36b6348b285cca6d19bde1f7b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">wst:GenericsCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i840ac8c485014ee99b6e1a87cfb8a764_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">wst:GenericsCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f33ea9ddf5f4c6990e93f50d03f03ef_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">wst:PharmaCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia894e91feb4a4bdf8293a2c2963731ab_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">wst:PharmaCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icca73618ae684d5ea52e3060af4ad383_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">wst:ContractManufacturedCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaceefe0fe985435aa372154902f65846_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">wst:ContractManufacturedCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29c510f38fbe49baa6388a40c6f045d8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27022197520642e3882ce31d9285e029_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6cdab3f33c048088340a1a1ac085f71_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wst:HighValueProductComponentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bcd5713f126432fa7b95d333a6687ed_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wst:HighValueProductComponentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ee7ca1522924116844090df73a38cfc_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wst:HighValueProductDeliveryDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb109b3e8b854eef8e2690d97b4deb83_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wst:HighValueProductDeliveryDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8964ed8d404e4ecd8cf51bf7dd57fd72_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wst:StandardPackagingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4878ca4f0234438bbe2231c100da361_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wst:StandardPackagingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69658dd90db2466aab6d25979a565ec5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wst:ContractManufacturedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a7534f872714dc0b6f41e800f834626_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wst:ContractManufacturedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieabcd647a4f94d14b6c41f5ed82c736e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bb4cbfdac1443989f5d65abc02019aa_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i705daa289597485c80cbe6c2a4295b55_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AmericasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f08de799c8b4bcf84f0b2388b9a1d63_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AmericasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72821269558f4965b1f01873aa17427e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i068419f0506343b79f1391a7f0d6cc2e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f79e1cf75c043448cd2aa1afd887c55_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cfb274b8db44a3e9f441e5bf17fc3ef_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fc7305b8607421d8a06a356da5a15ed_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib884bebbba5c4e049f608852aff2075d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73b55d82d73748a38f69bd594560eb79_I20130630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wst:SmartDoseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2013-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f009365e828466d98af8bbc2bce4411_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wst:SmartDoseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i866c5a8fb2f748d0b77d31bceb45da81_I20230228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecf3cc3f4a2e4356986ecea0d53b720d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">wst:TermLoanDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i820fab327f6443ae978dfa28318d48f4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">wst:TermLoanDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id38fa53f753e49438df00d22e5b777e6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">wst:SeniorBNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a8404bd9ab74326a8394ec3e7f36919_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">wst:SeniorBNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85a6072962d04208ae531a2b2fbfef0e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">wst:SeniorCNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2b66dd4040640348f96693d6e7be1d5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">wst:SeniorCNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id48d782f5bfb4fe6a7905309804dadd4_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">wst:RevolvingCreditFacilityDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98cb2924a74a4bcbb3d3520ea87d52f0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">wst:RevolvingCreditFacilityDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if46b82c9c68b443482333077a49f48e9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:SGD</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sgd"><xbrli:measure>iso4217:SGD</xbrli:measure></xbrli:unit><xbrli:context id="i82f3bc098630498582401da701e7b138_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:SGD</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09563dd08c64439c84993944fccfc6db_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdb1000004bd47589080d94726e76022_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f005fe228a0408495ca4180dcc39feb_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9728ffcf312e4ac4bdb6aae4a7b23a44_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PositionAxis">us-gaap:LongMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="if6ea04af1eff40db88226330d1e25200_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PositionAxis">us-gaap:ShortMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdd3e55c2a7a4212801e02cabd651cfc_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PositionAxis">us-gaap:LongMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="jpy"><xbrli:measure>iso4217:JPY</xbrli:measure></xbrli:unit><xbrli:context id="i63dca94e686c450eb00428ac82177d9d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PositionAxis">us-gaap:ShortMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2a16112236a46548494c875fa25e7c6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PositionAxis">us-gaap:LongMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:SGD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i049f03d104874040b8a9e20dca208dd8_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PositionAxis">us-gaap:ShortMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:SGD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86cd8c4c0adb4f0bb284e66a3b57f3be_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i949b0ebb4cdd40e8a2bfd21565e1e3e0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3dbbddaad3d544529fc30c5aa103c052_D20171101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:OptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="bbl"><xbrli:measure>utr:bbl</xbrli:measure></xbrli:unit><xbrli:context id="i0a775eaad7ab4fb2b9ed736aefbf5955_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:OptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i024bb3a09a8d4ff89a1465c610f13094_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:OptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerBbl"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>wst:bbl</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ic2b6751140ae4a8a905c7349d2d7fab8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">wst:OtherExpenseIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i512c05fc14444680a4b01af74b3b7f07_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">wst:OtherExpenseIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie403ae300c3c4982a693b55e66f3705f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifeb72d8b516e4addb0181e1f85261c85_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ed146d13e5f4eb2a012abb762cc10f0_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">wst:OtherExpenseIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88d56264e84240aaa4c3afb58fcf626e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">wst:OtherExpenseIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i550fe20240f54b029e378c9bf7ce6f5d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">wst:NetSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89d9d14f5ff4438cafe884c5b0d2718f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">wst:NetSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2aaae598465a460fb7b809258de6e1a5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3800bdd574354a39a20ce84a4092c158_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5c0ef7c3e0147a483d139e864147374_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:TreasuryLockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d9e67f88dce43dd8855ccc2dbc02a22_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:TreasuryLockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c377e143e9d48d0ae6ce22294a8da16_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9abb09cb5a64fc0b766d1350855b2db_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e6599d390d0401bba4ccd616c8136c8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">wst:OtherExpenseIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f6ac6dfc13d492b82ae66056c8cdfa7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">wst:OtherExpenseIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i014caa55d11343438f2b721d5b51d6c8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab874b4cf2374c38a4cc92deabe110c7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7f2039fc421408da2abf39c8fa7f3e1_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">wst:NetSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0856bab3e85491fb635e56eda1444de_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">wst:NetSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i143f14fa720c48e8a013cf77a4efde31_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i067a51880daf4861907b0950720d904c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5d4916f585e4d42bfc35a013fb84cdf_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibca67bb324884ac1a4bd92682b0eef05_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7e54bd1a6644a0e8981abafbc1190e8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">wst:OtherExpenseIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CommodityOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03f4edf339b2471dac58f1cdbd5df6a5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">wst:OtherExpenseIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CommodityOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97dea892f5984be0a0fd08b4eee5ed4a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ee1aea1aac947e59b4311a420cdabdf_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8472e48bf22848d09276489a66c9e03e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief4d8a0c3b5e40789e9de34c75e432bf_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d4597dfd1ba407789166d3d2ab3a1c6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id11dee14a78441cf8e6ce24a522f88c7_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74d73afd5be44336b5735abe19adc044_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f682024fc3e4a7a9e5d718533d31677_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i270bac59038e42c6a92535138d33ff29_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6fbf09378a54c02a5743d72f4ef99da_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommodityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11a99f1a1d3645feb7815067a68cd81f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommodityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia53ac927db8b457d821c732f6d7f4f61_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommodityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i520386d8aa8046dc8b6ed7c632c7c7f9_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommodityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie176087c2e0f4f9aaf6886e4438cdcf1_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20dc5476975c412a9dfc88d9c2216dee_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e410a2ff35b4d57982b319abc1e1768_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89f31e1b854b43c68d198cca6624635e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idecab62008c846caa537823da6bf68cf_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d38876b8687498fb75a9d1921176e0b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53b64dbcb5d24234b5920850cfdbdd10_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5022b45891414a1794bd141aad661062_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd5224d49fab426a864b9ef841b2bd25_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7fc7fba1d244cd09a928fc5c9b89075_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e31f6f4b77a4341b3844eaafe791605_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3855c26361a747a6a2063f8669213b1d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommodityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba6b68a438dd4a579b4713432d302e3d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommodityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8ff7bccbad64151ab6ea9014d5cc59f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommodityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1b304b4749d406ba788dcf08bc89106_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommodityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1036a3de1ea4f318261a593515df52b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9dd9da2fad4544178dd80a8db1ca4501_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie68882e1ec5c418487d91aaacd73759d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i564b193142034a3dad5d2192d388c8df_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0a2e4816674455e8c1653b4d67a05eb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i526f045cc6ae4ef9aebfa54634f321c7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b4825baaa3d4e808f9edc322c950ac0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a916ac5970f44c4ae05918807b57f65_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6339e7f0f9e847638d0b1e918478a17b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe54e8c2da3440aebf4d2616a05e64c2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i797411f0d816497e9411895884b514e7_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8b0a91f9e20469aa04a865d19bf4454_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia80d875680634e70a48cb73ff07b85e4_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a6e09ceadea4cf28bdd80365b649ab0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60c9aeeca640474289ca4b0da5cf3a7d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic60c39b0c368406f8cd641a4d764ddc1_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5cd3bf0b3e6469e9da46a298c4c805d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6630ce4dbb7747e8858856ea430b90ab_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fca80d6c8df481687a29bccfb487856_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c6c1d8c2b4f4a0b89ca2e9a9ddd447c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a3f5a8af8064476820608f696c42e1d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i936367d439194b7fbc90a34743134e4f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0df22a14170c4331a1256c9f757e5090_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie71d1ab95f7344af96897b0090a0e58d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia67d15eb184042d897c6efc17a13b799_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i111ee7c976334a21a8a888af218b7e87_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6421c8aef05242b2af4fa57c824c4efa_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a6c194a67cd4b14b2fe810f1803d2fa_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15d499d767e34686aa1263510f1d36a3_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43311d97b8684c7d99964d6c9ce008f6_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90887b06cf074badac168937eaf76a7d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83a0a64e641241259400ffb042bd9b69_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a7ae72bcc2f46119331a447f5c3150d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d0c261740c340ebb7fdb92c09b03f4e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e3c4dec591644f5b67d216f6b423622_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:TreasuryLockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6588c22fb7d242729097d46bc107e464_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:TreasuryLockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c7ca8ad39694e71b583c7ef4a4b1e4d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i840ed86b8d83428dae98a9709644d509_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie947ff5eae324b458a796759ec01b073_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i051025edf9d84083b951a5c2120b859e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i594dfb15b16f4f3b94b3e4c667ae6f31_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0cbe79b5a944e7ea8c8155a043cfb0c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5974879a41634c43937d0fdc678376ef_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e4f2583d5104db2b4d1e647dc99032f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i516dc67ea1934343bbf9ab9c724c74fe_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ad958aa230d4452800e1a411e50a1da_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c00de3c1e304a8ba1d6c714fc5be20a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i353cb27834c543849553e5d0b7bbf5c1_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica8dcddf1bfb4c518886c671739fd284_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b66fb1404f0411794600214ad5981bc_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8c8c941591f438a9e38e52390bd7143_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ca2730fabca4305a997b6e33c1c770e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b96f9bbddfb400fb15bf48690acfac4_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24c88cbf61274655b654ef8032885498_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9824a1206b949e9a0e697dab83ac7c1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18b4fa445330470da5ef68248c88e734_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32ef532505b441b1806a8f09cd91cd70_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32bd0566d819471cba804ab5cc28ab44_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8e072fd9e914a71afd49e2d9a5e79c6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i083cbb87646e4c8ba193971c93fd6efe_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4063d23292b47168eedc6bfb33a3fbd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5fc6b2b23e84ec4bc5d35849e3156f6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48e325bcbc074931a2dd945f8078f5f8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b1173baba244d369e85b0aaae78c105_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83dbf680868b48b9b005cf05def0fad3_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb84c364648d488ba64727ae4d194a34_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ea1399aa8514b6fb5e425e47f1f53b4_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cea666f1a3e4fca9565501a1a97da9f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9485a9306be43498daef6ad2c76774a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaac3fbfd1951416da909602aa595a831_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15f25764805440459934b22b2c76b3b4_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6b03745b52d4c23b5f91243d9f4d0c7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icea6ecda38c04a1980ef2da02b46df03_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18f818cb77b7453cbd94313211a8df44_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i209901cc4ed54159a25df88bd1b8faee_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida333f1205fc4fcfb7b85636d28c908d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbcc67097f9240329c190bf9487f2480_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05073a750c324193a92113cb4a636965_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42e6f528867c45a7b7da2f9fe313486e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13c26150d9794fafb5581ccf36e02580_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia68ac2f16d2949e69b481796f2242932_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28fde86f84534f35b341997ed553fd3b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ad6bf31a752453bb990cc27c2ba0854_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cb4b2a7f3bc479997ddd2c09c37cf63_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8343aec575e3454988060e5f6ce66a0d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i577299ca8e5a4684b6ab0d6a77f3cabe_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fe28b57298646bca10b9de129f3bac3_D20221201-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">wst:The2020RestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i966f8dcfe0c8437bb80311fd4f44d03d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">wst:The2020RestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i173c567741e44c9180c9525060447224_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">wst:The2020RestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23c5432999954af5a1ded50a2d12617d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">wst:The2020RestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00f636ccc7fe4a40bff18a2475aee5fb_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">wst:The2020RestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief1173cf0c9c47e8a1b90da1b941c509_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">wst:A2020RestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i320c37f388f0402ebe72c6e91de76520_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">wst:A2020RestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i741e48b8c43549918dae0d3e9f2835dc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">wst:A2020RestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5751a6a227b4cd09e42603236f7ce4b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">wst:A2020RestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib58ff9d1a085489cb685ece3967cd85c_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">wst:A2020RestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic32e88fe332446cd865cf4708f70ecbd_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">wst:A2020RestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5dddcfaad27c4e2bb489c4f35ed023eb_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">wst:A2020RestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic23b01e75b1e4bc5a81f42b0e6c8108b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">wst:A2020RestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fa2298580b64ebfb1db3e0ca8424d94_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">wst:A2020RestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b6114e84e5644b6b9435baa1eba9515_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wst:ProprietaryProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>wst:segment</xbrli:measure></xbrli:unit><xbrli:context id="i776c2fc9c0314d5dbc1af6c8aa146ea9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wst:ProprietaryProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ec1bf24d76645649ff514efc6f320dd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wst:ProprietaryProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedc77d2ee3884279ae4e3b4f74b210ca_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wst:ContractManufacturedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i379b3e02ffff4f65b6f70a4e51167f3b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wst:ContractManufacturedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i237555183941451e8d5f239492f90b93_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i959bea7c7da543dfaa998842a57cfc20_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8cd20fa40094f43a596ebe943a0379a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92736af48f534f498e235c076ae54733_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i934ac1f9eaf94ecfb00d07b8084f9292_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icac424a9ffb64141aa0d33bcd8b4fcfb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000105770</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i7bf87d07bb544f48851c48374130181b_1"></div><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">UNITED STATES</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C.&#160;&#160;20549</span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xL2ZyYWc6MTQ1NzAyMDg4MzdlNDQ2N2JkNjY3YWNlMzFlNGExZmUvdGV4dHJlZ2lvbjoxNDU3MDIwODgzN2U0NDY3YmQ2NjdhY2UzMWU0YTFmZV8xMw_181cc52a-082e-44bb-992f-da891c33af98">10-Q</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.883%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xL2ZyYWc6MTQ1NzAyMDg4MzdlNDQ2N2JkNjY3YWNlMzFlNGExZmUvdGFibGU6MDVhYzM5NDc4ZTU2NDkzMWIzNmM0MTE5OWMyNTQzNmYvdGFibGVyYW5nZTowNWFjMzk0NzhlNTY0OTMxYjM2YzQxMTk5YzI1NDM2Zl8wLTAtMS0xLTgyNzgy_851c526c-d115-4940-8841-24b2c776e10b">&#9745;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xL2ZyYWc6MTQ1NzAyMDg4MzdlNDQ2N2JkNjY3YWNlMzFlNGExZmUvdGV4dHJlZ2lvbjoxNDU3MDIwODgzN2U0NDY3YmQ2NjdhY2UzMWU0YTFmZV82MA_209ca534-5f97-4552-b00d-22dc0ffd2e7a">March&#160;31, 2023</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.883%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xL2ZyYWc6MTQ1NzAyMDg4MzdlNDQ2N2JkNjY3YWNlMzFlNGExZmUvdGFibGU6MWJmOWNjNjMxMjcwNGRhYTlmZDgyZDk0ODFiYmY3MmUvdGFibGVyYW5nZToxYmY5Y2M2MzEyNzA0ZGFhOWZkODJkOTQ4MWJiZjcyZV8wLTAtMS0xLTgyNzgy_c2b68058-0b74-4ab9-856c-9a574ca7b02e">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number <ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xL2ZyYWc6MTQ1NzAyMDg4MzdlNDQ2N2JkNjY3YWNlMzFlNGExZmUvdGV4dHJlZ2lvbjoxNDU3MDIwODgzN2U0NDY3YmQ2NjdhY2UzMWU0YTFmZV8xMzc_b04eba54-c9d0-4f58-b198-b797317b96fd"><ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xL2ZyYWc6MTQ1NzAyMDg4MzdlNDQ2N2JkNjY3YWNlMzFlNGExZmUvdGV4dHJlZ2lvbjoxNDU3MDIwODgzN2U0NDY3YmQ2NjdhY2UzMWU0YTFmZV8xMzc_f8c11bef-6230-4cbe-8263-6bc053de0c51">1-8036</ix:nonNumeric></ix:nonNumeric> </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xL2ZyYWc6MTQ1NzAyMDg4MzdlNDQ2N2JkNjY3YWNlMzFlNGExZmUvdGV4dHJlZ2lvbjoxNDU3MDIwODgzN2U0NDY3YmQ2NjdhY2UzMWU0YTFmZV8xNDI_4646003a-819d-4835-8425-9ff9aa79235d"><ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xL2ZyYWc6MTQ1NzAyMDg4MzdlNDQ2N2JkNjY3YWNlMzFlNGExZmUvdGV4dHJlZ2lvbjoxNDU3MDIwODgzN2U0NDY3YmQ2NjdhY2UzMWU0YTFmZV8xNDI_77161ff7-98b3-4c44-8770-36529d1d770a">WEST PHARMACEUTICAL SERVICES, INC.</ix:nonNumeric></ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.107%"><tr><td style="width:1.0%"></td><td style="width:6.107%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.975%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.758%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.109%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xL2ZyYWc6MTQ1NzAyMDg4MzdlNDQ2N2JkNjY3YWNlMzFlNGExZmUvdGFibGU6ZDUxMzE1OTMxNjBjNDFkZWJlZjFiYzNkNWExZjVhNGYvdGFibGVyYW5nZTpkNTEzMTU5MzE2MGM0MWRlYmVmMWJjM2Q1YTFmNWE0Zl8wLTEtMS0xLTgyNzgy_80998e2e-4641-465c-ac01-1358abb464c9">Pennsylvania</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xL2ZyYWc6MTQ1NzAyMDg4MzdlNDQ2N2JkNjY3YWNlMzFlNGExZmUvdGFibGU6ZDUxMzE1OTMxNjBjNDFkZWJlZjFiYzNkNWExZjVhNGYvdGFibGVyYW5nZTpkNTEzMTU5MzE2MGM0MWRlYmVmMWJjM2Q1YTFmNWE0Zl8wLTYtMS0xLTgyNzgy_f260fdd9-dab7-487c-adb7-bec47ec8f400">23-1210010</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification Number)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xL2ZyYWc6MTQ1NzAyMDg4MzdlNDQ2N2JkNjY3YWNlMzFlNGExZmUvdGFibGU6ZDUxMzE1OTMxNjBjNDFkZWJlZjFiYzNkNWExZjVhNGYvdGFibGVyYW5nZTpkNTEzMTU5MzE2MGM0MWRlYmVmMWJjM2Q1YTFmNWE0Zl8zLTEtMS0xLTgyNzgyL3RleHRyZWdpb246ZDJkZDA5YzIzM2JiNDc2ZGE0MmE2NDdiOGNiOTJlNDJfNA_bb631f17-7ecd-4cf8-a086-75533af20df8">530 Herman O. West Drive</ix:nonNumeric>, <ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xL2ZyYWc6MTQ1NzAyMDg4MzdlNDQ2N2JkNjY3YWNlMzFlNGExZmUvdGFibGU6ZDUxMzE1OTMxNjBjNDFkZWJlZjFiYzNkNWExZjVhNGYvdGFibGVyYW5nZTpkNTEzMTU5MzE2MGM0MWRlYmVmMWJjM2Q1YTFmNWE0Zl8zLTEtMS0xLTgyNzgyL3RleHRyZWdpb246ZDJkZDA5YzIzM2JiNDc2ZGE0MmE2NDdiOGNiOTJlNDJfOA_6ee063f2-e06a-43e9-bbf3-471863c94147">Exton</ix:nonNumeric>, <ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xL2ZyYWc6MTQ1NzAyMDg4MzdlNDQ2N2JkNjY3YWNlMzFlNGExZmUvdGFibGU6ZDUxMzE1OTMxNjBjNDFkZWJlZjFiYzNkNWExZjVhNGYvdGFibGVyYW5nZTpkNTEzMTU5MzE2MGM0MWRlYmVmMWJjM2Q1YTFmNWE0Zl8zLTEtMS0xLTgyNzgyL3RleHRyZWdpb246ZDJkZDA5YzIzM2JiNDc2ZGE0MmE2NDdiOGNiOTJlNDJfMTI_5d2ee00e-f9c4-45dc-89d6-c5e532ee3acc">PA</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xL2ZyYWc6MTQ1NzAyMDg4MzdlNDQ2N2JkNjY3YWNlMzFlNGExZmUvdGFibGU6ZDUxMzE1OTMxNjBjNDFkZWJlZjFiYzNkNWExZjVhNGYvdGFibGVyYW5nZTpkNTEzMTU5MzE2MGM0MWRlYmVmMWJjM2Q1YTFmNWE0Zl8zLTYtMS0xLTgyNzgy_5c47f0f5-1b46-412f-8a5f-36ec5d5a1cbb">19341-0645</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Zip Code)</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xL2ZyYWc6MTQ1NzAyMDg4MzdlNDQ2N2JkNjY3YWNlMzFlNGExZmUvdGV4dHJlZ2lvbjoxNDU3MDIwODgzN2U0NDY3YmQ2NjdhY2UzMWU0YTFmZV8yNTU_844816c7-975f-4b21-943a-652a4ef96567">610</ix:nonNumeric>-<ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xL2ZyYWc6MTQ1NzAyMDg4MzdlNDQ2N2JkNjY3YWNlMzFlNGExZmUvdGV4dHJlZ2lvbjoxNDU3MDIwODgzN2U0NDY3YmQ2NjdhY2UzMWU0YTFmZV8yNTg_65866845-790f-415f-b0de-ebea54a8f649">594-2900</ix:nonNumeric> </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:40.181%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.336%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.183%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xL2ZyYWc6MTQ1NzAyMDg4MzdlNDQ2N2JkNjY3YWNlMzFlNGExZmUvdGFibGU6ZDJiMzMwYjM3MjdjNDY4ZDk5OWUzNmEzMWFkYzUzYzYvdGFibGVyYW5nZTpkMmIzMzBiMzcyN2M0NjhkOTk5ZTM2YTMxYWRjNTNjNl8xLTAtMS0xLTgyNzgy_e50c2c6a-55a7-4090-a562-570532b6c584">Common Stock, par value $0.25 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xL2ZyYWc6MTQ1NzAyMDg4MzdlNDQ2N2JkNjY3YWNlMzFlNGExZmUvdGFibGU6ZDJiMzMwYjM3MjdjNDY4ZDk5OWUzNmEzMWFkYzUzYzYvdGFibGVyYW5nZTpkMmIzMzBiMzcyN2M0NjhkOTk5ZTM2YTMxYWRjNTNjNl8xLTEtMS0xLTgyNzgy_d91335b3-ca3d-48b5-b8f4-6fe0cfa41354">WST</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xL2ZyYWc6MTQ1NzAyMDg4MzdlNDQ2N2JkNjY3YWNlMzFlNGExZmUvdGFibGU6ZDJiMzMwYjM3MjdjNDY4ZDk5OWUzNmEzMWFkYzUzYzYvdGFibGVyYW5nZTpkMmIzMzBiMzcyN2M0NjhkOTk5ZTM2YTMxYWRjNTNjNl8xLTItMS0xLTgyNzgy_490ef85b-76c7-4146-850e-e5b183a0cb96">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;   <ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xL2ZyYWc6MTQ1NzAyMDg4MzdlNDQ2N2JkNjY3YWNlMzFlNGExZmUvdGV4dHJlZ2lvbjoxNDU3MDIwODgzN2U0NDY3YmQ2NjdhY2UzMWU0YTFmZV82Nzg_0dbb2c42-1465-48c9-9441-b71f7a4ab379"><ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xL2ZyYWc6MTQ1NzAyMDg4MzdlNDQ2N2JkNjY3YWNlMzFlNGExZmUvdGV4dHJlZ2lvbjoxNDU3MDIwODgzN2U0NDY3YmQ2NjdhY2UzMWU0YTFmZV82Nzg_948db9a8-4fdf-41d2-b0af-d766b6f8b85c">Yes</ix:nonNumeric></ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).   &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;   <ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xL2ZyYWc6MTQ1NzAyMDg4MzdlNDQ2N2JkNjY3YWNlMzFlNGExZmUvdGV4dHJlZ2lvbjoxNDU3MDIwODgzN2U0NDY3YmQ2NjdhY2UzMWU0YTFmZV8xMDA3_0c6284da-0133-4fa8-8922-0f402d814207"><ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xL2ZyYWc6MTQ1NzAyMDg4MzdlNDQ2N2JkNjY3YWNlMzFlNGExZmUvdGV4dHJlZ2lvbjoxNDU3MDIwODgzN2U0NDY3YmQ2NjdhY2UzMWU0YTFmZV8xMDA3_4252b5dc-397d-4d59-88cd-8b593d045751">Yes</ix:nonNumeric></ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.&#160;&#160;See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:27.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.332%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.933%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xL2ZyYWc6MTQ1NzAyMDg4MzdlNDQ2N2JkNjY3YWNlMzFlNGExZmUvdGFibGU6NmZiNzk4OWM0MTUxNGEyM2E0NjdlZGQ2ZTM4MjhhZTMvdGFibGVyYW5nZTo2ZmI3OTg5YzQxNTE0YTIzYTQ2N2VkZDZlMzgyOGFlM18wLTAtMS0xLTgyNzgy_2993c655-7138-4075-9f38-c5d9d3342843">Large accelerated filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9745;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xL2ZyYWc6MTQ1NzAyMDg4MzdlNDQ2N2JkNjY3YWNlMzFlNGExZmUvdGFibGU6NmZiNzk4OWM0MTUxNGEyM2E0NjdlZGQ2ZTM4MjhhZTMvdGFibGVyYW5nZTo2ZmI3OTg5YzQxNTE0YTIzYTQ2N2VkZDZlMzgyOGFlM18xLTQtMS0xLTgyNzgy_9275abe8-7ca5-4699-a360-45e98f5f5351">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xL2ZyYWc6MTQ1NzAyMDg4MzdlNDQ2N2JkNjY3YWNlMzFlNGExZmUvdGFibGU6NmZiNzk4OWM0MTUxNGEyM2E0NjdlZGQ2ZTM4MjhhZTMvdGFibGVyYW5nZTo2ZmI3OTg5YzQxNTE0YTIzYTQ2N2VkZDZlMzgyOGFlM18yLTQtMS0xLTgyNzgy_59bba59b-1108-468b-9b14-84ceb40ba2e3">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;       </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></div><div style="margin-bottom:6pt;text-indent:432pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Yes&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xL2ZyYWc6MTQ1NzAyMDg4MzdlNDQ2N2JkNjY3YWNlMzFlNGExZmUvdGV4dHJlZ2lvbjoxNDU3MDIwODgzN2U0NDY3YmQ2NjdhY2UzMWU0YTFmZV8xODQx_85f0816a-7062-483f-93a1-3827c748444a">&#9745;</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April 12, 2023, there were <ix:nonFraction unitRef="shares" contextRef="id65f0e55c9ce468dab69a4cf20c6ce02_I20230412" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xL2ZyYWc6MTQ1NzAyMDg4MzdlNDQ2N2JkNjY3YWNlMzFlNGExZmUvdGV4dHJlZ2lvbjoxNDU3MDIwODgzN2U0NDY3YmQ2NjdhY2UzMWU0YTFmZV8xNzg3_2fa1f345-2426-40e7-9ffe-bc6320ba1151">74,242,584</ix:nonFraction> shares of the registrant&#8217;s common stock outstanding.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i7bf87d07bb544f48851c48374130181b_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:63.002%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.882%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Page</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_13">PART I. FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_16">FINANCIAL STATEMENTS (UNAUDITED)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_19">Condensed Consolidated Statements of Income for the Three Months ended March&#160;31, 2023 and 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_19">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_22">Condensed Consolidated Statements of Comprehensive Income for the Three Months ended March 31, 2023 and 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_22">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_25">Condensed Consolidated Balance Sheets at March&#160;31, 2023 and December 31, 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_25">5</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_28">Condensed Consolidated Statements of Cash Flows for the Three Months ended March 31, 2023 and 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_28">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_31">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_31">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_88">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_88">23</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_100">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_100">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_103">CONTROLS AND PROCEDURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_103">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_106">PART II. OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_109">LEGAL PROCEEDINGS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_109">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM 1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_112">RISK FACTORS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_112">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_115">UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_115">35</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM 6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_118">EXHIBITS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_118">36</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_121">SIGNATURE</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_121">37</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i7bf87d07bb544f48851c48374130181b_13"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I.   FINANCIAL INFORMATION</span></div><div><span><br/></span></div><div id="i7bf87d07bb544f48851c48374130181b_16"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;&#160;FINANCIAL STATEMENTS</span></div><div><span><br/></span></div><div id="i7bf87d07bb544f48851c48374130181b_19"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">West Pharmaceutical Services, Inc. and Subsidiaries</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in millions, except per share data)</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.241%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfMi0xLTEtMS04Mjc4Mg_e184e5c5-25a1-40f8-864f-b93a56f4851a">716.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfMi0zLTEtMS04Mjc4Mg_9451859e-784b-48fd-bfc0-d1f69301a635">720.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods and services sold</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfMy0xLTEtMS04Mjc4Mg_f6d7884c-b39e-4001-ba70-e459ae4cd048">445.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfMy0zLTEtMS04Mjc4Mg_77bfb2b1-3dc4-43a3-b2e0-e3f4e631b2d8">435.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfNC0xLTEtMS04Mjc4Mg_7dfd7742-405e-4bbf-8bbd-ccc34e882024">271.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfNC0zLTEtMS04Mjc4Mg_c5e0515c-f3d4-4dba-bc74-1e3642742580">284.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfNS0xLTEtMS04Mjc4Mg_4cc763af-1457-4d76-9ecc-24c3096aa718">17.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfNS0zLTEtMS04Mjc4Mg_600af603-3bff-4f89-b774-900a8ea4f67b">14.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfNi0xLTEtMS04Mjc4Mg_28d38d5f-081f-48bb-ad41-c6230a188218">86.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfNi0zLTEtMS04Mjc4Mg_29fa1977-86f0-4f7c-bc5a-e66c08d5887c">83.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income) (Note 15)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" sign="-" name="wst:OtherIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfNy0xLTEtMS04Mjc4Mg_94957656-ff35-434d-a874-581ad39f0853">12.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="wst:OtherIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfNy0zLTEtMS04Mjc4Mg_265e42b9-aa52-4d09-997d-4562af34e004">3.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfOC0xLTEtMS04Mjc4Mg_1a0bedaa-b026-46b8-8d93-e629d91dd486">155.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfOC0zLTEtMS04Mjc4Mg_dc2d4d90-6208-4412-97e2-e945d5237402">189.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfOS0xLTEtMS04Mjc4Mg_1d4d3bc1-a8ce-4fd5-b773-2aea4cf748b9">2.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfOS0zLTEtMS04Mjc4Mg_64a41286-430b-44b1-85ff-5dc18288cebe">2.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:InvestmentIncomeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfMTAtMS0xLTEtODI3ODI_79bbc097-1861-4078-849f-37e2d6e10633">4.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:InvestmentIncomeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfMTAtMy0xLTEtODI3ODI_abea9ac7-fd02-4be7-bba2-6db5b203bf8a">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes and equity in net income of affiliated companies</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfMTItMS0xLTEtODI3ODI_27aab035-14fa-4622-8330-d5191fb8b601">157.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfMTItMy0xLTEtODI3ODI_3f4ec394-d75b-44ad-9842-7afce28c29d5">187.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfMTMtMS0xLTEtODI3ODI_926e1ebb-79d5-4493-a40d-195ed579fa00">23.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfMTMtMy0xLTEtODI3ODI_d8948721-3f85-4a5f-988b-4e3c5cbdda9b">21.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net income of affiliated companies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfMTQtMS0xLTEtODI3ODI_2edc27fa-cd12-44d6-b082-b6ec76098149">5.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfMTQtMy0xLTEtODI3ODI_a1ec3984-9d4f-4369-97a9-8f34148068af">7.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfMTUtMS0xLTEtODI3ODI_705e8955-590c-4b2b-936f-2758c2b1492b">140.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfMTUtMy0xLTEtODI3ODI_cbb963c9-630c-4947-8ce3-2a160fc1bb48">173.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfMTgtMS0xLTEtODI3ODI_9b1ac7df-9b7f-4f0d-a3cc-875087c8edb7">1.88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfMTgtMy0xLTEtODI3ODI_f419e28c-cb8c-4ab7-8c46-8116760aa970">2.34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfMTktMS0xLTEtODI3ODI_24496375-e97b-4b05-b14d-4f1b8d7af1da">1.85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfMTktMy0xLTEtODI3ODI_3662c576-2322-4733-bef2-c2e61c9e33cd">2.29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfMjItMS0xLTEtODI3ODI_cb01958b-91bc-4fcb-931b-e67c79ea3ca3">74.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfMjItMy0xLTEtODI3ODI_f87f444b-59a4-46f0-a9ef-6d341980e779">74.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfMjMtMS0xLTEtODI3ODI_bbe1ef08-e382-4bad-a9ff-7d77ed27209c">75.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfMjMtMy0xLTEtODI3ODI_b3b45b70-60e3-42ec-adc1-ed614eceebae">76.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i7bf87d07bb544f48851c48374130181b_22"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">West Pharmaceutical Services, Inc. and Subsidiaries</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in millions)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yMi9mcmFnOjRmYjc5NjVjNGNlNTRlN2JhNzY5ODNhZjJjYmZlZGNlL3RhYmxlOmU1ODQ5OTBhZjE1OTQ5MDE4YzllZmNlNjIyYzU1MmEzL3RhYmxlcmFuZ2U6ZTU4NDk5MGFmMTU5NDkwMThjOWVmY2U2MjJjNTUyYTNfMi0xLTEtMS04Mjc4Mg_f9525929-bca2-4a47-913c-cdebda39e35f">140.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yMi9mcmFnOjRmYjc5NjVjNGNlNTRlN2JhNzY5ODNhZjJjYmZlZGNlL3RhYmxlOmU1ODQ5OTBhZjE1OTQ5MDE4YzllZmNlNjIyYzU1MmEzL3RhYmxlcmFuZ2U6ZTU4NDk5MGFmMTU5NDkwMThjOWVmY2U2MjJjNTUyYTNfMi0zLTEtMS04Mjc4Mg_141108f4-ac3d-4548-bf81-4a6c31cec9e4">173.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments, net of tax of $<ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yMi9mcmFnOjRmYjc5NjVjNGNlNTRlN2JhNzY5ODNhZjJjYmZlZGNlL3RhYmxlOmU1ODQ5OTBhZjE1OTQ5MDE4YzllZmNlNjIyYzU1MmEzL3RhYmxlcmFuZ2U6ZTU4NDk5MGFmMTU5NDkwMThjOWVmY2U2MjJjNTUyYTNfNC0wLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOmE1ODAzMzM1MTUyZTRiNzk5ODE1ZTIyMjIzYTk0YzEyXzI3NDg3NzkwNjk1MTc_f88e4e91-b066-4165-b04d-6c7c59893504">0.2</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yMi9mcmFnOjRmYjc5NjVjNGNlNTRlN2JhNzY5ODNhZjJjYmZlZGNlL3RhYmxlOmU1ODQ5OTBhZjE1OTQ5MDE4YzllZmNlNjIyYzU1MmEzL3RhYmxlcmFuZ2U6ZTU4NDk5MGFmMTU5NDkwMThjOWVmY2U2MjJjNTUyYTNfNC0wLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOmE1ODAzMzM1MTUyZTRiNzk5ODE1ZTIyMjIzYTk0YzEyXzI3NDg3NzkwNjk1Mjg_775aa3b0-0f6a-4d38-9461-ff3954212c94">1.0</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yMi9mcmFnOjRmYjc5NjVjNGNlNTRlN2JhNzY5ODNhZjJjYmZlZGNlL3RhYmxlOmU1ODQ5OTBhZjE1OTQ5MDE4YzllZmNlNjIyYzU1MmEzL3RhYmxlcmFuZ2U6ZTU4NDk5MGFmMTU5NDkwMThjOWVmY2U2MjJjNTUyYTNfNC0xLTEtMS04Mjc4Mg_a311905c-01de-4196-b505-220f8d8a0fda">15.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yMi9mcmFnOjRmYjc5NjVjNGNlNTRlN2JhNzY5ODNhZjJjYmZlZGNlL3RhYmxlOmU1ODQ5OTBhZjE1OTQ5MDE4YzllZmNlNjIyYzU1MmEzL3RhYmxlcmFuZ2U6ZTU4NDk5MGFmMTU5NDkwMThjOWVmY2U2MjJjNTUyYTNfNC0zLTEtMS04Mjc4Mg_bd417d4b-e7c2-4309-b000-485da0fe339e">22.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit pension and other postretirement plan adjustments, net of tax of $(<ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yMi9mcmFnOjRmYjc5NjVjNGNlNTRlN2JhNzY5ODNhZjJjYmZlZGNlL3RhYmxlOmU1ODQ5OTBhZjE1OTQ5MDE4YzllZmNlNjIyYzU1MmEzL3RhYmxlcmFuZ2U6ZTU4NDk5MGFmMTU5NDkwMThjOWVmY2U2MjJjNTUyYTNfNS0wLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOjliNjZjMjEyNmM2NDRkNGNiOWQ2YzVkMDJiNTUyZWZiXzg1_89ad8e0a-d17a-4b96-a7df-24e90ae75937">0.2</ix:nonFraction>) and $<ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yMi9mcmFnOjRmYjc5NjVjNGNlNTRlN2JhNzY5ODNhZjJjYmZlZGNlL3RhYmxlOmU1ODQ5OTBhZjE1OTQ5MDE4YzllZmNlNjIyYzU1MmEzL3RhYmxlcmFuZ2U6ZTU4NDk5MGFmMTU5NDkwMThjOWVmY2U2MjJjNTUyYTNfNS0wLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOjliNjZjMjEyNmM2NDRkNGNiOWQ2YzVkMDJiNTUyZWZiXzky_ce113bb8-4645-4b14-acfe-bc76541f245a">0.3</ix:nonFraction> </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yMi9mcmFnOjRmYjc5NjVjNGNlNTRlN2JhNzY5ODNhZjJjYmZlZGNlL3RhYmxlOmU1ODQ5OTBhZjE1OTQ5MDE4YzllZmNlNjIyYzU1MmEzL3RhYmxlcmFuZ2U6ZTU4NDk5MGFmMTU5NDkwMThjOWVmY2U2MjJjNTUyYTNfNS0xLTEtMS04Mjc4Mg_7d379b08-90d5-434d-b984-66d032c742c6">0.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yMi9mcmFnOjRmYjc5NjVjNGNlNTRlN2JhNzY5ODNhZjJjYmZlZGNlL3RhYmxlOmU1ODQ5OTBhZjE1OTQ5MDE4YzllZmNlNjIyYzU1MmEzL3RhYmxlcmFuZ2U6ZTU4NDk5MGFmMTU5NDkwMThjOWVmY2U2MjJjNTUyYTNfNS0zLTEtMS04Mjc4Mg_cfd3ac24-c178-4b6f-b50f-e763561a06dd">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss on derivatives, net of tax of $(<ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yMi9mcmFnOjRmYjc5NjVjNGNlNTRlN2JhNzY5ODNhZjJjYmZlZGNlL3RhYmxlOmU1ODQ5OTBhZjE1OTQ5MDE4YzllZmNlNjIyYzU1MmEzL3RhYmxlcmFuZ2U6ZTU4NDk5MGFmMTU5NDkwMThjOWVmY2U2MjJjNTUyYTNfNy0wLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOjg0YjA0MGNmNDNkZjQ0MzhiNDk4OTIwZmE4M2RkNGUwXzQz_fe23029f-f12a-4258-aa53-5166fc882eba">0.1</ix:nonFraction>) and $(<ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yMi9mcmFnOjRmYjc5NjVjNGNlNTRlN2JhNzY5ODNhZjJjYmZlZGNlL3RhYmxlOmU1ODQ5OTBhZjE1OTQ5MDE4YzllZmNlNjIyYzU1MmEzL3RhYmxlcmFuZ2U6ZTU4NDk5MGFmMTU5NDkwMThjOWVmY2U2MjJjNTUyYTNfNy0wLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOjg0YjA0MGNmNDNkZjQ0MzhiNDk4OTIwZmE4M2RkNGUwXzUw_6e6d2dbf-e445-4848-a15f-ffd38190226a">0.8</ix:nonFraction>)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yMi9mcmFnOjRmYjc5NjVjNGNlNTRlN2JhNzY5ODNhZjJjYmZlZGNlL3RhYmxlOmU1ODQ5OTBhZjE1OTQ5MDE4YzllZmNlNjIyYzU1MmEzL3RhYmxlcmFuZ2U6ZTU4NDk5MGFmMTU5NDkwMThjOWVmY2U2MjJjNTUyYTNfNy0xLTEtMS04Mjc4Mg_51c52b76-921a-4b16-a2bc-bb2c19490391">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yMi9mcmFnOjRmYjc5NjVjNGNlNTRlN2JhNzY5ODNhZjJjYmZlZGNlL3RhYmxlOmU1ODQ5OTBhZjE1OTQ5MDE4YzllZmNlNjIyYzU1MmEzL3RhYmxlcmFuZ2U6ZTU4NDk5MGFmMTU5NDkwMThjOWVmY2U2MjJjNTUyYTNfNy0zLTEtMS04Mjc4Mg_c867c8f8-0d4d-4834-95a6-2758b38d923b">1.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yMi9mcmFnOjRmYjc5NjVjNGNlNTRlN2JhNzY5ODNhZjJjYmZlZGNlL3RhYmxlOmU1ODQ5OTBhZjE1OTQ5MDE4YzllZmNlNjIyYzU1MmEzL3RhYmxlcmFuZ2U6ZTU4NDk5MGFmMTU5NDkwMThjOWVmY2U2MjJjNTUyYTNfOC0xLTEtMS04Mjc4Mg_96f952fe-6c15-4b70-b992-196fb67466f2">14.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yMi9mcmFnOjRmYjc5NjVjNGNlNTRlN2JhNzY5ODNhZjJjYmZlZGNlL3RhYmxlOmU1ODQ5OTBhZjE1OTQ5MDE4YzllZmNlNjIyYzU1MmEzL3RhYmxlcmFuZ2U6ZTU4NDk5MGFmMTU5NDkwMThjOWVmY2U2MjJjNTUyYTNfOC0zLTEtMS04Mjc4Mg_95a6a69a-bcec-4aab-9c70-1bfb8d9856c2">22.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yMi9mcmFnOjRmYjc5NjVjNGNlNTRlN2JhNzY5ODNhZjJjYmZlZGNlL3RhYmxlOmU1ODQ5OTBhZjE1OTQ5MDE4YzllZmNlNjIyYzU1MmEzL3RhYmxlcmFuZ2U6ZTU4NDk5MGFmMTU5NDkwMThjOWVmY2U2MjJjNTUyYTNfOS0xLTEtMS04Mjc4Mg_8f3e4c63-584a-48b9-8145-372a8fa19f62">154.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yMi9mcmFnOjRmYjc5NjVjNGNlNTRlN2JhNzY5ODNhZjJjYmZlZGNlL3RhYmxlOmU1ODQ5OTBhZjE1OTQ5MDE4YzllZmNlNjIyYzU1MmEzL3RhYmxlcmFuZ2U6ZTU4NDk5MGFmMTU5NDkwMThjOWVmY2U2MjJjNTUyYTNfOS0zLTEtMS04Mjc4Mg_15a70692-e8ca-4c58-8494-8d131b309e8c">151.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i7bf87d07bb544f48851c48374130181b_25"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">West Pharmaceutical Services, Inc. and Subsidiaries</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(in millions, except per share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMy0xLTEtMS04Mjc4Mg_86b37227-64c1-4d55-bf40-4e20b1956c42">886.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMy0zLTEtMS04Mjc4Mg_b07cec91-2408-484f-a58d-a12b49747ce2">894.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNC0xLTEtMS04Mjc4Mg_c98d91d2-f1b3-4ccf-a2f3-77ff59a0466b">513.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNC0zLTEtMS04Mjc4Mg_f93cbd55-2235-41bf-839a-d3054fa80565">507.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNS0xLTEtMS04Mjc4Mg_3079db6f-c751-4be6-9380-20cb84a885ff">447.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNS0zLTEtMS04Mjc4Mg_fec4d473-fc89-4c9a-9f15-efe6ea5ac361">414.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNi0xLTEtMS04Mjc4Mg_4ae2545d-b523-46a3-9602-bdd9b348b00a">90.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNi0zLTEtMS04Mjc4Mg_ce8a5d4d-80ab-4a9c-9141-c1aa59299fe9">103.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNy0xLTEtMS04Mjc4Mg_feb60313-e114-4e8b-a066-91259c70bfa6">1,937.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNy0zLTEtMS04Mjc4Mg_80304108-58e9-4649-89e8-43b10516ad39">1,919.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfOC0xLTEtMS04Mjc4Mg_e0121d40-f1c0-4d69-9a59-60ce6ea75605">2,478.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfOC0zLTEtMS04Mjc4Mg_8d078082-0190-44f4-a75b-6e93c1934f5e">2,386.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfOS0xLTEtMS04Mjc4Mg_0c64f7b7-d868-420d-97e8-2346f211b7cc">1,263.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfOS0zLTEtMS04Mjc4Mg_5f51c58f-11a9-4bd0-ad66-71ec1f43c832">1,228.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMTAtMS0xLTEtODI3ODI_7ffd6abf-eaec-4ac0-93e5-805e0d1cc068">1,215.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMTAtMy0xLTEtODI3ODI_3ede6d77-4112-4b74-9678-9ed45bd4f725">1,158.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMTEtMS0xLTEtODI3ODI_22de5108-296f-4342-8c86-9d283be6a380">101.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMTEtMy0xLTEtODI3ODI_2f1c7f4b-44db-4d50-af85-94371c31b8b0">104.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Investments in affiliated companies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMTItMS0xLTEtODI3ODI_110d20cb-a602-4249-b92d-026361bfcc24">208.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMTItMy0xLTEtODI3ODI_f309d9f7-993a-4171-a80b-f848ed437873">204.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMTMtMS0xLTEtODI3ODI_1d38a526-0cbb-49be-8ef7-dd60b32fe0c2">107.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMTMtMy0xLTEtODI3ODI_6dc0e946-3052-4660-875f-47e2b62d18fd">107.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMTQtMS0xLTEtODI3ODI_6a82602a-1005-4fd4-be74-c0ff485679e8">17.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMTQtMy0xLTEtODI3ODI_51833dbc-8dc3-404a-93ab-852763975496">18.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMTUtMS0xLTEtODI3ODI_9f4b0f38-de2b-4667-b53f-82ee14da11d2">99.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMTUtMy0xLTEtODI3ODI_36ff4437-b4eb-4e28-91fb-75fb1e627fb2">65.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMTctMS0xLTEtODI3ODI_c56a844c-1798-445c-b772-4575d772351e">36.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMTctMy0xLTEtODI3ODI_31b99201-efa2-4409-8d38-a34d4ffb28ce">38.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total Assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMTgtMS0xLTEtODI3ODI_74946ab4-ff72-4c68-863c-bfbb16ebe172">3,723.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMTgtMy0xLTEtODI3ODI_e62440e5-98cf-4774-8bb4-4ea9108acdf0">3,616.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">LIABILITIES AND EQUITY</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Notes payable and other current debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="wst:NotesPayableAndOtherDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMjItMS0xLTEtODI3ODI_ecfa3f6f-796a-4b15-992d-edacf7047156">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="wst:NotesPayableAndOtherDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMjItMy0xLTEtODI3ODI_719ddaa4-6175-46cb-a08a-c019ad7e5ed5">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMjMtMS0xLTEtODI3ODI_17843e1f-1009-4b55-8e4f-0159184cc434">233.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMjMtMy0xLTEtODI3ODI_21485563-9e59-4926-bc1f-69685986e244">215.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accrued salaries, wages and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="wst:AccruedSalariesWagesAndBenefitsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMjUtMS0xLTEtODI3ODI_b8b911fa-8575-4094-8769-545537f11e36">65.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="wst:AccruedSalariesWagesAndBenefitsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMjUtMy0xLTEtODI3ODI_c72ff569-6e6b-4bcc-a61e-bc3705a03e58">76.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMjYtMS0xLTEtODI3ODI_781463a6-725d-4b99-8f2b-69b0903c3046">59.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMjYtMy0xLTEtODI3ODI_ca856412-b818-47e0-99dd-4264296594b9">24.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMjctMS0xLTEtODI3ODI_01bef3ac-1923-435d-8f60-1659e2a2c284">16.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMjctMy0xLTEtODI3ODI_e1fd0ac6-43fe-4fa7-b6a1-b2c3402bef37">16.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMjgtMS0xLTEtODI3ODI_47015a15-e6c7-4fd9-ae4d-a9c9c600128e">158.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMjgtMy0xLTEtODI3ODI_9073d580-1868-4bd3-b9cd-8896a202b6be">183.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMjktMS0xLTEtODI3ODI_0d0edbaf-3268-4bc2-8644-46e53a1915fa">534.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMjktMy0xLTEtODI3ODI_652179cc-3cc0-46ad-8a15-2baa3d7b0b47">519.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMzAtMS0xLTEtODI3ODI_89008558-fa1e-4501-afed-7f34c9f3cabe">206.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMzAtMy0xLTEtODI3ODI_f70a89f3-6df7-4395-9feb-8d35655565a3">206.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMzEtMS0xLTEtODI3ODI_67b09a46-0f14-40ab-9365-ef3526fc7c99">14.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMzEtMy0xLTEtODI3ODI_5ceedb35-a94c-4a49-9623-cb7989bae2c1">14.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Pension and other postretirement benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMzItMS0xLTEtODI3ODI_cfa484cf-962d-4469-8b0a-43beea59648c">27.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMzItMy0xLTEtODI3ODI_103f5c1f-38bc-4cd7-a6c5-681ada889345">28.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMzMtMS0xLTEtODI3ODI_b6cc5136-1325-4faf-ad8c-dc766099ead9">89.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMzMtMy0xLTEtODI3ODI_4f520b9f-65df-4b6f-a2df-09b619542fea">93.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Deferred compensation benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMzQtMS0xLTEtODI3ODI_c5e2ceb7-acfb-4474-87d6-0f71d5bd7f64">19.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMzQtMy0xLTEtODI3ODI_f1898add-1d62-439f-8ea5-fdab2af95abb">19.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMzUtMS0xLTEtODI3ODI_e8f86602-8cad-4a9c-899d-14ce4575ea03">55.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMzUtMy0xLTEtODI3ODI_3daa90cc-de9e-4db1-b72e-e54e95be910f">51.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total Liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMzYtMS0xLTEtODI3ODI_1b78c298-881f-4640-8eb8-113522c47830">947.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMzYtMy0xLTEtODI3ODI_cf2b8b3f-5294-4d84-9e5a-1f6380467980">931.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 17)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMzgtMS0xLTEtODI3ODI_89ab87de-91d0-402e-a9bb-4f62b6f0526b"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMzgtMy0xLTEtODI3ODI_9b83b822-1c66-4e2c-91b4-f2b261bc0a20"></ix:nonFraction></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Preferred stock, <ix:nonFraction unitRef="shares" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDEtMC0xLTEtODI3ODIvdGV4dHJlZ2lvbjozOWI4ZGNmYTk4ZTg0YjNkYjE2YjRhYjg0ZTZmNjYzOV8yMg_02dd9c68-0815-4244-9a8a-59d1ac7d2ce7"><ix:nonFraction unitRef="shares" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDEtMC0xLTEtODI3ODIvdGV4dHJlZ2lvbjozOWI4ZGNmYTk4ZTg0YjNkYjE2YjRhYjg0ZTZmNjYzOV8yMg_736ee117-de20-4afc-bb21-b662bfedf0a6">3.0</ix:nonFraction></ix:nonFraction>&#160;million shares authorized; <ix:nonFraction unitRef="shares" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDEtMC0xLTEtODI3ODIvdGV4dHJlZ2lvbjozOWI4ZGNmYTk4ZTg0YjNkYjE2YjRhYjg0ZTZmNjYzOV80NA_0ba96407-f485-4d42-a3fa-3fd45e6bc007"><ix:nonFraction unitRef="shares" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDEtMC0xLTEtODI3ODIvdGV4dHJlZ2lvbjozOWI4ZGNmYTk4ZTg0YjNkYjE2YjRhYjg0ZTZmNjYzOV80NA_7e721fb7-5f7b-4acd-b1e1-f938efa2e505"><ix:nonFraction unitRef="shares" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDEtMC0xLTEtODI3ODIvdGV4dHJlZ2lvbjozOWI4ZGNmYTk4ZTg0YjNkYjE2YjRhYjg0ZTZmNjYzOV80NA_dc603ca1-6341-4e8c-a67f-52c9a54c2af7"><ix:nonFraction unitRef="shares" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDEtMC0xLTEtODI3ODIvdGV4dHJlZ2lvbjozOWI4ZGNmYTk4ZTg0YjNkYjE2YjRhYjg0ZTZmNjYzOV80NA_f62302e9-7a5d-4488-aff9-fa23bb8d2422">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDEtMS0xLTEtODI3ODI_4bee5c56-17d8-4fbb-bf3f-50b5c4a96259">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDEtMy0xLTEtODI3ODI_c08bf99a-af2a-4d69-ab27-17721f1384d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDItMC0xLTEtODI3ODIvdGV4dHJlZ2lvbjo4YzM0ZDZlMjg3NzM0YTk1YWRhMGNkOGVjZDZjZDBiMV8yOA_64d869ee-0bfc-4637-964c-62a4e75c1ec2"><ix:nonFraction unitRef="usdPerShare" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDItMC0xLTEtODI3ODIvdGV4dHJlZ2lvbjo4YzM0ZDZlMjg3NzM0YTk1YWRhMGNkOGVjZDZjZDBiMV8yOA_ef79cd3b-90f5-40bb-a7f5-05f6b48b616e">0.25</ix:nonFraction></ix:nonFraction> per share; <ix:nonFraction unitRef="shares" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDItMC0xLTEtODI3ODIvdGV4dHJlZ2lvbjo4YzM0ZDZlMjg3NzM0YTk1YWRhMGNkOGVjZDZjZDBiMV80Mg_41483808-6527-460e-b30e-c66952bc840d"><ix:nonFraction unitRef="shares" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDItMC0xLTEtODI3ODIvdGV4dHJlZ2lvbjo4YzM0ZDZlMjg3NzM0YTk1YWRhMGNkOGVjZDZjZDBiMV80Mg_9039baaf-7577-4180-a714-5862345d4055">200.0</ix:nonFraction></ix:nonFraction> million shares authorized; shares issued: <ix:nonFraction unitRef="shares" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDItMC0xLTEtODI3ODIvdGV4dHJlZ2lvbjo4YzM0ZDZlMjg3NzM0YTk1YWRhMGNkOGVjZDZjZDBiMV83OQ_d44b4452-b692-41cb-9ac5-884bdfd02d86"><ix:nonFraction unitRef="shares" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDItMC0xLTEtODI3ODIvdGV4dHJlZ2lvbjo4YzM0ZDZlMjg3NzM0YTk1YWRhMGNkOGVjZDZjZDBiMV83OQ_deed5bb7-add2-4add-b3ff-c215f184406b">75.3</ix:nonFraction></ix:nonFraction>&#160;million in 2023 and 2022; shares outstanding: <ix:nonFraction unitRef="shares" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDItMC0xLTEtODI3ODIvdGV4dHJlZ2lvbjo4YzM0ZDZlMjg3NzM0YTk1YWRhMGNkOGVjZDZjZDBiMV8xMjA_4765f3f9-4c84-46b8-9b4b-38e4992fedd8">74.2</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="shares" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDItMC0xLTEtODI3ODIvdGV4dHJlZ2lvbjo4YzM0ZDZlMjg3NzM0YTk1YWRhMGNkOGVjZDZjZDBiMV8xMjc_674195a4-44da-4bbf-80c1-9712451a9ae8">74.1</ix:nonFraction> million </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDItMS0xLTEtODI3ODI_5ef2a619-b95a-41be-b801-5198c517142e">18.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDItMy0xLTEtODI3ODI_3475699e-f0e2-4f1c-b7d4-00e0fac3dfbf">18.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Capital in excess of par value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:AdditionalPaidInCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDMtMS0xLTEtODI3ODI_4cf91c4a-c871-4336-bce2-28fb6bf8a787">181.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:AdditionalPaidInCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDMtMy0xLTEtODI3ODI_161ccb2d-4635-4763-a1fa-dfb2f46c21ce">232.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDQtMS0xLTEtODI3ODI_15a239d4-2571-47c6-aa79-1a419e943b8a">3,113.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDQtMy0xLTEtODI3ODI_72324ce9-b87e-499a-bd68-a176ad4f3ca3">2,987.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDUtMS0xLTEtODI3ODI_315427ee-0adc-415a-992e-6a4c806331ed">168.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDUtMy0xLTEtODI3ODI_edac1d32-8013-490d-871c-b805b27dd44a">183.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Treasury stock, at cost (<ix:nonFraction unitRef="shares" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDYtMC0xLTEtODI3ODIvdGV4dHJlZ2lvbjo2ZjdiYmM1NmFlNzM0NjY5YTg1MGM3NTg3NTVjODA4NF8yOQ_b0235866-b7b7-4392-a24b-77fce11fc644">1.1</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="shares" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDYtMC0xLTEtODI3ODIvdGV4dHJlZ2lvbjo2ZjdiYmM1NmFlNzM0NjY5YTg1MGM3NTg3NTVjODA4NF8zNg_4e421ccc-961f-4e37-a568-10c6136ee7d6">1.2</ix:nonFraction> million shares)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:TreasuryStockCommonValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDYtMS0xLTEtODI3ODI_a5535321-2bd0-45d8-aee7-c8b5bc3a88a4">369.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:TreasuryStockCommonValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDYtMy0xLTEtODI3ODI_012e50fe-7774-4f36-a321-a7b9627aae5f">370.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total Equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDctMS0xLTEtODI3ODI_92f1a375-355a-4307-8e37-e38134d8970e">2,776.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDctMy0xLTEtODI3ODI_83d30692-05e2-4329-ade5-e39e54c31871">2,684.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total Liabilities and Equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDgtMS0xLTEtODI3ODI_cf67fbcf-46f2-4c76-8f8d-ff8fa05fdace">3,723.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDgtMy0xLTEtODI3ODI_ad96a924-3e0e-4ba7-a246-9d60deb97c9b">3,616.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i7bf87d07bb544f48851c48374130181b_28"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">West Pharmaceutical Services, Inc. and Subsidiaries</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in millions)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMy0xLTEtMS04Mjc4Mg_53a12c26-88a0-41d6-9f84-14d79f192cd9">140.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMy0zLTEtMS04Mjc4Mg_3f56d4f9-48a3-4b0f-972d-16f0a73b5e9c">173.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfNS0xLTEtMS04Mjc4Mg_28bafc5c-beeb-454b-8f6d-6f4793d5c44b">30.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfNS0zLTEtMS04Mjc4Mg_7e4f7e4e-5036-4bdb-9049-d94c00347861">28.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:AdjustmentForAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfNi0xLTEtMS04Mjc4Mg_dab655c8-2588-4255-82d6-a35e08bf5276">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:AdjustmentForAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfNi0zLTEtMS04Mjc4Mg_acdfa388-9f1f-4e17-9809-aad0d2d2c3d4">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfNy0xLTEtMS04Mjc4Mg_243526d1-06d6-44f2-99cf-e1b1b23c01c6">8.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfNy0zLTEtMS04Mjc4Mg_b96d4a3f-2db3-4546-b62a-df36161eb4e8">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMTAtMS0xLTEtODI3ODI_b76b5962-5907-48e8-a3d6-f59a3dfb6cbf">11.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMTAtMy0xLTEtODI3ODI_79a6e4c3-cd8d-4d2e-a2fb-7675eb9f1a58">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-cash items, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMTItMS0xLTEtODI3ODI_c319f0f5-2a2f-415c-bb40-6074742377ff">6.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMTItMy0xLTEtODI3ODI_5dc724dd-4f72-4518-b5c1-dae6c0db47a1">7.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in assets and liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMTMtMS0xLTEtODI3ODI_45c9d2d0-c5f9-4562-88a9-c8848068886e">46.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMTMtMy0xLTEtODI3ODI_d1ad2a4b-a502-48b8-9f63-638d820ac40e">50.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMTQtMS0xLTEtODI3ODI_b7390dc5-2805-4582-ae47-730cedbc379d">138.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMTQtMy0xLTEtODI3ODI_1d33c3eb-2e99-46c9-80c6-633bbd8c1b34">151.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMTctMS0xLTEtODI3ODI_53de721a-9ab3-464b-ac40-1b15176efd2c">82.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMTctMy0xLTEtODI3ODI_43696e78-5dbb-4463-a9b2-999db4da8308">65.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMjMtMS0xLTEtODI3ODI_a23db7d0-7166-4ca8-a4cd-c003fb3d36ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMjMtMy0xLTEtODI3ODI_611c6850-b67d-467a-b7c8-5b726f55632f">2.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMjQtMS0xLTEtODI3ODI_c08a8d1a-54d1-4736-b725-44bc0803a325">82.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMjQtMy0xLTEtODI3ODI_ec06b186-5119-45dd-add7-4adfff121ac8">68.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayments of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:RepaymentsOfOtherLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMzAtMS0xLTEtODI3ODI_4851980c-3e1e-424f-bd6e-025cd13b4fb4">0.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:RepaymentsOfOtherLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMzAtMy0xLTEtODI3ODI_e6368fe7-c46e-4e6a-8ba6-5c54d5272bae">0.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMzEtMS0xLTEtODI3ODI_947ce76c-f6ee-4692-9481-e37f0404565c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMzEtMy0xLTEtODI3ODI_e0f7f75a-930a-4d4b-ae27-9fdc315ebc9a">1.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMzItMS0xLTEtODI3ODI_fd13875d-7b13-4f5b-8aae-2061346addef">14.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMzItMy0xLTEtODI3ODI_134d2961-624e-4aef-9a54-692ce1432060">13.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from stock-based compensation awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMzMtMS0xLTEtODI3ODI_9ed84fe0-b81b-44fa-874f-11e767778d91">13.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMzMtMy0xLTEtODI3ODI_6ac4bd61-22a2-45ec-ae80-be1a59d2b2d4">6.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:ProceedsFromOtherEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMzQtMS0xLTEtODI3ODI_96bae1c9-9735-43ca-820f-20c1f6a941b1">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:ProceedsFromOtherEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMzQtMy0xLTEtODI3ODI_0d39c5a0-f777-4a55-afe4-2f8a1c913308">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares purchased under share repurchase program</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMzUtMS0xLTEtODI3ODI_a4f3668d-aa9a-4be5-b675-07c0fd7a3be0">60.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMzUtMy0xLTEtODI3ODI_3e80c0e3-dbf2-47e4-b61f-9741ebfed0de">147.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares repurchased for employee tax withholdings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMzYtMS0xLTEtODI3ODI_ce94de5c-9576-41bb-beb6-0b58723ec712">11.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMzYtMy0xLTEtODI3ODI_50d3669e-246b-4d9c-acf6-9f90906cb5cc">18.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMzctMS0xLTEtODI3ODI_3ced26f8-b2d9-46b2-baf1-c0366d4358d2">71.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMzctMy0xLTEtODI3ODI_3e0f25f8-1a22-403a-95a4-6f94992cae7f">172.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rates on cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMzgtMS0xLTEtODI3ODI_b3ebe803-751a-43f0-b64b-11a528f7f55b">7.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMzgtMy0xLTEtODI3ODI_d902db61-b257-4012-8493-661d707d2493">5.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMzktMS0xLTEtODI3ODI_a4775cf5-bdbb-48d7-9fcf-b4a58369415d">8.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMzktMy0xLTEtODI3ODI_84c1c40a-0919-4b46-8ee6-de69cf5a9057">94.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, including cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfNDEtMS0xLTEtODI3ODI_064ea7ef-db20-406a-9873-00ace72c3308">894.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00c9b6f38a304d5190000b6168ba7dce_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfNDEtMy0xLTEtODI3ODI_fd1eb3e8-48aa-4bf6-b44e-b1ccea027f9d">762.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, including cash equivalents at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfNDItMS0xLTEtODI3ODI_70185352-31a9-4b55-8028-500a570a50a5">886.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3cc75f001344ce095d702cd95b46078_I20220331" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfNDItMy0xLTEtODI3ODI_730872e6-cf67-445d-9c9d-638aab1b1da0">667.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i7bf87d07bb544f48851c48374130181b_31"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</span></div><div><span><br/></span></div><div id="i7bf87d07bb544f48851c48374130181b_34"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1:&#160;&#160;<ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8zNC9mcmFnOmY1NTQ1ZTI5ODI5MDRmNjE5NzYzMmVlOTI2NzRmOTY4L3RleHRyZWdpb246ZjU1NDVlMjk4MjkwNGY2MTk3NjMyZWU5MjY3NGY5NjhfMjAxNA_cceccab8-86da-4a3a-af6f-adb22b8763f2" continuedAt="idea6369e6e3244b4bf893f2d0dd9b984" escape="true">Basis of Presentation and Summary of Significant Accounting Policies</ix:nonNumeric></span></div><div><span><br/></span></div><div><ix:continuation id="idea6369e6e3244b4bf893f2d0dd9b984"><ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8zNC9mcmFnOmY1NTQ1ZTI5ODI5MDRmNjE5NzYzMmVlOTI2NzRmOTY4L3RleHRyZWdpb246ZjU1NDVlMjk4MjkwNGY2MTk3NjMyZWU5MjY3NGY5NjhfMjAyMg_3e2aeeff-ceab-41e6-acfb-f13ca88d2c4a" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The condensed consolidated financial statements included in this report are unaudited and have been prepared in accordance with United States (&#8220;U.S.&#8221;) generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) for interim financial reporting and U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) regulations. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, these financial statements include all adjustments, which are of a normal recurring nature, necessary for a fair statement of the financial position, results of operations, cash flows and the change in equity for the periods presented. The condensed consolidated financial statements for the three months ended March&#160;31, 2023, should be read in conjunction with the consolidated financial statements and notes thereto of West Pharmaceutical Services, Inc. and its majority-owned subsidiaries (which may be referred to as &#8220;West,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221;) appearing in our Annual Report on Form 10-K for the year ended December&#160;31, 2022 (the &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/105770/000010577023000012/wst-20221231.htm#i8148abfe270d4f15aa2ba9319df722dc_58">2022 Annual Report</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The results of operations for any interim period are not necessarily indicative of results for the full year.</span></ix:nonNumeric></ix:continuation></div><div><span><br/></span></div><div id="i7bf87d07bb544f48851c48374130181b_37"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2:&#160;&#160;<ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8zNy9mcmFnOmE1NGYzZGQ0NTM0ZDQxMDJhZGRkOTQ3MTg1ZDU0NzEwL3RleHRyZWdpb246YTU0ZjNkZDQ1MzRkNDEwMmFkZGQ5NDcxODVkNTQ3MTBfMTQ1MA_f2ef32b1-23f6-48f2-8c64-90e3c4a937f8" continuedAt="ia175553cc814408ab21752c2911d3838" escape="true">New Accounting Standards</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ia175553cc814408ab21752c2911d3838"><ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8zNy9mcmFnOmE1NGYzZGQ0NTM0ZDQxMDJhZGRkOTQ3MTg1ZDU0NzEwL3RleHRyZWdpb246YTU0ZjNkZDQ1MzRkNDEwMmFkZGQ5NDcxODVkNTQ3MTBfMTQ1Mw_62c2aedb-a6f3-4409-8c14-257377a930a3" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Standards</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, the Financial Accounting Standards Board ("FASB") issued guidance that seeks to enhance transparency around entities' use of supplier finance programs. The amendment requires the buyer in a supplier finance program to disclose information about the key terms of the program, outstanding confirmed amounts as of the end of the period, a rollforward of such amounts during each annual period, and a description of where in the financial statements outstanding amounts are presented. This guidance is effective for fiscal years beginning after December 15, 2022. We adopted this guidance as of January 1, 2023, on a prospective basis. The adoption did not have a material impact on our financial statements, as supplier finance programs are not material to the Company as of March&#160;31, 2023.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i7bf87d07bb544f48851c48374130181b_40"></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3:&#160;&#160;<ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RleHRyZWdpb246MGQyN2ViN2QyYTg3NDczOWJhYzU3MmY2ZDJhMjVkZDhfMjA1NA_a90aa9bf-71b5-4500-bee5-1ff7b5beb522" continuedAt="i4e9b5b85aa13430583299c11af09a137" escape="true">Revenue</ix:nonNumeric></span></div><div style="margin-bottom:1pt"><span><br/></span></div><ix:continuation id="i4e9b5b85aa13430583299c11af09a137" continuedAt="i5dd8024234554070bf4cf3f0f58409a4"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue results from the sale of goods or services and reflects the consideration to which we expect to be entitled in exchange for those goods or services. We record revenue based on a five-step model, in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 606. Following the identification of a contract with a customer, we identify the performance obligations (goods or services) in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize the revenue when (or as) we satisfy the performance obligations by transferring the promised goods or services to our customers. A good or service is transferred when (or as) the customer obtains control of that good or service. </span></div><div style="margin-bottom:1pt"><span><br/></span></div><div style="margin-bottom:1pt"><ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RleHRyZWdpb246MGQyN2ViN2QyYTg3NDczOWJhYzU3MmY2ZDJhMjVkZDhfMjA1NQ_ee9c52d6-ba69-4e0b-b2dd-9bda645d7ec2" continuedAt="i06871940c31a41d29804010a95b15352" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the approximate percentage of our net sales by market group:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biologics</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iae34400f53bb478b90a83802a119f9f9_D20230101-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOjdkYzlkYTgwZWJhZTQwZGQ4YWVmZGM1M2Y2MWYwOTNiL3RhYmxlcmFuZ2U6N2RjOWRhODBlYmFlNDBkZDhhZWZkYzUzZjYxZjA5M2JfMi0xLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOjM3N2Q0YWU1MjRlNjQ5YjQ4ZGU5Y2MzOWU2ZDI0NzQ5XzQ_ff50123e-affc-4ee7-8195-036ff90a81d7">34</ix:nonFraction> %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icda5c4d11f62428a95249de65f0fefd2_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOjdkYzlkYTgwZWJhZTQwZGQ4YWVmZGM1M2Y2MWYwOTNiL3RhYmxlcmFuZ2U6N2RjOWRhODBlYmFlNDBkZDhhZWZkYzUzZjYxZjA5M2JfMi0zLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOmM5ZWY3MzQ5NTAwZTRmNTk5YmZiZDYyMjA1MzdiY2E5XzQ_331c7d15-70ea-43f1-a165-91e5c9942c8d">43</ix:nonFraction> %</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Generics</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;<ix:nonFraction unitRef="number" contextRef="ie37ebad36b6348b285cca6d19bde1f7b_D20230101-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOjdkYzlkYTgwZWJhZTQwZGQ4YWVmZGM1M2Y2MWYwOTNiL3RhYmxlcmFuZ2U6N2RjOWRhODBlYmFlNDBkZDhhZWZkYzUzZjYxZjA5M2JfMy0xLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOjA4MjViZmYxYjkzYzQ4NjlhOGZkMjM0ODhiYTFmNjBjXzU_244dcd28-06f9-458b-88d6-46abf19e15d2">20</ix:nonFraction> %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i840ac8c485014ee99b6e1a87cfb8a764_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOjdkYzlkYTgwZWJhZTQwZGQ4YWVmZGM1M2Y2MWYwOTNiL3RhYmxlcmFuZ2U6N2RjOWRhODBlYmFlNDBkZDhhZWZkYzUzZjYxZjA5M2JfMy0zLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOjI1ZGYwNGZkM2Q2ZjRjM2U4NGUzODQ4MDE4ZWZjNjZjXzQ_d068a859-42f5-4f80-b22d-4c9c7216319f">17</ix:nonFraction> %</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3f33ea9ddf5f4c6990e93f50d03f03ef_D20230101-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOjdkYzlkYTgwZWJhZTQwZGQ4YWVmZGM1M2Y2MWYwOTNiL3RhYmxlcmFuZ2U6N2RjOWRhODBlYmFlNDBkZDhhZWZkYzUzZjYxZjA5M2JfNC0xLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOjUzNTdiMzU4N2JlODQ5Y2FhZWNhZDYxMDY1ZDVlMGIzXzQ_ef0ec5b6-2d9b-4efc-bb75-f6fc1be13a19">27</ix:nonFraction> %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia894e91feb4a4bdf8293a2c2963731ab_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOjdkYzlkYTgwZWJhZTQwZGQ4YWVmZGM1M2Y2MWYwOTNiL3RhYmxlcmFuZ2U6N2RjOWRhODBlYmFlNDBkZDhhZWZkYzUzZjYxZjA5M2JfNC0zLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOmViMTFjYjhjZjFmMjRjNGI5NWI1YTY1MTg0MDlmNGNkXzQ_a3121150-5383-451c-bc94-d1d896b34f5a">24</ix:nonFraction> %</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract-Manufactured Products</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icca73618ae684d5ea52e3060af4ad383_D20230101-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOjdkYzlkYTgwZWJhZTQwZGQ4YWVmZGM1M2Y2MWYwOTNiL3RhYmxlcmFuZ2U6N2RjOWRhODBlYmFlNDBkZDhhZWZkYzUzZjYxZjA5M2JfNS0xLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOmIzNmNiYWY0MDc0NTQ2ZjY4Nzc5MTg4MGY3NzllZTRlXzQ_72276000-acb7-4b6a-89eb-dd484bd1fbf3">19</ix:nonFraction> %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaceefe0fe985435aa372154902f65846_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOjdkYzlkYTgwZWJhZTQwZGQ4YWVmZGM1M2Y2MWYwOTNiL3RhYmxlcmFuZ2U6N2RjOWRhODBlYmFlNDBkZDhhZWZkYzUzZjYxZjA5M2JfNS0zLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOjY0MzU4NTcxNTdlNTQ0NDliYzBkYmNhMGUzMzI5NTBlXzQ_b85b68e4-65f8-4743-8180-abfc0a63f99b">16</ix:nonFraction> %</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i29c510f38fbe49baa6388a40c6f045d8_D20230101-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOjdkYzlkYTgwZWJhZTQwZGQ4YWVmZGM1M2Y2MWYwOTNiL3RhYmxlcmFuZ2U6N2RjOWRhODBlYmFlNDBkZDhhZWZkYzUzZjYxZjA5M2JfNi0xLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOmUyNTQyNjNjMThjODQ5MzQ4YTk3NWEwODViMjg3YmFjXzQ_30bf9a8b-7cd9-4e02-bf99-a5e912ef7b73">100</ix:nonFraction> %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i27022197520642e3882ce31d9285e029_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOjdkYzlkYTgwZWJhZTQwZGQ4YWVmZGM1M2Y2MWYwOTNiL3RhYmxlcmFuZ2U6N2RjOWRhODBlYmFlNDBkZDhhZWZkYzUzZjYxZjA5M2JfNi0zLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOjZmMzM0MWRmNGEzMTQ5NThiNjQzNzY4MmEyNjAyMDkxXzQ_2852b56a-d0ee-43af-93d6-6023e3760d08">100</ix:nonFraction> %</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="margin-bottom:1pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_7">Table of Contents</a></span></div></div><ix:continuation id="i5dd8024234554070bf4cf3f0f58409a4"><ix:continuation id="i06871940c31a41d29804010a95b15352"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the approximate percentage of our net sales by product category: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">High-Value Product Components</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie6cdab3f33c048088340a1a1ac085f71_D20230101-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOjZiODI5ZDc3MmFjYzQ4OGI5MTQ3ZDAwNDU0MTFjMTkyL3RhYmxlcmFuZ2U6NmI4MjlkNzcyYWNjNDg4YjkxNDdkMDA0NTQxMWMxOTJfMi0xLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOjhhYjBmNTA5ZTE1NTRmNjg5ZDY2OTUyYzhkOGE3NGZkXzQ_c30cbe30-5f97-41c7-81f1-18ea6632b8ba">51</ix:nonFraction> %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0bcd5713f126432fa7b95d333a6687ed_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOjZiODI5ZDc3MmFjYzQ4OGI5MTQ3ZDAwNDU0MTFjMTkyL3RhYmxlcmFuZ2U6NmI4MjlkNzcyYWNjNDg4YjkxNDdkMDA0NTQxMWMxOTJfMi0zLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOjlkODA1YTA0OTIyNjRiZWI5ZDM5Y2E0NzAyOGVmZGE1XzQ_a6cf27a5-a754-41ec-8366-8b0a1d34e33e">56</ix:nonFraction> %</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">High-Value Product Delivery Devices</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4ee7ca1522924116844090df73a38cfc_D20230101-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOjZiODI5ZDc3MmFjYzQ4OGI5MTQ3ZDAwNDU0MTFjMTkyL3RhYmxlcmFuZ2U6NmI4MjlkNzcyYWNjNDg4YjkxNDdkMDA0NTQxMWMxOTJfMy0xLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOjZlNzdhMDI2Zjk1ZDRiODRiZGMyOWQ5MjNkZjQ2OTRhXzQ_eb9ce2b3-815f-4a87-8be1-bb1e3fcd63a2">7</ix:nonFraction> %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ieb109b3e8b854eef8e2690d97b4deb83_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOjZiODI5ZDc3MmFjYzQ4OGI5MTQ3ZDAwNDU0MTFjMTkyL3RhYmxlcmFuZ2U6NmI4MjlkNzcyYWNjNDg4YjkxNDdkMDA0NTQxMWMxOTJfMy0zLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOmZlYWEwZmI2YjhmZTQ4YWViMTlhNzYzN2ViYTJmZWJlXzQ_0f8151fc-e4f5-402f-847c-a8286a37c9b2">5</ix:nonFraction> %</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Standard Packaging</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8964ed8d404e4ecd8cf51bf7dd57fd72_D20230101-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOjZiODI5ZDc3MmFjYzQ4OGI5MTQ3ZDAwNDU0MTFjMTkyL3RhYmxlcmFuZ2U6NmI4MjlkNzcyYWNjNDg4YjkxNDdkMDA0NTQxMWMxOTJfNC0xLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOjdkYWM3NzgxYzdlZjQ2NGE5MWZiYzQyYWI0MWI3ZTZiXzQ_7f61b70e-a97d-4178-a0fc-f202b2f23b13">23</ix:nonFraction> %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id4878ca4f0234438bbe2231c100da361_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOjZiODI5ZDc3MmFjYzQ4OGI5MTQ3ZDAwNDU0MTFjMTkyL3RhYmxlcmFuZ2U6NmI4MjlkNzcyYWNjNDg4YjkxNDdkMDA0NTQxMWMxOTJfNC0zLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOmMwMzY3MzEyNzlmYjQyN2VhNTZjOTUzYWFiYTJjY2IyXzQ_cb868169-c03a-4455-8464-63b2b2b3b424">23</ix:nonFraction> %</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract-Manufactured Products</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i69658dd90db2466aab6d25979a565ec5_D20230101-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOjZiODI5ZDc3MmFjYzQ4OGI5MTQ3ZDAwNDU0MTFjMTkyL3RhYmxlcmFuZ2U6NmI4MjlkNzcyYWNjNDg4YjkxNDdkMDA0NTQxMWMxOTJfNS0xLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOjU0MWQ3OTZiNTk1ZDQ5ZGFhNjQzZmM5MThlM2QwNjBiXzQ_b10312fa-bf11-42c9-abd5-3091fced2182">19</ix:nonFraction> %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1a7534f872714dc0b6f41e800f834626_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOjZiODI5ZDc3MmFjYzQ4OGI5MTQ3ZDAwNDU0MTFjMTkyL3RhYmxlcmFuZ2U6NmI4MjlkNzcyYWNjNDg4YjkxNDdkMDA0NTQxMWMxOTJfNS0zLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOmZkNmJmMDA0Y2U3OTRiZGJiZjJjYmRiMDEwZWQyNTA3XzQ_fb3e9c21-8403-4fc2-8661-dbed7d7feedc">16</ix:nonFraction> %</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ieabcd647a4f94d14b6c41f5ed82c736e_D20230101-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOjZiODI5ZDc3MmFjYzQ4OGI5MTQ3ZDAwNDU0MTFjMTkyL3RhYmxlcmFuZ2U6NmI4MjlkNzcyYWNjNDg4YjkxNDdkMDA0NTQxMWMxOTJfNi0xLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOjEzNzAwOTAzYzI1ZTRhM2RhNDNjZjYyNDJkMGNiNDA0XzQ_70bed6df-4cd4-4bb0-904a-1d40706b22e6">100</ix:nonFraction> %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0bb4cbfdac1443989f5d65abc02019aa_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOjZiODI5ZDc3MmFjYzQ4OGI5MTQ3ZDAwNDU0MTFjMTkyL3RhYmxlcmFuZ2U6NmI4MjlkNzcyYWNjNDg4YjkxNDdkMDA0NTQxMWMxOTJfNi0zLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOjFlNDhhNzEyNDZiMjQyOTA5MzQ4MmZkZmUxODBmZjc1XzQ_2362cd6a-b27b-4111-818b-ab4036d667a2">100</ix:nonFraction> %</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:1pt"><span><br/></span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the approximate percentage of our net sales by geographic location: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Americas</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i705daa289597485c80cbe6c2a4295b55_D20230101-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOjc5ZjMwZTU2NjRhMTRhYjRiZTEyNTA0NjYyZjFlM2VjL3RhYmxlcmFuZ2U6NzlmMzBlNTY2NGExNGFiNGJlMTI1MDQ2NjJmMWUzZWNfMi0xLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOjUwNDgxODI0YjUyMTRkZTJhMTE5MjNlOWE4MTkwZTIwXzQ_55053622-152a-4301-9d76-8d708c96adb0">44</ix:nonFraction> %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6f08de799c8b4bcf84f0b2388b9a1d63_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOjc5ZjMwZTU2NjRhMTRhYjRiZTEyNTA0NjYyZjFlM2VjL3RhYmxlcmFuZ2U6NzlmMzBlNTY2NGExNGFiNGJlMTI1MDQ2NjJmMWUzZWNfMi0zLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOjQ5OWYzMzExMTVhNDQ5YTZhZWE4ODcxNTg3OTgzN2VmXzQ_354d5cb8-a32d-4c5b-a01f-62ed7876d3e0">45</ix:nonFraction> %</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe, Middle East, Africa</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i72821269558f4965b1f01873aa17427e_D20230101-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOjc5ZjMwZTU2NjRhMTRhYjRiZTEyNTA0NjYyZjFlM2VjL3RhYmxlcmFuZ2U6NzlmMzBlNTY2NGExNGFiNGJlMTI1MDQ2NjJmMWUzZWNfMy0xLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOjYwYzVmYTE0NzU5NzQwNThiZDI1ZTI1OTc5OTQxYTMyXzQ_48c865e2-b61a-4b0c-a293-13339b7fadea">47</ix:nonFraction> %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i068419f0506343b79f1391a7f0d6cc2e_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOjc5ZjMwZTU2NjRhMTRhYjRiZTEyNTA0NjYyZjFlM2VjL3RhYmxlcmFuZ2U6NzlmMzBlNTY2NGExNGFiNGJlMTI1MDQ2NjJmMWUzZWNfMy0zLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOjhlMmExZDUzOGIyYTQ3YWQ4OTQxMGRkMjBhZDc2NjgzXzQ_24d41ead-f0a5-4591-974a-9830be509d07">45</ix:nonFraction> %</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9f79e1cf75c043448cd2aa1afd887c55_D20230101-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOjc5ZjMwZTU2NjRhMTRhYjRiZTEyNTA0NjYyZjFlM2VjL3RhYmxlcmFuZ2U6NzlmMzBlNTY2NGExNGFiNGJlMTI1MDQ2NjJmMWUzZWNfNC0xLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOjc4MTBmZGZlZTIzZTRlYjY4MjUxMjBhMjY4Y2I1ZmFlXzQ_ed0fde5f-7b7a-4d59-9d8b-1ff0714e5be6">9</ix:nonFraction> %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4cfb274b8db44a3e9f441e5bf17fc3ef_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOjc5ZjMwZTU2NjRhMTRhYjRiZTEyNTA0NjYyZjFlM2VjL3RhYmxlcmFuZ2U6NzlmMzBlNTY2NGExNGFiNGJlMTI1MDQ2NjJmMWUzZWNfNC0zLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOmZhZmRjN2UyNjcyYTQ5YjRiNzdlYmM1NWY2M2JiN2ZmXzQ_7026d486-362d-4663-81fa-994bb5505864">10</ix:nonFraction> %</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1fc7305b8607421d8a06a356da5a15ed_D20230101-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOjc5ZjMwZTU2NjRhMTRhYjRiZTEyNTA0NjYyZjFlM2VjL3RhYmxlcmFuZ2U6NzlmMzBlNTY2NGExNGFiNGJlMTI1MDQ2NjJmMWUzZWNfNS0xLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOmZiZTU4MWViYzMzZTQzYTU5Y2QyYWFhNjc4YmU2ODFhXzQ_c5fd4e2b-9f22-47fe-95c1-82945544a4d4">100</ix:nonFraction> %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib884bebbba5c4e049f608852aff2075d_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOjc5ZjMwZTU2NjRhMTRhYjRiZTEyNTA0NjYyZjFlM2VjL3RhYmxlcmFuZ2U6NzlmMzBlNTY2NGExNGFiNGJlMTI1MDQ2NjJmMWUzZWNfNS0zLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOjZkNDlkNTEwY2QzODQ1OGI5YzdiNjFiMjdlYmQ1MTYyXzQ_10262dda-2786-4fdc-b17c-2dbde172cb4b">100</ix:nonFraction> %</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><div style="margin-bottom:1pt"><span><br/></span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Assets and Liabilities</span></div><div style="margin-bottom:1pt"><span><br/></span></div><div style="margin-bottom:1pt"><ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RleHRyZWdpb246MGQyN2ViN2QyYTg3NDczOWJhYzU3MmY2ZDJhMjVkZDhfMjA1OA_80754310-666a-4983-a0c6-ec4d0bdab5f7" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our contract assets and liabilities, excluding amounts included in accounts receivable, net:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets, December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOmZkMWM2ZWJiY2VhYTRmODJhZGYxYzkyMDQxNjQ5M2RlL3RhYmxlcmFuZ2U6ZmQxYzZlYmJjZWFhNGY4MmFkZjFjOTIwNDE2NDkzZGVfMS0xLTEtMS04Mjc4Mg_5a2acee7-80c3-4521-9675-75f5a19f4c2b">16.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets, March&#160;31, 2023</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOmZkMWM2ZWJiY2VhYTRmODJhZGYxYzkyMDQxNjQ5M2RlL3RhYmxlcmFuZ2U6ZmQxYzZlYmJjZWFhNGY4MmFkZjFjOTIwNDE2NDkzZGVfMi0xLTEtMS04Mjc4Mg_cf8f2b94-5f05-4c63-a472-6ff5824e3969">19.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in contract assets - increase (decrease)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="wst:ContractWithCustomerAssetIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOmZkMWM2ZWJiY2VhYTRmODJhZGYxYzkyMDQxNjQ5M2RlL3RhYmxlcmFuZ2U6ZmQxYzZlYmJjZWFhNGY4MmFkZjFjOTIwNDE2NDkzZGVfMy0xLTEtMS04Mjc4Mg_8083e52b-90db-4bf5-b197-570ca9e10af8">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income, December 31, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOmZkMWM2ZWJiY2VhYTRmODJhZGYxYzkyMDQxNjQ5M2RlL3RhYmxlcmFuZ2U6ZmQxYzZlYmJjZWFhNGY4MmFkZjFjOTIwNDE2NDkzZGVfNS0xLTEtMS04Mjc4Mg_c94bf854-917d-4764-af25-9d346a2e6e9c">68.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income, March&#160;31, 2023</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOmZkMWM2ZWJiY2VhYTRmODJhZGYxYzkyMDQxNjQ5M2RlL3RhYmxlcmFuZ2U6ZmQxYzZlYmJjZWFhNGY4MmFkZjFjOTIwNDE2NDkzZGVfNi0xLTEtMS04Mjc4Mg_6a5dd5c9-d1fb-4964-bbb2-ea265965e2e7">57.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in deferred income - decrease (increase)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOmZkMWM2ZWJiY2VhYTRmODJhZGYxYzkyMDQxNjQ5M2RlL3RhYmxlcmFuZ2U6ZmQxYzZlYmJjZWFhNGY4MmFkZjFjOTIwNDE2NDkzZGVfNy0xLTEtMS04Mjc4Mg_6e27c77b-1111-4b56-b547-26c6a5a06105">10.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:1pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contract assets are included within other current assets and deferred income is included within other current liabilities and other long-term liabilities. During the three months ended March&#160;31, 2023, $<ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RleHRyZWdpb246MGQyN2ViN2QyYTg3NDczOWJhYzU3MmY2ZDJhMjVkZDhfMTI0MA_c0999151-af24-497c-98d3-b853c75fb10d">21.3</ix:nonFraction>&#160;million of revenue was recognized that was included in deferred income at the beginning of the year.</span></div><div style="margin-bottom:1pt"><span><br/></span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the performance obligations within our contracts are satisfied within one year or less. Performance obligations satisfied beyond one year include those relating to a nonrefundable customer payment of $<ix:nonFraction unitRef="usd" contextRef="i73b55d82d73748a38f69bd594560eb79_I20130630" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RleHRyZWdpb246MGQyN2ViN2QyYTg3NDczOWJhYzU3MmY2ZDJhMjVkZDhfMTU1Mw_6d9462d2-d816-4520-b2f0-0a233ca5c03a">20.0</ix:nonFraction> million received in June 2013 in return for the exclusive use of the SmartDose</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology platform within a specific therapeutic area. As of March&#160;31, 2023, there was $<ix:nonFraction unitRef="usd" contextRef="i3f009365e828466d98af8bbc2bce4411_I20230331" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RleHRyZWdpb246MGQyN2ViN2QyYTg3NDczOWJhYzU3MmY2ZDJhMjVkZDhfMTY5Nw_934277bc-440f-46db-b86b-6f0fe519aef1">2.8</ix:nonFraction> million of deferred income related to this payment, of which $<ix:nonFraction unitRef="usd" contextRef="i3f009365e828466d98af8bbc2bce4411_I20230331" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RleHRyZWdpb246MGQyN2ViN2QyYTg3NDczOWJhYzU3MmY2ZDJhMjVkZDhfMTc1Mw_49760ebc-487e-4cca-b72c-e9acbb519fee">0.9</ix:nonFraction> million was included in other current liabilities and $<ix:nonFraction unitRef="usd" contextRef="i3f009365e828466d98af8bbc2bce4411_I20230331" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RleHRyZWdpb246MGQyN2ViN2QyYTg3NDczOWJhYzU3MmY2ZDJhMjVkZDhfMTgwMg_a647d14d-b0b9-4b0d-9e24-cb77dbbeb438">1.9</ix:nonFraction> million was included in other long-term liabilities. The deferred income is being recognized as income on a straight-line basis over the remaining term of the agreement. The agreement does not include a future minimum purchase commitment from the customer.</span></div></ix:continuation><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i7bf87d07bb544f48851c48374130181b_43"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4:&#160;&#160;<ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80My9mcmFnOjk1NGE1OTkxNWE0MDRiMjk5MTAzMDU1OWQ1NmM0YTY5L3RleHRyZWdpb246OTU0YTU5OTE1YTQwNGIyOTkxMDMwNTU5ZDU2YzRhNjlfMTAyNQ_60d4ea1c-cc8f-4a59-9790-5a0e0d3ce4fb" continuedAt="idd4b28ddae2f46d5b47f7d97bbbd0760" escape="true">Net Income Per Share</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="idd4b28ddae2f46d5b47f7d97bbbd0760"><ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80My9mcmFnOjk1NGE1OTkxNWE0MDRiMjk5MTAzMDU1OWQ1NmM0YTY5L3RleHRyZWdpb246OTU0YTU5OTE1YTQwNGIyOTkxMDMwNTU5ZDU2YzRhNjlfMTAyMg_10e8d1ff-57e9-495f-ae8a-0047fcf604e1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the shares used in the calculation of basic net income per share to those used for diluted net income per share:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80My9mcmFnOjk1NGE1OTkxNWE0MDRiMjk5MTAzMDU1OWQ1NmM0YTY5L3RhYmxlOmQwOWFhNjlmOGQ5NTRmMmJhYzlhNjVkOTY0NTZkZTAzL3RhYmxlcmFuZ2U6ZDA5YWE2OWY4ZDk1NGYyYmFjOWE2NWQ5NjQ1NmRlMDNfMi0xLTEtMS04Mjc4Mg_e7734aa1-7406-4930-9ee6-6fa9ed50bfcb">140.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80My9mcmFnOjk1NGE1OTkxNWE0MDRiMjk5MTAzMDU1OWQ1NmM0YTY5L3RhYmxlOmQwOWFhNjlmOGQ5NTRmMmJhYzlhNjVkOTY0NTZkZTAzL3RhYmxlcmFuZ2U6ZDA5YWE2OWY4ZDk1NGYyYmFjOWE2NWQ5NjQ1NmRlMDNfMi0zLTEtMS04Mjc4Mg_2fb94b74-1923-4f9f-ba4c-aa0aefbc373c">173.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80My9mcmFnOjk1NGE1OTkxNWE0MDRiMjk5MTAzMDU1OWQ1NmM0YTY5L3RhYmxlOmQwOWFhNjlmOGQ5NTRmMmJhYzlhNjVkOTY0NTZkZTAzL3RhYmxlcmFuZ2U6ZDA5YWE2OWY4ZDk1NGYyYmFjOWE2NWQ5NjQ1NmRlMDNfMy0xLTEtMS04Mjc4Mg_9f7ee68f-7d29-478e-a939-da05c8bf629a">74.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80My9mcmFnOjk1NGE1OTkxNWE0MDRiMjk5MTAzMDU1OWQ1NmM0YTY5L3RhYmxlOmQwOWFhNjlmOGQ5NTRmMmJhYzlhNjVkOTY0NTZkZTAzL3RhYmxlcmFuZ2U6ZDA5YWE2OWY4ZDk1NGYyYmFjOWE2NWQ5NjQ1NmRlMDNfMy0zLTEtMS04Mjc4Mg_6fe1730f-f86f-4b9c-ad42-955edabefe5a">74.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of equity awards, based on the treasury stock method</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80My9mcmFnOjk1NGE1OTkxNWE0MDRiMjk5MTAzMDU1OWQ1NmM0YTY5L3RhYmxlOmQwOWFhNjlmOGQ5NTRmMmJhYzlhNjVkOTY0NTZkZTAzL3RhYmxlcmFuZ2U6ZDA5YWE2OWY4ZDk1NGYyYmFjOWE2NWQ5NjQ1NmRlMDNfNC0xLTEtMS04Mjc4Mg_d271a299-6946-4106-af8b-1671d4db0796">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80My9mcmFnOjk1NGE1OTkxNWE0MDRiMjk5MTAzMDU1OWQ1NmM0YTY5L3RhYmxlOmQwOWFhNjlmOGQ5NTRmMmJhYzlhNjVkOTY0NTZkZTAzL3RhYmxlcmFuZ2U6ZDA5YWE2OWY4ZDk1NGYyYmFjOWE2NWQ5NjQ1NmRlMDNfNC0zLTEtMS04Mjc4Mg_1c24dea5-b17e-4d09-8ab7-a938ff0f3820">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares assuming dilution</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80My9mcmFnOjk1NGE1OTkxNWE0MDRiMjk5MTAzMDU1OWQ1NmM0YTY5L3RhYmxlOmQwOWFhNjlmOGQ5NTRmMmJhYzlhNjVkOTY0NTZkZTAzL3RhYmxlcmFuZ2U6ZDA5YWE2OWY4ZDk1NGYyYmFjOWE2NWQ5NjQ1NmRlMDNfNS0xLTEtMS04Mjc4Mg_4da8eef9-f175-455c-a633-cd4da7813a2a">75.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80My9mcmFnOjk1NGE1OTkxNWE0MDRiMjk5MTAzMDU1OWQ1NmM0YTY5L3RhYmxlOmQwOWFhNjlmOGQ5NTRmMmJhYzlhNjVkOTY0NTZkZTAzL3RhYmxlcmFuZ2U6ZDA5YWE2OWY4ZDk1NGYyYmFjOWE2NWQ5NjQ1NmRlMDNfNS0zLTEtMS04Mjc4Mg_1a9e3d22-a290-4833-8b9a-f53927e30467">76.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023 and 2022, there were <ix:nonFraction unitRef="shares" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80My9mcmFnOjk1NGE1OTkxNWE0MDRiMjk5MTAzMDU1OWQ1NmM0YTY5L3RleHRyZWdpb246OTU0YTU5OTE1YTQwNGIyOTkxMDMwNTU5ZDU2YzRhNjlfMjE5_175cefcf-167e-4612-aeaa-8abbb4bbb6e1">0.3</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80My9mcmFnOjk1NGE1OTkxNWE0MDRiMjk5MTAzMDU1OWQ1NmM0YTY5L3RleHRyZWdpb246OTU0YTU5OTE1YTQwNGIyOTkxMDMwNTU5ZDU2YzRhNjlfMjI2_f6b58491-1e40-4ccc-b5e3-64825b302ed5">0.0 million</ix:nonFraction> shares, respectively, from stock-based compensation plans not included in the computation of diluted net income per share because their impact was antidilutive. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, the Board of Directors approved a share repurchase program under which we may repurchase up to $<ix:nonFraction unitRef="usd" contextRef="i866c5a8fb2f748d0b77d31bceb45da81_I20230228" decimals="-8" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80My9mcmFnOjk1NGE1OTkxNWE0MDRiMjk5MTAzMDU1OWQ1NmM0YTY5L3RleHRyZWdpb246OTU0YTU5OTE1YTQwNGIyOTkxMDMwNTU5ZDU2YzRhNjlfNTQ5NzU1ODE2Njc3_b42f4ee4-79df-4afc-b735-f88a57b098c7">1.0</ix:nonFraction>&#160;billion in shares of common stock. The share repurchase program does not have an expiration date under which we may repurchase common stock on the open market or in privately-negotiated transactions. The number of shares to be repurchased and the timing of such transactions will depend on a variety of factors, including market conditions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, we purchased <ix:nonFraction unitRef="shares" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="INF" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80My9mcmFnOjk1NGE1OTkxNWE0MDRiMjk5MTAzMDU1OWQ1NmM0YTY5L3RleHRyZWdpb246OTU0YTU5OTE1YTQwNGIyOTkxMDMwNTU5ZDU2YzRhNjlfOTE4_091eaf0b-b54d-4347-b6c6-f8151b47eb07">183,360</ix:nonFraction> shares of our common stock under the program at a cost of $<ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80My9mcmFnOjk1NGE1OTkxNWE0MDRiMjk5MTAzMDU1OWQ1NmM0YTY5L3RleHRyZWdpb246OTU0YTU5OTE1YTQwNGIyOTkxMDMwNTU5ZDU2YzRhNjlfOTc5_89fedffe-7019-4bdb-a3a6-229b8474889b">60.1</ix:nonFraction> million, or an average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80My9mcmFnOjk1NGE1OTkxNWE0MDRiMjk5MTAzMDU1OWQ1NmM0YTY5L3RleHRyZWdpb246OTU0YTU5OTE1YTQwNGIyOTkxMDMwNTU5ZDU2YzRhNjlfMTAwNg_d7d69ea2-7afb-4693-90b3-f97c57e4e4f6">327.90</ix:nonFraction> per share. During the three months ended March 31, 2022, we purchased <ix:nonFraction unitRef="shares" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="INF" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80My9mcmFnOjk1NGE1OTkxNWE0MDRiMjk5MTAzMDU1OWQ1NmM0YTY5L3RleHRyZWdpb246OTU0YTU5OTE1YTQwNGIyOTkxMDMwNTU5ZDU2YzRhNjlfODI0NjMzNzIxMTM2Ng_2143b40a-8763-4f0b-9742-4f2bad80ad27">390,000</ix:nonFraction> shares of our common stock under the program at a cost of $<ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80My9mcmFnOjk1NGE1OTkxNWE0MDRiMjk5MTAzMDU1OWQ1NmM0YTY5L3RleHRyZWdpb246OTU0YTU5OTE1YTQwNGIyOTkxMDMwNTU5ZDU2YzRhNjlfODI0NjMzNzIxMTM5MA_45572047-82a8-43b7-88cf-72096d690a6a">147.1</ix:nonFraction>&#160;million, or an average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80My9mcmFnOjk1NGE1OTkxNWE0MDRiMjk5MTAzMDU1OWQ1NmM0YTY5L3RleHRyZWdpb246OTU0YTU5OTE1YTQwNGIyOTkxMDMwNTU5ZDU2YzRhNjlfODI0NjMzNzIxMTQxNA_fdf40cab-7736-4c06-b4ac-8673d6207a43">377.23</ix:nonFraction> per share.</span></div></ix:continuation><div><span><br/></span></div><div id="i7bf87d07bb544f48851c48374130181b_46"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5:&#160;&#160;<ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80Ni9mcmFnOjVjN2IyYWIzOGE0NTQ1ZGRiMDcyOGVmZTdlNzM5ZDQ2L3RleHRyZWdpb246NWM3YjJhYjM4YTQ1NDVkZGIwNzI4ZWZlN2U3MzlkNDZfMTc4_0d1e1707-416d-4417-bc52-72cb9ad4e096" continuedAt="i43fa897aa1ea4a799d5f852cb69d27ec" escape="true">Inventories</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i43fa897aa1ea4a799d5f852cb69d27ec"><ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80Ni9mcmFnOjVjN2IyYWIzOGE0NTQ1ZGRiMDcyOGVmZTdlNzM5ZDQ2L3RleHRyZWdpb246NWM3YjJhYjM4YTQ1NDVkZGIwNzI4ZWZlN2U3MzlkNDZfMTgx_29df51c5-5350-427f-be25-78f9986d26ff" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are valued at the lower of cost (on a first-in, first-out basis) and net realizable value. Inventory balances were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.611%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.933%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80Ni9mcmFnOjVjN2IyYWIzOGE0NTQ1ZGRiMDcyOGVmZTdlNzM5ZDQ2L3RhYmxlOmQ3MmQxYWJlNDk0MjQ2NDliZjk4YzBiZDMyZTI0MTdlL3RhYmxlcmFuZ2U6ZDcyZDFhYmU0OTQyNDY0OWJmOThjMGJkMzJlMjQxN2VfMS0xLTEtMS04Mjc4Mg_4ba26184-7a9e-4e6d-bc5e-40a16b55d233">181.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80Ni9mcmFnOjVjN2IyYWIzOGE0NTQ1ZGRiMDcyOGVmZTdlNzM5ZDQ2L3RhYmxlOmQ3MmQxYWJlNDk0MjQ2NDliZjk4YzBiZDMyZTI0MTdlL3RhYmxlcmFuZ2U6ZDcyZDFhYmU0OTQyNDY0OWJmOThjMGJkMzJlMjQxN2VfMS0zLTEtMS04Mjc4Mg_7ac4b16d-522a-4368-b9ea-7b0c02d93d84">170.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80Ni9mcmFnOjVjN2IyYWIzOGE0NTQ1ZGRiMDcyOGVmZTdlNzM5ZDQ2L3RhYmxlOmQ3MmQxYWJlNDk0MjQ2NDliZjk4YzBiZDMyZTI0MTdlL3RhYmxlcmFuZ2U6ZDcyZDFhYmU0OTQyNDY0OWJmOThjMGJkMzJlMjQxN2VfMi0xLTEtMS04Mjc4Mg_40f814aa-1713-443f-be39-949ffb53266c">95.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80Ni9mcmFnOjVjN2IyYWIzOGE0NTQ1ZGRiMDcyOGVmZTdlNzM5ZDQ2L3RhYmxlOmQ3MmQxYWJlNDk0MjQ2NDliZjk4YzBiZDMyZTI0MTdlL3RhYmxlcmFuZ2U6ZDcyZDFhYmU0OTQyNDY0OWJmOThjMGJkMzJlMjQxN2VfMi0zLTEtMS04Mjc4Mg_220a45c6-0364-4f35-822d-84b2db00fd3b">79.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80Ni9mcmFnOjVjN2IyYWIzOGE0NTQ1ZGRiMDcyOGVmZTdlNzM5ZDQ2L3RhYmxlOmQ3MmQxYWJlNDk0MjQ2NDliZjk4YzBiZDMyZTI0MTdlL3RhYmxlcmFuZ2U6ZDcyZDFhYmU0OTQyNDY0OWJmOThjMGJkMzJlMjQxN2VfMy0xLTEtMS04Mjc4Mg_23708830-b55e-49ee-9b12-5c0db93561e5">170.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80Ni9mcmFnOjVjN2IyYWIzOGE0NTQ1ZGRiMDcyOGVmZTdlNzM5ZDQ2L3RhYmxlOmQ3MmQxYWJlNDk0MjQ2NDliZjk4YzBiZDMyZTI0MTdlL3RhYmxlcmFuZ2U6ZDcyZDFhYmU0OTQyNDY0OWJmOThjMGJkMzJlMjQxN2VfMy0zLTEtMS04Mjc4Mg_cd1a0b1c-4aab-44a7-9a3f-e80adac3e9b9">165.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80Ni9mcmFnOjVjN2IyYWIzOGE0NTQ1ZGRiMDcyOGVmZTdlNzM5ZDQ2L3RhYmxlOmQ3MmQxYWJlNDk0MjQ2NDliZjk4YzBiZDMyZTI0MTdlL3RhYmxlcmFuZ2U6ZDcyZDFhYmU0OTQyNDY0OWJmOThjMGJkMzJlMjQxN2VfNC0xLTEtMS04Mjc4Mg_092df6bc-d3b9-4461-a975-dcfa5b87889c">447.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80Ni9mcmFnOjVjN2IyYWIzOGE0NTQ1ZGRiMDcyOGVmZTdlNzM5ZDQ2L3RhYmxlOmQ3MmQxYWJlNDk0MjQ2NDliZjk4YzBiZDMyZTI0MTdlL3RhYmxlcmFuZ2U6ZDcyZDFhYmU0OTQyNDY0OWJmOThjMGJkMzJlMjQxN2VfNC0zLTEtMS04Mjc4Mg_bb72bd0c-8f4a-451f-b9d4-13e42e029935">414.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i7bf87d07bb544f48851c48374130181b_49"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6:&#160;&#160;<ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RleHRyZWdpb246Zjc4MTEwNTVkY2ExNDkxMGE1NTljZTNlM2ViMTE0YWJfMTIwOQ_5d3f9251-66aa-49e5-a6ec-8fa119a85070" continuedAt="i3d4eac74708f4a908ad41d4cbc19cd45" escape="true">Leases</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3d4eac74708f4a908ad41d4cbc19cd45" continuedAt="i285690649e5d4a55a53f1cf09362a97b">A lease exists when a contract conveys to the customer the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. The definition of a lease embodies two conditions: 1) there is an identified asset in the contract that is land or a depreciable asset (i.e., property, plant, and equipment); and 2) the customer has the right to control the use of the identified asset. Lease payments included in the measurement of the operating lease right-of-use assets and lease liabilities are comprised of fixed payments (including in-substance fixed payments), variable payments that depend on an index or rate, and the exercise price of a lessee option to purchase the underlying asset if the lessee is reasonably certain to exercise.</ix:continuation></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_7">Table of Contents</a></span></div></div><ix:continuation id="i285690649e5d4a55a53f1cf09362a97b"><div><ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RleHRyZWdpb246Zjc4MTEwNTVkY2ExNDkxMGE1NTljZTNlM2ViMTE0YWJfMTIwMQ_2e678fc4-2538-4c79-9744-68b7b1b0d0d8" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.451%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.805%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOjU2YjIwMTUyN2YzMTQ0ZmY4YTJiZjNkZTc1NzI1N2U2L3RhYmxlcmFuZ2U6NTZiMjAxNTI3ZjMxNDRmZjhhMmJmM2RlNzU3MjU3ZTZfMi0xLTEtMS04Mjc4Mg_d672fc3e-6abd-4142-950b-4b60fb7bc84b">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOjU2YjIwMTUyN2YzMTQ0ZmY4YTJiZjNkZTc1NzI1N2U2L3RhYmxlcmFuZ2U6NTZiMjAxNTI3ZjMxNDRmZjhhMmJmM2RlNzU3MjU3ZTZfMi0zLTEtMS04Mjc4Mg_2858cf21-f451-41ff-86c5-cf04b6bef0b3">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:ShortTermLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOjU2YjIwMTUyN2YzMTQ0ZmY4YTJiZjNkZTc1NzI1N2U2L3RhYmxlcmFuZ2U6NTZiMjAxNTI3ZjMxNDRmZjhhMmJmM2RlNzU3MjU3ZTZfMy0xLTEtMS04Mjc4Mg_9aaba31b-2151-4a82-9aa1-cd6d32be2cfa">1.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:ShortTermLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOjU2YjIwMTUyN2YzMTQ0ZmY4YTJiZjNkZTc1NzI1N2U2L3RhYmxlcmFuZ2U6NTZiMjAxNTI3ZjMxNDRmZjhhMmJmM2RlNzU3MjU3ZTZfMy0zLTEtMS04Mjc4Mg_10c096f6-969b-4b87-86c2-7f931b3ef443">0.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:VariableLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOjU2YjIwMTUyN2YzMTQ0ZmY4YTJiZjNkZTc1NzI1N2U2L3RhYmxlcmFuZ2U6NTZiMjAxNTI3ZjMxNDRmZjhhMmJmM2RlNzU3MjU3ZTZfNC0xLTEtMS04Mjc4Mg_3c57084c-0e0f-4f96-a8ea-9eadda20fe88">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:VariableLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOjU2YjIwMTUyN2YzMTQ0ZmY4YTJiZjNkZTc1NzI1N2U2L3RhYmxlcmFuZ2U6NTZiMjAxNTI3ZjMxNDRmZjhhMmJmM2RlNzU3MjU3ZTZfNC0zLTEtMS04Mjc4Mg_dfe632ce-5a21-4b3e-83a5-021cfd0efeb9">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOjU2YjIwMTUyN2YzMTQ0ZmY4YTJiZjNkZTc1NzI1N2U2L3RhYmxlcmFuZ2U6NTZiMjAxNTI3ZjMxNDRmZjhhMmJmM2RlNzU3MjU3ZTZfNS0xLTEtMS04Mjc4Mg_a2357a9c-60de-4d27-8fee-b3dfbdf55c02">8.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOjU2YjIwMTUyN2YzMTQ0ZmY4YTJiZjNkZTc1NzI1N2U2L3RhYmxlcmFuZ2U6NTZiMjAxNTI3ZjMxNDRmZjhhMmJmM2RlNzU3MjU3ZTZfNS0zLTEtMS04Mjc4Mg_a63b7a36-5531-4f97-a316-9e0f5c9c1035">5.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div><ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="wst:LesseeLeaseCashFlowAndSupplementalInformationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RleHRyZWdpb246Zjc4MTEwNTVkY2ExNDkxMGE1NTljZTNlM2ViMTE0YWJfMTIwNg_995a3aeb-d4be-4cf2-a542-709b8f1beb3f" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.451%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.805%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOjc1Y2I0YWYwY2IwZDQ4Y2ViYWM5YjVlZDIwNTNkMzJlL3RhYmxlcmFuZ2U6NzVjYjRhZjBjYjBkNDhjZWJhYzliNWVkMjA1M2QzMmVfMy0xLTEtMS04Mjc4Mg_2c955383-c410-4c57-b4cd-5d788427ee81">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOjc1Y2I0YWYwY2IwZDQ4Y2ViYWM5YjVlZDIwNTNkMzJlL3RhYmxlcmFuZ2U6NzVjYjRhZjBjYjBkNDhjZWJhYzliNWVkMjA1M2QzMmVfMy00LTEtMS04Mjc4Mg_162a6d0b-42e7-438d-8ea3-d11f8ba97758">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOjc1Y2I0YWYwY2IwZDQ4Y2ViYWM5YjVlZDIwNTNkMzJlL3RhYmxlcmFuZ2U6NzVjYjRhZjBjYjBkNDhjZWJhYzliNWVkMjA1M2QzMmVfNC0xLTEtMS04Mjc4Mg_ecc3dcab-78ec-4481-8f46-708957665448">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOjc1Y2I0YWYwY2IwZDQ4Y2ViYWM5YjVlZDIwNTNkMzJlL3RhYmxlcmFuZ2U6NzVjYjRhZjBjYjBkNDhjZWJhYzliNWVkMjA1M2QzMmVfNC00LTEtMS04Mjc4Mg_fd094f7d-27db-435d-adc2-3485b9d5ad0a">9.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023 and December&#160;31, 2022, the weighted average remaining lease term for operating leases was <ix:nonNumeric contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RleHRyZWdpb246Zjc4MTEwNTVkY2ExNDkxMGE1NTljZTNlM2ViMTE0YWJfMTAxOA_2f52e38a-3fc6-4aee-aa1b-61d62e405e0c">9.3</ix:nonNumeric> years and <ix:nonNumeric contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RleHRyZWdpb246Zjc4MTEwNTVkY2ExNDkxMGE1NTljZTNlM2ViMTE0YWJfMTAzMQ_8792dbe1-f6af-4810-8565-054645a38623">9.3</ix:nonNumeric> years, respectively. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023 and December&#160;31, 2022, the weighted average discount rate was <ix:nonFraction unitRef="number" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RleHRyZWdpb246Zjc4MTEwNTVkY2ExNDkxMGE1NTljZTNlM2ViMTE0YWJfMTExMw_596ff66c-5d30-4688-b69d-283087d275e3">3.26</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RleHRyZWdpb246Zjc4MTEwNTVkY2ExNDkxMGE1NTljZTNlM2ViMTE0YWJfMTEyMA_c4990424-0182-46d1-be3f-0e8547633366">3.25</ix:nonFraction>%, respectively.</span></div><div><span><br/></span></div><div><ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RleHRyZWdpb246Zjc4MTEwNTVkY2ExNDkxMGE1NTljZTNlM2ViMTE0YWJfMTIwOA_36aa585e-9ff9-4e09-8ef2-0d805b540066" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of operating lease liabilities were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (remaining period as of)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOmY3M2MxNTVkMmUyMzQzODg5NjE1OWEzYTA3NzMzN2M4L3RhYmxlcmFuZ2U6ZjczYzE1NWQyZTIzNDM4ODk2MTU5YTNhMDc3MzM3YzhfMi0xLTEtMS04Mjc4Mg_5fd59460-c7ee-4b06-b4bf-d0ad36e800e9">14.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOmY3M2MxNTVkMmUyMzQzODg5NjE1OWEzYTA3NzMzN2M4L3RhYmxlcmFuZ2U6ZjczYzE1NWQyZTIzNDM4ODk2MTU5YTNhMDc3MzM3YzhfMi0zLTEtMS04Mjc4Mg_9c515415-632d-448d-95a5-23982e499f35">19.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOmY3M2MxNTVkMmUyMzQzODg5NjE1OWEzYTA3NzMzN2M4L3RhYmxlcmFuZ2U6ZjczYzE1NWQyZTIzNDM4ODk2MTU5YTNhMDc3MzM3YzhfMy0xLTEtMS04Mjc4Mg_267bfa25-774f-4cff-b346-264058f482bc">18.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOmY3M2MxNTVkMmUyMzQzODg5NjE1OWEzYTA3NzMzN2M4L3RhYmxlcmFuZ2U6ZjczYzE1NWQyZTIzNDM4ODk2MTU5YTNhMDc3MzM3YzhfMy0zLTEtMS04Mjc4Mg_fe33f318-ba00-4a26-b7b6-970a6777d81b">18.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOmY3M2MxNTVkMmUyMzQzODg5NjE1OWEzYTA3NzMzN2M4L3RhYmxlcmFuZ2U6ZjczYzE1NWQyZTIzNDM4ODk2MTU5YTNhMDc3MzM3YzhfNC0xLTEtMS04Mjc4Mg_b1feb8de-18d5-479c-9208-b2b0419c50d9">16.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOmY3M2MxNTVkMmUyMzQzODg5NjE1OWEzYTA3NzMzN2M4L3RhYmxlcmFuZ2U6ZjczYzE1NWQyZTIzNDM4ODk2MTU5YTNhMDc3MzM3YzhfNC0zLTEtMS04Mjc4Mg_059b3916-e1af-4308-9778-45157f92041c">16.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOmY3M2MxNTVkMmUyMzQzODg5NjE1OWEzYTA3NzMzN2M4L3RhYmxlcmFuZ2U6ZjczYzE1NWQyZTIzNDM4ODk2MTU5YTNhMDc3MzM3YzhfNS0xLTEtMS04Mjc4Mg_4989fdd2-0198-44f2-b1ce-2cec944ce201">13.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOmY3M2MxNTVkMmUyMzQzODg5NjE1OWEzYTA3NzMzN2M4L3RhYmxlcmFuZ2U6ZjczYzE1NWQyZTIzNDM4ODk2MTU5YTNhMDc3MzM3YzhfNS0zLTEtMS04Mjc4Mg_55f57f52-26e7-44e3-a7b9-8e742bd44c8f">13.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOmY3M2MxNTVkMmUyMzQzODg5NjE1OWEzYTA3NzMzN2M4L3RhYmxlcmFuZ2U6ZjczYzE1NWQyZTIzNDM4ODk2MTU5YTNhMDc3MzM3YzhfNi0xLTEtMS04Mjc4Mg_c907ab5b-f8f8-436a-a33c-8b099977c30f">9.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOmY3M2MxNTVkMmUyMzQzODg5NjE1OWEzYTA3NzMzN2M4L3RhYmxlcmFuZ2U6ZjczYzE1NWQyZTIzNDM4ODk2MTU5YTNhMDc3MzM3YzhfNi0zLTEtMS04Mjc4Mg_c661f07e-a204-44c5-b68f-37e0bf20d481">9.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="wst:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOmY3M2MxNTVkMmUyMzQzODg5NjE1OWEzYTA3NzMzN2M4L3RhYmxlcmFuZ2U6ZjczYzE1NWQyZTIzNDM4ODk2MTU5YTNhMDc3MzM3YzhfNy0xLTEtMS04Mjc4Mg_e8ab5786-e6b6-484e-b761-54d49a3857b2">51.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOmY3M2MxNTVkMmUyMzQzODg5NjE1OWEzYTA3NzMzN2M4L3RhYmxlcmFuZ2U6ZjczYzE1NWQyZTIzNDM4ODk2MTU5YTNhMDc3MzM3YzhfNy0zLTEtMS04Mjc4Mg_405c5c74-5728-418d-b698-c55c6a5017e9">50.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOmY3M2MxNTVkMmUyMzQzODg5NjE1OWEzYTA3NzMzN2M4L3RhYmxlcmFuZ2U6ZjczYzE1NWQyZTIzNDM4ODk2MTU5YTNhMDc3MzM3YzhfOC0xLTEtMS04Mjc4Mg_3920f4a0-ea4a-4b42-ad88-a76f08eb4776">123.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOmY3M2MxNTVkMmUyMzQzODg5NjE1OWEzYTA3NzMzN2M4L3RhYmxlcmFuZ2U6ZjczYzE1NWQyZTIzNDM4ODk2MTU5YTNhMDc3MzM3YzhfOC0zLTEtMS04Mjc4Mg_42f2a0c8-b991-4713-b1b9-907bec32c425">126.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed lease interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOmY3M2MxNTVkMmUyMzQzODg5NjE1OWEzYTA3NzMzN2M4L3RhYmxlcmFuZ2U6ZjczYzE1NWQyZTIzNDM4ODk2MTU5YTNhMDc3MzM3YzhfOS0xLTEtMS04Mjc4Mg_8c12840f-1cb4-4ec6-a9a7-f7439a0a0fdb">17.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOmY3M2MxNTVkMmUyMzQzODg5NjE1OWEzYTA3NzMzN2M4L3RhYmxlcmFuZ2U6ZjczYzE1NWQyZTIzNDM4ODk2MTU5YTNhMDc3MzM3YzhfOS0zLTEtMS04Mjc4Mg_6de8acb7-2498-4be8-a876-2e5f6b15ef38">17.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOmY3M2MxNTVkMmUyMzQzODg5NjE1OWEzYTA3NzMzN2M4L3RhYmxlcmFuZ2U6ZjczYzE1NWQyZTIzNDM4ODk2MTU5YTNhMDc3MzM3YzhfMTAtMS0xLTEtODI3ODI_81aa75a0-5c5f-4b79-951f-d8200c03cc12">106.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOmY3M2MxNTVkMmUyMzQzODg5NjE1OWEzYTA3NzMzN2M4L3RhYmxlcmFuZ2U6ZjczYzE1NWQyZTIzNDM4ODk2MTU5YTNhMDc3MzM3YzhfMTAtMy0xLTEtODI3ODI_93f82791-ab0b-4c4f-add1-7c9ae96717af">109.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div></ix:continuation><div><span><br/></span></div><div id="i7bf87d07bb544f48851c48374130181b_52"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7:&#160;&#160;<ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81Mi9mcmFnOmRhNjNhOGU3ZmQxZDRlNWFhOGZhNjM1NzY4Mjg1OTM4L3RleHRyZWdpb246ZGE2M2E4ZTdmZDFkNGU1YWE4ZmE2MzU3NjgyODU5MzhfMTM3Mw_bce24f1c-291c-4e6f-bff1-fed8ebae3009" continuedAt="i29f15459b7b84003bf2085711618f3ea" escape="true">Affiliated Companies</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i29f15459b7b84003bf2085711618f3ea" continuedAt="i6172b1e59a7343a5bd4d033618935d00">At March&#160;31, 2023 and December&#160;31, 2022, the aggregate carrying amount of our investment in affiliated companies that are accounted for under the equity method was $<ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81Mi9mcmFnOmRhNjNhOGU3ZmQxZDRlNWFhOGZhNjM1NzY4Mjg1OTM4L3RleHRyZWdpb246ZGE2M2E4ZTdmZDFkNGU1YWE4ZmE2MzU3NjgyODU5MzhfMTcz_054e2fb3-7315-46ca-a922-6653922e08b6">200.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81Mi9mcmFnOmRhNjNhOGU3ZmQxZDRlNWFhOGZhNjM1NzY4Mjg1OTM4L3RleHRyZWdpb246ZGE2M2E4ZTdmZDFkNGU1YWE4ZmE2MzU3NjgyODU5MzhfMTgw_60e39e5e-60a8-456a-8ebd-1088bede01f1">197.0</ix:nonFraction> million, respectively, and the aggregate carrying amount of our investment in affiliated companies that are not accounted for under the equity method was $<ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81Mi9mcmFnOmRhNjNhOGU3ZmQxZDRlNWFhOGZhNjM1NzY4Mjg1OTM4L3RleHRyZWdpb246ZGE2M2E4ZTdmZDFkNGU1YWE4ZmE2MzU3NjgyODU5MzhfMzI5_70561c0b-d575-4822-9357-9d363be7ae80">7.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81Mi9mcmFnOmRhNjNhOGU3ZmQxZDRlNWFhOGZhNjM1NzY4Mjg1OTM4L3RleHRyZWdpb246ZGE2M2E4ZTdmZDFkNGU1YWE4ZmE2MzU3NjgyODU5MzhfMzM2_ee125f03-2b78-4018-bc08-fe6b2f737691">7.9</ix:nonFraction> million at March&#160;31, 2023 and December&#160;31, 2022, respectively. We have elected to record these investments, for which fair value was not readily determinable, at cost, less impairment, adjusted for subsequent observable price changes. We test these investments for impairment whenever circumstances indicate that the carrying value of the investments may not be recoverable. </ix:continuation></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_7">Table of Contents</a></span></div></div><ix:continuation id="i6172b1e59a7343a5bd4d033618935d00"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our purchases from, and royalty payments made to, affiliates totaled $<ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="wst:PurchasesAndRoyaltyPaymentsFromEquityMethodInvestees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81Mi9mcmFnOmRhNjNhOGU3ZmQxZDRlNWFhOGZhNjM1NzY4Mjg1OTM4L3RleHRyZWdpb246ZGE2M2E4ZTdmZDFkNGU1YWE4ZmE2MzU3NjgyODU5MzhfNzU4_a737ff89-6332-4c0a-9155-c0becbfe2b92">44.2</ix:nonFraction> million for the three months ended March&#160;31, 2023, as compared to $<ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="wst:PurchasesAndRoyaltyPaymentsFromEquityMethodInvestees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81Mi9mcmFnOmRhNjNhOGU3ZmQxZDRlNWFhOGZhNjM1NzY4Mjg1OTM4L3RleHRyZWdpb246ZGE2M2E4ZTdmZDFkNGU1YWE4ZmE2MzU3NjgyODU5MzhfNzkx_5a9b86b2-03ba-426f-9ace-24a3bb169038">58.5</ix:nonFraction> million for the same period in 2022. As of March&#160;31, 2023 and December&#160;31, 2022, the payable balance due to affiliates was $<ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:DueToAffiliateCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81Mi9mcmFnOmRhNjNhOGU3ZmQxZDRlNWFhOGZhNjM1NzY4Mjg1OTM4L3RleHRyZWdpb246ZGE2M2E4ZTdmZDFkNGU1YWE4ZmE2MzU3NjgyODU5MzhfODgw_5ab30206-e1a8-4101-b91e-8ab231f608e7">30.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:DueToAffiliateCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81Mi9mcmFnOmRhNjNhOGU3ZmQxZDRlNWFhOGZhNjM1NzY4Mjg1OTM4L3RleHRyZWdpb246ZGE2M2E4ZTdmZDFkNGU1YWE4ZmE2MzU3NjgyODU5MzhfODg3_f99855a7-1c8b-4da5-a982-f373efe4bc87">31.2</ix:nonFraction> million, respectively. The majority of these transactions related to a distributorship agreement with Daikyo Seiko, LTD ("Daikyo") that allows us to purchase and re-sell Daikyo products. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales to affiliates were $<ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="wst:SalesToEquityMethodInvestees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81Mi9mcmFnOmRhNjNhOGU3ZmQxZDRlNWFhOGZhNjM1NzY4Mjg1OTM4L3RleHRyZWdpb246ZGE2M2E4ZTdmZDFkNGU1YWE4ZmE2MzU3NjgyODU5MzhfMTA3NA_be824b64-7946-453b-be5d-f6377fcb7311">3.3</ix:nonFraction> million for the three months ended March&#160;31, 2023, as compared to $<ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="wst:SalesToEquityMethodInvestees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81Mi9mcmFnOmRhNjNhOGU3ZmQxZDRlNWFhOGZhNjM1NzY4Mjg1OTM4L3RleHRyZWdpb246ZGE2M2E4ZTdmZDFkNGU1YWE4ZmE2MzU3NjgyODU5MzhfMTEwNw_b2b27ba2-a8f8-40d6-bf63-ba94146a164a">4.0</ix:nonFraction> million for the same period in 2022. As of March&#160;31, 2023 and December&#160;31, 2022, the receivable balance due from affiliates was $<ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:DueFromAffiliates" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81Mi9mcmFnOmRhNjNhOGU3ZmQxZDRlNWFhOGZhNjM1NzY4Mjg1OTM4L3RleHRyZWdpb246ZGE2M2E4ZTdmZDFkNGU1YWE4ZmE2MzU3NjgyODU5MzhfMTIwOQ_54f7473c-4a80-48ee-bb58-330e9bd61e53">2.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:DueFromAffiliates" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81Mi9mcmFnOmRhNjNhOGU3ZmQxZDRlNWFhOGZhNjM1NzY4Mjg1OTM4L3RleHRyZWdpb246ZGE2M2E4ZTdmZDFkNGU1YWE4ZmE2MzU3NjgyODU5MzhfMTIxNg_7743c64f-dab1-4628-893d-c50cf6f03b3e">2.2</ix:nonFraction> million, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please refer to Note 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Affiliated Companies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the consolidated financial statements in our </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/105770/000010577023000012/wst-20221231.htm#i8148abfe270d4f15aa2ba9319df722dc_58">2022 Annual Report</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional details.</span></div></ix:continuation><div><span><br/></span></div><div id="i7bf87d07bb544f48851c48374130181b_55"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8:&#160;&#160;<ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81NS9mcmFnOjQxZTE3ZjI0MTViZjRkM2Q4Mzg1YjllOTA2ZTdkMjJlL3RleHRyZWdpb246NDFlMTdmMjQxNWJmNGQzZDgzODViOWU5MDZlN2QyMmVfMzA1Mg_13115024-ccdf-4c7f-889d-d8a307cba5bc" continuedAt="if54d38c53d7d4619a8f542f6a18bd6ca" escape="true">Debt</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="if54d38c53d7d4619a8f542f6a18bd6ca"><ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="us-gaap:ScheduleOfDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81NS9mcmFnOjQxZTE3ZjI0MTViZjRkM2Q4Mzg1YjllOTA2ZTdkMjJlL3RleHRyZWdpb246NDFlMTdmMjQxNWJmNGQzZDgzODViOWU5MDZlN2QyMmVfMzA2OA_797d8870-4c2b-4573-88dd-445ad740aff2" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our long-term debt obligations, net of unamortized debt issuance costs and current maturities. The interest rates shown in parentheses are as of March&#160;31, 2023.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:69.982%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan, due December 31, 2024 (<ix:nonFraction unitRef="number" contextRef="iecf3cc3f4a2e4356986ecea0d53b720d_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81NS9mcmFnOjQxZTE3ZjI0MTViZjRkM2Q4Mzg1YjllOTA2ZTdkMjJlL3RhYmxlOjM3NzAxY2ExYWFiMTRmNWJhNzc1ZTcxNGI5YmYwZjdmL3RhYmxlcmFuZ2U6Mzc3MDFjYTFhYWIxNGY1YmE3NzVlNzE0YjliZjBmN2ZfNS0wLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOjY3YTcyOGQ0N2E5YzQ0NDJiN2Q3MjRjZjQ5MmI0ZGQ5XzM4_a8a55958-599b-4bcd-85a3-d73875b2efd5">5.87</ix:nonFraction>%)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf3cc3f4a2e4356986ecea0d53b720d_I20230331" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81NS9mcmFnOjQxZTE3ZjI0MTViZjRkM2Q4Mzg1YjllOTA2ZTdkMjJlL3RhYmxlOjM3NzAxY2ExYWFiMTRmNWJhNzc1ZTcxNGI5YmYwZjdmL3RhYmxlcmFuZ2U6Mzc3MDFjYTFhYWIxNGY1YmE3NzVlNzE0YjliZjBmN2ZfNS0xLTEtMS04Mjc4Mg_686fd137-cfd9-4ce7-bb69-d0a2bad283f0">82.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i820fab327f6443ae978dfa28318d48f4_I20221231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81NS9mcmFnOjQxZTE3ZjI0MTViZjRkM2Q4Mzg1YjllOTA2ZTdkMjJlL3RhYmxlOjM3NzAxY2ExYWFiMTRmNWJhNzc1ZTcxNGI5YmYwZjdmL3RhYmxlcmFuZ2U6Mzc3MDFjYTFhYWIxNGY1YmE3NzVlNzE0YjliZjBmN2ZfNS0zLTEtMS04Mjc4Mg_40bcc328-dce5-4d26-adfc-35365fed3b2a">83.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B notes, due July 5, 2024 (<ix:nonFraction unitRef="number" contextRef="id38fa53f753e49438df00d22e5b777e6_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81NS9mcmFnOjQxZTE3ZjI0MTViZjRkM2Q4Mzg1YjllOTA2ZTdkMjJlL3RhYmxlOjM3NzAxY2ExYWFiMTRmNWJhNzc1ZTcxNGI5YmYwZjdmL3RhYmxlcmFuZ2U6Mzc3MDFjYTFhYWIxNGY1YmE3NzVlNzE0YjliZjBmN2ZfNy0wLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOjUxMGI0YzYyZTNkODRiNTBhNmU0ZWMyMWEyNGUzOTA5XzM4_b159483e-9f07-440d-8c22-84f08788f85c">3.82</ix:nonFraction>%)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id38fa53f753e49438df00d22e5b777e6_I20230331" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81NS9mcmFnOjQxZTE3ZjI0MTViZjRkM2Q4Mzg1YjllOTA2ZTdkMjJlL3RhYmxlOjM3NzAxY2ExYWFiMTRmNWJhNzc1ZTcxNGI5YmYwZjdmL3RhYmxlcmFuZ2U6Mzc3MDFjYTFhYWIxNGY1YmE3NzVlNzE0YjliZjBmN2ZfNy0xLTEtMS04Mjc4Mg_dcca88b2-4d8e-453d-98dd-74df43cc1431">53.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a8404bd9ab74326a8394ec3e7f36919_I20221231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81NS9mcmFnOjQxZTE3ZjI0MTViZjRkM2Q4Mzg1YjllOTA2ZTdkMjJlL3RhYmxlOjM3NzAxY2ExYWFiMTRmNWJhNzc1ZTcxNGI5YmYwZjdmL3RhYmxlcmFuZ2U6Mzc3MDFjYTFhYWIxNGY1YmE3NzVlNzE0YjliZjBmN2ZfNy0zLTEtMS04Mjc4Mg_6584cc31-98ee-4971-ab48-0ef95f10e265">53.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series C notes, due July 5, 2027 (<ix:nonFraction unitRef="number" contextRef="i85a6072962d04208ae531a2b2fbfef0e_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81NS9mcmFnOjQxZTE3ZjI0MTViZjRkM2Q4Mzg1YjllOTA2ZTdkMjJlL3RhYmxlOjM3NzAxY2ExYWFiMTRmNWJhNzc1ZTcxNGI5YmYwZjdmL3RhYmxlcmFuZ2U6Mzc3MDFjYTFhYWIxNGY1YmE3NzVlNzE0YjliZjBmN2ZfOC0wLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOjczNWQ3Y2ZiNGVhMDRlNmFhNjFhMDg5MWExNjYwZjA3XzM4_c4bec8bd-584f-4322-af76-ec7f240be2c5">4.02</ix:nonFraction>%) </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85a6072962d04208ae531a2b2fbfef0e_I20230331" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81NS9mcmFnOjQxZTE3ZjI0MTViZjRkM2Q4Mzg1YjllOTA2ZTdkMjJlL3RhYmxlOjM3NzAxY2ExYWFiMTRmNWJhNzc1ZTcxNGI5YmYwZjdmL3RhYmxlcmFuZ2U6Mzc3MDFjYTFhYWIxNGY1YmE3NzVlNzE0YjliZjBmN2ZfOC0xLTEtMS04Mjc4Mg_2e3ab626-ba2b-473f-b52c-6d19ee4adb4e">73.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2b66dd4040640348f96693d6e7be1d5_I20221231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81NS9mcmFnOjQxZTE3ZjI0MTViZjRkM2Q4Mzg1YjllOTA2ZTdkMjJlL3RhYmxlOjM3NzAxY2ExYWFiMTRmNWJhNzc1ZTcxNGI5YmYwZjdmL3RhYmxlcmFuZ2U6Mzc3MDFjYTFhYWIxNGY1YmE3NzVlNzE0YjliZjBmN2ZfOC0zLTEtMS04Mjc4Mg_774763e2-7370-4c12-9227-4e4c83dc64b7">73.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81NS9mcmFnOjQxZTE3ZjI0MTViZjRkM2Q4Mzg1YjllOTA2ZTdkMjJlL3RhYmxlOjM3NzAxY2ExYWFiMTRmNWJhNzc1ZTcxNGI5YmYwZjdmL3RhYmxlcmFuZ2U6Mzc3MDFjYTFhYWIxNGY1YmE3NzVlNzE0YjliZjBmN2ZfOS0xLTEtMS04Mjc4Mg_4a2d1c02-491f-48a2-b7c8-d44104f4da7c">208.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81NS9mcmFnOjQxZTE3ZjI0MTViZjRkM2Q4Mzg1YjllOTA2ZTdkMjJlL3RhYmxlOjM3NzAxY2ExYWFiMTRmNWJhNzc1ZTcxNGI5YmYwZjdmL3RhYmxlcmFuZ2U6Mzc3MDFjYTFhYWIxNGY1YmE3NzVlNzE0YjliZjBmN2ZfOS0zLTEtMS04Mjc4Mg_05fd7139-35b8-415d-8ec5-fe66257015f4">209.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized debt issuance costs for Term Loan and Series Notes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:UnamortizedDebtIssuanceExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81NS9mcmFnOjQxZTE3ZjI0MTViZjRkM2Q4Mzg1YjllOTA2ZTdkMjJlL3RhYmxlOjM3NzAxY2ExYWFiMTRmNWJhNzc1ZTcxNGI5YmYwZjdmL3RhYmxlcmFuZ2U6Mzc3MDFjYTFhYWIxNGY1YmE3NzVlNzE0YjliZjBmN2ZfMTAtMS0xLTEtODI3ODI_12badf4a-453b-4705-9e4d-1f730839c49d">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:UnamortizedDebtIssuanceExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81NS9mcmFnOjQxZTE3ZjI0MTViZjRkM2Q4Mzg1YjllOTA2ZTdkMjJlL3RhYmxlOjM3NzAxY2ExYWFiMTRmNWJhNzc1ZTcxNGI5YmYwZjdmL3RhYmxlcmFuZ2U6Mzc3MDFjYTFhYWIxNGY1YmE3NzVlNzE0YjliZjBmN2ZfMTAtMy0xLTEtODI3ODI_03cb67a0-fb84-444a-bd8b-dae364213c29">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81NS9mcmFnOjQxZTE3ZjI0MTViZjRkM2Q4Mzg1YjllOTA2ZTdkMjJlL3RhYmxlOjM3NzAxY2ExYWFiMTRmNWJhNzc1ZTcxNGI5YmYwZjdmL3RhYmxlcmFuZ2U6Mzc3MDFjYTFhYWIxNGY1YmE3NzVlNzE0YjliZjBmN2ZfMTEtMS0xLTEtODI3ODI_04704b9c-ef7e-4469-85ca-66ca455710ea">208.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81NS9mcmFnOjQxZTE3ZjI0MTViZjRkM2Q4Mzg1YjllOTA2ZTdkMjJlL3RhYmxlOjM3NzAxY2ExYWFiMTRmNWJhNzc1ZTcxNGI5YmYwZjdmL3RhYmxlcmFuZ2U6Mzc3MDFjYTFhYWIxNGY1YmE3NzVlNzE0YjliZjBmN2ZfMTEtMy0xLTEtODI3ODI_3ced6187-86a5-437e-9898-22a7e5b1d0f5">208.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81NS9mcmFnOjQxZTE3ZjI0MTViZjRkM2Q4Mzg1YjllOTA2ZTdkMjJlL3RhYmxlOjM3NzAxY2ExYWFiMTRmNWJhNzc1ZTcxNGI5YmYwZjdmL3RhYmxlcmFuZ2U6Mzc3MDFjYTFhYWIxNGY1YmE3NzVlNzE0YjliZjBmN2ZfMTItMS0xLTEtODI3ODI_c0e8a502-fa0c-403a-87d1-f8a45f15a0fd">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81NS9mcmFnOjQxZTE3ZjI0MTViZjRkM2Q4Mzg1YjllOTA2ZTdkMjJlL3RhYmxlOjM3NzAxY2ExYWFiMTRmNWJhNzc1ZTcxNGI5YmYwZjdmL3RhYmxlcmFuZ2U6Mzc3MDFjYTFhYWIxNGY1YmE3NzVlNzE0YjliZjBmN2ZfMTItMy0xLTEtODI3ODI_1fa3895a-eb18-40b3-920e-9048fc89605d">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81NS9mcmFnOjQxZTE3ZjI0MTViZjRkM2Q4Mzg1YjllOTA2ZTdkMjJlL3RhYmxlOjM3NzAxY2ExYWFiMTRmNWJhNzc1ZTcxNGI5YmYwZjdmL3RhYmxlcmFuZ2U6Mzc3MDFjYTFhYWIxNGY1YmE3NzVlNzE0YjliZjBmN2ZfMTMtMS0xLTEtODI3ODI_f504f4f6-320c-443d-b4d3-63a3047f97bd">206.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81NS9mcmFnOjQxZTE3ZjI0MTViZjRkM2Q4Mzg1YjllOTA2ZTdkMjJlL3RhYmxlOjM3NzAxY2ExYWFiMTRmNWJhNzc1ZTcxNGI5YmYwZjdmL3RhYmxlcmFuZ2U6Mzc3MDFjYTFhYWIxNGY1YmE3NzVlNzE0YjliZjBmN2ZfMTMtMy0xLTEtODI3ODI_747e787c-7b7b-4fd1-a0f8-434bc42e449b">206.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Facility</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2023, the borrowing capacity available under our $<ix:nonFraction unitRef="usd" contextRef="id48d782f5bfb4fe6a7905309804dadd4_I20230331" decimals="-5" name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81NS9mcmFnOjQxZTE3ZjI0MTViZjRkM2Q4Mzg1YjllOTA2ZTdkMjJlL3RleHRyZWdpb246NDFlMTdmMjQxNWJmNGQzZDgzODViOWU5MDZlN2QyMmVfMjUxOA_7b77db55-3c21-416d-8fbc-695d904a673b">500.0</ix:nonFraction>&#160;million multi-currency revolving credit facility, including outstanding letters of credit of $<ix:nonFraction unitRef="usd" contextRef="i98cb2924a74a4bcbb3d3520ea87d52f0_I20230331" decimals="-5" name="us-gaap:LineOfCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81NS9mcmFnOjQxZTE3ZjI0MTViZjRkM2Q4Mzg1YjllOTA2ZTdkMjJlL3RleHRyZWdpb246NDFlMTdmMjQxNWJmNGQzZDgzODViOWU5MDZlN2QyMmVfMjYwNg_7f286c43-2827-4a76-9ee2-252cef7c75ac">2.4</ix:nonFraction> million, was $<ix:nonFraction unitRef="usd" contextRef="id48d782f5bfb4fe6a7905309804dadd4_I20230331" decimals="-5" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81NS9mcmFnOjQxZTE3ZjI0MTViZjRkM2Q4Mzg1YjllOTA2ZTdkMjJlL3RleHRyZWdpb246NDFlMTdmMjQxNWJmNGQzZDgzODViOWU5MDZlN2QyMmVfMjYxNA_74465786-6bac-4742-a7e4-d8b9cab281b0">497.6</ix:nonFraction> million. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Term Loan</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2023, we had $<ix:nonFraction unitRef="usd" contextRef="iecf3cc3f4a2e4356986ecea0d53b720d_I20230331" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81NS9mcmFnOjQxZTE3ZjI0MTViZjRkM2Q4Mzg1YjllOTA2ZTdkMjJlL3RleHRyZWdpb246NDFlMTdmMjQxNWJmNGQzZDgzODViOWU5MDZlN2QyMmVfMjY1Mw_df2dbd51-4df9-427b-8fde-fbc8b3b3f982">82.6</ix:nonFraction> million in borrowings under the Term Loan, of which $<ix:nonFraction unitRef="usd" contextRef="iecf3cc3f4a2e4356986ecea0d53b720d_I20230331" decimals="-5" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81NS9mcmFnOjQxZTE3ZjI0MTViZjRkM2Q4Mzg1YjllOTA2ZTdkMjJlL3RleHRyZWdpb246NDFlMTdmMjQxNWJmNGQzZDgzODViOWU5MDZlN2QyMmVfMjcwMA_91cb1d27-7f34-4366-9630-6bb045967067">2.2</ix:nonFraction> million was classified as current and $<ix:nonFraction unitRef="usd" contextRef="iecf3cc3f4a2e4356986ecea0d53b720d_I20230331" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81NS9mcmFnOjQxZTE3ZjI0MTViZjRkM2Q4Mzg1YjllOTA2ZTdkMjJlL3RleHRyZWdpb246NDFlMTdmMjQxNWJmNGQzZDgzODViOWU5MDZlN2QyMmVfMjczMw_a34a79bb-582f-4fe9-9994-d7aae2bac731">80.4</ix:nonFraction> million was classified as long-term. Please refer to Note 9, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_58">Derivative Financial Instruments</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for a discussion of the foreign currency hedge associated with the Term Loan.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the financial covenants in our debt agreements, we are required to maintain established interest coverage ratios and to not exceed established leverage ratios. In addition, the agreements contain other customary covenants, none of which we consider restrictive to our operations. At March&#160;31, 2023, we were in compliance with all of our debt covenants.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please refer to Note 10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the consolidated financial statements in our </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/105770/000010577023000012/wst-20221231.htm#i8148abfe270d4f15aa2ba9319df722dc_58">2022 Annual Report</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional details regarding our debt agreements.</span></div></ix:continuation><div><span><br/></span></div><div id="i7bf87d07bb544f48851c48374130181b_58"></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9:&#160;&#160;<ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RleHRyZWdpb246YjI0ZGFjYzg3YWNmNDkzNTk3NDEwOWFhZGYxY2I0ZmNfNDA2Mw_632b86dc-1066-419e-b429-e14738f9df9f" continuedAt="i3ec92696e1c1462ab2fd85ddeda61b0c" escape="true">Derivative Financial Instruments</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i3ec92696e1c1462ab2fd85ddeda61b0c" continuedAt="id833e674700a43d8b7e30ca9599b64da"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ongoing business operations expose us to various risks, such as fluctuating interest rates, foreign currency exchange rates and increasing commodity prices. To manage these market risks, we periodically enter into derivative financial instruments, such as interest rate swaps, options and foreign exchange contracts for periods consistent with, and for notional amounts equal to or less than, the related underlying exposures. We do not purchase or hold any derivative financial instruments for investment or trading purposes. All derivatives are recorded in our condensed consolidated balance sheet at fair value.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Exchange Rate Risk</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into forward exchange contracts, designated as fair value hedges, to manage our exposure to fluctuating foreign exchange rates on cross-currency intercompany loans. As of both March&#160;31, 2023 and December&#160;31, 2022, the total amount of these forward exchange contracts was Singapore Dollar (&#8220;SGD&#8221;) <ix:nonFraction unitRef="sgd" contextRef="if46b82c9c68b443482333077a49f48e9_I20221231" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RleHRyZWdpb246YjI0ZGFjYzg3YWNmNDkzNTk3NDEwOWFhZGYxY2I0ZmNfOTgx_8558b8ea-902d-4da5-90c3-2c61a1b96f71"><ix:nonFraction unitRef="sgd" contextRef="i82f3bc098630498582401da701e7b138_I20230331" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RleHRyZWdpb246YjI0ZGFjYzg3YWNmNDkzNTk3NDEwOWFhZGYxY2I0ZmNfOTgx_c09d2157-0f6d-42aa-b67b-4a88dbd44823">601.5</ix:nonFraction></ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i09563dd08c64439c84993944fccfc6db_I20230331" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RleHRyZWdpb246YjI0ZGFjYzg3YWNmNDkzNTk3NDEwOWFhZGYxY2I0ZmNfOTg4_3bf245c8-1dfd-4d9e-93d4-0128e8b7d745"><ix:nonFraction unitRef="usd" contextRef="ifdb1000004bd47589080d94726e76022_I20221231" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RleHRyZWdpb246YjI0ZGFjYzg3YWNmNDkzNTk3NDEwOWFhZGYxY2I0ZmNfOTg4_d45f5f4a-4cb3-4c93-88b1-4e834c88b98b">13.4</ix:nonFraction></ix:nonFraction> million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have entered into several foreign currency contracts, designated as cash flow hedges, for periods of up to <ix:nonNumeric contextRef="i5f005fe228a0408495ca4180dcc39feb_D20230101-20230331" name="us-gaap:DerivativeTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RleHRyZWdpb246YjI0ZGFjYzg3YWNmNDkzNTk3NDEwOWFhZGYxY2I0ZmNfMTExNg_9889f86e-1405-474f-a687-3308ef278247">eighteen months</ix:nonNumeric>, intended to hedge the currency risk associated with a portion of our forecasted transactions denominated in foreign currencies. <ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="us-gaap:ScheduleOfDerivativeInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RleHRyZWdpb246YjI0ZGFjYzg3YWNmNDkzNTk3NDEwOWFhZGYxY2I0ZmNfNDA2OA_c494e45c-2ac5-4969-b1f2-262510992814" continuedAt="ia42e6f7b9ec940beb18a131a2a7f6e93" escape="true">As of March&#160;31, 2023, we had outstanding foreign currency contracts to purchase and sell certain pairs of currencies, as follows:</ix:nonNumeric></span></div><div><ix:continuation id="ia42e6f7b9ec940beb18a131a2a7f6e93"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"><tr><td style="width:1.0%"></td><td style="width:33.421%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.459%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sell</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">USD</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EUR</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EUR</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i9728ffcf312e4ac4bdb6aae4a7b23a44_I20230331" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOmIzOGJhOGRkYTc5YjRlY2Q4M2UzYmM0OWM3NmM0NTg0L3RhYmxlcmFuZ2U6YjM4YmE4ZGRhNzliNGVjZDgzZTNiYzQ5Yzc2YzQ1ODRfMi0xLTEtMS04Mjc4Mg_8655445a-c2e8-4575-9632-2b0208975af7">8.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6ea04af1eff40db88226330d1e25200_I20230331" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOmIzOGJhOGRkYTc5YjRlY2Q4M2UzYmM0OWM3NmM0NTg0L3RhYmxlcmFuZ2U6YjM4YmE4ZGRhNzliNGVjZDgzZTNiYzQ5Yzc2YzQ1ODRfMi0zLTEtMS04Mjc4Mg_d145f952-c688-4924-9232-f60b7e39fab2">8.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="if6ea04af1eff40db88226330d1e25200_I20230331" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOmIzOGJhOGRkYTc5YjRlY2Q4M2UzYmM0OWM3NmM0NTg0L3RhYmxlcmFuZ2U6YjM4YmE4ZGRhNzliNGVjZDgzZTNiYzQ5Yzc2YzQ1ODRfMi00LTEtMS04Mjc4Mg_c9c0f48e-f129-4f10-b6ea-b7ecccc39865">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yen</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="jpy" contextRef="icdd3e55c2a7a4212801e02cabd651cfc_I20230331" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOmIzOGJhOGRkYTc5YjRlY2Q4M2UzYmM0OWM3NmM0NTg0L3RhYmxlcmFuZ2U6YjM4YmE4ZGRhNzliNGVjZDgzZTNiYzQ5Yzc2YzQ1ODRfMy0xLTEtMS04Mjc4Mg_bfad8536-75e9-4111-8cab-3b0f8d41973c">5,629.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63dca94e686c450eb00428ac82177d9d_I20230331" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOmIzOGJhOGRkYTc5YjRlY2Q4M2UzYmM0OWM3NmM0NTg0L3RhYmxlcmFuZ2U6YjM4YmE4ZGRhNzliNGVjZDgzZTNiYzQ5Yzc2YzQ1ODRfMy0zLTEtMS04Mjc4Mg_ba84a109-5027-4dee-a996-0ea7062cd837">30.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i63dca94e686c450eb00428ac82177d9d_I20230331" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOmIzOGJhOGRkYTc5YjRlY2Q4M2UzYmM0OWM3NmM0NTg0L3RhYmxlcmFuZ2U6YjM4YmE4ZGRhNzliNGVjZDgzZTNiYzQ5Yzc2YzQ1ODRfMy00LTEtMS04Mjc4Mg_da5585de-49df-44f3-99e3-da28ec7bde69">12.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SGD</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="sgd" contextRef="if2a16112236a46548494c875fa25e7c6_I20230331" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOmIzOGJhOGRkYTc5YjRlY2Q4M2UzYmM0OWM3NmM0NTg0L3RhYmxlcmFuZ2U6YjM4YmE4ZGRhNzliNGVjZDgzZTNiYzQ5Yzc2YzQ1ODRfNC0xLTEtMS04Mjc4Mg_e7d4fd7b-69a4-45c3-89c5-3a9328b30f6d">67.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i049f03d104874040b8a9e20dca208dd8_I20230331" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOmIzOGJhOGRkYTc5YjRlY2Q4M2UzYmM0OWM3NmM0NTg0L3RhYmxlcmFuZ2U6YjM4YmE4ZGRhNzliNGVjZDgzZTNiYzQ5Yzc2YzQ1ODRfNC0zLTEtMS04Mjc4Mg_18e7c603-ae47-4b85-a19a-b8522046b11b">24.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i049f03d104874040b8a9e20dca208dd8_I20230331" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOmIzOGJhOGRkYTc5YjRlY2Q4M2UzYmM0OWM3NmM0NTg0L3RhYmxlcmFuZ2U6YjM4YmE4ZGRhNzliNGVjZDgzZTNiYzQ5Yzc2YzQ1ODRfNC00LTEtMS04Mjc4Mg_3bc2e30f-c02c-4486-b371-717e36cc0c29">23.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, we entered into a cross-currency swap for $<ix:nonFraction unitRef="usd" contextRef="i86cd8c4c0adb4f0bb284e66a3b57f3be_I20201231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RleHRyZWdpb246YjI0ZGFjYzg3YWNmNDkzNTk3NDEwOWFhZGYxY2I0ZmNfMTQyOQ_f935624c-e26c-413d-98a8-edc4b7326fb1">90</ix:nonFraction>&#160;million, which we designated as a hedge of our net investment in Daikyo. As of March&#160;31, 2023, the notional amount of the cross-currency swap was &#165;<ix:nonFraction unitRef="jpy" contextRef="i949b0ebb4cdd40e8a2bfd21565e1e3e0_I20230331" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RleHRyZWdpb246YjI0ZGFjYzg3YWNmNDkzNTk3NDEwOWFhZGYxY2I0ZmNfNzE0NjgyNTU4NTA1MA_cb2ec46e-6327-45e7-a056-9b85e3567111">9.0</ix:nonFraction>&#160;billion ($<ix:nonFraction unitRef="usd" contextRef="i949b0ebb4cdd40e8a2bfd21565e1e3e0_I20230331" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RleHRyZWdpb246YjI0ZGFjYzg3YWNmNDkzNTk3NDEwOWFhZGYxY2I0ZmNfNzE0NjgyNTU4NTA1OQ_008bd9f9-ccf4-4dea-9378-c10d1402a262">82.6</ix:nonFraction>&#160;million) and the swap termination date is December 31, 2024. Under the cross-currency swap, we receive floating interest rate payments based on USD compounded SOFR plus a margin, in return for paying floating interest rate payments based on Japanese Yen (&#8220;Yen&#8221;) Tokyo Overnight Average Rate ("TONAR") plus a margin. In addition, we receive periodic fixed payments of USD in return for paying fixed principal payments of Yen.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commodity Price Risk</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our proprietary products are made from synthetic elastomers, which are derived from the petroleum refining process. We purchase the majority of our elastomers via long-term supply contracts, some of which contain clauses that provide for surcharges related to fluctuations in crude oil prices. The following economic hedges did not qualify for hedge accounting treatment since they did not meet the highly effective requirement at inception.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From November 2017 through March 2023, we purchased several series of call options for a total of <ix:nonFraction unitRef="bbl" contextRef="i3dbbddaad3d544529fc30c5aa103c052_D20171101-20230331" decimals="INF" name="us-gaap:DerivativeNonmonetaryNotionalAmountVolume" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RleHRyZWdpb246YjI0ZGFjYzg3YWNmNDkzNTk3NDEwOWFhZGYxY2I0ZmNfMjQzOA_7cc5289e-01d5-417a-881b-c0d963b9e423">903,932</ix:nonFraction> barrels of crude oil to mitigate our exposure to such oil-based surcharges and protect operating cash flows with regards to a portion of our forecasted elastomer purchases. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, we had outstanding contracts to purchase <ix:nonFraction unitRef="bbl" contextRef="i0a775eaad7ab4fb2b9ed736aefbf5955_D20230101-20230331" decimals="INF" name="us-gaap:DerivativeNonmonetaryNotionalAmountVolume" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RleHRyZWdpb246YjI0ZGFjYzg3YWNmNDkzNTk3NDEwOWFhZGYxY2I0ZmNfNzE0NjgyNTU4NTAwMw_c97eb90e-3511-472e-a601-ef1868c709d3">250,742</ix:nonFraction> barrels of crude oil from March 2023 to December 2024, at a weighted-average strike price of <ix:nonFraction unitRef="usdPerBbl" contextRef="i024bb3a09a8d4ff89a1465c610f13094_I20230331" decimals="2" name="us-gaap:DerivativeAveragePriceRiskOptionStrikePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RleHRyZWdpb246YjI0ZGFjYzg3YWNmNDkzNTk3NDEwOWFhZGYxY2I0ZmNfNzE0NjgyNTU4NTAyOQ_e7593a19-79a9-4bb9-bfbe-3b603198a333">104.21</ix:nonFraction> per barrel.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effects of Derivative Instruments on Financial Position and Results of Operations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please refer to Note 10, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_61">Fair Value Measurements</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the balance sheet location and fair values of our derivative instruments as of March&#160;31, 2023 and December&#160;31, 2022.</span></div></ix:continuation><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_7">Table of Contents</a></span></div></div><ix:continuation id="id833e674700a43d8b7e30ca9599b64da" continuedAt="icf12dcc1cd7442fe9114d3e62e792cf9"><div><ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RleHRyZWdpb246YjI0ZGFjYzg3YWNmNDkzNTk3NDEwOWFhZGYxY2I0ZmNfNDA1NA_66165338-9626-4f0f-a7c7-8c38a56a5fdb" continuedAt="ibcdda6c33b6b4b648cfb998f30a479d5" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effects of derivative instruments designated as fair value hedges on the condensed consolidated statements of income:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:24.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount of Gain (Loss) Recognized in Income for the</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Location on Statement of Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value Hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedged item (intercompany loan)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2b6751140ae4a8a905c7349d2d7fab8_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOmRjNDhhZDAzZWE5MjQ5NGViODRiZWUyNjM2ZWExODg5L3RhYmxlcmFuZ2U6ZGM0OGFkMDNlYTkyNDk0ZWI4NGJlZTI2MzZlYTE4ODlfNC0xLTEtMS04Mjc4Mg_3113ef85-fcb1-4cb5-9023-ae5d4879121c">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i512c05fc14444680a4b01af74b3b7f07_D20220101-20220331" decimals="-5" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOmRjNDhhZDAzZWE5MjQ5NGViODRiZWUyNjM2ZWExODg5L3RhYmxlcmFuZ2U6ZGM0OGFkMDNlYTkyNDk0ZWI4NGJlZTI2MzZlYTE4ODlfNC0zLTEtMS04Mjc4Mg_4019e1f6-7d7d-4a45-a88f-791ad78a15b8">9.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative designated as hedging instrument </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2b6751140ae4a8a905c7349d2d7fab8_D20230101-20230331" decimals="-5" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOmRjNDhhZDAzZWE5MjQ5NGViODRiZWUyNjM2ZWExODg5L3RhYmxlcmFuZ2U6ZGM0OGFkMDNlYTkyNDk0ZWI4NGJlZTI2MzZlYTE4ODlfNS0xLTEtMS04Mjc4Mg_f7a7ccbd-f75f-42a7-af76-22f4447d4087">2.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i512c05fc14444680a4b01af74b3b7f07_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOmRjNDhhZDAzZWE5MjQ5NGViODRiZWUyNjM2ZWExODg5L3RhYmxlcmFuZ2U6ZGM0OGFkMDNlYTkyNDk0ZWI4NGJlZTI2MzZlYTE4ODlfNS0zLTEtMS04Mjc4Mg_e0fd7d49-fdf4-43e6-8998-8fd2742e3194">9.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount excluded from effectiveness testing</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2b6751140ae4a8a905c7349d2d7fab8_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOmRjNDhhZDAzZWE5MjQ5NGViODRiZWUyNjM2ZWExODg5L3RhYmxlcmFuZ2U6ZGM0OGFkMDNlYTkyNDk0ZWI4NGJlZTI2MzZlYTE4ODlfNi0xLTEtMS04Mjc4Mg_63c5f7f7-584f-4d53-9ba6-15caf916a258">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i512c05fc14444680a4b01af74b3b7f07_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOmRjNDhhZDAzZWE5MjQ5NGViODRiZWUyNjM2ZWExODg5L3RhYmxlcmFuZ2U6ZGM0OGFkMDNlYTkyNDk0ZWI4NGJlZTI2MzZlYTE4ODlfNi0zLTEtMS04Mjc4Mg_0defc768-0a7c-4c97-81bf-02c8e917dc51">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOmRjNDhhZDAzZWE5MjQ5NGViODRiZWUyNjM2ZWExODg5L3RhYmxlcmFuZ2U6ZGM0OGFkMDNlYTkyNDk0ZWI4NGJlZTI2MzZlYTE4ODlfNy0xLTEtMS04Mjc4Mg_29d80df4-fe1b-49cd-9790-f4b33fe4c5ca">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOmRjNDhhZDAzZWE5MjQ5NGViODRiZWUyNjM2ZWExODg5L3RhYmxlcmFuZ2U6ZGM0OGFkMDNlYTkyNDk0ZWI4NGJlZTI2MzZlYTE4ODlfNy0zLTEtMS04Mjc4Mg_0a856096-32d6-4dd5-a66f-32fa23bed914">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize in earnings the initial value of forward point components on a straight-line basis over the life of the fair value hedge. The amounts recognized in earnings, pre-tax, for forward point components for the three months ended March&#160;31, 2023 and 2022 were $<ix:nonFraction unitRef="usd" contextRef="ie403ae300c3c4982a693b55e66f3705f_D20230101-20230331" decimals="-5" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RleHRyZWdpb246YjI0ZGFjYzg3YWNmNDkzNTk3NDEwOWFhZGYxY2I0ZmNfMzM3OA_40ccf493-a989-45cf-a22a-ef1eab6fa100">1.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifeb72d8b516e4addb0181e1f85261c85_D20220101-20220331" decimals="-5" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RleHRyZWdpb246YjI0ZGFjYzg3YWNmNDkzNTk3NDEwOWFhZGYxY2I0ZmNfMzM4Ng_f5359b44-f1ab-4355-9f25-1edf9fbc6640">0.8</ix:nonFraction> million, respectively.</span></div><div><span><br/></span></div><div><ix:continuation id="ibcdda6c33b6b4b648cfb998f30a479d5" continuedAt="i6fabaa4fb46f4bb58092d2bd0c6d9757"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effects of derivative instruments designated as fair value, cash flow, and net investment hedges on other comprehensive income (&#8220;OCI&#8221;) and earnings, net of tax:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:26.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.706%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.706%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.867%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.867%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.227%"></td><td style="width:0.1%"></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount of (Loss) Gain Recognized in OCI for the</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount of (Gain) Loss Reclassified from Accumulated OCI into Income for the</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Location of (Gain) Loss Reclassified from Accumulated OCI into Income</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value Hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency hedge contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ed146d13e5f4eb2a012abb762cc10f0_D20230101-20230331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfNC0xLTEtMS04Mjc4Mg_08f58a79-d3f1-4fb0-9f39-98d0a948c2b5">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88d56264e84240aaa4c3afb58fcf626e_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfNC0zLTEtMS04Mjc4Mg_503448c0-730c-4648-accf-2010f55fe6b6">1.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ed146d13e5f4eb2a012abb762cc10f0_D20230101-20230331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfNC01LTEtMS04Mjc4Mg_b686ed0a-f53b-4c4b-a3ab-b2fd9ad9b3c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88d56264e84240aaa4c3afb58fcf626e_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfNC03LTEtMS04Mjc4Mg_46846f48-f8ec-4b43-aa42-7d90b1f3ba36">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie403ae300c3c4982a693b55e66f3705f_D20230101-20230331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfNS0xLTEtMS04Mjc4Mg_4642a2bd-b327-4e28-96cf-5dd16f408bdc">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifeb72d8b516e4addb0181e1f85261c85_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfNS0zLTEtMS04Mjc4Mg_b6ec0617-6985-4145-b9ee-e117da588486">1.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie403ae300c3c4982a693b55e66f3705f_D20230101-20230331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfNS01LTEtMS04Mjc4Mg_57d07179-d6ca-45b0-a331-2f153df1ef59">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb72d8b516e4addb0181e1f85261c85_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfNS03LTEtMS04Mjc4Mg_a77bc723-a09f-458f-bf27-d57e6a71941d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash Flow Hedges:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency hedge contracts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i550fe20240f54b029e378c9bf7ce6f5d_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfNy0xLTEtMS04Mjc4Mg_430a6b4d-9d37-4567-a046-b01072bb52cb">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89d9d14f5ff4438cafe884c5b0d2718f_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfNy0zLTEtMS04Mjc4Mg_6e7f628e-70bd-4af0-b212-d87070dc9f11">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i550fe20240f54b029e378c9bf7ce6f5d_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfNy01LTEtMS04Mjc4Mg_2307b764-09f6-46f1-95a9-198289e70f97">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89d9d14f5ff4438cafe884c5b0d2718f_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfNy03LTEtMS04Mjc4Mg_21e38a62-b133-4f7f-8cd0-6ef011d4e912">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency hedge contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2aaae598465a460fb7b809258de6e1a5_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfOC0xLTEtMS04Mjc4Mg_dc38dc22-bd92-48ac-903e-a480e2f22c94">1.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3800bdd574354a39a20ce84a4092c158_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfOC0zLTEtMS04Mjc4Mg_ac6398a5-8ddd-4591-a473-a3f5c45a15cc">1.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aaae598465a460fb7b809258de6e1a5_D20230101-20230331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfOC01LTEtMS04Mjc4Mg_da97a9e1-9c48-4dc5-a54a-ed61c036cc99">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3800bdd574354a39a20ce84a4092c158_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfOC03LTEtMS04Mjc4Mg_3f704894-43ff-498e-a8e2-8febc5e554f8">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods and services sold</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward treasury locks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5c0ef7c3e0147a483d139e864147374_D20230101-20230331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfMTAtMS0xLTEtODI3ODI_780568d9-e5ed-464e-a6c0-2239757b0f1a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d9e67f88dce43dd8855ccc2dbc02a22_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfMTAtMy0xLTEtODI3ODI_7d6c6fa2-f5bc-4c38-b4a8-b2ef5a1f67b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5c0ef7c3e0147a483d139e864147374_D20230101-20230331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfMTAtNS0xLTEtODI3ODI_c8000b26-03df-42cf-a61a-c2ec1abd51a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d9e67f88dce43dd8855ccc2dbc02a22_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfMTAtNy0xLTEtODI3ODI_7b79ac7b-8249-4493-95cb-d240c0b41342">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c377e143e9d48d0ae6ce22294a8da16_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfMTEtMS0xLTEtODI3ODI_f7182003-6501-4420-8871-fceb796e5b37">1.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9abb09cb5a64fc0b766d1350855b2db_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfMTEtMy0xLTEtODI3ODI_a4491a13-4d51-4aed-ad27-cd0daa8afa2e">0.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c377e143e9d48d0ae6ce22294a8da16_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfMTEtNS0xLTEtODI3ODI_3eae0e68-1392-4d42-a82b-eb0e91d04af1">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9abb09cb5a64fc0b766d1350855b2db_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfMTEtNy0xLTEtODI3ODI_e3a6e9f1-16b1-489a-b427-73dd0c46a1a7">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Investment Hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e6599d390d0401bba4ccd616c8136c8_D20230101-20230331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfMTQtMS0xLTEtODI3ODI_38c7d386-adef-4ad8-83b3-c52a7cd0ceda">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f6ac6dfc13d492b82ae66056c8cdfa7_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfMTQtMy0xLTEtODI3ODI_0b3235e7-e376-4d8f-b904-5ef230950449">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e6599d390d0401bba4ccd616c8136c8_D20230101-20230331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfMTQtNS0xLTEtODI3ODI_752bd04f-a1e2-4dba-936f-8dcf98aac5d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f6ac6dfc13d492b82ae66056c8cdfa7_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfMTQtNy0xLTEtODI3ODI_248a3ce8-c441-440c-af4a-369a1f50fcaa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i014caa55d11343438f2b721d5b51d6c8_D20230101-20230331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfMTUtMS0xLTEtODI3ODI_83808c73-eaff-4746-ae4f-f467b1763158">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab874b4cf2374c38a4cc92deabe110c7_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfMTUtMy0xLTEtODI3ODI_38b84cea-36c1-4ca8-80bd-d04ec35ed9ea">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i014caa55d11343438f2b721d5b51d6c8_D20230101-20230331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfMTUtNS0xLTEtODI3ODI_38874bde-ab58-4bec-a998-27d9d35404eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab874b4cf2374c38a4cc92deabe110c7_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfMTUtNy0xLTEtODI3ODI_8951d6ed-9ffa-4b4d-bd34-1c00d6565954">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></ix:continuation></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_7">Table of Contents</a></span></div></div><ix:continuation id="icf12dcc1cd7442fe9114d3e62e792cf9"><div><ix:continuation id="i6fabaa4fb46f4bb58092d2bd0c6d9757"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to the above table which summarizes the effects of derivative instruments designated as fair value hedges within the other expense (income) line in our condensed consolidated statements of income for the three months ended March&#160;31, 2023 and 2022. The following table summarizes the effects of derivative instruments designated as cash flow and net investment hedges by line item in our condensed consolidated statements of income:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7f2039fc421408da2abf39c8fa7f3e1_D20230101-20230331" decimals="-5" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOmMyMzZhOGE2YmVjZjRhYzE4NzYxNWI2MTg3ZThlMjk0L3RhYmxlcmFuZ2U6YzIzNmE4YTZiZWNmNGFjMTg3NjE1YjYxODdlOGUyOTRfMi0xLTEtMS04Mjc4Mg_08279cc5-4197-49ec-82d6-4d268898aa70">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if0856bab3e85491fb635e56eda1444de_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOmMyMzZhOGE2YmVjZjRhYzE4NzYxNWI2MTg3ZThlMjk0L3RhYmxlcmFuZ2U6YzIzNmE4YTZiZWNmNGFjMTg3NjE1YjYxODdlOGUyOTRfMi0zLTEtMS04Mjc4Mg_55d38a51-1527-4239-9246-0d3cf3a4fd10">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods and services sold</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i143f14fa720c48e8a013cf77a4efde31_D20230101-20230331" decimals="-5" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOmMyMzZhOGE2YmVjZjRhYzE4NzYxNWI2MTg3ZThlMjk0L3RhYmxlcmFuZ2U6YzIzNmE4YTZiZWNmNGFjMTg3NjE1YjYxODdlOGUyOTRfMy0xLTEtMS04Mjc4Mg_6c4a6a94-5097-438a-8526-13c52ca6f931">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i067a51880daf4861907b0950720d904c_D20220101-20220331" decimals="-5" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOmMyMzZhOGE2YmVjZjRhYzE4NzYxNWI2MTg3ZThlMjk0L3RhYmxlcmFuZ2U6YzIzNmE4YTZiZWNmNGFjMTg3NjE1YjYxODdlOGUyOTRfMy0zLTEtMS04Mjc4Mg_e9fbdd45-21fa-495c-b532-0dcc9aec5858">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d4916f585e4d42bfc35a013fb84cdf_D20230101-20230331" decimals="-5" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOmMyMzZhOGE2YmVjZjRhYzE4NzYxNWI2MTg3ZThlMjk0L3RhYmxlcmFuZ2U6YzIzNmE4YTZiZWNmNGFjMTg3NjE1YjYxODdlOGUyOTRfNC0xLTEtMS04Mjc4Mg_e68dda3d-3119-4e31-849c-6ae40d3d7415">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibca67bb324884ac1a4bd92682b0eef05_D20220101-20220331" decimals="-5" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOmMyMzZhOGE2YmVjZjRhYzE4NzYxNWI2MTg3ZThlMjk0L3RhYmxlcmFuZ2U6YzIzNmE4YTZiZWNmNGFjMTg3NjE1YjYxODdlOGUyOTRfNC0zLTEtMS04Mjc4Mg_a38f5c6e-4e68-4492-8441-2c82237a8926">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div><span><br/></span></div><div><span><br/></span></div><div><ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RleHRyZWdpb246YjI0ZGFjYzg3YWNmNDkzNTk3NDEwOWFhZGYxY2I0ZmNfNDA1NQ_ed78bd07-7b6f-4983-bb2b-9aabf3105363" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effects of derivative instruments not designated as hedges on the condensed consolidated statements of income:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.252%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:30.472%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount of Gain (Loss) Recognized in Income for the</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Location on Statement of Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity call options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7e54bd1a6644a0e8981abafbc1190e8_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOmY0ZmIzMmNiZmViZjQyNThhOTNkMTZjZGNmMTRjNmZlL3RhYmxlcmFuZ2U6ZjRmYjMyY2JmZWJmNDI1OGE5M2QxNmNkY2YxNGM2ZmVfMy0xLTEtMS04Mjc4Mg_358d0443-f4eb-4ad7-9905-49fb1cec7f52">0.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03f4edf339b2471dac58f1cdbd5df6a5_D20220101-20220331" decimals="-5" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOmY0ZmIzMmNiZmViZjQyNThhOTNkMTZjZGNmMTRjNmZlL3RhYmxlcmFuZ2U6ZjRmYjMyY2JmZWJmNDI1OGE5M2QxNmNkY2YxNGM2ZmVfMy0zLTEtMS04Mjc4Mg_bcc18245-d3f3-493e-a58e-53e5710a9b97">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income) </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97dea892f5984be0a0fd08b4eee5ed4a_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOmY0ZmIzMmNiZmViZjQyNThhOTNkMTZjZGNmMTRjNmZlL3RhYmxlcmFuZ2U6ZjRmYjMyY2JmZWJmNDI1OGE5M2QxNmNkY2YxNGM2ZmVfNC0xLTEtMS04Mjc4Mg_43ee6d43-befd-48e9-8446-e55e173f6890">0.6</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ee1aea1aac947e59b4311a420cdabdf_D20220101-20220331" decimals="-5" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOmY0ZmIzMmNiZmViZjQyNThhOTNkMTZjZGNmMTRjNmZlL3RhYmxlcmFuZ2U6ZjRmYjMyY2JmZWJmNDI1OGE5M2QxNmNkY2YxNGM2ZmVfNC0zLTEtMS04Mjc4Mg_d75650c3-29c2-437b-986f-8cca307bfa62">2.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2023 and 2022, there was no material ineffectiveness related to our hedges.</span></div></ix:continuation><div><span><br/></span></div><div id="i7bf87d07bb544f48851c48374130181b_61"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 10:&#160;&#160;<ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RleHRyZWdpb246M2E2NWEyYmZhYTFiNDU3OGI0ZjgyMDg2MTQ5ZjcyYzNfMzA5Mw_e301c673-2609-41e5-8046-59d86ec26dc0" continuedAt="ia1dd2c23549341cb99c6d23c16b6964f" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ia1dd2c23549341cb99c6d23c16b6964f" continuedAt="icf3e01b459de47dfb8fb6b459fe95983"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The following fair value hierarchy classifies the inputs to valuation techniques used to measure fair value into one of three levels:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Unadjusted quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Unobservable inputs that reflect the reporting entity&#8217;s own assumptions.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_7">Table of Contents</a></span></div></div><ix:continuation id="icf3e01b459de47dfb8fb6b459fe95983" continuedAt="ibc7cb608739a43cda0cc5553bf83e768"><ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RleHRyZWdpb246M2E2NWEyYmZhYTFiNDU3OGI0ZjgyMDg2MTQ5ZjcyYzNfMzEwNA_3bbc138a-f7dc-4662-ae1a-f08a42449208" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the assets and liabilities recorded at fair value on a recurring basis:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basis of Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:DeferredCompensationPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfMy0xLTEtMS04Mjc4Mg_d3781a45-3ba8-44aa-be5b-b9a15f2f33b0">10.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8472e48bf22848d09276489a66c9e03e_I20230331" decimals="-5" name="us-gaap:DeferredCompensationPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfMy0zLTEtMS04Mjc4Mg_4608f50d-7acd-4d89-ba4b-8c102213c2b8">10.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief4d8a0c3b5e40789e9de34c75e432bf_I20230331" decimals="-5" name="us-gaap:DeferredCompensationPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfMy01LTEtMS04Mjc4Mg_b75a29c2-38de-4121-84a9-0528b0346be8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d4597dfd1ba407789166d3d2ab3a1c6_I20230331" decimals="-5" name="us-gaap:DeferredCompensationPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfMy03LTEtMS04Mjc4Mg_6b1b3165-7548-42d9-942e-3c7bbf22c141">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfNC0xLTEtMS04Mjc4Mg_1f5748b8-ce1b-4675-91b7-e9a65decda00">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8472e48bf22848d09276489a66c9e03e_I20230331" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfNC0zLTEtMS04Mjc4Mg_1f05ef8a-261c-4d97-8fb0-e413996613a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief4d8a0c3b5e40789e9de34c75e432bf_I20230331" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfNC01LTEtMS04Mjc4Mg_0ced4885-313d-41ee-8704-43cfc3437156">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d4597dfd1ba407789166d3d2ab3a1c6_I20230331" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfNC03LTEtMS04Mjc4Mg_c70baf74-8d3f-480b-ae4e-4649bfc93b05">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id11dee14a78441cf8e6ce24a522f88c7_I20230331" decimals="-5" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfNS0xLTEtMS04Mjc4Mg_f3880ba2-64d5-4515-a3bd-2119c40cc558">14.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74d73afd5be44336b5735abe19adc044_I20230331" decimals="-5" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfNS0zLTEtMS04Mjc4Mg_2c433e32-083a-44fe-afa8-2e34626a314a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f682024fc3e4a7a9e5d718533d31677_I20230331" decimals="-5" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfNS01LTEtMS04Mjc4Mg_e7be2a07-3808-4869-8873-384db56b526c">14.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i270bac59038e42c6a92535138d33ff29_I20230331" decimals="-5" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfNS03LTEtMS04Mjc4Mg_62548d37-009f-4b0a-b92e-b3c6d1b4cc88">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity call options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6fbf09378a54c02a5743d72f4ef99da_I20230331" decimals="-5" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfNi0xLTEtMS04Mjc4Mg_03b3fd53-2c1c-4235-8d45-8289d0ab7a4f">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11a99f1a1d3645feb7815067a68cd81f_I20230331" decimals="-5" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfNi0zLTEtMS04Mjc4Mg_0f413f41-85e7-436c-a25d-00ad4efa95df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia53ac927db8b457d821c732f6d7f4f61_I20230331" decimals="-5" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfNi01LTEtMS04Mjc4Mg_4441152b-cfbd-4a09-8f76-7f7bf684b66a">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i520386d8aa8046dc8b6ed7c632c7c7f9_I20230331" decimals="-5" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfNi03LTEtMS04Mjc4Mg_9cb5f730-32d9-4f50-85e9-80a79e8044d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfNy0xLTEtMS04Mjc4Mg_f34eccd8-ec1b-4568-9290-5fd94a2a08d2">29.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8472e48bf22848d09276489a66c9e03e_I20230331" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfNy0zLTEtMS04Mjc4Mg_1d3ff5e0-f8ea-4c5c-a0a0-19d4401241b3">10.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief4d8a0c3b5e40789e9de34c75e432bf_I20230331" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfNy01LTEtMS04Mjc4Mg_0847cf99-fd4e-4f4d-b12a-c6ff042fcfd8">19.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d4597dfd1ba407789166d3d2ab3a1c6_I20230331" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfNy03LTEtMS04Mjc4Mg_a863cb22-ca64-4f5b-b232-579e5ebb84ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfOS0xLTEtMS04Mjc4Mg_eb6b1f42-fa64-45a9-a5cb-2df60690903a">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8472e48bf22848d09276489a66c9e03e_I20230331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfOS0zLTEtMS04Mjc4Mg_27ad4d43-62e6-4d05-9837-b7c1c1f76ddd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief4d8a0c3b5e40789e9de34c75e432bf_I20230331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfOS01LTEtMS04Mjc4Mg_59761665-59b4-46b3-a06b-65ccd7633f23">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d4597dfd1ba407789166d3d2ab3a1c6_I20230331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfOS03LTEtMS04Mjc4Mg_0ef5b8de-4aa8-46bf-b09f-7df542f8f3a5">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfMTAtMS0xLTEtODI3ODI_c27a21d8-378e-4e68-9b5a-7e92af9caf57">10.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8472e48bf22848d09276489a66c9e03e_I20230331" decimals="-5" name="us-gaap:OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfMTAtMy0xLTEtODI3ODI_ddaeff50-8f12-4ca2-9b88-9bdad1d67a87">10.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief4d8a0c3b5e40789e9de34c75e432bf_I20230331" decimals="-5" name="us-gaap:OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfMTAtNS0xLTEtODI3ODI_bc94f0ba-abf3-4ae7-b4f8-ec36aa6dd713">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d4597dfd1ba407789166d3d2ab3a1c6_I20230331" decimals="-5" name="us-gaap:OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfMTAtNy0xLTEtODI3ODI_4117c766-bf0b-44a1-a871-8b43918c6a77">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie176087c2e0f4f9aaf6886e4438cdcf1_I20230331" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfMTItMS0xLTEtODI3ODI_1c2d36e1-dbe9-40c7-b651-6a0296286ecb">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20dc5476975c412a9dfc88d9c2216dee_I20230331" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfMTItMy0xLTEtODI3ODI_46fab7e6-7809-4f71-b3c2-6bf5ebff0258">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e410a2ff35b4d57982b319abc1e1768_I20230331" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfMTItNS0xLTEtODI3ODI_6d3510ab-1210-4f17-ad9e-dad8efee79c0">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89f31e1b854b43c68d198cca6624635e_I20230331" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfMTItNy0xLTEtODI3ODI_bd27644a-a511-4847-9677-1f0646d1aeea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfMTMtMS0xLTEtODI3ODI_053ff08a-dd1d-4952-b3b3-125c16c373ff">17.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8472e48bf22848d09276489a66c9e03e_I20230331" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfMTMtMy0xLTEtODI3ODI_ad7d327e-fc26-4283-8a2e-9f5407565b08">10.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief4d8a0c3b5e40789e9de34c75e432bf_I20230331" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfMTMtNS0xLTEtODI3ODI_6eccea95-5f5c-4e1d-ac89-2fcf32e9d1f0">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d4597dfd1ba407789166d3d2ab3a1c6_I20230331" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfMTMtNy0xLTEtODI3ODI_b5e76e4b-132f-4ec3-8d13-661c4aa6f51d">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basis of Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:DeferredCompensationPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfMy0xLTEtMS04Mjc4Mg_c7f880c7-484a-463f-a96a-b0127cc18766">12.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecab62008c846caa537823da6bf68cf_I20221231" decimals="-5" name="us-gaap:DeferredCompensationPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfMy0zLTEtMS04Mjc4Mg_f58c8df2-2678-4df4-8efa-ec654b088ce7">12.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d38876b8687498fb75a9d1921176e0b_I20221231" decimals="-5" name="us-gaap:DeferredCompensationPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfMy01LTEtMS04Mjc4Mg_fdbc18c2-e4db-4809-89df-51cd8ce15bbf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53b64dbcb5d24234b5920850cfdbdd10_I20221231" decimals="-5" name="us-gaap:DeferredCompensationPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfMy03LTEtMS04Mjc4Mg_d61efa7d-3f59-4db1-9dc6-7d7f52d2aa4b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfNC0xLTEtMS04Mjc4Mg_568480c4-a717-4642-a6d8-4746181f40df">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecab62008c846caa537823da6bf68cf_I20221231" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfNC0zLTEtMS04Mjc4Mg_ea2d104b-2488-4441-ab9e-3722d37083c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d38876b8687498fb75a9d1921176e0b_I20221231" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfNC01LTEtMS04Mjc4Mg_3723f069-cb8f-434c-a1de-4c3d9969c035">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53b64dbcb5d24234b5920850cfdbdd10_I20221231" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfNC03LTEtMS04Mjc4Mg_d299e424-ee75-4aa8-8f88-4772450a19fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5022b45891414a1794bd141aad661062_I20221231" decimals="-5" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfNS0xLTEtMS04Mjc4Mg_f7e9eba0-269f-4788-adf3-8ef8d2ce23f0">13.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd5224d49fab426a864b9ef841b2bd25_I20221231" decimals="-5" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfNS0zLTEtMS04Mjc4Mg_201e1de6-cc79-42fa-ae8c-dff3949eb6f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7fc7fba1d244cd09a928fc5c9b89075_I20221231" decimals="-5" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfNS01LTEtMS04Mjc4Mg_11e035f1-98c0-401b-ad16-b717b9afa337">13.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e31f6f4b77a4341b3844eaafe791605_I20221231" decimals="-5" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfNS03LTEtMS04Mjc4Mg_2d402e71-74c0-4b6e-922f-f95ce354cad4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity call options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3855c26361a747a6a2063f8669213b1d_I20221231" decimals="-5" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfNi0xLTEtMS04Mjc4Mg_11989bd3-3031-4b15-802f-7bb0e349387d">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba6b68a438dd4a579b4713432d302e3d_I20221231" decimals="-5" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfNi0zLTEtMS04Mjc4Mg_be15e10b-55fd-4570-85a6-0833084e945a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8ff7bccbad64151ab6ea9014d5cc59f_I20221231" decimals="-5" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfNi01LTEtMS04Mjc4Mg_16444611-bd14-4e27-ac07-07f648c5935d">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b304b4749d406ba788dcf08bc89106_I20221231" decimals="-5" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfNi03LTEtMS04Mjc4Mg_8609e82b-7a0e-477a-aa7f-01761d26f647">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfNy0xLTEtMS04Mjc4Mg_30c4d3e6-d02d-427b-8ad5-f810b33dd26a">32.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecab62008c846caa537823da6bf68cf_I20221231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfNy0zLTEtMS04Mjc4Mg_4d65fb11-2121-439d-b1d7-767e1e7d1fd2">12.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d38876b8687498fb75a9d1921176e0b_I20221231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfNy01LTEtMS04Mjc4Mg_fc96809f-1653-463f-a142-72fbef37e7ef">19.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53b64dbcb5d24234b5920850cfdbdd10_I20221231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfNy03LTEtMS04Mjc4Mg_2f19a633-5f65-4a42-9536-d7ddc5baeb2c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfOS0xLTEtMS04Mjc4Mg_c8ecf23b-86b1-45f4-9b13-9b25199b682b">4.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecab62008c846caa537823da6bf68cf_I20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfOS0zLTEtMS04Mjc4Mg_5ad006d3-8930-4a96-bf8d-f95edc6aea04">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d38876b8687498fb75a9d1921176e0b_I20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfOS01LTEtMS04Mjc4Mg_8bd63cdf-53dc-44d8-97ec-88afefcdb635">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53b64dbcb5d24234b5920850cfdbdd10_I20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfOS03LTEtMS04Mjc4Mg_a33cc124-a582-49f5-8e7d-4392b48c7ff6">4.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfMTAtMS0xLTEtODI3ODI_97550988-e3cb-4ad5-b1ab-20be0a224aaa">12.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecab62008c846caa537823da6bf68cf_I20221231" decimals="-5" name="us-gaap:OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfMTAtMy0xLTEtODI3ODI_2a2d07ab-b4a5-43b8-9b4e-de5f8a471629">12.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d38876b8687498fb75a9d1921176e0b_I20221231" decimals="-5" name="us-gaap:OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfMTAtNS0xLTEtODI3ODI_ce6ae26a-85d7-43af-b053-967dc77f7a13">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53b64dbcb5d24234b5920850cfdbdd10_I20221231" decimals="-5" name="us-gaap:OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfMTAtNy0xLTEtODI3ODI_6394329c-f199-4406-914c-95bd4f8f0b05">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1036a3de1ea4f318261a593515df52b_I20221231" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfMTEtMS0xLTEtODI3ODI_4e87dec9-7330-42c5-93d0-3cc7dddbda98">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dd9da2fad4544178dd80a8db1ca4501_I20221231" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfMTEtMy0xLTEtODI3ODI_ae3d6c84-c794-4cee-bd6f-a9a0840515a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie68882e1ec5c418487d91aaacd73759d_I20221231" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfMTEtNS0xLTEtODI3ODI_ec221539-8c98-4322-9bd5-0196d5b4cd5a">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i564b193142034a3dad5d2192d388c8df_I20221231" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfMTEtNy0xLTEtODI3ODI_36fdbefa-279d-4e76-8cb3-61254c7aff56">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfMTItMS0xLTEtODI3ODI_c1f08cb6-94a2-4f20-aece-018cae33e826">18.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecab62008c846caa537823da6bf68cf_I20221231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfMTItMy0xLTEtODI3ODI_808bbb62-be47-486d-8aeb-5a37eec4e800">12.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d38876b8687498fb75a9d1921176e0b_I20221231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfMTItNS0xLTEtODI3ODI_e009f915-e91b-40f0-af91-75df6bfaefe3">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53b64dbcb5d24234b5920850cfdbdd10_I20221231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfMTItNy0xLTEtODI3ODI_18f0c705-7c76-4892-89bd-59d0d80fc9b5">4.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred compensation assets are included within other noncurrent assets and are valued using a market approach based on quoted market prices in an active market. The fair value of our foreign currency contracts, included within other current and other noncurrent assets, as well as other current and other long-term liabilities, is valued using an income approach based on quoted forward foreign exchange rates and spot rates at the reporting date. The fair value of the cross-currency swap, included within other noncurrent assets, is valued using a market approach. Please refer to Note 9, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_58">Derivative Financial Instruments</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of our derivatives. The fair value of our commodity call options, included within other current and other noncurrent assets, is valued using a market approach. The fair value of the contingent consideration liability, within current and long-term liabilities, related to the SmartDose</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology platform (the &#8220;SmartDose</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contingent consideration&#8221;) was initially determined using a probability-weighted income approach, and is revalued at each reporting date or more frequently if circumstances dictate. Changes in the fair value of this obligation are recorded as income or expense within other expense (income) in our condensed consolidated statements of income. The fair value of deferred compensation liabilities is based on quoted prices of the underlying employees&#8217; investment selections and is included within other long-term liabilities. </span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_7">Table of Contents</a></span></div></div><ix:continuation id="ibc7cb608739a43cda0cc5553bf83e768"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Financial Instruments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the carrying amounts of our cash and cash equivalents and accounts receivable approximate their fair values due to their near-term maturities. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of long-term debt is based on quoted market prices for debt issuances with similar terms and maturities and is classified as Level 2 within the fair value hierarchy. At March&#160;31, 2023, the estimated fair value of long-term debt was $<ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RleHRyZWdpb246M2E2NWEyYmZhYTFiNDU3OGI0ZjgyMDg2MTQ5ZjcyYzNfMjk2MQ_7131a07d-e506-4733-b3b1-1c098edd33fb">201.2</ix:nonFraction> million compared to a carrying amount of $<ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RleHRyZWdpb246M2E2NWEyYmZhYTFiNDU3OGI0ZjgyMDg2MTQ5ZjcyYzNfMjk5Nw_3ca98cf0-9081-493d-8eca-616f7b77dc16">206.1</ix:nonFraction> million. At December&#160;31, 2022, the estimated fair value of long-term debt was $<ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RleHRyZWdpb246M2E2NWEyYmZhYTFiNDU3OGI0ZjgyMDg2MTQ5ZjcyYzNfMzA1NQ_c2bf7fca-c1ae-4b74-99bd-622716bde44b">201.8</ix:nonFraction> million and the carrying amount was $<ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RleHRyZWdpb246M2E2NWEyYmZhYTFiNDU3OGI0ZjgyMDg2MTQ5ZjcyYzNfMzA4Ng_248c52cc-99a1-418c-84e8-d9e93329c33b">206.7</ix:nonFraction> million.</span></div></ix:continuation><div><span><br/></span></div><div id="i7bf87d07bb544f48851c48374130181b_64"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 11:&#160;<ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RleHRyZWdpb246MTMzYTc0MjA3OWQ0NGNmOGFkNGJhNTc3MGVmNzA0YWJfNjMw_dff65dd8-2fd5-4aac-a3f2-4ae741dda98a" continuedAt="i1a27080a49cc4a71a440edc4a326cea9" escape="true">Accumulated Other Comprehensive Loss</ix:nonNumeric></span></div><ix:continuation id="i1a27080a49cc4a71a440edc4a326cea9" continuedAt="ic17f5321072b4424848f0a3bc4d1637c"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RleHRyZWdpb246MTMzYTc0MjA3OWQ0NGNmOGFkNGJhNTc3MGVmNzA0YWJfNjU4_1948ca4f-bc7f-499f-bdf2-e248f5369868" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the three months ended March&#160;31, 2023:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.726%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.878%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Losses) gains on<br/>derivatives</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in equity affiliate investment AOCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit<br/>pension and other <br/>postretirement plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign <br/>currency <br/>translation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0a2e4816674455e8c1653b4d67a05eb_I20221231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjNjNTRjM2QyNmZhYjQyZWViMDc2YTM0NDdjNjE0Zjc5L3RhYmxlcmFuZ2U6M2M1NGMzZDI2ZmFiNDJlZWIwNzZhMzQ0N2M2MTRmNzlfMS0xLTEtMS04Mjc4Mg_9dfaa790-fb8c-4635-a3f1-4784993fc058">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i526f045cc6ae4ef9aebfa54634f321c7_I20221231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjNjNTRjM2QyNmZhYjQyZWViMDc2YTM0NDdjNjE0Zjc5L3RhYmxlcmFuZ2U6M2M1NGMzZDI2ZmFiNDJlZWIwNzZhMzQ0N2M2MTRmNzlfMS0zLTEtMS04Mjc4Mg_ec49b96d-ee08-468a-be7b-409e84783c73">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b4825baaa3d4e808f9edc322c950ac0_I20221231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjNjNTRjM2QyNmZhYjQyZWViMDc2YTM0NDdjNjE0Zjc5L3RhYmxlcmFuZ2U6M2M1NGMzZDI2ZmFiNDJlZWIwNzZhMzQ0N2M2MTRmNzlfMS01LTEtMS04Mjc4Mg_90a45975-3704-4337-bc9b-69062cc9f3c9">9.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a916ac5970f44c4ae05918807b57f65_I20221231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjNjNTRjM2QyNmZhYjQyZWViMDc2YTM0NDdjNjE0Zjc5L3RhYmxlcmFuZ2U6M2M1NGMzZDI2ZmFiNDJlZWIwNzZhMzQ0N2M2MTRmNzlfMS03LTEtMS04Mjc4Mg_7e330016-1ca4-4a97-8810-b50f45dfff70">175.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6339e7f0f9e847638d0b1e918478a17b_I20221231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjNjNTRjM2QyNmZhYjQyZWViMDc2YTM0NDdjNjE0Zjc5L3RhYmxlcmFuZ2U6M2M1NGMzZDI2ZmFiNDJlZWIwNzZhMzQ0N2M2MTRmNzlfMS05LTEtMS04Mjc4Mg_419447f0-63ea-408a-9cb1-63c58d5de05a">183.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe54e8c2da3440aebf4d2616a05e64c2_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjNjNTRjM2QyNmZhYjQyZWViMDc2YTM0NDdjNjE0Zjc5L3RhYmxlcmFuZ2U6M2M1NGMzZDI2ZmFiNDJlZWIwNzZhMzQ0N2M2MTRmNzlfMi0xLTEtMS04Mjc4Mg_dd4a31b3-7b72-4477-bb21-6d6f69045db0">0.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i797411f0d816497e9411895884b514e7_D20230101-20230331" decimals="-5" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjNjNTRjM2QyNmZhYjQyZWViMDc2YTM0NDdjNjE0Zjc5L3RhYmxlcmFuZ2U6M2M1NGMzZDI2ZmFiNDJlZWIwNzZhMzQ0N2M2MTRmNzlfMi0zLTEtMS04Mjc4Mg_5e5c872a-35a9-4fa8-8d62-1c7a5c144a0b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8b0a91f9e20469aa04a865d19bf4454_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjNjNTRjM2QyNmZhYjQyZWViMDc2YTM0NDdjNjE0Zjc5L3RhYmxlcmFuZ2U6M2M1NGMzZDI2ZmFiNDJlZWIwNzZhMzQ0N2M2MTRmNzlfMi01LTEtMS04Mjc4Mg_805700b5-0350-4ccb-b1ed-be1f2ab2ccb1">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80d875680634e70a48cb73ff07b85e4_D20230101-20230331" decimals="-5" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjNjNTRjM2QyNmZhYjQyZWViMDc2YTM0NDdjNjE0Zjc5L3RhYmxlcmFuZ2U6M2M1NGMzZDI2ZmFiNDJlZWIwNzZhMzQ0N2M2MTRmNzlfMi03LTEtMS04Mjc4Mg_832f0680-7978-4a82-9b5d-8dc3342794e6">15.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjNjNTRjM2QyNmZhYjQyZWViMDc2YTM0NDdjNjE0Zjc5L3RhYmxlcmFuZ2U6M2M1NGMzZDI2ZmFiNDJlZWIwNzZhMzQ0N2M2MTRmNzlfMi05LTEtMS04Mjc4Mg_6ef0dc28-1268-4e69-bb5d-a128515b2608">14.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified out from accumulated other comprehensive income (loss)  </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe54e8c2da3440aebf4d2616a05e64c2_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjNjNTRjM2QyNmZhYjQyZWViMDc2YTM0NDdjNjE0Zjc5L3RhYmxlcmFuZ2U6M2M1NGMzZDI2ZmFiNDJlZWIwNzZhMzQ0N2M2MTRmNzlfMy0xLTEtMS04Mjc4Mg_b57c46db-cea8-4a14-98ca-6ad8029bc604">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i797411f0d816497e9411895884b514e7_D20230101-20230331" decimals="-5" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjNjNTRjM2QyNmZhYjQyZWViMDc2YTM0NDdjNjE0Zjc5L3RhYmxlcmFuZ2U6M2M1NGMzZDI2ZmFiNDJlZWIwNzZhMzQ0N2M2MTRmNzlfMy0zLTEtMS04Mjc4Mg_f6e9d9e7-b02d-45a7-aca0-f347ffad2026">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8b0a91f9e20469aa04a865d19bf4454_D20230101-20230331" decimals="-5" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjNjNTRjM2QyNmZhYjQyZWViMDc2YTM0NDdjNjE0Zjc5L3RhYmxlcmFuZ2U6M2M1NGMzZDI2ZmFiNDJlZWIwNzZhMzQ0N2M2MTRmNzlfMy01LTEtMS04Mjc4Mg_4dde5a40-c72c-4699-8451-f7d37cd112e1">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80d875680634e70a48cb73ff07b85e4_D20230101-20230331" decimals="-5" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjNjNTRjM2QyNmZhYjQyZWViMDc2YTM0NDdjNjE0Zjc5L3RhYmxlcmFuZ2U6M2M1NGMzZDI2ZmFiNDJlZWIwNzZhMzQ0N2M2MTRmNzlfMy03LTEtMS04Mjc4Mg_7c7f2616-8a44-4a17-946b-972a0c6c6b67">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjNjNTRjM2QyNmZhYjQyZWViMDc2YTM0NDdjNjE0Zjc5L3RhYmxlcmFuZ2U6M2M1NGMzZDI2ZmFiNDJlZWIwNzZhMzQ0N2M2MTRmNzlfMy05LTEtMS04Mjc4Mg_4859b982-1481-49cd-b2d3-9f2ca5645de8">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe54e8c2da3440aebf4d2616a05e64c2_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjNjNTRjM2QyNmZhYjQyZWViMDc2YTM0NDdjNjE0Zjc5L3RhYmxlcmFuZ2U6M2M1NGMzZDI2ZmFiNDJlZWIwNzZhMzQ0N2M2MTRmNzlfNC0xLTEtMS04Mjc4Mg_de7fa52c-8f72-4131-b71b-fd1024e24706">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i797411f0d816497e9411895884b514e7_D20230101-20230331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjNjNTRjM2QyNmZhYjQyZWViMDc2YTM0NDdjNjE0Zjc5L3RhYmxlcmFuZ2U6M2M1NGMzZDI2ZmFiNDJlZWIwNzZhMzQ0N2M2MTRmNzlfNC0zLTEtMS04Mjc4Mg_bf0aaef6-0d00-479f-856d-bdfd8fa02942">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8b0a91f9e20469aa04a865d19bf4454_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjNjNTRjM2QyNmZhYjQyZWViMDc2YTM0NDdjNjE0Zjc5L3RhYmxlcmFuZ2U6M2M1NGMzZDI2ZmFiNDJlZWIwNzZhMzQ0N2M2MTRmNzlfNC01LTEtMS04Mjc4Mg_8c79f3ca-0761-41e8-8566-d1ef75857682">0.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80d875680634e70a48cb73ff07b85e4_D20230101-20230331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjNjNTRjM2QyNmZhYjQyZWViMDc2YTM0NDdjNjE0Zjc5L3RhYmxlcmFuZ2U6M2M1NGMzZDI2ZmFiNDJlZWIwNzZhMzQ0N2M2MTRmNzlfNC03LTEtMS04Mjc4Mg_caeb04e2-c45a-473e-9ff9-bbff2fb084bc">15.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjNjNTRjM2QyNmZhYjQyZWViMDc2YTM0NDdjNjE0Zjc5L3RhYmxlcmFuZ2U6M2M1NGMzZDI2ZmFiNDJlZWIwNzZhMzQ0N2M2MTRmNzlfNC05LTEtMS04Mjc4Mg_dc531131-cb7a-497d-8b91-b524f5953f64">14.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a6e09ceadea4cf28bdd80365b649ab0_I20230331" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjNjNTRjM2QyNmZhYjQyZWViMDc2YTM0NDdjNjE0Zjc5L3RhYmxlcmFuZ2U6M2M1NGMzZDI2ZmFiNDJlZWIwNzZhMzQ0N2M2MTRmNzlfNS0xLTEtMS04Mjc4Mg_c86b7d46-27d4-4f29-8f11-004db01eef44">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60c9aeeca640474289ca4b0da5cf3a7d_I20230331" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjNjNTRjM2QyNmZhYjQyZWViMDc2YTM0NDdjNjE0Zjc5L3RhYmxlcmFuZ2U6M2M1NGMzZDI2ZmFiNDJlZWIwNzZhMzQ0N2M2MTRmNzlfNS0zLTEtMS04Mjc4Mg_c983b3b1-cf51-41ad-9de8-0d6d0ca9dd1b">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic60c39b0c368406f8cd641a4d764ddc1_I20230331" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjNjNTRjM2QyNmZhYjQyZWViMDc2YTM0NDdjNjE0Zjc5L3RhYmxlcmFuZ2U6M2M1NGMzZDI2ZmFiNDJlZWIwNzZhMzQ0N2M2MTRmNzlfNS01LTEtMS04Mjc4Mg_6532b558-9f1e-4912-b020-c9dddd705b56">9.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5cd3bf0b3e6469e9da46a298c4c805d_I20230331" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjNjNTRjM2QyNmZhYjQyZWViMDc2YTM0NDdjNjE0Zjc5L3RhYmxlcmFuZ2U6M2M1NGMzZDI2ZmFiNDJlZWIwNzZhMzQ0N2M2MTRmNzlfNS03LTEtMS04Mjc4Mg_6837d7b6-89c8-4d55-9c75-c67a3caf433f">160.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6630ce4dbb7747e8858856ea430b90ab_I20230331" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjNjNTRjM2QyNmZhYjQyZWViMDc2YTM0NDdjNjE0Zjc5L3RhYmxlcmFuZ2U6M2M1NGMzZDI2ZmFiNDJlZWIwNzZhMzQ0N2M2MTRmNzlfNS05LTEtMS04Mjc4Mg_ec349eff-217e-4fe4-8597-4d4997e427bb">168.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the three months ended March&#160;31, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.726%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.878%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Losses) gains on<br/>derivatives</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in equity affiliate investment AOCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit<br/>pension and other <br/>postretirement plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign <br/>currency <br/>translation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4fca80d6c8df481687a29bccfb487856_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjAzMjIzNDRiZWFmZTQ4NGZiODQyMDEyOTVjMjUxNzU5L3RhYmxlcmFuZ2U6MDMyMjM0NGJlYWZlNDg0ZmI4NDIwMTI5NWMyNTE3NTlfMS0xLTEtMS04Mjc4Mg_39bac2de-30d2-44e3-b064-835d83c01269">1.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c6c1d8c2b4f4a0b89ca2e9a9ddd447c_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjAzMjIzNDRiZWFmZTQ4NGZiODQyMDEyOTVjMjUxNzU5L3RhYmxlcmFuZ2U6MDMyMjM0NGJlYWZlNDg0ZmI4NDIwMTI5NWMyNTE3NTlfMS0zLTEtMS04Mjc4Mg_07cad67a-296c-4107-8b78-7f6439cdd591">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a3f5a8af8064476820608f696c42e1d_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjAzMjIzNDRiZWFmZTQ4NGZiODQyMDEyOTVjMjUxNzU5L3RhYmxlcmFuZ2U6MDMyMjM0NGJlYWZlNDg0ZmI4NDIwMTI5NWMyNTE3NTlfMS01LTEtMS04Mjc4Mg_68ecc4cf-1b8f-468e-b1fb-16ebe45b0062">31.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i936367d439194b7fbc90a34743134e4f_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjAzMjIzNDRiZWFmZTQ4NGZiODQyMDEyOTVjMjUxNzU5L3RhYmxlcmFuZ2U6MDMyMjM0NGJlYWZlNDg0ZmI4NDIwMTI5NWMyNTE3NTlfMS03LTEtMS04Mjc4Mg_98c76629-bb80-436d-ad86-889b1bbf23d4">128.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0df22a14170c4331a1256c9f757e5090_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjAzMjIzNDRiZWFmZTQ4NGZiODQyMDEyOTVjMjUxNzU5L3RhYmxlcmFuZ2U6MDMyMjM0NGJlYWZlNDg0ZmI4NDIwMTI5NWMyNTE3NTlfMS05LTEtMS04Mjc4Mg_ef6bcf67-b0fb-4fdf-a618-aa59707d3247">159.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie71d1ab95f7344af96897b0090a0e58d_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjAzMjIzNDRiZWFmZTQ4NGZiODQyMDEyOTVjMjUxNzU5L3RhYmxlcmFuZ2U6MDMyMjM0NGJlYWZlNDg0ZmI4NDIwMTI5NWMyNTE3NTlfMi0xLTEtMS04Mjc4Mg_89f8a170-393e-4a22-9a37-9003d1480d2d">1.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia67d15eb184042d897c6efc17a13b799_D20220101-20220331" decimals="-5" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjAzMjIzNDRiZWFmZTQ4NGZiODQyMDEyOTVjMjUxNzU5L3RhYmxlcmFuZ2U6MDMyMjM0NGJlYWZlNDg0ZmI4NDIwMTI5NWMyNTE3NTlfMi0zLTEtMS04Mjc4Mg_9c19a062-c24d-48dc-b58d-dea226b5e970">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i111ee7c976334a21a8a888af218b7e87_D20220101-20220331" decimals="-5" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjAzMjIzNDRiZWFmZTQ4NGZiODQyMDEyOTVjMjUxNzU5L3RhYmxlcmFuZ2U6MDMyMjM0NGJlYWZlNDg0ZmI4NDIwMTI5NWMyNTE3NTlfMi01LTEtMS04Mjc4Mg_a72d286e-02ad-4355-bdfa-63ae38bb13ba">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6421c8aef05242b2af4fa57c824c4efa_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjAzMjIzNDRiZWFmZTQ4NGZiODQyMDEyOTVjMjUxNzU5L3RhYmxlcmFuZ2U6MDMyMjM0NGJlYWZlNDg0ZmI4NDIwMTI5NWMyNTE3NTlfMi03LTEtMS04Mjc4Mg_de013afc-b9bf-4180-bf95-cfe950c286d9">22.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjAzMjIzNDRiZWFmZTQ4NGZiODQyMDEyOTVjMjUxNzU5L3RhYmxlcmFuZ2U6MDMyMjM0NGJlYWZlNDg0ZmI4NDIwMTI5NWMyNTE3NTlfMi05LTEtMS04Mjc4Mg_18e84c48-bd58-471e-9180-98c324caf0f5">23.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified out from accumulated other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie71d1ab95f7344af96897b0090a0e58d_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjAzMjIzNDRiZWFmZTQ4NGZiODQyMDEyOTVjMjUxNzU5L3RhYmxlcmFuZ2U6MDMyMjM0NGJlYWZlNDg0ZmI4NDIwMTI5NWMyNTE3NTlfMy0xLTEtMS04Mjc4Mg_9750ea6a-774e-4da2-8fac-20b80e17500d">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia67d15eb184042d897c6efc17a13b799_D20220101-20220331" decimals="-5" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjAzMjIzNDRiZWFmZTQ4NGZiODQyMDEyOTVjMjUxNzU5L3RhYmxlcmFuZ2U6MDMyMjM0NGJlYWZlNDg0ZmI4NDIwMTI5NWMyNTE3NTlfMy0zLTEtMS04Mjc4Mg_49016e02-fd5b-4b2b-969e-8f30d1c10cfa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i111ee7c976334a21a8a888af218b7e87_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjAzMjIzNDRiZWFmZTQ4NGZiODQyMDEyOTVjMjUxNzU5L3RhYmxlcmFuZ2U6MDMyMjM0NGJlYWZlNDg0ZmI4NDIwMTI5NWMyNTE3NTlfMy01LTEtMS04Mjc4Mg_b52934f8-efb9-4fdc-b44e-22e27c853357">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6421c8aef05242b2af4fa57c824c4efa_D20220101-20220331" decimals="-5" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjAzMjIzNDRiZWFmZTQ4NGZiODQyMDEyOTVjMjUxNzU5L3RhYmxlcmFuZ2U6MDMyMjM0NGJlYWZlNDg0ZmI4NDIwMTI5NWMyNTE3NTlfMy03LTEtMS04Mjc4Mg_efca7060-3042-4a96-a7c7-a587630feed8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjAzMjIzNDRiZWFmZTQ4NGZiODQyMDEyOTVjMjUxNzU5L3RhYmxlcmFuZ2U6MDMyMjM0NGJlYWZlNDg0ZmI4NDIwMTI5NWMyNTE3NTlfMy05LTEtMS04Mjc4Mg_5fafb3af-0a06-4b6c-a6f9-4f7f90cc2534">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie71d1ab95f7344af96897b0090a0e58d_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjAzMjIzNDRiZWFmZTQ4NGZiODQyMDEyOTVjMjUxNzU5L3RhYmxlcmFuZ2U6MDMyMjM0NGJlYWZlNDg0ZmI4NDIwMTI5NWMyNTE3NTlfNC0xLTEtMS04Mjc4Mg_2cbc5763-f14e-4561-820f-65fa9c02108b">1.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia67d15eb184042d897c6efc17a13b799_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjAzMjIzNDRiZWFmZTQ4NGZiODQyMDEyOTVjMjUxNzU5L3RhYmxlcmFuZ2U6MDMyMjM0NGJlYWZlNDg0ZmI4NDIwMTI5NWMyNTE3NTlfNC0zLTEtMS04Mjc4Mg_fd427319-8bd5-4365-929e-f84ccee9e09e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i111ee7c976334a21a8a888af218b7e87_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjAzMjIzNDRiZWFmZTQ4NGZiODQyMDEyOTVjMjUxNzU5L3RhYmxlcmFuZ2U6MDMyMjM0NGJlYWZlNDg0ZmI4NDIwMTI5NWMyNTE3NTlfNC01LTEtMS04Mjc4Mg_59a17e9a-82ff-49ef-8455-0c1f4edb8e3d">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6421c8aef05242b2af4fa57c824c4efa_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjAzMjIzNDRiZWFmZTQ4NGZiODQyMDEyOTVjMjUxNzU5L3RhYmxlcmFuZ2U6MDMyMjM0NGJlYWZlNDg0ZmI4NDIwMTI5NWMyNTE3NTlfNC03LTEtMS04Mjc4Mg_1d577540-95c5-419d-bb69-0c5df24ae60c">22.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjAzMjIzNDRiZWFmZTQ4NGZiODQyMDEyOTVjMjUxNzU5L3RhYmxlcmFuZ2U6MDMyMjM0NGJlYWZlNDg0ZmI4NDIwMTI5NWMyNTE3NTlfNC05LTEtMS04Mjc4Mg_986f3c4a-2d7f-4143-bdd4-45663ae71699">22.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a6c194a67cd4b14b2fe810f1803d2fa_I20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjAzMjIzNDRiZWFmZTQ4NGZiODQyMDEyOTVjMjUxNzU5L3RhYmxlcmFuZ2U6MDMyMjM0NGJlYWZlNDg0ZmI4NDIwMTI5NWMyNTE3NTlfNS0xLTEtMS04Mjc4Mg_681fdb55-2489-4074-b3e4-f508e2cb4644">2.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d499d767e34686aa1263510f1d36a3_I20220331" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjAzMjIzNDRiZWFmZTQ4NGZiODQyMDEyOTVjMjUxNzU5L3RhYmxlcmFuZ2U6MDMyMjM0NGJlYWZlNDg0ZmI4NDIwMTI5NWMyNTE3NTlfNS0zLTEtMS04Mjc4Mg_583842be-fa2f-40ea-9d38-1891756a2551">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i43311d97b8684c7d99964d6c9ce008f6_I20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjAzMjIzNDRiZWFmZTQ4NGZiODQyMDEyOTVjMjUxNzU5L3RhYmxlcmFuZ2U6MDMyMjM0NGJlYWZlNDg0ZmI4NDIwMTI5NWMyNTE3NTlfNS01LTEtMS04Mjc4Mg_329ef849-a43d-4af9-b017-5bebfc10e6f6">30.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i90887b06cf074badac168937eaf76a7d_I20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjAzMjIzNDRiZWFmZTQ4NGZiODQyMDEyOTVjMjUxNzU5L3RhYmxlcmFuZ2U6MDMyMjM0NGJlYWZlNDg0ZmI4NDIwMTI5NWMyNTE3NTlfNS03LTEtMS04Mjc4Mg_d1560c4e-2bbf-41ab-8ff0-7cd35578c195">150.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i83a0a64e641241259400ffb042bd9b69_I20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjAzMjIzNDRiZWFmZTQ4NGZiODQyMDEyOTVjMjUxNzU5L3RhYmxlcmFuZ2U6MDMyMjM0NGJlYWZlNDg0ZmI4NDIwMTI5NWMyNTE3NTlfNS05LTEtMS04Mjc4Mg_0b184b4a-3a7b-47c3-b88f-b8cf2075a58f">182.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_7">Table of Contents</a></span></div></div><ix:continuation id="ic17f5321072b4424848f0a3bc4d1637c"><ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RleHRyZWdpb246MTMzYTc0MjA3OWQ0NGNmOGFkNGJhNTc3MGVmNzA0YWJfNjU5_af5c8e34-2690-498d-af77-f9bebd57eb1d" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the reclassifications out of accumulated other comprehensive loss is presented in the following table: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.267%"></td><td style="width:0.1%"></td></tr><tr style="height:35pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Location on Statement of Income</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Detail of components</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Losses) gains on derivatives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a7ae72bcc2f46119331a447f5c3150d_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOmEzNzE3ZTAyNDM3YTQxZTE5MDEyYjNjYjBhMjczMTRkL3RhYmxlcmFuZ2U6YTM3MTdlMDI0MzdhNDFlMTkwMTJiM2NiMGEyNzMxNGRfMy0yLTEtMS04Mjc4Mg_39a5f41e-d603-4b90-9aca-48a138735bca">0.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0c261740c340ebb7fdb92c09b03f4e_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOmEzNzE3ZTAyNDM3YTQxZTE5MDEyYjNjYjBhMjczMTRkL3RhYmxlcmFuZ2U6YTM3MTdlMDI0MzdhNDFlMTkwMTJiM2NiMGEyNzMxNGRfMy00LTEtMS04Mjc4Mg_6281c888-c6ed-440e-a503-91b44f3b7e53">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a7ae72bcc2f46119331a447f5c3150d_D20230101-20230331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOmEzNzE3ZTAyNDM3YTQxZTE5MDEyYjNjYjBhMjczMTRkL3RhYmxlcmFuZ2U6YTM3MTdlMDI0MzdhNDFlMTkwMTJiM2NiMGEyNzMxNGRfNC0yLTEtMS04Mjc4Mg_508b95a9-5ec9-4aa4-bc61-2aa6875ad7fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d0c261740c340ebb7fdb92c09b03f4e_D20220101-20220331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOmEzNzE3ZTAyNDM3YTQxZTE5MDEyYjNjYjBhMjczMTRkL3RhYmxlcmFuZ2U6YTM3MTdlMDI0MzdhNDFlMTkwMTJiM2NiMGEyNzMxNGRfNC00LTEtMS04Mjc4Mg_3748c1e7-afee-43a5-be7f-22eb908c1f3e">0.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods and services sold</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward treasury locks</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e3c4dec591644f5b67d216f6b423622_D20230101-20230331" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOmEzNzE3ZTAyNDM3YTQxZTE5MDEyYjNjYjBhMjczMTRkL3RhYmxlcmFuZ2U6YTM3MTdlMDI0MzdhNDFlMTkwMTJiM2NiMGEyNzMxNGRfNi0yLTEtMS04Mjc4Mg_5488087e-f4f3-447e-bf9c-d2551828e05c">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6588c22fb7d242729097d46bc107e464_D20220101-20220331" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOmEzNzE3ZTAyNDM3YTQxZTE5MDEyYjNjYjBhMjczMTRkL3RhYmxlcmFuZ2U6YTM3MTdlMDI0MzdhNDFlMTkwMTJiM2NiMGEyNzMxNGRfNi00LTEtMS04Mjc4Mg_b42af8cb-e200-40e5-8e7c-603086e0d904">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c7ca8ad39694e71b583c7ef4a4b1e4d_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOmEzNzE3ZTAyNDM3YTQxZTE5MDEyYjNjYjBhMjczMTRkL3RhYmxlcmFuZ2U6YTM3MTdlMDI0MzdhNDFlMTkwMTJiM2NiMGEyNzMxNGRfNy0yLTEtMS04Mjc4Mg_7b577a87-656d-4a57-abb4-90805fba008c">0.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i840ed86b8d83428dae98a9709644d509_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOmEzNzE3ZTAyNDM3YTQxZTE5MDEyYjNjYjBhMjczMTRkL3RhYmxlcmFuZ2U6YTM3MTdlMDI0MzdhNDFlMTkwMTJiM2NiMGEyNzMxNGRfNy00LTEtMS04Mjc4Mg_773e441c-6e08-4ba0-8111-4b91619a5a5d">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c7ca8ad39694e71b583c7ef4a4b1e4d_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOmEzNzE3ZTAyNDM3YTQxZTE5MDEyYjNjYjBhMjczMTRkL3RhYmxlcmFuZ2U6YTM3MTdlMDI0MzdhNDFlMTkwMTJiM2NiMGEyNzMxNGRfOC0yLTEtMS04Mjc4Mg_06c0a9cc-d56d-45a4-8e5a-a0621310fb97">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i840ed86b8d83428dae98a9709644d509_D20220101-20220331" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOmEzNzE3ZTAyNDM3YTQxZTE5MDEyYjNjYjBhMjczMTRkL3RhYmxlcmFuZ2U6YTM3MTdlMDI0MzdhNDFlMTkwMTJiM2NiMGEyNzMxNGRfOC00LTEtMS04Mjc4Mg_503eab72-79d4-4fa7-87dd-85ccca965794">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c7ca8ad39694e71b583c7ef4a4b1e4d_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOmEzNzE3ZTAyNDM3YTQxZTE5MDEyYjNjYjBhMjczMTRkL3RhYmxlcmFuZ2U6YTM3MTdlMDI0MzdhNDFlMTkwMTJiM2NiMGEyNzMxNGRfOS0yLTEtMS04Mjc4Mg_6acda5f0-2dc6-418f-8617-97b3639fc2c0">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i840ed86b8d83428dae98a9709644d509_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOmEzNzE3ZTAyNDM3YTQxZTE5MDEyYjNjYjBhMjczMTRkL3RhYmxlcmFuZ2U6YTM3MTdlMDI0MzdhNDFlMTkwMTJiM2NiMGEyNzMxNGRfOS00LTEtMS04Mjc4Mg_fa67e9bd-4c81-4c8a-bb70-99632419fd0c">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of defined benefit pension and other postretirement plans:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial gains</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie947ff5eae324b458a796759ec01b073_D20230101-20230331" decimals="-5" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOmEzNzE3ZTAyNDM3YTQxZTE5MDEyYjNjYjBhMjczMTRkL3RhYmxlcmFuZ2U6YTM3MTdlMDI0MzdhNDFlMTkwMTJiM2NiMGEyNzMxNGRfMTItMi0xLTEtODI3ODI_149c59da-0c9b-446f-b86c-6394b2ab4548">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i051025edf9d84083b951a5c2120b859e_D20220101-20220331" decimals="-5" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOmEzNzE3ZTAyNDM3YTQxZTE5MDEyYjNjYjBhMjczMTRkL3RhYmxlcmFuZ2U6YTM3MTdlMDI0MzdhNDFlMTkwMTJiM2NiMGEyNzMxNGRfMTItNC0xLTEtODI3ODI_f4c3e5b2-3fa6-4c19-abf7-7b13b29fc6fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie947ff5eae324b458a796759ec01b073_D20230101-20230331" decimals="-5" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOmEzNzE3ZTAyNDM3YTQxZTE5MDEyYjNjYjBhMjczMTRkL3RhYmxlcmFuZ2U6YTM3MTdlMDI0MzdhNDFlMTkwMTJiM2NiMGEyNzMxNGRfMTMtMi0xLTEtODI3ODI_72aed061-dde5-49f4-88c7-c05f273bba5e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i051025edf9d84083b951a5c2120b859e_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOmEzNzE3ZTAyNDM3YTQxZTE5MDEyYjNjYjBhMjczMTRkL3RhYmxlcmFuZ2U6YTM3MTdlMDI0MzdhNDFlMTkwMTJiM2NiMGEyNzMxNGRfMTMtNC0xLTEtODI3ODI_f8fb1a4b-5148-4431-9df8-0279e6da2582">0.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie947ff5eae324b458a796759ec01b073_D20230101-20230331" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOmEzNzE3ZTAyNDM3YTQxZTE5MDEyYjNjYjBhMjczMTRkL3RhYmxlcmFuZ2U6YTM3MTdlMDI0MzdhNDFlMTkwMTJiM2NiMGEyNzMxNGRfMTQtMi0xLTEtODI3ODI_dbce5bf1-475b-41ce-8436-5c8460f02a31">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i051025edf9d84083b951a5c2120b859e_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOmEzNzE3ZTAyNDM3YTQxZTE5MDEyYjNjYjBhMjczMTRkL3RhYmxlcmFuZ2U6YTM3MTdlMDI0MzdhNDFlMTkwMTJiM2NiMGEyNzMxNGRfMTQtNC0xLTEtODI3ODI_24ef0965-701e-4fbf-b7bb-bad0704ec44e">0.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax (expense) benefit </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie947ff5eae324b458a796759ec01b073_D20230101-20230331" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOmEzNzE3ZTAyNDM3YTQxZTE5MDEyYjNjYjBhMjczMTRkL3RhYmxlcmFuZ2U6YTM3MTdlMDI0MzdhNDFlMTkwMTJiM2NiMGEyNzMxNGRfMTUtMi0xLTEtODI3ODI_eb58725e-6fda-4625-a1ca-2f473f21e8ed">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i051025edf9d84083b951a5c2120b859e_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOmEzNzE3ZTAyNDM3YTQxZTE5MDEyYjNjYjBhMjczMTRkL3RhYmxlcmFuZ2U6YTM3MTdlMDI0MzdhNDFlMTkwMTJiM2NiMGEyNzMxNGRfMTUtNC0xLTEtODI3ODI_4b913ac8-c6dc-49a3-a340-ea72afb4b722">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie947ff5eae324b458a796759ec01b073_D20230101-20230331" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOmEzNzE3ZTAyNDM3YTQxZTE5MDEyYjNjYjBhMjczMTRkL3RhYmxlcmFuZ2U6YTM3MTdlMDI0MzdhNDFlMTkwMTJiM2NiMGEyNzMxNGRfMTYtMi0xLTEtODI3ODI_2ee76e44-3c28-4dc2-a2a0-5826dc05ee44">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i051025edf9d84083b951a5c2120b859e_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOmEzNzE3ZTAyNDM3YTQxZTE5MDEyYjNjYjBhMjczMTRkL3RhYmxlcmFuZ2U6YTM3MTdlMDI0MzdhNDFlMTkwMTJiM2NiMGEyNzMxNGRfMTYtNC0xLTEtODI3ODI_4e5c2737-64a4-45e1-b9c5-6e1d82b91d61">0.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications for the period, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i594dfb15b16f4f3b94b3e4c667ae6f31_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOmEzNzE3ZTAyNDM3YTQxZTE5MDEyYjNjYjBhMjczMTRkL3RhYmxlcmFuZ2U6YTM3MTdlMDI0MzdhNDFlMTkwMTJiM2NiMGEyNzMxNGRfMTctMi0xLTEtODI3ODI_d007806c-1187-4f4c-be38-ba09e2844f1d">0.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0cbe79b5a944e7ea8c8155a043cfb0c_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOmEzNzE3ZTAyNDM3YTQxZTE5MDEyYjNjYjBhMjczMTRkL3RhYmxlcmFuZ2U6YTM3MTdlMDI0MzdhNDFlMTkwMTJiM2NiMGEyNzMxNGRfMTctNC0xLTEtODI3ODI_d069c28d-7ce2-4c18-877f-890a2e2ea061">0.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) These components are included in the computation of net periodic benefit cost. Please refer to Note 14, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_73">Benefit Plans</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional details.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="i7bf87d07bb544f48851c48374130181b_67"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 12: <ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RleHRyZWdpb246NDNkNTgwZGQ3ZWRmNGY2M2IyNzY4ZmEzYzlkNzg4ZTZfMjAw_10fbc855-88d8-44b2-b7f6-e4efc4af9b82" continuedAt="id663871703b44cfc96c9ed64d044b23f" escape="true">Shareholders</ix:nonNumeric></span><ix:continuation id="id663871703b44cfc96c9ed64d044b23f" continuedAt="ib230031edeee4fe1a33781a7e998d227"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Equity</span></ix:continuation></div><div><span><br/></span></div><ix:continuation id="ib230031edeee4fe1a33781a7e998d227"><ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="us-gaap:ScheduleOfStockholdersEquityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RleHRyZWdpb246NDNkNTgwZGQ3ZWRmNGY2M2IyNzY4ZmEzYzlkNzg4ZTZfMjA0_f9b1c01d-d6c8-45f9-9450-58ad9deac587" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in shareholders&#8217; equity for the three months ended March&#160;31, 2023:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.895%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.728%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.886%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.728%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.390%"></td><td style="width:0.1%"></td></tr><tr style="height:30pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Shares Issued</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital in Excess of Par Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of Treasury Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5974879a41634c43937d0fdc678376ef_I20221231" decimals="-5" name="us-gaap:SharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfMi0xLTEtMS04Mjc4Mg_e4f9af0f-2dce-4c4e-8b14-4be1ddc1f48f">75.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5974879a41634c43937d0fdc678376ef_I20221231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfMi0zLTEtMS04Mjc4Mg_04b75f33-4140-4b9f-a4d7-bf1af8b978a0">18.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e4f2583d5104db2b4d1e647dc99032f_I20221231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfMi01LTEtMS04Mjc4Mg_18bbc905-700a-453a-8465-1ff600d118b8">232.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i516dc67ea1934343bbf9ab9c724c74fe_I20221231" decimals="-5" name="us-gaap:TreasuryStockCommonShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfMi03LTEtMS04Mjc4Mg_1a13fc3a-e693-41a6-bd17-318c20e4947f">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i516dc67ea1934343bbf9ab9c724c74fe_I20221231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfMi05LTEtMS04Mjc4Mg_8d1f688b-ab1e-4d32-bc41-6e0137447fa8">370.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ad958aa230d4452800e1a411e50a1da_I20221231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfMi0xMS0xLTEtODI3ODI_f192a78e-8109-4121-8219-c748cb5bba52">2,987.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6339e7f0f9e847638d0b1e918478a17b_I20221231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfMi0xMy0xLTEtODI3ODI_d9a49660-b07b-444c-a615-c7229495cae3">183.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfMi0xNS0xLTEtODI3ODI_3a579f72-336f-49a6-857d-f12168a0af9f">2,684.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c00de3c1e304a8ba1d6c714fc5be20a_D20230101-20230331" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfMy0xMS0xLTEtODI3ODI_765c42a3-c540-4f64-b7d4-f433c955397e">140.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfMy0xNS0xLTEtODI3ODI_b2ff9db7-9fe9-457b-8df3-02811c01321f">140.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i353cb27834c543849553e5d0b7bbf5c1_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfNC01LTEtMS04Mjc4Mg_eb021fee-392f-4f06-9cfd-ddf111cbb63b">50.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ica8dcddf1bfb4c518886c671739fd284_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfNC03LTEtMS04Mjc4Mg_8525a3f4-bdc1-41de-a10d-d6bd9db7e705">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica8dcddf1bfb4c518886c671739fd284_D20230101-20230331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfNC05LTEtMS04Mjc4Mg_684daec1-f8de-497c-8c43-1e7d7dc3c32e">61.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfNC0xNS0xLTEtODI3ODI_8e339fcf-ea81-4627-bacf-c94bd840f66b">11.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares purchased under share repurchase program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ica8dcddf1bfb4c518886c671739fd284_D20230101-20230331" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfNS03LTEtMS04Mjc4Mg_77346de3-4ef6-4534-902b-c5bdb397b5b6">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica8dcddf1bfb4c518886c671739fd284_D20230101-20230331" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfNS05LTEtMS04Mjc4Mg_2b7505fa-df1c-43b7-8eec-8f8baa66e90d">60.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfNS0xNS0xLTEtODI3ODI_bb526302-8725-49a4-9e67-fd3d3c315497">60.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends declared ($<ix:nonFraction unitRef="usdPerShare" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfNi0wLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOjFhOTljNTU5MDMzNTQ4MjViODA2NTdhNzgxZDAxMzBjXzI0_de04a3a0-82cf-45b0-8718-8b07f7888d72">0.19</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c00de3c1e304a8ba1d6c714fc5be20a_D20230101-20230331" decimals="-5" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfNi0xMS0xLTEtODI3ODI_8128eeb7-53b0-4b83-9ec1-571a85d9791b">14.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfNi0xNS0xLTEtODI3ODI_f75f420e-24d7-443e-b4a8-97a9aa3dccdb">14.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b66fb1404f0411794600214ad5981bc_D20230101-20230331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfNy0xMy0xLTEtODI3ODI_6f2defa5-6d14-482f-8fc2-742cf2113000">14.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfNy0xNS0xLTEtODI3ODI_606a7a47-75b8-4207-a234-89b995958d5e">14.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if8c8c941591f438a9e38e52390bd7143_I20230331" decimals="-5" name="us-gaap:SharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfOC0xLTEtMS04Mjc4Mg_c62a8dc3-edef-4d81-a486-37e520d2439f">75.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c8c941591f438a9e38e52390bd7143_I20230331" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfOC0zLTEtMS04Mjc4Mg_0b664d42-7c5b-4e01-8111-4f8dffb9c04a">18.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ca2730fabca4305a997b6e33c1c770e_I20230331" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfOC01LTEtMS04Mjc4Mg_70dc814b-d6e2-451f-988a-4f9f517b4d35">181.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8b96f9bbddfb400fb15bf48690acfac4_I20230331" decimals="-5" name="us-gaap:TreasuryStockCommonShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfOC03LTEtMS04Mjc4Mg_4a93fac1-70cb-4f0a-a3f1-1b75b3b2dd38">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b96f9bbddfb400fb15bf48690acfac4_I20230331" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfOC05LTEtMS04Mjc4Mg_a7d2047c-8c1d-4135-825c-12ee5b8b138d">369.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24c88cbf61274655b654ef8032885498_I20230331" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfOC0xMS0xLTEtODI3ODI_7afa6ae1-3959-49f3-a003-7834637fdf98">3,113.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6630ce4dbb7747e8858856ea430b90ab_I20230331" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfOC0xMy0xLTEtODI3ODI_597f8659-01e3-4bf3-a869-f9c71570f679">168.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfOC0xNS0xLTEtODI3ODI_25aba86d-ef25-4b43-b81e-33decfa0cea3">2,776.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in shareholders&#8217; equity for the three months ended March&#160;31, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.895%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.728%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.886%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.728%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.390%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Shares Issued</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital in Excess of Par Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of Treasury Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic9824a1206b949e9a0e697dab83ac7c1_I20211231" decimals="-5" name="us-gaap:SharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfMi0xLTEtMS04Mjc4Mg_3b33d79c-38c1-4d6e-9097-634f866db7d9">75.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9824a1206b949e9a0e697dab83ac7c1_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfMi0zLTEtMS04Mjc4Mg_cf4fb4f4-80f9-4133-9391-ee574e09ba73">18.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18b4fa445330470da5ef68248c88e734_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfMi01LTEtMS04Mjc4Mg_eda24a2d-2364-431d-bd1d-212ab0f2a28d">249.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i32ef532505b441b1806a8f09cd91cd70_I20211231" decimals="-5" name="us-gaap:TreasuryStockCommonShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfMi03LTEtMS04Mjc4Mg_dbd576bf-0b48-4003-8361-f436c7d75aea">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i32ef532505b441b1806a8f09cd91cd70_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfMi05LTEtMS04Mjc4Mg_a37754f1-c64b-4067-9355-f34de1627d7d">229.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32bd0566d819471cba804ab5cc28ab44_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfMi0xMS0xLTEtODI3ODI_ac946b65-fd6b-4995-a486-14e10bcf046f">2,456.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0df22a14170c4331a1256c9f757e5090_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfMi0xMy0xLTEtODI3ODI_ff553eb2-d25d-46d4-9625-f2ab2c1e40f3">159.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00c9b6f38a304d5190000b6168ba7dce_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfMi0xNS0xLTEtODI3ODI_05c775b1-f962-4ae2-a656-f638b277e25b">2,335.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8e072fd9e914a71afd49e2d9a5e79c6_D20220101-20220331" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfMy0xMS0xLTEtODI3ODI_d98224a6-3894-4cf1-beec-e54147c9e7b0">173.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfMy0xNS0xLTEtODI3ODI_0d873fb6-ad04-43eb-82a9-d20a7f72a89d">173.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i083cbb87646e4c8ba193971c93fd6efe_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfNC01LTEtMS04Mjc4Mg_ab7fb7c5-faac-4a1c-b268-39eab4bf7e0b">29.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie4063d23292b47168eedc6bfb33a3fbd_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfNC03LTEtMS04Mjc4Mg_df518dc8-278f-4091-8ac3-4dc5e183e140">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4063d23292b47168eedc6bfb33a3fbd_D20220101-20220331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfNC05LTEtMS04Mjc4Mg_f6eec225-3f84-411c-bcf4-75d849babfff">29.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfNC0xNS0xLTEtODI3ODI_136ffd71-8d5b-4ae6-afb8-b65ccf7ba915">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares purchased under share repurchase program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie4063d23292b47168eedc6bfb33a3fbd_D20220101-20220331" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfNS03LTEtMS04Mjc4Mg_09dc199f-41f4-4dce-8822-aa92a415a7d4">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4063d23292b47168eedc6bfb33a3fbd_D20220101-20220331" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfNS05LTEtMS04Mjc4Mg_d9361e75-f8d6-4d9a-9962-3fccb1381696">147.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfNS0xNS0xLTEtODI3ODI_f4b181c7-5309-4f75-9b55-8c6c86ffa6c4">147.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends declared ($<ix:nonFraction unitRef="usdPerShare" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfNi0wLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOmJiM2E3ZTQ2ODkxMDQ4YzliNWY4ODJlNjE1M2FmNzQ3XzI0_732895b0-4557-44bf-a191-40a483f9783f">0.18</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8e072fd9e914a71afd49e2d9a5e79c6_D20220101-20220331" decimals="-5" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfNi0xMS0xLTEtODI3ODI_72800444-729c-4db3-8502-74c5d62369d1">13.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfNi0xNS0xLTEtODI3ODI_64066806-f003-462e-877d-44cb9b1d85af">13.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia5fc6b2b23e84ec4bc5d35849e3156f6_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfNy0xMy0xLTEtODI3ODI_e750d152-a549-44b1-b075-d865ed9604df">22.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfNy0xNS0xLTEtODI3ODI_aae94223-f29e-4124-932e-6d501b7128ec">22.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i48e325bcbc074931a2dd945f8078f5f8_I20220331" decimals="-5" name="us-gaap:SharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfOC0xLTEtMS04Mjc4Mg_751fc33a-b537-4362-93b5-c47755036542">75.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e325bcbc074931a2dd945f8078f5f8_I20220331" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfOC0zLTEtMS04Mjc4Mg_a2a7bb52-98dc-4b91-90dd-11689866496c">18.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b1173baba244d369e85b0aaae78c105_I20220331" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfOC01LTEtMS04Mjc4Mg_d094cb82-bbbe-4b80-8b30-41d8bbdaf8a9">219.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i83dbf680868b48b9b005cf05def0fad3_I20220331" decimals="-5" name="us-gaap:TreasuryStockCommonShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfOC03LTEtMS04Mjc4Mg_c2d8b229-845e-425d-abda-7aaf5631cec6">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i83dbf680868b48b9b005cf05def0fad3_I20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfOC05LTEtMS04Mjc4Mg_72cd26fe-74f0-4778-86ea-98397df88a55">347.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb84c364648d488ba64727ae4d194a34_I20220331" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfOC0xMS0xLTEtODI3ODI_48665b25-c378-4465-a3e5-3a6419a9a512">2,617.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i83a0a64e641241259400ffb042bd9b69_I20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfOC0xMy0xLTEtODI3ODI_adf1eeb3-4278-4da7-8640-fd25f5e4eb7d">182.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3cc75f001344ce095d702cd95b46078_I20220331" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfOC0xNS0xLTEtODI3ODI_1f7092e9-1559-48ae-b447-6e37ee503e8f">2,326.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><div id="i7bf87d07bb544f48851c48374130181b_70"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 13:&#160;<ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83MC9mcmFnOmIxODkxNjY4MTM4MDRlMWY4MDAwNDA0NmFkYjJhMWU5L3RleHRyZWdpb246YjE4OTE2NjgxMzgwNGUxZjgwMDA0MDQ2YWRiMmExZTlfMjQ4MA_e92ab1d5-db21-44c8-b7d0-14a5a22e93e0" continuedAt="i1c596a5e68b142108e018bfd6a988891" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i1c596a5e68b142108e018bfd6a988891" continuedAt="i17e950970a0c4cfb985166a6febd78ea"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The West Pharmaceutical Services, Inc. 2016 Omnibus Incentive Compensation Plan (the &#8220;2016 Plan&#8221;) provides for the granting of stock options, stock appreciation rights, restricted stock awards and performance awards to employees and non-employee directors. A committee of the Board of Directors determines the terms and conditions of awards to be granted. Vesting requirements vary by award. At March&#160;31, 2023, there were <ix:nonFraction unitRef="shares" contextRef="i2af6ba55593d446686e312e0578684c6_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83MC9mcmFnOmIxODkxNjY4MTM4MDRlMWY4MDAwNDA0NmFkYjJhMWU5L3RleHRyZWdpb246YjE4OTE2NjgxMzgwNGUxZjgwMDA0MDQ2YWRiMmExZTlfNDUw_ca116094-6b55-4e06-8042-8ff7d7c767a9">1,444,472</ix:nonFraction> shares remaining in the 2016 Plan for future grants.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, we granted <ix:nonFraction unitRef="shares" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83MC9mcmFnOmIxODkxNjY4MTM4MDRlMWY4MDAwNDA0NmFkYjJhMWU5L3RleHRyZWdpb246YjE4OTE2NjgxMzgwNGUxZjgwMDA0MDQ2YWRiMmExZTlfNTM2_6302f4fc-56dd-4b07-b336-d4e25a3c11d9">105,244</ix:nonFraction> stock options at a weighted average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83MC9mcmFnOmIxODkxNjY4MTM4MDRlMWY4MDAwNDA0NmFkYjJhMWU5L3RleHRyZWdpb246YjE4OTE2NjgxMzgwNGUxZjgwMDA0MDQ2YWRiMmExZTlfNTkz_b687a182-71f3-4405-92dd-55d5fd5744dd">306.68</ix:nonFraction> per share based on the grant-date fair value of our stock to employees under the 2016 Plan. The weighted average grant date fair value of options granted was $<ix:nonFraction unitRef="usdPerShare" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83MC9mcmFnOmIxODkxNjY4MTM4MDRlMWY4MDAwNDA0NmFkYjJhMWU5L3RleHRyZWdpb246YjE4OTE2NjgxMzgwNGUxZjgwMDA0MDQ2YWRiMmExZTlfNzU0_30c91cbd-d60d-444f-8d2e-620ced0c2c7e">108.80</ix:nonFraction> per share as determined by the Black-Scholes option valuation model using the following weighted average assumptions: a risk-free interest rate of <ix:nonFraction unitRef="number" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83MC9mcmFnOmIxODkxNjY4MTM4MDRlMWY4MDAwNDA0NmFkYjJhMWU5L3RleHRyZWdpb246YjE4OTE2NjgxMzgwNGUxZjgwMDA0MDQ2YWRiMmExZTlfOTA0_37d22183-0c6f-4404-8722-15ba8e7725ef">4.1</ix:nonFraction>%; expected life of <ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83MC9mcmFnOmIxODkxNjY4MTM4MDRlMWY4MDAwNDA0NmFkYjJhMWU5L3RleHRyZWdpb246YjE4OTE2NjgxMzgwNGUxZjgwMDA0MDQ2YWRiMmExZTlfOTI1_8a74d675-1bad-45b9-8b32-26e23ed3abb6">5.7</ix:nonNumeric> years based on prior experience; stock volatility of <ix:nonFraction unitRef="number" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83MC9mcmFnOmIxODkxNjY4MTM4MDRlMWY4MDAwNDA0NmFkYjJhMWU5L3RleHRyZWdpb246YjE4OTE2NjgxMzgwNGUxZjgwMDA0MDQ2YWRiMmExZTlfOTgx_4650a3e6-1fc2-4276-b6cd-5947d9a490ff">29.8</ix:nonFraction>% based on historical data; and a dividend yield of <ix:nonFraction unitRef="number" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83MC9mcmFnOmIxODkxNjY4MTM4MDRlMWY4MDAwNDA0NmFkYjJhMWU5L3RleHRyZWdpb246YjE4OTE2NjgxMzgwNGUxZjgwMDA0MDQ2YWRiMmExZTlfMTAzNA_119daef5-2834-4212-b13b-8311364fae8d">0.3</ix:nonFraction>%. Stock option expense is recognized over the vesting period, net of forfeitures.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, we granted <ix:nonFraction unitRef="shares" contextRef="i9ea1399aa8514b6fb5e425e47f1f53b4_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83MC9mcmFnOmIxODkxNjY4MTM4MDRlMWY4MDAwNDA0NmFkYjJhMWU5L3RleHRyZWdpb246YjE4OTE2NjgxMzgwNGUxZjgwMDA0MDQ2YWRiMmExZTlfODI0NjMzNzIxMDg2MQ_5c9db2e7-c4b1-434c-a87f-79f4dd863bf0">37,397</ix:nonFraction> stock-settled performance share unit ("PSU") awards at a weighted average grant-date fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i9ea1399aa8514b6fb5e425e47f1f53b4_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83MC9mcmFnOmIxODkxNjY4MTM4MDRlMWY4MDAwNDA0NmFkYjJhMWU5L3RleHRyZWdpb246YjE4OTE2NjgxMzgwNGUxZjgwMDA0MDQ2YWRiMmExZTlfODI0NjMzNzIxMDg2NQ_2f231cc4-0c58-44b4-8514-51d74debd9ff">306.68</ix:nonFraction> per share to eligible employees. These awards are earned based on the Company's performance against pre-established targets, including annual growth rate of revenue and return on invested capital, over a specified performance period. Depending on the achievement of the targets, recipients of stock-settled PSU awards are entitled to receive a certain numbers of shares of common stock. Shares earned under PSU awards may vary from <ix:nonFraction unitRef="number" contextRef="i5cea666f1a3e4fca9565501a1a97da9f_D20230101-20230331" decimals="2" name="wst:ShareBasedCompensationArrangementByShareBasedPaymentAwardActualPayoutPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83MC9mcmFnOmIxODkxNjY4MTM4MDRlMWY4MDAwNDA0NmFkYjJhMWU5L3RleHRyZWdpb246YjE4OTE2NjgxMzgwNGUxZjgwMDA0MDQ2YWRiMmExZTlfMTcxMw_de4c912c-c509-4d57-bc8a-4cbc5f27d138">0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="if9485a9306be43498daef6ad2c76774a_D20230101-20230331" decimals="2" name="wst:ShareBasedCompensationArrangementByShareBasedPaymentAwardActualPayoutPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83MC9mcmFnOmIxODkxNjY4MTM4MDRlMWY4MDAwNDA0NmFkYjJhMWU5L3RleHRyZWdpb246YjE4OTE2NjgxMzgwNGUxZjgwMDA0MDQ2YWRiMmExZTlfMTcxOQ_bd445061-a7b2-452f-85a5-46b3d39a665e">200</ix:nonFraction>% of an employee's targeted award. The fair value of stock-settled PSU awards is based on the market price of our stock at the grant date and is recognized as expense over the performance period, adjusted for estimated target outcomes and net of forfeitures.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, we granted <ix:nonFraction unitRef="shares" contextRef="iaac3fbfd1951416da909602aa595a831_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83MC9mcmFnOmIxODkxNjY4MTM4MDRlMWY4MDAwNDA0NmFkYjJhMWU5L3RleHRyZWdpb246YjE4OTE2NjgxMzgwNGUxZjgwMDA0MDQ2YWRiMmExZTlfMjAwOQ_45bc67ba-5773-4c68-b668-d6fe4157101c">4,284</ix:nonFraction> stock-settled restricted share unit (&#8220;RSU&#8221;) awards at a weighted average grant-date fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="iaac3fbfd1951416da909602aa595a831_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83MC9mcmFnOmIxODkxNjY4MTM4MDRlMWY4MDAwNDA0NmFkYjJhMWU5L3RleHRyZWdpb246YjE4OTE2NjgxMzgwNGUxZjgwMDA0MDQ2YWRiMmExZTlfMjExMA_0bcbd86d-4779-4353-852d-38f80d637e2f">306.68</ix:nonFraction> per share to eligible employees. These awards are earned over a specified performance period. The fair value of stock-settled RSU awards is based on the market price of our stock at the grant date and is recognized as expense over the vesting period, net of forfeitures. </span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i17e950970a0c4cfb985166a6febd78ea">Stock-based compensation expense was $<ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83MC9mcmFnOmIxODkxNjY4MTM4MDRlMWY4MDAwNDA0NmFkYjJhMWU5L3RleHRyZWdpb246YjE4OTE2NjgxMzgwNGUxZjgwMDA0MDQ2YWRiMmExZTlfMjQyMw_6f0de80e-03e6-4683-bd17-f698dfd92603">8.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83MC9mcmFnOmIxODkxNjY4MTM4MDRlMWY4MDAwNDA0NmFkYjJhMWU5L3RleHRyZWdpb246YjE4OTE2NjgxMzgwNGUxZjgwMDA0MDQ2YWRiMmExZTlfMjQzMA_1b804cda-8a9c-443f-a9f1-b34567784df3">5.5</ix:nonFraction> million for the three months ended March&#160;31, 2023 and 2022, respectively.</ix:continuation> </span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="i7bf87d07bb544f48851c48374130181b_73"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 14:&#160;&#160;<ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RleHRyZWdpb246YWNjMzlmMTg3MGJhNDM4YWJlZjYwZDY0ZTcyODllNTNfNDQ1_bb822ad4-ba3a-43b1-a097-631aade8a7a4" continuedAt="i8dbd00f4779c44d38cd4bdd8eca5e59f" escape="true">Benefit Plans</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i8dbd00f4779c44d38cd4bdd8eca5e59f"><ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RleHRyZWdpb246YWNjMzlmMTg3MGJhNDM4YWJlZjYwZDY0ZTcyODllNTNfNDQ3_678415b3-9a7b-4c69-9378-883190f24e93" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net periodic benefit cost for the three months ended March&#160;31 were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:32.286%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.975%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.975%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.018%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other retirement benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15f25764805440459934b22b2c76b3b4_D20230101-20230331" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfMi0xLTEtMS04Mjc4Mg_4cb8cb54-9625-444c-85fd-7638d2878788">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6b03745b52d4c23b5f91243d9f4d0c7_D20220101-20220331" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfMi0zLTEtMS04Mjc4Mg_ca242102-93ab-46d6-91a7-3fd59c46a24a">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea6ecda38c04a1980ef2da02b46df03_D20230101-20230331" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfMi01LTEtMS04Mjc4Mg_7b39c620-b113-4de0-8d66-aa24d8098839">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f818cb77b7453cbd94313211a8df44_D20220101-20220331" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfMi03LTEtMS04Mjc4Mg_a09a2b8a-9a49-4133-b799-8a3b2d29e80e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfMi05LTEtMS04Mjc4Mg_d0524a63-5059-41f3-b13c-0edb9d5a29f9">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfMi0xMS0xLTEtODI3ODI_9c8c324f-b6ba-4c04-ae30-d524f5e13c75">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15f25764805440459934b22b2c76b3b4_D20230101-20230331" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfMy0xLTEtMS04Mjc4Mg_24b55727-d9e7-4357-ae1a-2f2192117f80">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6b03745b52d4c23b5f91243d9f4d0c7_D20220101-20220331" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfMy0zLTEtMS04Mjc4Mg_e62c5f7b-98ef-4a9a-98dd-a753935480bf">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea6ecda38c04a1980ef2da02b46df03_D20230101-20230331" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfMy01LTEtMS04Mjc4Mg_f1ef031c-1d2b-455d-abe5-e3c7c29052d0">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f818cb77b7453cbd94313211a8df44_D20220101-20220331" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfMy03LTEtMS04Mjc4Mg_18c36f4b-d9e1-47fe-a83c-0ca0a2897999">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfMy05LTEtMS04Mjc4Mg_20b0ace6-1557-499e-b285-ea25e3622534">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfMy0xMS0xLTEtODI3ODI_b672792f-aa5e-4f05-bd9f-b66af9a99a6f">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15f25764805440459934b22b2c76b3b4_D20230101-20230331" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfNC0xLTEtMS04Mjc4Mg_7b6c3711-37d7-49f7-a676-6504336eff12">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6b03745b52d4c23b5f91243d9f4d0c7_D20220101-20220331" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfNC0zLTEtMS04Mjc4Mg_1a948a04-9fbd-43c8-b2c5-8eedaadbf31f">2.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea6ecda38c04a1980ef2da02b46df03_D20230101-20230331" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfNC01LTEtMS04Mjc4Mg_783f6b3d-3d72-420a-982a-7bd73402663a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f818cb77b7453cbd94313211a8df44_D20220101-20220331" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfNC03LTEtMS04Mjc4Mg_7f896060-5a2d-4f8c-a135-5ce442439fc1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfNC05LTEtMS04Mjc4Mg_33fd44b6-7ba3-4f98-b9df-3c2b95757359">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfNC0xMS0xLTEtODI3ODI_d71d4d10-2676-4aa2-ab10-90279aea1710">2.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial losses (gains)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15f25764805440459934b22b2c76b3b4_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfNy0xLTEtMS04Mjc4Mg_8daef805-abbe-4186-92c4-f597e4d85d7b">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6b03745b52d4c23b5f91243d9f4d0c7_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfNy0zLTEtMS04Mjc4Mg_cb1def65-75d0-4888-9ac1-8dce2d21f685">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icea6ecda38c04a1980ef2da02b46df03_D20230101-20230331" decimals="-5" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfNy01LTEtMS04Mjc4Mg_b345277b-e5d0-4f8e-88a3-8f34a1007e78">0.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18f818cb77b7453cbd94313211a8df44_D20220101-20220331" decimals="-5" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfNy03LTEtMS04Mjc4Mg_86aea262-5fca-4cd2-8be5-5de1367d8f23">0.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfNy05LTEtMS04Mjc4Mg_20093da7-fb81-4a2f-8e67-c2392636cf44">0.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfNy0xMS0xLTEtODI3ODI_fe403cc7-3f3b-465c-9611-b70369afb9c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15f25764805440459934b22b2c76b3b4_D20230101-20230331" decimals="-5" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfOS0xLTEtMS04Mjc4Mg_b2e97a4e-7316-4d58-8a64-664ab4325b92">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6b03745b52d4c23b5f91243d9f4d0c7_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfOS0zLTEtMS04Mjc4Mg_806bc5e6-83b2-4e30-b01d-293462fdd691">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea6ecda38c04a1980ef2da02b46df03_D20230101-20230331" decimals="-5" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfOS01LTEtMS04Mjc4Mg_e941cc96-ad60-4c6d-89fc-8b76dc69099b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f818cb77b7453cbd94313211a8df44_D20220101-20220331" decimals="-5" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfOS03LTEtMS04Mjc4Mg_f29a7e06-0f5e-4bfb-a4e6-c3411507bde9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfOS05LTEtMS04Mjc4Mg_401bc75b-26b5-4b70-b051-3a07df7aeef3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfOS0xMS0xLTEtODI3ODI_4aacaabb-a059-45fd-b839-d52648ba930d">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15f25764805440459934b22b2c76b3b4_D20230101-20230331" decimals="-5" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfMTAtMS0xLTEtODI3ODI_b01b57fe-58db-466e-aaf7-993fbafc722f">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6b03745b52d4c23b5f91243d9f4d0c7_D20220101-20220331" decimals="-5" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfMTAtMy0xLTEtODI3ODI_9b2984e5-26f2-4d4b-a84c-b5fe07fd9419">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icea6ecda38c04a1980ef2da02b46df03_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfMTAtNS0xLTEtODI3ODI_8227c716-4c93-4dc9-9bc0-530c068f6a44">0.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18f818cb77b7453cbd94313211a8df44_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfMTAtNy0xLTEtODI3ODI_fd420fc4-adb7-43f9-ba0a-236efad2d928">0.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfMTAtOS0xLTEtODI3ODI_0bcb30fe-52da-41fd-8647-23b01069dc11">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfMTAtMTEtMS0xLTgyNzgy_5ee3d6df-206b-4b01-be5b-9f1605d78fab">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:32.286%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.975%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.975%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.018%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other retirement benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. plans</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i209901cc4ed54159a25df88bd1b8faee_D20230101-20230331" decimals="-5" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjEwY2EyMzI2ZjQwOTQ2ODJiMzZlMGQzMGM2MjczOWYxL3RhYmxlcmFuZ2U6MTBjYTIzMjZmNDA5NDY4MmIzNmUwZDMwYzYyNzM5ZjFfMi0xLTEtMS04Mjc4Mg_ed4f8f1e-b12a-4480-a3b6-24f1a3dffead">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida333f1205fc4fcfb7b85636d28c908d_D20220101-20220331" decimals="-5" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjEwY2EyMzI2ZjQwOTQ2ODJiMzZlMGQzMGM2MjczOWYxL3RhYmxlcmFuZ2U6MTBjYTIzMjZmNDA5NDY4MmIzNmUwZDMwYzYyNzM5ZjFfMi0zLTEtMS04Mjc4Mg_734c0732-e8be-4b71-b45f-259ecfa7c559">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idbcc67097f9240329c190bf9487f2480_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjEwY2EyMzI2ZjQwOTQ2ODJiMzZlMGQzMGM2MjczOWYxL3RhYmxlcmFuZ2U6MTBjYTIzMjZmNDA5NDY4MmIzNmUwZDMwYzYyNzM5ZjFfMi01LTEtMS04Mjc4Mg_19cba568-99b7-476d-98b7-071249602446">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i05073a750c324193a92113cb4a636965_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjEwY2EyMzI2ZjQwOTQ2ODJiMzZlMGQzMGM2MjczOWYxL3RhYmxlcmFuZ2U6MTBjYTIzMjZmNDA5NDY4MmIzNmUwZDMwYzYyNzM5ZjFfMi03LTEtMS04Mjc4Mg_a86cabb8-fc1d-4917-bf50-8b910a628cd3">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i42e6f528867c45a7b7da2f9fe313486e_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjEwY2EyMzI2ZjQwOTQ2ODJiMzZlMGQzMGM2MjczOWYxL3RhYmxlcmFuZ2U6MTBjYTIzMjZmNDA5NDY4MmIzNmUwZDMwYzYyNzM5ZjFfMi05LTEtMS04Mjc4Mg_7969fd60-a496-45ef-a0e8-0a11473e322d">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13c26150d9794fafb5581ccf36e02580_D20220101-20220331" decimals="-5" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjEwY2EyMzI2ZjQwOTQ2ODJiMzZlMGQzMGM2MjczOWYxL3RhYmxlcmFuZ2U6MTBjYTIzMjZmNDA5NDY4MmIzNmUwZDMwYzYyNzM5ZjFfMi0xMS0xLTEtODI3ODI_5ab9d5c6-cd70-4ee7-b6b7-ee6cd03b63ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International plans</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68ac2f16d2949e69b481796f2242932_D20230101-20230331" decimals="-5" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjEwY2EyMzI2ZjQwOTQ2ODJiMzZlMGQzMGM2MjczOWYxL3RhYmxlcmFuZ2U6MTBjYTIzMjZmNDA5NDY4MmIzNmUwZDMwYzYyNzM5ZjFfMy0xLTEtMS04Mjc4Mg_73d27d33-13b0-4e60-8212-49553ca645aa">0.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28fde86f84534f35b341997ed553fd3b_D20220101-20220331" decimals="-5" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjEwY2EyMzI2ZjQwOTQ2ODJiMzZlMGQzMGM2MjczOWYxL3RhYmxlcmFuZ2U6MTBjYTIzMjZmNDA5NDY4MmIzNmUwZDMwYzYyNzM5ZjFfMy0zLTEtMS04Mjc4Mg_d6c5472d-3f67-482a-9518-ba80340a774a">0.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ad6bf31a752453bb990cc27c2ba0854_D20230101-20230331" decimals="-5" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjEwY2EyMzI2ZjQwOTQ2ODJiMzZlMGQzMGM2MjczOWYxL3RhYmxlcmFuZ2U6MTBjYTIzMjZmNDA5NDY4MmIzNmUwZDMwYzYyNzM5ZjFfMy01LTEtMS04Mjc4Mg_6766814b-9a1b-4357-a85d-6bc57638a17f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cb4b2a7f3bc479997ddd2c09c37cf63_D20220101-20220331" decimals="-5" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjEwY2EyMzI2ZjQwOTQ2ODJiMzZlMGQzMGM2MjczOWYxL3RhYmxlcmFuZ2U6MTBjYTIzMjZmNDA5NDY4MmIzNmUwZDMwYzYyNzM5ZjFfMy03LTEtMS04Mjc4Mg_0c4784f6-0a67-417e-8f95-6155f178a6bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8343aec575e3454988060e5f6ce66a0d_D20230101-20230331" decimals="-5" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjEwY2EyMzI2ZjQwOTQ2ODJiMzZlMGQzMGM2MjczOWYxL3RhYmxlcmFuZ2U6MTBjYTIzMjZmNDA5NDY4MmIzNmUwZDMwYzYyNzM5ZjFfMy05LTEtMS04Mjc4Mg_40fabdd5-2251-4773-9e6f-adef6039c482">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i577299ca8e5a4684b6ab0d6a77f3cabe_D20220101-20220331" decimals="-5" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjEwY2EyMzI2ZjQwOTQ2ODJiMzZlMGQzMGM2MjczOWYxL3RhYmxlcmFuZ2U6MTBjYTIzMjZmNDA5NDY4MmIzNmUwZDMwYzYyNzM5ZjFfMy0xMS0xLTEtODI3ODI_f8ab62e5-0fe3-4852-94ec-ac86b168a211">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15f25764805440459934b22b2c76b3b4_D20230101-20230331" decimals="-5" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjEwY2EyMzI2ZjQwOTQ2ODJiMzZlMGQzMGM2MjczOWYxL3RhYmxlcmFuZ2U6MTBjYTIzMjZmNDA5NDY4MmIzNmUwZDMwYzYyNzM5ZjFfNC0xLTEtMS04Mjc4Mg_f919ee3e-40a1-4919-ac47-62bc34dd66cb">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6b03745b52d4c23b5f91243d9f4d0c7_D20220101-20220331" decimals="-5" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjEwY2EyMzI2ZjQwOTQ2ODJiMzZlMGQzMGM2MjczOWYxL3RhYmxlcmFuZ2U6MTBjYTIzMjZmNDA5NDY4MmIzNmUwZDMwYzYyNzM5ZjFfNC0zLTEtMS04Mjc4Mg_f4b58f37-5840-43ba-936a-85233127716d">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icea6ecda38c04a1980ef2da02b46df03_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjEwY2EyMzI2ZjQwOTQ2ODJiMzZlMGQzMGM2MjczOWYxL3RhYmxlcmFuZ2U6MTBjYTIzMjZmNDA5NDY4MmIzNmUwZDMwYzYyNzM5ZjFfNC01LTEtMS04Mjc4Mg_b487369b-1879-4efb-a3e0-3f0ab6a7434f">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18f818cb77b7453cbd94313211a8df44_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjEwY2EyMzI2ZjQwOTQ2ODJiMzZlMGQzMGM2MjczOWYxL3RhYmxlcmFuZ2U6MTBjYTIzMjZmNDA5NDY4MmIzNmUwZDMwYzYyNzM5ZjFfNC03LTEtMS04Mjc4Mg_8ba8a9be-affc-41b1-8748-c22aa0fc51e1">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjEwY2EyMzI2ZjQwOTQ2ODJiMzZlMGQzMGM2MjczOWYxL3RhYmxlcmFuZ2U6MTBjYTIzMjZmNDA5NDY4MmIzNmUwZDMwYzYyNzM5ZjFfNC05LTEtMS04Mjc4Mg_e3bc37d8-fd75-4236-8be1-156dfb6cb630">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjEwY2EyMzI2ZjQwOTQ2ODJiMzZlMGQzMGM2MjczOWYxL3RhYmxlcmFuZ2U6MTBjYTIzMjZmNDA5NDY4MmIzNmUwZDMwYzYyNzM5ZjFfNC0xMS0xLTEtODI3ODI_69594514-9e0f-4a4a-8bce-8ae54f422a5b">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:0.641%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:0.641%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022, we recorded a pension settlement charge of $<ix:nonFraction unitRef="usd" contextRef="ib6b03745b52d4c23b5f91243d9f4d0c7_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RleHRyZWdpb246YWNjMzlmMTg3MGJhNDM4YWJlZjYwZDY0ZTcyODllNTNfMTk3_096abd0a-c478-4a5d-b8fa-2a388b40a8e3">0.6</ix:nonFraction>&#160;million within other nonoperating expense (income), as we determined that normal-course lump-sum payments for our U.S. qualified defined benefit pension plan exceeded the threshold for settlement accounting under U.S. GAAP for the year.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:0.801%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><div><span><br/></span></div><div id="i7bf87d07bb544f48851c48374130181b_76"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 15:&#160;&#160;<ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RleHRyZWdpb246ZWUxYzI1YTM0ZTc5NGFhY2I4ZjE0MTY5OTg4ZWRjNDlfMTM0Mg_49242b1f-a532-4e40-8435-5403a7f541d0" continuedAt="i1e067bf3745247c59b853b1c0bb24123" escape="true">Other Expense (Income) </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i1e067bf3745247c59b853b1c0bb24123" continuedAt="i76b9b12bd5b7493f844490c0b1c4721f"><div><ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="wst:ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RleHRyZWdpb246ZWUxYzI1YTM0ZTc5NGFhY2I4ZjE0MTY5OTg4ZWRjNDlfMTM1Mg_7a3ea384-1461-4fda-8452-385bb8b0b940" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense (income) consists of:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RhYmxlOmJkNTczYmE0MTgwNDQyZWI5MjFkNTBhMzcyYzlhN2FhL3RhYmxlcmFuZ2U6YmQ1NzNiYTQxODA0NDJlYjkyMWQ1MGEzNzJjOWE3YWFfMy0xLTEtMS04Mjc4Mg_9e1bcd67-d4b3-47df-b93f-07b38c10b286">11.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RhYmxlOmJkNTczYmE0MTgwNDQyZWI5MjFkNTBhMzcyYzlhN2FhL3RhYmxlcmFuZ2U6YmQ1NzNiYTQxODA0NDJlYjkyMWQ1MGEzNzJjOWE3YWFfMy0zLTEtMS04Mjc4Mg_c45e8437-133c-4423-a209-c052206d546a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss (gain) on oil hedges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RhYmxlOmJkNTczYmE0MTgwNDQyZWI5MjFkNTBhMzcyYzlhN2FhL3RhYmxlcmFuZ2U6YmQ1NzNiYTQxODA0NDJlYjkyMWQ1MGEzNzJjOWE3YWFfNC0xLTEtMS04Mjc4Mg_ca7521d9-53cd-4f2c-879f-832d02c787f1">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RhYmxlOmJkNTczYmE0MTgwNDQyZWI5MjFkNTBhMzcyYzlhN2FhL3RhYmxlcmFuZ2U6YmQ1NzNiYTQxODA0NDJlYjkyMWQ1MGEzNzJjOWE3YWFfNC0zLTEtMS04Mjc4Mg_77173b00-4c63-4917-92ac-2a796ddff0f4">2.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RhYmxlOmJkNTczYmE0MTgwNDQyZWI5MjFkNTBhMzcyYzlhN2FhL3RhYmxlcmFuZ2U6YmQ1NzNiYTQxODA0NDJlYjkyMWQ1MGEzNzJjOWE3YWFfOC0xLTEtMS04Mjc4Mg_7c6a994c-8d75-4652-9d32-5b5d148dfeb8">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RhYmxlOmJkNTczYmE0MTgwNDQyZWI5MjFkNTBhMzcyYzlhN2FhL3RhYmxlcmFuZ2U6YmQ1NzNiYTQxODA0NDJlYjkyMWQ1MGEzNzJjOWE3YWFfOC0zLTEtMS04Mjc4Mg_37c47b7d-23a5-4891-80e9-b3210acb0ff5">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange transaction losses (gains)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RhYmxlOmJkNTczYmE0MTgwNDQyZWI5MjFkNTBhMzcyYzlhN2FhL3RhYmxlcmFuZ2U6YmQ1NzNiYTQxODA0NDJlYjkyMWQ1MGEzNzJjOWE3YWFfOS0xLTEtMS04Mjc4Mg_bb60a190-c804-4722-aaca-9d11cccbf940">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RhYmxlOmJkNTczYmE0MTgwNDQyZWI5MjFkNTBhMzcyYzlhN2FhL3RhYmxlcmFuZ2U6YmQ1NzNiYTQxODA0NDJlYjkyMWQ1MGEzNzJjOWE3YWFfOS0zLTEtMS04Mjc4Mg_96b09350-e90d-4e84-9008-ad6f72cce03a">1.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RhYmxlOmJkNTczYmE0MTgwNDQyZWI5MjFkNTBhMzcyYzlhN2FhL3RhYmxlcmFuZ2U6YmQ1NzNiYTQxODA0NDJlYjkyMWQ1MGEzNzJjOWE3YWFfMTAtMS0xLTEtODI3ODI_01bfc122-1e16-44cf-a447-86c22a5f4dd8">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RhYmxlOmJkNTczYmE0MTgwNDQyZWI5MjFkNTBhMzcyYzlhN2FhL3RhYmxlcmFuZ2U6YmQ1NzNiYTQxODA0NDJlYjkyMWQ1MGEzNzJjOWE3YWFfMTAtMy0xLTEtODI3ODI_fd2f65ac-b58a-4b43-b2f2-94cfac080042">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other expense (income)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" sign="-" name="wst:OtherIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RhYmxlOmJkNTczYmE0MTgwNDQyZWI5MjFkNTBhMzcyYzlhN2FhL3RhYmxlcmFuZ2U6YmQ1NzNiYTQxODA0NDJlYjkyMWQ1MGEzNzJjOWE3YWFfMTEtMS0xLTEtODI3ODI_85a77d71-d8da-473b-81bd-bb4a7fdd3316">12.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="wst:OtherIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RhYmxlOmJkNTczYmE0MTgwNDQyZWI5MjFkNTBhMzcyYzlhN2FhL3RhYmxlcmFuZ2U6YmQ1NzNiYTQxODA0NDJlYjkyMWQ1MGEzNzJjOWE3YWFfMTEtMy0xLTEtODI3ODI_e013efe1-ecb7-40d4-8b0d-3737b4b935e3">3.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring and Related Charges</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, the Company approved a restructuring plan to adjust our operating cost base to better respond to the macroeconomic factors influencing our business. These changes are expected to be implemented over a period of up to <ix:nonNumeric contextRef="i7fe28b57298646bca10b9de129f3bac3_D20221201-20221231" name="wst:RestructuringAndRelatedActivitiesPeriodOfImplementation" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RleHRyZWdpb246ZWUxYzI1YTM0ZTc5NGFhY2I4ZjE0MTY5OTg4ZWRjNDlfMzc5_735b2c5b-d525-467a-b5f2-b43ee0ce43db">twelve months</ix:nonNumeric> from the date of approval. The plan is expected to require restructuring and related charges of approximately $<ix:nonFraction unitRef="usd" contextRef="i966f8dcfe0c8437bb80311fd4f44d03d_I20230331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RleHRyZWdpb246ZWUxYzI1YTM0ZTc5NGFhY2I4ZjE0MTY5OTg4ZWRjNDlfNDY5_0bb3c1fb-7980-4490-b5a8-d83b1c2e9d88">25</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="i173c567741e44c9180c9525060447224_I20230331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RleHRyZWdpb246ZWUxYzI1YTM0ZTc5NGFhY2I4ZjE0MTY5OTg4ZWRjNDlfNDc1_4ef8c3b2-9bef-4c5c-aa84-5849326bc7e2">27</ix:nonFraction>&#160;million, with annualized savings in the range of $<ix:nonFraction unitRef="usd" contextRef="i23c5432999954af5a1ded50a2d12617d_D20230101-20230331" decimals="-5" name="us-gaap:EffectOnFutureEarningsAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RleHRyZWdpb246ZWUxYzI1YTM0ZTc5NGFhY2I4ZjE0MTY5OTg4ZWRjNDlfNTE5_d6e39a30-11c3-4625-8e13-573c8eb1f26a">22.0</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="i00f636ccc7fe4a40bff18a2475aee5fb_D20230101-20230331" decimals="-5" name="us-gaap:EffectOnFutureEarningsAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RleHRyZWdpb246ZWUxYzI1YTM0ZTc5NGFhY2I4ZjE0MTY5OTg4ZWRjNDlfNTI1_ec497130-4f17-49d8-919c-2bab33864b31">24.0</ix:nonFraction>&#160;million. </span></div></ix:continuation><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_7">Table of Contents</a></span></div></div><ix:continuation id="i76b9b12bd5b7493f844490c0b1c4721f"><ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RleHRyZWdpb246ZWUxYzI1YTM0ZTc5NGFhY2I4ZjE0MTY5OTg4ZWRjNDlfMTM0Ng_d1fbd74d-6231-423b-94d2-ebbc33120f03" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents activity related to our restructuring obligations related to our 2022 restructuring plan:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.124%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:19.893%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.210%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance<br/>and benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-related charges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1173cf0c9c47e8a1b90da1b941c509_I20221231" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RhYmxlOjA5OWZiMTg2MDY2OTRkZThiNzkyZjEwMjIxNjg0ZmY5L3RhYmxlcmFuZ2U6MDk5ZmIxODYwNjY5NGRlOGI3OTJmMTAyMjE2ODRmZjlfMS0xLTEtMS04Mjc4Mg_85291e6e-2a93-4633-bc7f-51c0fcf797c1">10.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i320c37f388f0402ebe72c6e91de76520_I20221231" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RhYmxlOjA5OWZiMTg2MDY2OTRkZThiNzkyZjEwMjIxNjg0ZmY5L3RhYmxlcmFuZ2U6MDk5ZmIxODYwNjY5NGRlOGI3OTJmMTAyMjE2ODRmZjlfMS01LTEtMS04Mjc4Mg_8e03f7b5-8e44-4ddd-9cb2-b2bf0212cb75">15.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i741e48b8c43549918dae0d3e9f2835dc_I20221231" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RhYmxlOjA5OWZiMTg2MDY2OTRkZThiNzkyZjEwMjIxNjg0ZmY5L3RhYmxlcmFuZ2U6MDk5ZmIxODYwNjY5NGRlOGI3OTJmMTAyMjE2ODRmZjlfMS03LTEtMS04Mjc4Mg_2c6b16be-4ebf-4ab9-8355-321c8a293935">25.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5751a6a227b4cd09e42603236f7ce4b_D20230101-20230331" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RhYmxlOjA5OWZiMTg2MDY2OTRkZThiNzkyZjEwMjIxNjg0ZmY5L3RhYmxlcmFuZ2U6MDk5ZmIxODYwNjY5NGRlOGI3OTJmMTAyMjE2ODRmZjlfMi0xLTEtMS04Mjc4Mg_0f524709-7436-4554-a7c4-e16540a27390">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib58ff9d1a085489cb685ece3967cd85c_D20230101-20230331" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RhYmxlOjA5OWZiMTg2MDY2OTRkZThiNzkyZjEwMjIxNjg0ZmY5L3RhYmxlcmFuZ2U6MDk5ZmIxODYwNjY5NGRlOGI3OTJmMTAyMjE2ODRmZjlfMi01LTEtMS04Mjc4Mg_08397f9e-ea07-42d2-ae50-a71348a6e325">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic32e88fe332446cd865cf4708f70ecbd_D20230101-20230331" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RhYmxlOjA5OWZiMTg2MDY2OTRkZThiNzkyZjEwMjIxNjg0ZmY5L3RhYmxlcmFuZ2U6MDk5ZmIxODYwNjY5NGRlOGI3OTJmMTAyMjE2ODRmZjlfMi03LTEtMS04Mjc4Mg_9329948c-7585-443f-80a9-ef8e00d4188e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5751a6a227b4cd09e42603236f7ce4b_D20230101-20230331" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RhYmxlOjA5OWZiMTg2MDY2OTRkZThiNzkyZjEwMjIxNjg0ZmY5L3RhYmxlcmFuZ2U6MDk5ZmIxODYwNjY5NGRlOGI3OTJmMTAyMjE2ODRmZjlfMy0xLTEtMS04Mjc4Mg_181daef0-9ff3-4354-829e-a9a97cf5ca53">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib58ff9d1a085489cb685ece3967cd85c_D20230101-20230331" decimals="-5" name="us-gaap:PaymentsForRestructuring" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RhYmxlOjA5OWZiMTg2MDY2OTRkZThiNzkyZjEwMjIxNjg0ZmY5L3RhYmxlcmFuZ2U6MDk5ZmIxODYwNjY5NGRlOGI3OTJmMTAyMjE2ODRmZjlfMy01LTEtMS04Mjc4Mg_d49ff4ee-1a57-41ff-ac4b-0a9fdb6dd23d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic32e88fe332446cd865cf4708f70ecbd_D20230101-20230331" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RhYmxlOjA5OWZiMTg2MDY2OTRkZThiNzkyZjEwMjIxNjg0ZmY5L3RhYmxlcmFuZ2U6MDk5ZmIxODYwNjY5NGRlOGI3OTJmMTAyMjE2ODRmZjlfMy03LTEtMS04Mjc4Mg_ea828c53-1fee-4971-a85d-9f4ba2ecd92a">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March&#160;31, 2023</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dddcfaad27c4e2bb489c4f35ed023eb_I20230331" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RhYmxlOjA5OWZiMTg2MDY2OTRkZThiNzkyZjEwMjIxNjg0ZmY5L3RhYmxlcmFuZ2U6MDk5ZmIxODYwNjY5NGRlOGI3OTJmMTAyMjE2ODRmZjlfNS0xLTEtMS04Mjc4Mg_e3fc54b0-2415-46ae-9a07-91f49bab7dc5">9.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic23b01e75b1e4bc5a81f42b0e6c8108b_I20230331" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RhYmxlOjA5OWZiMTg2MDY2OTRkZThiNzkyZjEwMjIxNjg0ZmY5L3RhYmxlcmFuZ2U6MDk5ZmIxODYwNjY5NGRlOGI3OTJmMTAyMjE2ODRmZjlfNS01LTEtMS04Mjc4Mg_575f9bbe-ce39-41c8-bb43-7a46430a64d9">15.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fa2298580b64ebfb1db3e0ca8424d94_I20230331" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RhYmxlOjA5OWZiMTg2MDY2OTRkZThiNzkyZjEwMjIxNjg0ZmY5L3RhYmxlcmFuZ2U6MDk5ZmIxODYwNjY5NGRlOGI3OTJmMTAyMjE2ODRmZjlfNS03LTEtMS04Mjc4Mg_bc96a100-01d9-4e0d-9851-fcacc3d44177">24.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asset Impairments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, in preparation for the sale of one of the Company&#8217;s manufacturing facilities within the Proprietary Products segment, the Company recorded an impairment expense of $<ix:nonFraction unitRef="usd" contextRef="i3b6114e84e5644b6b9435baa1eba9515_D20230101-20230331" decimals="-5" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RleHRyZWdpb246ZWUxYzI1YTM0ZTc5NGFhY2I4ZjE0MTY5OTg4ZWRjNDlfODI0NjMzNzIxMzg3NQ_e879862c-4661-4ef5-adc5-fbfeb2525184">9.4</ix:nonFraction>&#160;million within other expense (income) and a corresponding reduction to the disposal group net assets to its fair value less cost to sell. The transaction is expected to close during the second quarter of 2023.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingent Consideration</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration represents changes in the fair value of the SmartDose</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contingent consideration. Please refer to Note 10, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_61">Fair Value Measurements</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional details.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Oil Hedges</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023 and 2022, we recorded a loss of $<ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RleHRyZWdpb246ZWUxYzI1YTM0ZTc5NGFhY2I4ZjE0MTY5OTg4ZWRjNDlfODI0NjMzNzIxMjA0NQ_ca7521d9-53cd-4f2c-879f-832d02c787f1">0.6</ix:nonFraction>&#160;million and a gain of $<ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RleHRyZWdpb246ZWUxYzI1YTM0ZTc5NGFhY2I4ZjE0MTY5OTg4ZWRjNDlfODI0NjMzNzIxMjA1Mw_77173b00-4c63-4917-92ac-2a796ddff0f4">2.8</ix:nonFraction>&#160;million, respectively, related to oil hedges. Please refer to Note 9, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_58">Derivative Financial Instruments</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of our hedging activity.</span></div></ix:continuation><div><span><br/></span></div><div id="i7bf87d07bb544f48851c48374130181b_79"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 16:&#160;&#160;<ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83OS9mcmFnOjY5MDBmYmNjYzllNTQyNjU5Y2UyNzBkNTc5NjkzOGY1L3RleHRyZWdpb246NjkwMGZiY2NjOWU1NDI2NTljZTI3MGQ1Nzk2OTM4ZjVfNzE1_8d348e78-4612-4d6c-aff9-37b1e5d0b555" continuedAt="i2b23500bbbca44af98038606bbb7e94d" escape="true">Income Taxes</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i2b23500bbbca44af98038606bbb7e94d"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax provision for interim periods is determined using the estimated annual effective consolidated tax rate, based on the current estimate of full-year earnings before taxes, adjusted for the impact of discrete quarterly items.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes was $<ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83OS9mcmFnOjY5MDBmYmNjYzllNTQyNjU5Y2UyNzBkNTc5NjkzOGY1L3RleHRyZWdpb246NjkwMGZiY2NjOWU1NDI2NTljZTI3MGQ1Nzk2OTM4ZjVfMjk2_926e1ebb-79d5-4493-a40d-195ed579fa00">23.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83OS9mcmFnOjY5MDBmYmNjYzllNTQyNjU5Y2UyNzBkNTc5NjkzOGY1L3RleHRyZWdpb246NjkwMGZiY2NjOWU1NDI2NTljZTI3MGQ1Nzk2OTM4ZjVfMzAz_d8948721-3f85-4a5f-988b-4e3c5cbdda9b">21.2</ix:nonFraction> million for the three months ended March&#160;31, 2023 and 2022, respectively, and the effective tax rate was <ix:nonFraction unitRef="number" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83OS9mcmFnOjY5MDBmYmNjYzllNTQyNjU5Y2UyNzBkNTc5NjkzOGY1L3RleHRyZWdpb246NjkwMGZiY2NjOWU1NDI2NTljZTI3MGQ1Nzk2OTM4ZjVfMzcz_23105ba5-2ee4-40ae-a74c-374bb9558a48">14.9</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83OS9mcmFnOjY5MDBmYmNjYzllNTQyNjU5Y2UyNzBkNTc5NjkzOGY1L3RleHRyZWdpb246NjkwMGZiY2NjOWU1NDI2NTljZTI3MGQ1Nzk2OTM4ZjVfMzgw_2ccecf90-d1e8-4786-aaba-121339538d37">11.3</ix:nonFraction>%, respectively. During the three months ended March&#160;31, 2023 and 2022, we recorded a tax benefit of $<ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83OS9mcmFnOjY5MDBmYmNjYzllNTQyNjU5Y2UyNzBkNTc5NjkzOGY1L3RleHRyZWdpb246NjkwMGZiY2NjOWU1NDI2NTljZTI3MGQ1Nzk2OTM4ZjVfODI0NjMzNzIwOTA0Nw_8ef4fb6d-0c70-40a7-b5a9-1c01fea08655">11.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83OS9mcmFnOjY5MDBmYmNjYzllNTQyNjU5Y2UyNzBkNTc5NjkzOGY1L3RleHRyZWdpb246NjkwMGZiY2NjOWU1NDI2NTljZTI3MGQ1Nzk2OTM4ZjVfNDU5_5b3ae0e4-5f12-434a-a667-914093f06e6c">8.9</ix:nonFraction>&#160;million, respectively, associated with stock-based compensation. The increase in the effective tax rate is primarily due to a shift in the geographic earnings mix and a $<ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83OS9mcmFnOjY5MDBmYmNjYzllNTQyNjU5Y2UyNzBkNTc5NjkzOGY1L3RleHRyZWdpb246NjkwMGZiY2NjOWU1NDI2NTljZTI3MGQ1Nzk2OTM4ZjVfODI0NjMzNzIwOTkwOA_f69a58b5-562b-4225-9310-e022a7cca3fb">5.9</ix:nonFraction>&#160;million tax benefit recorded as a result of a state tax valuation allowance reversal in the three months ended March 31, 2022 that was not repeated in 2023. This was offset by an increase in the tax benefit related to stock-based compensation for the three months ended March&#160;31, 2023, as compared to the same period in 2022.</span></div></ix:continuation><div><span><br/></span></div><div id="i7bf87d07bb544f48851c48374130181b_82"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 17:&#160;&#160;<ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84Mi9mcmFnOmM3NTczZGRkMTUxNTQ5NjM5OGZlOGIyMmU0ODBkODNjL3RleHRyZWdpb246Yzc1NzNkZGQxNTE1NDk2Mzk4ZmU4YjIyZTQ4MGQ4M2NfNjg3_02652471-d635-46a9-8615-d127870659d5" continuedAt="i6e1e5abfde3544f3816eac557b54f2c0" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i6e1e5abfde3544f3816eac557b54f2c0"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we are involved in product liability matters and other legal proceedings and claims generally incidental to our normal business activities. We accrue for loss contingencies when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. While the outcome of current proceedings cannot be accurately predicted, we believe their ultimate resolution should not have a material adverse effect on our business, financial condition, results of operations or liquidity.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes to the commitments and contingencies included in our </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/105770/000010577023000012/wst-20221231.htm#i8148abfe270d4f15aa2ba9319df722dc_58">2022 Annual Report</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="i7bf87d07bb544f48851c48374130181b_85"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 18:&#160;&#160;<ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RleHRyZWdpb246NTc5MjcyZTI5NDUyNDU2NzlmNGZlNGRmZDA4YjBhMGNfMjUxNw_87bb340b-10fe-43d4-9b07-cfa81f7c6879" continuedAt="i6c1bdf438cbc4d4885f954908f8f80a9" escape="true">Segment Information</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i6c1bdf438cbc4d4885f954908f8f80a9" continuedAt="i9f26b6acc1154dad84863919684b159a"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business operations are organized into <ix:nonFraction unitRef="segment" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RleHRyZWdpb246NTc5MjcyZTI5NDUyNDU2NzlmNGZlNGRmZDA4YjBhMGNfNzk_2c043096-ae10-4896-b114-ffd0abb3e9b8">two</ix:nonFraction> reportable segments, Proprietary Products and Contract-Manufactured Products. Our Proprietary Products reportable segment offers proprietary packaging, containment solutions and drug delivery products, along with analytical lab services and other integrated services and solutions, primarily to biologic, generic and pharmaceutical drug customers. Our Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Chief Operating Decision Maker ("CODM") evaluates the performance of our segments based upon, among other things, segment net sales and operating profit. Segment operating profit excludes general corporate costs, which include executive and director compensation, stock-based compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments. Also excluded are items that the CODM considers not representative of ongoing operations. Such items are referred to as other unallocated items and generally include restructuring and related charges, certain asset impairments and other specifically-identified income or expense items. The segment operating profit metric is what the CODM uses in evaluating our results of operations and the financial measure that provides a valuable insight into our overall performance and financial position.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RleHRyZWdpb246NTc5MjcyZTI5NDUyNDU2NzlmNGZlNGRmZDA4YjBhMGNfMjUwNg_fedc0235-4e93-487e-a02a-f407f0e50e93" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about our reportable segments, reconciled to consolidated totals:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:57.609%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proprietary Products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776c2fc9c0314d5dbc1af6c8aa146ea9_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOjEzMjk0YjUxNzJlMjRkYTViZjdiZWYyMDFiNTc1MDhiL3RhYmxlcmFuZ2U6MTMyOTRiNTE3MmUyNGRhNWJmN2JlZjIwMWI1NzUwOGJfMy0yLTEtMS04Mjc4Mg_46c5573b-8fa8-4471-9e53-2c454ed24bc9">583.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ec1bf24d76645649ff514efc6f320dd_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOjEzMjk0YjUxNzJlMjRkYTViZjdiZWYyMDFiNTc1MDhiL3RhYmxlcmFuZ2U6MTMyOTRiNTE3MmUyNGRhNWJmN2JlZjIwMWI1NzUwOGJfMy00LTEtMS04Mjc4Mg_8957fe5d-a707-48f9-9bc4-d6fb3aa6b391">601.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract-Manufactured Products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedc77d2ee3884279ae4e3b4f74b210ca_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOjEzMjk0YjUxNzJlMjRkYTViZjdiZWYyMDFiNTc1MDhiL3RhYmxlcmFuZ2U6MTMyOTRiNTE3MmUyNGRhNWJmN2JlZjIwMWI1NzUwOGJfNC0yLTEtMS04Mjc4Mg_13f9b5a6-eaea-453a-b024-880dc0447504">133.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i379b3e02ffff4f65b6f70a4e51167f3b_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOjEzMjk0YjUxNzJlMjRkYTViZjdiZWYyMDFiNTc1MDhiL3RhYmxlcmFuZ2U6MTMyOTRiNTE3MmUyNGRhNWJmN2JlZjIwMWI1NzUwOGJfNC00LTEtMS04Mjc4Mg_fe214a54-fc65-4b75-977b-0216829926d9">118.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment sales elimination</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i237555183941451e8d5f239492f90b93_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOjEzMjk0YjUxNzJlMjRkYTViZjdiZWYyMDFiNTc1MDhiL3RhYmxlcmFuZ2U6MTMyOTRiNTE3MmUyNGRhNWJmN2JlZjIwMWI1NzUwOGJfNS0yLTEtMS04Mjc4Mg_217680a7-deba-4981-a06d-35a5b077071b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i959bea7c7da543dfaa998842a57cfc20_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOjEzMjk0YjUxNzJlMjRkYTViZjdiZWYyMDFiNTc1MDhiL3RhYmxlcmFuZ2U6MTMyOTRiNTE3MmUyNGRhNWJmN2JlZjIwMWI1NzUwOGJfNS00LTEtMS04Mjc4Mg_5e3341a4-f0b4-4ffb-9c30-92eec58d08a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated net sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOjEzMjk0YjUxNzJlMjRkYTViZjdiZWYyMDFiNTc1MDhiL3RhYmxlcmFuZ2U6MTMyOTRiNTE3MmUyNGRhNWJmN2JlZjIwMWI1NzUwOGJfNi0yLTEtMS04Mjc4Mg_260b976d-b96c-4849-b62f-a3a400deffdb">716.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOjEzMjk0YjUxNzJlMjRkYTViZjdiZWYyMDFiNTc1MDhiL3RhYmxlcmFuZ2U6MTMyOTRiNTE3MmUyNGRhNWJmN2JlZjIwMWI1NzUwOGJfNi00LTEtMS04Mjc4Mg_630cdf7b-dd96-4da2-9380-6faa31c51f81">720.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intersegment sales elimination, which is required for the presentation of consolidated net sales, represents the elimination of components sold between our segments.</span></div></ix:continuation><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_7">Table of Contents</a></span></div></div><ix:continuation id="i9f26b6acc1154dad84863919684b159a"><ix:nonNumeric contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RleHRyZWdpb246NTc5MjcyZTI5NDUyNDU2NzlmNGZlNGRmZDA4YjBhMGNfMjUxNQ_9759e32d-7397-4d4a-a792-007748853ba4" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides summarized financial information for our segments:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proprietary Products</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776c2fc9c0314d5dbc1af6c8aa146ea9_D20230101-20230331" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOmFiMTU3MTBmNjQ5OTRjYzViNGU3MjgyZDVmZjQ1MGIwL3RhYmxlcmFuZ2U6YWIxNTcxMGY2NDk5NGNjNWI0ZTcyODJkNWZmNDUwYjBfMi0xLTEtMS04Mjc4Mg_092274bb-0d9e-40d0-89c7-df0ca67957f4">170.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ec1bf24d76645649ff514efc6f320dd_D20220101-20220331" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOmFiMTU3MTBmNjQ5OTRjYzViNGU3MjgyZDVmZjQ1MGIwL3RhYmxlcmFuZ2U6YWIxNTcxMGY2NDk5NGNjNWI0ZTcyODJkNWZmNDUwYjBfMi0zLTEtMS04Mjc4Mg_e3c7fe62-99e8-49e7-abd5-13b5a006e5f3">193.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract-Manufactured Products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedc77d2ee3884279ae4e3b4f74b210ca_D20230101-20230331" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOmFiMTU3MTBmNjQ5OTRjYzViNGU3MjgyZDVmZjQ1MGIwL3RhYmxlcmFuZ2U6YWIxNTcxMGY2NDk5NGNjNWI0ZTcyODJkNWZmNDUwYjBfMy0xLTEtMS04Mjc4Mg_e86b6cf1-9f9d-4e1b-93b7-86a3a2044ff5">17.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i379b3e02ffff4f65b6f70a4e51167f3b_D20220101-20220331" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOmFiMTU3MTBmNjQ5OTRjYzViNGU3MjgyZDVmZjQ1MGIwL3RhYmxlcmFuZ2U6YWIxNTcxMGY2NDk5NGNjNWI0ZTcyODJkNWZmNDUwYjBfMy0zLTEtMS04Mjc4Mg_6d038868-8636-4d86-9b47-d152251cad66">19.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total business segment operating profit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8cd20fa40094f43a596ebe943a0379a_D20230101-20230331" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOmFiMTU3MTBmNjQ5OTRjYzViNGU3MjgyZDVmZjQ1MGIwL3RhYmxlcmFuZ2U6YWIxNTcxMGY2NDk5NGNjNWI0ZTcyODJkNWZmNDUwYjBfNC0xLTEtMS04Mjc4Mg_462c9c1c-9391-4dbb-a1a2-77df5755c640">188.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92736af48f534f498e235c076ae54733_D20220101-20220331" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOmFiMTU3MTBmNjQ5OTRjYzViNGU3MjgyZDVmZjQ1MGIwL3RhYmxlcmFuZ2U6YWIxNTcxMGY2NDk5NGNjNWI0ZTcyODJkNWZmNDUwYjBfNC0zLTEtMS04Mjc4Mg_20bc2311-5594-4a37-a482-8b3ba85c0957">212.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and Unallocated</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i934ac1f9eaf94ecfb00d07b8084f9292_D20230101-20230331" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOmFiMTU3MTBmNjQ5OTRjYzViNGU3MjgyZDVmZjQ1MGIwL3RhYmxlcmFuZ2U6YWIxNTcxMGY2NDk5NGNjNWI0ZTcyODJkNWZmNDUwYjBfNi0xLTEtMS04Mjc4Mg_56270b36-ff19-44c1-a484-7ae0daa054c8">8.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icac424a9ffb64141aa0d33bcd8b4fcfb_D20220101-20220331" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOmFiMTU3MTBmNjQ5OTRjYzViNGU3MjgyZDVmZjQ1MGIwL3RhYmxlcmFuZ2U6YWIxNTcxMGY2NDk5NGNjNWI0ZTcyODJkNWZmNDUwYjBfNi0zLTEtMS04Mjc4Mg_e0853562-a3a0-4dac-8c3b-864ee2b2f1ac">5.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate general costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i934ac1f9eaf94ecfb00d07b8084f9292_D20230101-20230331" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOmFiMTU3MTBmNjQ5OTRjYzViNGU3MjgyZDVmZjQ1MGIwL3RhYmxlcmFuZ2U6YWIxNTcxMGY2NDk5NGNjNWI0ZTcyODJkNWZmNDUwYjBfNy0xLTEtMS04Mjc4Mg_4f7a110c-0156-4e4a-ad60-598a6309b160">14.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icac424a9ffb64141aa0d33bcd8b4fcfb_D20220101-20220331" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOmFiMTU3MTBmNjQ5OTRjYzViNGU3MjgyZDVmZjQ1MGIwL3RhYmxlcmFuZ2U6YWIxNTcxMGY2NDk5NGNjNWI0ZTcyODJkNWZmNDUwYjBfNy0zLTEtMS04Mjc4Mg_1cb818ab-5fbe-4534-9c7a-eb77c332710a">17.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated Items:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment for planned sale of plant </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i934ac1f9eaf94ecfb00d07b8084f9292_D20230101-20230331" decimals="-5" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOmFiMTU3MTBmNjQ5OTRjYzViNGU3MjgyZDVmZjQ1MGIwL3RhYmxlcmFuZ2U6YWIxNTcxMGY2NDk5NGNjNWI0ZTcyODJkNWZmNDUwYjBfOS0xLTEtMS04Mjc4Mg_2914896c-a175-4566-af3a-3cc5e372a979">9.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icac424a9ffb64141aa0d33bcd8b4fcfb_D20220101-20220331" decimals="-5" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOmFiMTU3MTBmNjQ5OTRjYzViNGU3MjgyZDVmZjQ1MGIwL3RhYmxlcmFuZ2U6YWIxNTcxMGY2NDk5NGNjNWI0ZTcyODJkNWZmNDUwYjBfOS0zLTEtMS04Mjc4Mg_91b9372d-f7cc-4340-a1fa-8e28871d560e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of acquisition-related intangible assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i934ac1f9eaf94ecfb00d07b8084f9292_D20230101-20230331" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOmFiMTU3MTBmNjQ5OTRjYzViNGU3MjgyZDVmZjQ1MGIwL3RhYmxlcmFuZ2U6YWIxNTcxMGY2NDk5NGNjNWI0ZTcyODJkNWZmNDUwYjBfMTAtMS0xLTEtODI3ODI_214f9428-99c2-4a99-a159-6ffcf21dda57">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icac424a9ffb64141aa0d33bcd8b4fcfb_D20220101-20220331" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOmFiMTU3MTBmNjQ5OTRjYzViNGU3MjgyZDVmZjQ1MGIwL3RhYmxlcmFuZ2U6YWIxNTcxMGY2NDk5NGNjNWI0ZTcyODJkNWZmNDUwYjBfMTAtMy0xLTEtODI3ODI_13fc18ea-7120-4d2f-9ad3-868d71d612f9">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Corporate and Unallocated</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i934ac1f9eaf94ecfb00d07b8084f9292_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOmFiMTU3MTBmNjQ5OTRjYzViNGU3MjgyZDVmZjQ1MGIwL3RhYmxlcmFuZ2U6YWIxNTcxMGY2NDk5NGNjNWI0ZTcyODJkNWZmNDUwYjBfMTItMS0xLTEtODI3ODI_1e3ae784-9034-487b-b629-db9632ce4edf">32.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icac424a9ffb64141aa0d33bcd8b4fcfb_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOmFiMTU3MTBmNjQ5OTRjYzViNGU3MjgyZDVmZjQ1MGIwL3RhYmxlcmFuZ2U6YWIxNTcxMGY2NDk5NGNjNWI0ZTcyODJkNWZmNDUwYjBfMTItMy0xLTEtODI3ODI_e52d7198-7ab6-4f8c-9cf4-430a782cefb3">22.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consolidated operating profit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOmFiMTU3MTBmNjQ5OTRjYzViNGU3MjgyZDVmZjQ1MGIwL3RhYmxlcmFuZ2U6YWIxNTcxMGY2NDk5NGNjNWI0ZTcyODJkNWZmNDUwYjBfMTMtMS0xLTEtODI3ODI_08035860-8947-4575-8a5d-c3271b966315">155.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOmFiMTU3MTBmNjQ5OTRjYzViNGU3MjgyZDVmZjQ1MGIwL3RhYmxlcmFuZ2U6YWIxNTcxMGY2NDk5NGNjNWI0ZTcyODJkNWZmNDUwYjBfMTMtMy0xLTEtODI3ODI_94f97c79-0853-4fcc-b969-e4f8c379f813">189.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOmFiMTU3MTBmNjQ5OTRjYzViNGU3MjgyZDVmZjQ1MGIwL3RhYmxlcmFuZ2U6YWIxNTcxMGY2NDk5NGNjNWI0ZTcyODJkNWZmNDUwYjBfMTQtMS0xLTEtODI3ODI_efc1c2ca-e56c-409f-b8b6-6f5e42e4ac4b">2.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOmFiMTU3MTBmNjQ5OTRjYzViNGU3MjgyZDVmZjQ1MGIwL3RhYmxlcmFuZ2U6YWIxNTcxMGY2NDk5NGNjNWI0ZTcyODJkNWZmNDUwYjBfMTQtMy0xLTEtODI3ODI_cf43b475-e599-46a1-b547-f32d50656450">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes and equity in net income of affiliated companies</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOmFiMTU3MTBmNjQ5OTRjYzViNGU3MjgyZDVmZjQ1MGIwL3RhYmxlcmFuZ2U6YWIxNTcxMGY2NDk5NGNjNWI0ZTcyODJkNWZmNDUwYjBfMTUtMS0xLTEtODI3ODI_8eae5704-ad0a-48fa-99a0-9d586bbf27f4">157.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOmFiMTU3MTBmNjQ5OTRjYzViNGU3MjgyZDVmZjQ1MGIwL3RhYmxlcmFuZ2U6YWIxNTcxMGY2NDk5NGNjNWI0ZTcyODJkNWZmNDUwYjBfMTUtMy0xLTEtODI3ODI_28be210c-b8be-4739-8bad-06017a94c4b7">187.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Corporate general costs includes executive and director compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) During the three months ended March&#160;31, 2023, in preparation for the sale of one of the Company&#8217;s manufacturing facilities within the Proprietary Products segment, the Company recorded an impairment expense of $<ix:nonFraction unitRef="usd" contextRef="i3b6114e84e5644b6b9435baa1eba9515_D20230101-20230331" decimals="-5" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RleHRyZWdpb246NTc5MjcyZTI5NDUyNDU2NzlmNGZlNGRmZDA4YjBhMGNfODI0NjMzNzIxMjU0OQ_e879862c-4661-4ef5-adc5-fbfeb2525184">9.4</ix:nonFraction>&#160;million within other expense (income) and a corresponding reduction to the disposal group net assets to its fair value less cost to sell. The transaction is expected to close during the second quarter of 2023.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) During the three months ended March&#160;31, 2023 and 2022, we recorded $<ix:nonFraction unitRef="usd" contextRef="i934ac1f9eaf94ecfb00d07b8084f9292_D20230101-20230331" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RleHRyZWdpb246NTc5MjcyZTI5NDUyNDU2NzlmNGZlNGRmZDA4YjBhMGNfMjc0ODc3OTA3NTIyMg_24c11a05-4326-4590-97c6-148fb25d0438"><ix:nonFraction unitRef="usd" contextRef="icac424a9ffb64141aa0d33bcd8b4fcfb_D20220101-20220331" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RleHRyZWdpb246NTc5MjcyZTI5NDUyNDU2NzlmNGZlNGRmZDA4YjBhMGNfMjc0ODc3OTA3NTIyMg_e335bca0-fdc1-4047-b870-d7cffe80e7ff">0.2</ix:nonFraction></ix:nonFraction>&#160;million of amortization expense within operating profit associated with an intangible asset acquired during the second quarter of 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please refer to Note 15, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_76">Other Expense (Income)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of certain unallocated items referenced above.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i7bf87d07bb544f48851c48374130181b_88"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OVERVIEW</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion is intended to further the reader&#8217;s understanding of the consolidated financial condition and results of operations of our Company. It should be read in conjunction with our condensed consolidated financial statements and accompanying notes elsewhere in this Quarterly Report on Form 10-Q (&#8220;Form 10-Q&#8221;) as well as Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations and the consolidated financial statements and accompanying notes included in our 2022 Annual Report. Our historical financial statements may not be indicative of our future performance. This Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations contains a number of forward-looking statements, all of which are based on our current expectations and could be affected by the uncertainties and risks discussed in Part I, Item 1A of our 2022 Annual Report and in Part II, Item 1A of this Form 10-Q.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout this section, references to &#8220;Notes&#8221; refer to the notes to our condensed consolidated financial statements (unaudited) in Part I, Item 1 of this Form 10-Q, unless otherwise indicated.</span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-U.S. GAAP Financial Measures</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the purpose of aiding the comparison of our year-over-year results, we may refer to net sales and other financial results excluding the effects of changes in foreign currency exchange rates. Organic net sales exclude the impact from acquisitions and/or divestitures and translate the current-period reported sales of subsidiaries whose functional currency is other than USD at the applicable foreign exchange rates in effect during the comparable prior-year period. We may also refer to adjusted consolidated operating profit and adjusted consolidated operating profit margin, which exclude the effects of unallocated items. The unallocated items are not representative of ongoing operations, and generally include restructuring and related charges, certain asset impairments, and other specifically-identified income or expense items. The re-measured results excluding effects from currency translation, the impact from acquisitions and/or divestitures, and excluding the effects of unallocated items are not in conformity with U.S. Generally Accepted Accounting Principles ("GAAP") and should not be used as a substitute for the comparable U.S. GAAP financial measures. The non-U.S. GAAP financial measures are incorporated in our discussion and analysis as management uses them in evaluating our results of operations and believes that this information provides users with a valuable insight into our overall performance and financial position.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Operations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a leading global manufacturer in the design and production of technologically advanced, high-quality, integrated containment and delivery systems for injectable drugs and healthcare products. Our products include a variety of primary proprietary packaging, containment solutions, reconstitution and transfer systems, and drug delivery systems, as well as contract manufacturing, analytical lab services and integrated solutions. Our customers include leading biologic, generic, pharmaceutical, diagnostic, and medical device companies around the world. Our top priority is delivering quality products that meet the exact product specifications and quality standards customers require and expect. This focus on quality includes a commitment to excellence in manufacturing, scientific and technical expertise and management, which enables us to partner with our customers in order to deliver safe, effective drug products to patients quickly and efficiently.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business operations are organized into two global segments, Proprietary Products and Contract-Manufactured Products. Our Proprietary Products reportable segment offers proprietary packaging, containment solutions and drug delivery systems, along with analytical lab services and other integrated services and solutions, primarily to biologic, generic and pharmaceutical drug customers. Our Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. We also maintain collaborations to share technologies and market products with affiliates in Japan and Mexico.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Macroeconomic Factors</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through the three months ended March&#160;31, 2023, the war between Russia and Ukraine has not had a material impact on the Company&#8217;s business, financial condition or results of operations as we do not have manufacturing operations or significant commercial relationships in either country. However, the continuation of the Russia-Ukraine military conflict and/or an escalation of the conflict beyond its current scope may further weaken the global economy and could result in additional inflationary pressures and supply chain constraints, including the unavailability and cost of energy. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During three months ended March&#160;31, 2023 we continued to experience high costs for raw materials in both domestic and international markets. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the uncertainty that exists relative to the duration and overall impact of the macroeconomic factors discussed above, our future operating performance, particularly in the short-term, may be subject to volatility. The impacts of macroeconomic conditions on our business, results of operations, financial condition and cash flows are dependent on certain factors, including those discussed in Item 1A. </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_112">Risk Factors</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the risk factors described in Part I, Item 1A of our 2022 Annual Report.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023 Financial Performance Summary</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present a reconciliation from U.S. GAAP to non-U.S. GAAP financial measures:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.596%"><tr><td style="width:1.0%"></td><td style="width:42.249%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.170%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.036%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.036%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.041%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions, except per share data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Profit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted EPS</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quarter ended March&#160;31, 2023 GAAP</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated items:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment for planned sale of plant </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of acquisition-related intangible assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quarter ended March&#160;31, 2023 adjusted amounts (non-U.S. GAAP)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.98&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter 2023, we recorded a tax benefit of $11.6&#160;million associated with stock-based compensation.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.596%"><tr><td style="width:1.0%"></td><td style="width:42.249%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.170%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.036%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.036%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.041%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions, except per share data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Profit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted EPS</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quarter ended March&#160;31, 2022 GAAP</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated items:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension settlement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of acquisition-related intangible assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.01</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quarter ended March&#160;31, 2022 adjusted amounts (non-U.S. GAAP)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.30&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter 2022, we recorded a tax benefit of $8.9&#160;million associated with stock-based compensation.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">During the three months ended March&#160;31, 2023, in preparation for the sale of one of the Company&#8217;s manufacturing facilities within the Proprietary Products segment, the Company recorded an impairment expense of $9.4&#160;million within other expense (income) and a corresponding reduction to the disposal group net assets to its fair value less cost to sell. The transaction is expected to close during the second quarter of 2023.  </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">During the three months ended March&#160;31, 2023 and 2022, the Company recorded $0.2 million of amortization expense within operating profit associated with an intangible asset acquired during the second quarter of 2020. During the three months ended March&#160;31, 2023 and 2022, the Company recorded $0.5&#160;million of amortization expense in association with an acquisition of increased ownership interest in Daikyo.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Company recorded a pension settlement charge within other nonoperating (income) expense, as it determined that normal-course lump-sum payments for our U.S. qualified defined benefit pension plan exceeded the threshold for settlement accounting.</span></div><div><span><br/></span></div><div id="i7bf87d07bb544f48851c48374130181b_91"></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate the performance of our segments based upon, among other things, segment net sales and operating profit. Segment operating profit excludes general corporate costs, which include executive and director compensation, stock-based compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments. Also excluded are items that we consider not representative of ongoing operations. Such items are referred to as other unallocated items for which further information can be found above in the reconciliation from U.S. GAAP to non-U.S. GAAP financial measures.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Percentages in the following tables and throughout the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section may reflect rounding adjustments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Sales</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents net sales, consolidated and by reportable segment, for the three months ended March&#160;31, 2023 and 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.291%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.201%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.201%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.201%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.203%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As-Reported</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Organic</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proprietary Products</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">601.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract-Manufactured Products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment sales elimination</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated net sales</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">716.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated net sales decreased by $3.4 million, or 0.5%, for the three months ended March&#160;31, 2023, as compared to the same period in 2022, including an unfavorable foreign currency translation impact of $20.1 million. Excluding foreign currency translation effects, consolidated net sales for the three months ended March&#160;31, 2023 increased by $16.7 million, or 2.3%, as compared to the same period in 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Proprietary Products &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Proprietary Products net sales decreased by $18.2 million, or 3.0%, for the three months ended March&#160;31, 2023, as compared to the same period in 2022, including an unfavorable foreign currency translation impact of $17.8 million. Excluding foreign currency translation effects, net sales for the three months ended March&#160;31, 2023 decreased by $0.4 million, or 0.1%, as compared to the same period in 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">primarily due to  a decline in COVID-related sales of approximately $88&#160;million, offset by sales price increases.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract-Manufactured Products &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Contract-Manufactured Products net sales increased by $14.8 million, or 12.5%, for the three months ended March&#160;31, 2023, as compared to the same period in 2022, including an unfavorable foreign currency translation impact of $2.3 million. Excluding foreign currency translation effects, net sales for the three months ended March&#160;31, 2023 increased by $17.1 million, or 14.4%, as co</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mpared to the same period in 2022, primarily</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> due to an increase in sales of components associated with injection-related devices and sales price increases. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intersegment sales elimination, which is required for the presentation of consolidated net sales, represents the elimination of components sold between our segments.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:0.641%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross Profit</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents gross profit and related gross profit margins, consolidated and by reportable segment:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proprietary Products:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit margin</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract-Manufactured Products:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit margin</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated gross profit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated gross profit margin</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.5&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated gross profit decreased by $13.3 million, or 4.7%, for the three months ended March&#160;31, 2023, as compared to the same period in 2022, including an unfavorable foreign currency translation impact of $6.7 million for the three months ended March&#160;31, 2023, as compared to the same period in 2022. Consolidated gross profit margin decreased by 1.6 margin points for the three months ended March&#160;31, 2023, as compared to the same period in 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Proprietary Products - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proprietary Products gross profit decreased by $12.9 million, or 4.9%, for the three months ended March&#160;31, 2023, as compared to the same period in 2022, including an unfavorable foreign currency translation impact of $6.2 million. Proprietary Products gross profit margin decreased</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by 0.9 margin points for the three months ended March&#160;31, 2023, as compared to the same periods in 2022, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">due to a decline in higher margin COVID-related sales, inflationary pressures primarily within transportation and compensation costs, and additional plant spend to meet ongoing product demand. These headwinds were partially offset by increased sales prices and production efficiencies.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract-Manufactured Products - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract-Manufactured Products gross profit decreased by $0.4 million, or 1.7%, for the three months ended March&#160;31, 2023, as compared to the same period in 2022, including an unfavorable foreign currency translation impact of $0.5 million. Contract-Manufactured Products gross profit margin decreased by 2.5 margin poi</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nts for the three months ended March&#160;31, 2023, as compared to the same period in 2022, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">due to inflationary pressures primarily within transportation and compensation costs and unfavorable mix of product sold. These headwinds were partially offset by increased sales prices.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development (&#8220;R&amp;D&#8221;) Costs</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents consolidated R&amp;D costs:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated R&amp;D costs</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated R&amp;D costs increased by $2.5 million, or 17.1%, for the three months ended March&#160;31, 2023, as compared to the same period in 2022, due to additional research performed to identify new product opportunities, of which $1.5&#160;million of the increase relates to research performed on glass systems. Efforts remain focused on the continued investment in elastomeric packaging components, formulation development, drug containment systems, self-injection systems and drug administration consumables.</span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the R&amp;D costs incurred during the three months ended March&#160;31, 2023 and 2022 related to Proprietary Products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selling, General and Administrative (&#8220;SG&amp;A&#8221;) Costs</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents SG&amp;A costs, consolidated and by reportable segment and corporate and unallocated items:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proprietary Products</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract-Manufactured Products</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and unallocated items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated SG&amp;A costs</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">SG&amp;A as a % of net sales</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">12.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated SG&amp;A costs increased b</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">y $2.6 million, or 3.1%, for the three months ended March&#160;31, 2023, as compared to the same period in 2022, due to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> an increase in compensation costs, offset by a decrease in costs related to professional services and a favorable foreign currency translation impact of $0.7 million.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Proprietary Products - </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proprietary Products SG&amp;A costs increased by $0.6 million, or 1.1%, for the three months ended March&#160;31, 2023, as compared to the same period in 2022. Proprietary Products SG&amp;A costs increased primarily due to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an increase in compensation costs</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, offset by a decrease in costs related to professional services, other discretionary spending </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and a favorable foreign currency translation impact of</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $0.6 million.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract-Manufactured Products - </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract-Manufactured Products SG&amp;A costs increased by $1.2 million, or 25.0% for the three months ended March&#160;31, 2023, as compared to the same period in 2022,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> primarily </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">due to a higher allocation of corporate function spend.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate and unallocated items - </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate SG&amp;A costs increased by $0.8 million, or 3.5%, for the three months ended March&#160;31, 2023, as compared to the same period in 2022, primarily due to an increase in mark-to-market expense related to stock-based compensation, offset by a decrease in costs related to professional services.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Expense (Income)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents other income and expense items, consolidated and by reportable segment, corporate and unallocated items:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Income) Expense</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proprietary Products</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract-Manufactured Products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and unallocated items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated other expense (income)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense and income items consist of foreign exchange transaction gains and losses, gains and losses on the sale of fixed assets, contingent consideration, fixed asset impairments and miscellaneous income and charges. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated other expense (income) changed by $16.0 million for the three months ended March&#160;31, 2023, as compared to the same period in 2022, due to the factors described below. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Proprietary Products - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proprietary Products other expense (income) changed by $6.7 million for the three months ended March&#160;31, 2023, as compared to the same period in 2022, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">primarily due to a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $0.6&#160;million loss related to oil hedges recorded during the three months ended March&#160;31, 2023 compared to a gain of $2.8 million for the three months ended March 31, 2022. Additionally, a loss of $0.9 million on foreign exchange transactions was recorded in the three months ended March&#160;31, 2023, while a gain of $1.1 million was recorded in the same period in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lastly, fixed asset impairments totaled $1.9&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the three months ended March&#160;31, 2023, while a gain on the sale of equipment of $0.1&#160;million was recorded in the same period in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract-Manufactured Products - </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract-Manufactured Products other expense (income) changed by $0.1 million for the three months ended March&#160;31, 2023, as compared to the same period in 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate and unallocated items - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate and unallocated items changed by $9.2 million for the three months ended March&#160;31, 2023, as compared to the same periods in 2022. During the three months ended March&#160;31, 2023, in preparation for the sale of one of the Company&#8217;s manufacturing facilities within the Proprietary Products segment, the Company recorded an impairment expense of $9.4&#160;million within other expense (income) and a corresponding reduction to the disposal group net assets to its fair value less cost to sell. The transaction is expected to close during the second quarter of 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Profit</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents operating profit and adjusted operating profit, consolidated and by reportable segment, corporate and unallocated items:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proprietary Products</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract-Manufactured Products</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and unallocated</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated operating profit</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated operating profit margin</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.7&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.3&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated items</span></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted consolidated operating profit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted consolidated operating profit margin</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated operating profit decreased by $34.4 million, or 18.1%, for the three months ended March&#160;31, 2023, as compared to the same period in 2022, including an unfavorable foreign currency translation impact of $5.8 million for the three months ended March&#160;31, 2023, as compared to the same period in 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Proprietary Products - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proprietary Products operating profit decreased by $22.7 million, or 11.7%, for the three months ended March&#160;31, 2023, as compared to the same period in 2022, including an unfavorable foreign currency translation impact of $5.3 million, due to the factors described above, most notably the decline in COVID-related sales.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract-Manufactured Products - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract-Manufactured Products operating profit decreased by $1.7 million, or 8.9%, for the three months ended March&#160;31, 2023, as compared to the same period in 2022, including an unfavorable foreign currency translation impact of $0.5 million, due to the factors described above, most notably increased overhead costs that were driven by inflation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding the unallocated items,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate costs increased by $0.6 million, or 2.7%, for the three months ended March&#160;31, 2023, as compared to the same period in 2022, due to the factors described above.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unallocated items </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Please refer to the Financial Performance Summary section above for details</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Expense, Net</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents interest expense, net, by significant component:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net, remained flat for the three months ended March&#160;31, 2023, as compared to the same period in 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income increased by $4.5 million for the three months ended March&#160;31, 2023, as compared to the same period in 2022, resulting from higher interest rates compared to the prior year, primarily within the US, Europe and South America.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Tax Expense</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes was $23.6 million and $21.2 million for the three months ended March&#160;31, 2023 and 2022, respectively, and the effective tax rate was 14.9% and 11.3%, respectively. The increase in the effective tax rate is primarily due to a shift in the geographic earnings mix and a $5.9&#160;million tax benefit recorded as a result of a state tax valuation allowance reversal in the three months ended March&#160;31, 2022 that was not repeated in 2023. This was offset by an increase in the tax benefit related to stock-based compensation for the three months ended March&#160;31, 2023, as compared to the same period in 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity in Net Income of Affiliated Companies</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity in net income of affiliated companies decreased by $1.5 million for the three months ended March&#160;31, 2023, as compared to the same period in 2022, due to less favorable operating results at Daikyo and the Mexico affiliates.</span></div><div><span><br/></span></div><div id="i7bf87d07bb544f48851c48374130181b_97"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION, LIQUIDITY AND CAPITAL RESOURCES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents cash flow data for the three months ended March&#160;31:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(172.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Cash Provided by Operating Activities &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Net cash provided by operating activities decreased by $13.1 million for the three months ended March&#160;31, 2023, as compared to the same period in 2022, primarily due to a decline in operating results.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Cash Used in Investing Activities &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Net cash used in investing activities increased by $13.8 million for the three months ended March&#160;31, 2023, as compared to the same period in 2022, primarily due to an increase in capital expenditures for additional manufacturing capacity in 2023 to meet customer demand.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Cash Used in Financing Activities &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Net cash used in financing activities decreased by $101.7 million for the three months ended March&#160;31, 2023, as compared to the same period in 2022, primarily due to decreases in purchases under our share repurchase program in 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents selected liquidity and capital measures:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">886.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">894.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">513.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">507.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">414.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,776.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,684.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,402.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents include all instruments that have maturities of ninety days or less when purchased. Working capital is defined as current assets less current liabilities. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and cash equivalents &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our cash and cash equivalents balance at March&#160;31, 2023 consisted of cash held in depository accounts with banks around the world and cash invested in high-quality, short-term investments. The cash and cash equivalents balance at March&#160;31, 2023 included $244.4&#160;million of cash held by subsidiaries within the U.S., and $641.9&#160;million of cash held by subsidiaries outside of the U.S. During the three months ended March&#160;31, 2023, we purchased 183,360 shares of our common stock under our calendar-year 2023 share repurchase program at a cost of $60.1 million, or an average price of $327.90 per share.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Working capital &#8211;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Working capital at March&#160;31, 2023 increased by $1.8 million, or 0.1%, as compared to December&#160;31, 2022, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which includes a favorable foreign currency translation impact of $8.1 million. Excluding the impact of currency exchange rates, cash and cash equivalents decreased by $15.0 million, while accounts receivable, inventories and total current liabilities increased by $2.5 million, $29.7 million and $11.9 million, respectively. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in cash and cash equivalents was due to capital expenditures and share repurchases, offset by positive operating results during the three months ended March&#160;31, 2023. The increase in inventories that occurred during the period was to ensure we have sufficient inventory on hand to support the needs of our customers. The increase in total current liabilities was caused an increase in accounts payable and income taxes payable during the three months ended March&#160;31, 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt and credit facilities &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The $0.6 million decrease in total debt at March&#160;31, 2023, as compared to December&#160;31, 2022, resulted from debt repayments under our Term Loan.</span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our sources of liquidity include our Credit Facility. At March&#160;31, 2023, we had no outstanding borrowings under the Credit Facility. At March&#160;31, 2023, the borrowing capacity available under the Credit Facility, including outstanding letters of credit of $2.4 million, was $497.6 million. We do not expect any significant limitations on our ability to access this source of funds.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the financial covenants in our debt agreements, we are required to maintain established interest coverage ratios and not to exceed established leverage ratios. In addition, the agreements contain other customary covenants, none of which we consider restrictive to our operations. At March&#160;31, 2023, we were in compliance with all of our debt covenants.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that cash on hand and cash generated from operations, together with availability under our Credit Facility, will be adequate to address our foreseeable liquidity needs based on our current expectations of our business operations, capital expenditures and scheduled payments of debt obligations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commitments and Contractual Obligations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of future material cash payments resulting from commitments and contractual obligations was provided in our 2022 Annual Report. During the three months ended March&#160;31, 2023, there were no material changes outside of the ordinary course of business to our commitments and contractual obligations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OFF-BALANCE SHEET ARRANGEMENTS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2023, we had no off-balance sheet financing arrangements other than unconditional purchase obligations incurred in the ordinary course of business and outstanding letters of credit related to various insurance programs, as noted in our 2022 Annual Report.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING POLICIES AND ESTIMATES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes to the Critical Accounting Policies and Estimates disclosed in Part II, Item 7 of our 2022 Annual Report.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEW ACCOUNTING STANDARDS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information on new accounting standards that were adopted during the three months ended March&#160;31, 2023, and the impact, if any, on our financial position or results of operations, see Note 2, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_37">New Accounting Standards</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our disclosure and analysis in this Form 10-Q contains some forward-looking statements that are based on management&#8217;s beliefs and assumptions, current expectations, estimates and forecasts. We also provide forward-looking statements in other materials we release to the public, as well as oral forward-looking statements. Such statements provide our current expectations or forecasts of future events. They do not relate strictly to historical or current facts. We have attempted, wherever possible, to identify forward-looking statements by using words such as &#8220;plan,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;intend,&#8221; &#8220;will,&#8221; &#8220;estimate,&#8221; &#8220;continue&#8221; and other words of similar meaning in conjunction with, among other things, discussions of future operations and financial performance, as well as our strategy for growth, product development, market position and expenditures. All statements that address operating performance or events or developments that we expect or anticipate will occur in the future - including statements relating to sales and earnings per share growth, cash flows or uses, and statements expressing views about future operating results - are forward-looking statements.</span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements are based on current expectations of future events. The forward-looking statements are, and will be, based on management&#8217;s then-current views and assumptions regarding future events and operating performance, and speak only as of their dates. Investors should realize that, if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from our expectations and projections. Investors are therefore cautioned not to place undue reliance on any forward-looking statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are some important factors that could cause our actual results to differ from our expectations in any forward-looking statements: </span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales demand and our ability to meet that demand;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competition from other providers in our businesses, including customers&#8217; in-house operations, and from lower-cost producers in emerging markets, which can impact unit volume, price and profitability;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">customers&#8217; changing inventory requirements and manufacturing plans that alter existing orders or ordering patterns for the products we supply to them;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruptions or weaknesses in our supply chain, including from reasons beyond our control such as extreme weather, longer-term climate changes, natural disasters, pandemic, war, accidental damage, or unauthorized access to our or our customers&#8217; information and systems, which could cause delivery delays or restrict the availability of raw materials, key purchased components and finished products;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, regulatory approval and commercial success of customer products that incorporate our products and systems;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether customers agree to incorporate our products and delivery systems with their new and existing drug products, the ultimate timing and successful commercialization of those products and systems, which involves substantial evaluations of the functional, operational, clinical and economic viability of our products, and the rate, timing and success of regulatory approval for the drug products that incorporate our components and systems;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timely and adequate availability of filling capacity, which is essential to conducting definitive stability trials and the timing of first commercialization of customers&#8217; products in Crystal Zenith prefilled syringes;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">profitability, or mix, of the products sold in any reporting period, including lower-than-expected sales growth of our high-value proprietary product offerings;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining or improving production efficiencies and overhead absorption;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">dependence on third-party suppliers and partners, some of which are single-source suppliers of critical materials and products, including our Japanese partner and affiliate, Daikyo;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the loss of key personnel or highly-skilled employees;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability and cost of skilled employees required to meet increased production, managerial, research and other needs, including professional employees and persons employed under collective bargaining agreements;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the successful and timely implementation of price increases necessary to offset rising production costs, including raw material prices, particularly petroleum-based raw materials;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and progress of development, regulatory approval and marketing of new products;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain licenses in any jurisdiction in which we do business;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the relative strength of USD in relation to other currencies, particularly the Euro, SGD, the Danish Krone, Yen, Colombian Peso, Brazilian Real, and the South Korean Won; and</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential adverse effects of global healthcare legislation on customer demand, product pricing and profitability.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This list sets forth many, but not all, of the factors that could affect our ability to achieve results described in any forward-looking statements. Investors should understand that it is not possible to predict or identify all of the factors and should not consider this list to be a complete statement of all potential risks and uncertainties. For further discussion of these and other factors, see the risk factors disclosed in Part I, Item 1A of our 2022 Annual Report as well as Part II, section 1A of this quarterly report. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as required by law or regulation, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. </span></div><div><span><br/></span></div><div id="i7bf87d07bb544f48851c48374130181b_100"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes in our exposure to market risk or the information provided in Part II, Item 7A of our 2022 Annual Report.</span></div><div><span><br/></span></div><div id="i7bf87d07bb544f48851c48374130181b_103"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONTROLS AND PROCEDURES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disclosure controls are controls and procedures designed to reasonably ensure that information required to be disclosed in our reports filed under the Exchange Act, such as this quarterly report, is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934, as amended, is accumulated and communicated to our management, including our Chief Executive Officer (&#8220;CEO&#8221;) and Chief Financial Officer (&#8220;CFO&#8221;), or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An evaluation was performed under the supervision and with the participation of our management, including our CEO and CFO, of the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934), as of the end of the period covered by this quarterly report on Form 10-Q. Based on this evaluation, our CEO and CFO have concluded that, as of March&#160;31, 2023, our disclosure controls and procedures are effective.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Controls</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the quarter ended March&#160;31, 2023, there have been no changes to our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div><span><br/></span></div><div id="i7bf87d07bb544f48851c48374130181b_106"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II.&#160;&#160;OTHER INFORMATION</span></div><div><span><br/></span></div><div id="i7bf87d07bb544f48851c48374130181b_109"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;LEGAL PROCEEDINGS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div id="i7bf87d07bb544f48851c48374130181b_112"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A.&#160;&#160;RISK FACTORS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are providing the disclosure below and supplementing the risk factors described in Part I, Item 1A of our 2022 Annual Report with the following risk factor. The additional risk factor identified should be read in conjunction with the risk factors described in the 2022 Annual Report and the information under the &#8220;Forward Looking Statements&#8221; in the 2022 Annual Report. </span></div><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Unstable market and economic conditions and adverse developments with respect to financial institutions and associated liquidity risk may have serious adverse consequences on our business and financial condition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The recent and potential future disruptions in access to bank deposits or lending commitments due to bank failure could materially and adversely affect our liquidity, our business and financial condition. Even with our continued effort to mitigate counterparty risk by working with highly liquid, well capitalized counterparties, the failure of any bank in which we deposit our funds could reduce the amount of cash we have available for our operations or delay our ability to access such funds. Any such failure may increase the possibility of a sustained deterioration of financial market liquidity, or illiquidity at clearing, cash management and/or custodial financial institutions. In the event we have a commercial relationship with a bank that has failed or is otherwise distressed, we may experience delays or other issues in meeting our financial obligations. If other banks and financial institutions enter receivership or become insolvent in the future in response to financial conditions affecting the banking system and financial markets, our ability to access our cash and cash equivalents and investments may be threatened and could have a material adverse effect on our business and financial condition.</span></div><div><span><br/></span></div><div id="i7bf87d07bb544f48851c48374130181b_115"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows information with respect to purchases of our common stock made during the three months ended March&#160;31, 2023 by us or any of our &#8220;affiliated purchasers&#8221; as defined in Rule 10b-18(a)(3) under the Exchange Act: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.396%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.396%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.396%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.396%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.404%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total number of shares purchased (1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average price paid per share (1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total number of shares purchased as part of publicly announced plans or programs (1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Approximate dollar value of shares that may yet be purchased under the plans or programs (1)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1 - 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 1 - 28, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1 - 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">939,900,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,360&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327.90&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,360&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">939,900,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">In February 2023, the Board of Directors approved a share repurchase program under which we may repurchase up to $1.0&#160;billion in shares of common stock. The share repurchase program does not have an expiration date under which we may repurchase common stock on the open market or in privately-negotiated transactions. The number of shares to be repurchased and the timing of such transactions will depend on a variety of factors, including market conditions.</span></div><div style="padding-left:54pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><div id="i7bf87d07bb544f48851c48374130181b_118"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6.&#160;&#160;EXHIBITS</span></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/105770/000010577020000045/ex31articlesofincorpor.htm">Our Amended and Restated Articles of Incorporation (incorporated by reference to Exhibit 3.1 to the Company's Form 10-Q report for the quarter ended June 30, 2020, filed July 24, 2020).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/105770/000010577021000014/wpsbylawamendmentsfinalfeb.htm">Our Bylaws, as amended through February 23, 2021 (incorporated by reference from our Form 8-k, filed March 1, 2021).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/105770/0000105770-99-000016-index.html">Form of stock certificate for common stock (incorporated by reference to Exhibit 4 to the Company's 1998 Form 10-K, filed May 6, 1999).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/105770/000010577020000045/ex31articlesofincorpor.htm">Article 5, 6, 8(c) and 9 of our Amended and Restated Articles of Incorporation (incorporated by reference to Exhibit 3.1 to the Company's Form 10-Q report for the quarter ended June 30, 2020, filed July 24, 2020).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/105770/000010577021000014/wpsbylawamendmentsfinalfeb.htm">Article I and V of our Bylaws, as amended through February 23, 2021 (incorporated by reference from our Form 8-k, filed March 1, 2021).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Instruments defining the rights of holders of long-term debt securities of West and its subsidiaries have been omitted.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex311q12023.htm">Certification by the Chief Executive Officer Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex312q12023.htm">Certification by the Chief Financial Officer Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex321q12023.htm">Certification by the Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex322q12023.htm">Certification by the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL for the cover page of this Quarterly Report on Form 10-Q, included in the Exhibit 101 Inline XBRL Document Set.</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We agree to furnish to the SEC, upon request, a copy of each instrument with respect to issuances of long-term debt of the Company and its subsidiaries.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Furnished, not filed.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><div id="i7bf87d07bb544f48851c48374130181b_121"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i7bf87d07bb544f48851c48374130181b_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">SIGNATURE</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, West Pharmaceutical Services, Inc. has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">WEST PHARMACEUTICAL SERVICES, INC.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant)</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">By: /s/ Bernard J. Birkett</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bernard J. Birkett</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Vice President, Chief Financial and Operations Officer</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April&#160;27, 2023 </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ex311q12023.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="icabefd64e56c4f03a6f5e491a5c88d37_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">CERTIFICATION</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Eric M. Green, certify that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this quarterly report on Form 10-Q of West Pharmaceutical Services, Inc.&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Eric M. Green</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eric M. Green</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President and Chief Executive Officer, Chair of the Board of Directors</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; April&#160;27, 2023 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ex312q12023.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ifb17f854cdfd4f3188d3f9c9138156d2_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">CERTIFICATION</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Bernard J. Birkett, certify that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this quarterly report on Form 10-Q of West Pharmaceutical Services, Inc.&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Bernard J. Birkett</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bernard J. Birkett</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Vice President, Chief Financial and Operations Officer</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; April&#160;27, 2023 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ex321q12023.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i6bc61e96cca345ec9a81b6facdf0665c_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 906 OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of West Pharmaceutical Services, Inc. (the &#8220;Company&#8221;) for the period ended March&#160;31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Eric M. Green, President and Chief Executive Officer, Chair of the Board of Directors of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Eric M. Green</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eric M. Green</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President and Chief Executive Officer, Chair of the Board of Directors</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; April&#160;27, 2023</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>ex322q12023.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i52c0f492d9d94866b68402a70de3aadd_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.2</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 906 OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of West Pharmaceutical Services, Inc. (the &#8220;Company&#8221;) for the period ended March&#160;31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Bernard J. Birkett, Senior Vice President, Chief Financial and Operations Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Bernard J. Birkett</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bernard J. Birkett</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Vice President, Chief Financial and Operations Officer</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; April&#160;27, 2023</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>wst-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:a34422fb-98f0-4bfc-83b0-7c0b1b7c96bb,g:fe42bdb5-3507-4fad-98a2-d4b1f779591c-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:wst="http://www.westpharma.com/20230331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.westpharma.com/20230331">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="wst-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="wst-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="wst-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="wst-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.westpharma.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" roleURI="http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED">
        <link:definition>0000002 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED" roleURI="http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED">
        <link:definition>0000003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITEDParenthetical" roleURI="http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITEDParenthetical">
        <link:definition>0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" roleURI="http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED">
        <link:definition>0000005 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" roleURI="http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical">
        <link:definition>0000006 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" roleURI="http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED">
        <link:definition>0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPolicies" roleURI="http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies">
        <link:definition>0000008 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NewAccountingStandards" roleURI="http://www.westpharma.com/role/NewAccountingStandards">
        <link:definition>0000009 - Disclosure - New Accounting Standards</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenue" roleURI="http://www.westpharma.com/role/Revenue">
        <link:definition>0000010 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShare" roleURI="http://www.westpharma.com/role/NetIncomePerShare">
        <link:definition>0000011 - Disclosure - Net Income Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.westpharma.com/role/Inventories">
        <link:definition>0000012 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.westpharma.com/role/Leases">
        <link:definition>0000013 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AffiliatedCompanies" roleURI="http://www.westpharma.com/role/AffiliatedCompanies">
        <link:definition>0000014 - Disclosure - Affiliated Companies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.westpharma.com/role/Debt">
        <link:definition>0000015 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstruments" roleURI="http://www.westpharma.com/role/DerivativeFinancialInstruments">
        <link:definition>0000016 - Disclosure - Derivative Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.westpharma.com/role/FairValueMeasurements">
        <link:definition>0000017 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveLoss" roleURI="http://www.westpharma.com/role/AccumulatedOtherComprehensiveLoss">
        <link:definition>0000018 - Disclosure - Accumulated Other Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquity" roleURI="http://www.westpharma.com/role/ShareholdersEquity">
        <link:definition>0000019 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.westpharma.com/role/StockBasedCompensation">
        <link:definition>0000020 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BenefitPlans" roleURI="http://www.westpharma.com/role/BenefitPlans">
        <link:definition>0000021 - Disclosure - Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherExpenseIncome" roleURI="http://www.westpharma.com/role/OtherExpenseIncome">
        <link:definition>0000022 - Disclosure - Other Expense (Income)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.westpharma.com/role/IncomeTaxes">
        <link:definition>0000023 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.westpharma.com/role/CommitmentsandContingencies">
        <link:definition>0000024 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformation" roleURI="http://www.westpharma.com/role/SegmentInformation">
        <link:definition>0000025 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000026 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueTables" roleURI="http://www.westpharma.com/role/RevenueTables">
        <link:definition>0000027 - Disclosure - Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareTables" roleURI="http://www.westpharma.com/role/NetIncomePerShareTables">
        <link:definition>0000028 - Disclosure - Net Income Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.westpharma.com/role/InventoriesTables">
        <link:definition>0000029 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.westpharma.com/role/LeasesTables">
        <link:definition>0000030 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://www.westpharma.com/role/DebtTables">
        <link:definition>0000031 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsTables" roleURI="http://www.westpharma.com/role/DerivativeFinancialInstrumentsTables">
        <link:definition>0000032 - Disclosure - Derivative Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.westpharma.com/role/FairValueMeasurementsTables">
        <link:definition>0000033 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveLossTables" roleURI="http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossTables">
        <link:definition>0000034 - Disclosure - Accumulated Other Comprehensive Loss (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityTables" roleURI="http://www.westpharma.com/role/ShareholdersEquityTables">
        <link:definition>0000035 - Disclosure - Shareholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BenefitPlansTables" roleURI="http://www.westpharma.com/role/BenefitPlansTables">
        <link:definition>0000036 - Disclosure - Benefit Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherExpenseIncomeTables" roleURI="http://www.westpharma.com/role/OtherExpenseIncomeTables">
        <link:definition>0000037 - Disclosure - Other Expense (Income) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationTables" roleURI="http://www.westpharma.com/role/SegmentInformationTables">
        <link:definition>0000038 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRevenueRecognitionDetails" roleURI="http://www.westpharma.com/role/RevenueRevenueRecognitionDetails">
        <link:definition>0000039 - Disclosure - Revenue - Revenue Recognition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueContractsandLiabilitiesDetails" roleURI="http://www.westpharma.com/role/RevenueContractsandLiabilitiesDetails">
        <link:definition>0000040 - Disclosure - Revenue - Contracts and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueContractsandLiabilitiesNarrativeDetails" roleURI="http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails">
        <link:definition>0000041 - Disclosure - Revenue - Contracts and Liabilities, Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareDetails" roleURI="http://www.westpharma.com/role/NetIncomePerShareDetails">
        <link:definition>0000042 - Disclosure - Net Income Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesDetails" roleURI="http://www.westpharma.com/role/InventoriesDetails">
        <link:definition>0000043 - Disclosure - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeaseCostDetails" roleURI="http://www.westpharma.com/role/LeasesLeaseCostDetails">
        <link:definition>0000044 - Disclosure - Leases - Lease Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeaseCashFlowandSupplementalInformationDetails" roleURI="http://www.westpharma.com/role/LeasesLeaseCashFlowandSupplementalInformationDetails">
        <link:definition>0000045 - Disclosure - Leases - Lease Cash Flow and Supplemental Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeaseWeightedAverageDetails" roleURI="http://www.westpharma.com/role/LeasesLeaseWeightedAverageDetails">
        <link:definition>0000046 - Disclosure - Leases - Lease Weighted Average (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" roleURI="http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails">
        <link:definition>0000047 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1" roleURI="http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1">
        <link:definition>0000047 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AffiliatedCompaniesDetails" roleURI="http://www.westpharma.com/role/AffiliatedCompaniesDetails">
        <link:definition>0000048 - Disclosure - Affiliated Companies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtLongtermDebtDetails" roleURI="http://www.westpharma.com/role/DebtLongtermDebtDetails">
        <link:definition>0000049 - Disclosure - Debt - Long-term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtLongtermDebtDetails_1" roleURI="http://www.westpharma.com/role/DebtLongtermDebtDetails_1">
        <link:definition>0000049 - Disclosure - Debt - Long-term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtCreditFacilityDetails" roleURI="http://www.westpharma.com/role/DebtCreditFacilityDetails">
        <link:definition>0000050 - Disclosure - Debt - Credit Facility (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" roleURI="http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails">
        <link:definition>0000051 - Disclosure - Derivative Financial Instruments - Foreign Exchange Rate Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsForeignCurrencyContractsDetails" roleURI="http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignCurrencyContractsDetails">
        <link:definition>0000052 - Disclosure - Derivative Financial Instruments - Foreign Currency Contracts (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" roleURI="http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails">
        <link:definition>0000053 - Disclosure - Derivative Financial Instruments - Effects of Derivative Instruments on OCI and Earnings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails" roleURI="http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails">
        <link:definition>0000054 - Disclosure - Derivative Financial Instruments - Derivative Instruments Not Designated as Hedges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" roleURI="http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails">
        <link:definition>0000055 - Disclosure - Fair Value Measurements - Assets and Liabilities Recorded at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsOtherFinancialInstrumentsDetails" roleURI="http://www.westpharma.com/role/FairValueMeasurementsOtherFinancialInstrumentsDetails">
        <link:definition>0000056 - Disclosure - Fair Value Measurements - Other Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails" roleURI="http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails">
        <link:definition>0000057 - Disclosure - Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails" roleURI="http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails">
        <link:definition>0000058 - Disclosure - Accumulated Other Comprehensive Loss - Other Comprehensive Loss Reclassifications (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityChangeinShareholdersEquityDetails" roleURI="http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails">
        <link:definition>0000059 - Disclosure - Shareholders' Equity - Change in Shareholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquitySupplementalEquityInformationDetails" roleURI="http://www.westpharma.com/role/ShareholdersEquitySupplementalEquityInformationDetails">
        <link:definition>0000060 - Disclosure - Shareholders' Equity - Supplemental Equity Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationDetails" roleURI="http://www.westpharma.com/role/StockBasedCompensationDetails">
        <link:definition>0000061 - Disclosure - Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" roleURI="http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails">
        <link:definition>0000062 - Disclosure - Benefit Plans - Schedule of Components of Net Periodic Benefit Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BenefitPlansNarrativeDetails" roleURI="http://www.westpharma.com/role/BenefitPlansNarrativeDetails">
        <link:definition>0000063 - Disclosure - Benefit Plans - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherExpenseIncomeScheduleofOtherIncomeExpenseDetails" roleURI="http://www.westpharma.com/role/OtherExpenseIncomeScheduleofOtherIncomeExpenseDetails">
        <link:definition>0000064 - Disclosure - Other Expense (Income) - Schedule of Other (Income) Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherExpenseIncomeNarrativeDetails" roleURI="http://www.westpharma.com/role/OtherExpenseIncomeNarrativeDetails">
        <link:definition>0000065 - Disclosure - Other Expense (Income) - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherExpenseIncomeScheduleofRestructuringandRelatedChargesDetails" roleURI="http://www.westpharma.com/role/OtherExpenseIncomeScheduleofRestructuringandRelatedChargesDetails">
        <link:definition>0000066 - Disclosure - Other Expense (Income) - Schedule of Restructuring and Related Charges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.westpharma.com/role/IncomeTaxesDetails">
        <link:definition>0000067 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationNarrativeDetails" roleURI="http://www.westpharma.com/role/SegmentInformationNarrativeDetails">
        <link:definition>0000068 - Disclosure - Segment Information - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationSalesbyProductGroupDetails" roleURI="http://www.westpharma.com/role/SegmentInformationSalesbyProductGroupDetails">
        <link:definition>0000069 - Disclosure - Segment Information - Sales by Product Group (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationSegmentFinancialInformationDetails" roleURI="http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails">
        <link:definition>0000070 - Disclosure - Segment Information - Segment Financial Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="wst_SalesToEquityMethodInvestees" abstract="false" name="SalesToEquityMethodInvestees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="wst_ContractWithCustomerLiabilityRollForward" abstract="true" name="ContractWithCustomerLiabilityRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="wst_RevolvingCreditFacilityDue2024Member" abstract="true" name="RevolvingCreditFacilityDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="wst_OtherIncomeExpense" abstract="false" name="OtherIncomeExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="wst_NetSalesMember" abstract="true" name="NetSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="wst_PurchasesAndRoyaltyPaymentsFromEquityMethodInvestees" abstract="false" name="PurchasesAndRoyaltyPaymentsFromEquityMethodInvestees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="wst_BiologicsCustomersMember" abstract="true" name="BiologicsCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="wst_LesseeLeaseCashFlowAndSupplementalInformationTableTextBlock" abstract="false" name="LesseeLeaseCashFlowAndSupplementalInformationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="wst_ContractWithCustomerAssetIncreaseDecrease" abstract="false" name="ContractWithCustomerAssetIncreaseDecrease" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="wst_GenericsCustomersMember" abstract="true" name="GenericsCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="wst_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="wst_ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock" abstract="false" name="ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="wst_ContractManufacturedCustomersMember" abstract="true" name="ContractManufacturedCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="wst_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" abstract="true" name="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="wst_RestructuringAndRelatedActivitiesPeriodOfImplementation" abstract="false" name="RestructuringAndRelatedActivitiesPeriodOfImplementation" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="wst_HighValueProductDeliveryDevicesMember" abstract="true" name="HighValueProductDeliveryDevicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="wst_TermLoanDue2024Member" abstract="true" name="TermLoanDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="wst_AccruedSalariesWagesAndBenefitsCurrent" abstract="false" name="AccruedSalariesWagesAndBenefitsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="wst_A2020RestructuringPlanMember" abstract="true" name="A2020RestructuringPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="wst_ShareBasedCompensationArrangementByShareBasedPaymentAwardActualPayoutPercentage" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardActualPayoutPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="wst_HighValueProductComponentsMember" abstract="true" name="HighValueProductComponentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="wst_ContractWithCustomerAssetRollForward" abstract="true" name="ContractWithCustomerAssetRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="wst_OtherFinancialInstrumentsAbstract" abstract="true" name="OtherFinancialInstrumentsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="wst_NotesPayableAndOtherDebtCurrent" abstract="false" name="NotesPayableAndOtherDebtCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="wst_OtherExpenseIncomeMember" abstract="true" name="OtherExpenseIncomeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="wst_SmartDoseMember" abstract="true" name="SmartDoseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="wst_SeniorCNotesDue2027Member" abstract="true" name="SeniorCNotesDue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="wst_ProprietaryProductsMember" abstract="true" name="ProprietaryProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="wst_StandardPackagingMember" abstract="true" name="StandardPackagingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="wst_The2020RestructuringPlanMember" abstract="true" name="The2020RestructuringPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="wst_ContractManufacturedProductsMember" abstract="true" name="ContractManufacturedProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="wst_PharmaCustomersMember" abstract="true" name="PharmaCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="wst_SeniorBNotesDue2024Member" abstract="true" name="SeniorBNotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>wst-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:a34422fb-98f0-4bfc-83b0-7c0b1b7c96bb,g:fe42bdb5-3507-4fad-98a2-d4b1f779591c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" xlink:type="simple" xlink:href="wst-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"/>
  <link:calculationLink xlink:role="http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bea2cbd4-eb24-4830-9a84-a318ead70378" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_29df7461-d351-4cba-b33d-91ae9395eae1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_bea2cbd4-eb24-4830-9a84-a318ead70378" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_29df7461-d351-4cba-b33d-91ae9395eae1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ce0eec39-c7d1-4a34-9d0f-1ec8f0e4690f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_bea2cbd4-eb24-4830-9a84-a318ead70378" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ce0eec39-c7d1-4a34-9d0f-1ec8f0e4690f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_166fc951-9f56-4c1a-a191-7d563e550936" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_bea2cbd4-eb24-4830-9a84-a318ead70378" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_166fc951-9f56-4c1a-a191-7d563e550936" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_539ca7b0-3de0-41a0-9911-444e5781dc80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9127a898-4d86-49a8-9ec6-8235a79d423a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_539ca7b0-3de0-41a0-9911-444e5781dc80" xlink:to="loc_us-gaap_OperatingIncomeLoss_9127a898-4d86-49a8-9ec6-8235a79d423a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_8f9e0a33-1e26-4049-aefa-910ee7d2c9bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_539ca7b0-3de0-41a0-9911-444e5781dc80" xlink:to="loc_us-gaap_InterestExpense_8f9e0a33-1e26-4049-aefa-910ee7d2c9bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_19780cab-a120-49fe-91e3-613f9854e1f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_539ca7b0-3de0-41a0-9911-444e5781dc80" xlink:to="loc_us-gaap_InvestmentIncomeNet_19780cab-a120-49fe-91e3-613f9854e1f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ef4396e7-bb35-44cf-9d27-8433181db948" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_a183e818-524a-46f5-8bac-060f17bd1093" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_ef4396e7-bb35-44cf-9d27-8433181db948" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_a183e818-524a-46f5-8bac-060f17bd1093" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_94c8135d-a18c-43a5-8084-e76dc38c69ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_ef4396e7-bb35-44cf-9d27-8433181db948" xlink:to="loc_us-gaap_GrossProfit_94c8135d-a18c-43a5-8084-e76dc38c69ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d2c12db3-7cbc-431a-bf57-9368ae188205" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_ef4396e7-bb35-44cf-9d27-8433181db948" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d2c12db3-7cbc-431a-bf57-9368ae188205" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_OtherIncomeExpense_4290402e-b928-47b5-8fe2-e47bf9a0353c" xlink:href="wst-20230331.xsd#wst_OtherIncomeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_ef4396e7-bb35-44cf-9d27-8433181db948" xlink:to="loc_wst_OtherIncomeExpense_4290402e-b928-47b5-8fe2-e47bf9a0353c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_93cfa98c-e21c-4d22-928a-4005d85871be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_14fa5e3a-52f5-43c9-8487-65f60f7042c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_93cfa98c-e21c-4d22-928a-4005d85871be" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_14fa5e3a-52f5-43c9-8487-65f60f7042c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_26e4d46c-8d04-4d99-b2f3-9355537eff8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_93cfa98c-e21c-4d22-928a-4005d85871be" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_26e4d46c-8d04-4d99-b2f3-9355537eff8e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED" xlink:type="simple" xlink:href="wst-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED"/>
  <link:calculationLink xlink:role="http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_2411e19f-59f1-49d3-a60a-c9b6ccb8e982" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_14800aec-1bbf-438c-a65e-9cc29f0694d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_2411e19f-59f1-49d3-a60a-c9b6ccb8e982" xlink:to="loc_us-gaap_NetIncomeLoss_14800aec-1bbf-438c-a65e-9cc29f0694d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_a71dc326-7d06-4535-982d-82a8d2c2367d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_2411e19f-59f1-49d3-a60a-c9b6ccb8e982" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_a71dc326-7d06-4535-982d-82a8d2c2367d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f6da31e3-7644-4d29-83b0-b08e4e200a52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_69ffed53-abc7-40cf-b2e7-0f301558ed42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f6da31e3-7644-4d29-83b0-b08e4e200a52" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_69ffed53-abc7-40cf-b2e7-0f301558ed42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_c14a2c8b-9575-405d-9aae-ddc6be80ac8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f6da31e3-7644-4d29-83b0-b08e4e200a52" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_c14a2c8b-9575-405d-9aae-ddc6be80ac8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_c7186a78-d0a6-4b20-bc0e-358144dcf290" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f6da31e3-7644-4d29-83b0-b08e4e200a52" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_c7186a78-d0a6-4b20-bc0e-358144dcf290" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" xlink:type="simple" xlink:href="wst-20230331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"/>
  <link:calculationLink xlink:role="http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_49bc9e95-b52a-4b78-8229-daa4c0ec39ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_93f380db-eeb5-4045-aaf2-f69d5468ad5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_49bc9e95-b52a-4b78-8229-daa4c0ec39ea" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_93f380db-eeb5-4045-aaf2-f69d5468ad5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_8d22e4b0-81d0-4ae5-8300-ccfd6a1323a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_49bc9e95-b52a-4b78-8229-daa4c0ec39ea" xlink:to="loc_us-gaap_TreasuryStockCommonValue_8d22e4b0-81d0-4ae5-8300-ccfd6a1323a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_0db4c9c3-2aba-4add-9cbd-87a74c561712" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_49bc9e95-b52a-4b78-8229-daa4c0ec39ea" xlink:to="loc_us-gaap_PreferredStockValue_0db4c9c3-2aba-4add-9cbd-87a74c561712" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_84e048b7-578d-463b-97e4-5cea7fa9a35f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_49bc9e95-b52a-4b78-8229-daa4c0ec39ea" xlink:to="loc_us-gaap_AdditionalPaidInCapital_84e048b7-578d-463b-97e4-5cea7fa9a35f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d100e76f-fbd6-4b32-aac1-76bd8f9fbb28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_49bc9e95-b52a-4b78-8229-daa4c0ec39ea" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d100e76f-fbd6-4b32-aac1-76bd8f9fbb28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_990700ec-f2e6-4044-a745-f669f4bd9d6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_49bc9e95-b52a-4b78-8229-daa4c0ec39ea" xlink:to="loc_us-gaap_CommonStockValue_990700ec-f2e6-4044-a745-f669f4bd9d6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_0fdc9d98-6bfe-4075-9706-8dfc17dcdd5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f5a49412-e9d1-418d-a111-8ad8041406c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_0fdc9d98-6bfe-4075-9706-8dfc17dcdd5d" xlink:to="loc_us-gaap_LiabilitiesCurrent_f5a49412-e9d1-418d-a111-8ad8041406c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_661166f1-8653-4bae-89d2-e6f15cc9d1ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_0fdc9d98-6bfe-4075-9706-8dfc17dcdd5d" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_661166f1-8653-4bae-89d2-e6f15cc9d1ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_2a3b8c87-e650-4b27-b5a3-81b0fd48fa63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_0fdc9d98-6bfe-4075-9706-8dfc17dcdd5d" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_2a3b8c87-e650-4b27-b5a3-81b0fd48fa63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_aa833f73-df7f-45a4-b6f4-edbb7b405a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_0fdc9d98-6bfe-4075-9706-8dfc17dcdd5d" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_aa833f73-df7f-45a4-b6f4-edbb7b405a4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_097da07b-cfac-4676-8ab2-4f1f104a6e18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_0fdc9d98-6bfe-4075-9706-8dfc17dcdd5d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_097da07b-cfac-4676-8ab2-4f1f104a6e18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_16438ba9-f34b-49c7-94c3-1b6fb7913dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_0fdc9d98-6bfe-4075-9706-8dfc17dcdd5d" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_16438ba9-f34b-49c7-94c3-1b6fb7913dfa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_2eb3fee9-75be-4c4e-99c5-eb944cb60bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_0fdc9d98-6bfe-4075-9706-8dfc17dcdd5d" xlink:to="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_2eb3fee9-75be-4c4e-99c5-eb944cb60bbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_479f8d55-1694-46e5-83ae-1422e133be3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1a61cc60-3db3-493e-9407-9039dd218eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_479f8d55-1694-46e5-83ae-1422e133be3d" xlink:to="loc_us-gaap_AssetsCurrent_1a61cc60-3db3-493e-9407-9039dd218eeb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c3996e84-6938-4155-8f2c-2f6b94ba0bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_479f8d55-1694-46e5-83ae-1422e133be3d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c3996e84-6938-4155-8f2c-2f6b94ba0bc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_f2ab2177-4146-4704-b72b-71adbb736b04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_479f8d55-1694-46e5-83ae-1422e133be3d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_f2ab2177-4146-4704-b72b-71adbb736b04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_25da2114-4cb7-4c3a-b836-99ee4b91c5a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_479f8d55-1694-46e5-83ae-1422e133be3d" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_25da2114-4cb7-4c3a-b836-99ee4b91c5a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_39dadf84-4af6-4ce6-b8d6-a2bbd215b6a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_479f8d55-1694-46e5-83ae-1422e133be3d" xlink:to="loc_us-gaap_Goodwill_39dadf84-4af6-4ce6-b8d6-a2bbd215b6a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_ef816b27-3861-47c1-bdb6-a81be3d883f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_479f8d55-1694-46e5-83ae-1422e133be3d" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_ef816b27-3861-47c1-bdb6-a81be3d883f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_c2d79aeb-1f12-4456-879f-c49f0c1c0cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_479f8d55-1694-46e5-83ae-1422e133be3d" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_c2d79aeb-1f12-4456-879f-c49f0c1c0cc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_fb6e1154-912b-44be-8db9-0329c9bce991" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_479f8d55-1694-46e5-83ae-1422e133be3d" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_fb6e1154-912b-44be-8db9-0329c9bce991" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_911dc1ea-6fac-4f72-80ac-637cfc2b01e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_2e4c281e-40d3-4420-86b7-fb74454ada23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_911dc1ea-6fac-4f72-80ac-637cfc2b01e4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_2e4c281e-40d3-4420-86b7-fb74454ada23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_fffbc180-4778-4423-9766-d4c200126a38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_911dc1ea-6fac-4f72-80ac-637cfc2b01e4" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_fffbc180-4778-4423-9766-d4c200126a38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a8a707b1-e7a7-48a2-bad1-1bff96b24015" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_NotesPayableAndOtherDebtCurrent_a02cfa10-4738-4b39-bcef-21200b68fd37" xlink:href="wst-20230331.xsd#wst_NotesPayableAndOtherDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a8a707b1-e7a7-48a2-bad1-1bff96b24015" xlink:to="loc_wst_NotesPayableAndOtherDebtCurrent_a02cfa10-4738-4b39-bcef-21200b68fd37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_9372af01-f1f8-4429-8e0d-4399c7381da8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a8a707b1-e7a7-48a2-bad1-1bff96b24015" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_9372af01-f1f8-4429-8e0d-4399c7381da8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_AccruedSalariesWagesAndBenefitsCurrent_00df3cba-2076-4da4-9809-42ba0b6809f9" xlink:href="wst-20230331.xsd#wst_AccruedSalariesWagesAndBenefitsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a8a707b1-e7a7-48a2-bad1-1bff96b24015" xlink:to="loc_wst_AccruedSalariesWagesAndBenefitsCurrent_00df3cba-2076-4da4-9809-42ba0b6809f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_b5897b66-244f-4f3e-bead-3fdc08c76273" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a8a707b1-e7a7-48a2-bad1-1bff96b24015" xlink:to="loc_us-gaap_AccountsPayableCurrent_b5897b66-244f-4f3e-bead-3fdc08c76273" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_626e46f8-3b7a-4f4a-aacc-8add1ad02115" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a8a707b1-e7a7-48a2-bad1-1bff96b24015" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_626e46f8-3b7a-4f4a-aacc-8add1ad02115" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_0ef8ec5c-33e3-413c-a492-e8cec44e283d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a8a707b1-e7a7-48a2-bad1-1bff96b24015" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_0ef8ec5c-33e3-413c-a492-e8cec44e283d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_87320e75-3a55-4ae1-b2d0-49d32f6c9769" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d5041c22-9b42-4c85-8324-eeaa640c6775" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_87320e75-3a55-4ae1-b2d0-49d32f6c9769" xlink:to="loc_us-gaap_Liabilities_d5041c22-9b42-4c85-8324-eeaa640c6775" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_81c91d94-a5c9-432c-a28d-0ad1b997b183" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_87320e75-3a55-4ae1-b2d0-49d32f6c9769" xlink:to="loc_us-gaap_CommitmentsAndContingencies_81c91d94-a5c9-432c-a28d-0ad1b997b183" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2aaa9e7f-c99b-43f1-a767-39a5412a245e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_87320e75-3a55-4ae1-b2d0-49d32f6c9769" xlink:to="loc_us-gaap_StockholdersEquity_2aaa9e7f-c99b-43f1-a767-39a5412a245e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0ca9ca0d-9909-444e-9854-2baa7160f23e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f823e740-97ba-4e41-98df-2f0625751d17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0ca9ca0d-9909-444e-9854-2baa7160f23e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f823e740-97ba-4e41-98df-2f0625751d17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_8fd497f2-f918-4c18-a044-99d7200172a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0ca9ca0d-9909-444e-9854-2baa7160f23e" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_8fd497f2-f918-4c18-a044-99d7200172a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_3d546906-3a65-4ac3-b641-501b99ae2743" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0ca9ca0d-9909-444e-9854-2baa7160f23e" xlink:to="loc_us-gaap_InventoryNet_3d546906-3a65-4ac3-b641-501b99ae2743" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_45efb13e-9acc-42f5-bcdb-663181394404" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0ca9ca0d-9909-444e-9854-2baa7160f23e" xlink:to="loc_us-gaap_OtherAssetsCurrent_45efb13e-9acc-42f5-bcdb-663181394404" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" xlink:type="simple" xlink:href="wst-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"/>
  <link:calculationLink xlink:role="http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f8e86a52-05eb-4c11-8f5b-8e2e4a476dfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_60bcf45f-8369-46ab-ab92-7e7e644ca049" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f8e86a52-05eb-4c11-8f5b-8e2e4a476dfe" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_60bcf45f-8369-46ab-ab92-7e7e644ca049" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_177be430-4d6a-4224-9952-b44fe77c6818" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f8e86a52-05eb-4c11-8f5b-8e2e4a476dfe" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_177be430-4d6a-4224-9952-b44fe77c6818" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8ed160c7-0963-4c66-8515-4c6ad5370c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f8e86a52-05eb-4c11-8f5b-8e2e4a476dfe" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8ed160c7-0963-4c66-8515-4c6ad5370c4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b8eb72b3-951b-442b-86cf-153d02e18557" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f8e86a52-05eb-4c11-8f5b-8e2e4a476dfe" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b8eb72b3-951b-442b-86cf-153d02e18557" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7cbb9aee-75f2-4f1b-a1b6-0ef94c048e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromOtherEquity_998ae72b-b965-4607-9518-8c2fcfb87c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromOtherEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7cbb9aee-75f2-4f1b-a1b6-0ef94c048e3e" xlink:to="loc_us-gaap_ProceedsFromOtherEquity_998ae72b-b965-4607-9518-8c2fcfb87c9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_0865bbb5-243c-47bf-8a83-73a905d36121" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7cbb9aee-75f2-4f1b-a1b6-0ef94c048e3e" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_0865bbb5-243c-47bf-8a83-73a905d36121" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_7519f957-3d3d-4225-85a8-ac5241c04a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7cbb9aee-75f2-4f1b-a1b6-0ef94c048e3e" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_7519f957-3d3d-4225-85a8-ac5241c04a6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_5b1387fa-5e78-4af8-a20f-921f944fd8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7cbb9aee-75f2-4f1b-a1b6-0ef94c048e3e" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_5b1387fa-5e78-4af8-a20f-921f944fd8a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_5dfab671-f348-45e6-9806-d6cf456e353f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7cbb9aee-75f2-4f1b-a1b6-0ef94c048e3e" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_5dfab671-f348-45e6-9806-d6cf456e353f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_d9d86bb4-6856-4d39-a9b9-13591f1a07a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7cbb9aee-75f2-4f1b-a1b6-0ef94c048e3e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_d9d86bb4-6856-4d39-a9b9-13591f1a07a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfOtherLongTermDebt_fc3ee9bc-942b-480d-9b52-59b7b488ea47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfOtherLongTermDebt"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7cbb9aee-75f2-4f1b-a1b6-0ef94c048e3e" xlink:to="loc_us-gaap_RepaymentsOfOtherLongTermDebt_fc3ee9bc-942b-480d-9b52-59b7b488ea47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_66c0920f-cde7-4e44-aa37-a64689dc7970" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f3c23b4d-2456-418a-9710-ac7bad8a03f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_66c0920f-cde7-4e44-aa37-a64689dc7970" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f3c23b4d-2456-418a-9710-ac7bad8a03f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_e4f32c0c-2be9-4a39-8bf7-d49f06926b49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_66c0920f-cde7-4e44-aa37-a64689dc7970" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_e4f32c0c-2be9-4a39-8bf7-d49f06926b49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c874fbdc-f08a-4c97-bed0-248b04292ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_0ce6f5e3-3bca-4f7b-9df1-50f70f74d01d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c874fbdc-f08a-4c97-bed0-248b04292ac0" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_0ce6f5e3-3bca-4f7b-9df1-50f70f74d01d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ad23c186-37f1-4fae-ba6d-626dd91a294d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c874fbdc-f08a-4c97-bed0-248b04292ac0" xlink:to="loc_us-gaap_NetIncomeLoss_ad23c186-37f1-4fae-ba6d-626dd91a294d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_4299d16b-1b39-4ba7-b982-59fa2f6b5b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c874fbdc-f08a-4c97-bed0-248b04292ac0" xlink:to="loc_us-gaap_ShareBasedCompensation_4299d16b-1b39-4ba7-b982-59fa2f6b5b5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_c58ef63e-5858-4844-b3e6-4190fb541644" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c874fbdc-f08a-4c97-bed0-248b04292ac0" xlink:to="loc_us-gaap_AdjustmentForAmortization_c58ef63e-5858-4844-b3e6-4190fb541644" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_6b75294d-acaf-4512-b2a3-459e633e5484" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c874fbdc-f08a-4c97-bed0-248b04292ac0" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_6b75294d-acaf-4512-b2a3-459e633e5484" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_4630d332-8082-403e-908b-03c34f421652" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c874fbdc-f08a-4c97-bed0-248b04292ac0" xlink:to="loc_us-gaap_Depreciation_4630d332-8082-403e-908b-03c34f421652" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_6506ab48-88cf-48d4-89fc-c5adaa35f4c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c874fbdc-f08a-4c97-bed0-248b04292ac0" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_6506ab48-88cf-48d4-89fc-c5adaa35f4c3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#RevenueContractsandLiabilitiesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_f3c35a7b-8465-4b06-8e9c-81ccbed81843" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_a752f3ea-5f99-4641-8c22-ef6bc1696204" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractWithCustomerLiability_f3c35a7b-8465-4b06-8e9c-81ccbed81843" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_a752f3ea-5f99-4641-8c22-ef6bc1696204" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_0f91b05e-2954-4839-94f7-a61799fbc24f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractWithCustomerLiability_f3c35a7b-8465-4b06-8e9c-81ccbed81843" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_0f91b05e-2954-4839-94f7-a61799fbc24f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/NetIncomePerShareDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#NetIncomePerShareDetails"/>
  <link:calculationLink xlink:role="http://www.westpharma.com/role/NetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d1ffbcbc-52c3-494b-b224-60f8be9534d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_56cbdf55-7b50-49d3-8967-1893588d970f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d1ffbcbc-52c3-494b-b224-60f8be9534d6" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_56cbdf55-7b50-49d3-8967-1893588d970f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_8ec37306-609b-4ebb-bfbb-eeba1a59322c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d1ffbcbc-52c3-494b-b224-60f8be9534d6" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_8ec37306-609b-4ebb-bfbb-eeba1a59322c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/InventoriesDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#InventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.westpharma.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_97849eb5-1717-45ac-a54d-dac9ed8f075d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_515b81a4-9bed-4de3-98a9-84e09a4f8f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_97849eb5-1717-45ac-a54d-dac9ed8f075d" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_515b81a4-9bed-4de3-98a9-84e09a4f8f6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_50e3c46c-1fbc-46b4-80b7-4338308d4653" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_97849eb5-1717-45ac-a54d-dac9ed8f075d" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_50e3c46c-1fbc-46b4-80b7-4338308d4653" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_5f6f9c35-933a-4c8d-b256-9e069e95ece5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_97849eb5-1717-45ac-a54d-dac9ed8f075d" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_5f6f9c35-933a-4c8d-b256-9e069e95ece5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/LeasesLeaseCostDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#LeasesLeaseCostDetails"/>
  <link:calculationLink xlink:role="http://www.westpharma.com/role/LeasesLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_ccdb7cdf-a89f-4ba4-b3f5-364351f5d7c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_642ecf2a-8ac4-4836-87c9-5069f8ab1be0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_ccdb7cdf-a89f-4ba4-b3f5-364351f5d7c5" xlink:to="loc_us-gaap_OperatingLeaseCost_642ecf2a-8ac4-4836-87c9-5069f8ab1be0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_dd7b151c-9c0f-40c7-823e-12514796f010" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_ccdb7cdf-a89f-4ba4-b3f5-364351f5d7c5" xlink:to="loc_us-gaap_ShortTermLeaseCost_dd7b151c-9c0f-40c7-823e-12514796f010" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_123cf92e-7e2c-464b-a60a-9cff2a19e6f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_ccdb7cdf-a89f-4ba4-b3f5-364351f5d7c5" xlink:to="loc_us-gaap_VariableLeaseCost_123cf92e-7e2c-464b-a60a-9cff2a19e6f4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e0343d2c-e822-4595-894b-9ee7b466f9d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f889eedf-ef20-4392-b8a7-c8a611d26307" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e0343d2c-e822-4595-894b-9ee7b466f9d2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f889eedf-ef20-4392-b8a7-c8a611d26307" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_3c8b1d68-2e62-4b7b-9207-919d963c54bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e0343d2c-e822-4595-894b-9ee7b466f9d2" xlink:to="loc_us-gaap_OperatingLeaseLiability_3c8b1d68-2e62-4b7b-9207-919d963c54bd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="wst-20230331.xsd#LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_442f2a30-5e7b-436c-852c-a5f297b5e0b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_79c10cd8-3c89-4dab-89ed-eda7ee386eff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_442f2a30-5e7b-436c-852c-a5f297b5e0b5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_79c10cd8-3c89-4dab-89ed-eda7ee386eff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_303d2d5d-50a6-4b1b-8333-6911d3c5b84f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_442f2a30-5e7b-436c-852c-a5f297b5e0b5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_303d2d5d-50a6-4b1b-8333-6911d3c5b84f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_bbea6d21-82c6-4df5-9749-75476f403b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_442f2a30-5e7b-436c-852c-a5f297b5e0b5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_bbea6d21-82c6-4df5-9749-75476f403b3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_b013d591-eb06-46ef-a041-9a157223f91d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_442f2a30-5e7b-436c-852c-a5f297b5e0b5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_b013d591-eb06-46ef-a041-9a157223f91d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_16b22c16-f620-45b9-9130-f58da86d27ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_442f2a30-5e7b-436c-852c-a5f297b5e0b5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_16b22c16-f620-45b9-9130-f58da86d27ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_dd63503d-21a5-47d9-a58a-b642a63357b4" xlink:href="wst-20230331.xsd#wst_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_442f2a30-5e7b-436c-852c-a5f297b5e0b5" xlink:to="loc_wst_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_dd63503d-21a5-47d9-a58a-b642a63357b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_c7b2c11a-18d7-43e7-9188-5c78b6df38a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_442f2a30-5e7b-436c-852c-a5f297b5e0b5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_c7b2c11a-18d7-43e7-9188-5c78b6df38a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1d416b65-2631-49b8-9e17-d58b69067bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_442f2a30-5e7b-436c-852c-a5f297b5e0b5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1d416b65-2631-49b8-9e17-d58b69067bc7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/DebtLongtermDebtDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#DebtLongtermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.westpharma.com/role/DebtLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_e05c2935-e9d0-448b-8cef-e307372174fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_b2930a46-f20c-42cd-ab6f-1462faf995f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_e05c2935-e9d0-448b-8cef-e307372174fb" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_b2930a46-f20c-42cd-ab6f-1462faf995f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_30a28e95-c22f-4d24-962f-5e5efa1c15f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_e05c2935-e9d0-448b-8cef-e307372174fb" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_30a28e95-c22f-4d24-962f-5e5efa1c15f2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/DebtLongtermDebtDetails_1" xlink:type="simple" xlink:href="wst-20230331.xsd#DebtLongtermDebtDetails_1"/>
  <link:calculationLink xlink:role="http://www.westpharma.com/role/DebtLongtermDebtDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_54e876d4-771a-494e-b2fa-e2875dbf086c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_7a1e8e55-317e-4209-9c9f-68900788bb67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_54e876d4-771a-494e-b2fa-e2875dbf086c" xlink:to="loc_us-gaap_LongTermDebtCurrent_7a1e8e55-317e-4209-9c9f-68900788bb67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_28984b18-f961-4931-91e9-0c67cc57b015" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_54e876d4-771a-494e-b2fa-e2875dbf086c" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_28984b18-f961-4931-91e9-0c67cc57b015" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails"/>
  <link:calculationLink xlink:role="http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings_c9bd99e4-3dac-4a3b-9a76-820c7d230ace" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_519686cb-4fff-45a8-820c-37fafcfcf7ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings_c9bd99e4-3dac-4a3b-9a76-820c7d230ace" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_519686cb-4fff-45a8-820c-37fafcfcf7ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_38706459-6e3d-48ce-812a-835a876ea5ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings_c9bd99e4-3dac-4a3b-9a76-820c7d230ace" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_38706459-6e3d-48ce-812a-835a876ea5ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet_c878cf32-c992-4bad-80d6-16040bff2d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings_c9bd99e4-3dac-4a3b-9a76-820c7d230ace" xlink:to="loc_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet_c878cf32-c992-4bad-80d6-16040bff2d4c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"/>
  <link:calculationLink xlink:role="http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_dc9f42b0-6fa7-40a1-8792-eab7f79f5702" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_b61dc4a3-0fc5-4854-8d5f-64a689f83370" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_dc9f42b0-6fa7-40a1-8792-eab7f79f5702" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_b61dc4a3-0fc5-4854-8d5f-64a689f83370" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_8b1bc40f-68f8-4f98-b8b3-b506a285a53a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_dc9f42b0-6fa7-40a1-8792-eab7f79f5702" xlink:to="loc_us-gaap_DerivativeAssets_8b1bc40f-68f8-4f98-b8b3-b506a285a53a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationPlanAssets_dd19f0fb-620e-4a9e-ba6c-e1af48b012da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationPlanAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_dc9f42b0-6fa7-40a1-8792-eab7f79f5702" xlink:to="loc_us-gaap_DeferredCompensationPlanAssets_dd19f0fb-620e-4a9e-ba6c-e1af48b012da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_1be5e985-aa9f-489c-a9bf-fbef531f71f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_27cb12c3-a8e7-4890-a34b-86d85d7ecf7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_1be5e985-aa9f-489c-a9bf-fbef531f71f0" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_27cb12c3-a8e7-4890-a34b-86d85d7ecf7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_4f7c5ddb-86e9-4ee8-8316-2d871fac2907" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_1be5e985-aa9f-489c-a9bf-fbef531f71f0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_4f7c5ddb-86e9-4ee8-8316-2d871fac2907" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent_5494adfc-4052-4ee5-8565-650eaab497d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_1be5e985-aa9f-489c-a9bf-fbef531f71f0" xlink:to="loc_us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent_5494adfc-4052-4ee5-8565-650eaab497d4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_91d49e88-3b8c-4f29-bfcf-f5b12d9e6801" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_b91248dd-b667-4948-8dfb-88ca359e9e75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_91d49e88-3b8c-4f29-bfcf-f5b12d9e6801" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_b91248dd-b667-4948-8dfb-88ca359e9e75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_df40c59a-2aab-4bc7-85a1-1921959dcc61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_91d49e88-3b8c-4f29-bfcf-f5b12d9e6801" xlink:to="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_df40c59a-2aab-4bc7-85a1-1921959dcc61" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails"/>
  <link:calculationLink xlink:role="http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_9eebc6c3-3aad-4c82-9e93-6f12cc4cc835" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_93a87994-6d5f-4f0c-8521-65481d358a19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_9eebc6c3-3aad-4c82-9e93-6f12cc4cc835" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_93a87994-6d5f-4f0c-8521-65481d358a19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_4545cf45-23f7-4ded-8366-27f73f44677e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_9eebc6c3-3aad-4c82-9e93-6f12cc4cc835" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_4545cf45-23f7-4ded-8366-27f73f44677e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_be69d9d2-e189-4465-b8a5-596ec305cfe7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_9eebc6c3-3aad-4c82-9e93-6f12cc4cc835" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_be69d9d2-e189-4465-b8a5-596ec305cfe7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_95c2bd7d-51b8-428e-9c59-530227aa1902" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_9eebc6c3-3aad-4c82-9e93-6f12cc4cc835" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_95c2bd7d-51b8-428e-9c59-530227aa1902" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_9d0bbb5f-3428-43fb-8128-952b84176f04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_9eebc6c3-3aad-4c82-9e93-6f12cc4cc835" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_9d0bbb5f-3428-43fb-8128-952b84176f04" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/OtherExpenseIncomeScheduleofOtherIncomeExpenseDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#OtherExpenseIncomeScheduleofOtherIncomeExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.westpharma.com/role/OtherExpenseIncomeScheduleofOtherIncomeExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_wst_OtherIncomeExpense_c592e94d-b4dd-47fc-b759-2b60ade0a74a" xlink:href="wst-20230331.xsd#wst_OtherIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_d951c1cc-fd59-4a18-b4cb-a593f0dca8b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_wst_OtherIncomeExpense_c592e94d-b4dd-47fc-b759-2b60ade0a74a" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_d951c1cc-fd59-4a18-b4cb-a593f0dca8b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_55036e38-299a-4c5b-b8e6-9d139dbb37f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_wst_OtherIncomeExpense_c592e94d-b4dd-47fc-b759-2b60ade0a74a" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_55036e38-299a-4c5b-b8e6-9d139dbb37f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_74b0f093-70e0-4d30-8bad-9b6e99d5f001" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_wst_OtherIncomeExpense_c592e94d-b4dd-47fc-b759-2b60ade0a74a" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_74b0f093-70e0-4d30-8bad-9b6e99d5f001" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_2c729cef-39b0-4372-9710-fef417d7da92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_wst_OtherIncomeExpense_c592e94d-b4dd-47fc-b759-2b60ade0a74a" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_2c729cef-39b0-4372-9710-fef417d7da92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_e2c4e339-7cb5-48a3-ae6b-f65fd5f12e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_wst_OtherIncomeExpense_c592e94d-b4dd-47fc-b759-2b60ade0a74a" xlink:to="loc_us-gaap_AssetImpairmentCharges_e2c4e339-7cb5-48a3-ae6b-f65fd5f12e5c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#SegmentInformationSegmentFinancialInformationDetails"/>
  <link:calculationLink xlink:role="http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_bbc608d2-2b90-42d5-affa-5f130bee5d87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_11a8414c-2171-4032-9814-9724daad4500" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_bbc608d2-2b90-42d5-affa-5f130bee5d87" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_11a8414c-2171-4032-9814-9724daad4500" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_cc0cf17d-e8b1-4936-8416-98faa3a87a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_bbc608d2-2b90-42d5-affa-5f130bee5d87" xlink:to="loc_us-gaap_OperatingIncomeLoss_cc0cf17d-e8b1-4936-8416-98faa3a87a3b" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>wst-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:a34422fb-98f0-4bfc-83b0-7c0b1b7c96bb,g:fe42bdb5-3507-4fad-98a2-d4b1f779591c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#RevenueRevenueRecognitionDetails"/>
  <link:definitionLink xlink:role="http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" xlink:type="extended" id="i2dfdba5e027841a0abe851f82b4013b9_RevenueRevenueRecognitionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_defa3bda-1a80-482b-a5e3-ec88d2c35268" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_1a6e73f1-5a87-4d26-bfe9-b65fef4b6253" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_defa3bda-1a80-482b-a5e3-ec88d2c35268" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_1a6e73f1-5a87-4d26-bfe9-b65fef4b6253" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_79cb5161-4868-4e07-be49-0f0282972ce7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_defa3bda-1a80-482b-a5e3-ec88d2c35268" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_79cb5161-4868-4e07-be49-0f0282972ce7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_9f3cca83-0e48-4e35-b3ce-80b5021eda70" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_79cb5161-4868-4e07-be49-0f0282972ce7" xlink:to="loc_srt_MajorCustomersAxis_9f3cca83-0e48-4e35-b3ce-80b5021eda70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_9f3cca83-0e48-4e35-b3ce-80b5021eda70_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_9f3cca83-0e48-4e35-b3ce-80b5021eda70" xlink:to="loc_srt_NameOfMajorCustomerDomain_9f3cca83-0e48-4e35-b3ce-80b5021eda70_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_172e0730-5449-4dfb-9ddb-790038e184e3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_9f3cca83-0e48-4e35-b3ce-80b5021eda70" xlink:to="loc_srt_NameOfMajorCustomerDomain_172e0730-5449-4dfb-9ddb-790038e184e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_BiologicsCustomersMember_6446da82-55ac-46f6-9146-6902143818b2" xlink:href="wst-20230331.xsd#wst_BiologicsCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_172e0730-5449-4dfb-9ddb-790038e184e3" xlink:to="loc_wst_BiologicsCustomersMember_6446da82-55ac-46f6-9146-6902143818b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_GenericsCustomersMember_bcdea95e-1a9e-475b-8889-b18621114c26" xlink:href="wst-20230331.xsd#wst_GenericsCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_172e0730-5449-4dfb-9ddb-790038e184e3" xlink:to="loc_wst_GenericsCustomersMember_bcdea95e-1a9e-475b-8889-b18621114c26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_PharmaCustomersMember_64a62dc0-9e09-40ac-8e9d-d46262c5ade2" xlink:href="wst-20230331.xsd#wst_PharmaCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_172e0730-5449-4dfb-9ddb-790038e184e3" xlink:to="loc_wst_PharmaCustomersMember_64a62dc0-9e09-40ac-8e9d-d46262c5ade2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_ContractManufacturedCustomersMember_bb4cfe34-8a0e-486e-952c-e7cf496c5485" xlink:href="wst-20230331.xsd#wst_ContractManufacturedCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_172e0730-5449-4dfb-9ddb-790038e184e3" xlink:to="loc_wst_ContractManufacturedCustomersMember_bb4cfe34-8a0e-486e-952c-e7cf496c5485" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a008e36d-c7d2-4a47-b420-56a129f6f134" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_79cb5161-4868-4e07-be49-0f0282972ce7" xlink:to="loc_srt_ProductOrServiceAxis_a008e36d-c7d2-4a47-b420-56a129f6f134" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a008e36d-c7d2-4a47-b420-56a129f6f134_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_a008e36d-c7d2-4a47-b420-56a129f6f134" xlink:to="loc_srt_ProductsAndServicesDomain_a008e36d-c7d2-4a47-b420-56a129f6f134_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_31bf6db6-0cc1-4138-980b-eb6550a7efa0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_a008e36d-c7d2-4a47-b420-56a129f6f134" xlink:to="loc_srt_ProductsAndServicesDomain_31bf6db6-0cc1-4138-980b-eb6550a7efa0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_HighValueProductComponentsMember_c3f9f531-be4f-4f6e-85b6-ecbd1fa10458" xlink:href="wst-20230331.xsd#wst_HighValueProductComponentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_31bf6db6-0cc1-4138-980b-eb6550a7efa0" xlink:to="loc_wst_HighValueProductComponentsMember_c3f9f531-be4f-4f6e-85b6-ecbd1fa10458" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_HighValueProductDeliveryDevicesMember_cefc920d-05ad-4357-9669-6b5c0060b2f4" xlink:href="wst-20230331.xsd#wst_HighValueProductDeliveryDevicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_31bf6db6-0cc1-4138-980b-eb6550a7efa0" xlink:to="loc_wst_HighValueProductDeliveryDevicesMember_cefc920d-05ad-4357-9669-6b5c0060b2f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_StandardPackagingMember_878da10d-0c85-4e47-9921-d486b69a7431" xlink:href="wst-20230331.xsd#wst_StandardPackagingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_31bf6db6-0cc1-4138-980b-eb6550a7efa0" xlink:to="loc_wst_StandardPackagingMember_878da10d-0c85-4e47-9921-d486b69a7431" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_ContractManufacturedProductsMember_6890b2d3-6976-4d37-ab90-7e7f8c91a5db" xlink:href="wst-20230331.xsd#wst_ContractManufacturedProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_31bf6db6-0cc1-4138-980b-eb6550a7efa0" xlink:to="loc_wst_ContractManufacturedProductsMember_6890b2d3-6976-4d37-ab90-7e7f8c91a5db" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_07301015-9559-46bd-9c5b-d937e45a8b16" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_79cb5161-4868-4e07-be49-0f0282972ce7" xlink:to="loc_srt_StatementGeographicalAxis_07301015-9559-46bd-9c5b-d937e45a8b16" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_07301015-9559-46bd-9c5b-d937e45a8b16_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_07301015-9559-46bd-9c5b-d937e45a8b16" xlink:to="loc_srt_SegmentGeographicalDomain_07301015-9559-46bd-9c5b-d937e45a8b16_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e49bb36d-a44e-4393-98f1-7e706d412310" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_07301015-9559-46bd-9c5b-d937e45a8b16" xlink:to="loc_srt_SegmentGeographicalDomain_e49bb36d-a44e-4393-98f1-7e706d412310" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AmericasMember_d23a74c4-26ce-4ad8-8499-0896bbb0049b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AmericasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e49bb36d-a44e-4393-98f1-7e706d412310" xlink:to="loc_srt_AmericasMember_d23a74c4-26ce-4ad8-8499-0896bbb0049b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember_d87642da-a00c-461e-a1f1-62fa024c4f78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EMEAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e49bb36d-a44e-4393-98f1-7e706d412310" xlink:to="loc_us-gaap_EMEAMember_d87642da-a00c-461e-a1f1-62fa024c4f78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember_850385b7-864f-498e-900e-1c72210c27b4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AsiaPacificMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e49bb36d-a44e-4393-98f1-7e706d412310" xlink:to="loc_srt_AsiaPacificMember_850385b7-864f-498e-900e-1c72210c27b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_91c1f69c-f86d-42f7-979c-a9ad4ebed6aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_79cb5161-4868-4e07-be49-0f0282972ce7" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_91c1f69c-f86d-42f7-979c-a9ad4ebed6aa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_91c1f69c-f86d-42f7-979c-a9ad4ebed6aa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_91c1f69c-f86d-42f7-979c-a9ad4ebed6aa" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_91c1f69c-f86d-42f7-979c-a9ad4ebed6aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1cc597e3-5dff-42fc-b9d5-333cca09edd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_91c1f69c-f86d-42f7-979c-a9ad4ebed6aa" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1cc597e3-5dff-42fc-b9d5-333cca09edd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_693b7c2c-d238-4ff8-af80-abc36e64b725" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1cc597e3-5dff-42fc-b9d5-333cca09edd4" xlink:to="loc_us-gaap_SalesRevenueNetMember_693b7c2c-d238-4ff8-af80-abc36e64b725" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_2c3cd0ce-6772-4595-a126-b3ecb41d4dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_79cb5161-4868-4e07-be49-0f0282972ce7" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_2c3cd0ce-6772-4595-a126-b3ecb41d4dc7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_2c3cd0ce-6772-4595-a126-b3ecb41d4dc7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_2c3cd0ce-6772-4595-a126-b3ecb41d4dc7" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_2c3cd0ce-6772-4595-a126-b3ecb41d4dc7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_c1fc7bcc-0917-4c05-bc53-a4c55755edb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_2c3cd0ce-6772-4595-a126-b3ecb41d4dc7" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_c1fc7bcc-0917-4c05-bc53-a4c55755edb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_aacd0ccb-d087-4d51-8a31-c2f7898e6d80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_c1fc7bcc-0917-4c05-bc53-a4c55755edb1" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_aacd0ccb-d087-4d51-8a31-c2f7898e6d80" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_3cf1a7e9-deda-4865-a7b2-5f14d454c7b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_c1fc7bcc-0917-4c05-bc53-a4c55755edb1" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_3cf1a7e9-deda-4865-a7b2-5f14d454c7b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_5f01a28b-ec84-4bb7-a774-5256edaeb9e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_c1fc7bcc-0917-4c05-bc53-a4c55755edb1" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_5f01a28b-ec84-4bb7-a774-5256edaeb9e1" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#RevenueContractsandLiabilitiesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails" xlink:type="extended" id="i6f2de4a518064ed9b9df259c9c309926_RevenueContractsandLiabilitiesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_710d4e31-0307-4c44-a154-3660f4f4931e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_b39d6716-bc82-42d3-a794-4dc82782b0ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_710d4e31-0307-4c44-a154-3660f4f4931e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_b39d6716-bc82-42d3-a794-4dc82782b0ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_84786ce0-5e75-4387-9e5e-0e6b9a8709ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_710d4e31-0307-4c44-a154-3660f4f4931e" xlink:to="loc_us-gaap_ContractWithCustomerLiability_84786ce0-5e75-4387-9e5e-0e6b9a8709ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_c96c5f40-e7c0-4e21-bb2e-7f39cec37e7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_710d4e31-0307-4c44-a154-3660f4f4931e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_c96c5f40-e7c0-4e21-bb2e-7f39cec37e7e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c7775e95-af53-4f2d-9b94-b501ec050fbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_710d4e31-0307-4c44-a154-3660f4f4931e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c7775e95-af53-4f2d-9b94-b501ec050fbb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_2a007af5-c0e1-450e-95d2-36fecc469b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_710d4e31-0307-4c44-a154-3660f4f4931e" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_2a007af5-c0e1-450e-95d2-36fecc469b6c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b8c52106-e2f9-415b-96a5-392cee12ff52" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2a007af5-c0e1-450e-95d2-36fecc469b6c" xlink:to="loc_srt_ProductOrServiceAxis_b8c52106-e2f9-415b-96a5-392cee12ff52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b8c52106-e2f9-415b-96a5-392cee12ff52_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_b8c52106-e2f9-415b-96a5-392cee12ff52" xlink:to="loc_srt_ProductsAndServicesDomain_b8c52106-e2f9-415b-96a5-392cee12ff52_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_412e2802-adf6-449d-9f78-6bf9f5e48553" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_b8c52106-e2f9-415b-96a5-392cee12ff52" xlink:to="loc_srt_ProductsAndServicesDomain_412e2802-adf6-449d-9f78-6bf9f5e48553" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_SmartDoseMember_87da5e79-20a1-420b-9899-f25378f508c1" xlink:href="wst-20230331.xsd#wst_SmartDoseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_412e2802-adf6-449d-9f78-6bf9f5e48553" xlink:to="loc_wst_SmartDoseMember_87da5e79-20a1-420b-9899-f25378f508c1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/DebtLongtermDebtDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#DebtLongtermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.westpharma.com/role/DebtLongtermDebtDetails" xlink:type="extended" id="i86286a905ed84019bad4b95a2c1c0173_DebtLongtermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_3726512d-5e08-4576-a919-b71b0fe01b52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d8fa3842-a5dc-42e1-959a-2f1ad83ecabe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3726512d-5e08-4576-a919-b71b0fe01b52" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d8fa3842-a5dc-42e1-959a-2f1ad83ecabe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_23cbbb85-4082-477b-b924-f58b7848683c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3726512d-5e08-4576-a919-b71b0fe01b52" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_23cbbb85-4082-477b-b924-f58b7848683c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_367c2c60-ffb8-4078-977d-d89f37e26fde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3726512d-5e08-4576-a919-b71b0fe01b52" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_367c2c60-ffb8-4078-977d-d89f37e26fde" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_1af15867-7287-4f28-bdb0-d0a0ecc14ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3726512d-5e08-4576-a919-b71b0fe01b52" xlink:to="loc_us-gaap_LongTermDebt_1af15867-7287-4f28-bdb0-d0a0ecc14ed8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_58d109bb-63ea-4dd1-ba48-a9082a0c861d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3726512d-5e08-4576-a919-b71b0fe01b52" xlink:to="loc_us-gaap_LongTermDebtCurrent_58d109bb-63ea-4dd1-ba48-a9082a0c861d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_afe7f38d-aa14-4e27-bced-102e4a36c8cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3726512d-5e08-4576-a919-b71b0fe01b52" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_afe7f38d-aa14-4e27-bced-102e4a36c8cd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_977df7b4-d0d3-4c0c-9af2-f390df201c18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3726512d-5e08-4576-a919-b71b0fe01b52" xlink:to="loc_us-gaap_DebtInstrumentTable_977df7b4-d0d3-4c0c-9af2-f390df201c18" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_be795ca1-cb6d-4b93-8fbd-0d8bde3f8d42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_977df7b4-d0d3-4c0c-9af2-f390df201c18" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_be795ca1-cb6d-4b93-8fbd-0d8bde3f8d42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_be795ca1-cb6d-4b93-8fbd-0d8bde3f8d42_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_be795ca1-cb6d-4b93-8fbd-0d8bde3f8d42" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_be795ca1-cb6d-4b93-8fbd-0d8bde3f8d42_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a83e6897-3bdb-48e0-80ca-96152947568b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_be795ca1-cb6d-4b93-8fbd-0d8bde3f8d42" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a83e6897-3bdb-48e0-80ca-96152947568b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_TermLoanDue2024Member_271a3a7c-ccd9-42cb-abe3-11556d9da321" xlink:href="wst-20230331.xsd#wst_TermLoanDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a83e6897-3bdb-48e0-80ca-96152947568b" xlink:to="loc_wst_TermLoanDue2024Member_271a3a7c-ccd9-42cb-abe3-11556d9da321" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_SeniorBNotesDue2024Member_ae11a36a-428b-4319-8dd0-01aa65801237" xlink:href="wst-20230331.xsd#wst_SeniorBNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a83e6897-3bdb-48e0-80ca-96152947568b" xlink:to="loc_wst_SeniorBNotesDue2024Member_ae11a36a-428b-4319-8dd0-01aa65801237" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_SeniorCNotesDue2027Member_25eda522-23d1-4837-9f4c-a3bfdd75aaab" xlink:href="wst-20230331.xsd#wst_SeniorCNotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a83e6897-3bdb-48e0-80ca-96152947568b" xlink:to="loc_wst_SeniorCNotesDue2027Member_25eda522-23d1-4837-9f4c-a3bfdd75aaab" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/DebtCreditFacilityDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#DebtCreditFacilityDetails"/>
  <link:definitionLink xlink:role="http://www.westpharma.com/role/DebtCreditFacilityDetails" xlink:type="extended" id="ia306777f790247389b6fb2a72e240cbf_DebtCreditFacilityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_3b9da317-9345-4859-ab95-fc0c1d4f7d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_dbfba8c1-29bf-40b9-86ff-5035d8a9a640" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_3b9da317-9345-4859-ab95-fc0c1d4f7d8a" xlink:to="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_dbfba8c1-29bf-40b9-86ff-5035d8a9a640" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_e79f2e90-9911-4574-98e8-eb2892147671" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_3b9da317-9345-4859-ab95-fc0c1d4f7d8a" xlink:to="loc_us-gaap_LineOfCredit_e79f2e90-9911-4574-98e8-eb2892147671" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_4054221f-71c1-496b-a92d-b737fd4d0dad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_3b9da317-9345-4859-ab95-fc0c1d4f7d8a" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_4054221f-71c1-496b-a92d-b737fd4d0dad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_91fcda91-a08e-4590-a6ca-a3bcde643d33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_3b9da317-9345-4859-ab95-fc0c1d4f7d8a" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_91fcda91-a08e-4590-a6ca-a3bcde643d33" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_6f4b4a0a-686b-4c84-923d-5ea29fc0cb48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_3b9da317-9345-4859-ab95-fc0c1d4f7d8a" xlink:to="loc_us-gaap_DebtCurrent_6f4b4a0a-686b-4c84-923d-5ea29fc0cb48" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_ebe3050a-368d-4ca8-ad4e-f9c9e2a9c1d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_3b9da317-9345-4859-ab95-fc0c1d4f7d8a" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_ebe3050a-368d-4ca8-ad4e-f9c9e2a9c1d8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_1ea061e1-05d8-4836-aff3-d0792ce996b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_3b9da317-9345-4859-ab95-fc0c1d4f7d8a" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_1ea061e1-05d8-4836-aff3-d0792ce996b2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_54813a1a-a2eb-4efe-8e55-d3664d4a1d12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_1ea061e1-05d8-4836-aff3-d0792ce996b2" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_54813a1a-a2eb-4efe-8e55-d3664d4a1d12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_54813a1a-a2eb-4efe-8e55-d3664d4a1d12_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_54813a1a-a2eb-4efe-8e55-d3664d4a1d12" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_54813a1a-a2eb-4efe-8e55-d3664d4a1d12_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_dff5a95f-eeee-4111-a048-53f503957b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_54813a1a-a2eb-4efe-8e55-d3664d4a1d12" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_dff5a95f-eeee-4111-a048-53f503957b4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_RevolvingCreditFacilityDue2024Member_b96d498a-5ca6-48b4-a943-215a9355822e" xlink:href="wst-20230331.xsd#wst_RevolvingCreditFacilityDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_dff5a95f-eeee-4111-a048-53f503957b4a" xlink:to="loc_wst_RevolvingCreditFacilityDue2024Member_b96d498a-5ca6-48b4-a943-215a9355822e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_TermLoanDue2024Member_dc6ee12b-a087-4ead-abf1-1fc73deb699b" xlink:href="wst-20230331.xsd#wst_TermLoanDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_dff5a95f-eeee-4111-a048-53f503957b4a" xlink:to="loc_wst_TermLoanDue2024Member_dc6ee12b-a087-4ead-abf1-1fc73deb699b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_fc8c24c3-c6ec-449f-a511-41ef9ff5bbfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_1ea061e1-05d8-4836-aff3-d0792ce996b2" xlink:to="loc_us-gaap_CreditFacilityAxis_fc8c24c3-c6ec-449f-a511-41ef9ff5bbfc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_fc8c24c3-c6ec-449f-a511-41ef9ff5bbfc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_fc8c24c3-c6ec-449f-a511-41ef9ff5bbfc" xlink:to="loc_us-gaap_CreditFacilityDomain_fc8c24c3-c6ec-449f-a511-41ef9ff5bbfc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_c94f5d97-01eb-4262-b8ba-19840dba266d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_fc8c24c3-c6ec-449f-a511-41ef9ff5bbfc" xlink:to="loc_us-gaap_CreditFacilityDomain_c94f5d97-01eb-4262-b8ba-19840dba266d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_50ba22c0-03c0-402d-a5fd-959228b4a1c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_c94f5d97-01eb-4262-b8ba-19840dba266d" xlink:to="loc_us-gaap_LetterOfCreditMember_50ba22c0-03c0-402d-a5fd-959228b4a1c9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails"/>
  <link:definitionLink xlink:role="http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" xlink:type="extended" id="i52829a418e7b4bb6b1d7ae0b97f241bb_DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_d94f0cda-7620-4d7d-a35e-7f17e506be63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_5907bfdc-9dd3-4d89-8104-a13e8bfe1fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_d94f0cda-7620-4d7d-a35e-7f17e506be63" xlink:to="loc_us-gaap_DerivativeNotionalAmount_5907bfdc-9dd3-4d89-8104-a13e8bfe1fbe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract_5496371b-58aa-4794-983e-66e34b442a37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_d94f0cda-7620-4d7d-a35e-7f17e506be63" xlink:to="loc_us-gaap_DerivativeTermOfContract_5496371b-58aa-4794-983e-66e34b442a37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNonmonetaryNotionalAmountVolume_e8a80823-d3d4-4cd3-830b-bb3a97ab0923" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNonmonetaryNotionalAmountVolume"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_d94f0cda-7620-4d7d-a35e-7f17e506be63" xlink:to="loc_us-gaap_DerivativeNonmonetaryNotionalAmountVolume_e8a80823-d3d4-4cd3-830b-bb3a97ab0923" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAveragePriceRiskOptionStrikePrice_cb51d615-9bbe-48c3-ba1d-4485004afab4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAveragePriceRiskOptionStrikePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_d94f0cda-7620-4d7d-a35e-7f17e506be63" xlink:to="loc_us-gaap_DerivativeAveragePriceRiskOptionStrikePrice_cb51d615-9bbe-48c3-ba1d-4485004afab4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_250b6c69-4f71-4727-a0ba-dc924d1f6fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_d94f0cda-7620-4d7d-a35e-7f17e506be63" xlink:to="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_250b6c69-4f71-4727-a0ba-dc924d1f6fc5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_894ad1d2-3bca-46de-a748-32d03389943a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_d94f0cda-7620-4d7d-a35e-7f17e506be63" xlink:to="loc_us-gaap_DerivativeTable_894ad1d2-3bca-46de-a748-32d03389943a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_db8b593b-2bd1-4721-b9b0-250df1641e93" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_894ad1d2-3bca-46de-a748-32d03389943a" xlink:to="loc_srt_CurrencyAxis_db8b593b-2bd1-4721-b9b0-250df1641e93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_db8b593b-2bd1-4721-b9b0-250df1641e93_default" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_db8b593b-2bd1-4721-b9b0-250df1641e93" xlink:to="loc_currency_AllCurrenciesDomain_db8b593b-2bd1-4721-b9b0-250df1641e93_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_6aeab976-bc0d-4e38-b4d3-9ee7422ac6fd" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_db8b593b-2bd1-4721-b9b0-250df1641e93" xlink:to="loc_currency_AllCurrenciesDomain_6aeab976-bc0d-4e38-b4d3-9ee7422ac6fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_SGD_104b5b7c-9709-40e3-89e4-205837753be9" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_SGD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_6aeab976-bc0d-4e38-b4d3-9ee7422ac6fd" xlink:to="loc_currency_SGD_104b5b7c-9709-40e3-89e4-205837753be9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_b483a53f-5719-4546-9a1c-7b37ffbf0b7d" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_6aeab976-bc0d-4e38-b4d3-9ee7422ac6fd" xlink:to="loc_currency_USD_b483a53f-5719-4546-9a1c-7b37ffbf0b7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_JPY_49bb569a-de82-4c5f-8f71-c548c92e5050" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_JPY"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_6aeab976-bc0d-4e38-b4d3-9ee7422ac6fd" xlink:to="loc_currency_JPY_49bb569a-de82-4c5f-8f71-c548c92e5050" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_9bc19462-4a1b-47b2-b23d-2e28ef23aa59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_894ad1d2-3bca-46de-a748-32d03389943a" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_9bc19462-4a1b-47b2-b23d-2e28ef23aa59" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_9bc19462-4a1b-47b2-b23d-2e28ef23aa59_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_9bc19462-4a1b-47b2-b23d-2e28ef23aa59" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_9bc19462-4a1b-47b2-b23d-2e28ef23aa59_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_dc7f20c2-8e98-4112-a1de-34609e681323" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_9bc19462-4a1b-47b2-b23d-2e28ef23aa59" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_dc7f20c2-8e98-4112-a1de-34609e681323" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_b88f0642-7472-41c6-ab1d-f52266d0cffc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForwardContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_dc7f20c2-8e98-4112-a1de-34609e681323" xlink:to="loc_us-gaap_ForwardContractsMember_b88f0642-7472-41c6-ab1d-f52266d0cffc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_04c43d60-6f35-4b0d-8d8a-f21f1f529cb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_dc7f20c2-8e98-4112-a1de-34609e681323" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_04c43d60-6f35-4b0d-8d8a-f21f1f529cb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_7853f443-eff8-46bd-a959-9f3a7dc099fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_dc7f20c2-8e98-4112-a1de-34609e681323" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_7853f443-eff8-46bd-a959-9f3a7dc099fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionMember_d877b02f-c41e-44dc-aba6-fc4bdc820359" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_dc7f20c2-8e98-4112-a1de-34609e681323" xlink:to="loc_us-gaap_OptionMember_d877b02f-c41e-44dc-aba6-fc4bdc820359" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_bf9a92e3-cd2e-40e8-9f39-6ea08b342718" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_894ad1d2-3bca-46de-a748-32d03389943a" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_bf9a92e3-cd2e-40e8-9f39-6ea08b342718" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_bf9a92e3-cd2e-40e8-9f39-6ea08b342718_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_bf9a92e3-cd2e-40e8-9f39-6ea08b342718" xlink:to="loc_us-gaap_HedgingRelationshipDomain_bf9a92e3-cd2e-40e8-9f39-6ea08b342718_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_be1a3c77-d00b-4b56-ba78-081e1cf01427" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_bf9a92e3-cd2e-40e8-9f39-6ea08b342718" xlink:to="loc_us-gaap_HedgingRelationshipDomain_be1a3c77-d00b-4b56-ba78-081e1cf01427" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_f3d25b3c-21e7-42c8-b409-4c567cce103e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_be1a3c77-d00b-4b56-ba78-081e1cf01427" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_f3d25b3c-21e7-42c8-b409-4c567cce103e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_173a5957-daec-49b2-a7b7-1d38ce062dec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_be1a3c77-d00b-4b56-ba78-081e1cf01427" xlink:to="loc_us-gaap_FairValueHedgingMember_173a5957-daec-49b2-a7b7-1d38ce062dec" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignCurrencyContractsDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#DerivativeFinancialInstrumentsForeignCurrencyContractsDetails"/>
  <link:definitionLink xlink:role="http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignCurrencyContractsDetails" xlink:type="extended" id="i295147faca2346c6b88a308b7deffeb5_DerivativeFinancialInstrumentsForeignCurrencyContractsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_26a2ea60-033d-46d6-b6d3-2f4f3e4d65b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_729c8e51-ab6a-4b95-a9c5-384dd967a555" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_26a2ea60-033d-46d6-b6d3-2f4f3e4d65b9" xlink:to="loc_us-gaap_DerivativeNotionalAmount_729c8e51-ab6a-4b95-a9c5-384dd967a555" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_e8aa9fa7-aa7a-4a5c-b23d-72ef65fb7c29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_26a2ea60-033d-46d6-b6d3-2f4f3e4d65b9" xlink:to="loc_us-gaap_DerivativeTable_e8aa9fa7-aa7a-4a5c-b23d-72ef65fb7c29" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_79a8dbd5-83dd-4821-8a33-c5ae23d2dd13" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_e8aa9fa7-aa7a-4a5c-b23d-72ef65fb7c29" xlink:to="loc_srt_CurrencyAxis_79a8dbd5-83dd-4821-8a33-c5ae23d2dd13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_79a8dbd5-83dd-4821-8a33-c5ae23d2dd13_default" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_79a8dbd5-83dd-4821-8a33-c5ae23d2dd13" xlink:to="loc_currency_AllCurrenciesDomain_79a8dbd5-83dd-4821-8a33-c5ae23d2dd13_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_f0c4086d-fd85-4b75-94c9-1f38a2fc8f6d" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_79a8dbd5-83dd-4821-8a33-c5ae23d2dd13" xlink:to="loc_currency_AllCurrenciesDomain_f0c4086d-fd85-4b75-94c9-1f38a2fc8f6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_01f737ed-104a-48a5-be29-eb2f2fe3479d" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_f0c4086d-fd85-4b75-94c9-1f38a2fc8f6d" xlink:to="loc_currency_USD_01f737ed-104a-48a5-be29-eb2f2fe3479d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_JPY_11c66832-0e2e-40cd-a9f5-8bbf07daad28" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_JPY"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_f0c4086d-fd85-4b75-94c9-1f38a2fc8f6d" xlink:to="loc_currency_JPY_11c66832-0e2e-40cd-a9f5-8bbf07daad28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_SGD_e996f747-2362-4313-af97-cd034124b76a" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_SGD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_f0c4086d-fd85-4b75-94c9-1f38a2fc8f6d" xlink:to="loc_currency_SGD_e996f747-2362-4313-af97-cd034124b76a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_f0290792-0045-487a-81e5-69846c37fbc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_e8aa9fa7-aa7a-4a5c-b23d-72ef65fb7c29" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_f0290792-0045-487a-81e5-69846c37fbc1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_f0290792-0045-487a-81e5-69846c37fbc1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_f0290792-0045-487a-81e5-69846c37fbc1" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_f0290792-0045-487a-81e5-69846c37fbc1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_db22e676-30d8-4eae-852b-78cdc8b95e20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_f0290792-0045-487a-81e5-69846c37fbc1" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_db22e676-30d8-4eae-852b-78cdc8b95e20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_bc4a66ba-15f7-4407-a652-58431ab4e136" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_db22e676-30d8-4eae-852b-78cdc8b95e20" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_bc4a66ba-15f7-4407-a652-58431ab4e136" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_f081c86e-b340-452c-bafd-87ec5dd1ee99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_db22e676-30d8-4eae-852b-78cdc8b95e20" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_f081c86e-b340-452c-bafd-87ec5dd1ee99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_c0f4560d-d373-4de7-9722-629e75ecf25f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_e8aa9fa7-aa7a-4a5c-b23d-72ef65fb7c29" xlink:to="loc_us-gaap_HedgingDesignationAxis_c0f4560d-d373-4de7-9722-629e75ecf25f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_c0f4560d-d373-4de7-9722-629e75ecf25f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_c0f4560d-d373-4de7-9722-629e75ecf25f" xlink:to="loc_us-gaap_HedgingDesignationDomain_c0f4560d-d373-4de7-9722-629e75ecf25f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_c7fc5ef7-40c7-40c4-90dc-4b7742bb8a73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_c0f4560d-d373-4de7-9722-629e75ecf25f" xlink:to="loc_us-gaap_HedgingDesignationDomain_c7fc5ef7-40c7-40c4-90dc-4b7742bb8a73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_89eafc21-8c08-4602-9488-ac4c878b3186" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_c7fc5ef7-40c7-40c4-90dc-4b7742bb8a73" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_89eafc21-8c08-4602-9488-ac4c878b3186" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PositionAxis_fb8dc25b-4edd-49e1-a3f5-727e82c6f4d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PositionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_e8aa9fa7-aa7a-4a5c-b23d-72ef65fb7c29" xlink:to="loc_us-gaap_PositionAxis_fb8dc25b-4edd-49e1-a3f5-727e82c6f4d1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PositionDomain_fb8dc25b-4edd-49e1-a3f5-727e82c6f4d1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PositionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PositionAxis_fb8dc25b-4edd-49e1-a3f5-727e82c6f4d1" xlink:to="loc_us-gaap_PositionDomain_fb8dc25b-4edd-49e1-a3f5-727e82c6f4d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PositionDomain_34d25241-035c-4b73-9a96-034cf68bc7d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PositionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PositionAxis_fb8dc25b-4edd-49e1-a3f5-727e82c6f4d1" xlink:to="loc_us-gaap_PositionDomain_34d25241-035c-4b73-9a96-034cf68bc7d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongMember_5673e7ff-72bf-4520-80ea-025dec4876a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PositionDomain_34d25241-035c-4b73-9a96-034cf68bc7d5" xlink:to="loc_us-gaap_LongMember_5673e7ff-72bf-4520-80ea-025dec4876a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortMember_f05a1ab7-94e9-469b-9123-4fec8fe7b722" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PositionDomain_34d25241-035c-4b73-9a96-034cf68bc7d5" xlink:to="loc_us-gaap_ShortMember_f05a1ab7-94e9-469b-9123-4fec8fe7b722" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_5ebf7a49-fb04-4ffc-97cd-15396ce50815" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_e8aa9fa7-aa7a-4a5c-b23d-72ef65fb7c29" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_5ebf7a49-fb04-4ffc-97cd-15396ce50815" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_5ebf7a49-fb04-4ffc-97cd-15396ce50815_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_5ebf7a49-fb04-4ffc-97cd-15396ce50815" xlink:to="loc_us-gaap_HedgingRelationshipDomain_5ebf7a49-fb04-4ffc-97cd-15396ce50815_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_ba6ad1b1-1c26-4e96-9014-bf78dfa3e4a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_5ebf7a49-fb04-4ffc-97cd-15396ce50815" xlink:to="loc_us-gaap_HedgingRelationshipDomain_ba6ad1b1-1c26-4e96-9014-bf78dfa3e4a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_be36fbad-5b1f-45cb-82aa-3217e281ef16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_ba6ad1b1-1c26-4e96-9014-bf78dfa3e4a8" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_be36fbad-5b1f-45cb-82aa-3217e281ef16" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails"/>
  <link:definitionLink xlink:role="http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" xlink:type="extended" id="i761e0b294e904d09afeef546f746e98c_DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_ebe959bb-b1e4-4e53-9a7e-5d2ce06c2fcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_b3574f88-19dd-44d8-9dc1-904a1c977ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_ebe959bb-b1e4-4e53-9a7e-5d2ce06c2fcc" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_b3574f88-19dd-44d8-9dc1-904a1c977ac0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_b0a6a790-26f0-4d3d-985e-b936db945e35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_ebe959bb-b1e4-4e53-9a7e-5d2ce06c2fcc" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_b0a6a790-26f0-4d3d-985e-b936db945e35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet_3da509b7-0cdc-4b59-bcd7-024fb4f350cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_ebe959bb-b1e4-4e53-9a7e-5d2ce06c2fcc" xlink:to="loc_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet_3da509b7-0cdc-4b59-bcd7-024fb4f350cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings_95e10871-7350-4a35-a159-aae36149d24b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_ebe959bb-b1e4-4e53-9a7e-5d2ce06c2fcc" xlink:to="loc_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings_95e10871-7350-4a35-a159-aae36149d24b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_3d7a625c-39bd-4a8d-a031-9cf66985c8ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_ebe959bb-b1e4-4e53-9a7e-5d2ce06c2fcc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_3d7a625c-39bd-4a8d-a031-9cf66985c8ad" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_2b9c2821-7a40-4d8d-93cd-fabacb0b3f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_ebe959bb-b1e4-4e53-9a7e-5d2ce06c2fcc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_2b9c2821-7a40-4d8d-93cd-fabacb0b3f9c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_02e34d41-7f53-4065-9f15-d5fb0eba44b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_ebe959bb-b1e4-4e53-9a7e-5d2ce06c2fcc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_02e34d41-7f53-4065-9f15-d5fb0eba44b3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax_f1e4cd61-b76f-406b-9322-3ce5354f076b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_ebe959bb-b1e4-4e53-9a7e-5d2ce06c2fcc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax_f1e4cd61-b76f-406b-9322-3ce5354f076b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_09e89f1b-52b7-424b-9a07-931921b626e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_ebe959bb-b1e4-4e53-9a7e-5d2ce06c2fcc" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_09e89f1b-52b7-424b-9a07-931921b626e8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_64dad1cb-f836-4710-812b-589aafcdcba9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_ebe959bb-b1e4-4e53-9a7e-5d2ce06c2fcc" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_64dad1cb-f836-4710-812b-589aafcdcba9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_051cf302-17c1-4f23-a2c2-e59e62bfd7c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_64dad1cb-f836-4710-812b-589aafcdcba9" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_051cf302-17c1-4f23-a2c2-e59e62bfd7c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_051cf302-17c1-4f23-a2c2-e59e62bfd7c0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_051cf302-17c1-4f23-a2c2-e59e62bfd7c0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_051cf302-17c1-4f23-a2c2-e59e62bfd7c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6638a625-6916-475e-9d3c-157f247e977e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_051cf302-17c1-4f23-a2c2-e59e62bfd7c0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6638a625-6916-475e-9d3c-157f247e977e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_OtherExpenseIncomeMember_61fc2050-b328-4767-b723-33da8a344a01" xlink:href="wst-20230331.xsd#wst_OtherExpenseIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6638a625-6916-475e-9d3c-157f247e977e" xlink:to="loc_wst_OtherExpenseIncomeMember_61fc2050-b328-4767-b723-33da8a344a01" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_NetSalesMember_03b80434-3474-4a9a-a591-1c5de8436ff0" xlink:href="wst-20230331.xsd#wst_NetSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6638a625-6916-475e-9d3c-157f247e977e" xlink:to="loc_wst_NetSalesMember_03b80434-3474-4a9a-a591-1c5de8436ff0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_2c0c4f67-8e4b-478e-b04e-803d8796c4fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6638a625-6916-475e-9d3c-157f247e977e" xlink:to="loc_us-gaap_CostOfSalesMember_2c0c4f67-8e4b-478e-b04e-803d8796c4fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_0ec727d7-2569-4022-ab7b-9f8bbba581b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6638a625-6916-475e-9d3c-157f247e977e" xlink:to="loc_us-gaap_InterestExpenseMember_0ec727d7-2569-4022-ab7b-9f8bbba581b3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_cdf03f52-1101-43d8-92cd-ef8db58fb790" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_64dad1cb-f836-4710-812b-589aafcdcba9" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_cdf03f52-1101-43d8-92cd-ef8db58fb790" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_cdf03f52-1101-43d8-92cd-ef8db58fb790_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_cdf03f52-1101-43d8-92cd-ef8db58fb790" xlink:to="loc_us-gaap_HedgingRelationshipDomain_cdf03f52-1101-43d8-92cd-ef8db58fb790_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_72b31b64-c5d5-480c-a6ef-3648eff33143" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_cdf03f52-1101-43d8-92cd-ef8db58fb790" xlink:to="loc_us-gaap_HedgingRelationshipDomain_72b31b64-c5d5-480c-a6ef-3648eff33143" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_0f73c746-ad38-4913-8852-34cee727c6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_72b31b64-c5d5-480c-a6ef-3648eff33143" xlink:to="loc_us-gaap_FairValueHedgingMember_0f73c746-ad38-4913-8852-34cee727c6cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_e45543ef-4b39-4b87-8548-0aca5bf36dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_72b31b64-c5d5-480c-a6ef-3648eff33143" xlink:to="loc_us-gaap_CashFlowHedgingMember_e45543ef-4b39-4b87-8548-0aca5bf36dc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_5ab984af-3e8d-4a7b-92dd-6ecad53e89fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_72b31b64-c5d5-480c-a6ef-3648eff33143" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_5ab984af-3e8d-4a7b-92dd-6ecad53e89fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_b6164967-7b99-42c5-bba6-f90a00c1c62f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_64dad1cb-f836-4710-812b-589aafcdcba9" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_b6164967-7b99-42c5-bba6-f90a00c1c62f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_b6164967-7b99-42c5-bba6-f90a00c1c62f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_b6164967-7b99-42c5-bba6-f90a00c1c62f" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_b6164967-7b99-42c5-bba6-f90a00c1c62f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_1f98d393-d329-49e1-8e7c-65c62a1f760e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_b6164967-7b99-42c5-bba6-f90a00c1c62f" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_1f98d393-d329-49e1-8e7c-65c62a1f760e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_fb1f0510-13d4-469a-9df5-b90217460fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_1f98d393-d329-49e1-8e7c-65c62a1f760e" xlink:to="loc_us-gaap_ForeignExchangeContractMember_fb1f0510-13d4-469a-9df5-b90217460fe3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryLockMember_3bb93140-6de3-4d0c-ab12-984f31f9e1ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryLockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_1f98d393-d329-49e1-8e7c-65c62a1f760e" xlink:to="loc_us-gaap_TreasuryLockMember_3bb93140-6de3-4d0c-ab12-984f31f9e1ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_cb12eae9-20de-4736-a874-12a13cd8f793" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrencySwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_1f98d393-d329-49e1-8e7c-65c62a1f760e" xlink:to="loc_us-gaap_CurrencySwapMember_cb12eae9-20de-4736-a874-12a13cd8f793" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails"/>
  <link:definitionLink xlink:role="http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails" xlink:type="extended" id="iba6ac151e48941aab511aa74982d3474_DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_4af4cc3f-3cd2-4baa-9151-642c53f7ab33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_7d852967-9b6f-4dd0-91bf-393e41e9b9f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_4af4cc3f-3cd2-4baa-9151-642c53f7ab33" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_7d852967-9b6f-4dd0-91bf-393e41e9b9f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_efc3d067-7780-4dfb-a11e-854e34506844" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_4af4cc3f-3cd2-4baa-9151-642c53f7ab33" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_efc3d067-7780-4dfb-a11e-854e34506844" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_e16bfe64-d8d2-4792-a20f-741c40ac4888" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_efc3d067-7780-4dfb-a11e-854e34506844" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_e16bfe64-d8d2-4792-a20f-741c40ac4888" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_e16bfe64-d8d2-4792-a20f-741c40ac4888_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_e16bfe64-d8d2-4792-a20f-741c40ac4888" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_e16bfe64-d8d2-4792-a20f-741c40ac4888_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a2b9cd30-c1f3-4658-8673-9a20b896e7ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_e16bfe64-d8d2-4792-a20f-741c40ac4888" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a2b9cd30-c1f3-4658-8673-9a20b896e7ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommodityOptionMember_6717c5d6-1101-4608-ac0e-0936d11f9199" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommodityOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a2b9cd30-c1f3-4658-8673-9a20b896e7ef" xlink:to="loc_us-gaap_CommodityOptionMember_6717c5d6-1101-4608-ac0e-0936d11f9199" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_46d8e9a1-6b66-4055-8f6a-8d5f721e1a72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_efc3d067-7780-4dfb-a11e-854e34506844" xlink:to="loc_us-gaap_HedgingDesignationAxis_46d8e9a1-6b66-4055-8f6a-8d5f721e1a72" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_46d8e9a1-6b66-4055-8f6a-8d5f721e1a72_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_46d8e9a1-6b66-4055-8f6a-8d5f721e1a72" xlink:to="loc_us-gaap_HedgingDesignationDomain_46d8e9a1-6b66-4055-8f6a-8d5f721e1a72_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_77c2f626-eb54-4d0c-b467-b6188fbe905d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_46d8e9a1-6b66-4055-8f6a-8d5f721e1a72" xlink:to="loc_us-gaap_HedgingDesignationDomain_77c2f626-eb54-4d0c-b467-b6188fbe905d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_922453cc-a79c-4201-a906-7e167a42cc78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_77c2f626-eb54-4d0c-b467-b6188fbe905d" xlink:to="loc_us-gaap_NondesignatedMember_922453cc-a79c-4201-a906-7e167a42cc78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_30297929-9cf5-49b0-ba26-25f53f96f43e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_efc3d067-7780-4dfb-a11e-854e34506844" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_30297929-9cf5-49b0-ba26-25f53f96f43e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_30297929-9cf5-49b0-ba26-25f53f96f43e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_30297929-9cf5-49b0-ba26-25f53f96f43e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_30297929-9cf5-49b0-ba26-25f53f96f43e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e407ace7-07db-46aa-9464-c6f2bb1f216d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_30297929-9cf5-49b0-ba26-25f53f96f43e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e407ace7-07db-46aa-9464-c6f2bb1f216d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_OtherExpenseIncomeMember_0ba92a34-b22b-42ac-86a2-ec00cc34ed97" xlink:href="wst-20230331.xsd#wst_OtherExpenseIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e407ace7-07db-46aa-9464-c6f2bb1f216d" xlink:to="loc_wst_OtherExpenseIncomeMember_0ba92a34-b22b-42ac-86a2-ec00cc34ed97" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" xlink:type="extended" id="ic20e961482824b16be31fcd092c3da88_FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d0354479-512a-469a-aa97-f58476f19d43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_a8cf9088-5aa8-4fc6-8eb9-a4a753c15389" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d0354479-512a-469a-aa97-f58476f19d43" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_a8cf9088-5aa8-4fc6-8eb9-a4a753c15389" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationPlanAssets_9315903e-c00b-424a-91b9-d82636d33ea2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a8cf9088-5aa8-4fc6-8eb9-a4a753c15389" xlink:to="loc_us-gaap_DeferredCompensationPlanAssets_9315903e-c00b-424a-91b9-d82636d33ea2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_d8f36443-e4cb-42aa-87d1-d5e56303889e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a8cf9088-5aa8-4fc6-8eb9-a4a753c15389" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_d8f36443-e4cb-42aa-87d1-d5e56303889e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_39c610ae-9923-4d96-b3ed-3bd2e60993d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a8cf9088-5aa8-4fc6-8eb9-a4a753c15389" xlink:to="loc_us-gaap_DerivativeAssets_39c610ae-9923-4d96-b3ed-3bd2e60993d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_6a220037-8b7c-42b1-996b-c354bf7ac7e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a8cf9088-5aa8-4fc6-8eb9-a4a753c15389" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_6a220037-8b7c-42b1-996b-c354bf7ac7e2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2261506d-adaa-4d97-8417-0690c5c8b5b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d0354479-512a-469a-aa97-f58476f19d43" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2261506d-adaa-4d97-8417-0690c5c8b5b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_660d014b-3074-4aa1-a1ad-718471ebbcad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2261506d-adaa-4d97-8417-0690c5c8b5b9" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_660d014b-3074-4aa1-a1ad-718471ebbcad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent_a4b66026-ef5c-4cc9-8346-376207c66b65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2261506d-adaa-4d97-8417-0690c5c8b5b9" xlink:to="loc_us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent_a4b66026-ef5c-4cc9-8346-376207c66b65" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_cb7481ad-06a6-481a-a6fe-e68403c04938" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2261506d-adaa-4d97-8417-0690c5c8b5b9" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_cb7481ad-06a6-481a-a6fe-e68403c04938" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_670ec332-9a55-4b51-b7f9-aaa770bbc811" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2261506d-adaa-4d97-8417-0690c5c8b5b9" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_670ec332-9a55-4b51-b7f9-aaa770bbc811" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1697704c-2a0a-4487-9489-dabb7ed77828" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d0354479-512a-469a-aa97-f58476f19d43" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1697704c-2a0a-4487-9489-dabb7ed77828" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_67b0b096-468d-409f-9479-72db25995258" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1697704c-2a0a-4487-9489-dabb7ed77828" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_67b0b096-468d-409f-9479-72db25995258" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_67b0b096-468d-409f-9479-72db25995258_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_67b0b096-468d-409f-9479-72db25995258" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_67b0b096-468d-409f-9479-72db25995258_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_976476e8-bd0f-439a-bd05-eef9c4d55a7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_67b0b096-468d-409f-9479-72db25995258" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_976476e8-bd0f-439a-bd05-eef9c4d55a7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_f7404648-e749-4a25-8bb8-162817c15646" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_976476e8-bd0f-439a-bd05-eef9c4d55a7e" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_f7404648-e749-4a25-8bb8-162817c15646" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_54443f30-7f41-468c-b208-93b24f5a8c51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_976476e8-bd0f-439a-bd05-eef9c4d55a7e" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_54443f30-7f41-468c-b208-93b24f5a8c51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_0832e549-f0a7-413a-b7ed-ef22fce3415f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_976476e8-bd0f-439a-bd05-eef9c4d55a7e" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_0832e549-f0a7-413a-b7ed-ef22fce3415f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_e1b2d160-021a-42b5-af84-2d429b748d71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1697704c-2a0a-4487-9489-dabb7ed77828" xlink:to="loc_us-gaap_FinancialInstrumentAxis_e1b2d160-021a-42b5-af84-2d429b748d71" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e1b2d160-021a-42b5-af84-2d429b748d71_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_e1b2d160-021a-42b5-af84-2d429b748d71" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e1b2d160-021a-42b5-af84-2d429b748d71_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_159ada3c-1474-41de-b816-f83d0ca6082e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_e1b2d160-021a-42b5-af84-2d429b748d71" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_159ada3c-1474-41de-b816-f83d0ca6082e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_7a31200e-63d6-40fd-9b22-a0c7270c8270" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrencySwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_159ada3c-1474-41de-b816-f83d0ca6082e" xlink:to="loc_us-gaap_CurrencySwapMember_7a31200e-63d6-40fd-9b22-a0c7270c8270" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommodityMember_a348dea8-543f-4b6e-88af-003742f327f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommodityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_159ada3c-1474-41de-b816-f83d0ca6082e" xlink:to="loc_us-gaap_CommodityMember_a348dea8-543f-4b6e-88af-003742f327f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_97892b2a-f02c-43ee-8f07-383880cb30a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_159ada3c-1474-41de-b816-f83d0ca6082e" xlink:to="loc_us-gaap_ForeignExchangeContractMember_97892b2a-f02c-43ee-8f07-383880cb30a1" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails" xlink:type="extended" id="if045ada5b08c425e8f1352b16083b096_AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_33227792-633a-436b-9c02-a9e2bc24e268" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5a81faa7-269d-4cdc-86a4-f135c712f8e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_33227792-633a-436b-9c02-a9e2bc24e268" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5a81faa7-269d-4cdc-86a4-f135c712f8e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_01c57741-a6cd-45fb-b868-b45b919659b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5a81faa7-269d-4cdc-86a4-f135c712f8e8" xlink:to="loc_us-gaap_StockholdersEquity_01c57741-a6cd-45fb-b868-b45b919659b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_518247e5-9132-4298-b3b3-7ee537caf79e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5a81faa7-269d-4cdc-86a4-f135c712f8e8" xlink:to="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_518247e5-9132-4298-b3b3-7ee537caf79e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_d969763c-9c07-4d88-815c-7e024993e13d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5a81faa7-269d-4cdc-86a4-f135c712f8e8" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_d969763c-9c07-4d88-815c-7e024993e13d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0ad558fa-8c12-4391-bdcf-051a9f1b62e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5a81faa7-269d-4cdc-86a4-f135c712f8e8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0ad558fa-8c12-4391-bdcf-051a9f1b62e4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b066677f-a0b3-407b-b9dc-987490454f1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_51b4513f-d289-42fd-aaa7-37ec9972e1a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_33227792-633a-436b-9c02-a9e2bc24e268" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_51b4513f-d289-42fd-aaa7-37ec9972e1a4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b55c6dc2-6b6d-4df5-846d-9291e2d39d62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_51b4513f-d289-42fd-aaa7-37ec9972e1a4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b55c6dc2-6b6d-4df5-846d-9291e2d39d62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b55c6dc2-6b6d-4df5-846d-9291e2d39d62_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b55c6dc2-6b6d-4df5-846d-9291e2d39d62" xlink:to="loc_us-gaap_EquityComponentDomain_b55c6dc2-6b6d-4df5-846d-9291e2d39d62_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_36f80e94-0e77-436e-b5d8-ff8d30d4e4a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b55c6dc2-6b6d-4df5-846d-9291e2d39d62" xlink:to="loc_us-gaap_EquityComponentDomain_36f80e94-0e77-436e-b5d8-ff8d30d4e4a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_04786310-a395-4db5-b083-2eff6e6ab5ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_36f80e94-0e77-436e-b5d8-ff8d30d4e4a1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_04786310-a395-4db5-b083-2eff6e6ab5ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_e3177b99-45e1-4e3c-b47f-b15c85f1e092" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_04786310-a395-4db5-b083-2eff6e6ab5ee" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_e3177b99-45e1-4e3c-b47f-b15c85f1e092" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_07d148cc-5de6-4f0f-96ff-d458789c75f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_04786310-a395-4db5-b083-2eff6e6ab5ee" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_07d148cc-5de6-4f0f-96ff-d458789c75f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_e7704233-b74f-46ed-ba20-32f70afa0a5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_04786310-a395-4db5-b083-2eff6e6ab5ee" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_e7704233-b74f-46ed-ba20-32f70afa0a5e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_e930fa69-463b-4779-876c-b52acfb82def" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_04786310-a395-4db5-b083-2eff6e6ab5ee" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_e930fa69-463b-4779-876c-b52acfb82def" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails"/>
  <link:definitionLink xlink:role="http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails" xlink:type="extended" id="id06ea64c78a5433e887c78b85c0466a5_AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_cc680d60-5e0f-4651-a873-8770966905cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_081beb39-3033-4e97-82da-34671580ba27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_cc680d60-5e0f-4651-a873-8770966905cf" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_081beb39-3033-4e97-82da-34671580ba27" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_2b2872d4-9a86-46ee-a42b-1e00b7bc60af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_cc680d60-5e0f-4651-a873-8770966905cf" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_2b2872d4-9a86-46ee-a42b-1e00b7bc60af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_9b6790b0-7527-47ca-ae47-0e0651fe8618" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_cc680d60-5e0f-4651-a873-8770966905cf" xlink:to="loc_us-gaap_InterestExpense_9b6790b0-7527-47ca-ae47-0e0651fe8618" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_d8c84cb6-40fc-45b9-a437-8abb7ec62538" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_cc680d60-5e0f-4651-a873-8770966905cf" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_d8c84cb6-40fc-45b9-a437-8abb7ec62538" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_fe8f4bc0-7782-43c1-aae8-458b6064436d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_cc680d60-5e0f-4651-a873-8770966905cf" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_fe8f4bc0-7782-43c1-aae8-458b6064436d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_b68a0ea6-9991-4427-b66f-07c9a81dc687" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_cc680d60-5e0f-4651-a873-8770966905cf" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_b68a0ea6-9991-4427-b66f-07c9a81dc687" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_60abbc3c-2af7-4aa0-976e-a9dcb6bbbb8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_cc680d60-5e0f-4651-a873-8770966905cf" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_60abbc3c-2af7-4aa0-976e-a9dcb6bbbb8f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_88fffe2a-2b23-45d5-98c7-5a2429579ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_cc680d60-5e0f-4651-a873-8770966905cf" xlink:to="loc_us-gaap_NetIncomeLoss_88fffe2a-2b23-45d5-98c7-5a2429579ee3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_371d6887-c66a-4033-9be4-a0f8e4d11b52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_cc680d60-5e0f-4651-a873-8770966905cf" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_371d6887-c66a-4033-9be4-a0f8e4d11b52" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_ea5f6fbf-417f-4f0c-a25d-b1a33147360b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_371d6887-c66a-4033-9be4-a0f8e4d11b52" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_ea5f6fbf-417f-4f0c-a25d-b1a33147360b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_ea5f6fbf-417f-4f0c-a25d-b1a33147360b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_ea5f6fbf-417f-4f0c-a25d-b1a33147360b" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_ea5f6fbf-417f-4f0c-a25d-b1a33147360b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c5a534e9-cba9-442a-acef-5dcec4e8e900" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_ea5f6fbf-417f-4f0c-a25d-b1a33147360b" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c5a534e9-cba9-442a-acef-5dcec4e8e900" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_8033030d-994e-4467-9acf-6088be3c3646" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c5a534e9-cba9-442a-acef-5dcec4e8e900" xlink:to="loc_us-gaap_ForeignExchangeContractMember_8033030d-994e-4467-9acf-6088be3c3646" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryLockMember_a562c62d-2d40-4b1c-bd2e-0f0775ddf3a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryLockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c5a534e9-cba9-442a-acef-5dcec4e8e900" xlink:to="loc_us-gaap_TreasuryLockMember_a562c62d-2d40-4b1c-bd2e-0f0775ddf3a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_da11be98-482c-49f8-87a0-4485ed3ed8ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_371d6887-c66a-4033-9be4-a0f8e4d11b52" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_da11be98-482c-49f8-87a0-4485ed3ed8ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_da11be98-482c-49f8-87a0-4485ed3ed8ad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_da11be98-482c-49f8-87a0-4485ed3ed8ad" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_da11be98-482c-49f8-87a0-4485ed3ed8ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_c06b1e5c-782a-41dc-8b92-0060f3fd3ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_da11be98-482c-49f8-87a0-4485ed3ed8ad" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_c06b1e5c-782a-41dc-8b92-0060f3fd3ca2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_b5d8e36f-8143-49e2-8b4e-7317e7097e74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_c06b1e5c-782a-41dc-8b92-0060f3fd3ca2" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_b5d8e36f-8143-49e2-8b4e-7317e7097e74" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f621d90e-9ed0-4f64-826e-b92b77350b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_371d6887-c66a-4033-9be4-a0f8e4d11b52" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f621d90e-9ed0-4f64-826e-b92b77350b4e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f621d90e-9ed0-4f64-826e-b92b77350b4e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f621d90e-9ed0-4f64-826e-b92b77350b4e" xlink:to="loc_us-gaap_EquityComponentDomain_f621d90e-9ed0-4f64-826e-b92b77350b4e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c876d00f-2246-4442-835e-dbdaf52dd88f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f621d90e-9ed0-4f64-826e-b92b77350b4e" xlink:to="loc_us-gaap_EquityComponentDomain_c876d00f-2246-4442-835e-dbdaf52dd88f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_e8ca23f2-a934-4532-9cbb-8206cd06871b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c876d00f-2246-4442-835e-dbdaf52dd88f" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_e8ca23f2-a934-4532-9cbb-8206cd06871b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_b5a420c0-d385-4d4b-8444-62684a41c582" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c876d00f-2246-4442-835e-dbdaf52dd88f" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_b5a420c0-d385-4d4b-8444-62684a41c582" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#ShareholdersEquityChangeinShareholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" xlink:type="extended" id="i3c4947179b6c4d5693c917f05a9a2b40_ShareholdersEquityChangeinShareholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_a52ed5a7-b33a-4680-ae19-6a7994519397" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fc1fffc2-1ec9-45b8-aca8-a2c5ec6625cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a52ed5a7-b33a-4680-ae19-6a7994519397" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fc1fffc2-1ec9-45b8-aca8-a2c5ec6625cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_6b779d13-cce4-434f-84cc-39d0740b33c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fc1fffc2-1ec9-45b8-aca8-a2c5ec6625cb" xlink:to="loc_us-gaap_SharesIssued_6b779d13-cce4-434f-84cc-39d0740b33c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fcd6a543-3091-436e-a05a-80dd3afc8f20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fc1fffc2-1ec9-45b8-aca8-a2c5ec6625cb" xlink:to="loc_us-gaap_StockholdersEquity_fcd6a543-3091-436e-a05a-80dd3afc8f20" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_31c26096-40fa-4088-b959-7f87c2a37601" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fc1fffc2-1ec9-45b8-aca8-a2c5ec6625cb" xlink:to="loc_us-gaap_TreasuryStockCommonShares_31c26096-40fa-4088-b959-7f87c2a37601" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_eb30cf0f-376e-40e0-8b13-5826e911712b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fc1fffc2-1ec9-45b8-aca8-a2c5ec6625cb" xlink:to="loc_us-gaap_NetIncomeLoss_eb30cf0f-376e-40e0-8b13-5826e911712b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2e6bdae8-4a46-4a9b-a14f-f04bc9abeea6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fc1fffc2-1ec9-45b8-aca8-a2c5ec6625cb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2e6bdae8-4a46-4a9b-a14f-f04bc9abeea6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_500174eb-b65c-431d-9a23-ddffcbbd904a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fc1fffc2-1ec9-45b8-aca8-a2c5ec6625cb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_500174eb-b65c-431d-9a23-ddffcbbd904a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_e9e2727d-9b5f-4f0a-a3de-706885db8174" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fc1fffc2-1ec9-45b8-aca8-a2c5ec6625cb" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_e9e2727d-9b5f-4f0a-a3de-706885db8174" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_2c5f2059-b94d-4e66-95d2-8545f1c50d22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fc1fffc2-1ec9-45b8-aca8-a2c5ec6625cb" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_2c5f2059-b94d-4e66-95d2-8545f1c50d22" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_da31b9d2-78a8-4943-8b1b-548e65cb10bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fc1fffc2-1ec9-45b8-aca8-a2c5ec6625cb" xlink:to="loc_us-gaap_DividendsCommonStockCash_da31b9d2-78a8-4943-8b1b-548e65cb10bb" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_07ced9ed-f956-49b2-bac0-7de694c8a48d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fc1fffc2-1ec9-45b8-aca8-a2c5ec6625cb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_07ced9ed-f956-49b2-bac0-7de694c8a48d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_739654b2-3453-46c8-9c0d-edffbb19a245" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_eaefc7f5-a892-4397-80e2-f15a6c609e77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_143e0a52-6c58-4fff-a2c2-cfe367dcb01d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_61c4064a-8966-46b4-8ded-55decc7fc446" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_a52ed5a7-b33a-4680-ae19-6a7994519397" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_61c4064a-8966-46b4-8ded-55decc7fc446" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ae1f4b60-3a89-45de-b3ee-2aa8d9b0d14c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_61c4064a-8966-46b4-8ded-55decc7fc446" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ae1f4b60-3a89-45de-b3ee-2aa8d9b0d14c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ae1f4b60-3a89-45de-b3ee-2aa8d9b0d14c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ae1f4b60-3a89-45de-b3ee-2aa8d9b0d14c" xlink:to="loc_us-gaap_EquityComponentDomain_ae1f4b60-3a89-45de-b3ee-2aa8d9b0d14c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8eee42cf-1f65-4859-8b90-6a0802ffd79d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ae1f4b60-3a89-45de-b3ee-2aa8d9b0d14c" xlink:to="loc_us-gaap_EquityComponentDomain_8eee42cf-1f65-4859-8b90-6a0802ffd79d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9a38abf1-1c70-4d63-a88e-695480aeae01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8eee42cf-1f65-4859-8b90-6a0802ffd79d" xlink:to="loc_us-gaap_CommonStockMember_9a38abf1-1c70-4d63-a88e-695480aeae01" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_eca601a7-43ca-4da8-87c5-df6c86726b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8eee42cf-1f65-4859-8b90-6a0802ffd79d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_eca601a7-43ca-4da8-87c5-df6c86726b9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_ffa06d75-7cb4-4e9c-8b84-82486f1190d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8eee42cf-1f65-4859-8b90-6a0802ffd79d" xlink:to="loc_us-gaap_TreasuryStockCommonMember_ffa06d75-7cb4-4e9c-8b84-82486f1190d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_4b448b25-a52f-42f7-87fd-e009718057e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8eee42cf-1f65-4859-8b90-6a0802ffd79d" xlink:to="loc_us-gaap_RetainedEarningsMember_4b448b25-a52f-42f7-87fd-e009718057e6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_36413be9-9c72-46fb-8b99-ccd421518a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8eee42cf-1f65-4859-8b90-6a0802ffd79d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_36413be9-9c72-46fb-8b99-ccd421518a8d" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/StockBasedCompensationDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#StockBasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://www.westpharma.com/role/StockBasedCompensationDetails" xlink:type="extended" id="i73f2af5f7f684fda9c1c79fe39a4f6bd_StockBasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6c1fc67-09ca-4e3a-b894-782db2c917a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f680e075-a532-4304-855b-0cb39cb7f09d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6c1fc67-09ca-4e3a-b894-782db2c917a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f680e075-a532-4304-855b-0cb39cb7f09d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_fa159140-85cc-40c1-942c-3e3dbb94afce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6c1fc67-09ca-4e3a-b894-782db2c917a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_fa159140-85cc-40c1-942c-3e3dbb94afce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a2f5ae58-0986-4fe6-89af-ea6a0bc6ddf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6c1fc67-09ca-4e3a-b894-782db2c917a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a2f5ae58-0986-4fe6-89af-ea6a0bc6ddf3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_39a1452b-4497-4a1e-b701-374f0ad922c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6c1fc67-09ca-4e3a-b894-782db2c917a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_39a1452b-4497-4a1e-b701-374f0ad922c6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_22025e5a-e4f4-4406-9610-fc7789c0e738" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6c1fc67-09ca-4e3a-b894-782db2c917a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_22025e5a-e4f4-4406-9610-fc7789c0e738" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_597c9d69-4001-4af4-92ef-bead4a83503c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6c1fc67-09ca-4e3a-b894-782db2c917a0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_597c9d69-4001-4af4-92ef-bead4a83503c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dcada2d4-97c6-4582-82cb-b08a4a6ef6b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6c1fc67-09ca-4e3a-b894-782db2c917a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dcada2d4-97c6-4582-82cb-b08a4a6ef6b9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_87cd5982-3135-4751-afb0-84430368bf2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6c1fc67-09ca-4e3a-b894-782db2c917a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_87cd5982-3135-4751-afb0-84430368bf2f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_670fe0ad-dcf6-4725-99a4-3805a36f458a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6c1fc67-09ca-4e3a-b894-782db2c917a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_670fe0ad-dcf6-4725-99a4-3805a36f458a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6b270330-a9c1-4764-bc0e-0bf80f9194f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6c1fc67-09ca-4e3a-b894-782db2c917a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6b270330-a9c1-4764-bc0e-0bf80f9194f9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_ShareBasedCompensationArrangementByShareBasedPaymentAwardActualPayoutPercentage_f6e4f703-3014-41e4-b2bd-4ad6aab22405" xlink:href="wst-20230331.xsd#wst_ShareBasedCompensationArrangementByShareBasedPaymentAwardActualPayoutPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6c1fc67-09ca-4e3a-b894-782db2c917a0" xlink:to="loc_wst_ShareBasedCompensationArrangementByShareBasedPaymentAwardActualPayoutPercentage_f6e4f703-3014-41e4-b2bd-4ad6aab22405" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_425ef095-5540-4bcd-a67e-0a10393ffee8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6c1fc67-09ca-4e3a-b894-782db2c917a0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_425ef095-5540-4bcd-a67e-0a10393ffee8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8674a5f2-860d-4b83-8efe-0f1911ea17ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6c1fc67-09ca-4e3a-b894-782db2c917a0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8674a5f2-860d-4b83-8efe-0f1911ea17ab" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_76cb6ae7-a578-4efe-926b-3ed8d8d9407f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8674a5f2-860d-4b83-8efe-0f1911ea17ab" xlink:to="loc_us-gaap_AwardTypeAxis_76cb6ae7-a578-4efe-926b-3ed8d8d9407f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_76cb6ae7-a578-4efe-926b-3ed8d8d9407f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_76cb6ae7-a578-4efe-926b-3ed8d8d9407f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_76cb6ae7-a578-4efe-926b-3ed8d8d9407f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d876f101-5416-418a-92f2-929ab0eedb9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_76cb6ae7-a578-4efe-926b-3ed8d8d9407f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d876f101-5416-418a-92f2-929ab0eedb9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_cb85b5b5-0291-4715-ab76-a25add3a417c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d876f101-5416-418a-92f2-929ab0eedb9a" xlink:to="loc_us-gaap_PerformanceSharesMember_cb85b5b5-0291-4715-ab76-a25add3a417c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_3fdaf18a-604c-4ff6-9b29-198ab0978dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d876f101-5416-418a-92f2-929ab0eedb9a" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_3fdaf18a-604c-4ff6-9b29-198ab0978dcc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4c57d20e-79ec-4219-bf3e-86b0cf3e9ff6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8674a5f2-860d-4b83-8efe-0f1911ea17ab" xlink:to="loc_srt_RangeAxis_4c57d20e-79ec-4219-bf3e-86b0cf3e9ff6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4c57d20e-79ec-4219-bf3e-86b0cf3e9ff6_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_4c57d20e-79ec-4219-bf3e-86b0cf3e9ff6" xlink:to="loc_srt_RangeMember_4c57d20e-79ec-4219-bf3e-86b0cf3e9ff6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bd2b109f-53f6-4a0b-9ec5-b88e5da11df7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_4c57d20e-79ec-4219-bf3e-86b0cf3e9ff6" xlink:to="loc_srt_RangeMember_bd2b109f-53f6-4a0b-9ec5-b88e5da11df7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1a4e7db5-abe2-4ef9-9f78-56e67d4665d3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_bd2b109f-53f6-4a0b-9ec5-b88e5da11df7" xlink:to="loc_srt_MinimumMember_1a4e7db5-abe2-4ef9-9f78-56e67d4665d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_06c46137-bb04-4405-bd94-62ab153466e4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_bd2b109f-53f6-4a0b-9ec5-b88e5da11df7" xlink:to="loc_srt_MaximumMember_06c46137-bb04-4405-bd94-62ab153466e4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails"/>
  <link:definitionLink xlink:role="http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended" id="i2be5339385ed4abdb6323299c7fe2d50_BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_617b10e4-56c4-4d77-af2d-88729ba0d02d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_14b0035f-3536-4bc7-8bb7-1ced98a279e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_617b10e4-56c4-4d77-af2d-88729ba0d02d" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_14b0035f-3536-4bc7-8bb7-1ced98a279e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_6b9e6e40-62d3-4e1b-93f3-14a3355b8217" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_617b10e4-56c4-4d77-af2d-88729ba0d02d" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_6b9e6e40-62d3-4e1b-93f3-14a3355b8217" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_deb81ea7-174f-4e9e-83f1-b8d4fed873b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_617b10e4-56c4-4d77-af2d-88729ba0d02d" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_deb81ea7-174f-4e9e-83f1-b8d4fed873b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_192be99a-7928-4b67-af28-7ce9f06a8117" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_617b10e4-56c4-4d77-af2d-88729ba0d02d" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_192be99a-7928-4b67-af28-7ce9f06a8117" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_e8e30095-a488-46fe-a329-fb0a4ea0d430" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_617b10e4-56c4-4d77-af2d-88729ba0d02d" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_e8e30095-a488-46fe-a329-fb0a4ea0d430" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_7eb8309d-3bf8-482b-ae1c-d7c840761155" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_617b10e4-56c4-4d77-af2d-88729ba0d02d" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_7eb8309d-3bf8-482b-ae1c-d7c840761155" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_ff85fb1e-f4fa-4436-964b-36ec6c287ef5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_617b10e4-56c4-4d77-af2d-88729ba0d02d" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_ff85fb1e-f4fa-4436-964b-36ec6c287ef5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_2f8b0b31-c93d-490c-bb3b-a006908ccf47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_ff85fb1e-f4fa-4436-964b-36ec6c287ef5" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_2f8b0b31-c93d-490c-bb3b-a006908ccf47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_2f8b0b31-c93d-490c-bb3b-a006908ccf47_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_2f8b0b31-c93d-490c-bb3b-a006908ccf47" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_2f8b0b31-c93d-490c-bb3b-a006908ccf47_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_152aa118-bc94-448b-9c8a-9ac3ae50e0c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_2f8b0b31-c93d-490c-bb3b-a006908ccf47" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_152aa118-bc94-448b-9c8a-9ac3ae50e0c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_b13e076e-5d4b-4c20-a53c-9e291105fea6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_152aa118-bc94-448b-9c8a-9ac3ae50e0c0" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_b13e076e-5d4b-4c20-a53c-9e291105fea6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_a53faa07-4502-42c5-9279-38f3fd55f72f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_152aa118-bc94-448b-9c8a-9ac3ae50e0c0" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_a53faa07-4502-42c5-9279-38f3fd55f72f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_e3caf733-d031-4d16-8d0a-e13877f8bad6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_ff85fb1e-f4fa-4436-964b-36ec6c287ef5" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_e3caf733-d031-4d16-8d0a-e13877f8bad6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_e3caf733-d031-4d16-8d0a-e13877f8bad6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_e3caf733-d031-4d16-8d0a-e13877f8bad6" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_e3caf733-d031-4d16-8d0a-e13877f8bad6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_2cdf5c02-d263-4434-8533-076e4ec8f5e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_e3caf733-d031-4d16-8d0a-e13877f8bad6" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_2cdf5c02-d263-4434-8533-076e4ec8f5e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_f3515086-c8e2-4f6e-98e5-a3d779e8ffbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_2cdf5c02-d263-4434-8533-076e4ec8f5e9" xlink:to="loc_us-gaap_DomesticPlanMember_f3515086-c8e2-4f6e-98e5-a3d779e8ffbe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_15acdd59-3b86-44ac-a8c4-986d35a476d2" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_f3515086-c8e2-4f6e-98e5-a3d779e8ffbe" xlink:to="loc_country_US_15acdd59-3b86-44ac-a8c4-986d35a476d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_3eebb21c-7765-4934-9754-571015aa2897" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_2cdf5c02-d263-4434-8533-076e4ec8f5e9" xlink:to="loc_us-gaap_ForeignPlanMember_3eebb21c-7765-4934-9754-571015aa2897" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/BenefitPlansNarrativeDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#BenefitPlansNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.westpharma.com/role/BenefitPlansNarrativeDetails" xlink:type="extended" id="ica851965c7da4474ba026e0e64aec53f_BenefitPlansNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_4b429a9d-c560-4872-862f-751573e80542" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_e5a1c040-5127-4664-a20d-e1cb788eab3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_4b429a9d-c560-4872-862f-751573e80542" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_e5a1c040-5127-4664-a20d-e1cb788eab3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_dd49bfa8-6b67-4eba-8400-765e5d4c8322" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_4b429a9d-c560-4872-862f-751573e80542" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_dd49bfa8-6b67-4eba-8400-765e5d4c8322" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_d38d6d1b-6f57-488f-9307-eeace4c86867" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_dd49bfa8-6b67-4eba-8400-765e5d4c8322" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_d38d6d1b-6f57-488f-9307-eeace4c86867" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_d38d6d1b-6f57-488f-9307-eeace4c86867_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_d38d6d1b-6f57-488f-9307-eeace4c86867" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_d38d6d1b-6f57-488f-9307-eeace4c86867_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_358995ec-b50b-424b-8d5b-8aad73cee845" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_d38d6d1b-6f57-488f-9307-eeace4c86867" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_358995ec-b50b-424b-8d5b-8aad73cee845" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_ce17411e-fdde-4b90-9f35-089604485ec5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_358995ec-b50b-424b-8d5b-8aad73cee845" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_ce17411e-fdde-4b90-9f35-089604485ec5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/OtherExpenseIncomeNarrativeDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#OtherExpenseIncomeNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.westpharma.com/role/OtherExpenseIncomeNarrativeDetails" xlink:type="extended" id="ia00abb16ae1c458b9a1ce26e74c29262_OtherExpenseIncomeNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_caf798fd-a2d3-48f8-80b4-a5e96eaa6610" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfInvestmentHoldingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_RestructuringAndRelatedActivitiesPeriodOfImplementation_860feebd-6fa8-411a-8254-85ad6fd8c4fd" xlink:href="wst-20230331.xsd#wst_RestructuringAndRelatedActivitiesPeriodOfImplementation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_caf798fd-a2d3-48f8-80b4-a5e96eaa6610" xlink:to="loc_wst_RestructuringAndRelatedActivitiesPeriodOfImplementation_860feebd-6fa8-411a-8254-85ad6fd8c4fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_be876be4-91c5-4d2a-bd88-2848a1851cda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_caf798fd-a2d3-48f8-80b4-a5e96eaa6610" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_be876be4-91c5-4d2a-bd88-2848a1851cda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOnFutureEarningsAmount_5edad1e7-5b6e-494e-a0be-9d1bae8f2b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOnFutureEarningsAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_caf798fd-a2d3-48f8-80b4-a5e96eaa6610" xlink:to="loc_us-gaap_EffectOnFutureEarningsAmount_5edad1e7-5b6e-494e-a0be-9d1bae8f2b2c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_cd8ad9f2-34e5-4825-b7cd-7bf1eed18537" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_caf798fd-a2d3-48f8-80b4-a5e96eaa6610" xlink:to="loc_us-gaap_AssetImpairmentCharges_cd8ad9f2-34e5-4825-b7cd-7bf1eed18537" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_b7c16a82-6c56-44fb-82d3-435d397cfb48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_caf798fd-a2d3-48f8-80b4-a5e96eaa6610" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_b7c16a82-6c56-44fb-82d3-435d397cfb48" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfInvestmentHoldingsTable_215be3c8-0dd7-4256-bcc4-9c07ced926cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfInvestmentHoldingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_caf798fd-a2d3-48f8-80b4-a5e96eaa6610" xlink:to="loc_us-gaap_SummaryOfInvestmentHoldingsTable_215be3c8-0dd7-4256-bcc4-9c07ced926cb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_6f3d5803-a85b-412d-afb9-1a492308b4dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsTable_215be3c8-0dd7-4256-bcc4-9c07ced926cb" xlink:to="loc_us-gaap_RestructuringPlanAxis_6f3d5803-a85b-412d-afb9-1a492308b4dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_6f3d5803-a85b-412d-afb9-1a492308b4dd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_6f3d5803-a85b-412d-afb9-1a492308b4dd" xlink:to="loc_us-gaap_RestructuringPlanDomain_6f3d5803-a85b-412d-afb9-1a492308b4dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_e3f9408e-ca5f-439c-aab6-bb88bf898f70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_6f3d5803-a85b-412d-afb9-1a492308b4dd" xlink:to="loc_us-gaap_RestructuringPlanDomain_e3f9408e-ca5f-439c-aab6-bb88bf898f70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_The2020RestructuringPlanMember_579a091a-09a7-4a00-beb8-9637aa9309ef" xlink:href="wst-20230331.xsd#wst_The2020RestructuringPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_e3f9408e-ca5f-439c-aab6-bb88bf898f70" xlink:to="loc_wst_The2020RestructuringPlanMember_579a091a-09a7-4a00-beb8-9637aa9309ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f98cd836-5662-4ae6-909a-bb07eb90fb03" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsTable_215be3c8-0dd7-4256-bcc4-9c07ced926cb" xlink:to="loc_srt_RangeAxis_f98cd836-5662-4ae6-909a-bb07eb90fb03" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f98cd836-5662-4ae6-909a-bb07eb90fb03_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f98cd836-5662-4ae6-909a-bb07eb90fb03" xlink:to="loc_srt_RangeMember_f98cd836-5662-4ae6-909a-bb07eb90fb03_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e5191857-8c54-49a1-b317-ff4e2df44bc2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f98cd836-5662-4ae6-909a-bb07eb90fb03" xlink:to="loc_srt_RangeMember_e5191857-8c54-49a1-b317-ff4e2df44bc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3fd7688f-ce55-456c-92d1-8f39263dc74c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e5191857-8c54-49a1-b317-ff4e2df44bc2" xlink:to="loc_srt_MinimumMember_3fd7688f-ce55-456c-92d1-8f39263dc74c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9fb88f77-ee3c-484b-81e6-ccf1c0c522cd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e5191857-8c54-49a1-b317-ff4e2df44bc2" xlink:to="loc_srt_MaximumMember_9fb88f77-ee3c-484b-81e6-ccf1c0c522cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_f6da7c4b-87fa-4a6a-bb7c-092e318e3a48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsTable_215be3c8-0dd7-4256-bcc4-9c07ced926cb" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_f6da7c4b-87fa-4a6a-bb7c-092e318e3a48" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f6da7c4b-87fa-4a6a-bb7c-092e318e3a48_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f6da7c4b-87fa-4a6a-bb7c-092e318e3a48" xlink:to="loc_us-gaap_SegmentDomain_f6da7c4b-87fa-4a6a-bb7c-092e318e3a48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d09f166a-f365-4206-a308-35313ad96a3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f6da7c4b-87fa-4a6a-bb7c-092e318e3a48" xlink:to="loc_us-gaap_SegmentDomain_d09f166a-f365-4206-a308-35313ad96a3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_ProprietaryProductsMember_e0f9510c-11db-49b2-9639-ffce480b79ed" xlink:href="wst-20230331.xsd#wst_ProprietaryProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_d09f166a-f365-4206-a308-35313ad96a3e" xlink:to="loc_wst_ProprietaryProductsMember_e0f9510c-11db-49b2-9639-ffce480b79ed" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/OtherExpenseIncomeScheduleofRestructuringandRelatedChargesDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#OtherExpenseIncomeScheduleofRestructuringandRelatedChargesDetails"/>
  <link:definitionLink xlink:role="http://www.westpharma.com/role/OtherExpenseIncomeScheduleofRestructuringandRelatedChargesDetails" xlink:type="extended" id="ifc91dd7788a642c1a17be1a7dc035520_OtherExpenseIncomeScheduleofRestructuringandRelatedChargesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_be9b42d6-6fc5-4cc8-a642-f0a34e1d17e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_84bd36cb-2c24-473a-8d94-b61c8c6ada68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_be9b42d6-6fc5-4cc8-a642-f0a34e1d17e4" xlink:to="loc_us-gaap_RestructuringReserveRollForward_84bd36cb-2c24-473a-8d94-b61c8c6ada68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_e9e4ecf7-4760-4536-a6ce-cdfe0175a97b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_84bd36cb-2c24-473a-8d94-b61c8c6ada68" xlink:to="loc_us-gaap_RestructuringReserve_e9e4ecf7-4760-4536-a6ce-cdfe0175a97b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_e479e488-4e8c-46df-9131-37ecc52dec69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_84bd36cb-2c24-473a-8d94-b61c8c6ada68" xlink:to="loc_us-gaap_RestructuringCharges_e479e488-4e8c-46df-9131-37ecc52dec69" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_4e6a7d7d-822a-4a30-9a44-aede6990b5d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_84bd36cb-2c24-473a-8d94-b61c8c6ada68" xlink:to="loc_us-gaap_PaymentsForRestructuring_4e6a7d7d-822a-4a30-9a44-aede6990b5d9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_6abd7d8c-3dd8-4756-b64a-69873167a1e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_527894c3-e598-4514-8f6a-a780bd8034f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_be9b42d6-6fc5-4cc8-a642-f0a34e1d17e4" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_527894c3-e598-4514-8f6a-a780bd8034f4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_c1255b65-1c73-4839-89fe-edd9588f236f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_527894c3-e598-4514-8f6a-a780bd8034f4" xlink:to="loc_us-gaap_RestructuringPlanAxis_c1255b65-1c73-4839-89fe-edd9588f236f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_c1255b65-1c73-4839-89fe-edd9588f236f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_c1255b65-1c73-4839-89fe-edd9588f236f" xlink:to="loc_us-gaap_RestructuringPlanDomain_c1255b65-1c73-4839-89fe-edd9588f236f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_98ae324b-034e-42ec-929f-1427d5b9d787" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_c1255b65-1c73-4839-89fe-edd9588f236f" xlink:to="loc_us-gaap_RestructuringPlanDomain_98ae324b-034e-42ec-929f-1427d5b9d787" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_A2020RestructuringPlanMember_eeef5621-9cd5-49e0-bb90-b0b00c9b4204" xlink:href="wst-20230331.xsd#wst_A2020RestructuringPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_98ae324b-034e-42ec-929f-1427d5b9d787" xlink:to="loc_wst_A2020RestructuringPlanMember_eeef5621-9cd5-49e0-bb90-b0b00c9b4204" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_2f6119ba-e810-442b-b6ad-d0dd3584e0bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_527894c3-e598-4514-8f6a-a780bd8034f4" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_2f6119ba-e810-442b-b6ad-d0dd3584e0bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_2f6119ba-e810-442b-b6ad-d0dd3584e0bf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_2f6119ba-e810-442b-b6ad-d0dd3584e0bf" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_2f6119ba-e810-442b-b6ad-d0dd3584e0bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_5227e73b-2456-41ed-963d-ec7e665e0798" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_2f6119ba-e810-442b-b6ad-d0dd3584e0bf" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_5227e73b-2456-41ed-963d-ec7e665e0798" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_e86cd9dd-c18c-490b-8a7a-6fefe318f78d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_5227e73b-2456-41ed-963d-ec7e665e0798" xlink:to="loc_us-gaap_EmployeeSeveranceMember_e86cd9dd-c18c-490b-8a7a-6fefe318f78d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_92022c33-89c0-4179-8914-8d230df771e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherRestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_5227e73b-2456-41ed-963d-ec7e665e0798" xlink:to="loc_us-gaap_OtherRestructuringMember_92022c33-89c0-4179-8914-8d230df771e8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/SegmentInformationSalesbyProductGroupDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#SegmentInformationSalesbyProductGroupDetails"/>
  <link:definitionLink xlink:role="http://www.westpharma.com/role/SegmentInformationSalesbyProductGroupDetails" xlink:type="extended" id="i7438d0b96a7141a4ae2de6c00b20e3ff_SegmentInformationSalesbyProductGroupDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_7e6ae077-791e-4dc2-9d6a-c72e963906a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_90fcf920-a382-4c8d-82a0-f1efe7ac2616" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_7e6ae077-791e-4dc2-9d6a-c72e963906a7" xlink:to="loc_us-gaap_Revenues_90fcf920-a382-4c8d-82a0-f1efe7ac2616" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_57e4449f-3d57-46cb-b76b-56163460df7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_7e6ae077-791e-4dc2-9d6a-c72e963906a7" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_57e4449f-3d57-46cb-b76b-56163460df7e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_a76e3fca-670c-4afc-9821-645fd24fbc2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_57e4449f-3d57-46cb-b76b-56163460df7e" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_a76e3fca-670c-4afc-9821-645fd24fbc2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_a76e3fca-670c-4afc-9821-645fd24fbc2c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a76e3fca-670c-4afc-9821-645fd24fbc2c" xlink:to="loc_us-gaap_SegmentDomain_a76e3fca-670c-4afc-9821-645fd24fbc2c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_5107502e-d044-4021-afb1-572b66f1e4f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a76e3fca-670c-4afc-9821-645fd24fbc2c" xlink:to="loc_us-gaap_SegmentDomain_5107502e-d044-4021-afb1-572b66f1e4f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_ProprietaryProductsMember_6f740318-6a93-4926-95e8-a6e97937a26a" xlink:href="wst-20230331.xsd#wst_ProprietaryProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_5107502e-d044-4021-afb1-572b66f1e4f9" xlink:to="loc_wst_ProprietaryProductsMember_6f740318-6a93-4926-95e8-a6e97937a26a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_ContractManufacturedProductsMember_de1ea9a2-b1f7-48d5-9cc8-3d7b9abe27c8" xlink:href="wst-20230331.xsd#wst_ContractManufacturedProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_5107502e-d044-4021-afb1-572b66f1e4f9" xlink:to="loc_wst_ContractManufacturedProductsMember_de1ea9a2-b1f7-48d5-9cc8-3d7b9abe27c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_fd95fa48-2ce0-4210-857e-daa1b8e6b0ff" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_57e4449f-3d57-46cb-b76b-56163460df7e" xlink:to="loc_srt_ConsolidationItemsAxis_fd95fa48-2ce0-4210-857e-daa1b8e6b0ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_fd95fa48-2ce0-4210-857e-daa1b8e6b0ff_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_fd95fa48-2ce0-4210-857e-daa1b8e6b0ff" xlink:to="loc_srt_ConsolidationItemsDomain_fd95fa48-2ce0-4210-857e-daa1b8e6b0ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_985520e1-5e6e-4b8b-afb8-5b87d5365343" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_fd95fa48-2ce0-4210-857e-daa1b8e6b0ff" xlink:to="loc_srt_ConsolidationItemsDomain_985520e1-5e6e-4b8b-afb8-5b87d5365343" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_4f3a0af9-9711-441f-800c-480ea6f561b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_985520e1-5e6e-4b8b-afb8-5b87d5365343" xlink:to="loc_us-gaap_OperatingSegmentsMember_4f3a0af9-9711-441f-800c-480ea6f561b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember_606f9e73-9061-4a53-befd-0f05d9e65852" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_985520e1-5e6e-4b8b-afb8-5b87d5365343" xlink:to="loc_us-gaap_IntersegmentEliminationMember_606f9e73-9061-4a53-befd-0f05d9e65852" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#SegmentInformationSegmentFinancialInformationDetails"/>
  <link:definitionLink xlink:role="http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" xlink:type="extended" id="i7db7893aa8884888a8a03b0a8ef00b53_SegmentInformationSegmentFinancialInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_73359cdb-3ff7-40ff-a1c0-5fb694bf41e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ec167309-a040-4224-b4d5-f19ca4c4e8c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73359cdb-3ff7-40ff-a1c0-5fb694bf41e8" xlink:to="loc_us-gaap_OperatingIncomeLoss_ec167309-a040-4224-b4d5-f19ca4c4e8c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_13aede37-f55f-4809-9912-288fdc8d2411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73359cdb-3ff7-40ff-a1c0-5fb694bf41e8" xlink:to="loc_us-gaap_ShareBasedCompensation_13aede37-f55f-4809-9912-288fdc8d2411" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_1170d453-bec1-403f-8016-58b00b68aae6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73359cdb-3ff7-40ff-a1c0-5fb694bf41e8" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_1170d453-bec1-403f-8016-58b00b68aae6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_53c59bd3-3b00-44d9-a022-527e037a77d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73359cdb-3ff7-40ff-a1c0-5fb694bf41e8" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_53c59bd3-3b00-44d9-a022-527e037a77d8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_0973f73c-bf20-4df3-b2d7-ba89474b7d67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73359cdb-3ff7-40ff-a1c0-5fb694bf41e8" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_0973f73c-bf20-4df3-b2d7-ba89474b7d67" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9a0b5ab3-eb74-4bca-ba81-58c133b1cae0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73359cdb-3ff7-40ff-a1c0-5fb694bf41e8" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_9a0b5ab3-eb74-4bca-ba81-58c133b1cae0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_bc10401f-7f5c-4797-930c-62aa6201e9c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73359cdb-3ff7-40ff-a1c0-5fb694bf41e8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_bc10401f-7f5c-4797-930c-62aa6201e9c8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_f9ae4d3f-2923-4dc4-806c-aa6b81bd2365" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73359cdb-3ff7-40ff-a1c0-5fb694bf41e8" xlink:to="loc_us-gaap_AssetImpairmentCharges_f9ae4d3f-2923-4dc4-806c-aa6b81bd2365" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e1b25bb5-cd88-45d1-b4c9-74f8d082f4d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73359cdb-3ff7-40ff-a1c0-5fb694bf41e8" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e1b25bb5-cd88-45d1-b4c9-74f8d082f4d8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_ef4aa977-1d8d-43a9-a7a5-0ff5aca13599" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e1b25bb5-cd88-45d1-b4c9-74f8d082f4d8" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_ef4aa977-1d8d-43a9-a7a5-0ff5aca13599" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ef4aa977-1d8d-43a9-a7a5-0ff5aca13599_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ef4aa977-1d8d-43a9-a7a5-0ff5aca13599" xlink:to="loc_us-gaap_SegmentDomain_ef4aa977-1d8d-43a9-a7a5-0ff5aca13599_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b81db43e-8d85-421d-a7a1-34983989628a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ef4aa977-1d8d-43a9-a7a5-0ff5aca13599" xlink:to="loc_us-gaap_SegmentDomain_b81db43e-8d85-421d-a7a1-34983989628a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_ProprietaryProductsMember_bd4c4b72-a239-40ae-be86-71051330e675" xlink:href="wst-20230331.xsd#wst_ProprietaryProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_b81db43e-8d85-421d-a7a1-34983989628a" xlink:to="loc_wst_ProprietaryProductsMember_bd4c4b72-a239-40ae-be86-71051330e675" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_ContractManufacturedProductsMember_6652634b-c232-41aa-ae4e-58d2f014fbf2" xlink:href="wst-20230331.xsd#wst_ContractManufacturedProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_b81db43e-8d85-421d-a7a1-34983989628a" xlink:to="loc_wst_ContractManufacturedProductsMember_6652634b-c232-41aa-ae4e-58d2f014fbf2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_370397bc-0e12-458f-8e2b-1ecfe1b02baa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e1b25bb5-cd88-45d1-b4c9-74f8d082f4d8" xlink:to="loc_srt_ConsolidationItemsAxis_370397bc-0e12-458f-8e2b-1ecfe1b02baa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_370397bc-0e12-458f-8e2b-1ecfe1b02baa_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_370397bc-0e12-458f-8e2b-1ecfe1b02baa" xlink:to="loc_srt_ConsolidationItemsDomain_370397bc-0e12-458f-8e2b-1ecfe1b02baa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_02c6e956-def9-440e-b1a1-3b1e8d3f48a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_370397bc-0e12-458f-8e2b-1ecfe1b02baa" xlink:to="loc_srt_ConsolidationItemsDomain_02c6e956-def9-440e-b1a1-3b1e8d3f48a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_7d11478c-f564-44da-81d1-29649676a7ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_02c6e956-def9-440e-b1a1-3b1e8d3f48a4" xlink:to="loc_us-gaap_OperatingSegmentsMember_7d11478c-f564-44da-81d1-29649676a7ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_1c18949f-2ccc-43fa-9de7-34ca0c48f910" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_02c6e956-def9-440e-b1a1-3b1e8d3f48a4" xlink:to="loc_us-gaap_CorporateNonSegmentMember_1c18949f-2ccc-43fa-9de7-34ca0c48f910" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>wst-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:a34422fb-98f0-4bfc-83b0-7c0b1b7c96bb,g:fe42bdb5-3507-4fad-98a2-d4b1f779591c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_GeographicConcentrationRiskMember_bf88bffd-816a-4fd1-9f0c-ce3185d4691d_terseLabel_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Concentration Risk</link:label>
    <link:label id="lab_us-gaap_GeographicConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicConcentrationRiskMember" xlink:to="lab_us-gaap_GeographicConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_404ef7e5-3d22-43c4-873f-1ce4f1cdbf18_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in the Components of Accumulated Other Comprehensive Loss, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77ac50ab-d300-4b06-9ee7-27199349f064_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ae552a17-7c1d-495e-b09a-69e0a6c1b8d1_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases liabilities payments due</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_7499faad-8378-4bbd-b839-1c1c385776d5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_f2c68587-256b-46eb-ae9a-249cd3c05d32_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, gross</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_e2e5a954-3821-4ed3-ae0b-3557b26e217d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_7c039dbe-fc05-45dd-a2b2-61e80f80fa09_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders Equity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders Equity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_c2e8eeb3-f833-4f65-8bb4-ead7eb412ed0_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_cb21f636-b3d1-4ca3-8cf3-e25ad036b586_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in unrealized gain (loss) on fair value hedging instruments</link:label>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_label_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_8506c08f-b595-4da0-96f6-4f0a1d23dbc1_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend payments</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Ordinary Dividends, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:to="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_125f2393-4a37-4063-97e6-59d378cb1b10_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_d23c88c0-84fc-4a79-8069-12ead39fb799_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_581a26ac-9e52-4f1f-b2a5-fe6e01a1825c_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, December 31, 2022</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_ceeb50e2-d6e9-48e3-b175-8683b26f0cb5_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, March 31, 2023</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_64bc01d1-6d2c-4d5f-90c8-5a4c0328689f_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency hedge contracts</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_e8e828f6-7e89-4879-a94b-8fa9ffad961f_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency contracts</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_363ebfd4-4d60-453f-b079-f5fbc065f10e_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in deferred income - decrease (increase)</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_wst_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_597695b4-8db3-42eb-921a-a5ec41e474a3_terseLabel_en-US" xlink:label="lab_wst_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_wst_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_wst_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:label id="lab_wst_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_wst_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wst_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:href="wst-20230331.xsd#wst_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wst_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_wst_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_3434b0cf-2cdb-4d6f-861e-a7922c918fef_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_ec67040a-9d8f-43bf-8247-95119a4d45bf_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital in excess of par value</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationPlanAssets_54d9ccdb-e1a6-4a73-a38e-c2e5bca718a8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred compensation assets</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationPlanAssets_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationPlanAssets" xlink:to="lab_us-gaap_DeferredCompensationPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_83723f5f-2e63-49f1-8a45-efd636fc4414_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_wst_ShareBasedCompensationArrangementByShareBasedPaymentAwardActualPayoutPercentage_8c4df77c-e4f2-4b20-8c8d-11e5c8ff587d_terseLabel_en-US" xlink:label="lab_wst_ShareBasedCompensationArrangementByShareBasedPaymentAwardActualPayoutPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Target award percentage</link:label>
    <link:label id="lab_wst_ShareBasedCompensationArrangementByShareBasedPaymentAwardActualPayoutPercentage_label_en-US" xlink:label="lab_wst_ShareBasedCompensationArrangementByShareBasedPaymentAwardActualPayoutPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Actual Payout, Percentage</link:label>
    <link:label id="lab_wst_ShareBasedCompensationArrangementByShareBasedPaymentAwardActualPayoutPercentage_documentation_en-US" xlink:label="lab_wst_ShareBasedCompensationArrangementByShareBasedPaymentAwardActualPayoutPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Actual Payout, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wst_ShareBasedCompensationArrangementByShareBasedPaymentAwardActualPayoutPercentage" xlink:href="wst-20230331.xsd#wst_ShareBasedCompensationArrangementByShareBasedPaymentAwardActualPayoutPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wst_ShareBasedCompensationArrangementByShareBasedPaymentAwardActualPayoutPercentage" xlink:to="lab_wst_ShareBasedCompensationArrangementByShareBasedPaymentAwardActualPayoutPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_4213a887-ed77-4b7c-90ed-087adc8658b3_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_a190cf9c-d1c0-42bc-9c60-d2e1d0f93997_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_bde69a04-64f7-4ad1-8843-f7b182fc9535_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet_ebedd751-caff-45d1-bc5b-689fefdd162a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative (gain) loss on amount excluded from effectiveness testing, fair value hedges</link:label>
    <link:label id="lab_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet_label_en-US" xlink:label="lab_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) from Components Excluded from Assessment of Fair Value Hedge Effectiveness, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet" xlink:to="lab_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_cf78e5d2-8753-4492-a008-b075335416c7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, stated interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_2b2e409c-0292-4c64-a132-113249e39db9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_c83323c0-8b8b-4908-9e77-d561f798991d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effects of Derivative Instruments on Other Comprehensive Income ('OCI') and Earnings</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_28737e7e-4f9c-43da-b306-67da7135a5c5_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_e12f9668-d8ce-461d-90fb-0b6c5eb54f48_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic benefit cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_f48ae607-28c2-41ea-b6af-3a43a6a6f904_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_e8c5708e-b901-425a-a115-88cfea6b39d7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-cash items, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_c821d64c-58f2-456c-a7e6-4215cab59369_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency contracts and swaps</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Contracts, Liability, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:to="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_fb605c10-10f6-4c05-a29d-d5425839d359_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock purchase program, cost of shares purchased</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_446198eb-36fd-490f-a1ec-eb17f95647be_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares purchased under share repurchase program</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_fd1f700c-e4ec-4888-a487-86b84265da91_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_41acee8c-491b-4142-a4fd-8a2398ee8cf8_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2dda945a-6ee8-468f-b308-c77e4069c9c9_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive options excluded from computation of diluted net income per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_wst_SeniorCNotesDue2027Member_d3e6cebe-d82a-448e-9983-d559677901c5_terseLabel_en-US" xlink:label="lab_wst_SeniorCNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series C notes, due July 5, 2027 (4.02%)</link:label>
    <link:label id="lab_wst_SeniorCNotesDue2027Member_label_en-US" xlink:label="lab_wst_SeniorCNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior C Notes Due 2027 [Member]</link:label>
    <link:label id="lab_wst_SeniorCNotesDue2027Member_documentation_en-US" xlink:label="lab_wst_SeniorCNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior C Notes Due 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wst_SeniorCNotesDue2027Member" xlink:href="wst-20230331.xsd#wst_SeniorCNotesDue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wst_SeniorCNotesDue2027Member" xlink:to="lab_wst_SeniorCNotesDue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_d1d68c07-54c4-4c90-9510-99ba748d326d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_3dbdbb72-7d12-4ec4-a2cb-c06d24400640_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseMember_83e35b9f-fd65-4b05-a9c9-85f7d2ba4d80_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseMember_label_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseMember" xlink:to="lab_us-gaap_InterestExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_781aca47-e876-47cf-a788-2611ab8aaa63_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit of state tax valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_09893cf7-8f67-4372-9d4d-d04e3a13ea58_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_ffaa5bdf-5a55-4e4f-8e81-97fa4f558c16_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_1a2120f1-b375-4e5f-9ac4-540ed530eeba_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_93f1187b-6c2d-4191-a573-97e15ac46a07_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost (1.1&#160;million and 1.2 million shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonValue" xlink:to="lab_us-gaap_TreasuryStockCommonValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_a622cc4c-b0fd-466d-8996-87c3c3fccf66_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets, December 31, 2022</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_0ad2f285-443f-442c-9c62-c7b7e7970ac2_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets, March&#160;31, 2023</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_04e2b352-f98e-4605-843c-9b622b80c38d_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_86abdbd3-9029-4fdf-a503-ccb817262ab1_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_a5df10ed-68d0-4b3c-ab97-93cf5086a904_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remainder of fiscal year</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_228e564e-2b59-44e1-bd49-354422877122_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_cd7fba27-5ea2-4d17-b3ab-d4aefa23192a_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term line of credit</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_34df9a18-4459-4645-85c2-83c6e2d2318a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_57ff7d2e-56ec-4589-9989-c0bc57eda888_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_wst_A2020RestructuringPlanMember_a43ae5ca-ac57-4443-a97e-d0b85662610c_terseLabel_en-US" xlink:label="lab_wst_A2020RestructuringPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Restructuring Plan</link:label>
    <link:label id="lab_wst_A2020RestructuringPlanMember_label_en-US" xlink:label="lab_wst_A2020RestructuringPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Restructuring Plan [Member]</link:label>
    <link:label id="lab_wst_A2020RestructuringPlanMember_documentation_en-US" xlink:label="lab_wst_A2020RestructuringPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Restructuring Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wst_A2020RestructuringPlanMember" xlink:href="wst-20230331.xsd#wst_A2020RestructuringPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wst_A2020RestructuringPlanMember" xlink:to="lab_wst_A2020RestructuringPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_90ea6089-bca4-4eac-85d0-4107cc6fc516_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_wst_RevolvingCreditFacilityDue2024Member_ed3068f9-7452-4fdd-b35b-c1ead7a1859b_terseLabel_en-US" xlink:label="lab_wst_RevolvingCreditFacilityDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility, Due 2024</link:label>
    <link:label id="lab_wst_RevolvingCreditFacilityDue2024Member_label_en-US" xlink:label="lab_wst_RevolvingCreditFacilityDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility, Due 2024 [Member]</link:label>
    <link:label id="lab_wst_RevolvingCreditFacilityDue2024Member_documentation_en-US" xlink:label="lab_wst_RevolvingCreditFacilityDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility, Due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wst_RevolvingCreditFacilityDue2024Member" xlink:href="wst-20230331.xsd#wst_RevolvingCreditFacilityDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wst_RevolvingCreditFacilityDue2024Member" xlink:to="lab_wst_RevolvingCreditFacilityDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_2ceb2214-620c-4cf3-b33f-529760c915c7_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss_85f60114-b9f0-4432-9d5f-25aaf70ad2d0_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial gains</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss_7ea70662-c1d6-4288-a5bc-6054da2482de_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized actuarial losses (gains)</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:to="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_f5a5b1d6-398c-4785-9d41-3944f339640c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_2ccc8d7a-f4b4-4fdd-9778-ecbb1bdeab69_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_a8d7cac9-bbac-4be3-b8e0-18e5a304798c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commodity call options</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_AllCurrenciesDomain_0600a801-307a-4fc7-8b78-75ea5f2d46d0_terseLabel_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:label id="lab_currency_AllCurrenciesDomain_label_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain" xlink:to="lab_currency_AllCurrenciesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent_82cde924-ee26-40ea-b32a-810edbf8d655_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit pension and other postretirement plan adjustments, tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_wst_GenericsCustomersMember_5a0388fd-133a-447a-bad8-0d2f3a91378d_terseLabel_en-US" xlink:label="lab_wst_GenericsCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Generics</link:label>
    <link:label id="lab_wst_GenericsCustomersMember_label_en-US" xlink:label="lab_wst_GenericsCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Generics Customers [Member]</link:label>
    <link:label id="lab_wst_GenericsCustomersMember_documentation_en-US" xlink:label="lab_wst_GenericsCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Generics Customers [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wst_GenericsCustomersMember" xlink:href="wst-20230331.xsd#wst_GenericsCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wst_GenericsCustomersMember" xlink:to="lab_wst_GenericsCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_4b75c5db-a7fa-4ed7-9aff-83de064a45d3_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and related cost, expected cost</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_59e7b848-a4c8-4d2a-8bbd-fde1e5c66a25_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_f916ef3e-00b6-4075-9b7b-e12044aa1920_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_6185788c-1ec3-4555-b47d-81d419f6e46d_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_c271154e-1238-47bf-b74e-4a726ebb5c9d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f520947-22c5-414e-bd52-5fa7e49e9afc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_a3c63377-090c-4d4d-b23b-99ba5643950c_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c67751ea-a9a6-4098-b73e-3a4af45dc856_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_7603394f-ade9-4f14-97e0-e44ff6eef495_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and other postretirement benefits</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Defined Benefit Plan, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:to="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PositionAxis_34b5d642-a70f-4435-b974-9e2ec2f17e97_terseLabel_en-US" xlink:label="lab_us-gaap_PositionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Position [Axis]</link:label>
    <link:label id="lab_us-gaap_PositionAxis_label_en-US" xlink:label="lab_us-gaap_PositionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Position [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PositionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PositionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PositionAxis" xlink:to="lab_us-gaap_PositionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueFromAffiliates_e909cbf8-46bb-4fbe-b81c-5ff55c96846d_terseLabel_en-US" xlink:label="lab_us-gaap_DueFromAffiliates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount receivable from affiliates</link:label>
    <link:label id="lab_us-gaap_DueFromAffiliates_label_en-US" xlink:label="lab_us-gaap_DueFromAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromAffiliates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromAffiliates" xlink:to="lab_us-gaap_DueFromAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_8d7b2b70-1912-4a4a-addc-c3eb0ea16681_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reclassification out of Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_2fa8b1a3-fae6-4e0a-95e3-7030605bf65a_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a3351406-6bf6-48d2-8686-9097a84834ad_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_43ad6d75-b547-4047-a6ea-6a078d6be745_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in equity affiliate investment AOCI</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_e4d4b12d-4dcb-4f81-bf15-7231af8dc7c6_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements and Changes in Accounting Principles [Abstract]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_2a64dd64-f20e-48c0-a774-06f776951783_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_59bef73e-781f-44aa-917d-44c7c3934a63_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_e23fe274-d60d-4289-be72-24561a0ad04d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_fa4fb06b-b941-4ff9-b049-dedc47119a1c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_0017ec25-6a6f-4a70-b326-8924b4f97b87_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_73ffee84-c07d-47a9-9672-7e581ed391c1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_3603771b-724f-4173-a562-408bd971fd6a_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_c4c7f564-4578-499f-8bcc-e494dfba4612_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_fd17b556-33b9-406b-a8a1-b43f129cd8ee_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9878f5d5-003d-4d84-a17c-b7f9c84f466e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year one</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_144ae94b-7131-497d-8091-fa0266e64813_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_01732e03-aae6-448d-8901-3b656dccac69_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow hedges, amount of gain (loss) recognized in OCI</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings_5ef7a924-ba68-45bd-9f50-5ba7c80e754c_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative (gain) loss recognized in income, fair value hedges</link:label>
    <link:label id="lab_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings_label_en-US" xlink:label="lab_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Fair Value Hedges Recognized in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings" xlink:to="lab_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_216d52cb-d038-44fe-a402-a73084c9218a_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_8591268a-6130-446c-84ea-89292674814b_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_53d184c5-17df-4d4c-8cd3-9e5f9ee323fd_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Change in Contract With Customer, Asset and Liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_6c34302f-2b7e-411e-8206-d8cfa244e7fa_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_ed80ae66-7777-4b72-be59-ba742f41628b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) by Hedging Relationship, by Income Statement Location, by Derivative Instrument Risk [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_dc391a66-7cd5-4ee0-9574-ba8bb6d3bc7b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_739215c0-843c-405b-ac5a-b66320eb4d93_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_c9d96ae1-ad96-441c-a432-e774e7e680f8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_84238f0c-f7bc-4db3-965b-690bac4c06e2_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_8d8af1a7-1b91-4f48-9963-b529c57ce481_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_338d5d1f-e6e5-49ef-8fab-6af959328ca0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfInvestmentHoldingsLineItems_2b273569-f1dd-4208-a344-9d3069079e6a_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Investment Holdings [Line Items]</link:label>
    <link:label id="lab_us-gaap_SummaryOfInvestmentHoldingsLineItems_label_en-US" xlink:label="lab_us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Investment Holdings [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfInvestmentHoldingsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="lab_us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_24cbff03-03f8-4211-a2ee-fd6f44b5bdf6_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share Unit (PSUs)</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_97ee8c32-fc05-47d6-920f-b525f43213ed_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_90696d7f-ff7e-4372-9da0-0387a2dae03d_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_7ea2f1d7-90d0-42fe-9fa3-9e8e54d11e98_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_29098c2f-56b8-4db0-a415-cd0116bca6ef_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_a0d0a098-3770-4561-a6cd-0fbcd1f6af84_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year five</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_52cd9b58-ee3b-4387-b2ce-7f2e2267789a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_1260ccab-bcb4-440b-8d95-9354fe9c0d2e_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, fair value</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_87af66bc-5b62-4127-b39f-587669870ad2_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_fbc40c87-339c-4fd4-9772-c4e72000d6ae_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, authorized repurchase amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_dfbd7bdd-4ffc-4eb1-83ef-98225994584d_negatedLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts reclassified out from accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:to="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNonmonetaryNotionalAmountVolume_12979efd-240b-4828-9045-3d3b18f1bdd7_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNonmonetaryNotionalAmountVolume" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, nonmonetary notional amount, volume</link:label>
    <link:label id="lab_us-gaap_DerivativeNonmonetaryNotionalAmountVolume_label_en-US" xlink:label="lab_us-gaap_DerivativeNonmonetaryNotionalAmountVolume" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Nonmonetary Notional Amount, Volume</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNonmonetaryNotionalAmountVolume" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNonmonetaryNotionalAmountVolume"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNonmonetaryNotionalAmountVolume" xlink:to="lab_us-gaap_DerivativeNonmonetaryNotionalAmountVolume" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_d72aa130-4e3f-4651-8a31-6ed1a93275da_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_ad26ad00-3183-433f-8fac-b18188d85eb1_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToAffiliateCurrentAndNoncurrent_1579c4e3-cbab-4b19-a9ee-b96225d89a08_terseLabel_en-US" xlink:label="lab_us-gaap_DueToAffiliateCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount due and payable to affiliates</link:label>
    <link:label id="lab_us-gaap_DueToAffiliateCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DueToAffiliateCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Affiliate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToAffiliateCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToAffiliateCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToAffiliateCurrentAndNoncurrent" xlink:to="lab_us-gaap_DueToAffiliateCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_93592131-c02c-4ad4-875f-6a4a190afd65_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_ebef7695-5a75-4da5-aa0b-46790bfc344d_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_JPY_e4b28c12-6632-40b7-bbe3-bba04e120164_terseLabel_en-US" xlink:label="lab_currency_JPY" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan, Yen</link:label>
    <link:label id="lab_currency_JPY_label_en-US" xlink:label="lab_currency_JPY" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan, Yen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_JPY" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_JPY"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_JPY" xlink:to="lab_currency_JPY" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_8b2764d3-c98f-4a39-8546-4e95f2b9355c_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Interest Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:to="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForwardContractsMember_912e7e0e-e413-4e4b-9110-76a4f5726a7d_terseLabel_en-US" xlink:label="lab_us-gaap_ForwardContractsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Contracts</link:label>
    <link:label id="lab_us-gaap_ForwardContractsMember_label_en-US" xlink:label="lab_us-gaap_ForwardContractsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Contracts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForwardContractsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForwardContractsMember" xlink:to="lab_us-gaap_ForwardContractsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_86491cce-e8dc-445f-ab1a-30f1596082a6_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred compensation benefits</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Liability, Classified, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:to="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax_bc24fb2e-a056-45b1-9432-7b4989c798d8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow hedges, amount of (gain) loss reclassified from accumulated OCI into income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Reclassification for Discontinuance, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_07b30575-dc30-41dc-8dd6-a4aabc48bfaf_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value and net investment hedges, amount of gain (loss) recognized in OCI</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2949456e-14b7-40d6-acdd-032e0e967b2e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_e0aaedb0-c8f7-41d1-9d2e-632eea57f034_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_bf43005c-80b3-4ef2-8cb6-81408511131b_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_fd352e7e-fe1f-4a62-850c-2355d68887b5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract Type [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_eb361f80-8f87-4a04-b21d-82e62441f2cd_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedges</link:label>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_label_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentHedgingMember" xlink:to="lab_us-gaap_NetInvestmentHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_239f0c6e-3d76-42d7-8b21-0f013b8ef2b0_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_72c6a00b-2e4f-4b08-9b81-befff0845d6e_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_c876315e-d793-4245-a02b-e8ddf8bd2710_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_969afcc4-4ed2-4a9a-8bcb-e4ef76f34054_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_595226ce-a15c-4d2a-a792-a95f59fabd21_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_d0faf93b-1c52-451b-8b20-a307882ef440_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_adb082c8-9404-44aa-a384-d138f8c94d9d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_20048e03-4eae-45ed-b4b0-7af20ea0e2e6_verboseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_640ede08-7d5f-4545-95ba-8a9ba3a2a4ee_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Losses) gains on derivatives</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_800e7457-b5a0-4e94-8f67-8abacda8ff35_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (Losses) on Derivatives</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EMEAMember_54ceb69c-23c8-40c5-99d6-018f70c324b1_terseLabel_en-US" xlink:label="lab_us-gaap_EMEAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe, Middle East, Africa</link:label>
    <link:label id="lab_us-gaap_EMEAMember_label_en-US" xlink:label="lab_us-gaap_EMEAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EMEA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EMEAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EMEAMember" xlink:to="lab_us-gaap_EMEAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_0f6c7240-f66b-454b-b9d3-bc465221911b_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntersegmentEliminationMember_4f516c17-45be-4cfe-9aa0-8d50fe229d6f_terseLabel_en-US" xlink:label="lab_us-gaap_IntersegmentEliminationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intersegment sales elimination</link:label>
    <link:label id="lab_us-gaap_IntersegmentEliminationMember_label_en-US" xlink:label="lab_us-gaap_IntersegmentEliminationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intersegment Eliminations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntersegmentEliminationMember" xlink:to="lab_us-gaap_IntersegmentEliminationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfInvestmentHoldingsTable_17c35f3e-2e42-4af7-997c-f5a760554b98_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfInvestmentHoldingsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Investment Holdings [Table]</link:label>
    <link:label id="lab_us-gaap_SummaryOfInvestmentHoldingsTable_label_en-US" xlink:label="lab_us-gaap_SummaryOfInvestmentHoldingsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Investment Holdings [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfInvestmentHoldingsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfInvestmentHoldingsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsTable" xlink:to="lab_us-gaap_SummaryOfInvestmentHoldingsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_3d4f9239-daac-499d-a400-e33289418f8e_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_5815555e-b79e-4d7c-9504-913cc6e2811b_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_1e6776a4-66ca-473b-8c50-6ae5768b00cb_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_b26443e6-fbc3-4663-b2b0-a173fc070b5f_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_40243a94-b024-4ebe-9f7e-52cad9de7216_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a633309f-396f-410d-b247-b115d7a0d88d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_71c62a64-0977-43f5-ae45-015a959e82fa_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_e763c23a-0972-473f-9652-bf484b852067_terseLabel_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension benefits</link:label>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:to="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_0675f821-f345-4e04-ac43-02b63da38ed5_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_343eee44-5aef-4ba8-a43d-bf209230f89e_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_a32bd0db-5aec-42e7-ba49-4f7d78e35971_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_2414f91c-c9c8-45ef-a00b-7a3909aa385f_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, average price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_label_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Acquired, Average Cost Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:to="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_51b69cbc-55d5-4b8f-8e77-9a6772716889_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_bda25c7e-fafb-4766-8f8b-8bf29ece75ff_periodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_42d5e435-2739-4d31-9585-e344d21a2a33_periodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_00ed16ac-3c1f-4ea6-a1d2-667f2bd79f20_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_bacf864c-3725-4fb7-b76c-ae8c91ab8402_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income, noncurrent</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_wst_StandardPackagingMember_44b1c1a3-cd90-4f70-a526-a060eac8bfd1_terseLabel_en-US" xlink:label="lab_wst_StandardPackagingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard Packaging</link:label>
    <link:label id="lab_wst_StandardPackagingMember_label_en-US" xlink:label="lab_wst_StandardPackagingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard Packaging [Member]</link:label>
    <link:label id="lab_wst_StandardPackagingMember_documentation_en-US" xlink:label="lab_wst_StandardPackagingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard Packaging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wst_StandardPackagingMember" xlink:href="wst-20230331.xsd#wst_StandardPackagingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wst_StandardPackagingMember" xlink:to="lab_wst_StandardPackagingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_d635e8ce-e5a8-4e60-b264-62ed5483b45d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9d4025ab-6631-4824-93eb-22ce38707aec_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_19bccd01-2f18-4bea-af44-78949cdd9bdb_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_795147cd-896d-43a0-aafb-c6ab99c4eb07_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_wst_ContractWithCustomerAssetIncreaseDecrease_facf3a3a-e1bd-4739-a46e-69be3ffd2b09_terseLabel_en-US" xlink:label="lab_wst_ContractWithCustomerAssetIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in contract assets - increase (decrease)</link:label>
    <link:label id="lab_wst_ContractWithCustomerAssetIncreaseDecrease_label_en-US" xlink:label="lab_wst_ContractWithCustomerAssetIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Asset, Increase (Decrease)</link:label>
    <link:label id="lab_wst_ContractWithCustomerAssetIncreaseDecrease_documentation_en-US" xlink:label="lab_wst_ContractWithCustomerAssetIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Asset, Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wst_ContractWithCustomerAssetIncreaseDecrease" xlink:href="wst-20230331.xsd#wst_ContractWithCustomerAssetIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wst_ContractWithCustomerAssetIncreaseDecrease" xlink:to="lab_wst_ContractWithCustomerAssetIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_0fd96ab5-ee26-4a78-b67f-226e278f98d2_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_wst_RestructuringAndRelatedActivitiesPeriodOfImplementation_5f103bbd-9da1-42cc-8f1e-8a623471a7db_terseLabel_en-US" xlink:label="lab_wst_RestructuringAndRelatedActivitiesPeriodOfImplementation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and related activities, period of implementation</link:label>
    <link:label id="lab_wst_RestructuringAndRelatedActivitiesPeriodOfImplementation_label_en-US" xlink:label="lab_wst_RestructuringAndRelatedActivitiesPeriodOfImplementation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities, Period of Implementation</link:label>
    <link:label id="lab_wst_RestructuringAndRelatedActivitiesPeriodOfImplementation_documentation_en-US" xlink:label="lab_wst_RestructuringAndRelatedActivitiesPeriodOfImplementation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities, Period of Implementation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wst_RestructuringAndRelatedActivitiesPeriodOfImplementation" xlink:href="wst-20230331.xsd#wst_RestructuringAndRelatedActivitiesPeriodOfImplementation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wst_RestructuringAndRelatedActivitiesPeriodOfImplementation" xlink:to="lab_wst_RestructuringAndRelatedActivitiesPeriodOfImplementation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_76974dcd-a021-4c00-8602-862efa72a8f8_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_21ad67e0-134a-4434-9c99-b360f4ded3e1_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net sales</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_36121121-0b9d-4c46-8570-d5ac95c19b4b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_6ae1a9da-6cfd-482f-9c45-b53751c90790_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNet" xlink:to="lab_us-gaap_InvestmentIncomeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_d36ad63a-1bd8-4414-ba8e-8abe90b82a97_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_ed2eebfd-0167-4a70-b57c-b74b688393c0_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_42bcb7ae-a3db-441e-9d13-2ea7acce72c3_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_e3e31b72-5288-4abb-8fce-d3511181f996_negatedLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of acquisition-related intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_189159aa-5112-4e17-8287-63a3238134a0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8b739578-5063-40e1-bb7d-792d59a6500e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year three</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOnFutureEarningsAmount_c05ccada-5fe3-43f2-a6f3-1dfff014a6f3_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOnFutureEarningsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect on future earnings, amount</link:label>
    <link:label id="lab_us-gaap_EffectOnFutureEarningsAmount_label_en-US" xlink:label="lab_us-gaap_EffectOnFutureEarningsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect on Future Earnings, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOnFutureEarningsAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOnFutureEarningsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOnFutureEarningsAmount" xlink:to="lab_us-gaap_EffectOnFutureEarningsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_9b39ea16-d5f4-4a53-94c7-39a4ac8690b0_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate and Unallocated</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_a5ea9e40-7fbf-4e14-8342-5a4d7612fe1b_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit pension and other postretirement plans</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_60f9e4c0-c432-4f06-a67a-4d71d2e767d7_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Defined Benefit Pension And Other Postretirement Plans</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommodityOptionMember_aef1bd3a-302d-4dfc-b4f3-3bd0a22bf69d_terseLabel_en-US" xlink:label="lab_us-gaap_CommodityOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commodity call options</link:label>
    <link:label id="lab_us-gaap_CommodityOptionMember_label_en-US" xlink:label="lab_us-gaap_CommodityOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commodity Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommodityOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommodityOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommodityOptionMember" xlink:to="lab_us-gaap_CommodityOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_5732bf99-1f8b-4041-800d-21bb8d917cc5_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_32b9324e-4f08-4a8d-8322-c8e33e4c166d_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_d885cbed-b002-49e3-b145-ba97c51dbb6e_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_ef75e166-6491-4c19-890c-0e2efa5c2fec_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, end of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_wst_ContractManufacturedProductsMember_3658200b-308a-433e-a8eb-a7e1ef0756f4_terseLabel_en-US" xlink:label="lab_wst_ContractManufacturedProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract-Manufactured Products</link:label>
    <link:label id="lab_wst_ContractManufacturedProductsMember_ed343fca-14ac-4f44-83d2-83cb07183980_verboseLabel_en-US" xlink:label="lab_wst_ContractManufacturedProductsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract-Manufactured Products</link:label>
    <link:label id="lab_wst_ContractManufacturedProductsMember_label_en-US" xlink:label="lab_wst_ContractManufacturedProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Manufactured Products [Member]</link:label>
    <link:label id="lab_wst_ContractManufacturedProductsMember_documentation_en-US" xlink:label="lab_wst_ContractManufacturedProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Manufactured Products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wst_ContractManufacturedProductsMember" xlink:href="wst-20230331.xsd#wst_ContractManufacturedProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wst_ContractManufacturedProductsMember" xlink:to="lab_wst_ContractManufacturedProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_55dea691-7854-456c-8e0b-369f40360fc2_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_wst_ContractManufacturedCustomersMember_d3de36b7-b91c-4b06-bd34-4a592abd822f_terseLabel_en-US" xlink:label="lab_wst_ContractManufacturedCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract-Manufactured Products</link:label>
    <link:label id="lab_wst_ContractManufacturedCustomersMember_label_en-US" xlink:label="lab_wst_ContractManufacturedCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract-Manufactured Customers [Member]</link:label>
    <link:label id="lab_wst_ContractManufacturedCustomersMember_documentation_en-US" xlink:label="lab_wst_ContractManufacturedCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract-Manufactured Customers [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wst_ContractManufacturedCustomersMember" xlink:href="wst-20230331.xsd#wst_ContractManufacturedCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wst_ContractManufacturedCustomersMember" xlink:to="lab_wst_ContractManufacturedCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_e2f2a81d-413a-46f9-871e-adc569b25957_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_1241a03c-d403-4345-a997-26ce8330c901_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_bb5499b5-461e-44ae-bbba-f4b4874de0ec_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_wst_NotesPayableAndOtherDebtCurrent_d4450b4a-6680-495b-b4c4-0d0d71671505_terseLabel_en-US" xlink:label="lab_wst_NotesPayableAndOtherDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable and other current debt</link:label>
    <link:label id="lab_wst_NotesPayableAndOtherDebtCurrent_label_en-US" xlink:label="lab_wst_NotesPayableAndOtherDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable and Other Debt, Current</link:label>
    <link:label id="lab_wst_NotesPayableAndOtherDebtCurrent_documentation_en-US" xlink:label="lab_wst_NotesPayableAndOtherDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable and Other Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wst_NotesPayableAndOtherDebtCurrent" xlink:href="wst-20230331.xsd#wst_NotesPayableAndOtherDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wst_NotesPayableAndOtherDebtCurrent" xlink:to="lab_wst_NotesPayableAndOtherDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_f38fd8e7-cd9c-4378-9373-4c56d9f9bd55_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_7927c826-613e-4e96-abc7-0a147517f9a1_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_b2231701-d2a2-42ba-a12d-0988ad2754ab_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends declared</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStockCash" xlink:to="lab_us-gaap_DividendsCommonStockCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_e9feb411-d67c-441f-9d9f-f0be6fdfd617_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_1a75cd89-d584-41d7-8012-fa7a0708d2ad_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_3f357fb1-d8fe-4b5c-b2f9-36bf902a20aa_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_18460422-a663-4ff2-b9c4-e0f43bdd4116_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0c6a915c-400b-44c2-949c-5553547653c8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Activity related to stock-based compensation</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_6ab8f092-abe8-4470-b55a-ad65c26ea88a_terseLabel_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss) before reclassifications</link:label>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, before Reclassifications, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:to="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_920d2119-6cbe-4c31-ab51-573dada9c362_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_63f1b40e-4e92-4601-b490-ce19fe7edc3a_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Lease, Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_490fc9c9-f46f-45c7-99dd-7a800f2b88f4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares purchased under share repurchase program</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d5dc8c0c-89ea-4c99-843a-3e46b97e07e7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for issuance under the 2016 Plan (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_018ad60c-f67f-450b-bff2-d198e1c4140c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfOtherLongTermDebt_5afc2d6c-89d6-4a08-9aa1-61cf9c1254c9_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfOtherLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfOtherLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfOtherLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Other Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfOtherLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfOtherLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfOtherLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfOtherLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_8dc2f646-d9f3-4647-a6d7-1e8eefbfe633_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_28d2c943-15f0-4a43-9757-3903c3efd82d_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_7b1ea3fa-9f2a-49a8-8b85-ff0c2fcbd5a0_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on derivative instruments, net, pretax</link:label>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_label_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Derivative Instruments, Net, Pretax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:to="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_727a6900-64b9-4cf1-9f78-2273a4d5d089_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_0b48c3e1-72b9-41cb-be04-938b5121ab6e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_b0cf8164-4d82-481b-a441-77d2b0639ae7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_9bf3ce0c-9c52-4323-80e5-65ae57291242_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit pension and other postretirement plan adjustments, net of tax of $(0.2) and $0.3</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_736e6951-5187-4625-97fb-57df49693cc5_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_19491c83-af36-477d-8e41-623e66727151_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, shares purchased (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_21b9d3ff-d7be-4dc7-ad9d-c8be0f8585c3_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share purchased under share repurchase program (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_fad5dd36-f2a8-4189-abfe-7efeff04a26a_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_89857253-1d91-4fec-867b-9c8781869f44_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_ee7000ef-f79b-4d74-9216-e54afcb9ecf8_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_f2c09a6b-3c86-4e2a-a8d1-8ef5ff46b8c0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:to="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_675d3783-58fe-4e5e-87d1-2998c0f4a0b9_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_3f16c470-53d2-4513-8303-1ef81c4cae78_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_wst_OtherFinancialInstrumentsAbstract_d3754c79-28d6-44ad-82df-9e0df5478dd3_terseLabel_en-US" xlink:label="lab_wst_OtherFinancialInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Instruments [Abstract]</link:label>
    <link:label id="lab_wst_OtherFinancialInstrumentsAbstract_label_en-US" xlink:label="lab_wst_OtherFinancialInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Instruments [Abstract]</link:label>
    <link:label id="lab_wst_OtherFinancialInstrumentsAbstract_documentation_en-US" xlink:label="lab_wst_OtherFinancialInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Instruments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wst_OtherFinancialInstrumentsAbstract" xlink:href="wst-20230331.xsd#wst_OtherFinancialInstrumentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wst_OtherFinancialInstrumentsAbstract" xlink:to="lab_wst_OtherFinancialInstrumentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_4e153b1d-9782-4fff-94ae-99bb4a2d4067_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignPlanMember_6f827d97-0814-4d8a-99bd-d4549fc884e9_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International plans</link:label>
    <link:label id="lab_us-gaap_ForeignPlanMember_label_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignPlanMember" xlink:to="lab_us-gaap_ForeignPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_757dc439-7fc4-4c12-afe8-2e9ca653d07f_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_e3c89cb4-58ee-4a9e-9bee-5932c707f036_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairments</link:label>
    <link:label id="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_b88c73d3-b4c3-4fc4-a0e9-1851660e34bf_negatedNetLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairment for planned sale of plant</link:label>
    <link:label id="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Sale of Assets and Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:to="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_1eb46672-d63f-4525-b7bb-aca4d42879a5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest (income) expense, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_f52a4981-c198-4141-9dbf-4a00eb40f489_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_1a997dfb-2129-4623-8016-de3b22216712_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_89403f55-0b83-43a0-95bb-4b4b6a92ef8e_verboseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_acc9ddb4-d0d5-4204-bce2-41610e6573ab_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_e949d665-d1fe-4aa8-a38f-d0a172760832_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2390faec-e4d0-4c6f-ac0d-b3e639b280e7_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9f01ddbf-971c-48a5-bd47-747e4a5d9b0b_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_18b274fe-b4e0-4e95-9863-b135a98060f8_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_0622cae7-7c5b-4019-b5ca-7cc2c0fd8c83_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_0f178229-d3cb-4c07-b849-48018a241ce8_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_a4f674d0-ced1-4ad1-83d8-5c383c185858_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_d65dcd90-6454-4bab-8ab2-37d57df6ef01_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating profit</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_b53241e4-4f7a-47d7-8675-f3c0d36689d7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating profit</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_wst_ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock_3d11c22d-4b7e-4bc5-b53b-ed6fa1244303_terseLabel_en-US" xlink:label="lab_wst_ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Expense (Income)</link:label>
    <link:label id="lab_wst_ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock_label_en-US" xlink:label="lab_wst_ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Other Income And Expense, By Component [Table Text Block]</link:label>
    <link:label id="lab_wst_ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock_documentation_en-US" xlink:label="lab_wst_ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Income and Expense, by Component [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wst_ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock" xlink:href="wst-20230331.xsd#wst_ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wst_ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock" xlink:to="lab_wst_ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_ad87a7f6-0028-4453-89d7-e832351c49bd_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_d7da4d36-dee1-4fc3-bd48-3ebee4f5064d_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit facility, current borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Current Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_68f4a189-c2a0-48a0-b858-0019da5b9203_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount, investments not accounted for under the equity method</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PositionDomain_6dbd5a6b-52b2-4eb6-9971-fc64582a5ad4_terseLabel_en-US" xlink:label="lab_us-gaap_PositionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Position [Domain]</link:label>
    <link:label id="lab_us-gaap_PositionDomain_label_en-US" xlink:label="lab_us-gaap_PositionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Position [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PositionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PositionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PositionDomain" xlink:to="lab_us-gaap_PositionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_b300fec5-dd03-4057-b2e8-aee2e5be356e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_79912aa8-57ca-4c07-b5db-b1ce594cd7dd_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_4c695db3-8c2f-4d77-b35c-ac92786e57aa_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in affiliated companies</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_label_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_2f67cf5e-887b-4db8-b8dd-04793eefc06e_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_5cd202e9-a144-4656-9b5f-330ef5949b9b_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities at fair value</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9da26e58-7cc8-4d47-991d-53662f99f1cd_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_f871412f-0b42-4a30-8aa3-a7448eca2995_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_b69ae5e5-e23f-4a0b-8345-def8eaf7a302_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax (expense) benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_57f5ab21-3627-40a5-8a87-4a359e24c12a_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_7887be54-e49c-4891-acb8-ae269d9ef664_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_73761e06-8d6c-41b1-ab7d-6e426bcb4368_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year four</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_88aeedb5-139a-4fba-9799-12678fc6430b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ea4df421-3f07-41fd-8be3-79e802ff4eb4_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_41c0abdb-7916-4d53-9174-76d56b0ed169_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital in Excess of Par Value</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_4248f2da-61e1-4463-8000-cfd5e7c024d7_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_5ee138b2-f5b5-412d-bd0f-c93f92ed0289_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods and services sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_45da5be0-8155-4c8e-8c73-7d18c9294e16_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods and services sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_18e5f498-2fdd-424c-9fc1-a08df9503748_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent_77b662df-5447-4d51-b392-0843bb44fd1f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments, tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b654ee75-e551-47bc-bddb-369f5df0c86c_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2bca1273-26de-40a2-bb7c-5c7c061b4e15_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares assuming dilution (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0c17dd7e-0dbb-4674-a36f-2d7ba530557a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_da70ba59-d0ca-4a3f-a9b7-9d03604751af_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5e258b58-7829-4697-ae20-10a8b95e4da5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_b7df0415-c196-4ad8-a2c6-79de208a12a4_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_wst_HighValueProductComponentsMember_40cb39f4-f200-4927-b137-4a9fa555792b_terseLabel_en-US" xlink:label="lab_wst_HighValueProductComponentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">High-Value Product Components</link:label>
    <link:label id="lab_wst_HighValueProductComponentsMember_label_en-US" xlink:label="lab_wst_HighValueProductComponentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">High-Value Product Components [Member]</link:label>
    <link:label id="lab_wst_HighValueProductComponentsMember_documentation_en-US" xlink:label="lab_wst_HighValueProductComponentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">High-Value Product Components [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wst_HighValueProductComponentsMember" xlink:href="wst-20230331.xsd#wst_HighValueProductComponentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wst_HighValueProductComponentsMember" xlink:to="lab_wst_HighValueProductComponentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_f179a2ec-127f-4ea0-94a1-71be2243b540_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value $0.25 per share; 200.0 million shares authorized; shares issued: 75.3&#160;million in 2023 and 2022; shares outstanding: 74.2&#160;million and 74.1 million</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_wst_SalesToEquityMethodInvestees_fc5f21ae-ebf4-4865-971b-82e84f041814_terseLabel_en-US" xlink:label="lab_wst_SalesToEquityMethodInvestees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales to affiliates</link:label>
    <link:label id="lab_wst_SalesToEquityMethodInvestees_label_en-US" xlink:label="lab_wst_SalesToEquityMethodInvestees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales to Equity Method Investees</link:label>
    <link:label id="lab_wst_SalesToEquityMethodInvestees_documentation_en-US" xlink:label="lab_wst_SalesToEquityMethodInvestees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales to Equity Method Investees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wst_SalesToEquityMethodInvestees" xlink:href="wst-20230331.xsd#wst_SalesToEquityMethodInvestees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wst_SalesToEquityMethodInvestees" xlink:to="lab_wst_SalesToEquityMethodInvestees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_74f4bc22-68bc-4b47-897a-01fdfdea2eb6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other items</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d8f01e80-9b92-413c-99a9-caa1f213eb2b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AsiaPacificMember_20eaa3be-e7f3-46b4-8c45-20b2d92f0720_terseLabel_en-US" xlink:label="lab_srt_AsiaPacificMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia Pacific</link:label>
    <link:label id="lab_srt_AsiaPacificMember_label_en-US" xlink:label="lab_srt_AsiaPacificMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia Pacific [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AsiaPacificMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AsiaPacificMember" xlink:to="lab_srt_AsiaPacificMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_b8bde25a-d67d-4281-a343-961339d88f72_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assets and Liabilities Measured at Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_fea06b93-c79c-4f9e-8efd-bd3dabcba71f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_wst_TermLoanDue2024Member_62126a38-802b-4187-9515-4ba3cd2cf8ff_terseLabel_en-US" xlink:label="lab_wst_TermLoanDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan, due December 31, 2024 (5.87%)</link:label>
    <link:label id="lab_wst_TermLoanDue2024Member_e821d84e-9d45-4ec2-9227-8f3cfb680dc7_verboseLabel_en-US" xlink:label="lab_wst_TermLoanDue2024Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Due 2024</link:label>
    <link:label id="lab_wst_TermLoanDue2024Member_label_en-US" xlink:label="lab_wst_TermLoanDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Due 2024 [Member]</link:label>
    <link:label id="lab_wst_TermLoanDue2024Member_documentation_en-US" xlink:label="lab_wst_TermLoanDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wst_TermLoanDue2024Member" xlink:href="wst-20230331.xsd#wst_TermLoanDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wst_TermLoanDue2024Member" xlink:to="lab_wst_TermLoanDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_546b2038-ba7f-4987-b9b7-0ea70bd5e3c8_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term lease cost</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_5f6d91a3-60e2-4099-9f25-aaa8d1120315_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_45fd3150-1573-45b1-8b39-181f89365835_terseLabel_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk</link:label>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductConcentrationRiskMember" xlink:to="lab_us-gaap_ProductConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_66a8129c-7305-4096-b1a8-cb15c104cd5a_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, including cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1a6f5073-3ad7-4014-a78e-65bf629c3977_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, including cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_576df085-7ff8-4b7e-99d4-b6bc6e912324_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_f14d25bc-299c-45fa-a8ad-d15045f86bb4_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeForwardMember_f689ce2d-c2f9-4b33-bb06-82987a401d36_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeForwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Forward</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeForwardMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeForwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Forward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeForwardMember" xlink:to="lab_us-gaap_ForeignExchangeForwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_803b14f0-fe80-4cd0-8d6c-afeefee97e00_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_960c4b0e-d041-4c25-8863-00c09b55aac2_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount, equity-method investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_66e1a530-8d34-4e24-836c-4c986af8b9aa_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income, current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_7912609a-7597-497f-961b-642371e322da_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange transaction losses (gains)</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_7ba4e7c9-a2eb-4304-9b57-9864ada2b815_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_us-gaap_RetirementPlanTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_b4e2a24c-e837-4860-9b8d-a56a3253516b_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_90de6eec-6931-41c4-9bb1-084cc38e7e2d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_a936cf28-0ad3-41f8-8f98-25e3be242571_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedges</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d97b0727-f13b-499d-bab4-94d4dfa6fac7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_102d4e20-e978-4f56-a49a-9ff93b6c5c3b_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_d508ec25-b7c2-4b66-b60b-1cf34c4f3f5e_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueHedgingMember_1b0dd2d5-b427-4beb-93a9-f23d45d02073_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedges</link:label>
    <link:label id="lab_us-gaap_FairValueHedgingMember_label_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueHedgingMember" xlink:to="lab_us-gaap_FairValueHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_36e92d8e-7a83-4697-9c2d-8b057eeb49d1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_e1230cd6-2a42-40d7-a1b9-668e8ea90eb8_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_wst_PharmaCustomersMember_a91f28a7-8883-4369-84e9-8ef6ff081ae4_terseLabel_en-US" xlink:label="lab_wst_PharmaCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharma</link:label>
    <link:label id="lab_wst_PharmaCustomersMember_label_en-US" xlink:label="lab_wst_PharmaCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharma Customers [Member]</link:label>
    <link:label id="lab_wst_PharmaCustomersMember_documentation_en-US" xlink:label="lab_wst_PharmaCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharma Customers [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wst_PharmaCustomersMember" xlink:href="wst-20230331.xsd#wst_PharmaCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wst_PharmaCustomersMember" xlink:to="lab_wst_PharmaCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_40191a30-a623-48c0-89fe-5ac999c164cf_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock-based compensation awards</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_d3ee9b50-019c-4e5d-9577-66d1687a26bf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_6de009e9-9899-4977-8e29-91e44a0aa856_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_bc04871a-b3f1-49e4-bdb5-54dfe7e1abae_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_9e62df02-8b79-4fdc-b856-5a58917ba16d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent_977f92fb-3681-4290-9cc7-02fa6d372f32_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss on derivatives, tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax, Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_39fb0957-3203-4787-876f-2789797cd1bc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payments</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CrossCurrencyInterestRateContractMember_9e0f4191-6fc0-4501-a310-7ea9f1d8b0d7_terseLabel_en-US" xlink:label="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross Currency Interest Rate Contract</link:label>
    <link:label id="lab_us-gaap_CrossCurrencyInterestRateContractMember_label_en-US" xlink:label="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross Currency Interest Rate Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CrossCurrencyInterestRateContractMember" xlink:to="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_470c5e86-f692-4ebc-90c5-e1e26a53505a_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_98f9a580-065e-4838-8aaa-957023e73352_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_5dfd0422-bfe5-42d9-b9df-09e4290d854e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_c12d1fd8-1189-4850-a941-b8cbc5ab661a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_359e4c9c-59a5-4139-8e9e-77ca28f68bd3_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_42933c4b-fc1a-496e-b3d2-d2df27c161a6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_c0184b63-1622-40eb-a7f0-1c82d95a7ee4_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_wst_ContractWithCustomerAssetRollForward_6f0a569d-11bd-45b5-8d94-db7f9acb16f5_terseLabel_en-US" xlink:label="lab_wst_ContractWithCustomerAssetRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Asset [Roll Forward]</link:label>
    <link:label id="lab_wst_ContractWithCustomerAssetRollForward_label_en-US" xlink:label="lab_wst_ContractWithCustomerAssetRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Asset [Roll Forward]</link:label>
    <link:label id="lab_wst_ContractWithCustomerAssetRollForward_documentation_en-US" xlink:label="lab_wst_ContractWithCustomerAssetRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Asset [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wst_ContractWithCustomerAssetRollForward" xlink:href="wst-20230331.xsd#wst_ContractWithCustomerAssetRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wst_ContractWithCustomerAssetRollForward" xlink:to="lab_wst_ContractWithCustomerAssetRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_d0b17b57-026c-467a-bd48-09b5d1699dc1_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_535f87ac-19dd-4f00-871f-f4f4e553ea73_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rates on cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_3b26071a-41e6-4a05-857a-cb4c327f2122_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CurrencyAxis_67d461ac-96bb-4476-8b0c-d8eb9a481424_terseLabel_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency [Axis]</link:label>
    <link:label id="lab_srt_CurrencyAxis_label_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CurrencyAxis" xlink:to="lab_srt_CurrencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_ed243445-d571-4b21-ae86-42a461ec69cb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract_34ee8f97-b57c-4088-aa82-bdb8145e02a8_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_SGD_6080d87a-146d-4da4-a42d-b2dd23f06924_terseLabel_en-US" xlink:label="lab_currency_SGD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SGD</link:label>
    <link:label id="lab_currency_SGD_label_en-US" xlink:label="lab_currency_SGD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Singapore, Dollars</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_SGD" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_SGD"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_SGD" xlink:to="lab_currency_SGD" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticPlanMember_af40a665-1a15-43d5-805a-b3a1ced5b270_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Plan</link:label>
    <link:label id="lab_us-gaap_DomesticPlanMember_label_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticPlanMember" xlink:to="lab_us-gaap_DomesticPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_bf719fab-bf65-4959-9361-c91bb13bd17c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_ccd6e4a8-3a94-4156-b442-085d735bd77d_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Expense (Income)</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Other Expense Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:to="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_09dc05fd-684c-4dd4-97ce-7979f62e6d97_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_0391186b-446c-45ee-8a51-af4e5fd3c362_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_7050285c-124f-4105-9cb1-29936db091fe_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative instruments not designated as hedging instruments, gain (loss), net</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_0d0e4a8d-113c-4b84-81ec-0cbe3ba48ff7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss (gain) on oil hedges</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_7a495888-a332-4233-9386-055a1e59f5b6_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ae83df29-3b8e-4d55-85ad-cb1529dc2204_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_b9e9e439-ce48-4a45-af3c-24f9b65750a8_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_6d5b1a74-e9c8-44e0-8341-b71d763e3716_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Sales by Significant Product Group</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d8c7a3f7-790d-4685-a309-83dc24040a5f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_wst_NetSalesMember_869511ac-a239-40ed-ae1b-9a6772f420eb_terseLabel_en-US" xlink:label="lab_wst_NetSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net sales</link:label>
    <link:label id="lab_wst_NetSalesMember_label_en-US" xlink:label="lab_wst_NetSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Sales [Member]</link:label>
    <link:label id="lab_wst_NetSalesMember_documentation_en-US" xlink:label="lab_wst_NetSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wst_NetSalesMember" xlink:href="wst-20230331.xsd#wst_NetSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wst_NetSalesMember" xlink:to="lab_wst_NetSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortMember_52232300-53c4-4364-ac46-908ae8a3e9fe_terseLabel_en-US" xlink:label="lab_us-gaap_ShortMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short</link:label>
    <link:label id="lab_us-gaap_ShortMember_label_en-US" xlink:label="lab_us-gaap_ShortMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortMember" xlink:to="lab_us-gaap_ShortMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_a1279356-6bc7-42df-97ce-4ba9b025ceca_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivatives Not Designated as Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives Not Designated as Hedging Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0321ffde-b036-44af-ad18-fd028dfe9382_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_4b24663e-26dd-4411-8162-4768861b6a85_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_0f4c16ba-5f17-4cc9-b5fb-4590bad7cce4_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_4664471b-2c7a-4bf0-9701-8cadd45dce07_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_c84d53bf-69a7-4d97-b54b-9727d2fd30a7_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized that was included in the deferred income balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_38cd5e01-aa88-4b9f-b84e-258265ab06a1_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_af2bcc0f-55e1-48c6-a91a-6c41da2c97f6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss on derivatives, net of tax of $(0.1) and $(0.8)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_cccc69da-6813-4929-848b-c9b352dfd6e0_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_2bef1179-0cc4-4acd-b8ca-887538139d3a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends declared per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_94f25cc4-0c7d-4399-a1d0-55604ce8d5be_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Net Periodic Benefit Cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Benefit Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_15062b70-f898-478e-9335-e87b468ebdfc_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_a3624c5d-1107-4951-8638-cb05aeed8094_verboseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_wst_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_ec9a18ca-10d2-4c48-bdd3-875d6aca326f_terseLabel_en-US" xlink:label="lab_wst_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
    <link:label id="lab_wst_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_label_en-US" xlink:label="lab_wst_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid for Amounts Included in the Measurement of Lease Liabilities [Abstract]</link:label>
    <link:label id="lab_wst_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_documentation_en-US" xlink:label="lab_wst_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid for Amounts Included in the Measurement of Lease Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wst_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:href="wst-20230331.xsd#wst_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wst_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="lab_wst_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_wst_The2020RestructuringPlanMember_5c56cb18-1426-4ac8-9352-a8ecd7d30354_terseLabel_en-US" xlink:label="lab_wst_The2020RestructuringPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Restructuring Plan</link:label>
    <link:label id="lab_wst_The2020RestructuringPlanMember_label_en-US" xlink:label="lab_wst_The2020RestructuringPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The 2020 Restructuring Plan [Member]</link:label>
    <link:label id="lab_wst_The2020RestructuringPlanMember_documentation_en-US" xlink:label="lab_wst_The2020RestructuringPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The 2020 Restructuring Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wst_The2020RestructuringPlanMember" xlink:href="wst-20230331.xsd#wst_The2020RestructuringPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wst_The2020RestructuringPlanMember" xlink:to="lab_wst_The2020RestructuringPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongMember_4bd8064b-fd7b-48d0-8274-01cf327e3513_terseLabel_en-US" xlink:label="lab_us-gaap_LongMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long</link:label>
    <link:label id="lab_us-gaap_LongMember_label_en-US" xlink:label="lab_us-gaap_LongMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongMember" xlink:to="lab_us-gaap_LongMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_2c09f478-5cc7-4a71-8d33-b4149204ba62_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of each class</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_7549d0e7-b1bc-4573-9f27-16d230b81ad0_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent_bb4692be-677d-45b4-8b7b-77708d4dba78_terseLabel_en-US" xlink:label="lab_us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred compensation liabilities</link:label>
    <link:label id="lab_us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Deferred Compensation Arrangements, Liability, Classified, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent" xlink:to="lab_us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_wst_SmartDoseMember_6658cd31-cef4-4786-afd2-186d7db20234_terseLabel_en-US" xlink:label="lab_wst_SmartDoseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Smart Dose</link:label>
    <link:label id="lab_wst_SmartDoseMember_label_en-US" xlink:label="lab_wst_SmartDoseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Smart Dose [Member]</link:label>
    <link:label id="lab_wst_SmartDoseMember_documentation_en-US" xlink:label="lab_wst_SmartDoseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Smart Dose [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wst_SmartDoseMember" xlink:href="wst-20230331.xsd#wst_SmartDoseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wst_SmartDoseMember" xlink:to="lab_wst_SmartDoseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_64c0c97f-dbb3-4f31-911b-5684c9358a51_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options, granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_90d92f89-b41b-4a45-95f1-160e0d34b969_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_e16442fc-f195-4f08-a267-1d7fa93d491a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Activity related to stock -based compensation (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_6dd96eb0-4a5b-4063-bd38-014d88db113a_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_51e3482c-3e43-4a85-a8a4-db7a9e208bd7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_1a4cbde6-d82e-4266-851c-f9ee919082c7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_wst_AccruedSalariesWagesAndBenefitsCurrent_9feaa3c8-21be-459f-b0a9-c304d6b7c6b2_terseLabel_en-US" xlink:label="lab_wst_AccruedSalariesWagesAndBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued salaries, wages and benefits</link:label>
    <link:label id="lab_wst_AccruedSalariesWagesAndBenefitsCurrent_label_en-US" xlink:label="lab_wst_AccruedSalariesWagesAndBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Salaries, Wages, and Benefits, Current</link:label>
    <link:label id="lab_wst_AccruedSalariesWagesAndBenefitsCurrent_documentation_en-US" xlink:label="lab_wst_AccruedSalariesWagesAndBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Salaries, Wages, and Benefits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wst_AccruedSalariesWagesAndBenefitsCurrent" xlink:href="wst-20230331.xsd#wst_AccruedSalariesWagesAndBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wst_AccruedSalariesWagesAndBenefitsCurrent" xlink:to="lab_wst_AccruedSalariesWagesAndBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_8369920c-d4b7-4ebc-8736-79a85c35d449_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_wst_HighValueProductDeliveryDevicesMember_9415677e-4ef1-4c25-8668-60dad059a19c_terseLabel_en-US" xlink:label="lab_wst_HighValueProductDeliveryDevicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">High-Value Product Delivery Devices</link:label>
    <link:label id="lab_wst_HighValueProductDeliveryDevicesMember_label_en-US" xlink:label="lab_wst_HighValueProductDeliveryDevicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">High-Value Product Delivery Devices [Member]</link:label>
    <link:label id="lab_wst_HighValueProductDeliveryDevicesMember_documentation_en-US" xlink:label="lab_wst_HighValueProductDeliveryDevicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">High-Value Product Delivery Devices [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wst_HighValueProductDeliveryDevicesMember" xlink:href="wst-20230331.xsd#wst_HighValueProductDeliveryDevicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wst_HighValueProductDeliveryDevicesMember" xlink:to="lab_wst_HighValueProductDeliveryDevicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_22c5ec11-94b8-4685-a60f-f2aa593d35cb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit associated with stock-based compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_56b973b5-3ae7-4825-a25c-ba2a56184401_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_4e1b4b11-b895-4ad0-a042-63b119ae3cee_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments, net of tax of $0.2 and $1.0</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_57b7770c-a878-4d3c-aecb-a4b5010b9564_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options, weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b3f6f275-ecf1-4c2c-b73a-eb2517f4ab4b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_9f8e79cc-417e-43b2-8137-ccc2f84ab314_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_cb8e935e-14db-4f8f-a0c3-173023f2df66_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_60362019-45ea-44b0-8939-f0a4dcd759aa_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_ad015d5b-bb25-4d3b-a0b2-e43174684d26_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_aafc2b8a-1b0d-48e4-9548-6df480360477_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_bb698b40-e20e-4c67-8074-a7e8e0dd19ce_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_wst_OtherIncomeExpense_2fef8f38-9260-43ba-833a-dd15767f4ef9_negatedLabel_en-US" xlink:label="lab_wst_OtherIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense (income)</link:label>
    <link:label id="lab_wst_OtherIncomeExpense_29360673-72b7-424e-b72b-d6a0205dcb3e_negatedTotalLabel_en-US" xlink:label="lab_wst_OtherIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other expense (income)</link:label>
    <link:label id="lab_wst_OtherIncomeExpense_label_en-US" xlink:label="lab_wst_OtherIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income (Expense)</link:label>
    <link:label id="lab_wst_OtherIncomeExpense_documentation_en-US" xlink:label="lab_wst_OtherIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The total amount of other income and expense items that are associated with the entity's normal revenue producing operation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wst_OtherIncomeExpense" xlink:href="wst-20230331.xsd#wst_OtherIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wst_OtherIncomeExpense" xlink:to="lab_wst_OtherIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_c05f4e37-c735-4180-bb06-96022097f35e_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_69a0bd54-ab76-4936-b48b-fea1396697e5_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d39622b0-1de3-4998-bbfd-bd62aa664cd1_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommodityMember_472b66a6-ed2b-46f1-b1e2-98e77809adcc_terseLabel_en-US" xlink:label="lab_us-gaap_CommodityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commodity call options</link:label>
    <link:label id="lab_us-gaap_CommodityMember_label_en-US" xlink:label="lab_us-gaap_CommodityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commodity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommodityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommodityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommodityMember" xlink:to="lab_us-gaap_CommodityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_0e459193-6648-4c8c-b4f5-c827f0f788ea_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. plans</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_08e6637e-756f-49dc-8ae8-7b7da1a9d136_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_39d6aa70-aded-498a-841c-26160078ca8a_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_593fae0f-25ad-4f4f-b350-042f4c5f072f_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_3a473c99-f672-451d-985e-d71f4e447040_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_c43189a8-7f69-4ff4-b4ac-80896eb64098_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_65c151fa-d677-412c-a383-a70584d0f23f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, 3.0&#160;million shares authorized; 0 shares issued and outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_727474e1-a0e8-4006-9858-264897b7fa06_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Obligations, Net of Current Maturities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cf6b550f-d576-4300-8aaa-f910027f03ee_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_b8e870d2-5a32-411f-89c0-2d75078af445_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Service Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:to="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtCurrent_ecd1050a-d7b3-40c1-a5a5-ac62506692b9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, current</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_label_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent" xlink:to="lab_us-gaap_DebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_090919e8-44f1-45a3-9774-9c14a83f6783_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_05375e2f-d049-4243-aa2c-e8548bce8932_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_58838ce5-1ff8-4558-93aa-dba3c2efce5d_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income taxes and equity in net income of affiliated companies</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ad932ec7-816f-47e5-9214-6f3d50427419_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_e29e22d4-118c-40d9-bb20-95e37153815c_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_bd252369-8e8f-438c-8d85-fb2228ab4483_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_575ba827-768e-408a-a43a-e638896f1d2e_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4c00680f-0ca5-4404-8d5b-dd1fe864b7dd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_65726e31-3ba1-4092-b33f-b6399043df45_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchased for employee tax withholdings</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_f1e9bc39-9899-4048-bd65-b6e58a0e841e_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Liabilities and Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_8309c132-f9ab-4d98-8c43-7f047bf508f3_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Loss [Line Items]</link:label>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_label_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:to="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_5fc18571-7e5e-4bac-9593-c43e97ddc776_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative (gain) loss on hedged item, fair value hedges</link:label>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_label_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_f664bc97-5288-4a1c-b926-eb2a063c4034_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_74f922ed-3a7c-4f2f-a23b-8b7a33a4e409_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive effect of equity awards, based on the treasury stock method (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_47243b67-9f70-4d66-a3b3-401fcaf745fa_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_5cc2d784-d20f-4dd2-aa02-dd7353733bcd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_2fe605c2-478f-4a52-a383-5fce4e6f0cd4_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5907d361-892e-4bbe-9423-050fd3b96201_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed lease interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_4a9e10ba-12ca-474a-9ff4-fdc50433d63b_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_f2eff8e6-2361-451a-b3d6-d90e60bf9364_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_1e86d689-79d6-45ae-84d8-e5ab0591c4d8_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_98421f72-6a7a-4316-beb8-263b560bebcb_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_b2ef50d8-fa1b-42f1-b4cb-c266bc24e260_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_wst_SeniorBNotesDue2024Member_60830fbc-0ac8-49ce-a0cd-4dbb74a29dc4_terseLabel_en-US" xlink:label="lab_wst_SeniorBNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B notes, due July 5, 2024 (3.82%)</link:label>
    <link:label id="lab_wst_SeniorBNotesDue2024Member_label_en-US" xlink:label="lab_wst_SeniorBNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior B Notes Due 2024 [Member]</link:label>
    <link:label id="lab_wst_SeniorBNotesDue2024Member_documentation_en-US" xlink:label="lab_wst_SeniorBNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior B Notes Due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wst_SeniorBNotesDue2024Member" xlink:href="wst-20230331.xsd#wst_SeniorBNotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wst_SeniorBNotesDue2024Member" xlink:to="lab_wst_SeniorBNotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherRestructuringMember_55ddc461-c5b7-43da-bc73-7bb36c3d2006_terseLabel_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-related charges</link:label>
    <link:label id="lab_us-gaap_OtherRestructuringMember_label_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Restructuring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherRestructuringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherRestructuringMember" xlink:to="lab_us-gaap_OtherRestructuringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_072cfeea-3097-4c6d-a0da-d79c9e1ef6f7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year two</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_92d9cc66-f15d-4252-bc85-7870558f6cdd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_f4ee5d0d-4e6a-472c-adb3-6b4b0e309d66_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_150f4514-94c8-4fe1-9d33-6a42b74c41d6_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_6f048db0-79a8-4546-a583-92b3f5e25a4f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Foreign Currency Contracts</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AmericasMember_fc87a281-2b81-4b68-bf93-41c528fde67f_terseLabel_en-US" xlink:label="lab_srt_AmericasMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Americas</link:label>
    <link:label id="lab_srt_AmericasMember_label_en-US" xlink:label="lab_srt_AmericasMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Americas [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AmericasMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AmericasMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AmericasMember" xlink:to="lab_srt_AmericasMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_2b2c56e8-32ac-43b1-b13c-64558e845ac1_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_label_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentForAmortization" xlink:to="lab_us-gaap_AdjustmentForAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OptionMember_e0d67533-669c-43d5-8f4d-848a86ebf24b_terseLabel_en-US" xlink:label="lab_us-gaap_OptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Held</link:label>
    <link:label id="lab_us-gaap_OptionMember_label_en-US" xlink:label="lab_us-gaap_OptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Held [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionMember" xlink:to="lab_us-gaap_OptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f042d89d-d55c-4817-bdfe-8cddb59368c2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Lessee, Operating Lease, Liability, Maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_e28c86b8-0e02-4cf3-8dba-14791baa940d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_wst_ContractWithCustomerLiabilityRollForward_b39f3a5c-b1cc-4927-a783-a9f7f03d101c_terseLabel_en-US" xlink:label="lab_wst_ContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability [Roll Forward]</link:label>
    <link:label id="lab_wst_ContractWithCustomerLiabilityRollForward_label_en-US" xlink:label="lab_wst_ContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability [Roll Forward]</link:label>
    <link:label id="lab_wst_ContractWithCustomerLiabilityRollForward_documentation_en-US" xlink:label="lab_wst_ContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wst_ContractWithCustomerLiabilityRollForward" xlink:href="wst-20230331.xsd#wst_ContractWithCustomerLiabilityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wst_ContractWithCustomerLiabilityRollForward" xlink:to="lab_wst_ContractWithCustomerLiabilityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_a31d11c2-8397-4544-bba8-bb6c83d5280c_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income, December 31, 2022</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_f62fa089-2780-4f47-ab40-3ca464763ef4_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income, March&#160;31, 2023</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_42fc55bd-3e57-4d81-9fd0-bee7c01246b8_totalLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_1e2be31c-7abd-4b66-9c8a-98b63e30ac61_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_40cec389-2e13-41e3-99f1-995f7a4ea0b4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value and net investment hedges, amount of (gain) loss reclassified from accumulated OCI into income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_8c2a34dc-047a-43d2-b165-0ec3c7683af5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, forward point components, gain (loss), recognized in earnings</link:label>
    <link:label id="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_label_en-US" xlink:label="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Excluded Component, Gain (Loss), Recognized in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:to="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_0286c643-cb71-4baf-8574-092adb8df506_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected return on assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Return (Loss) on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAveragePriceRiskOptionStrikePrice_0cacb443-197d-41c4-9358-613f59c3793e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAveragePriceRiskOptionStrikePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, average price risk option strike price</link:label>
    <link:label id="lab_us-gaap_DerivativeAveragePriceRiskOptionStrikePrice_label_en-US" xlink:label="lab_us-gaap_DerivativeAveragePriceRiskOptionStrikePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Average Price Risk Option Strike Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAveragePriceRiskOptionStrikePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAveragePriceRiskOptionStrikePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAveragePriceRiskOptionStrikePrice" xlink:to="lab_us-gaap_DerivativeAveragePriceRiskOptionStrikePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_af9e02e1-0b3a-4ac8-9252-96d9f2de9ad7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_wst_ProprietaryProductsMember_b53ca1e2-aaec-424a-ae4b-ff101a371d7a_terseLabel_en-US" xlink:label="lab_wst_ProprietaryProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proprietary Products</link:label>
    <link:label id="lab_wst_ProprietaryProductsMember_label_en-US" xlink:label="lab_wst_ProprietaryProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proprietary Products [Member]</link:label>
    <link:label id="lab_wst_ProprietaryProductsMember_documentation_en-US" xlink:label="lab_wst_ProprietaryProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proprietary Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wst_ProprietaryProductsMember" xlink:href="wst-20230331.xsd#wst_ProprietaryProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wst_ProprietaryProductsMember" xlink:to="lab_wst_ProprietaryProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_11605b38-fdad-4b11-9394-daf99400b5c7_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit facility, unused commitment level</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_4508cf61-cf2b-46fa-ba61-054bcedd9eec_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_d916cc05-52be-4098-a385-b0291a5626e7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2ece72ff-6ca7-4e7f-9c1f-d87e35e8b464_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_64ed4482-c91e-4aeb-a4ee-b4df58341f60_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_e2bc762b-cc3f-4e91-8442-4568ab2ec332_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_us-gaap_RetirementPlanTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_2fd42f7e-3828-4e73-893e-db55bed0687f_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_USD_b89fad2a-5cd4-4b20-b474-d41f782fc69b_terseLabel_en-US" xlink:label="lab_currency_USD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EUR</link:label>
    <link:label id="lab_currency_USD_label_en-US" xlink:label="lab_currency_USD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States of America, Dollars</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_USD" xlink:to="lab_currency_USD" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_ee6724b1-c521-446c-830b-6f90dbbc3371_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_e03bb95f-5ce2-4042-a1ff-85519df2a78d_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_d9511681-edaa-445e-b582-ff7b4c65e9d4_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_3f28ab23-9541-41d0-85e3-5004ac3b928d_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_e2d04c24-2018-45af-b7d5-215b6cbce1f7_terseLabel_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: unamortized debt issuance costs for Term Loan and Series Notes</link:label>
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_label_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized Debt Issuance Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnamortizedDebtIssuanceExpense" xlink:to="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_dff0991d-b77d-42a8-a2d3-db10b4ff17ba_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Contract, Asset, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:to="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_d7ccc0c7-9177-442e-87f1-efac084da173_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_fd181da0-455c-4006-8f60-2b3bb9a7294c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrencySwapMember_74303603-e6b0-4129-bd71-b4ce29cd6f08_terseLabel_en-US" xlink:label="lab_us-gaap_CurrencySwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross-currency swap</link:label>
    <link:label id="lab_us-gaap_CurrencySwapMember_label_en-US" xlink:label="lab_us-gaap_CurrencySwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrencySwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrencySwapMember" xlink:to="lab_us-gaap_CurrencySwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7b27719c-37f3-497f-a024-77f1d2d9e589_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_d29eef04-406e-46ec-b2de-c20c88785c2d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_6e71efe8-3cdb-44b7-a3e6-73e3889f488d_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_wst_PurchasesAndRoyaltyPaymentsFromEquityMethodInvestees_bce66d33-c594-4bc2-b154-f4ad7f6ea087_terseLabel_en-US" xlink:label="lab_wst_PurchasesAndRoyaltyPaymentsFromEquityMethodInvestees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases and royalty payments made to affiliates</link:label>
    <link:label id="lab_wst_PurchasesAndRoyaltyPaymentsFromEquityMethodInvestees_label_en-US" xlink:label="lab_wst_PurchasesAndRoyaltyPaymentsFromEquityMethodInvestees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases and Royalty Payments from Equity Method Investees</link:label>
    <link:label id="lab_wst_PurchasesAndRoyaltyPaymentsFromEquityMethodInvestees_documentation_en-US" xlink:label="lab_wst_PurchasesAndRoyaltyPaymentsFromEquityMethodInvestees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases and Royalty Payments from Equity Method Investees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wst_PurchasesAndRoyaltyPaymentsFromEquityMethodInvestees" xlink:href="wst-20230331.xsd#wst_PurchasesAndRoyaltyPaymentsFromEquityMethodInvestees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wst_PurchasesAndRoyaltyPaymentsFromEquityMethodInvestees" xlink:to="lab_wst_PurchasesAndRoyaltyPaymentsFromEquityMethodInvestees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_45cd0c3d-a1ee-4516-a85a-c0159ace9482_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_8681c0b5-e586-4226-b6ff-6f8993841e21_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_9de8ac7f-8573-4908-be2b-da48c0cf6879_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate general costs</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_e60c6932-2a02-4c8c-a6db-08c129446b8d_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_d3c19115-65f2-4032-9a49-53880b43d545_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_6972bacb-f023-45c6-9547-3d78aff42ce4_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a53301f9-92af-4c2e-9d43-41e0e4fa1031_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_3306030e-cf52-4de6-b904-594193bc0068_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_4bb55b81-505a-41aa-825a-29e7c524c7c2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_aaaafae6-2ea2-4a68-a79e-3a90ab3c9d98_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options, weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_wst_BiologicsCustomersMember_1c54291e-12e1-4921-b1e9-614214b64a05_terseLabel_en-US" xlink:label="lab_wst_BiologicsCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biologics</link:label>
    <link:label id="lab_wst_BiologicsCustomersMember_label_en-US" xlink:label="lab_wst_BiologicsCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biologics Customers [Member]</link:label>
    <link:label id="lab_wst_BiologicsCustomersMember_documentation_en-US" xlink:label="lab_wst_BiologicsCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biologics Customers [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wst_BiologicsCustomersMember" xlink:href="wst-20230331.xsd#wst_BiologicsCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wst_BiologicsCustomersMember" xlink:to="lab_wst_BiologicsCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_c39edfab-88a3-4078-8932-0470c574e128_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_8f488624-0eef-4fa5-bc11-c445ec516774_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Companies</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_9ca63770-875b-4a6e-adc2-92e836dd2b4e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in net income of affiliated companies</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_7c01df76-0714-43f5-bc3f-d84fa93721fc_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairments</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2688e047-3cd7-4d3b-acb7-45417ab456ad_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_wst_OtherExpenseIncomeMember_d1586d14-6b65-47be-bb84-37f45e76421c_terseLabel_en-US" xlink:label="lab_wst_OtherExpenseIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense (income)</link:label>
    <link:label id="lab_wst_OtherExpenseIncomeMember_label_en-US" xlink:label="lab_wst_OtherExpenseIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Expense (Income) [Member]</link:label>
    <link:label id="lab_wst_OtherExpenseIncomeMember_documentation_en-US" xlink:label="lab_wst_OtherExpenseIncomeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Expense (Income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wst_OtherExpenseIncomeMember" xlink:href="wst-20230331.xsd#wst_OtherExpenseIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wst_OtherExpenseIncomeMember" xlink:to="lab_wst_OtherExpenseIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryLockMember_ffebdaa6-3e03-40c6-91e6-a150ebdca365_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryLockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward treasury locks</link:label>
    <link:label id="lab_us-gaap_TreasuryLockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryLockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Lock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryLockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryLockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryLockMember" xlink:to="lab_us-gaap_TreasuryLockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_85835e20-d46c-4326-8765-3509620bf315_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative contract term</link:label>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_label_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTermOfContract" xlink:to="lab_us-gaap_DerivativeTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_73b80b43-dcfd-4a81-882e-73f8cc51fce3_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_19097862-c9b7-40ae-8ed2-b94ff4f92194_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Basic to Diluted Net Income Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromOtherEquity_a060048a-061c-4f51-86f1-28011b2d1034_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromOtherEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan contributions</link:label>
    <link:label id="lab_us-gaap_ProceedsFromOtherEquity_label_en-US" xlink:label="lab_us-gaap_ProceedsFromOtherEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Other Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromOtherEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromOtherEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromOtherEquity" xlink:to="lab_us-gaap_ProceedsFromOtherEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_75e46e45-dc0d-45c0-b29b-4c247c1c0f7d_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for new operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_1dca805c-1dbb-4c93-bfa3-bc152ea93d2a_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods and services sold</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_wst_LesseeLeaseCashFlowAndSupplementalInformationTableTextBlock_ba74965c-ce75-48b7-9e60-0a69c1df4ba3_terseLabel_en-US" xlink:label="lab_wst_LesseeLeaseCashFlowAndSupplementalInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow and Supplemental Information</link:label>
    <link:label id="lab_wst_LesseeLeaseCashFlowAndSupplementalInformationTableTextBlock_label_en-US" xlink:label="lab_wst_LesseeLeaseCashFlowAndSupplementalInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease Cash Flow And Supplemental Information [Table Text Block]</link:label>
    <link:label id="lab_wst_LesseeLeaseCashFlowAndSupplementalInformationTableTextBlock_documentation_en-US" xlink:label="lab_wst_LesseeLeaseCashFlowAndSupplementalInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease Cash Flow And Supplemental Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wst_LesseeLeaseCashFlowAndSupplementalInformationTableTextBlock" xlink:href="wst-20230331.xsd#wst_LesseeLeaseCashFlowAndSupplementalInformationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wst_LesseeLeaseCashFlowAndSupplementalInformationTableTextBlock" xlink:to="lab_wst_LesseeLeaseCashFlowAndSupplementalInformationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_8ced0aa4-7841-4a19-8355-8f2a7425d381_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other retirement benefits</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefits Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:to="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_47b4529a-a99e-401d-b7fb-ce91bfad29a7_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>wst-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:a34422fb-98f0-4bfc-83b0-7c0b1b7c96bb,g:fe42bdb5-3507-4fad-98a2-d4b1f779591c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.westpharma.com/role/Cover" xlink:type="simple" xlink:href="wst-20230331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_1c690c3b-cc22-4fb8-9193-4b7f501577ae" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_de47ccde-eaf5-44c0-bbcf-b46e5d406a9b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c690c3b-cc22-4fb8-9193-4b7f501577ae" xlink:to="loc_dei_DocumentType_de47ccde-eaf5-44c0-bbcf-b46e5d406a9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_86d39470-b055-433b-8ae7-e50c82b56b20" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c690c3b-cc22-4fb8-9193-4b7f501577ae" xlink:to="loc_dei_DocumentQuarterlyReport_86d39470-b055-433b-8ae7-e50c82b56b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_c9d2f757-5113-424a-bf87-fdca4c4d89c7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c690c3b-cc22-4fb8-9193-4b7f501577ae" xlink:to="loc_dei_DocumentPeriodEndDate_c9d2f757-5113-424a-bf87-fdca4c4d89c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_14d917c4-06dd-4661-9b79-be5f1f461357" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c690c3b-cc22-4fb8-9193-4b7f501577ae" xlink:to="loc_dei_DocumentTransitionReport_14d917c4-06dd-4661-9b79-be5f1f461357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_d2e65009-8d5e-4c0b-adaf-57c986d4ecc6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c690c3b-cc22-4fb8-9193-4b7f501577ae" xlink:to="loc_dei_EntityFileNumber_d2e65009-8d5e-4c0b-adaf-57c986d4ecc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_8d7b5984-d19c-4de7-8777-14f8b6020a9c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c690c3b-cc22-4fb8-9193-4b7f501577ae" xlink:to="loc_dei_EntityRegistrantName_8d7b5984-d19c-4de7-8777-14f8b6020a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_0d5f5f65-6d0f-498b-9129-fe74de6810a2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c690c3b-cc22-4fb8-9193-4b7f501577ae" xlink:to="loc_dei_EntityIncorporationStateCountryCode_0d5f5f65-6d0f-498b-9129-fe74de6810a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_0dcb7537-756c-4a63-9b87-e5e2251cf9ae" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c690c3b-cc22-4fb8-9193-4b7f501577ae" xlink:to="loc_dei_EntityTaxIdentificationNumber_0dcb7537-756c-4a63-9b87-e5e2251cf9ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_d908a04b-3e27-4d75-aa21-c12eb529a56a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c690c3b-cc22-4fb8-9193-4b7f501577ae" xlink:to="loc_dei_EntityAddressAddressLine1_d908a04b-3e27-4d75-aa21-c12eb529a56a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_dc368e8a-4c85-453e-8f48-8c1e28831433" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c690c3b-cc22-4fb8-9193-4b7f501577ae" xlink:to="loc_dei_EntityAddressCityOrTown_dc368e8a-4c85-453e-8f48-8c1e28831433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_34742146-3484-4f87-a5d5-1f102fc7b772" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c690c3b-cc22-4fb8-9193-4b7f501577ae" xlink:to="loc_dei_EntityAddressStateOrProvince_34742146-3484-4f87-a5d5-1f102fc7b772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_c0124ebd-42e6-456b-8c0d-d8f1a9354d19" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c690c3b-cc22-4fb8-9193-4b7f501577ae" xlink:to="loc_dei_EntityAddressPostalZipCode_c0124ebd-42e6-456b-8c0d-d8f1a9354d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_c47859c4-2d0b-40bd-9e21-b113de00f5c2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c690c3b-cc22-4fb8-9193-4b7f501577ae" xlink:to="loc_dei_CityAreaCode_c47859c4-2d0b-40bd-9e21-b113de00f5c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_2ddeafaa-278b-438a-816f-6260c458c8bc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c690c3b-cc22-4fb8-9193-4b7f501577ae" xlink:to="loc_dei_LocalPhoneNumber_2ddeafaa-278b-438a-816f-6260c458c8bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_f2bc3ddd-5e62-4089-9b4a-1948136efd44" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c690c3b-cc22-4fb8-9193-4b7f501577ae" xlink:to="loc_dei_Security12bTitle_f2bc3ddd-5e62-4089-9b4a-1948136efd44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_1f0d12c1-fc18-4b45-8181-b5f41479eeb0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c690c3b-cc22-4fb8-9193-4b7f501577ae" xlink:to="loc_dei_TradingSymbol_1f0d12c1-fc18-4b45-8181-b5f41479eeb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_58886bd3-8728-49b2-8281-151955ab3c2e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c690c3b-cc22-4fb8-9193-4b7f501577ae" xlink:to="loc_dei_SecurityExchangeName_58886bd3-8728-49b2-8281-151955ab3c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_24c00ceb-8fd0-43ec-a182-c99b46fceedf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c690c3b-cc22-4fb8-9193-4b7f501577ae" xlink:to="loc_dei_EntityCurrentReportingStatus_24c00ceb-8fd0-43ec-a182-c99b46fceedf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_c7cd7c79-7914-4444-b3e2-94558c40ade1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c690c3b-cc22-4fb8-9193-4b7f501577ae" xlink:to="loc_dei_EntityInteractiveDataCurrent_c7cd7c79-7914-4444-b3e2-94558c40ade1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_9c17eb84-430b-4216-9c02-c16e5bcc5d3c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c690c3b-cc22-4fb8-9193-4b7f501577ae" xlink:to="loc_dei_EntityFilerCategory_9c17eb84-430b-4216-9c02-c16e5bcc5d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_55c69b8c-1928-4d00-9e93-f9bdd5c390dd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c690c3b-cc22-4fb8-9193-4b7f501577ae" xlink:to="loc_dei_EntitySmallBusiness_55c69b8c-1928-4d00-9e93-f9bdd5c390dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_def4a786-d5e4-410c-ab86-f916bc93219d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c690c3b-cc22-4fb8-9193-4b7f501577ae" xlink:to="loc_dei_EntityEmergingGrowthCompany_def4a786-d5e4-410c-ab86-f916bc93219d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_0498b9fd-96e0-4a74-b366-47fe05553816" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c690c3b-cc22-4fb8-9193-4b7f501577ae" xlink:to="loc_dei_EntityShellCompany_0498b9fd-96e0-4a74-b366-47fe05553816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_c614a38a-7d2a-46a8-bc18-d813d5a2907f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c690c3b-cc22-4fb8-9193-4b7f501577ae" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_c614a38a-7d2a-46a8-bc18-d813d5a2907f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_b9a35e69-0e01-4e1b-a47b-733f1596b41d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c690c3b-cc22-4fb8-9193-4b7f501577ae" xlink:to="loc_dei_EntityCentralIndexKey_b9a35e69-0e01-4e1b-a47b-733f1596b41d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_a8c2d7b4-177b-4bee-a09a-dd3ef21c4c6a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c690c3b-cc22-4fb8-9193-4b7f501577ae" xlink:to="loc_dei_CurrentFiscalYearEndDate_a8c2d7b4-177b-4bee-a09a-dd3ef21c4c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_c6f99b4e-254d-47d9-80af-e65188472cbc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c690c3b-cc22-4fb8-9193-4b7f501577ae" xlink:to="loc_dei_DocumentFiscalYearFocus_c6f99b4e-254d-47d9-80af-e65188472cbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_65819e07-9401-45ee-912a-91a4e966a390" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c690c3b-cc22-4fb8-9193-4b7f501577ae" xlink:to="loc_dei_DocumentFiscalPeriodFocus_65819e07-9401-45ee-912a-91a4e966a390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_c99f71ff-2a0d-401d-9882-b2d844aadf30" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c690c3b-cc22-4fb8-9193-4b7f501577ae" xlink:to="loc_dei_AmendmentFlag_c99f71ff-2a0d-401d-9882-b2d844aadf30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" xlink:type="simple" xlink:href="wst-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_c7115b88-7bd6-4a53-87cd-9b50769ae589" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_458ee0ba-400e-4e1d-bc58-8fd04d9fa6ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c7115b88-7bd6-4a53-87cd-9b50769ae589" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_458ee0ba-400e-4e1d-bc58-8fd04d9fa6ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_55f44ff2-be7a-416d-a212-1d96adc8255f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c7115b88-7bd6-4a53-87cd-9b50769ae589" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_55f44ff2-be7a-416d-a212-1d96adc8255f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_7cec4ea7-a4ec-4d2e-b489-70c98ef30e97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c7115b88-7bd6-4a53-87cd-9b50769ae589" xlink:to="loc_us-gaap_GrossProfit_7cec4ea7-a4ec-4d2e-b489-70c98ef30e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9b94d83a-f672-40f3-a8bf-fbcfa5f093de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c7115b88-7bd6-4a53-87cd-9b50769ae589" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_9b94d83a-f672-40f3-a8bf-fbcfa5f093de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d73ff15f-444c-4103-9a9d-98303cd42605" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c7115b88-7bd6-4a53-87cd-9b50769ae589" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d73ff15f-444c-4103-9a9d-98303cd42605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_OtherIncomeExpense_c1494ea4-5778-4e03-8fba-fd8dcc9580b2" xlink:href="wst-20230331.xsd#wst_OtherIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c7115b88-7bd6-4a53-87cd-9b50769ae589" xlink:to="loc_wst_OtherIncomeExpense_c1494ea4-5778-4e03-8fba-fd8dcc9580b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_eb9d7241-5445-4ccd-a4e5-93c58a4ed3c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c7115b88-7bd6-4a53-87cd-9b50769ae589" xlink:to="loc_us-gaap_OperatingIncomeLoss_eb9d7241-5445-4ccd-a4e5-93c58a4ed3c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_b8efe099-58f0-468f-93db-0771aebf1f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c7115b88-7bd6-4a53-87cd-9b50769ae589" xlink:to="loc_us-gaap_InterestExpense_b8efe099-58f0-468f-93db-0771aebf1f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_715fcfd0-e3c4-41e6-bdf0-2c967af6dd4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c7115b88-7bd6-4a53-87cd-9b50769ae589" xlink:to="loc_us-gaap_InvestmentIncomeNet_715fcfd0-e3c4-41e6-bdf0-2c967af6dd4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_eaecef86-d65b-4437-b7f6-07c1ef077c24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c7115b88-7bd6-4a53-87cd-9b50769ae589" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_eaecef86-d65b-4437-b7f6-07c1ef077c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_7a000525-9f69-4a37-804e-7a06e7e28183" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c7115b88-7bd6-4a53-87cd-9b50769ae589" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_7a000525-9f69-4a37-804e-7a06e7e28183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d3426107-00b0-4cdf-be01-295424c01c95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c7115b88-7bd6-4a53-87cd-9b50769ae589" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d3426107-00b0-4cdf-be01-295424c01c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_69dc8e89-aed9-47c7-a13a-bcfd2cccffe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c7115b88-7bd6-4a53-87cd-9b50769ae589" xlink:to="loc_us-gaap_NetIncomeLoss_69dc8e89-aed9-47c7-a13a-bcfd2cccffe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_fd2e177a-0275-408e-a52c-a9d7134fcbb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c7115b88-7bd6-4a53-87cd-9b50769ae589" xlink:to="loc_us-gaap_EarningsPerShareAbstract_fd2e177a-0275-408e-a52c-a9d7134fcbb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_f55cb8d3-b3b8-4339-9f24-b0b475d8707e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fd2e177a-0275-408e-a52c-a9d7134fcbb5" xlink:to="loc_us-gaap_EarningsPerShareBasic_f55cb8d3-b3b8-4339-9f24-b0b475d8707e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_aae36f35-4f8b-408f-8eee-11cdd8d38c19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fd2e177a-0275-408e-a52c-a9d7134fcbb5" xlink:to="loc_us-gaap_EarningsPerShareDiluted_aae36f35-4f8b-408f-8eee-11cdd8d38c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_94462e69-ed48-4557-b14f-56b08813b6d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c7115b88-7bd6-4a53-87cd-9b50769ae589" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_94462e69-ed48-4557-b14f-56b08813b6d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_df8b99e0-2eb8-440f-8275-a4e5b778256e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_94462e69-ed48-4557-b14f-56b08813b6d6" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_df8b99e0-2eb8-440f-8275-a4e5b778256e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_796f6df6-ee3b-44c4-b60b-8cf0dcd9b2bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_94462e69-ed48-4557-b14f-56b08813b6d6" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_796f6df6-ee3b-44c4-b60b-8cf0dcd9b2bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED" xlink:type="simple" xlink:href="wst-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0ea14bde-5432-4298-958a-8c60bb35cef0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4368a418-fb5d-4450-99cf-61aaa2eb030f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0ea14bde-5432-4298-958a-8c60bb35cef0" xlink:to="loc_us-gaap_NetIncomeLoss_4368a418-fb5d-4450-99cf-61aaa2eb030f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_12656cc2-cb0b-4454-9ec5-05e5ab67df04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0ea14bde-5432-4298-958a-8c60bb35cef0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_12656cc2-cb0b-4454-9ec5-05e5ab67df04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_7f72be4b-59de-483e-be2a-e6e382690317" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_12656cc2-cb0b-4454-9ec5-05e5ab67df04" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_7f72be4b-59de-483e-be2a-e6e382690317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_c8628a99-5a21-4ab9-bf8a-058b64c051fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_12656cc2-cb0b-4454-9ec5-05e5ab67df04" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_c8628a99-5a21-4ab9-bf8a-058b64c051fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_d5e6c42f-7e9f-48d3-bea1-69506348ea12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_12656cc2-cb0b-4454-9ec5-05e5ab67df04" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_d5e6c42f-7e9f-48d3-bea1-69506348ea12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_89e54501-6609-4da7-bedf-544aaf881521" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_12656cc2-cb0b-4454-9ec5-05e5ab67df04" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_89e54501-6609-4da7-bedf-544aaf881521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5be76935-cbc8-4727-904d-44a2a2f65cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0ea14bde-5432-4298-958a-8c60bb35cef0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_5be76935-cbc8-4727-904d-44a2a2f65cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITEDParenthetical" xlink:type="simple" xlink:href="wst-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITEDParenthetical"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITEDParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_de8b872e-4d44-4644-9d2f-6cfb767c43bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent_8a899727-e9f2-45e0-8f8f-87ae2cb4aea7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_de8b872e-4d44-4644-9d2f-6cfb767c43bf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent_8a899727-e9f2-45e0-8f8f-87ae2cb4aea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent_27bd6d98-dbff-443c-8b78-2ade4c9c001d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_de8b872e-4d44-4644-9d2f-6cfb767c43bf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent_27bd6d98-dbff-443c-8b78-2ade4c9c001d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent_941253a5-2082-4930-8516-a2be616868b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_de8b872e-4d44-4644-9d2f-6cfb767c43bf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent_941253a5-2082-4930-8516-a2be616868b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" xlink:type="simple" xlink:href="wst-20230331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_ede8d857-f6b9-4d07-9099-d8cb5efd2c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_978c44df-3a78-42d5-b68c-8245bd06ee52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ede8d857-f6b9-4d07-9099-d8cb5efd2c3a" xlink:to="loc_us-gaap_AssetsAbstract_978c44df-3a78-42d5-b68c-8245bd06ee52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_67e2564a-0ee2-4074-b89e-cdc4fb3fb05a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_978c44df-3a78-42d5-b68c-8245bd06ee52" xlink:to="loc_us-gaap_AssetsCurrentAbstract_67e2564a-0ee2-4074-b89e-cdc4fb3fb05a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1d285293-4e7a-4ebd-8f71-b70c9d4f21ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_67e2564a-0ee2-4074-b89e-cdc4fb3fb05a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1d285293-4e7a-4ebd-8f71-b70c9d4f21ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_e0ec081b-106e-4e8e-bac9-23bd67f8baaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_67e2564a-0ee2-4074-b89e-cdc4fb3fb05a" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_e0ec081b-106e-4e8e-bac9-23bd67f8baaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_488b5ce0-611a-4512-8051-d89bc7a06d25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_67e2564a-0ee2-4074-b89e-cdc4fb3fb05a" xlink:to="loc_us-gaap_InventoryNet_488b5ce0-611a-4512-8051-d89bc7a06d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_06d1affc-3416-4913-b247-a7011d09c210" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_67e2564a-0ee2-4074-b89e-cdc4fb3fb05a" xlink:to="loc_us-gaap_OtherAssetsCurrent_06d1affc-3416-4913-b247-a7011d09c210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7e8df287-99dc-4383-a19f-c7c90c384d23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_67e2564a-0ee2-4074-b89e-cdc4fb3fb05a" xlink:to="loc_us-gaap_AssetsCurrent_7e8df287-99dc-4383-a19f-c7c90c384d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_4a1bf9f0-816f-4f8d-8d43-def77114a0f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_978c44df-3a78-42d5-b68c-8245bd06ee52" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_4a1bf9f0-816f-4f8d-8d43-def77114a0f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3556d4ea-84e1-4fdb-8fed-6e8385057c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_978c44df-3a78-42d5-b68c-8245bd06ee52" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3556d4ea-84e1-4fdb-8fed-6e8385057c2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_346c5466-f67d-40e5-9306-c7bc0439b6e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_978c44df-3a78-42d5-b68c-8245bd06ee52" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_346c5466-f67d-40e5-9306-c7bc0439b6e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_187e95e1-a28d-4b78-b70f-856ab7b5ce7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_978c44df-3a78-42d5-b68c-8245bd06ee52" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_187e95e1-a28d-4b78-b70f-856ab7b5ce7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_0551ffb6-90ef-4053-be15-df40b76d509a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_978c44df-3a78-42d5-b68c-8245bd06ee52" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_0551ffb6-90ef-4053-be15-df40b76d509a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_1f7c213d-d85c-41ad-9a20-10477d1a98c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_978c44df-3a78-42d5-b68c-8245bd06ee52" xlink:to="loc_us-gaap_Goodwill_1f7c213d-d85c-41ad-9a20-10477d1a98c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_e1a29911-75f1-4a0b-b7f4-16be90cb8cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_978c44df-3a78-42d5-b68c-8245bd06ee52" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_e1a29911-75f1-4a0b-b7f4-16be90cb8cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_24e1aa9b-9b55-4276-85ad-ab784b239695" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_978c44df-3a78-42d5-b68c-8245bd06ee52" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_24e1aa9b-9b55-4276-85ad-ab784b239695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_3ce46fba-bb5c-4944-8016-f857b9e443d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_978c44df-3a78-42d5-b68c-8245bd06ee52" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_3ce46fba-bb5c-4944-8016-f857b9e443d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_bb8fa370-51d2-4d9b-b2fa-2808182fd8cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_978c44df-3a78-42d5-b68c-8245bd06ee52" xlink:to="loc_us-gaap_Assets_bb8fa370-51d2-4d9b-b2fa-2808182fd8cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b1203a87-516b-44e9-9172-5c6442673e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ede8d857-f6b9-4d07-9099-d8cb5efd2c3a" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b1203a87-516b-44e9-9172-5c6442673e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_57a6854a-9846-4504-a1e3-701f264e0f91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b1203a87-516b-44e9-9172-5c6442673e8c" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_57a6854a-9846-4504-a1e3-701f264e0f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_NotesPayableAndOtherDebtCurrent_99b7cd73-5285-42c6-b719-afac51509e81" xlink:href="wst-20230331.xsd#wst_NotesPayableAndOtherDebtCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_57a6854a-9846-4504-a1e3-701f264e0f91" xlink:to="loc_wst_NotesPayableAndOtherDebtCurrent_99b7cd73-5285-42c6-b719-afac51509e81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_4e3f742f-0465-4442-9caa-97214adeffe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_57a6854a-9846-4504-a1e3-701f264e0f91" xlink:to="loc_us-gaap_AccountsPayableCurrent_4e3f742f-0465-4442-9caa-97214adeffe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_AccruedSalariesWagesAndBenefitsCurrent_3cbb0f91-e545-441c-a561-21579f43f206" xlink:href="wst-20230331.xsd#wst_AccruedSalariesWagesAndBenefitsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_57a6854a-9846-4504-a1e3-701f264e0f91" xlink:to="loc_wst_AccruedSalariesWagesAndBenefitsCurrent_3cbb0f91-e545-441c-a561-21579f43f206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_9dcd3cae-2123-4820-8007-f3d9531670ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_57a6854a-9846-4504-a1e3-701f264e0f91" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_9dcd3cae-2123-4820-8007-f3d9531670ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_d4ff3257-4d5f-4027-ad41-db039c7a1bea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_57a6854a-9846-4504-a1e3-701f264e0f91" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_d4ff3257-4d5f-4027-ad41-db039c7a1bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_a0c6bcb6-d62c-4377-8dec-a31ad8348cce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_57a6854a-9846-4504-a1e3-701f264e0f91" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_a0c6bcb6-d62c-4377-8dec-a31ad8348cce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c055e4c7-501a-4262-8434-72b23e022892" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_57a6854a-9846-4504-a1e3-701f264e0f91" xlink:to="loc_us-gaap_LiabilitiesCurrent_c055e4c7-501a-4262-8434-72b23e022892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_b1f971d1-eeb2-4adc-af58-d870d416c2af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b1203a87-516b-44e9-9172-5c6442673e8c" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_b1f971d1-eeb2-4adc-af58-d870d416c2af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_4c8d2551-1a66-4db0-9c51-20caebcdd6a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b1203a87-516b-44e9-9172-5c6442673e8c" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_4c8d2551-1a66-4db0-9c51-20caebcdd6a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_3a2c23a7-ab4c-4aef-a908-d7e5dcde4045" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b1203a87-516b-44e9-9172-5c6442673e8c" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_3a2c23a7-ab4c-4aef-a908-d7e5dcde4045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_945b6995-8755-42ef-896f-590473b23b57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b1203a87-516b-44e9-9172-5c6442673e8c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_945b6995-8755-42ef-896f-590473b23b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_293621e6-28cf-4cbd-a14e-23ae1eac8fae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b1203a87-516b-44e9-9172-5c6442673e8c" xlink:to="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_293621e6-28cf-4cbd-a14e-23ae1eac8fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_6bd5447f-9318-40db-b5ca-1d72c7c95f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b1203a87-516b-44e9-9172-5c6442673e8c" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_6bd5447f-9318-40db-b5ca-1d72c7c95f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d5600815-94ee-428a-94a6-8c79333ce06a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b1203a87-516b-44e9-9172-5c6442673e8c" xlink:to="loc_us-gaap_Liabilities_d5600815-94ee-428a-94a6-8c79333ce06a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_ed34511d-ed5d-4cf9-80ec-eab33cbd3964" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b1203a87-516b-44e9-9172-5c6442673e8c" xlink:to="loc_us-gaap_CommitmentsAndContingencies_ed34511d-ed5d-4cf9-80ec-eab33cbd3964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_423a0c8c-edcc-4969-a502-c68d587c4c62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b1203a87-516b-44e9-9172-5c6442673e8c" xlink:to="loc_us-gaap_EquityAbstract_423a0c8c-edcc-4969-a502-c68d587c4c62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_419bf9c4-f1fe-424c-b496-9664822d6d37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_423a0c8c-edcc-4969-a502-c68d587c4c62" xlink:to="loc_us-gaap_PreferredStockValue_419bf9c4-f1fe-424c-b496-9664822d6d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_3fb96c13-9cf0-4b14-8399-20a7cf7dca58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_423a0c8c-edcc-4969-a502-c68d587c4c62" xlink:to="loc_us-gaap_CommonStockValue_3fb96c13-9cf0-4b14-8399-20a7cf7dca58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_9292ae41-1161-4ee2-b963-3147dae3fec5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_423a0c8c-edcc-4969-a502-c68d587c4c62" xlink:to="loc_us-gaap_AdditionalPaidInCapital_9292ae41-1161-4ee2-b963-3147dae3fec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a9a39b66-f721-4c13-a88a-efe2b98d4e25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_423a0c8c-edcc-4969-a502-c68d587c4c62" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a9a39b66-f721-4c13-a88a-efe2b98d4e25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9e976464-9aef-425c-8a32-afe7109b762d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_423a0c8c-edcc-4969-a502-c68d587c4c62" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9e976464-9aef-425c-8a32-afe7109b762d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_b623226e-7451-4005-95ac-cded62257034" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_423a0c8c-edcc-4969-a502-c68d587c4c62" xlink:to="loc_us-gaap_TreasuryStockCommonValue_b623226e-7451-4005-95ac-cded62257034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_09d086bd-1e89-4ff2-af6f-7e4e0727223c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_423a0c8c-edcc-4969-a502-c68d587c4c62" xlink:to="loc_us-gaap_StockholdersEquity_09d086bd-1e89-4ff2-af6f-7e4e0727223c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_6922ed31-527c-41c8-967f-596500cbe429" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b1203a87-516b-44e9-9172-5c6442673e8c" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_6922ed31-527c-41c8-967f-596500cbe429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" xlink:type="simple" xlink:href="wst-20230331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_3d58625b-ef19-4167-9d1a-3207cbb57800" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_5d350f2a-af7a-42cb-831b-812f871edd48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3d58625b-ef19-4167-9d1a-3207cbb57800" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_5d350f2a-af7a-42cb-831b-812f871edd48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_a615f580-f14f-4418-9475-e0506878ee8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3d58625b-ef19-4167-9d1a-3207cbb57800" xlink:to="loc_us-gaap_PreferredStockSharesIssued_a615f580-f14f-4418-9475-e0506878ee8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_1c744d65-d210-45d0-aaa8-d8c890055983" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3d58625b-ef19-4167-9d1a-3207cbb57800" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_1c744d65-d210-45d0-aaa8-d8c890055983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_40e5a0de-7359-4528-8032-e26711480d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3d58625b-ef19-4167-9d1a-3207cbb57800" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_40e5a0de-7359-4528-8032-e26711480d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_b917ad76-34dd-4b83-8348-6391cfa63940" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3d58625b-ef19-4167-9d1a-3207cbb57800" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_b917ad76-34dd-4b83-8348-6391cfa63940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_1304cb08-c1e5-4afd-8091-21df0b9a18e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3d58625b-ef19-4167-9d1a-3207cbb57800" xlink:to="loc_us-gaap_CommonStockSharesIssued_1304cb08-c1e5-4afd-8091-21df0b9a18e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_2749643c-5149-4582-8c58-643bd4f3da96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3d58625b-ef19-4167-9d1a-3207cbb57800" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_2749643c-5149-4582-8c58-643bd4f3da96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_d2aa8baf-6758-4337-8888-d13ac3da2791" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3d58625b-ef19-4167-9d1a-3207cbb57800" xlink:to="loc_us-gaap_TreasuryStockCommonShares_d2aa8baf-6758-4337-8888-d13ac3da2791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" xlink:type="simple" xlink:href="wst-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_778f1d24-7c50-4b09-8984-b26d3d6a5950" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f34282b6-8f59-472f-b172-520b10b690d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_778f1d24-7c50-4b09-8984-b26d3d6a5950" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f34282b6-8f59-472f-b172-520b10b690d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_71446955-70f4-435f-81b6-9699521197f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f34282b6-8f59-472f-b172-520b10b690d0" xlink:to="loc_us-gaap_NetIncomeLoss_71446955-70f4-435f-81b6-9699521197f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fc1b3bbc-20f7-4ccd-b794-d826c3d664f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f34282b6-8f59-472f-b172-520b10b690d0" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fc1b3bbc-20f7-4ccd-b794-d826c3d664f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_a681bf0e-1cf9-4c4f-a9ba-3fc3d18b3924" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fc1b3bbc-20f7-4ccd-b794-d826c3d664f8" xlink:to="loc_us-gaap_Depreciation_a681bf0e-1cf9-4c4f-a9ba-3fc3d18b3924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_f81539d7-ba03-410d-a5e4-69d59b253662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fc1b3bbc-20f7-4ccd-b794-d826c3d664f8" xlink:to="loc_us-gaap_AdjustmentForAmortization_f81539d7-ba03-410d-a5e4-69d59b253662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_acde5adb-e2a2-4304-92dd-11004ac0390c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fc1b3bbc-20f7-4ccd-b794-d826c3d664f8" xlink:to="loc_us-gaap_ShareBasedCompensation_acde5adb-e2a2-4304-92dd-11004ac0390c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_8572696c-fedd-4d8b-a8e3-1fb24c284394" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fc1b3bbc-20f7-4ccd-b794-d826c3d664f8" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_8572696c-fedd-4d8b-a8e3-1fb24c284394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_60dbd734-4942-429d-88b2-9c9ac2fc853a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fc1b3bbc-20f7-4ccd-b794-d826c3d664f8" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_60dbd734-4942-429d-88b2-9c9ac2fc853a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_515ad9f4-1f72-4642-b45e-cdf8d2812f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f34282b6-8f59-472f-b172-520b10b690d0" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_515ad9f4-1f72-4642-b45e-cdf8d2812f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1270bc54-4988-4e2a-a231-f1dabc840502" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f34282b6-8f59-472f-b172-520b10b690d0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1270bc54-4988-4e2a-a231-f1dabc840502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_235ed602-3940-494d-ae11-6792bd4cf3b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_778f1d24-7c50-4b09-8984-b26d3d6a5950" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_235ed602-3940-494d-ae11-6792bd4cf3b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5bf75ec3-5740-4902-b1ee-2843a498591c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_235ed602-3940-494d-ae11-6792bd4cf3b1" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5bf75ec3-5740-4902-b1ee-2843a498591c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_3a51dfa3-a672-40eb-8959-080211b4839e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_235ed602-3940-494d-ae11-6792bd4cf3b1" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_3a51dfa3-a672-40eb-8959-080211b4839e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bd571dfc-8e18-46f2-9fb8-13faaad865f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_235ed602-3940-494d-ae11-6792bd4cf3b1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bd571dfc-8e18-46f2-9fb8-13faaad865f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_509218e7-97a4-428e-9bb5-336b1b94aa54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_778f1d24-7c50-4b09-8984-b26d3d6a5950" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_509218e7-97a4-428e-9bb5-336b1b94aa54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfOtherLongTermDebt_d2dead36-7825-41ee-aae2-19ca51e133ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfOtherLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_509218e7-97a4-428e-9bb5-336b1b94aa54" xlink:to="loc_us-gaap_RepaymentsOfOtherLongTermDebt_d2dead36-7825-41ee-aae2-19ca51e133ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_56a4b6bd-6e12-4649-9a19-8a2dc79f7b72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_509218e7-97a4-428e-9bb5-336b1b94aa54" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_56a4b6bd-6e12-4649-9a19-8a2dc79f7b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_e05df15b-7a98-4462-88ef-69fc680cdb28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_509218e7-97a4-428e-9bb5-336b1b94aa54" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_e05df15b-7a98-4462-88ef-69fc680cdb28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_478ee4c4-5465-4a8a-ab17-ffcc1a2f1d49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_509218e7-97a4-428e-9bb5-336b1b94aa54" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_478ee4c4-5465-4a8a-ab17-ffcc1a2f1d49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromOtherEquity_16c18ed8-8256-4459-9116-b3bbc5fa9141" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromOtherEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_509218e7-97a4-428e-9bb5-336b1b94aa54" xlink:to="loc_us-gaap_ProceedsFromOtherEquity_16c18ed8-8256-4459-9116-b3bbc5fa9141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_f4bcfbf2-d3dc-4029-8429-cce3e49337dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_509218e7-97a4-428e-9bb5-336b1b94aa54" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_f4bcfbf2-d3dc-4029-8429-cce3e49337dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_b2ce0a4c-aee6-466c-8bcb-d883ff6b119e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_509218e7-97a4-428e-9bb5-336b1b94aa54" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_b2ce0a4c-aee6-466c-8bcb-d883ff6b119e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9cda09fe-7fc9-40a2-a3cd-ea3f8aa3cd4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_509218e7-97a4-428e-9bb5-336b1b94aa54" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9cda09fe-7fc9-40a2-a3cd-ea3f8aa3cd4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_22e6372d-834c-4314-b962-e3fd4f646363" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_778f1d24-7c50-4b09-8984-b26d3d6a5950" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_22e6372d-834c-4314-b962-e3fd4f646363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2eeb2ad4-494c-4752-afe0-11900e22bca5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_778f1d24-7c50-4b09-8984-b26d3d6a5950" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2eeb2ad4-494c-4752-afe0-11900e22bca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9911973a-9c32-4414-bb06-6cddea8e8fcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_778f1d24-7c50-4b09-8984-b26d3d6a5950" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9911973a-9c32-4414-bb06-6cddea8e8fcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a9dc3a8d-7bb0-41a2-a672-713b4b9c6ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_778f1d24-7c50-4b09-8984-b26d3d6a5950" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a9dc3a8d-7bb0-41a2-a672-713b4b9c6ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="wst-20230331.xsd#BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_00519d05-e15c-4236-8a2f-842de2b31884" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_ec54db6d-63c2-42a1-8ff6-b6f5f2f7aa65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_00519d05-e15c-4236-8a2f-842de2b31884" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_ec54db6d-63c2-42a1-8ff6-b6f5f2f7aa65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/NewAccountingStandards" xlink:type="simple" xlink:href="wst-20230331.xsd#NewAccountingStandards"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/NewAccountingStandards" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_21c2c938-4be1-40eb-8af9-b026fa151d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_dd947827-208f-4857-afbb-2f8deb2e6385" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_21c2c938-4be1-40eb-8af9-b026fa151d2b" xlink:to="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_dd947827-208f-4857-afbb-2f8deb2e6385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/Revenue" xlink:type="simple" xlink:href="wst-20230331.xsd#Revenue"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/Revenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ef87a493-df2f-4ef4-b65a-3b9f874be008" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_bb921fca-0e69-4592-99be-fd78325b852a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ef87a493-df2f-4ef4-b65a-3b9f874be008" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_bb921fca-0e69-4592-99be-fd78325b852a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/NetIncomePerShare" xlink:type="simple" xlink:href="wst-20230331.xsd#NetIncomePerShare"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/NetIncomePerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_8c429084-6b27-4112-ba43-3333eea8dff6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_8c141a1f-adb2-4481-96f0-ee6e6237dad9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8c429084-6b27-4112-ba43-3333eea8dff6" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_8c141a1f-adb2-4481-96f0-ee6e6237dad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/Inventories" xlink:type="simple" xlink:href="wst-20230331.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_ba4b8fd8-970c-4919-8d19-ad88b4e7ece5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_524d6841-b748-4ca7-8257-9f70c7d3d29b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_ba4b8fd8-970c-4919-8d19-ad88b4e7ece5" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_524d6841-b748-4ca7-8257-9f70c7d3d29b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/Leases" xlink:type="simple" xlink:href="wst-20230331.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_30480a35-ad4f-48fa-9bf3-32a00a5eec94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_620e2514-4746-4407-9d51-09eefc692ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_30480a35-ad4f-48fa-9bf3-32a00a5eec94" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_620e2514-4746-4407-9d51-09eefc692ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/AffiliatedCompanies" xlink:type="simple" xlink:href="wst-20230331.xsd#AffiliatedCompanies"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/AffiliatedCompanies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_16cade6a-ed75-4078-b330-78b0e93feaf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_2ce83b11-85fe-4b64-8656-0c19e8408c89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_16cade6a-ed75-4078-b330-78b0e93feaf4" xlink:to="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_2ce83b11-85fe-4b64-8656-0c19e8408c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/Debt" xlink:type="simple" xlink:href="wst-20230331.xsd#Debt"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_46dd33a2-8c87-419c-9257-018a1d2506cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_246cb6d3-fc7f-44be-8598-a1ab07404e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_46dd33a2-8c87-419c-9257-018a1d2506cb" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_246cb6d3-fc7f-44be-8598-a1ab07404e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/DerivativeFinancialInstruments" xlink:type="simple" xlink:href="wst-20230331.xsd#DerivativeFinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/DerivativeFinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_b2b3f0ac-0b4e-4eca-bfcc-4c718c4913d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_947c6427-ce1c-468a-8540-166c95acfbdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_b2b3f0ac-0b4e-4eca-bfcc-4c718c4913d2" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_947c6427-ce1c-468a-8540-166c95acfbdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="wst-20230331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_818bb3ef-8b97-4e80-9046-dd0d63370e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_e4552198-f9a7-4536-9fb5-41d09acc05e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_818bb3ef-8b97-4e80-9046-dd0d63370e2f" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_e4552198-f9a7-4536-9fb5-41d09acc05e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/AccumulatedOtherComprehensiveLoss" xlink:type="simple" xlink:href="wst-20230331.xsd#AccumulatedOtherComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/AccumulatedOtherComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_02d03f17-762d-4f92-9705-ab94f00f5af5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_bfb04c19-1485-49d0-8985-dad17a859bce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_02d03f17-762d-4f92-9705-ab94f00f5af5" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_bfb04c19-1485-49d0-8985-dad17a859bce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="wst-20230331.xsd#ShareholdersEquity"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/ShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_1c9122f4-7b13-47f2-a97b-ea6fdd5b00bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_a37400ec-61e5-4fe5-a5fa-bd785ea5913b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1c9122f4-7b13-47f2-a97b-ea6fdd5b00bb" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_a37400ec-61e5-4fe5-a5fa-bd785ea5913b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="wst-20230331.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_eb18cde6-ffe7-4d8a-8bc5-020188669286" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_79308ce8-28d4-44b7-ba9a-7d7450477225" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_eb18cde6-ffe7-4d8a-8bc5-020188669286" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_79308ce8-28d4-44b7-ba9a-7d7450477225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/BenefitPlans" xlink:type="simple" xlink:href="wst-20230331.xsd#BenefitPlans"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/BenefitPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract_67253c12-3a93-4beb-b779-0ad5308740f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_b37389a2-bc59-4b69-9955-1ec4f343b577" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract_67253c12-3a93-4beb-b779-0ad5308740f4" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_b37389a2-bc59-4b69-9955-1ec4f343b577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/OtherExpenseIncome" xlink:type="simple" xlink:href="wst-20230331.xsd#OtherExpenseIncome"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/OtherExpenseIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_f8058606-ec5d-4ea0-8480-81848e2b2a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_df807ffe-a37a-486c-b2a5-90524b647f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_f8058606-ec5d-4ea0-8480-81848e2b2a4e" xlink:to="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_df807ffe-a37a-486c-b2a5-90524b647f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/IncomeTaxes" xlink:type="simple" xlink:href="wst-20230331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3a06dc34-fe37-488b-a298-8d0464691688" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1d4f913c-ffd1-49f1-b3f4-8a82775c24e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3a06dc34-fe37-488b-a298-8d0464691688" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1d4f913c-ffd1-49f1-b3f4-8a82775c24e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="wst-20230331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_78e36497-f00d-4584-842f-b7a47031d052" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_fb13f747-5824-4d85-8020-906be4c631dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_78e36497-f00d-4584-842f-b7a47031d052" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_fb13f747-5824-4d85-8020-906be4c631dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/SegmentInformation" xlink:type="simple" xlink:href="wst-20230331.xsd#SegmentInformation"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/SegmentInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_aa79057f-5203-4ab0-9175-098292dc3d20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_ec206a6a-43be-4ce1-8dbb-af6992c2f87b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_aa79057f-5203-4ab0-9175-098292dc3d20" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_ec206a6a-43be-4ce1-8dbb-af6992c2f87b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="wst-20230331.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8ed74912-d732-4afd-a7a7-bb97d3bacb59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_8ffe49d5-4197-4b33-8c43-2fa206fc51c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8ed74912-d732-4afd-a7a7-bb97d3bacb59" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_8ffe49d5-4197-4b33-8c43-2fa206fc51c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_b7e10e14-a394-4966-bb16-1ab3a5a63dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8ed74912-d732-4afd-a7a7-bb97d3bacb59" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_b7e10e14-a394-4966-bb16-1ab3a5a63dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/RevenueTables" xlink:type="simple" xlink:href="wst-20230331.xsd#RevenueTables"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/RevenueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a65ed06f-461d-4a4a-8884-08bec0d43e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_d3b6e54c-53a2-40d5-97d7-9edab9410a81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a65ed06f-461d-4a4a-8884-08bec0d43e9f" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_d3b6e54c-53a2-40d5-97d7-9edab9410a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_6e7565ba-abe8-43c6-b27a-c8de681eef76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a65ed06f-461d-4a4a-8884-08bec0d43e9f" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_6e7565ba-abe8-43c6-b27a-c8de681eef76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/NetIncomePerShareTables" xlink:type="simple" xlink:href="wst-20230331.xsd#NetIncomePerShareTables"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/NetIncomePerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7d62832a-48f2-4df2-b89c-dbdfae298e2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_712b233e-cea5-489a-ad35-9b6a88f58891" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7d62832a-48f2-4df2-b89c-dbdfae298e2d" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_712b233e-cea5-489a-ad35-9b6a88f58891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/InventoriesTables" xlink:type="simple" xlink:href="wst-20230331.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_90f07bb0-396c-4e9f-a419-374adee8b61b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_ed595543-5d42-45a8-a081-5484db295a74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_90f07bb0-396c-4e9f-a419-374adee8b61b" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_ed595543-5d42-45a8-a081-5484db295a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/LeasesTables" xlink:type="simple" xlink:href="wst-20230331.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_27c5bb6c-1412-4bda-9bf8-7262eff45770" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_d105b7d7-e25f-4d82-a6a0-a714af6d540d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_27c5bb6c-1412-4bda-9bf8-7262eff45770" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_d105b7d7-e25f-4d82-a6a0-a714af6d540d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_LesseeLeaseCashFlowAndSupplementalInformationTableTextBlock_a1389dcc-8cf0-40bf-95de-346d0aa87460" xlink:href="wst-20230331.xsd#wst_LesseeLeaseCashFlowAndSupplementalInformationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_27c5bb6c-1412-4bda-9bf8-7262eff45770" xlink:to="loc_wst_LesseeLeaseCashFlowAndSupplementalInformationTableTextBlock_a1389dcc-8cf0-40bf-95de-346d0aa87460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_be2bdecb-8f18-4737-8da4-f23dbd106701" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_27c5bb6c-1412-4bda-9bf8-7262eff45770" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_be2bdecb-8f18-4737-8da4-f23dbd106701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/DebtTables" xlink:type="simple" xlink:href="wst-20230331.xsd#DebtTables"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_6df00355-9477-4640-a3ff-8d12d9c0c929" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_fb45ed01-8bf4-488a-aea2-9b18f628eef8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6df00355-9477-4640-a3ff-8d12d9c0c929" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_fb45ed01-8bf4-488a-aea2-9b18f628eef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/DerivativeFinancialInstrumentsTables" xlink:type="simple" xlink:href="wst-20230331.xsd#DerivativeFinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/DerivativeFinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0ada189a-95be-438c-9a0f-df259cdf4e73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_fd0e37de-225f-4bf6-8779-1328351890db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0ada189a-95be-438c-9a0f-df259cdf4e73" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_fd0e37de-225f-4bf6-8779-1328351890db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_593e2a10-5606-47c8-ab60-378eb09a152e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0ada189a-95be-438c-9a0f-df259cdf4e73" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_593e2a10-5606-47c8-ab60-378eb09a152e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_f39f5d36-969d-4165-a45d-f39deb4759b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0ada189a-95be-438c-9a0f-df259cdf4e73" xlink:to="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_f39f5d36-969d-4165-a45d-f39deb4759b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="wst-20230331.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_857bc421-a74c-461e-940e-a78a24ee0789" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_46de937b-a263-45ba-8db0-64060d266b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_857bc421-a74c-461e-940e-a78a24ee0789" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_46de937b-a263-45ba-8db0-64060d266b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossTables" xlink:type="simple" xlink:href="wst-20230331.xsd#AccumulatedOtherComprehensiveLossTables"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_582f5b17-5036-46d1-a5d7-ac0102b86b27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_28e19747-8fac-4d30-9d6b-a77a32d4aa7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_582f5b17-5036-46d1-a5d7-ac0102b86b27" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_28e19747-8fac-4d30-9d6b-a77a32d4aa7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_511d25a1-81df-49db-be09-42a979de8c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_582f5b17-5036-46d1-a5d7-ac0102b86b27" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_511d25a1-81df-49db-be09-42a979de8c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/ShareholdersEquityTables" xlink:type="simple" xlink:href="wst-20230331.xsd#ShareholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/ShareholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_a1a5d85f-b5cd-4a86-b940-c7d3900cf07f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_bff8778b-36d0-4ef6-853e-70adbc28b0a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a1a5d85f-b5cd-4a86-b940-c7d3900cf07f" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_bff8778b-36d0-4ef6-853e-70adbc28b0a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/BenefitPlansTables" xlink:type="simple" xlink:href="wst-20230331.xsd#BenefitPlansTables"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/BenefitPlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract_0850b9b7-d512-4f8a-b411-503db53c2fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_754dbc30-815b-4b09-aeb2-bfe59ecb4253" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract_0850b9b7-d512-4f8a-b411-503db53c2fe5" xlink:to="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_754dbc30-815b-4b09-aeb2-bfe59ecb4253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/OtherExpenseIncomeTables" xlink:type="simple" xlink:href="wst-20230331.xsd#OtherExpenseIncomeTables"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/OtherExpenseIncomeTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_54017507-af44-4c68-8c8d-466be845ebee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock_427bbfcb-1ce0-468b-8840-451849cb7d51" xlink:href="wst-20230331.xsd#wst_ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_54017507-af44-4c68-8c8d-466be845ebee" xlink:to="loc_wst_ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock_427bbfcb-1ce0-468b-8840-451849cb7d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_d0840b07-1285-4194-9169-b203d5d21b22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_54017507-af44-4c68-8c8d-466be845ebee" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_d0840b07-1285-4194-9169-b203d5d21b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/SegmentInformationTables" xlink:type="simple" xlink:href="wst-20230331.xsd#SegmentInformationTables"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/SegmentInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_090c14c8-c9bb-4162-b80e-fb5812577a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_98569b92-b21d-4b0a-b0e7-90f1cfbb0df8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_090c14c8-c9bb-4162-b80e-fb5812577a5a" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_98569b92-b21d-4b0a-b0e7-90f1cfbb0df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_afb2115c-e642-4834-ae6e-735d2e091c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_090c14c8-c9bb-4162-b80e-fb5812577a5a" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_afb2115c-e642-4834-ae6e-735d2e091c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#RevenueRevenueRecognitionDetails"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0f9650af-67e1-4e4c-a839-8e2c0ca7cd5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_79cb5161-4868-4e07-be49-0f0282972ce7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0f9650af-67e1-4e4c-a839-8e2c0ca7cd5b" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_79cb5161-4868-4e07-be49-0f0282972ce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_9f3cca83-0e48-4e35-b3ce-80b5021eda70" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_79cb5161-4868-4e07-be49-0f0282972ce7" xlink:to="loc_srt_MajorCustomersAxis_9f3cca83-0e48-4e35-b3ce-80b5021eda70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_172e0730-5449-4dfb-9ddb-790038e184e3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_9f3cca83-0e48-4e35-b3ce-80b5021eda70" xlink:to="loc_srt_NameOfMajorCustomerDomain_172e0730-5449-4dfb-9ddb-790038e184e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_BiologicsCustomersMember_6446da82-55ac-46f6-9146-6902143818b2" xlink:href="wst-20230331.xsd#wst_BiologicsCustomersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_172e0730-5449-4dfb-9ddb-790038e184e3" xlink:to="loc_wst_BiologicsCustomersMember_6446da82-55ac-46f6-9146-6902143818b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_GenericsCustomersMember_bcdea95e-1a9e-475b-8889-b18621114c26" xlink:href="wst-20230331.xsd#wst_GenericsCustomersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_172e0730-5449-4dfb-9ddb-790038e184e3" xlink:to="loc_wst_GenericsCustomersMember_bcdea95e-1a9e-475b-8889-b18621114c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_PharmaCustomersMember_64a62dc0-9e09-40ac-8e9d-d46262c5ade2" xlink:href="wst-20230331.xsd#wst_PharmaCustomersMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_172e0730-5449-4dfb-9ddb-790038e184e3" xlink:to="loc_wst_PharmaCustomersMember_64a62dc0-9e09-40ac-8e9d-d46262c5ade2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_ContractManufacturedCustomersMember_bb4cfe34-8a0e-486e-952c-e7cf496c5485" xlink:href="wst-20230331.xsd#wst_ContractManufacturedCustomersMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_172e0730-5449-4dfb-9ddb-790038e184e3" xlink:to="loc_wst_ContractManufacturedCustomersMember_bb4cfe34-8a0e-486e-952c-e7cf496c5485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a008e36d-c7d2-4a47-b420-56a129f6f134" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_79cb5161-4868-4e07-be49-0f0282972ce7" xlink:to="loc_srt_ProductOrServiceAxis_a008e36d-c7d2-4a47-b420-56a129f6f134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_31bf6db6-0cc1-4138-980b-eb6550a7efa0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_a008e36d-c7d2-4a47-b420-56a129f6f134" xlink:to="loc_srt_ProductsAndServicesDomain_31bf6db6-0cc1-4138-980b-eb6550a7efa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_HighValueProductComponentsMember_c3f9f531-be4f-4f6e-85b6-ecbd1fa10458" xlink:href="wst-20230331.xsd#wst_HighValueProductComponentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_31bf6db6-0cc1-4138-980b-eb6550a7efa0" xlink:to="loc_wst_HighValueProductComponentsMember_c3f9f531-be4f-4f6e-85b6-ecbd1fa10458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_HighValueProductDeliveryDevicesMember_cefc920d-05ad-4357-9669-6b5c0060b2f4" xlink:href="wst-20230331.xsd#wst_HighValueProductDeliveryDevicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_31bf6db6-0cc1-4138-980b-eb6550a7efa0" xlink:to="loc_wst_HighValueProductDeliveryDevicesMember_cefc920d-05ad-4357-9669-6b5c0060b2f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_StandardPackagingMember_878da10d-0c85-4e47-9921-d486b69a7431" xlink:href="wst-20230331.xsd#wst_StandardPackagingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_31bf6db6-0cc1-4138-980b-eb6550a7efa0" xlink:to="loc_wst_StandardPackagingMember_878da10d-0c85-4e47-9921-d486b69a7431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_ContractManufacturedProductsMember_6890b2d3-6976-4d37-ab90-7e7f8c91a5db" xlink:href="wst-20230331.xsd#wst_ContractManufacturedProductsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_31bf6db6-0cc1-4138-980b-eb6550a7efa0" xlink:to="loc_wst_ContractManufacturedProductsMember_6890b2d3-6976-4d37-ab90-7e7f8c91a5db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_07301015-9559-46bd-9c5b-d937e45a8b16" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_79cb5161-4868-4e07-be49-0f0282972ce7" xlink:to="loc_srt_StatementGeographicalAxis_07301015-9559-46bd-9c5b-d937e45a8b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e49bb36d-a44e-4393-98f1-7e706d412310" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_07301015-9559-46bd-9c5b-d937e45a8b16" xlink:to="loc_srt_SegmentGeographicalDomain_e49bb36d-a44e-4393-98f1-7e706d412310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AmericasMember_d23a74c4-26ce-4ad8-8499-0896bbb0049b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AmericasMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e49bb36d-a44e-4393-98f1-7e706d412310" xlink:to="loc_srt_AmericasMember_d23a74c4-26ce-4ad8-8499-0896bbb0049b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember_d87642da-a00c-461e-a1f1-62fa024c4f78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EMEAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e49bb36d-a44e-4393-98f1-7e706d412310" xlink:to="loc_us-gaap_EMEAMember_d87642da-a00c-461e-a1f1-62fa024c4f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember_850385b7-864f-498e-900e-1c72210c27b4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AsiaPacificMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e49bb36d-a44e-4393-98f1-7e706d412310" xlink:to="loc_srt_AsiaPacificMember_850385b7-864f-498e-900e-1c72210c27b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_91c1f69c-f86d-42f7-979c-a9ad4ebed6aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_79cb5161-4868-4e07-be49-0f0282972ce7" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_91c1f69c-f86d-42f7-979c-a9ad4ebed6aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1cc597e3-5dff-42fc-b9d5-333cca09edd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_91c1f69c-f86d-42f7-979c-a9ad4ebed6aa" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1cc597e3-5dff-42fc-b9d5-333cca09edd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_693b7c2c-d238-4ff8-af80-abc36e64b725" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1cc597e3-5dff-42fc-b9d5-333cca09edd4" xlink:to="loc_us-gaap_SalesRevenueNetMember_693b7c2c-d238-4ff8-af80-abc36e64b725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_2c3cd0ce-6772-4595-a126-b3ecb41d4dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_79cb5161-4868-4e07-be49-0f0282972ce7" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_2c3cd0ce-6772-4595-a126-b3ecb41d4dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_c1fc7bcc-0917-4c05-bc53-a4c55755edb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_2c3cd0ce-6772-4595-a126-b3ecb41d4dc7" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_c1fc7bcc-0917-4c05-bc53-a4c55755edb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_aacd0ccb-d087-4d51-8a31-c2f7898e6d80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_c1fc7bcc-0917-4c05-bc53-a4c55755edb1" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_aacd0ccb-d087-4d51-8a31-c2f7898e6d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_3cf1a7e9-deda-4865-a7b2-5f14d454c7b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_c1fc7bcc-0917-4c05-bc53-a4c55755edb1" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_3cf1a7e9-deda-4865-a7b2-5f14d454c7b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_5f01a28b-ec84-4bb7-a774-5256edaeb9e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_c1fc7bcc-0917-4c05-bc53-a4c55755edb1" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_5f01a28b-ec84-4bb7-a774-5256edaeb9e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_defa3bda-1a80-482b-a5e3-ec88d2c35268" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_79cb5161-4868-4e07-be49-0f0282972ce7" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_defa3bda-1a80-482b-a5e3-ec88d2c35268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_1a6e73f1-5a87-4d26-bfe9-b65fef4b6253" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_defa3bda-1a80-482b-a5e3-ec88d2c35268" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_1a6e73f1-5a87-4d26-bfe9-b65fef4b6253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/RevenueContractsandLiabilitiesDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#RevenueContractsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/RevenueContractsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c6357140-8715-4116-a62f-2a6adf6f2950" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_ContractWithCustomerAssetRollForward_6c0adcf4-a88b-4143-a899-9afcdd0113ac" xlink:href="wst-20230331.xsd#wst_ContractWithCustomerAssetRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c6357140-8715-4116-a62f-2a6adf6f2950" xlink:to="loc_wst_ContractWithCustomerAssetRollForward_6c0adcf4-a88b-4143-a899-9afcdd0113ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_448bf58e-6c1b-4b33-9c71-912cd581afa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wst_ContractWithCustomerAssetRollForward_6c0adcf4-a88b-4143-a899-9afcdd0113ac" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_448bf58e-6c1b-4b33-9c71-912cd581afa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_76f1b2d7-52aa-4d84-823f-6c3bcaa4732e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wst_ContractWithCustomerAssetRollForward_6c0adcf4-a88b-4143-a899-9afcdd0113ac" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_76f1b2d7-52aa-4d84-823f-6c3bcaa4732e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_ContractWithCustomerAssetIncreaseDecrease_7376f208-daf2-4c06-88e4-d049be793b1c" xlink:href="wst-20230331.xsd#wst_ContractWithCustomerAssetIncreaseDecrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wst_ContractWithCustomerAssetRollForward_6c0adcf4-a88b-4143-a899-9afcdd0113ac" xlink:to="loc_wst_ContractWithCustomerAssetIncreaseDecrease_7376f208-daf2-4c06-88e4-d049be793b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_ContractWithCustomerLiabilityRollForward_394548b9-8c5b-472b-a8fe-741d9ad66053" xlink:href="wst-20230331.xsd#wst_ContractWithCustomerLiabilityRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c6357140-8715-4116-a62f-2a6adf6f2950" xlink:to="loc_wst_ContractWithCustomerLiabilityRollForward_394548b9-8c5b-472b-a8fe-741d9ad66053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_2f48a8f9-2875-4c28-bec9-1ba5c28c3f71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wst_ContractWithCustomerLiabilityRollForward_394548b9-8c5b-472b-a8fe-741d9ad66053" xlink:to="loc_us-gaap_ContractWithCustomerLiability_2f48a8f9-2875-4c28-bec9-1ba5c28c3f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_c81a1b19-c99c-4d81-82a9-4c790dcac45c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wst_ContractWithCustomerLiabilityRollForward_394548b9-8c5b-472b-a8fe-741d9ad66053" xlink:to="loc_us-gaap_ContractWithCustomerLiability_c81a1b19-c99c-4d81-82a9-4c790dcac45c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_38f344b6-3aaa-4ce4-8660-5ab2efb55f32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wst_ContractWithCustomerLiabilityRollForward_394548b9-8c5b-472b-a8fe-741d9ad66053" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_38f344b6-3aaa-4ce4-8660-5ab2efb55f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#RevenueContractsandLiabilitiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d3303dc2-6a83-49e3-b8a4-5f3603df9ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_2a007af5-c0e1-450e-95d2-36fecc469b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d3303dc2-6a83-49e3-b8a4-5f3603df9ac2" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_2a007af5-c0e1-450e-95d2-36fecc469b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b8c52106-e2f9-415b-96a5-392cee12ff52" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2a007af5-c0e1-450e-95d2-36fecc469b6c" xlink:to="loc_srt_ProductOrServiceAxis_b8c52106-e2f9-415b-96a5-392cee12ff52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_412e2802-adf6-449d-9f78-6bf9f5e48553" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_b8c52106-e2f9-415b-96a5-392cee12ff52" xlink:to="loc_srt_ProductsAndServicesDomain_412e2802-adf6-449d-9f78-6bf9f5e48553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_SmartDoseMember_87da5e79-20a1-420b-9899-f25378f508c1" xlink:href="wst-20230331.xsd#wst_SmartDoseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_412e2802-adf6-449d-9f78-6bf9f5e48553" xlink:to="loc_wst_SmartDoseMember_87da5e79-20a1-420b-9899-f25378f508c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_710d4e31-0307-4c44-a154-3660f4f4931e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2a007af5-c0e1-450e-95d2-36fecc469b6c" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_710d4e31-0307-4c44-a154-3660f4f4931e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_b39d6716-bc82-42d3-a794-4dc82782b0ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_710d4e31-0307-4c44-a154-3660f4f4931e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_b39d6716-bc82-42d3-a794-4dc82782b0ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_84786ce0-5e75-4387-9e5e-0e6b9a8709ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_710d4e31-0307-4c44-a154-3660f4f4931e" xlink:to="loc_us-gaap_ContractWithCustomerLiability_84786ce0-5e75-4387-9e5e-0e6b9a8709ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_c96c5f40-e7c0-4e21-bb2e-7f39cec37e7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_710d4e31-0307-4c44-a154-3660f4f4931e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_c96c5f40-e7c0-4e21-bb2e-7f39cec37e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c7775e95-af53-4f2d-9b94-b501ec050fbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_710d4e31-0307-4c44-a154-3660f4f4931e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c7775e95-af53-4f2d-9b94-b501ec050fbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/NetIncomePerShareDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#NetIncomePerShareDetails"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/NetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1d8d23b9-3f44-473c-898d-b01471f19212" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9e2b132b-935e-4e29-abee-bea8a0b2f1ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1d8d23b9-3f44-473c-898d-b01471f19212" xlink:to="loc_us-gaap_NetIncomeLoss_9e2b132b-935e-4e29-abee-bea8a0b2f1ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8e722630-ba07-4dde-8f77-c0201a38d5ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1d8d23b9-3f44-473c-898d-b01471f19212" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8e722630-ba07-4dde-8f77-c0201a38d5ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_7df726a4-68ba-4b33-b6ab-352e32898640" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1d8d23b9-3f44-473c-898d-b01471f19212" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_7df726a4-68ba-4b33-b6ab-352e32898640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_027fe82c-4fa2-4e6f-b785-eab18d9c3263" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1d8d23b9-3f44-473c-898d-b01471f19212" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_027fe82c-4fa2-4e6f-b785-eab18d9c3263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f56fab72-f9ac-4a0a-8ff2-2d4a633642fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1d8d23b9-3f44-473c-898d-b01471f19212" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f56fab72-f9ac-4a0a-8ff2-2d4a633642fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_dae51941-d599-4d79-bdd6-61e4afd35fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1d8d23b9-3f44-473c-898d-b01471f19212" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_dae51941-d599-4d79-bdd6-61e4afd35fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_2fed8296-35da-4f5d-87fe-7f9020cec600" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1d8d23b9-3f44-473c-898d-b01471f19212" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_2fed8296-35da-4f5d-87fe-7f9020cec600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_d64c3bbd-4654-468d-aaf8-48aa3a6655a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1d8d23b9-3f44-473c-898d-b01471f19212" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_d64c3bbd-4654-468d-aaf8-48aa3a6655a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_79d42ba9-a793-4719-b6c3-759f1dfb8e73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1d8d23b9-3f44-473c-898d-b01471f19212" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_79d42ba9-a793-4719-b6c3-759f1dfb8e73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/InventoriesDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#InventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_37b5936f-352e-4bcf-a8af-a1aa9c110cac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_84612ab0-cfad-4e00-bc1c-911503f3cd0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_37b5936f-352e-4bcf-a8af-a1aa9c110cac" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_84612ab0-cfad-4e00-bc1c-911503f3cd0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_9c06b9f7-78d9-4f11-aea6-771489f8a7ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_37b5936f-352e-4bcf-a8af-a1aa9c110cac" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_9c06b9f7-78d9-4f11-aea6-771489f8a7ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_cf4b7fb6-93b8-4023-aa0a-341d9f3455e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_37b5936f-352e-4bcf-a8af-a1aa9c110cac" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_cf4b7fb6-93b8-4023-aa0a-341d9f3455e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_33f98104-2055-40dc-a34d-c728066d37de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_37b5936f-352e-4bcf-a8af-a1aa9c110cac" xlink:to="loc_us-gaap_InventoryNet_33f98104-2055-40dc-a34d-c728066d37de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/LeasesLeaseCostDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#LeasesLeaseCostDetails"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/LeasesLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_10d59de9-c174-481d-a3a6-a9f0187730d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_ac6829fe-4b74-44c0-a2eb-760130cde485" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_10d59de9-c174-481d-a3a6-a9f0187730d2" xlink:to="loc_us-gaap_OperatingLeaseCost_ac6829fe-4b74-44c0-a2eb-760130cde485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_66da6391-0e87-48a6-98fd-3c72309a42ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_10d59de9-c174-481d-a3a6-a9f0187730d2" xlink:to="loc_us-gaap_ShortTermLeaseCost_66da6391-0e87-48a6-98fd-3c72309a42ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_de801e85-05a2-47e3-9be5-438f704f502c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_10d59de9-c174-481d-a3a6-a9f0187730d2" xlink:to="loc_us-gaap_VariableLeaseCost_de801e85-05a2-47e3-9be5-438f704f502c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_5585a331-f4a0-4179-a886-984a44250e06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_10d59de9-c174-481d-a3a6-a9f0187730d2" xlink:to="loc_us-gaap_LeaseCost_5585a331-f4a0-4179-a886-984a44250e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/LeasesLeaseCashFlowandSupplementalInformationDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#LeasesLeaseCashFlowandSupplementalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/LeasesLeaseCashFlowandSupplementalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_1e7d07c5-2dab-491d-a97f-1b52cfdf3ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_7ddbcada-c063-4f23-866a-f6c4102618c7" xlink:href="wst-20230331.xsd#wst_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1e7d07c5-2dab-491d-a97f-1b52cfdf3ea9" xlink:to="loc_wst_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_7ddbcada-c063-4f23-866a-f6c4102618c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_6cdaf7f2-f170-48eb-b2b2-7713f0a0986b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wst_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_7ddbcada-c063-4f23-866a-f6c4102618c7" xlink:to="loc_us-gaap_OperatingLeasePayments_6cdaf7f2-f170-48eb-b2b2-7713f0a0986b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_d4437f13-23e6-447c-8438-f57dd13b134b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wst_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_7ddbcada-c063-4f23-866a-f6c4102618c7" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_d4437f13-23e6-447c-8438-f57dd13b134b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/LeasesLeaseWeightedAverageDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#LeasesLeaseWeightedAverageDetails"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/LeasesLeaseWeightedAverageDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_184b6378-a232-4d48-8c36-bdc4c9b53519" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_574dc2ee-acfd-4e3e-984f-1b47a8703e34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_184b6378-a232-4d48-8c36-bdc4c9b53519" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_574dc2ee-acfd-4e3e-984f-1b47a8703e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9dd62a12-8a71-4652-bbe1-9ff943275de2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_184b6378-a232-4d48-8c36-bdc4c9b53519" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9dd62a12-8a71-4652-bbe1-9ff943275de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c3e28bf9-8fbf-43a5-a8fc-a10969385735" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_d5b20be3-2099-4e3e-b0e8-194154cddc80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c3e28bf9-8fbf-43a5-a8fc-a10969385735" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_d5b20be3-2099-4e3e-b0e8-194154cddc80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ecd98087-becc-4039-afb4-c35306b4d49c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c3e28bf9-8fbf-43a5-a8fc-a10969385735" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ecd98087-becc-4039-afb4-c35306b4d49c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_93a51346-0da8-4845-9e7e-c1287ea5ba80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c3e28bf9-8fbf-43a5-a8fc-a10969385735" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_93a51346-0da8-4845-9e7e-c1287ea5ba80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e5e36877-fc7e-4510-8643-daa6dc8ce135" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c3e28bf9-8fbf-43a5-a8fc-a10969385735" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e5e36877-fc7e-4510-8643-daa6dc8ce135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5c0a8254-d85f-42ad-ab9e-5f14deb154a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c3e28bf9-8fbf-43a5-a8fc-a10969385735" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5c0a8254-d85f-42ad-ab9e-5f14deb154a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_ba11869f-b3fc-427c-906d-a5574ea9ef12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c3e28bf9-8fbf-43a5-a8fc-a10969385735" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_ba11869f-b3fc-427c-906d-a5574ea9ef12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_959e855f-3f10-4976-bfd4-c0a24c9102a1" xlink:href="wst-20230331.xsd#wst_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c3e28bf9-8fbf-43a5-a8fc-a10969385735" xlink:to="loc_wst_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_959e855f-3f10-4976-bfd4-c0a24c9102a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_8445c117-7b73-4b59-9c14-094297381fd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c3e28bf9-8fbf-43a5-a8fc-a10969385735" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_8445c117-7b73-4b59-9c14-094297381fd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_02ee15ba-521c-4718-92e9-74d034f7d377" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c3e28bf9-8fbf-43a5-a8fc-a10969385735" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_02ee15ba-521c-4718-92e9-74d034f7d377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_94d0b05c-1be8-4f86-b7bb-711299fd7a40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c3e28bf9-8fbf-43a5-a8fc-a10969385735" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_94d0b05c-1be8-4f86-b7bb-711299fd7a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_5b797874-9680-41b0-8214-88f2e0702d43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c3e28bf9-8fbf-43a5-a8fc-a10969385735" xlink:to="loc_us-gaap_OperatingLeaseLiability_5b797874-9680-41b0-8214-88f2e0702d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="wst-20230331.xsd#LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.westpharma.com/role/AffiliatedCompaniesDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#AffiliatedCompaniesDetails"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/AffiliatedCompaniesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_5f8fdf5e-88fb-4bff-b3b6-1ae85c06692c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_5a452ff5-ad7d-4268-8eeb-0a6bc0678e53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_5f8fdf5e-88fb-4bff-b3b6-1ae85c06692c" xlink:to="loc_us-gaap_EquityMethodInvestments_5a452ff5-ad7d-4268-8eeb-0a6bc0678e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_4866da66-1833-4961-9440-8fd374d0e78e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_5f8fdf5e-88fb-4bff-b3b6-1ae85c06692c" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_4866da66-1833-4961-9440-8fd374d0e78e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_PurchasesAndRoyaltyPaymentsFromEquityMethodInvestees_31a82245-4d11-44df-b973-b2b749883402" xlink:href="wst-20230331.xsd#wst_PurchasesAndRoyaltyPaymentsFromEquityMethodInvestees"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_5f8fdf5e-88fb-4bff-b3b6-1ae85c06692c" xlink:to="loc_wst_PurchasesAndRoyaltyPaymentsFromEquityMethodInvestees_31a82245-4d11-44df-b973-b2b749883402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToAffiliateCurrentAndNoncurrent_442751f8-2e13-4232-9f6d-ceaff5f70edc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToAffiliateCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_5f8fdf5e-88fb-4bff-b3b6-1ae85c06692c" xlink:to="loc_us-gaap_DueToAffiliateCurrentAndNoncurrent_442751f8-2e13-4232-9f6d-ceaff5f70edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_SalesToEquityMethodInvestees_ad4821cb-b5d9-4169-b243-0f886554fa87" xlink:href="wst-20230331.xsd#wst_SalesToEquityMethodInvestees"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_5f8fdf5e-88fb-4bff-b3b6-1ae85c06692c" xlink:to="loc_wst_SalesToEquityMethodInvestees_ad4821cb-b5d9-4169-b243-0f886554fa87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromAffiliates_89d833e7-042e-486c-8144-75593fcbde61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromAffiliates"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_5f8fdf5e-88fb-4bff-b3b6-1ae85c06692c" xlink:to="loc_us-gaap_DueFromAffiliates_89d833e7-042e-486c-8144-75593fcbde61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/DebtLongtermDebtDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#DebtLongtermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/DebtLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_9474e848-4cf4-4f86-baaa-71be3c41c6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_977df7b4-d0d3-4c0c-9af2-f390df201c18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9474e848-4cf4-4f86-baaa-71be3c41c6cf" xlink:to="loc_us-gaap_DebtInstrumentTable_977df7b4-d0d3-4c0c-9af2-f390df201c18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_be795ca1-cb6d-4b93-8fbd-0d8bde3f8d42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_977df7b4-d0d3-4c0c-9af2-f390df201c18" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_be795ca1-cb6d-4b93-8fbd-0d8bde3f8d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a83e6897-3bdb-48e0-80ca-96152947568b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_be795ca1-cb6d-4b93-8fbd-0d8bde3f8d42" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a83e6897-3bdb-48e0-80ca-96152947568b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_TermLoanDue2024Member_271a3a7c-ccd9-42cb-abe3-11556d9da321" xlink:href="wst-20230331.xsd#wst_TermLoanDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a83e6897-3bdb-48e0-80ca-96152947568b" xlink:to="loc_wst_TermLoanDue2024Member_271a3a7c-ccd9-42cb-abe3-11556d9da321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_SeniorBNotesDue2024Member_ae11a36a-428b-4319-8dd0-01aa65801237" xlink:href="wst-20230331.xsd#wst_SeniorBNotesDue2024Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a83e6897-3bdb-48e0-80ca-96152947568b" xlink:to="loc_wst_SeniorBNotesDue2024Member_ae11a36a-428b-4319-8dd0-01aa65801237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_SeniorCNotesDue2027Member_25eda522-23d1-4837-9f4c-a3bfdd75aaab" xlink:href="wst-20230331.xsd#wst_SeniorCNotesDue2027Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a83e6897-3bdb-48e0-80ca-96152947568b" xlink:to="loc_wst_SeniorCNotesDue2027Member_25eda522-23d1-4837-9f4c-a3bfdd75aaab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_3726512d-5e08-4576-a919-b71b0fe01b52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_977df7b4-d0d3-4c0c-9af2-f390df201c18" xlink:to="loc_us-gaap_DebtInstrumentLineItems_3726512d-5e08-4576-a919-b71b0fe01b52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d8fa3842-a5dc-42e1-959a-2f1ad83ecabe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3726512d-5e08-4576-a919-b71b0fe01b52" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d8fa3842-a5dc-42e1-959a-2f1ad83ecabe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_23cbbb85-4082-477b-b924-f58b7848683c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3726512d-5e08-4576-a919-b71b0fe01b52" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_23cbbb85-4082-477b-b924-f58b7848683c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_367c2c60-ffb8-4078-977d-d89f37e26fde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3726512d-5e08-4576-a919-b71b0fe01b52" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_367c2c60-ffb8-4078-977d-d89f37e26fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_1af15867-7287-4f28-bdb0-d0a0ecc14ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3726512d-5e08-4576-a919-b71b0fe01b52" xlink:to="loc_us-gaap_LongTermDebt_1af15867-7287-4f28-bdb0-d0a0ecc14ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_58d109bb-63ea-4dd1-ba48-a9082a0c861d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3726512d-5e08-4576-a919-b71b0fe01b52" xlink:to="loc_us-gaap_LongTermDebtCurrent_58d109bb-63ea-4dd1-ba48-a9082a0c861d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_afe7f38d-aa14-4e27-bced-102e4a36c8cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3726512d-5e08-4576-a919-b71b0fe01b52" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_afe7f38d-aa14-4e27-bced-102e4a36c8cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/DebtLongtermDebtDetails_1" xlink:type="simple" xlink:href="wst-20230331.xsd#DebtLongtermDebtDetails_1"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/DebtLongtermDebtDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.westpharma.com/role/DebtCreditFacilityDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#DebtCreditFacilityDetails"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/DebtCreditFacilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d1255b42-730f-4398-96cd-69aac91a6688" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_1ea061e1-05d8-4836-aff3-d0792ce996b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d1255b42-730f-4398-96cd-69aac91a6688" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_1ea061e1-05d8-4836-aff3-d0792ce996b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_54813a1a-a2eb-4efe-8e55-d3664d4a1d12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_1ea061e1-05d8-4836-aff3-d0792ce996b2" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_54813a1a-a2eb-4efe-8e55-d3664d4a1d12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_dff5a95f-eeee-4111-a048-53f503957b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_54813a1a-a2eb-4efe-8e55-d3664d4a1d12" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_dff5a95f-eeee-4111-a048-53f503957b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_RevolvingCreditFacilityDue2024Member_b96d498a-5ca6-48b4-a943-215a9355822e" xlink:href="wst-20230331.xsd#wst_RevolvingCreditFacilityDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_dff5a95f-eeee-4111-a048-53f503957b4a" xlink:to="loc_wst_RevolvingCreditFacilityDue2024Member_b96d498a-5ca6-48b4-a943-215a9355822e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_TermLoanDue2024Member_dc6ee12b-a087-4ead-abf1-1fc73deb699b" xlink:href="wst-20230331.xsd#wst_TermLoanDue2024Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_dff5a95f-eeee-4111-a048-53f503957b4a" xlink:to="loc_wst_TermLoanDue2024Member_dc6ee12b-a087-4ead-abf1-1fc73deb699b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_fc8c24c3-c6ec-449f-a511-41ef9ff5bbfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_1ea061e1-05d8-4836-aff3-d0792ce996b2" xlink:to="loc_us-gaap_CreditFacilityAxis_fc8c24c3-c6ec-449f-a511-41ef9ff5bbfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_c94f5d97-01eb-4262-b8ba-19840dba266d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_fc8c24c3-c6ec-449f-a511-41ef9ff5bbfc" xlink:to="loc_us-gaap_CreditFacilityDomain_c94f5d97-01eb-4262-b8ba-19840dba266d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_50ba22c0-03c0-402d-a5fd-959228b4a1c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_c94f5d97-01eb-4262-b8ba-19840dba266d" xlink:to="loc_us-gaap_LetterOfCreditMember_50ba22c0-03c0-402d-a5fd-959228b4a1c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_3b9da317-9345-4859-ab95-fc0c1d4f7d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_1ea061e1-05d8-4836-aff3-d0792ce996b2" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_3b9da317-9345-4859-ab95-fc0c1d4f7d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_dbfba8c1-29bf-40b9-86ff-5035d8a9a640" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_3b9da317-9345-4859-ab95-fc0c1d4f7d8a" xlink:to="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_dbfba8c1-29bf-40b9-86ff-5035d8a9a640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_e79f2e90-9911-4574-98e8-eb2892147671" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_3b9da317-9345-4859-ab95-fc0c1d4f7d8a" xlink:to="loc_us-gaap_LineOfCredit_e79f2e90-9911-4574-98e8-eb2892147671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_4054221f-71c1-496b-a92d-b737fd4d0dad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_3b9da317-9345-4859-ab95-fc0c1d4f7d8a" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_4054221f-71c1-496b-a92d-b737fd4d0dad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_91fcda91-a08e-4590-a6ca-a3bcde643d33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_3b9da317-9345-4859-ab95-fc0c1d4f7d8a" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_91fcda91-a08e-4590-a6ca-a3bcde643d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_6f4b4a0a-686b-4c84-923d-5ea29fc0cb48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_3b9da317-9345-4859-ab95-fc0c1d4f7d8a" xlink:to="loc_us-gaap_DebtCurrent_6f4b4a0a-686b-4c84-923d-5ea29fc0cb48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_ebe3050a-368d-4ca8-ad4e-f9c9e2a9c1d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_3b9da317-9345-4859-ab95-fc0c1d4f7d8a" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_ebe3050a-368d-4ca8-ad4e-f9c9e2a9c1d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0c362233-f552-4466-af58-7b1e0e5b6a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_894ad1d2-3bca-46de-a748-32d03389943a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0c362233-f552-4466-af58-7b1e0e5b6a8c" xlink:to="loc_us-gaap_DerivativeTable_894ad1d2-3bca-46de-a748-32d03389943a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_db8b593b-2bd1-4721-b9b0-250df1641e93" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_894ad1d2-3bca-46de-a748-32d03389943a" xlink:to="loc_srt_CurrencyAxis_db8b593b-2bd1-4721-b9b0-250df1641e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_6aeab976-bc0d-4e38-b4d3-9ee7422ac6fd" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_db8b593b-2bd1-4721-b9b0-250df1641e93" xlink:to="loc_currency_AllCurrenciesDomain_6aeab976-bc0d-4e38-b4d3-9ee7422ac6fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_SGD_104b5b7c-9709-40e3-89e4-205837753be9" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_SGD"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_6aeab976-bc0d-4e38-b4d3-9ee7422ac6fd" xlink:to="loc_currency_SGD_104b5b7c-9709-40e3-89e4-205837753be9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_b483a53f-5719-4546-9a1c-7b37ffbf0b7d" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_6aeab976-bc0d-4e38-b4d3-9ee7422ac6fd" xlink:to="loc_currency_USD_b483a53f-5719-4546-9a1c-7b37ffbf0b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_JPY_49bb569a-de82-4c5f-8f71-c548c92e5050" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_JPY"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_6aeab976-bc0d-4e38-b4d3-9ee7422ac6fd" xlink:to="loc_currency_JPY_49bb569a-de82-4c5f-8f71-c548c92e5050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_9bc19462-4a1b-47b2-b23d-2e28ef23aa59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_894ad1d2-3bca-46de-a748-32d03389943a" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_9bc19462-4a1b-47b2-b23d-2e28ef23aa59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_dc7f20c2-8e98-4112-a1de-34609e681323" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_9bc19462-4a1b-47b2-b23d-2e28ef23aa59" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_dc7f20c2-8e98-4112-a1de-34609e681323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_b88f0642-7472-41c6-ab1d-f52266d0cffc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForwardContractsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_dc7f20c2-8e98-4112-a1de-34609e681323" xlink:to="loc_us-gaap_ForwardContractsMember_b88f0642-7472-41c6-ab1d-f52266d0cffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_04c43d60-6f35-4b0d-8d8a-f21f1f529cb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_dc7f20c2-8e98-4112-a1de-34609e681323" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_04c43d60-6f35-4b0d-8d8a-f21f1f529cb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_7853f443-eff8-46bd-a959-9f3a7dc099fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_dc7f20c2-8e98-4112-a1de-34609e681323" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_7853f443-eff8-46bd-a959-9f3a7dc099fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionMember_d877b02f-c41e-44dc-aba6-fc4bdc820359" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_dc7f20c2-8e98-4112-a1de-34609e681323" xlink:to="loc_us-gaap_OptionMember_d877b02f-c41e-44dc-aba6-fc4bdc820359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_bf9a92e3-cd2e-40e8-9f39-6ea08b342718" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_894ad1d2-3bca-46de-a748-32d03389943a" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_bf9a92e3-cd2e-40e8-9f39-6ea08b342718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_be1a3c77-d00b-4b56-ba78-081e1cf01427" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_bf9a92e3-cd2e-40e8-9f39-6ea08b342718" xlink:to="loc_us-gaap_HedgingRelationshipDomain_be1a3c77-d00b-4b56-ba78-081e1cf01427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_f3d25b3c-21e7-42c8-b409-4c567cce103e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_be1a3c77-d00b-4b56-ba78-081e1cf01427" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_f3d25b3c-21e7-42c8-b409-4c567cce103e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_173a5957-daec-49b2-a7b7-1d38ce062dec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueHedgingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_be1a3c77-d00b-4b56-ba78-081e1cf01427" xlink:to="loc_us-gaap_FairValueHedgingMember_173a5957-daec-49b2-a7b7-1d38ce062dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_d94f0cda-7620-4d7d-a35e-7f17e506be63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_894ad1d2-3bca-46de-a748-32d03389943a" xlink:to="loc_us-gaap_DerivativeLineItems_d94f0cda-7620-4d7d-a35e-7f17e506be63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_5907bfdc-9dd3-4d89-8104-a13e8bfe1fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_d94f0cda-7620-4d7d-a35e-7f17e506be63" xlink:to="loc_us-gaap_DerivativeNotionalAmount_5907bfdc-9dd3-4d89-8104-a13e8bfe1fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract_5496371b-58aa-4794-983e-66e34b442a37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_d94f0cda-7620-4d7d-a35e-7f17e506be63" xlink:to="loc_us-gaap_DerivativeTermOfContract_5496371b-58aa-4794-983e-66e34b442a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNonmonetaryNotionalAmountVolume_e8a80823-d3d4-4cd3-830b-bb3a97ab0923" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNonmonetaryNotionalAmountVolume"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_d94f0cda-7620-4d7d-a35e-7f17e506be63" xlink:to="loc_us-gaap_DerivativeNonmonetaryNotionalAmountVolume_e8a80823-d3d4-4cd3-830b-bb3a97ab0923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAveragePriceRiskOptionStrikePrice_cb51d615-9bbe-48c3-ba1d-4485004afab4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAveragePriceRiskOptionStrikePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_d94f0cda-7620-4d7d-a35e-7f17e506be63" xlink:to="loc_us-gaap_DerivativeAveragePriceRiskOptionStrikePrice_cb51d615-9bbe-48c3-ba1d-4485004afab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_250b6c69-4f71-4727-a0ba-dc924d1f6fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_d94f0cda-7620-4d7d-a35e-7f17e506be63" xlink:to="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_250b6c69-4f71-4727-a0ba-dc924d1f6fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignCurrencyContractsDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#DerivativeFinancialInstrumentsForeignCurrencyContractsDetails"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignCurrencyContractsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2266a3d9-91da-4cd0-ad1e-570aa427b8ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_e8aa9fa7-aa7a-4a5c-b23d-72ef65fb7c29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2266a3d9-91da-4cd0-ad1e-570aa427b8ce" xlink:to="loc_us-gaap_DerivativeTable_e8aa9fa7-aa7a-4a5c-b23d-72ef65fb7c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_79a8dbd5-83dd-4821-8a33-c5ae23d2dd13" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_e8aa9fa7-aa7a-4a5c-b23d-72ef65fb7c29" xlink:to="loc_srt_CurrencyAxis_79a8dbd5-83dd-4821-8a33-c5ae23d2dd13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_f0c4086d-fd85-4b75-94c9-1f38a2fc8f6d" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_79a8dbd5-83dd-4821-8a33-c5ae23d2dd13" xlink:to="loc_currency_AllCurrenciesDomain_f0c4086d-fd85-4b75-94c9-1f38a2fc8f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_01f737ed-104a-48a5-be29-eb2f2fe3479d" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_f0c4086d-fd85-4b75-94c9-1f38a2fc8f6d" xlink:to="loc_currency_USD_01f737ed-104a-48a5-be29-eb2f2fe3479d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_JPY_11c66832-0e2e-40cd-a9f5-8bbf07daad28" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_JPY"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_f0c4086d-fd85-4b75-94c9-1f38a2fc8f6d" xlink:to="loc_currency_JPY_11c66832-0e2e-40cd-a9f5-8bbf07daad28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_SGD_e996f747-2362-4313-af97-cd034124b76a" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_SGD"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_f0c4086d-fd85-4b75-94c9-1f38a2fc8f6d" xlink:to="loc_currency_SGD_e996f747-2362-4313-af97-cd034124b76a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_f0290792-0045-487a-81e5-69846c37fbc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_e8aa9fa7-aa7a-4a5c-b23d-72ef65fb7c29" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_f0290792-0045-487a-81e5-69846c37fbc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_db22e676-30d8-4eae-852b-78cdc8b95e20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_f0290792-0045-487a-81e5-69846c37fbc1" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_db22e676-30d8-4eae-852b-78cdc8b95e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_bc4a66ba-15f7-4407-a652-58431ab4e136" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_db22e676-30d8-4eae-852b-78cdc8b95e20" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_bc4a66ba-15f7-4407-a652-58431ab4e136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_f081c86e-b340-452c-bafd-87ec5dd1ee99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_db22e676-30d8-4eae-852b-78cdc8b95e20" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_f081c86e-b340-452c-bafd-87ec5dd1ee99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_c0f4560d-d373-4de7-9722-629e75ecf25f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_e8aa9fa7-aa7a-4a5c-b23d-72ef65fb7c29" xlink:to="loc_us-gaap_HedgingDesignationAxis_c0f4560d-d373-4de7-9722-629e75ecf25f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_c7fc5ef7-40c7-40c4-90dc-4b7742bb8a73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_c0f4560d-d373-4de7-9722-629e75ecf25f" xlink:to="loc_us-gaap_HedgingDesignationDomain_c7fc5ef7-40c7-40c4-90dc-4b7742bb8a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_89eafc21-8c08-4602-9488-ac4c878b3186" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_c7fc5ef7-40c7-40c4-90dc-4b7742bb8a73" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_89eafc21-8c08-4602-9488-ac4c878b3186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PositionAxis_fb8dc25b-4edd-49e1-a3f5-727e82c6f4d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PositionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_e8aa9fa7-aa7a-4a5c-b23d-72ef65fb7c29" xlink:to="loc_us-gaap_PositionAxis_fb8dc25b-4edd-49e1-a3f5-727e82c6f4d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PositionDomain_34d25241-035c-4b73-9a96-034cf68bc7d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PositionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PositionAxis_fb8dc25b-4edd-49e1-a3f5-727e82c6f4d1" xlink:to="loc_us-gaap_PositionDomain_34d25241-035c-4b73-9a96-034cf68bc7d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongMember_5673e7ff-72bf-4520-80ea-025dec4876a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PositionDomain_34d25241-035c-4b73-9a96-034cf68bc7d5" xlink:to="loc_us-gaap_LongMember_5673e7ff-72bf-4520-80ea-025dec4876a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortMember_f05a1ab7-94e9-469b-9123-4fec8fe7b722" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PositionDomain_34d25241-035c-4b73-9a96-034cf68bc7d5" xlink:to="loc_us-gaap_ShortMember_f05a1ab7-94e9-469b-9123-4fec8fe7b722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_5ebf7a49-fb04-4ffc-97cd-15396ce50815" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_e8aa9fa7-aa7a-4a5c-b23d-72ef65fb7c29" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_5ebf7a49-fb04-4ffc-97cd-15396ce50815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_ba6ad1b1-1c26-4e96-9014-bf78dfa3e4a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_5ebf7a49-fb04-4ffc-97cd-15396ce50815" xlink:to="loc_us-gaap_HedgingRelationshipDomain_ba6ad1b1-1c26-4e96-9014-bf78dfa3e4a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_be36fbad-5b1f-45cb-82aa-3217e281ef16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_ba6ad1b1-1c26-4e96-9014-bf78dfa3e4a8" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_be36fbad-5b1f-45cb-82aa-3217e281ef16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_26a2ea60-033d-46d6-b6d3-2f4f3e4d65b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_e8aa9fa7-aa7a-4a5c-b23d-72ef65fb7c29" xlink:to="loc_us-gaap_DerivativeLineItems_26a2ea60-033d-46d6-b6d3-2f4f3e4d65b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_729c8e51-ab6a-4b95-a9c5-384dd967a555" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_26a2ea60-033d-46d6-b6d3-2f4f3e4d65b9" xlink:to="loc_us-gaap_DerivativeNotionalAmount_729c8e51-ab6a-4b95-a9c5-384dd967a555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9dbb21af-07ef-4854-a015-3e74a2b579b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_64dad1cb-f836-4710-812b-589aafcdcba9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9dbb21af-07ef-4854-a015-3e74a2b579b2" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_64dad1cb-f836-4710-812b-589aafcdcba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_051cf302-17c1-4f23-a2c2-e59e62bfd7c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_64dad1cb-f836-4710-812b-589aafcdcba9" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_051cf302-17c1-4f23-a2c2-e59e62bfd7c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6638a625-6916-475e-9d3c-157f247e977e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_051cf302-17c1-4f23-a2c2-e59e62bfd7c0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6638a625-6916-475e-9d3c-157f247e977e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_OtherExpenseIncomeMember_61fc2050-b328-4767-b723-33da8a344a01" xlink:href="wst-20230331.xsd#wst_OtherExpenseIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6638a625-6916-475e-9d3c-157f247e977e" xlink:to="loc_wst_OtherExpenseIncomeMember_61fc2050-b328-4767-b723-33da8a344a01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_NetSalesMember_03b80434-3474-4a9a-a591-1c5de8436ff0" xlink:href="wst-20230331.xsd#wst_NetSalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6638a625-6916-475e-9d3c-157f247e977e" xlink:to="loc_wst_NetSalesMember_03b80434-3474-4a9a-a591-1c5de8436ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_2c0c4f67-8e4b-478e-b04e-803d8796c4fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6638a625-6916-475e-9d3c-157f247e977e" xlink:to="loc_us-gaap_CostOfSalesMember_2c0c4f67-8e4b-478e-b04e-803d8796c4fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_0ec727d7-2569-4022-ab7b-9f8bbba581b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6638a625-6916-475e-9d3c-157f247e977e" xlink:to="loc_us-gaap_InterestExpenseMember_0ec727d7-2569-4022-ab7b-9f8bbba581b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_cdf03f52-1101-43d8-92cd-ef8db58fb790" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_64dad1cb-f836-4710-812b-589aafcdcba9" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_cdf03f52-1101-43d8-92cd-ef8db58fb790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_72b31b64-c5d5-480c-a6ef-3648eff33143" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_cdf03f52-1101-43d8-92cd-ef8db58fb790" xlink:to="loc_us-gaap_HedgingRelationshipDomain_72b31b64-c5d5-480c-a6ef-3648eff33143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_0f73c746-ad38-4913-8852-34cee727c6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_72b31b64-c5d5-480c-a6ef-3648eff33143" xlink:to="loc_us-gaap_FairValueHedgingMember_0f73c746-ad38-4913-8852-34cee727c6cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_e45543ef-4b39-4b87-8548-0aca5bf36dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_72b31b64-c5d5-480c-a6ef-3648eff33143" xlink:to="loc_us-gaap_CashFlowHedgingMember_e45543ef-4b39-4b87-8548-0aca5bf36dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_5ab984af-3e8d-4a7b-92dd-6ecad53e89fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_72b31b64-c5d5-480c-a6ef-3648eff33143" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_5ab984af-3e8d-4a7b-92dd-6ecad53e89fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_b6164967-7b99-42c5-bba6-f90a00c1c62f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_64dad1cb-f836-4710-812b-589aafcdcba9" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_b6164967-7b99-42c5-bba6-f90a00c1c62f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_1f98d393-d329-49e1-8e7c-65c62a1f760e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_b6164967-7b99-42c5-bba6-f90a00c1c62f" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_1f98d393-d329-49e1-8e7c-65c62a1f760e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_fb1f0510-13d4-469a-9df5-b90217460fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_1f98d393-d329-49e1-8e7c-65c62a1f760e" xlink:to="loc_us-gaap_ForeignExchangeContractMember_fb1f0510-13d4-469a-9df5-b90217460fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryLockMember_3bb93140-6de3-4d0c-ab12-984f31f9e1ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryLockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_1f98d393-d329-49e1-8e7c-65c62a1f760e" xlink:to="loc_us-gaap_TreasuryLockMember_3bb93140-6de3-4d0c-ab12-984f31f9e1ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_cb12eae9-20de-4736-a874-12a13cd8f793" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrencySwapMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_1f98d393-d329-49e1-8e7c-65c62a1f760e" xlink:to="loc_us-gaap_CurrencySwapMember_cb12eae9-20de-4736-a874-12a13cd8f793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_ebe959bb-b1e4-4e53-9a7e-5d2ce06c2fcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_64dad1cb-f836-4710-812b-589aafcdcba9" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_ebe959bb-b1e4-4e53-9a7e-5d2ce06c2fcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_b3574f88-19dd-44d8-9dc1-904a1c977ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_ebe959bb-b1e4-4e53-9a7e-5d2ce06c2fcc" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_b3574f88-19dd-44d8-9dc1-904a1c977ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_b0a6a790-26f0-4d3d-985e-b936db945e35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_ebe959bb-b1e4-4e53-9a7e-5d2ce06c2fcc" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_b0a6a790-26f0-4d3d-985e-b936db945e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet_3da509b7-0cdc-4b59-bcd7-024fb4f350cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_ebe959bb-b1e4-4e53-9a7e-5d2ce06c2fcc" xlink:to="loc_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet_3da509b7-0cdc-4b59-bcd7-024fb4f350cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings_95e10871-7350-4a35-a159-aae36149d24b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_ebe959bb-b1e4-4e53-9a7e-5d2ce06c2fcc" xlink:to="loc_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings_95e10871-7350-4a35-a159-aae36149d24b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_3d7a625c-39bd-4a8d-a031-9cf66985c8ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_ebe959bb-b1e4-4e53-9a7e-5d2ce06c2fcc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_3d7a625c-39bd-4a8d-a031-9cf66985c8ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_2b9c2821-7a40-4d8d-93cd-fabacb0b3f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_ebe959bb-b1e4-4e53-9a7e-5d2ce06c2fcc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_2b9c2821-7a40-4d8d-93cd-fabacb0b3f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_02e34d41-7f53-4065-9f15-d5fb0eba44b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_ebe959bb-b1e4-4e53-9a7e-5d2ce06c2fcc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_02e34d41-7f53-4065-9f15-d5fb0eba44b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax_f1e4cd61-b76f-406b-9322-3ce5354f076b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_ebe959bb-b1e4-4e53-9a7e-5d2ce06c2fcc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax_f1e4cd61-b76f-406b-9322-3ce5354f076b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_09e89f1b-52b7-424b-9a07-931921b626e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_ebe959bb-b1e4-4e53-9a7e-5d2ce06c2fcc" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_09e89f1b-52b7-424b-9a07-931921b626e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_020f2176-28cd-4671-8b70-c3cb34b83dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_efc3d067-7780-4dfb-a11e-854e34506844" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_020f2176-28cd-4671-8b70-c3cb34b83dc6" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_efc3d067-7780-4dfb-a11e-854e34506844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_e16bfe64-d8d2-4792-a20f-741c40ac4888" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_efc3d067-7780-4dfb-a11e-854e34506844" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_e16bfe64-d8d2-4792-a20f-741c40ac4888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a2b9cd30-c1f3-4658-8673-9a20b896e7ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_e16bfe64-d8d2-4792-a20f-741c40ac4888" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a2b9cd30-c1f3-4658-8673-9a20b896e7ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommodityOptionMember_6717c5d6-1101-4608-ac0e-0936d11f9199" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommodityOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a2b9cd30-c1f3-4658-8673-9a20b896e7ef" xlink:to="loc_us-gaap_CommodityOptionMember_6717c5d6-1101-4608-ac0e-0936d11f9199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_46d8e9a1-6b66-4055-8f6a-8d5f721e1a72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_efc3d067-7780-4dfb-a11e-854e34506844" xlink:to="loc_us-gaap_HedgingDesignationAxis_46d8e9a1-6b66-4055-8f6a-8d5f721e1a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_77c2f626-eb54-4d0c-b467-b6188fbe905d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_46d8e9a1-6b66-4055-8f6a-8d5f721e1a72" xlink:to="loc_us-gaap_HedgingDesignationDomain_77c2f626-eb54-4d0c-b467-b6188fbe905d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_922453cc-a79c-4201-a906-7e167a42cc78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_77c2f626-eb54-4d0c-b467-b6188fbe905d" xlink:to="loc_us-gaap_NondesignatedMember_922453cc-a79c-4201-a906-7e167a42cc78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_30297929-9cf5-49b0-ba26-25f53f96f43e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_efc3d067-7780-4dfb-a11e-854e34506844" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_30297929-9cf5-49b0-ba26-25f53f96f43e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e407ace7-07db-46aa-9464-c6f2bb1f216d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_30297929-9cf5-49b0-ba26-25f53f96f43e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e407ace7-07db-46aa-9464-c6f2bb1f216d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_OtherExpenseIncomeMember_0ba92a34-b22b-42ac-86a2-ec00cc34ed97" xlink:href="wst-20230331.xsd#wst_OtherExpenseIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e407ace7-07db-46aa-9464-c6f2bb1f216d" xlink:to="loc_wst_OtherExpenseIncomeMember_0ba92a34-b22b-42ac-86a2-ec00cc34ed97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_4af4cc3f-3cd2-4baa-9151-642c53f7ab33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_efc3d067-7780-4dfb-a11e-854e34506844" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_4af4cc3f-3cd2-4baa-9151-642c53f7ab33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_7d852967-9b6f-4dd0-91bf-393e41e9b9f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_4af4cc3f-3cd2-4baa-9151-642c53f7ab33" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_7d852967-9b6f-4dd0-91bf-393e41e9b9f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_264af656-bc8e-4926-98af-b734d87f03a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1697704c-2a0a-4487-9489-dabb7ed77828" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_264af656-bc8e-4926-98af-b734d87f03a7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1697704c-2a0a-4487-9489-dabb7ed77828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_67b0b096-468d-409f-9479-72db25995258" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1697704c-2a0a-4487-9489-dabb7ed77828" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_67b0b096-468d-409f-9479-72db25995258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_976476e8-bd0f-439a-bd05-eef9c4d55a7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_67b0b096-468d-409f-9479-72db25995258" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_976476e8-bd0f-439a-bd05-eef9c4d55a7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_f7404648-e749-4a25-8bb8-162817c15646" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_976476e8-bd0f-439a-bd05-eef9c4d55a7e" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_f7404648-e749-4a25-8bb8-162817c15646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_54443f30-7f41-468c-b208-93b24f5a8c51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_976476e8-bd0f-439a-bd05-eef9c4d55a7e" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_54443f30-7f41-468c-b208-93b24f5a8c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_0832e549-f0a7-413a-b7ed-ef22fce3415f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_976476e8-bd0f-439a-bd05-eef9c4d55a7e" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_0832e549-f0a7-413a-b7ed-ef22fce3415f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_e1b2d160-021a-42b5-af84-2d429b748d71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1697704c-2a0a-4487-9489-dabb7ed77828" xlink:to="loc_us-gaap_FinancialInstrumentAxis_e1b2d160-021a-42b5-af84-2d429b748d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_159ada3c-1474-41de-b816-f83d0ca6082e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_e1b2d160-021a-42b5-af84-2d429b748d71" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_159ada3c-1474-41de-b816-f83d0ca6082e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_7a31200e-63d6-40fd-9b22-a0c7270c8270" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrencySwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_159ada3c-1474-41de-b816-f83d0ca6082e" xlink:to="loc_us-gaap_CurrencySwapMember_7a31200e-63d6-40fd-9b22-a0c7270c8270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommodityMember_a348dea8-543f-4b6e-88af-003742f327f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommodityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_159ada3c-1474-41de-b816-f83d0ca6082e" xlink:to="loc_us-gaap_CommodityMember_a348dea8-543f-4b6e-88af-003742f327f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_97892b2a-f02c-43ee-8f07-383880cb30a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_159ada3c-1474-41de-b816-f83d0ca6082e" xlink:to="loc_us-gaap_ForeignExchangeContractMember_97892b2a-f02c-43ee-8f07-383880cb30a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d0354479-512a-469a-aa97-f58476f19d43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1697704c-2a0a-4487-9489-dabb7ed77828" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d0354479-512a-469a-aa97-f58476f19d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_a8cf9088-5aa8-4fc6-8eb9-a4a753c15389" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d0354479-512a-469a-aa97-f58476f19d43" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_a8cf9088-5aa8-4fc6-8eb9-a4a753c15389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationPlanAssets_9315903e-c00b-424a-91b9-d82636d33ea2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a8cf9088-5aa8-4fc6-8eb9-a4a753c15389" xlink:to="loc_us-gaap_DeferredCompensationPlanAssets_9315903e-c00b-424a-91b9-d82636d33ea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_d8f36443-e4cb-42aa-87d1-d5e56303889e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a8cf9088-5aa8-4fc6-8eb9-a4a753c15389" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_d8f36443-e4cb-42aa-87d1-d5e56303889e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_39c610ae-9923-4d96-b3ed-3bd2e60993d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a8cf9088-5aa8-4fc6-8eb9-a4a753c15389" xlink:to="loc_us-gaap_DerivativeAssets_39c610ae-9923-4d96-b3ed-3bd2e60993d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_6a220037-8b7c-42b1-996b-c354bf7ac7e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a8cf9088-5aa8-4fc6-8eb9-a4a753c15389" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_6a220037-8b7c-42b1-996b-c354bf7ac7e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2261506d-adaa-4d97-8417-0690c5c8b5b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d0354479-512a-469a-aa97-f58476f19d43" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2261506d-adaa-4d97-8417-0690c5c8b5b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_660d014b-3074-4aa1-a1ad-718471ebbcad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2261506d-adaa-4d97-8417-0690c5c8b5b9" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_660d014b-3074-4aa1-a1ad-718471ebbcad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent_a4b66026-ef5c-4cc9-8346-376207c66b65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2261506d-adaa-4d97-8417-0690c5c8b5b9" xlink:to="loc_us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent_a4b66026-ef5c-4cc9-8346-376207c66b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_cb7481ad-06a6-481a-a6fe-e68403c04938" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2261506d-adaa-4d97-8417-0690c5c8b5b9" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_cb7481ad-06a6-481a-a6fe-e68403c04938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_670ec332-9a55-4b51-b7f9-aaa770bbc811" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2261506d-adaa-4d97-8417-0690c5c8b5b9" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_670ec332-9a55-4b51-b7f9-aaa770bbc811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/FairValueMeasurementsOtherFinancialInstrumentsDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#FairValueMeasurementsOtherFinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/FairValueMeasurementsOtherFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2e8dc69e-287e-4a29-83a4-1194862921b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_OtherFinancialInstrumentsAbstract_6bb0d43e-e788-4db1-b9db-4ea923043b1a" xlink:href="wst-20230331.xsd#wst_OtherFinancialInstrumentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2e8dc69e-287e-4a29-83a4-1194862921b5" xlink:to="loc_wst_OtherFinancialInstrumentsAbstract_6bb0d43e-e788-4db1-b9db-4ea923043b1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_83ed64d7-8650-45e7-880b-ae80cb8058ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wst_OtherFinancialInstrumentsAbstract_6bb0d43e-e788-4db1-b9db-4ea923043b1a" xlink:to="loc_us-gaap_LongTermDebtFairValue_83ed64d7-8650-45e7-880b-ae80cb8058ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_ce720abb-b38e-4f4e-8403-e465801e665a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wst_OtherFinancialInstrumentsAbstract_6bb0d43e-e788-4db1-b9db-4ea923043b1a" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_ce720abb-b38e-4f4e-8403-e465801e665a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_80253c26-8413-4d52-9da6-2134c1a9177e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_51b4513f-d289-42fd-aaa7-37ec9972e1a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_80253c26-8413-4d52-9da6-2134c1a9177e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_51b4513f-d289-42fd-aaa7-37ec9972e1a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b55c6dc2-6b6d-4df5-846d-9291e2d39d62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_51b4513f-d289-42fd-aaa7-37ec9972e1a4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b55c6dc2-6b6d-4df5-846d-9291e2d39d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_36f80e94-0e77-436e-b5d8-ff8d30d4e4a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b55c6dc2-6b6d-4df5-846d-9291e2d39d62" xlink:to="loc_us-gaap_EquityComponentDomain_36f80e94-0e77-436e-b5d8-ff8d30d4e4a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_04786310-a395-4db5-b083-2eff6e6ab5ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_36f80e94-0e77-436e-b5d8-ff8d30d4e4a1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_04786310-a395-4db5-b083-2eff6e6ab5ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_e3177b99-45e1-4e3c-b47f-b15c85f1e092" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_04786310-a395-4db5-b083-2eff6e6ab5ee" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_e3177b99-45e1-4e3c-b47f-b15c85f1e092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_07d148cc-5de6-4f0f-96ff-d458789c75f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_04786310-a395-4db5-b083-2eff6e6ab5ee" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_07d148cc-5de6-4f0f-96ff-d458789c75f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_e7704233-b74f-46ed-ba20-32f70afa0a5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_04786310-a395-4db5-b083-2eff6e6ab5ee" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_e7704233-b74f-46ed-ba20-32f70afa0a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_e930fa69-463b-4779-876c-b52acfb82def" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_04786310-a395-4db5-b083-2eff6e6ab5ee" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_e930fa69-463b-4779-876c-b52acfb82def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_33227792-633a-436b-9c02-a9e2bc24e268" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_51b4513f-d289-42fd-aaa7-37ec9972e1a4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_33227792-633a-436b-9c02-a9e2bc24e268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5a81faa7-269d-4cdc-86a4-f135c712f8e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_33227792-633a-436b-9c02-a9e2bc24e268" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5a81faa7-269d-4cdc-86a4-f135c712f8e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_01c57741-a6cd-45fb-b868-b45b919659b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5a81faa7-269d-4cdc-86a4-f135c712f8e8" xlink:to="loc_us-gaap_StockholdersEquity_01c57741-a6cd-45fb-b868-b45b919659b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_518247e5-9132-4298-b3b3-7ee537caf79e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5a81faa7-269d-4cdc-86a4-f135c712f8e8" xlink:to="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_518247e5-9132-4298-b3b3-7ee537caf79e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_d969763c-9c07-4d88-815c-7e024993e13d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5a81faa7-269d-4cdc-86a4-f135c712f8e8" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_d969763c-9c07-4d88-815c-7e024993e13d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0ad558fa-8c12-4391-bdcf-051a9f1b62e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5a81faa7-269d-4cdc-86a4-f135c712f8e8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0ad558fa-8c12-4391-bdcf-051a9f1b62e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b066677f-a0b3-407b-b9dc-987490454f1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5a81faa7-269d-4cdc-86a4-f135c712f8e8" xlink:to="loc_us-gaap_StockholdersEquity_b066677f-a0b3-407b-b9dc-987490454f1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f7702a21-eff6-4064-b392-43482582c10c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_371d6887-c66a-4033-9be4-a0f8e4d11b52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f7702a21-eff6-4064-b392-43482582c10c" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_371d6887-c66a-4033-9be4-a0f8e4d11b52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_ea5f6fbf-417f-4f0c-a25d-b1a33147360b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_371d6887-c66a-4033-9be4-a0f8e4d11b52" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_ea5f6fbf-417f-4f0c-a25d-b1a33147360b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c5a534e9-cba9-442a-acef-5dcec4e8e900" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_ea5f6fbf-417f-4f0c-a25d-b1a33147360b" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c5a534e9-cba9-442a-acef-5dcec4e8e900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_8033030d-994e-4467-9acf-6088be3c3646" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c5a534e9-cba9-442a-acef-5dcec4e8e900" xlink:to="loc_us-gaap_ForeignExchangeContractMember_8033030d-994e-4467-9acf-6088be3c3646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryLockMember_a562c62d-2d40-4b1c-bd2e-0f0775ddf3a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryLockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c5a534e9-cba9-442a-acef-5dcec4e8e900" xlink:to="loc_us-gaap_TreasuryLockMember_a562c62d-2d40-4b1c-bd2e-0f0775ddf3a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_da11be98-482c-49f8-87a0-4485ed3ed8ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_371d6887-c66a-4033-9be4-a0f8e4d11b52" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_da11be98-482c-49f8-87a0-4485ed3ed8ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_c06b1e5c-782a-41dc-8b92-0060f3fd3ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_da11be98-482c-49f8-87a0-4485ed3ed8ad" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_c06b1e5c-782a-41dc-8b92-0060f3fd3ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_b5d8e36f-8143-49e2-8b4e-7317e7097e74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_c06b1e5c-782a-41dc-8b92-0060f3fd3ca2" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_b5d8e36f-8143-49e2-8b4e-7317e7097e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f621d90e-9ed0-4f64-826e-b92b77350b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_371d6887-c66a-4033-9be4-a0f8e4d11b52" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f621d90e-9ed0-4f64-826e-b92b77350b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c876d00f-2246-4442-835e-dbdaf52dd88f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f621d90e-9ed0-4f64-826e-b92b77350b4e" xlink:to="loc_us-gaap_EquityComponentDomain_c876d00f-2246-4442-835e-dbdaf52dd88f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_e8ca23f2-a934-4532-9cbb-8206cd06871b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c876d00f-2246-4442-835e-dbdaf52dd88f" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_e8ca23f2-a934-4532-9cbb-8206cd06871b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_b5a420c0-d385-4d4b-8444-62684a41c582" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c876d00f-2246-4442-835e-dbdaf52dd88f" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_b5a420c0-d385-4d4b-8444-62684a41c582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_cc680d60-5e0f-4651-a873-8770966905cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_371d6887-c66a-4033-9be4-a0f8e4d11b52" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_cc680d60-5e0f-4651-a873-8770966905cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_081beb39-3033-4e97-82da-34671580ba27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_cc680d60-5e0f-4651-a873-8770966905cf" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_081beb39-3033-4e97-82da-34671580ba27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_2b2872d4-9a86-46ee-a42b-1e00b7bc60af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_cc680d60-5e0f-4651-a873-8770966905cf" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_2b2872d4-9a86-46ee-a42b-1e00b7bc60af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_9b6790b0-7527-47ca-ae47-0e0651fe8618" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_cc680d60-5e0f-4651-a873-8770966905cf" xlink:to="loc_us-gaap_InterestExpense_9b6790b0-7527-47ca-ae47-0e0651fe8618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_d8c84cb6-40fc-45b9-a437-8abb7ec62538" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_cc680d60-5e0f-4651-a873-8770966905cf" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_d8c84cb6-40fc-45b9-a437-8abb7ec62538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_fe8f4bc0-7782-43c1-aae8-458b6064436d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_cc680d60-5e0f-4651-a873-8770966905cf" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_fe8f4bc0-7782-43c1-aae8-458b6064436d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_b68a0ea6-9991-4427-b66f-07c9a81dc687" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_cc680d60-5e0f-4651-a873-8770966905cf" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_b68a0ea6-9991-4427-b66f-07c9a81dc687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_60abbc3c-2af7-4aa0-976e-a9dcb6bbbb8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_cc680d60-5e0f-4651-a873-8770966905cf" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_60abbc3c-2af7-4aa0-976e-a9dcb6bbbb8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_88fffe2a-2b23-45d5-98c7-5a2429579ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_cc680d60-5e0f-4651-a873-8770966905cf" xlink:to="loc_us-gaap_NetIncomeLoss_88fffe2a-2b23-45d5-98c7-5a2429579ee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#ShareholdersEquityChangeinShareholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_af28341e-6ba8-4a15-95b8-e6ea2b02ab6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_61c4064a-8966-46b4-8ded-55decc7fc446" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_af28341e-6ba8-4a15-95b8-e6ea2b02ab6b" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_61c4064a-8966-46b4-8ded-55decc7fc446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ae1f4b60-3a89-45de-b3ee-2aa8d9b0d14c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_61c4064a-8966-46b4-8ded-55decc7fc446" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ae1f4b60-3a89-45de-b3ee-2aa8d9b0d14c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8eee42cf-1f65-4859-8b90-6a0802ffd79d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ae1f4b60-3a89-45de-b3ee-2aa8d9b0d14c" xlink:to="loc_us-gaap_EquityComponentDomain_8eee42cf-1f65-4859-8b90-6a0802ffd79d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9a38abf1-1c70-4d63-a88e-695480aeae01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8eee42cf-1f65-4859-8b90-6a0802ffd79d" xlink:to="loc_us-gaap_CommonStockMember_9a38abf1-1c70-4d63-a88e-695480aeae01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_eca601a7-43ca-4da8-87c5-df6c86726b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8eee42cf-1f65-4859-8b90-6a0802ffd79d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_eca601a7-43ca-4da8-87c5-df6c86726b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_ffa06d75-7cb4-4e9c-8b84-82486f1190d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8eee42cf-1f65-4859-8b90-6a0802ffd79d" xlink:to="loc_us-gaap_TreasuryStockCommonMember_ffa06d75-7cb4-4e9c-8b84-82486f1190d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_4b448b25-a52f-42f7-87fd-e009718057e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8eee42cf-1f65-4859-8b90-6a0802ffd79d" xlink:to="loc_us-gaap_RetainedEarningsMember_4b448b25-a52f-42f7-87fd-e009718057e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_36413be9-9c72-46fb-8b99-ccd421518a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8eee42cf-1f65-4859-8b90-6a0802ffd79d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_36413be9-9c72-46fb-8b99-ccd421518a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_a52ed5a7-b33a-4680-ae19-6a7994519397" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_61c4064a-8966-46b4-8ded-55decc7fc446" xlink:to="loc_us-gaap_ClassOfStockLineItems_a52ed5a7-b33a-4680-ae19-6a7994519397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fc1fffc2-1ec9-45b8-aca8-a2c5ec6625cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a52ed5a7-b33a-4680-ae19-6a7994519397" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fc1fffc2-1ec9-45b8-aca8-a2c5ec6625cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_6b779d13-cce4-434f-84cc-39d0740b33c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fc1fffc2-1ec9-45b8-aca8-a2c5ec6625cb" xlink:to="loc_us-gaap_SharesIssued_6b779d13-cce4-434f-84cc-39d0740b33c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fcd6a543-3091-436e-a05a-80dd3afc8f20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fc1fffc2-1ec9-45b8-aca8-a2c5ec6625cb" xlink:to="loc_us-gaap_StockholdersEquity_fcd6a543-3091-436e-a05a-80dd3afc8f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_31c26096-40fa-4088-b959-7f87c2a37601" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fc1fffc2-1ec9-45b8-aca8-a2c5ec6625cb" xlink:to="loc_us-gaap_TreasuryStockCommonShares_31c26096-40fa-4088-b959-7f87c2a37601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_eb30cf0f-376e-40e0-8b13-5826e911712b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fc1fffc2-1ec9-45b8-aca8-a2c5ec6625cb" xlink:to="loc_us-gaap_NetIncomeLoss_eb30cf0f-376e-40e0-8b13-5826e911712b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2e6bdae8-4a46-4a9b-a14f-f04bc9abeea6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fc1fffc2-1ec9-45b8-aca8-a2c5ec6625cb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2e6bdae8-4a46-4a9b-a14f-f04bc9abeea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_500174eb-b65c-431d-9a23-ddffcbbd904a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fc1fffc2-1ec9-45b8-aca8-a2c5ec6625cb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_500174eb-b65c-431d-9a23-ddffcbbd904a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_e9e2727d-9b5f-4f0a-a3de-706885db8174" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fc1fffc2-1ec9-45b8-aca8-a2c5ec6625cb" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_e9e2727d-9b5f-4f0a-a3de-706885db8174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_2c5f2059-b94d-4e66-95d2-8545f1c50d22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fc1fffc2-1ec9-45b8-aca8-a2c5ec6625cb" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_2c5f2059-b94d-4e66-95d2-8545f1c50d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_da31b9d2-78a8-4943-8b1b-548e65cb10bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fc1fffc2-1ec9-45b8-aca8-a2c5ec6625cb" xlink:to="loc_us-gaap_DividendsCommonStockCash_da31b9d2-78a8-4943-8b1b-548e65cb10bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_07ced9ed-f956-49b2-bac0-7de694c8a48d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fc1fffc2-1ec9-45b8-aca8-a2c5ec6625cb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_07ced9ed-f956-49b2-bac0-7de694c8a48d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_739654b2-3453-46c8-9c0d-edffbb19a245" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fc1fffc2-1ec9-45b8-aca8-a2c5ec6625cb" xlink:to="loc_us-gaap_SharesIssued_739654b2-3453-46c8-9c0d-edffbb19a245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_eaefc7f5-a892-4397-80e2-f15a6c609e77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fc1fffc2-1ec9-45b8-aca8-a2c5ec6625cb" xlink:to="loc_us-gaap_StockholdersEquity_eaefc7f5-a892-4397-80e2-f15a6c609e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_143e0a52-6c58-4fff-a2c2-cfe367dcb01d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fc1fffc2-1ec9-45b8-aca8-a2c5ec6625cb" xlink:to="loc_us-gaap_TreasuryStockCommonShares_143e0a52-6c58-4fff-a2c2-cfe367dcb01d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/ShareholdersEquitySupplementalEquityInformationDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#ShareholdersEquitySupplementalEquityInformationDetails"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/ShareholdersEquitySupplementalEquityInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_d2e18261-632b-4339-a66a-0847e9956850" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_f8a65c8a-a057-4911-ae67-b2da0e3d21b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d2e18261-632b-4339-a66a-0847e9956850" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_f8a65c8a-a057-4911-ae67-b2da0e3d21b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/StockBasedCompensationDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#StockBasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/StockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_84077e36-c288-4bd4-a196-80b26a0427f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8674a5f2-860d-4b83-8efe-0f1911ea17ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_84077e36-c288-4bd4-a196-80b26a0427f2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8674a5f2-860d-4b83-8efe-0f1911ea17ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_76cb6ae7-a578-4efe-926b-3ed8d8d9407f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8674a5f2-860d-4b83-8efe-0f1911ea17ab" xlink:to="loc_us-gaap_AwardTypeAxis_76cb6ae7-a578-4efe-926b-3ed8d8d9407f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d876f101-5416-418a-92f2-929ab0eedb9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_76cb6ae7-a578-4efe-926b-3ed8d8d9407f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d876f101-5416-418a-92f2-929ab0eedb9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_cb85b5b5-0291-4715-ab76-a25add3a417c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d876f101-5416-418a-92f2-929ab0eedb9a" xlink:to="loc_us-gaap_PerformanceSharesMember_cb85b5b5-0291-4715-ab76-a25add3a417c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_3fdaf18a-604c-4ff6-9b29-198ab0978dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d876f101-5416-418a-92f2-929ab0eedb9a" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_3fdaf18a-604c-4ff6-9b29-198ab0978dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4c57d20e-79ec-4219-bf3e-86b0cf3e9ff6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8674a5f2-860d-4b83-8efe-0f1911ea17ab" xlink:to="loc_srt_RangeAxis_4c57d20e-79ec-4219-bf3e-86b0cf3e9ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bd2b109f-53f6-4a0b-9ec5-b88e5da11df7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4c57d20e-79ec-4219-bf3e-86b0cf3e9ff6" xlink:to="loc_srt_RangeMember_bd2b109f-53f6-4a0b-9ec5-b88e5da11df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1a4e7db5-abe2-4ef9-9f78-56e67d4665d3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_bd2b109f-53f6-4a0b-9ec5-b88e5da11df7" xlink:to="loc_srt_MinimumMember_1a4e7db5-abe2-4ef9-9f78-56e67d4665d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_06c46137-bb04-4405-bd94-62ab153466e4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_bd2b109f-53f6-4a0b-9ec5-b88e5da11df7" xlink:to="loc_srt_MaximumMember_06c46137-bb04-4405-bd94-62ab153466e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6c1fc67-09ca-4e3a-b894-782db2c917a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8674a5f2-860d-4b83-8efe-0f1911ea17ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6c1fc67-09ca-4e3a-b894-782db2c917a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f680e075-a532-4304-855b-0cb39cb7f09d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6c1fc67-09ca-4e3a-b894-782db2c917a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f680e075-a532-4304-855b-0cb39cb7f09d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_fa159140-85cc-40c1-942c-3e3dbb94afce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6c1fc67-09ca-4e3a-b894-782db2c917a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_fa159140-85cc-40c1-942c-3e3dbb94afce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a2f5ae58-0986-4fe6-89af-ea6a0bc6ddf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6c1fc67-09ca-4e3a-b894-782db2c917a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a2f5ae58-0986-4fe6-89af-ea6a0bc6ddf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_39a1452b-4497-4a1e-b701-374f0ad922c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6c1fc67-09ca-4e3a-b894-782db2c917a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_39a1452b-4497-4a1e-b701-374f0ad922c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_22025e5a-e4f4-4406-9610-fc7789c0e738" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6c1fc67-09ca-4e3a-b894-782db2c917a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_22025e5a-e4f4-4406-9610-fc7789c0e738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_597c9d69-4001-4af4-92ef-bead4a83503c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6c1fc67-09ca-4e3a-b894-782db2c917a0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_597c9d69-4001-4af4-92ef-bead4a83503c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dcada2d4-97c6-4582-82cb-b08a4a6ef6b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6c1fc67-09ca-4e3a-b894-782db2c917a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dcada2d4-97c6-4582-82cb-b08a4a6ef6b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_87cd5982-3135-4751-afb0-84430368bf2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6c1fc67-09ca-4e3a-b894-782db2c917a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_87cd5982-3135-4751-afb0-84430368bf2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_670fe0ad-dcf6-4725-99a4-3805a36f458a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6c1fc67-09ca-4e3a-b894-782db2c917a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_670fe0ad-dcf6-4725-99a4-3805a36f458a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6b270330-a9c1-4764-bc0e-0bf80f9194f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6c1fc67-09ca-4e3a-b894-782db2c917a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6b270330-a9c1-4764-bc0e-0bf80f9194f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_ShareBasedCompensationArrangementByShareBasedPaymentAwardActualPayoutPercentage_f6e4f703-3014-41e4-b2bd-4ad6aab22405" xlink:href="wst-20230331.xsd#wst_ShareBasedCompensationArrangementByShareBasedPaymentAwardActualPayoutPercentage"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6c1fc67-09ca-4e3a-b894-782db2c917a0" xlink:to="loc_wst_ShareBasedCompensationArrangementByShareBasedPaymentAwardActualPayoutPercentage_f6e4f703-3014-41e4-b2bd-4ad6aab22405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_425ef095-5540-4bcd-a67e-0a10393ffee8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6c1fc67-09ca-4e3a-b894-782db2c917a0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_425ef095-5540-4bcd-a67e-0a10393ffee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract_c2fbe0e0-44ee-4c93-ae16-ad5e7cea8858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_ff85fb1e-f4fa-4436-964b-36ec6c287ef5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract_c2fbe0e0-44ee-4c93-ae16-ad5e7cea8858" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_ff85fb1e-f4fa-4436-964b-36ec6c287ef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_2f8b0b31-c93d-490c-bb3b-a006908ccf47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_ff85fb1e-f4fa-4436-964b-36ec6c287ef5" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_2f8b0b31-c93d-490c-bb3b-a006908ccf47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_152aa118-bc94-448b-9c8a-9ac3ae50e0c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_2f8b0b31-c93d-490c-bb3b-a006908ccf47" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_152aa118-bc94-448b-9c8a-9ac3ae50e0c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_b13e076e-5d4b-4c20-a53c-9e291105fea6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_152aa118-bc94-448b-9c8a-9ac3ae50e0c0" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_b13e076e-5d4b-4c20-a53c-9e291105fea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_a53faa07-4502-42c5-9279-38f3fd55f72f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_152aa118-bc94-448b-9c8a-9ac3ae50e0c0" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_a53faa07-4502-42c5-9279-38f3fd55f72f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_e3caf733-d031-4d16-8d0a-e13877f8bad6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_ff85fb1e-f4fa-4436-964b-36ec6c287ef5" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_e3caf733-d031-4d16-8d0a-e13877f8bad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_2cdf5c02-d263-4434-8533-076e4ec8f5e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_e3caf733-d031-4d16-8d0a-e13877f8bad6" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_2cdf5c02-d263-4434-8533-076e4ec8f5e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_f3515086-c8e2-4f6e-98e5-a3d779e8ffbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_2cdf5c02-d263-4434-8533-076e4ec8f5e9" xlink:to="loc_us-gaap_DomesticPlanMember_f3515086-c8e2-4f6e-98e5-a3d779e8ffbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_15acdd59-3b86-44ac-a8c4-986d35a476d2" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_f3515086-c8e2-4f6e-98e5-a3d779e8ffbe" xlink:to="loc_country_US_15acdd59-3b86-44ac-a8c4-986d35a476d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_3eebb21c-7765-4934-9754-571015aa2897" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_2cdf5c02-d263-4434-8533-076e4ec8f5e9" xlink:to="loc_us-gaap_ForeignPlanMember_3eebb21c-7765-4934-9754-571015aa2897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_617b10e4-56c4-4d77-af2d-88729ba0d02d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_ff85fb1e-f4fa-4436-964b-36ec6c287ef5" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_617b10e4-56c4-4d77-af2d-88729ba0d02d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_14b0035f-3536-4bc7-8bb7-1ced98a279e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_617b10e4-56c4-4d77-af2d-88729ba0d02d" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_14b0035f-3536-4bc7-8bb7-1ced98a279e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_6b9e6e40-62d3-4e1b-93f3-14a3355b8217" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_617b10e4-56c4-4d77-af2d-88729ba0d02d" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_6b9e6e40-62d3-4e1b-93f3-14a3355b8217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_deb81ea7-174f-4e9e-83f1-b8d4fed873b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_617b10e4-56c4-4d77-af2d-88729ba0d02d" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_deb81ea7-174f-4e9e-83f1-b8d4fed873b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_192be99a-7928-4b67-af28-7ce9f06a8117" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_617b10e4-56c4-4d77-af2d-88729ba0d02d" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_192be99a-7928-4b67-af28-7ce9f06a8117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_e8e30095-a488-46fe-a329-fb0a4ea0d430" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_617b10e4-56c4-4d77-af2d-88729ba0d02d" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_e8e30095-a488-46fe-a329-fb0a4ea0d430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_7eb8309d-3bf8-482b-ae1c-d7c840761155" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_617b10e4-56c4-4d77-af2d-88729ba0d02d" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_7eb8309d-3bf8-482b-ae1c-d7c840761155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/BenefitPlansNarrativeDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#BenefitPlansNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/BenefitPlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract_d3fef5ea-6255-4a40-9e93-513020422800" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_dd49bfa8-6b67-4eba-8400-765e5d4c8322" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract_d3fef5ea-6255-4a40-9e93-513020422800" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_dd49bfa8-6b67-4eba-8400-765e5d4c8322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_d38d6d1b-6f57-488f-9307-eeace4c86867" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_dd49bfa8-6b67-4eba-8400-765e5d4c8322" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_d38d6d1b-6f57-488f-9307-eeace4c86867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_358995ec-b50b-424b-8d5b-8aad73cee845" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_d38d6d1b-6f57-488f-9307-eeace4c86867" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_358995ec-b50b-424b-8d5b-8aad73cee845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_ce17411e-fdde-4b90-9f35-089604485ec5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_358995ec-b50b-424b-8d5b-8aad73cee845" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_ce17411e-fdde-4b90-9f35-089604485ec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_4b429a9d-c560-4872-862f-751573e80542" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_dd49bfa8-6b67-4eba-8400-765e5d4c8322" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_4b429a9d-c560-4872-862f-751573e80542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_e5a1c040-5127-4664-a20d-e1cb788eab3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_4b429a9d-c560-4872-862f-751573e80542" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_e5a1c040-5127-4664-a20d-e1cb788eab3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/OtherExpenseIncomeScheduleofOtherIncomeExpenseDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#OtherExpenseIncomeScheduleofOtherIncomeExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/OtherExpenseIncomeScheduleofOtherIncomeExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_e391f8c7-be6e-4926-98e0-50d5403d5d99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_47c2a7ed-199d-4c7e-866e-c387eca0308a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_e391f8c7-be6e-4926-98e0-50d5403d5d99" xlink:to="loc_us-gaap_AssetImpairmentCharges_47c2a7ed-199d-4c7e-866e-c387eca0308a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_7f43e18b-372d-45ea-add3-07da543a4070" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_e391f8c7-be6e-4926-98e0-50d5403d5d99" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_7f43e18b-372d-45ea-add3-07da543a4070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_01317f25-d490-467b-8ce1-0aa9eab3d980" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_e391f8c7-be6e-4926-98e0-50d5403d5d99" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_01317f25-d490-467b-8ce1-0aa9eab3d980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_c28177c5-d398-4f7e-91e1-86182b4992a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_e391f8c7-be6e-4926-98e0-50d5403d5d99" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_c28177c5-d398-4f7e-91e1-86182b4992a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_0646a15b-4e1f-4d93-8d35-51145abd8863" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_e391f8c7-be6e-4926-98e0-50d5403d5d99" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_0646a15b-4e1f-4d93-8d35-51145abd8863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_OtherIncomeExpense_cc819a9d-f96c-4aaa-a594-37a385a4c6d6" xlink:href="wst-20230331.xsd#wst_OtherIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_e391f8c7-be6e-4926-98e0-50d5403d5d99" xlink:to="loc_wst_OtherIncomeExpense_cc819a9d-f96c-4aaa-a594-37a385a4c6d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/OtherExpenseIncomeNarrativeDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#OtherExpenseIncomeNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/OtherExpenseIncomeNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_70171afa-a44e-40d7-b7bf-22c9b7c4a168" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfInvestmentHoldingsTable_215be3c8-0dd7-4256-bcc4-9c07ced926cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfInvestmentHoldingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_70171afa-a44e-40d7-b7bf-22c9b7c4a168" xlink:to="loc_us-gaap_SummaryOfInvestmentHoldingsTable_215be3c8-0dd7-4256-bcc4-9c07ced926cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_6f3d5803-a85b-412d-afb9-1a492308b4dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsTable_215be3c8-0dd7-4256-bcc4-9c07ced926cb" xlink:to="loc_us-gaap_RestructuringPlanAxis_6f3d5803-a85b-412d-afb9-1a492308b4dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_e3f9408e-ca5f-439c-aab6-bb88bf898f70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_6f3d5803-a85b-412d-afb9-1a492308b4dd" xlink:to="loc_us-gaap_RestructuringPlanDomain_e3f9408e-ca5f-439c-aab6-bb88bf898f70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_The2020RestructuringPlanMember_579a091a-09a7-4a00-beb8-9637aa9309ef" xlink:href="wst-20230331.xsd#wst_The2020RestructuringPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_e3f9408e-ca5f-439c-aab6-bb88bf898f70" xlink:to="loc_wst_The2020RestructuringPlanMember_579a091a-09a7-4a00-beb8-9637aa9309ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f98cd836-5662-4ae6-909a-bb07eb90fb03" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsTable_215be3c8-0dd7-4256-bcc4-9c07ced926cb" xlink:to="loc_srt_RangeAxis_f98cd836-5662-4ae6-909a-bb07eb90fb03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e5191857-8c54-49a1-b317-ff4e2df44bc2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f98cd836-5662-4ae6-909a-bb07eb90fb03" xlink:to="loc_srt_RangeMember_e5191857-8c54-49a1-b317-ff4e2df44bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3fd7688f-ce55-456c-92d1-8f39263dc74c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e5191857-8c54-49a1-b317-ff4e2df44bc2" xlink:to="loc_srt_MinimumMember_3fd7688f-ce55-456c-92d1-8f39263dc74c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9fb88f77-ee3c-484b-81e6-ccf1c0c522cd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e5191857-8c54-49a1-b317-ff4e2df44bc2" xlink:to="loc_srt_MaximumMember_9fb88f77-ee3c-484b-81e6-ccf1c0c522cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_f6da7c4b-87fa-4a6a-bb7c-092e318e3a48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsTable_215be3c8-0dd7-4256-bcc4-9c07ced926cb" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_f6da7c4b-87fa-4a6a-bb7c-092e318e3a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d09f166a-f365-4206-a308-35313ad96a3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f6da7c4b-87fa-4a6a-bb7c-092e318e3a48" xlink:to="loc_us-gaap_SegmentDomain_d09f166a-f365-4206-a308-35313ad96a3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_ProprietaryProductsMember_e0f9510c-11db-49b2-9639-ffce480b79ed" xlink:href="wst-20230331.xsd#wst_ProprietaryProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_d09f166a-f365-4206-a308-35313ad96a3e" xlink:to="loc_wst_ProprietaryProductsMember_e0f9510c-11db-49b2-9639-ffce480b79ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_caf798fd-a2d3-48f8-80b4-a5e96eaa6610" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfInvestmentHoldingsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsTable_215be3c8-0dd7-4256-bcc4-9c07ced926cb" xlink:to="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_caf798fd-a2d3-48f8-80b4-a5e96eaa6610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_RestructuringAndRelatedActivitiesPeriodOfImplementation_860feebd-6fa8-411a-8254-85ad6fd8c4fd" xlink:href="wst-20230331.xsd#wst_RestructuringAndRelatedActivitiesPeriodOfImplementation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_caf798fd-a2d3-48f8-80b4-a5e96eaa6610" xlink:to="loc_wst_RestructuringAndRelatedActivitiesPeriodOfImplementation_860feebd-6fa8-411a-8254-85ad6fd8c4fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_be876be4-91c5-4d2a-bd88-2848a1851cda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_caf798fd-a2d3-48f8-80b4-a5e96eaa6610" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_be876be4-91c5-4d2a-bd88-2848a1851cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOnFutureEarningsAmount_5edad1e7-5b6e-494e-a0be-9d1bae8f2b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOnFutureEarningsAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_caf798fd-a2d3-48f8-80b4-a5e96eaa6610" xlink:to="loc_us-gaap_EffectOnFutureEarningsAmount_5edad1e7-5b6e-494e-a0be-9d1bae8f2b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_cd8ad9f2-34e5-4825-b7cd-7bf1eed18537" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_caf798fd-a2d3-48f8-80b4-a5e96eaa6610" xlink:to="loc_us-gaap_AssetImpairmentCharges_cd8ad9f2-34e5-4825-b7cd-7bf1eed18537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_b7c16a82-6c56-44fb-82d3-435d397cfb48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_caf798fd-a2d3-48f8-80b4-a5e96eaa6610" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_b7c16a82-6c56-44fb-82d3-435d397cfb48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/OtherExpenseIncomeScheduleofRestructuringandRelatedChargesDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#OtherExpenseIncomeScheduleofRestructuringandRelatedChargesDetails"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/OtherExpenseIncomeScheduleofRestructuringandRelatedChargesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_0bba9201-5a22-407e-b531-74dd008431ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_527894c3-e598-4514-8f6a-a780bd8034f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_0bba9201-5a22-407e-b531-74dd008431ba" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_527894c3-e598-4514-8f6a-a780bd8034f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_c1255b65-1c73-4839-89fe-edd9588f236f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_527894c3-e598-4514-8f6a-a780bd8034f4" xlink:to="loc_us-gaap_RestructuringPlanAxis_c1255b65-1c73-4839-89fe-edd9588f236f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_98ae324b-034e-42ec-929f-1427d5b9d787" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_c1255b65-1c73-4839-89fe-edd9588f236f" xlink:to="loc_us-gaap_RestructuringPlanDomain_98ae324b-034e-42ec-929f-1427d5b9d787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_A2020RestructuringPlanMember_eeef5621-9cd5-49e0-bb90-b0b00c9b4204" xlink:href="wst-20230331.xsd#wst_A2020RestructuringPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_98ae324b-034e-42ec-929f-1427d5b9d787" xlink:to="loc_wst_A2020RestructuringPlanMember_eeef5621-9cd5-49e0-bb90-b0b00c9b4204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_2f6119ba-e810-442b-b6ad-d0dd3584e0bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_527894c3-e598-4514-8f6a-a780bd8034f4" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_2f6119ba-e810-442b-b6ad-d0dd3584e0bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_5227e73b-2456-41ed-963d-ec7e665e0798" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_2f6119ba-e810-442b-b6ad-d0dd3584e0bf" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_5227e73b-2456-41ed-963d-ec7e665e0798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_e86cd9dd-c18c-490b-8a7a-6fefe318f78d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_5227e73b-2456-41ed-963d-ec7e665e0798" xlink:to="loc_us-gaap_EmployeeSeveranceMember_e86cd9dd-c18c-490b-8a7a-6fefe318f78d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_92022c33-89c0-4179-8914-8d230df771e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherRestructuringMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_5227e73b-2456-41ed-963d-ec7e665e0798" xlink:to="loc_us-gaap_OtherRestructuringMember_92022c33-89c0-4179-8914-8d230df771e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_be9b42d6-6fc5-4cc8-a642-f0a34e1d17e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_527894c3-e598-4514-8f6a-a780bd8034f4" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_be9b42d6-6fc5-4cc8-a642-f0a34e1d17e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_84bd36cb-2c24-473a-8d94-b61c8c6ada68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_be9b42d6-6fc5-4cc8-a642-f0a34e1d17e4" xlink:to="loc_us-gaap_RestructuringReserveRollForward_84bd36cb-2c24-473a-8d94-b61c8c6ada68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_e9e4ecf7-4760-4536-a6ce-cdfe0175a97b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_84bd36cb-2c24-473a-8d94-b61c8c6ada68" xlink:to="loc_us-gaap_RestructuringReserve_e9e4ecf7-4760-4536-a6ce-cdfe0175a97b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_e479e488-4e8c-46df-9131-37ecc52dec69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_84bd36cb-2c24-473a-8d94-b61c8c6ada68" xlink:to="loc_us-gaap_RestructuringCharges_e479e488-4e8c-46df-9131-37ecc52dec69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_4e6a7d7d-822a-4a30-9a44-aede6990b5d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_84bd36cb-2c24-473a-8d94-b61c8c6ada68" xlink:to="loc_us-gaap_PaymentsForRestructuring_4e6a7d7d-822a-4a30-9a44-aede6990b5d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_6abd7d8c-3dd8-4756-b64a-69873167a1e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_84bd36cb-2c24-473a-8d94-b61c8c6ada68" xlink:to="loc_us-gaap_RestructuringReserve_6abd7d8c-3dd8-4756-b64a-69873167a1e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_74e92121-2ecf-440b-a72b-9c7a8ef889b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_deaef7cd-83a0-4160-b5cc-143d6c35b590" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_74e92121-2ecf-440b-a72b-9c7a8ef889b9" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_deaef7cd-83a0-4160-b5cc-143d6c35b590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b058a990-e357-4eb8-ac26-4528fb28429a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_74e92121-2ecf-440b-a72b-9c7a8ef889b9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b058a990-e357-4eb8-ac26-4528fb28429a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_fa7cddc1-f5ad-45a3-bfec-d8b0757afb84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_74e92121-2ecf-440b-a72b-9c7a8ef889b9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_fa7cddc1-f5ad-45a3-bfec-d8b0757afb84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_30a24d74-6cd9-44c8-875f-a85e979113d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_74e92121-2ecf-440b-a72b-9c7a8ef889b9" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_30a24d74-6cd9-44c8-875f-a85e979113d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/SegmentInformationNarrativeDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#SegmentInformationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/SegmentInformationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_e50a953b-f0ff-4185-a9d2-87427445c500" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_bac00464-e631-488b-93cf-e9b926bed53f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_e50a953b-f0ff-4185-a9d2-87427445c500" xlink:to="loc_us-gaap_NumberOfReportableSegments_bac00464-e631-488b-93cf-e9b926bed53f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/SegmentInformationSalesbyProductGroupDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#SegmentInformationSalesbyProductGroupDetails"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/SegmentInformationSalesbyProductGroupDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_293e56b2-b1bc-4d08-a2e7-a6dbf4a139e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_57e4449f-3d57-46cb-b76b-56163460df7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_293e56b2-b1bc-4d08-a2e7-a6dbf4a139e0" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_57e4449f-3d57-46cb-b76b-56163460df7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_a76e3fca-670c-4afc-9821-645fd24fbc2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_57e4449f-3d57-46cb-b76b-56163460df7e" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_a76e3fca-670c-4afc-9821-645fd24fbc2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_5107502e-d044-4021-afb1-572b66f1e4f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a76e3fca-670c-4afc-9821-645fd24fbc2c" xlink:to="loc_us-gaap_SegmentDomain_5107502e-d044-4021-afb1-572b66f1e4f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_ProprietaryProductsMember_6f740318-6a93-4926-95e8-a6e97937a26a" xlink:href="wst-20230331.xsd#wst_ProprietaryProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_5107502e-d044-4021-afb1-572b66f1e4f9" xlink:to="loc_wst_ProprietaryProductsMember_6f740318-6a93-4926-95e8-a6e97937a26a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_ContractManufacturedProductsMember_de1ea9a2-b1f7-48d5-9cc8-3d7b9abe27c8" xlink:href="wst-20230331.xsd#wst_ContractManufacturedProductsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_5107502e-d044-4021-afb1-572b66f1e4f9" xlink:to="loc_wst_ContractManufacturedProductsMember_de1ea9a2-b1f7-48d5-9cc8-3d7b9abe27c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_fd95fa48-2ce0-4210-857e-daa1b8e6b0ff" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_57e4449f-3d57-46cb-b76b-56163460df7e" xlink:to="loc_srt_ConsolidationItemsAxis_fd95fa48-2ce0-4210-857e-daa1b8e6b0ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_985520e1-5e6e-4b8b-afb8-5b87d5365343" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_fd95fa48-2ce0-4210-857e-daa1b8e6b0ff" xlink:to="loc_srt_ConsolidationItemsDomain_985520e1-5e6e-4b8b-afb8-5b87d5365343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_4f3a0af9-9711-441f-800c-480ea6f561b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_985520e1-5e6e-4b8b-afb8-5b87d5365343" xlink:to="loc_us-gaap_OperatingSegmentsMember_4f3a0af9-9711-441f-800c-480ea6f561b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember_606f9e73-9061-4a53-befd-0f05d9e65852" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_985520e1-5e6e-4b8b-afb8-5b87d5365343" xlink:to="loc_us-gaap_IntersegmentEliminationMember_606f9e73-9061-4a53-befd-0f05d9e65852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_7e6ae077-791e-4dc2-9d6a-c72e963906a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_57e4449f-3d57-46cb-b76b-56163460df7e" xlink:to="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_7e6ae077-791e-4dc2-9d6a-c72e963906a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_90fcf920-a382-4c8d-82a0-f1efe7ac2616" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_7e6ae077-791e-4dc2-9d6a-c72e963906a7" xlink:to="loc_us-gaap_Revenues_90fcf920-a382-4c8d-82a0-f1efe7ac2616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" xlink:type="simple" xlink:href="wst-20230331.xsd#SegmentInformationSegmentFinancialInformationDetails"/>
  <link:presentationLink xlink:role="http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_afe0067e-4e87-4b58-b523-e3609dfc279a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e1b25bb5-cd88-45d1-b4c9-74f8d082f4d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_afe0067e-4e87-4b58-b523-e3609dfc279a" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e1b25bb5-cd88-45d1-b4c9-74f8d082f4d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_ef4aa977-1d8d-43a9-a7a5-0ff5aca13599" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e1b25bb5-cd88-45d1-b4c9-74f8d082f4d8" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_ef4aa977-1d8d-43a9-a7a5-0ff5aca13599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b81db43e-8d85-421d-a7a1-34983989628a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ef4aa977-1d8d-43a9-a7a5-0ff5aca13599" xlink:to="loc_us-gaap_SegmentDomain_b81db43e-8d85-421d-a7a1-34983989628a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_ProprietaryProductsMember_bd4c4b72-a239-40ae-be86-71051330e675" xlink:href="wst-20230331.xsd#wst_ProprietaryProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_b81db43e-8d85-421d-a7a1-34983989628a" xlink:to="loc_wst_ProprietaryProductsMember_bd4c4b72-a239-40ae-be86-71051330e675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wst_ContractManufacturedProductsMember_6652634b-c232-41aa-ae4e-58d2f014fbf2" xlink:href="wst-20230331.xsd#wst_ContractManufacturedProductsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_b81db43e-8d85-421d-a7a1-34983989628a" xlink:to="loc_wst_ContractManufacturedProductsMember_6652634b-c232-41aa-ae4e-58d2f014fbf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_370397bc-0e12-458f-8e2b-1ecfe1b02baa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e1b25bb5-cd88-45d1-b4c9-74f8d082f4d8" xlink:to="loc_srt_ConsolidationItemsAxis_370397bc-0e12-458f-8e2b-1ecfe1b02baa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_02c6e956-def9-440e-b1a1-3b1e8d3f48a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_370397bc-0e12-458f-8e2b-1ecfe1b02baa" xlink:to="loc_srt_ConsolidationItemsDomain_02c6e956-def9-440e-b1a1-3b1e8d3f48a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_7d11478c-f564-44da-81d1-29649676a7ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_02c6e956-def9-440e-b1a1-3b1e8d3f48a4" xlink:to="loc_us-gaap_OperatingSegmentsMember_7d11478c-f564-44da-81d1-29649676a7ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_1c18949f-2ccc-43fa-9de7-34ca0c48f910" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_02c6e956-def9-440e-b1a1-3b1e8d3f48a4" xlink:to="loc_us-gaap_CorporateNonSegmentMember_1c18949f-2ccc-43fa-9de7-34ca0c48f910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_73359cdb-3ff7-40ff-a1c0-5fb694bf41e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e1b25bb5-cd88-45d1-b4c9-74f8d082f4d8" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_73359cdb-3ff7-40ff-a1c0-5fb694bf41e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ec167309-a040-4224-b4d5-f19ca4c4e8c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73359cdb-3ff7-40ff-a1c0-5fb694bf41e8" xlink:to="loc_us-gaap_OperatingIncomeLoss_ec167309-a040-4224-b4d5-f19ca4c4e8c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_13aede37-f55f-4809-9912-288fdc8d2411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73359cdb-3ff7-40ff-a1c0-5fb694bf41e8" xlink:to="loc_us-gaap_ShareBasedCompensation_13aede37-f55f-4809-9912-288fdc8d2411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_1170d453-bec1-403f-8016-58b00b68aae6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73359cdb-3ff7-40ff-a1c0-5fb694bf41e8" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_1170d453-bec1-403f-8016-58b00b68aae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_53c59bd3-3b00-44d9-a022-527e037a77d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73359cdb-3ff7-40ff-a1c0-5fb694bf41e8" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_53c59bd3-3b00-44d9-a022-527e037a77d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedNetLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_0973f73c-bf20-4df3-b2d7-ba89474b7d67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73359cdb-3ff7-40ff-a1c0-5fb694bf41e8" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_0973f73c-bf20-4df3-b2d7-ba89474b7d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9a0b5ab3-eb74-4bca-ba81-58c133b1cae0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73359cdb-3ff7-40ff-a1c0-5fb694bf41e8" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_9a0b5ab3-eb74-4bca-ba81-58c133b1cae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_bc10401f-7f5c-4797-930c-62aa6201e9c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73359cdb-3ff7-40ff-a1c0-5fb694bf41e8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_bc10401f-7f5c-4797-930c-62aa6201e9c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_f9ae4d3f-2923-4dc4-806c-aa6b81bd2365" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_73359cdb-3ff7-40ff-a1c0-5fb694bf41e8" xlink:to="loc_us-gaap_AssetImpairmentCharges_f9ae4d3f-2923-4dc4-806c-aa6b81bd2365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932988039728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Apr. 12, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-8036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">WEST PHARMACEUTICAL SERVICES, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">23-1210010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">530 Herman O. West Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Exton<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19341-0645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">594-2900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of each class</a></td>
<td class="text">Common Stock, par value $0.25 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">WST<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,242,584<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000105770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932985576352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">$ 716.6<span></span>
</td>
<td class="nump">$ 720.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods and services sold</a></td>
<td class="nump">445.3<span></span>
</td>
<td class="nump">435.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">271.3<span></span>
</td>
<td class="nump">284.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">17.1<span></span>
</td>
<td class="nump">14.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="nump">86.0<span></span>
</td>
<td class="nump">83.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wst_OtherIncomeExpense', window );">Other expense (income)</a></td>
<td class="nump">12.9<span></span>
</td>
<td class="num">(3.1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating profit</a></td>
<td class="nump">155.3<span></span>
</td>
<td class="nump">189.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">2.2<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Interest income</a></td>
<td class="num">(4.8)<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income taxes and equity in net income of affiliated companies</a></td>
<td class="nump">157.9<span></span>
</td>
<td class="nump">187.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">23.6<span></span>
</td>
<td class="nump">21.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in net income of affiliated companies</a></td>
<td class="num">(5.7)<span></span>
</td>
<td class="num">(7.2)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 140.0<span></span>
</td>
<td class="nump">$ 173.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="nump">$ 1.88<span></span>
</td>
<td class="nump">$ 2.34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="nump">$ 1.85<span></span>
</td>
<td class="nump">$ 2.29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted average shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">74.5<span></span>
</td>
<td class="nump">74.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">75.7<span></span>
</td>
<td class="nump">76.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wst_OtherIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of other income and expense items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wst_OtherIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932987913248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 140.0<span></span>
</td>
<td class="nump">$ 173.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss), net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments, net of tax of $0.2 and $1.0</a></td>
<td class="nump">15.3<span></span>
</td>
<td class="num">(22.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent', window );">Defined benefit pension and other postretirement plan adjustments, net of tax of $(0.2) and $0.3</a></td>
<td class="num">(0.5)<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent', window );">Net loss on derivatives, net of tax of $(0.1) and $(0.8)</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="num">(1.6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">14.6<span></span>
</td>
<td class="num">(22.8)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="nump">$ 154.6<span></span>
</td>
<td class="nump">$ 151.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932987930080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent', window );">Foreign currency translation adjustments, tax</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent', window );">Defined benefit pension and other postretirement plan adjustments, tax</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent', window );">Net loss on derivatives, tax</a></td>
<td class="num">$ (0.1)<span></span>
</td>
<td class="num">$ (0.8)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932984315728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 886.3<span></span>
</td>
<td class="nump">$ 894.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">513.4<span></span>
</td>
<td class="nump">507.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">447.0<span></span>
</td>
<td class="nump">414.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">90.5<span></span>
</td>
<td class="nump">103.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,937.2<span></span>
</td>
<td class="nump">1,919.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment</a></td>
<td class="nump">2,478.9<span></span>
</td>
<td class="nump">2,386.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="nump">1,263.7<span></span>
</td>
<td class="nump">1,228.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">1,215.2<span></span>
</td>
<td class="nump">1,158.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">101.1<span></span>
</td>
<td class="nump">104.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Investments in affiliated companies</a></td>
<td class="nump">208.8<span></span>
</td>
<td class="nump">204.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">107.8<span></span>
</td>
<td class="nump">107.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">17.8<span></span>
</td>
<td class="nump">18.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred income taxes</a></td>
<td class="nump">99.0<span></span>
</td>
<td class="nump">65.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">36.7<span></span>
</td>
<td class="nump">38.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">3,723.6<span></span>
</td>
<td class="nump">3,616.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wst_NotesPayableAndOtherDebtCurrent', window );">Notes payable and other current debt</a></td>
<td class="nump">2.2<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">233.8<span></span>
</td>
<td class="nump">215.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wst_AccruedSalariesWagesAndBenefitsCurrent', window );">Accrued salaries, wages and benefits</a></td>
<td class="nump">65.7<span></span>
</td>
<td class="nump">76.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="nump">59.0<span></span>
</td>
<td class="nump">24.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">16.2<span></span>
</td>
<td class="nump">16.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">158.0<span></span>
</td>
<td class="nump">183.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">534.9<span></span>
</td>
<td class="nump">519.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">206.1<span></span>
</td>
<td class="nump">206.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income taxes</a></td>
<td class="nump">14.5<span></span>
</td>
<td class="nump">14.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Pension and other postretirement benefits</a></td>
<td class="nump">27.2<span></span>
</td>
<td class="nump">28.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">89.9<span></span>
</td>
<td class="nump">93.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent', window );">Deferred compensation benefits</a></td>
<td class="nump">19.0<span></span>
</td>
<td class="nump">19.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">55.8<span></span>
</td>
<td class="nump">51.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">947.4<span></span>
</td>
<td class="nump">931.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, 3.0&#160;million shares authorized; 0 shares issued and outstanding</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.25 per share; 200.0 million shares authorized; shares issued: 75.3&#160;million in 2023 and 2022; shares outstanding: 74.2&#160;million and 74.1 million</a></td>
<td class="nump">18.8<span></span>
</td>
<td class="nump">18.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Capital in excess of par value</a></td>
<td class="nump">181.4<span></span>
</td>
<td class="nump">232.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">3,113.6<span></span>
</td>
<td class="nump">2,987.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(168.4)<span></span>
</td>
<td class="num">(183.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Treasury stock, at cost (1.1&#160;million and 1.2 million shares)</a></td>
<td class="num">(369.2)<span></span>
</td>
<td class="num">(370.9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Equity</a></td>
<td class="nump">2,776.2<span></span>
</td>
<td class="nump">2,684.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Equity</a></td>
<td class="nump">$ 3,723.6<span></span>
</td>
<td class="nump">$ 3,616.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wst_AccruedSalariesWagesAndBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Salaries, Wages, and Benefits, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wst_AccruedSalariesWagesAndBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wst_NotesPayableAndOtherDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes Payable and Other Debt, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wst_NotesPayableAndOtherDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932986987440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">75,300,000<span></span>
</td>
<td class="nump">75,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">74,200,000<span></span>
</td>
<td class="nump">74,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, at cost (in shares)</a></td>
<td class="nump">1,100,000<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932987661680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 140.0<span></span>
</td>
<td class="nump">$ 173.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">30.7<span></span>
</td>
<td class="nump">28.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">8.5<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges', window );">Asset impairments</a></td>
<td class="nump">11.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash items, net</a></td>
<td class="num">(6.5)<span></span>
</td>
<td class="num">(7.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Changes in assets and liabilities</a></td>
<td class="num">(46.8)<span></span>
</td>
<td class="num">(50.2)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">138.1<span></span>
</td>
<td class="nump">151.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditures</a></td>
<td class="num">(82.1)<span></span>
</td>
<td class="num">(65.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other, net</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(2.5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(82.1)<span></span>
</td>
<td class="num">(68.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfOtherLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="num">(0.6)<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Debt issuance costs</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(1.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsCommonStock', window );">Dividend payments</a></td>
<td class="num">(14.1)<span></span>
</td>
<td class="num">(13.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from stock-based compensation awards</a></td>
<td class="nump">13.5<span></span>
</td>
<td class="nump">6.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherEquity', window );">Employee stock purchase plan contributions</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Shares purchased under share repurchase program</a></td>
<td class="num">(60.1)<span></span>
</td>
<td class="num">(147.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares repurchased for employee tax withholdings</a></td>
<td class="num">(11.5)<span></span>
</td>
<td class="num">(18.8)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(71.0)<span></span>
</td>
<td class="num">(172.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rates on cash</a></td>
<td class="nump">7.0<span></span>
</td>
<td class="num">(5.1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(8.0)<span></span>
</td>
<td class="num">(94.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, including cash equivalents at beginning of period</a></td>
<td class="nump">894.3<span></span>
</td>
<td class="nump">762.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, including cash equivalents at end of period</a></td>
<td class="nump">$ 886.3<span></span>
</td>
<td class="nump">$ 667.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the issuance of equity classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfOtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the payment of debt classified as other, maturing after one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfOtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932990831216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text">Basis of Presentation and Summary of Significant Accounting Policies<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The condensed consolidated financial statements included in this report are unaudited and have been prepared in accordance with United States (&#8220;U.S.&#8221;) generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) for interim financial reporting and U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) regulations. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, these financial statements include all adjustments, which are of a normal recurring nature, necessary for a fair statement of the financial position, results of operations, cash flows and the change in equity for the periods presented. The condensed consolidated financial statements for the three months ended March&#160;31, 2023, should be read in conjunction with the consolidated financial statements and notes thereto of West Pharmaceutical Services, Inc. and its majority-owned subsidiaries (which may be referred to as &#8220;West,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221;) appearing in our Annual Report on Form 10-K for the year ended December&#160;31, 2022 (the &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/105770/000010577023000012/wst-20221231.htm#i8148abfe270d4f15aa2ba9319df722dc_58" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2022 Annual Report</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The results of operations for any interim period are not necessarily indicative of results for the full year.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932993829280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>New Accounting Standards<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract', window );"><strong>Accounting Standards Update and Change in Accounting Principle [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">New Accounting Standards</a></td>
<td class="text">New Accounting Standards<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Standards</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, the Financial Accounting Standards Board ("FASB") issued guidance that seeks to enhance transparency around entities' use of supplier finance programs. The amendment requires the buyer in a supplier finance program to disclose information about the key terms of the program, outstanding confirmed amounts as of the end of the period, a rollforward of such amounts during each annual period, and a description of where in the financial statements outstanding amounts are presented. This guidance is effective for fiscal years beginning after December 15, 2022. We adopted this guidance as of January 1, 2023, on a prospective basis. The adoption did not have a material impact on our financial statements, as supplier finance programs are not material to the Company as of March&#160;31, 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI https://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31137-122693<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=SL108384541-122693<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932990860592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue</a></td>
<td class="text">Revenue<div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue results from the sale of goods or services and reflects the consideration to which we expect to be entitled in exchange for those goods or services. We record revenue based on a five-step model, in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 606. Following the identification of a contract with a customer, we identify the performance obligations (goods or services) in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize the revenue when (or as) we satisfy the performance obligations by transferring the promised goods or services to our customers. A good or service is transferred when (or as) the customer obtains control of that good or service. </span></div><div style="margin-bottom:1pt"><span><br/></span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the approximate percentage of our net sales by market group:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biologics</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 %</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Generics</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;20 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 %</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 %</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract-Manufactured Products</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 %</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the approximate percentage of our net sales by product category: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">High-Value Product Components</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 %</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">High-Value Product Delivery Devices</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 %</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Standard Packaging</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 %</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract-Manufactured Products</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 %</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:1pt"><span><br/></span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the approximate percentage of our net sales by geographic location: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Americas</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 %</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe, Middle East, Africa</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 %</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 %</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:1pt"><span><br/></span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Assets and Liabilities</span></div><div style="margin-bottom:1pt"><span><br/></span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our contract assets and liabilities, excluding amounts included in accounts receivable, net:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets, December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets, March&#160;31, 2023</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in contract assets - increase (decrease)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income, December 31, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income, March&#160;31, 2023</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in deferred income - decrease (increase)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:1pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contract assets are included within other current assets and deferred income is included within other current liabilities and other long-term liabilities. During the three months ended March&#160;31, 2023, $21.3&#160;million of revenue was recognized that was included in deferred income at the beginning of the year.</span></div><div style="margin-bottom:1pt"><span><br/></span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the performance obligations within our contracts are satisfied within one year or less. Performance obligations satisfied beyond one year include those relating to a nonrefundable customer payment of $20.0 million received in June 2013 in return for the exclusive use of the SmartDose</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology platform within a specific therapeutic area. As of March&#160;31, 2023, there was $2.8 million of deferred income related to this payment, of which $0.9 million was included in other current liabilities and $1.9 million was included in other long-term liabilities. The deferred income is being recognized as income on a straight-line basis over the remaining term of the agreement. The agreement does not include a future minimum purchase commitment from the customer.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932993785456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Income Per Share</a></td>
<td class="text">Net Income Per Share<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the shares used in the calculation of basic net income per share to those used for diluted net income per share:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.5&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.4&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of equity awards, based on the treasury stock method</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares assuming dilution</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023 and 2022, there were 0.3 million and 0.0 million shares, respectively, from stock-based compensation plans not included in the computation of diluted net income per share because their impact was antidilutive. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, the Board of Directors approved a share repurchase program under which we may repurchase up to $1.0&#160;billion in shares of common stock. The share repurchase program does not have an expiration date under which we may repurchase common stock on the open market or in privately-negotiated transactions. The number of shares to be repurchased and the timing of such transactions will depend on a variety of factors, including market conditions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, we purchased 183,360 shares of our common stock under the program at a cost of $60.1 million, or an average price of $327.90 per share. During the three months ended March 31, 2022, we purchased 390,000 shares of our common stock under the program at a cost of $147.1&#160;million, or an average price of $377.23 per share.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932993861024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text">Inventories<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are valued at the lower of cost (on a first-in, first-out basis) and net realizable value. Inventory balances were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.611%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.933%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">414.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932993669504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">LeasesA lease exists when a contract conveys to the customer the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. The definition of a lease embodies two conditions: 1) there is an identified asset in the contract that is land or a depreciable asset (i.e., property, plant, and equipment); and 2) the customer has the right to control the use of the identified asset. Lease payments included in the measurement of the operating lease right-of-use assets and lease liabilities are comprised of fixed payments (including in-substance fixed payments), variable payments that depend on an index or rate, and the exercise price of a lessee option to purchase the underlying asset if the lessee is reasonably certain to exercise.<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.451%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.805%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.451%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.805%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023 and December&#160;31, 2022, the weighted average remaining lease term for operating leases was 9.3 years and 9.3 years, respectively. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023 and December&#160;31, 2022, the weighted average discount rate was 3.26% and 3.25%, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of operating lease liabilities were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (remaining period as of)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed lease interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932993671088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Affiliated Companies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Affiliated Companies</a></td>
<td class="text">Affiliated CompaniesAt March&#160;31, 2023 and December&#160;31, 2022, the aggregate carrying amount of our investment in affiliated companies that are accounted for under the equity method was $200.9 million and $197.0 million, respectively, and the aggregate carrying amount of our investment in affiliated companies that are not accounted for under the equity method was $7.9 million and $7.9 million at March&#160;31, 2023 and December&#160;31, 2022, respectively. We have elected to record these investments, for which fair value was not readily determinable, at cost, less impairment, adjusted for subsequent observable price changes. We test these investments for impairment whenever circumstances indicate that the carrying value of the investments may not be recoverable. <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our purchases from, and royalty payments made to, affiliates totaled $44.2 million for the three months ended March&#160;31, 2023, as compared to $58.5 million for the same period in 2022. As of March&#160;31, 2023 and December&#160;31, 2022, the payable balance due to affiliates was $30.3 million and $31.2 million, respectively. The majority of these transactions related to a distributorship agreement with Daikyo Seiko, LTD ("Daikyo") that allows us to purchase and re-sell Daikyo products. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales to affiliates were $3.3 million for the three months ended March&#160;31, 2023, as compared to $4.0 million for the same period in 2022. As of March&#160;31, 2023 and December&#160;31, 2022, the receivable balance due from affiliates was $2.5 million and $2.2 million, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please refer to Note 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Affiliated Companies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the consolidated financial statements in our </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/105770/000010577023000012/wst-20221231.htm#i8148abfe270d4f15aa2ba9319df722dc_58" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2022 Annual Report</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional details.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI https://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932993699392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our long-term debt obligations, net of unamortized debt issuance costs and current maturities. The interest rates shown in parentheses are as of March&#160;31, 2023.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"/><td style="width:69.982%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan, due December 31, 2024 (5.87%)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B notes, due July 5, 2024 (3.82%)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series C notes, due July 5, 2027 (4.02%) </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized debt issuance costs for Term Loan and Series Notes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Facility</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2023, the borrowing capacity available under our $500.0&#160;million multi-currency revolving credit facility, including outstanding letters of credit of $2.4 million, was $497.6 million. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Term Loan</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2023, we had $82.6 million in borrowings under the Term Loan, of which $2.2 million was classified as current and $80.4 million was classified as long-term. Please refer to Note 9, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i7bf87d07bb544f48851c48374130181b_58" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Derivative Financial Instruments</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for a discussion of the foreign currency hedge associated with the Term Loan.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the financial covenants in our debt agreements, we are required to maintain established interest coverage ratios and to not exceed established leverage ratios. In addition, the agreements contain other customary covenants, none of which we consider restrictive to our operations. At March&#160;31, 2023, we were in compliance with all of our debt covenants.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please refer to Note 10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the consolidated financial statements in our </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/105770/000010577023000012/wst-20221231.htm#i8148abfe270d4f15aa2ba9319df722dc_58" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2022 Annual Report</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional details regarding our debt agreements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932987547456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Financial Instruments</a></td>
<td class="text">Derivative Financial Instruments<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ongoing business operations expose us to various risks, such as fluctuating interest rates, foreign currency exchange rates and increasing commodity prices. To manage these market risks, we periodically enter into derivative financial instruments, such as interest rate swaps, options and foreign exchange contracts for periods consistent with, and for notional amounts equal to or less than, the related underlying exposures. We do not purchase or hold any derivative financial instruments for investment or trading purposes. All derivatives are recorded in our condensed consolidated balance sheet at fair value.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Exchange Rate Risk</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into forward exchange contracts, designated as fair value hedges, to manage our exposure to fluctuating foreign exchange rates on cross-currency intercompany loans. As of both March&#160;31, 2023 and December&#160;31, 2022, the total amount of these forward exchange contracts was Singapore Dollar (&#8220;SGD&#8221;) 601.5 million and $13.4 million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have entered into several foreign currency contracts, designated as cash flow hedges, for periods of up to eighteen months, intended to hedge the currency risk associated with a portion of our forecasted transactions denominated in foreign currencies. As of March&#160;31, 2023, we had outstanding foreign currency contracts to purchase and sell certain pairs of currencies, as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"><tr><td style="width:1.0%"/><td style="width:33.421%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.610%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.459%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sell</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">USD</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EUR</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EUR</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yen</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,629.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SGD</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, we entered into a cross-currency swap for $90&#160;million, which we designated as a hedge of our net investment in Daikyo. As of March&#160;31, 2023, the notional amount of the cross-currency swap was &#165;9.0&#160;billion ($82.6&#160;million) and the swap termination date is December 31, 2024. Under the cross-currency swap, we receive floating interest rate payments based on USD compounded SOFR plus a margin, in return for paying floating interest rate payments based on Japanese Yen (&#8220;Yen&#8221;) Tokyo Overnight Average Rate ("TONAR") plus a margin. In addition, we receive periodic fixed payments of USD in return for paying fixed principal payments of Yen.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commodity Price Risk</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our proprietary products are made from synthetic elastomers, which are derived from the petroleum refining process. We purchase the majority of our elastomers via long-term supply contracts, some of which contain clauses that provide for surcharges related to fluctuations in crude oil prices. The following economic hedges did not qualify for hedge accounting treatment since they did not meet the highly effective requirement at inception.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From November 2017 through March 2023, we purchased several series of call options for a total of 903,932 barrels of crude oil to mitigate our exposure to such oil-based surcharges and protect operating cash flows with regards to a portion of our forecasted elastomer purchases. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, we had outstanding contracts to purchase 250,742 barrels of crude oil from March 2023 to December 2024, at a weighted-average strike price of 104.21 per barrel.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effects of Derivative Instruments on Financial Position and Results of Operations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please refer to Note 10, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i7bf87d07bb544f48851c48374130181b_61" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Fair Value Measurements</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the balance sheet location and fair values of our derivative instruments as of March&#160;31, 2023 and December&#160;31, 2022.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effects of derivative instruments designated as fair value hedges on the condensed consolidated statements of income:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.662%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:24.062%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount of Gain (Loss) Recognized in Income for the</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Location on Statement of Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value Hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedged item (intercompany loan)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative designated as hedging instrument </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount excluded from effectiveness testing</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize in earnings the initial value of forward point components on a straight-line basis over the life of the fair value hedge. The amounts recognized in earnings, pre-tax, for forward point components for the three months ended March&#160;31, 2023 and 2022 were $1.2 million and $0.8 million, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effects of derivative instruments designated as fair value, cash flow, and net investment hedges on other comprehensive income (&#8220;OCI&#8221;) and earnings, net of tax:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"/><td style="width:26.803%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.706%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.706%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.867%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.867%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.227%"/><td style="width:0.1%"/></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount of (Loss) Gain Recognized in OCI for the</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount of (Gain) Loss Reclassified from Accumulated OCI into Income for the</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Location of (Gain) Loss Reclassified from Accumulated OCI into Income</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value Hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency hedge contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash Flow Hedges:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency hedge contracts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency hedge contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods and services sold</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward treasury locks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Investment Hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to the above table which summarizes the effects of derivative instruments designated as fair value hedges within the other expense (income) line in our condensed consolidated statements of income for the three months ended March&#160;31, 2023 and 2022. The following table summarizes the effects of derivative instruments designated as cash flow and net investment hedges by line item in our condensed consolidated statements of income:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods and services sold</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effects of derivative instruments not designated as hedges on the condensed consolidated statements of income:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.252%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:30.472%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount of Gain (Loss) Recognized in Income for the</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Location on Statement of Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity call options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income) </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2023 and 2022, there was no material ineffectiveness related to our hedges.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI https://asc.fasb.org/topic&amp;trid=2229140<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=d3e90205-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932987724560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The following fair value hierarchy classifies the inputs to valuation techniques used to measure fair value into one of three levels:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Unadjusted quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Unobservable inputs that reflect the reporting entity&#8217;s own assumptions.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the assets and liabilities recorded at fair value on a recurring basis:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.726%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basis of Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity call options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.726%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basis of Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity call options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred compensation assets are included within other noncurrent assets and are valued using a market approach based on quoted market prices in an active market. The fair value of our foreign currency contracts, included within other current and other noncurrent assets, as well as other current and other long-term liabilities, is valued using an income approach based on quoted forward foreign exchange rates and spot rates at the reporting date. The fair value of the cross-currency swap, included within other noncurrent assets, is valued using a market approach. Please refer to Note 9, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i7bf87d07bb544f48851c48374130181b_58" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Derivative Financial Instruments</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of our derivatives. The fair value of our commodity call options, included within other current and other noncurrent assets, is valued using a market approach. The fair value of the contingent consideration liability, within current and long-term liabilities, related to the SmartDose</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology platform (the &#8220;SmartDose</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contingent consideration&#8221;) was initially determined using a probability-weighted income approach, and is revalued at each reporting date or more frequently if circumstances dictate. Changes in the fair value of this obligation are recorded as income or expense within other expense (income) in our condensed consolidated statements of income. The fair value of deferred compensation liabilities is based on quoted prices of the underlying employees&#8217; investment selections and is included within other long-term liabilities. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Financial Instruments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the carrying amounts of our cash and cash equivalents and accounts receivable approximate their fair values due to their near-term maturities. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of long-term debt is based on quoted market prices for debt issuances with similar terms and maturities and is classified as Level 2 within the fair value hierarchy. At March&#160;31, 2023, the estimated fair value of long-term debt was $201.2 million compared to a carrying amount of $206.1 million. At December&#160;31, 2022, the estimated fair value of long-term debt was $201.8 million and the carrying amount was $206.7 million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932987144208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Loss<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Accumulated Other Comprehensive Loss</a></td>
<td class="text">Accumulated Other Comprehensive Loss<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the three months ended March&#160;31, 2023:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.746%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.726%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.291%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.957%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.878%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Losses) gains on<br/>derivatives</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in equity affiliate investment AOCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit<br/>pension and other <br/>postretirement plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign <br/>currency <br/>translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(175.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(183.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified out from accumulated other comprehensive income (loss)  </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.9)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(160.1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(168.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the three months ended March&#160;31, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.746%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.726%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.291%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.957%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.878%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Losses) gains on<br/>derivatives</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in equity affiliate investment AOCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit<br/>pension and other <br/>postretirement plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign <br/>currency <br/>translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(159.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified out from accumulated other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.9)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the reclassifications out of accumulated other comprehensive loss is presented in the following table: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.267%"/><td style="width:0.1%"/></tr><tr style="height:35pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Location on Statement of Income</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Detail of components</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Losses) gains on derivatives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods and services sold</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward treasury locks</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of defined benefit pension and other postretirement plans:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial gains</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax (expense) benefit </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications for the period, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) These components are included in the computation of net periodic benefit cost. Please refer to Note 14, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i7bf87d07bb544f48851c48374130181b_73" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Benefit Plans</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional details.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI https://asc.fasb.org/topic&amp;trid=2134417<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932993725664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders' Equity</a></td>
<td class="text">Shareholders<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Equity</span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in shareholders&#8217; equity for the three months ended March&#160;31, 2023:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.895%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.728%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.886%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.728%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.390%"/><td style="width:0.1%"/></tr><tr style="height:30pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Shares Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital in Excess of Par Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of Treasury Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(370.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,987.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(183.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,684.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares purchased under share repurchase program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends declared ($0.19 per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(369.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,113.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(168.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,776.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in shareholders&#8217; equity for the three months ended March&#160;31, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.895%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.728%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.886%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.728%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.390%"/><td style="width:0.1%"/></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Shares Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital in Excess of Par Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of Treasury Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(229.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,456.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(159.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,335.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares purchased under share repurchase program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends declared ($0.18 per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(347.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,617.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,326.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932993787936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The West Pharmaceutical Services, Inc. 2016 Omnibus Incentive Compensation Plan (the &#8220;2016 Plan&#8221;) provides for the granting of stock options, stock appreciation rights, restricted stock awards and performance awards to employees and non-employee directors. A committee of the Board of Directors determines the terms and conditions of awards to be granted. Vesting requirements vary by award. At March&#160;31, 2023, there were 1,444,472 shares remaining in the 2016 Plan for future grants.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, we granted 105,244 stock options at a weighted average exercise price of $306.68 per share based on the grant-date fair value of our stock to employees under the 2016 Plan. The weighted average grant date fair value of options granted was $108.80 per share as determined by the Black-Scholes option valuation model using the following weighted average assumptions: a risk-free interest rate of 4.1%; expected life of 5.7 years based on prior experience; stock volatility of 29.8% based on historical data; and a dividend yield of 0.3%. Stock option expense is recognized over the vesting period, net of forfeitures.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, we granted 37,397 stock-settled performance share unit ("PSU") awards at a weighted average grant-date fair value of $306.68 per share to eligible employees. These awards are earned based on the Company's performance against pre-established targets, including annual growth rate of revenue and return on invested capital, over a specified performance period. Depending on the achievement of the targets, recipients of stock-settled PSU awards are entitled to receive a certain numbers of shares of common stock. Shares earned under PSU awards may vary from 0% to 200% of an employee's targeted award. The fair value of stock-settled PSU awards is based on the market price of our stock at the grant date and is recognized as expense over the performance period, adjusted for estimated target outcomes and net of forfeitures.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, we granted 4,284 stock-settled restricted share unit (&#8220;RSU&#8221;) awards at a weighted average grant-date fair value of $306.68 per share to eligible employees. These awards are earned over a specified performance period. The fair value of stock-settled RSU awards is based on the market price of our stock at the grant date and is recognized as expense over the vesting period, net of forfeitures. </span></div>Stock-based compensation expense was $8.5 million and $5.5 million for the three months ended March&#160;31, 2023 and 2022, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932993693232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Benefit Plans</a></td>
<td class="text">Benefit Plans<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net periodic benefit cost for the three months ended March&#160;31 were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:32.286%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.975%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.975%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.018%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other retirement benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial losses (gains)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:32.286%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.975%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.975%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.018%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other retirement benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. plans</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International plans</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:0.641%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:0.641%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022, we recorded a pension settlement charge of $0.6&#160;million within other nonoperating expense (income), as we determined that normal-course lump-sum payments for our U.S. qualified defined benefit pension plan exceeded the threshold for settlement accounting under U.S. GAAP for the year.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:0.801%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932993785456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Expense (Income)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock', window );">Other Expense (Income)</a></td>
<td class="text">Other Expense (Income) <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense (income) consists of:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss (gain) on oil hedges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange transaction losses (gains)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other expense (income)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring and Related Charges</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, the Company approved a restructuring plan to adjust our operating cost base to better respond to the macroeconomic factors influencing our business. These changes are expected to be implemented over a period of up to twelve months from the date of approval. The plan is expected to require restructuring and related charges of approximately $25&#160;million to $27&#160;million, with annualized savings in the range of $22.0&#160;million to $24.0&#160;million. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents activity related to our restructuring obligations related to our 2022 restructuring plan:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.124%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:19.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.210%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance<br/>and benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-related charges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March&#160;31, 2023</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asset Impairments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, in preparation for the sale of one of the Company&#8217;s manufacturing facilities within the Proprietary Products segment, the Company recorded an impairment expense of $9.4&#160;million within other expense (income) and a corresponding reduction to the disposal group net assets to its fair value less cost to sell. The transaction is expected to close during the second quarter of 2023.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingent Consideration</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration represents changes in the fair value of the SmartDose</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contingent consideration. Please refer to Note 10, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i7bf87d07bb544f48851c48374130181b_61" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Fair Value Measurements</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional details.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Oil Hedges</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023 and 2022, we recorded a loss of $0.6&#160;million and a gain of $2.8&#160;million, respectively, related to oil hedges. Please refer to Note 9, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i7bf87d07bb544f48851c48374130181b_58" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Derivative Financial Instruments</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of our hedging activity.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -URI https://asc.fasb.org/topic&amp;trid=2122503<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 610<br> -URI https://asc.fasb.org/topic&amp;trid=49130413<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932993675680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax provision for interim periods is determined using the estimated annual effective consolidated tax rate, based on the current estimate of full-year earnings before taxes, adjusted for the impact of discrete quarterly items.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes was $23.6 million and $21.2 million for the three months ended March&#160;31, 2023 and 2022, respectively, and the effective tax rate was 14.9% and 11.3%, respectively. During the three months ended March&#160;31, 2023 and 2022, we recorded a tax benefit of $11.6&#160;million and $8.9&#160;million, respectively, associated with stock-based compensation. The increase in the effective tax rate is primarily due to a shift in the geographic earnings mix and a $5.9&#160;million tax benefit recorded as a result of a state tax valuation allowance reversal in the three months ended March 31, 2022 that was not repeated in 2023. This was offset by an increase in the tax benefit related to stock-based compensation for the three months ended March&#160;31, 2023, as compared to the same period in 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932993731776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we are involved in product liability matters and other legal proceedings and claims generally incidental to our normal business activities. We accrue for loss contingencies when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. While the outcome of current proceedings cannot be accurately predicted, we believe their ultimate resolution should not have a material adverse effect on our business, financial condition, results of operations or liquidity.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes to the commitments and contingencies included in our </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/105770/000010577023000012/wst-20221231.htm#i8148abfe270d4f15aa2ba9319df722dc_58" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2022 Annual Report</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932993780672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text">Segment Information<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business operations are organized into two reportable segments, Proprietary Products and Contract-Manufactured Products. Our Proprietary Products reportable segment offers proprietary packaging, containment solutions and drug delivery products, along with analytical lab services and other integrated services and solutions, primarily to biologic, generic and pharmaceutical drug customers. Our Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Chief Operating Decision Maker ("CODM") evaluates the performance of our segments based upon, among other things, segment net sales and operating profit. Segment operating profit excludes general corporate costs, which include executive and director compensation, stock-based compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments. Also excluded are items that the CODM considers not representative of ongoing operations. Such items are referred to as other unallocated items and generally include restructuring and related charges, certain asset impairments and other specifically-identified income or expense items. The segment operating profit metric is what the CODM uses in evaluating our results of operations and the financial measure that provides a valuable insight into our overall performance and financial position.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about our reportable segments, reconciled to consolidated totals:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"/><td style="width:57.609%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.901%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proprietary Products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">601.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract-Manufactured Products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment sales elimination</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated net sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">716.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intersegment sales elimination, which is required for the presentation of consolidated net sales, represents the elimination of components sold between our segments.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides summarized financial information for our segments:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proprietary Products</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract-Manufactured Products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total business segment operating profit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and Unallocated</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate general costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated Items:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment for planned sale of plant </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of acquisition-related intangible assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Corporate and Unallocated</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consolidated operating profit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes and equity in net income of affiliated companies</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Corporate general costs includes executive and director compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) During the three months ended March&#160;31, 2023, in preparation for the sale of one of the Company&#8217;s manufacturing facilities within the Proprietary Products segment, the Company recorded an impairment expense of $9.4&#160;million within other expense (income) and a corresponding reduction to the disposal group net assets to its fair value less cost to sell. The transaction is expected to close during the second quarter of 2023.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) During the three months ended March&#160;31, 2023 and 2022, we recorded $0.2&#160;million of amortization expense within operating profit associated with an intangible asset acquired during the second quarter of 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please refer to Note 15, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i7bf87d07bb544f48851c48374130181b_76" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Other Expense (Income)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of certain unallocated items referenced above.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932986977296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The condensed consolidated financial statements included in this report are unaudited and have been prepared in accordance with United States (&#8220;U.S.&#8221;) generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) for interim financial reporting and U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) regulations. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, these financial statements include all adjustments, which are of a normal recurring nature, necessary for a fair statement of the financial position, results of operations, cash flows and the change in equity for the periods presented. The condensed consolidated financial statements for the three months ended March&#160;31, 2023, should be read in conjunction with the consolidated financial statements and notes thereto of West Pharmaceutical Services, Inc. and its majority-owned subsidiaries (which may be referred to as &#8220;West,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221;) appearing in our Annual Report on Form 10-K for the year ended December&#160;31, 2022 (the &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/105770/000010577023000012/wst-20221231.htm#i8148abfe270d4f15aa2ba9319df722dc_58" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2022 Annual Report</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The results of operations for any interim period are not necessarily indicative of results for the full year.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Standards</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Standards</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, the Financial Accounting Standards Board ("FASB") issued guidance that seeks to enhance transparency around entities' use of supplier finance programs. The amendment requires the buyer in a supplier finance program to disclose information about the key terms of the program, outstanding confirmed amounts as of the end of the period, a rollforward of such amounts during each annual period, and a description of where in the financial statements outstanding amounts are presented. This guidance is effective for fiscal years beginning after December 15, 2022. We adopted this guidance as of January 1, 2023, on a prospective basis. The adoption did not have a material impact on our financial statements, as supplier finance programs are not material to the Company as of March&#160;31, 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932993702112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregation of Revenue</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the approximate percentage of our net sales by market group:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biologics</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 %</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Generics</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;20 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 %</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 %</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract-Manufactured Products</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 %</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the approximate percentage of our net sales by product category: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">High-Value Product Components</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 %</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">High-Value Product Delivery Devices</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 %</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Standard Packaging</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 %</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract-Manufactured Products</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 %</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:1pt"><span><br/></span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the approximate percentage of our net sales by geographic location: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Americas</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 %</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe, Middle East, Africa</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 %</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 %</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 %</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 %</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Change in Contract With Customer, Asset and Liability</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our contract assets and liabilities, excluding amounts included in accounts receivable, net:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets, December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets, March&#160;31, 2023</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in contract assets - increase (decrease)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income, December 31, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income, March&#160;31, 2023</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in deferred income - decrease (increase)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932993669504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Reconciliation of Basic to Diluted Net Income Per Share</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the shares used in the calculation of basic net income per share to those used for diluted net income per share:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.5&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.4&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of equity awards, based on the treasury stock method</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares assuming dilution</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932993731776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventories</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are valued at the lower of cost (on a first-in, first-out basis) and net realizable value. Inventory balances were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.611%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.933%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">414.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932988008144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease, Cost</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.451%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.805%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wst_LesseeLeaseCashFlowAndSupplementalInformationTableTextBlock', window );">Schedule of Cash Flow and Supplemental Information</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.451%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.805%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Lessee, Operating Lease, Liability, Maturity</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of operating lease liabilities were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (remaining period as of)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed lease interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wst_LesseeLeaseCashFlowAndSupplementalInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Lease Cash Flow And Supplemental Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wst_LesseeLeaseCashFlowAndSupplementalInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932993786272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Long-term Debt Obligations, Net of Current Maturities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our long-term debt obligations, net of unamortized debt issuance costs and current maturities. The interest rates shown in parentheses are as of March&#160;31, 2023.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"/><td style="width:69.982%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan, due December 31, 2024 (5.87%)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B notes, due July 5, 2024 (3.82%)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series C notes, due July 5, 2027 (4.02%) </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized debt issuance costs for Term Loan and Series Notes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932993635680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock', window );">Schedule of Foreign Currency Contracts</a></td>
<td class="text">As of March&#160;31, 2023, we had outstanding foreign currency contracts to purchase and sell certain pairs of currencies, as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"><tr><td style="width:1.0%"/><td style="width:33.421%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.610%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.459%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sell</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">USD</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EUR</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EUR</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yen</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,629.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SGD</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Schedule of Effects of Derivative Instruments on Other Comprehensive Income ('OCI') and Earnings</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effects of derivative instruments designated as fair value hedges on the condensed consolidated statements of income:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.662%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:24.062%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount of Gain (Loss) Recognized in Income for the</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Location on Statement of Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value Hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedged item (intercompany loan)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative designated as hedging instrument </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount excluded from effectiveness testing</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effects of derivative instruments designated as fair value, cash flow, and net investment hedges on other comprehensive income (&#8220;OCI&#8221;) and earnings, net of tax:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"/><td style="width:26.803%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.706%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.706%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.867%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.867%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.227%"/><td style="width:0.1%"/></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount of (Loss) Gain Recognized in OCI for the</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount of (Gain) Loss Reclassified from Accumulated OCI into Income for the</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Location of (Gain) Loss Reclassified from Accumulated OCI into Income</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value Hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency hedge contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash Flow Hedges:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency hedge contracts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency hedge contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods and services sold</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward treasury locks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Investment Hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to the above table which summarizes the effects of derivative instruments designated as fair value hedges within the other expense (income) line in our condensed consolidated statements of income for the three months ended March&#160;31, 2023 and 2022. The following table summarizes the effects of derivative instruments designated as cash flow and net investment hedges by line item in our condensed consolidated statements of income:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods and services sold</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Schedule of Derivatives Not Designated as Hedging Instruments</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effects of derivative instruments not designated as hedges on the condensed consolidated statements of income:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.252%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:30.472%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount of Gain (Loss) Recognized in Income for the</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Location on Statement of Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity call options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income) </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41678-113959<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41641-113959<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932993889424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Assets and Liabilities Measured at Fair Value</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the assets and liabilities recorded at fair value on a recurring basis:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.726%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basis of Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity call options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.726%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basis of Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity call options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932993890832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Loss (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Components of Accumulated Other Comprehensive Loss</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the three months ended March&#160;31, 2023:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.746%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.726%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.291%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.957%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.878%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Losses) gains on<br/>derivatives</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in equity affiliate investment AOCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit<br/>pension and other <br/>postretirement plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign <br/>currency <br/>translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(175.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(183.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified out from accumulated other comprehensive income (loss)  </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.9)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(160.1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(168.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the three months ended March&#160;31, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.746%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.726%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.291%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.957%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.878%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Losses) gains on<br/>derivatives</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in equity affiliate investment AOCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit<br/>pension and other <br/>postretirement plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign <br/>currency <br/>translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(159.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified out from accumulated other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.9)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock', window );">Schedule of Reclassification out of Accumulated Other Comprehensive Loss</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the reclassifications out of accumulated other comprehensive loss is presented in the following table: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.267%"/><td style="width:0.1%"/></tr><tr style="height:35pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Location on Statement of Income</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Detail of components</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Losses) gains on derivatives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods and services sold</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward treasury locks</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of defined benefit pension and other postretirement plans:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial gains</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax (expense) benefit </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications for the period, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) These components are included in the computation of net periodic benefit cost. Please refer to Note 14, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i7bf87d07bb544f48851c48374130181b_73" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Benefit Plans</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional details.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932992893728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityTableTextBlock', window );">Schedule of Stockholders Equity</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in shareholders&#8217; equity for the three months ended March&#160;31, 2023:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.895%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.728%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.886%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.728%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.390%"/><td style="width:0.1%"/></tr><tr style="height:30pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Shares Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital in Excess of Par Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of Treasury Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(370.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,987.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(183.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,684.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares purchased under share repurchase program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends declared ($0.19 per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(369.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,113.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(168.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,776.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in shareholders&#8217; equity for the three months ended March&#160;31, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.895%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.728%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.886%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.728%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.390%"/><td style="width:0.1%"/></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Shares Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital in Excess of Par Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of Treasury Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(229.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,456.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(159.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,335.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares purchased under share repurchase program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends declared ($0.18 per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(347.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,617.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,326.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932987547456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Benefit Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock', window );">Schedule of Components of Net Periodic Benefit Cost</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net periodic benefit cost for the three months ended March&#160;31 were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:32.286%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.975%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.975%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.018%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other retirement benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial losses (gains)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:32.286%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.975%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.975%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.018%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other retirement benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. plans</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International plans</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetBenefitCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932992901408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Expense (Income) (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wst_ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock', window );">Schedule of Other Expense (Income)</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense (income) consists of:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss (gain) on oil hedges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange transaction losses (gains)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other expense (income)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Schedule of Restructuring Reserve</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents activity related to our restructuring obligations related to our 2022 restructuring plan:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.124%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:19.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.210%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance<br/>and benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-related charges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March&#160;31, 2023</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wst_ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Other Income and Expense, by Component [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wst_ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932992964448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Schedule of Sales by Significant Product Group</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about our reportable segments, reconciled to consolidated totals:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"/><td style="width:57.609%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.901%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proprietary Products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">601.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract-Manufactured Products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment sales elimination</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated net sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">716.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information, by Segment</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides summarized financial information for our segments:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proprietary Products</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract-Manufactured Products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total business segment operating profit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and Unallocated</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate general costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated Items:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment for planned sale of plant </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of acquisition-related intangible assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Corporate and Unallocated</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consolidated operating profit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes and equity in net income of affiliated companies</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Corporate general costs includes executive and director compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) During the three months ended March&#160;31, 2023, in preparation for the sale of one of the Company&#8217;s manufacturing facilities within the Proprietary Products segment, the Company recorded an impairment expense of $9.4&#160;million within other expense (income) and a corresponding reduction to the disposal group net assets to its fair value less cost to sell. The transaction is expected to close during the second quarter of 2023.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) During the three months ended March&#160;31, 2023 and 2022, we recorded $0.2&#160;million of amortization expense within operating profit associated with an intangible asset acquired during the second quarter of 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please refer to Note 15, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i7bf87d07bb544f48851c48374130181b_76" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Other Expense (Income)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of certain unallocated items referenced above.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932984416736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Revenue Recognition (Details) - Revenue Benchmark<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Product Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Geographic Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_AmericasMember', window );">Americas | Geographic Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">44.00%<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_EMEAMember', window );">Europe, Middle East, Africa | Geographic Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">47.00%<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_AsiaPacificMember', window );">Asia Pacific | Geographic Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=wst_HighValueProductComponentsMember', window );">High-Value Product Components | Product Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">51.00%<span></span>
</td>
<td class="nump">56.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=wst_HighValueProductDeliveryDevicesMember', window );">High-Value Product Delivery Devices | Product Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=wst_StandardPackagingMember', window );">Standard Packaging | Product Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=wst_ContractManufacturedProductsMember', window );">Contract-Manufactured Products | Product Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=wst_BiologicsCustomersMember', window );">Biologics | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">43.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=wst_GenericsCustomersMember', window );">Generics | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=wst_PharmaCustomersMember', window );">Pharma | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=wst_ContractManufacturedCustomersMember', window );">Contract-Manufactured Products | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_AmericasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_AmericasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_EMEAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_EMEAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_AsiaPacificMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_AsiaPacificMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=wst_HighValueProductComponentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=wst_HighValueProductComponentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=wst_HighValueProductDeliveryDevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=wst_HighValueProductDeliveryDevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=wst_StandardPackagingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=wst_StandardPackagingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=wst_ContractManufacturedProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=wst_ContractManufacturedProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=wst_BiologicsCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=wst_BiologicsCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=wst_GenericsCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=wst_GenericsCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=wst_PharmaCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=wst_PharmaCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=wst_ContractManufacturedCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=wst_ContractManufacturedCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932987715280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Contracts and Liabilities (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wst_ContractWithCustomerAssetRollForward', window );"><strong>Contract With Customer, Asset [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets, December 31, 2022</a></td>
<td class="nump">$ 16.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets, March&#160;31, 2023</a></td>
<td class="nump">19.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wst_ContractWithCustomerAssetIncreaseDecrease', window );">Change in contract assets - increase (decrease)</a></td>
<td class="nump">3.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wst_ContractWithCustomerLiabilityRollForward', window );"><strong>Contract With Customer, Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred income, December 31, 2022</a></td>
<td class="num">(68.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred income, March&#160;31, 2023</a></td>
<td class="num">(57.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized', window );">Change in deferred income - decrease (increase)</a></td>
<td class="nump">$ 10.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized arising from contract liability from change in timeframe for performance obligation to be satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wst_ContractWithCustomerAssetIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Asset, Increase (Decrease)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wst_ContractWithCustomerAssetIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wst_ContractWithCustomerAssetRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Asset [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wst_ContractWithCustomerAssetRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wst_ContractWithCustomerLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wst_ContractWithCustomerLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932985599696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Contracts and Liabilities, Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2013</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized that was included in the deferred income balance</a></td>
<td class="nump">$ 21.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred income</a></td>
<td class="nump">57.5<span></span>
</td>
<td class="nump">$ 68.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=wst_SmartDoseMember', window );">Smart Dose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred income</a></td>
<td class="nump">2.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred income, current</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred income, noncurrent</a></td>
<td class="nump">$ 1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=wst_SmartDoseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=wst_SmartDoseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932983812064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Feb. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 140.0<span></span>
</td>
<td class="nump">$ 173.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding (in shares)</a></td>
<td class="nump">74,500,000<span></span>
</td>
<td class="nump">74,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive effect of equity awards, based on the treasury stock method (in shares)</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares assuming dilution (in shares)</a></td>
<td class="nump">75,700,000<span></span>
</td>
<td class="nump">76,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive options excluded from computation of diluted net income per share (in shares)</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized repurchase amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Stock repurchase program, shares purchased (in shares)</a></td>
<td class="nump">183,360<span></span>
</td>
<td class="nump">390,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Stock purchase program, cost of shares purchased</a></td>
<td class="nump">$ 60.1<span></span>
</td>
<td class="nump">$ 147.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Stock repurchase program, average price per share (in dollars per share)</a></td>
<td class="nump">$ 327.90<span></span>
</td>
<td class="nump">$ 377.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126962052&amp;loc=d3e4991-113900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1707-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1500-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932985587008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 181.0<span></span>
</td>
<td class="nump">$ 170.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">95.9<span></span>
</td>
<td class="nump">79.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">170.1<span></span>
</td>
<td class="nump">165.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">$ 447.0<span></span>
</td>
<td class="nump">$ 414.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932989426704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Lease Cost (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 5.9<span></span>
</td>
<td class="nump">$ 3.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">1.3<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">1.7<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 8.9<span></span>
</td>
<td class="nump">$ 5.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932987517584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Lease Cash Flow and Supplemental Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wst_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 4.9<span></span>
</td>
<td class="nump">$ 3.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 9.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wst_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Paid for Amounts Included in the Measurement of Lease Liabilities [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wst_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932987665728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Lease Weighted Average (Details)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">9 years 3 months 18 days<span></span>
</td>
<td class="text">9 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">3.26%<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932987760320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Maturities of Operating Lease Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of fiscal year</a></td>
<td class="nump">$ 14.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Year one</a></td>
<td class="nump">18.3<span></span>
</td>
<td class="nump">$ 19.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">Year two</a></td>
<td class="nump">16.2<span></span>
</td>
<td class="nump">18.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">Year three</a></td>
<td class="nump">13.4<span></span>
</td>
<td class="nump">16.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">Year four</a></td>
<td class="nump">9.3<span></span>
</td>
<td class="nump">13.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">Year five</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wst_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">51.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Operating leases liabilities payments due</a></td>
<td class="nump">123.2<span></span>
</td>
<td class="nump">126.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed lease interest</a></td>
<td class="num">(17.1)<span></span>
</td>
<td class="num">(17.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 106.1<span></span>
</td>
<td class="nump">$ 109.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wst_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, To Be Paid, After Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wst_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139933082788816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Affiliated Companies (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Carrying amount, equity-method investments</a></td>
<td class="nump">$ 200.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 197.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Carrying amount, investments not accounted for under the equity method</a></td>
<td class="nump">7.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wst_PurchasesAndRoyaltyPaymentsFromEquityMethodInvestees', window );">Purchases and royalty payments made to affiliates</a></td>
<td class="nump">44.2<span></span>
</td>
<td class="nump">$ 58.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToAffiliateCurrentAndNoncurrent', window );">Amount due and payable to affiliates</a></td>
<td class="nump">30.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wst_SalesToEquityMethodInvestees', window );">Sales to affiliates</a></td>
<td class="nump">3.3<span></span>
</td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueFromAffiliates', window );">Amount receivable from affiliates</a></td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amount of receivables due from an entity that is affiliated with the reporting entity by means of direct or indirect ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39599-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToAffiliateCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payable due to an entity that is affiliated with the reporting entity by means of direct or indirect ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04.12(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=d3e56071-112765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToAffiliateCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wst_PurchasesAndRoyaltyPaymentsFromEquityMethodInvestees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchases and Royalty Payments from Equity Method Investees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wst_PurchasesAndRoyaltyPaymentsFromEquityMethodInvestees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wst_SalesToEquityMethodInvestees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales to Equity Method Investees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wst_SalesToEquityMethodInvestees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932984948928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Long-term Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 208.6<span></span>
</td>
<td class="nump">$ 209.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Less: unamortized debt issuance costs for Term Loan and Series Notes</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">208.3<span></span>
</td>
<td class="nump">208.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: current portion of long-term debt</a></td>
<td class="nump">2.2<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net</a></td>
<td class="nump">$ 206.1<span></span>
</td>
<td class="nump">206.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=wst_TermLoanDue2024Member', window );">Term Loan, due December 31, 2024 (5.87%)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, stated interest rate</a></td>
<td class="nump">5.87%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 82.6<span></span>
</td>
<td class="nump">83.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net</a></td>
<td class="nump">$ 80.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=wst_SeniorBNotesDue2024Member', window );">Series B notes, due July 5, 2024 (3.82%)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, stated interest rate</a></td>
<td class="nump">3.82%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 53.0<span></span>
</td>
<td class="nump">53.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=wst_SeniorCNotesDue2027Member', window );">Series C notes, due July 5, 2027 (4.02%)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, stated interest rate</a></td>
<td class="nump">4.02%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 73.0<span></span>
</td>
<td class="nump">$ 73.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=wst_TermLoanDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=wst_TermLoanDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=wst_SeniorBNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=wst_SeniorBNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=wst_SeniorCNotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=wst_SeniorCNotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932983832224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Credit Facility (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 208.6<span></span>
</td>
<td class="nump">$ 209.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">206.1<span></span>
</td>
<td class="nump">206.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=wst_RevolvingCreditFacilityDue2024Member', window );">Revolving Credit Facility, Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity', window );">Line of credit facility, current borrowing capacity</a></td>
<td class="nump">500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Line of credit facility, unused commitment level</a></td>
<td class="nump">497.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=wst_RevolvingCreditFacilityDue2024Member', window );">Revolving Credit Facility, Due 2024 | Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Long-term line of credit</a></td>
<td class="nump">2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=wst_TermLoanDue2024Member', window );">Term Loan Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">82.6<span></span>
</td>
<td class="nump">$ 83.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Long-term debt, current</a></td>
<td class="nump">2.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 80.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=wst_RevolvingCreditFacilityDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=wst_RevolvingCreditFacilityDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=wst_TermLoanDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=wst_TermLoanDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932987851056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments - Foreign Exchange Rate Risk (Details)<br> $ in Millions, $ in Millions, &#165; in Billions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">65 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>bbl</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>SGD ($) </div>
<div>$ / bbl </div>
<div>bbl</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / bbl</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>JPY (&#165;) </div>
<div>$ / bbl</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Derivative, forward point components, gain (loss), recognized in earnings</a></td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember', window );">Foreign Exchange Forward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeTermOfContract', window );">Derivative contract term</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_OptionMember', window );">Options Held</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNonmonetaryNotionalAmountVolume', window );">Derivative, nonmonetary notional amount, volume | bbl</a></td>
<td class="nump">250,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">903,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAveragePriceRiskOptionStrikePrice', window );">Derivative, average price risk option strike price | $ / bbl</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104.21<span></span>
</td>
<td class="nump">104.21<span></span>
</td>
<td class="nump">104.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_SGD', window );">SGD | Forward Contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 601.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 601.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">EUR | Forward Contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">EUR | Cross Currency Interest Rate Contract | Net Investment Hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82.6<span></span>
</td>
<td class="nump">&#165; 9.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAveragePriceRiskOptionStrikePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average strike price on the group of price risk option contracts such as put options or call options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAveragePriceRiskOptionStrikePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:perUnitItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from excluded component of derivative hedge, recognized in earnings. Excludes recognition under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061172-113977<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNonmonetaryNotionalAmountVolume">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal volume used to calculate payments on a derivative instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNonmonetaryNotionalAmountVolume</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:volumeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_OptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_OptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_SGD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_SGD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932985790064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative Financial Instruments - Foreign Currency Contracts (Details)<br> &#8364; in Millions, &#165; in Millions, $ in Millions, $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>JPY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">EUR | Foreign Exchange Forward | Designated as Hedging Instrument | Long</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 8.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">EUR | Foreign Exchange Forward | Designated as Hedging Instrument | Short</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">EUR | Cross Currency Interest Rate Contract | Net Investment Hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 9,000.0<span></span>
</td>
<td class="nump">$ 90.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_JPY', window );">Japan, Yen | Foreign Exchange Forward | Designated as Hedging Instrument | Long</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 5,629.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_JPY', window );">Japan, Yen | Foreign Exchange Forward | Designated as Hedging Instrument | Short</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.2<span></span>
</td>
<td class="nump">12.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_SGD', window );">SGD | Foreign Exchange Forward | Designated as Hedging Instrument | Long</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount | $</a></td>
<td class="nump">$ 67.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_SGD', window );">SGD | Foreign Exchange Forward | Designated as Hedging Instrument | Short</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.9<span></span>
</td>
<td class="nump">&#8364; 23.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PositionAxis=us-gaap_LongMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PositionAxis=us-gaap_LongMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PositionAxis=us-gaap_ShortMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PositionAxis=us-gaap_ShortMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_JPY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_JPY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_SGD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_SGD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932984135296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments - Effects of Derivative Instruments on OCI and Earnings (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings', window );">Derivative (gain) loss recognized in income, fair value hedges</a></td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Fair value and net investment hedges, amount of gain (loss) recognized in OCI</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax', window );">Fair value and net investment hedges, amount of (gain) loss reclassified from accumulated OCI into income</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Cash flow hedges, amount of gain (loss) recognized in OCI</a></td>
<td class="num">(1.1)<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax', window );">Cash flow hedges, amount of (gain) loss reclassified from accumulated OCI into income</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedges | Forward treasury locks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Cash flow hedges, amount of gain (loss) recognized in OCI</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax', window );">Cash flow hedges, amount of (gain) loss reclassified from accumulated OCI into income</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Fair value and net investment hedges, amount of gain (loss) recognized in OCI</a></td>
<td class="nump">1.7<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax', window );">Fair value and net investment hedges, amount of (gain) loss reclassified from accumulated OCI into income</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=wst_OtherExpenseIncomeMember', window );">Other expense (income)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1', window );">Derivative (gain) loss on hedged item, fair value hedges</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="num">(9.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1', window );">Change in unrealized gain (loss) on fair value hedging instruments</a></td>
<td class="num">(2.5)<span></span>
</td>
<td class="nump">9.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet', window );">Derivative (gain) loss on amount excluded from effectiveness testing, fair value hedges</a></td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=wst_OtherExpenseIncomeMember', window );">Other expense (income) | Fair Value Hedges | Foreign currency hedge contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Fair value and net investment hedges, amount of gain (loss) recognized in OCI</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax', window );">Fair value and net investment hedges, amount of (gain) loss reclassified from accumulated OCI into income</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=wst_OtherExpenseIncomeMember', window );">Other expense (income) | Net Investment Hedges | Cross-currency swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Fair value and net investment hedges, amount of gain (loss) recognized in OCI</a></td>
<td class="nump">1.7<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax', window );">Fair value and net investment hedges, amount of (gain) loss reclassified from accumulated OCI into income</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=wst_NetSalesMember', window );">Net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain (loss) on derivative instruments, net, pretax</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=wst_NetSalesMember', window );">Net sales | Cash Flow Hedges | Foreign currency hedge contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Cash flow hedges, amount of gain (loss) recognized in OCI</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax', window );">Cash flow hedges, amount of (gain) loss reclassified from accumulated OCI into income</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of goods and services sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain (loss) on derivative instruments, net, pretax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of goods and services sold | Cash Flow Hedges | Foreign currency hedge contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Cash flow hedges, amount of gain (loss) recognized in OCI</a></td>
<td class="num">(1.0)<span></span>
</td>
<td class="num">(1.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax', window );">Cash flow hedges, amount of (gain) loss reclassified from accumulated OCI into income</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain (loss) on derivative instruments, net, pretax</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net gain (loss) relating to components of the gain (loss) on the fair value hedging instrument excluded from the assessment of fair value hedge effectiveness. Recognized in earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total amount of gain (loss) derived from fair value hedges recognized in earnings in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from discontinuance of cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_TreasuryLockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_TreasuryLockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=wst_OtherExpenseIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=wst_OtherExpenseIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=wst_NetSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=wst_NetSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932983829760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments - Derivative Instruments Not Designated as Hedges (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Derivative instruments not designated as hedging instruments, gain (loss), net</a></td>
<td class="num">$ (0.6)<span></span>
</td>
<td class="nump">$ 2.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Derivative instruments not designated as hedging instruments, gain (loss), net</a></td>
<td class="num">(0.6)<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CommodityOptionMember', window );">Commodity call options | Not Designated as Hedging Instrument | Other expense (income)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Derivative instruments not designated as hedging instruments, gain (loss), net</a></td>
<td class="num">$ (0.6)<span></span>
</td>
<td class="nump">$ 2.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CommodityOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CommodityOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=wst_OtherExpenseIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=wst_OtherExpenseIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932984575744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Assets and Liabilities Recorded at Fair Value (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationPlanAssets', window );">Deferred compensation assets</a></td>
<td class="nump">$ 10.4<span></span>
</td>
<td class="nump">$ 12.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign currency contracts</a></td>
<td class="nump">3.5<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">29.4<span></span>
</td>
<td class="nump">32.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">4.5<span></span>
</td>
<td class="nump">4.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent', window );">Deferred compensation liabilities</a></td>
<td class="nump">10.6<span></span>
</td>
<td class="nump">12.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities at fair value</a></td>
<td class="nump">17.5<span></span>
</td>
<td class="nump">18.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CurrencySwapMember', window );">Cross-currency swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Commodity call options</a></td>
<td class="nump">14.6<span></span>
</td>
<td class="nump">13.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommodityMember', window );">Commodity call options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Commodity call options</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign currency contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency contracts and swaps</a></td>
<td class="nump">2.4<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationPlanAssets', window );">Deferred compensation assets</a></td>
<td class="nump">10.4<span></span>
</td>
<td class="nump">12.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign currency contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">10.4<span></span>
</td>
<td class="nump">12.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent', window );">Deferred compensation liabilities</a></td>
<td class="nump">10.6<span></span>
</td>
<td class="nump">12.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities at fair value</a></td>
<td class="nump">10.6<span></span>
</td>
<td class="nump">12.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Cross-currency swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Commodity call options</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Commodity call options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Commodity call options</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Foreign currency contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency contracts and swaps</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationPlanAssets', window );">Deferred compensation assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign currency contracts</a></td>
<td class="nump">3.5<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">19.0<span></span>
</td>
<td class="nump">19.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent', window );">Deferred compensation liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities at fair value</a></td>
<td class="nump">2.4<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Cross-currency swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Commodity call options</a></td>
<td class="nump">14.6<span></span>
</td>
<td class="nump">13.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Commodity call options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Commodity call options</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Foreign currency contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency contracts and swaps</a></td>
<td class="nump">2.4<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationPlanAssets', window );">Deferred compensation assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign currency contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">4.5<span></span>
</td>
<td class="nump">4.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent', window );">Deferred compensation liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities at fair value</a></td>
<td class="nump">4.5<span></span>
</td>
<td class="nump">4.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Cross-currency swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Commodity call options</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Commodity call options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Commodity call options</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Foreign currency contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency contracts and swaps</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of assets held under deferred compensation agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractAssetFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the liabilities, classified as other, for deferred compensation arrangements payable after one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CurrencySwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CurrencySwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommodityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommodityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932993690000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Other Financial Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wst_OtherFinancialInstrumentsAbstract', window );"><strong>Other Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term debt, fair value</a></td>
<td class="nump">$ 201.2<span></span>
</td>
<td class="nump">$ 201.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 206.1<span></span>
</td>
<td class="nump">$ 206.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wst_OtherFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Financial Instruments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wst_OtherFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932984508032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Income (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Changes in the Components of Accumulated Other Comprehensive Loss, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning of period</a></td>
<td class="nump">$ 2,684.9<span></span>
</td>
<td class="nump">$ 2,335.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="nump">14.2<span></span>
</td>
<td class="num">(23.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Amounts reclassified out from accumulated other comprehensive income (loss)</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">14.6<span></span>
</td>
<td class="num">(22.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, end of period</a></td>
<td class="nump">2,776.2<span></span>
</td>
<td class="nump">2,326.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Changes in the Components of Accumulated Other Comprehensive Loss, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning of period</a></td>
<td class="num">(183.0)<span></span>
</td>
<td class="num">(159.6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">14.6<span></span>
</td>
<td class="num">(22.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, end of period</a></td>
<td class="num">(168.4)<span></span>
</td>
<td class="num">(182.4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">(Losses) gains on derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Changes in the Components of Accumulated Other Comprehensive Loss, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning of period</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="num">(0.9)<span></span>
</td>
<td class="num">(1.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Amounts reclassified out from accumulated other comprehensive income (loss)</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="num">(1.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, end of period</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(2.8)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Change in equity affiliate investment AOCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Changes in the Components of Accumulated Other Comprehensive Loss, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning of period</a></td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Amounts reclassified out from accumulated other comprehensive income (loss)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, end of period</a></td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Defined benefit pension and other postretirement plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Changes in the Components of Accumulated Other Comprehensive Loss, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning of period</a></td>
<td class="num">(9.4)<span></span>
</td>
<td class="num">(31.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Amounts reclassified out from accumulated other comprehensive income (loss)</a></td>
<td class="num">(0.3)<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(0.5)<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, end of period</a></td>
<td class="num">(9.9)<span></span>
</td>
<td class="num">(30.9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Changes in the Components of Accumulated Other Comprehensive Loss, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning of period</a></td>
<td class="num">(175.4)<span></span>
</td>
<td class="num">(128.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="nump">15.3<span></span>
</td>
<td class="num">(22.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Amounts reclassified out from accumulated other comprehensive income (loss)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">15.3<span></span>
</td>
<td class="num">(22.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, end of period</a></td>
<td class="num">$ (160.1)<span></span>
</td>
<td class="num">$ (150.2)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932985736128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Loss - Other Comprehensive Loss Reclassifications (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification out of Accumulated Other Comprehensive Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">$ 716.6<span></span>
</td>
<td class="nump">$ 720.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods and services sold</a></td>
<td class="num">(445.3)<span></span>
</td>
<td class="num">(435.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(2.2)<span></span>
</td>
<td class="num">(2.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Actuarial gains</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1', window );">Settlements</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income taxes and equity in net income of affiliated companies</a></td>
<td class="nump">157.9<span></span>
</td>
<td class="nump">187.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Tax (expense) benefit</a></td>
<td class="num">(23.6)<span></span>
</td>
<td class="num">(21.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">140.0<span></span>
</td>
<td class="nump">173.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of Accumulated Other Comprehensive Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification out of Accumulated Other Comprehensive Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="num">(0.4)<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of Accumulated Other Comprehensive Loss | Gains (Losses) on Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification out of Accumulated Other Comprehensive Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income taxes and equity in net income of affiliated companies</a></td>
<td class="num">(0.8)<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Tax (expense) benefit</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="num">(0.7)<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of Accumulated Other Comprehensive Loss | Amortization of Defined Benefit Pension And Other Postretirement Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification out of Accumulated Other Comprehensive Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Actuarial gains</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1', window );">Settlements</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income taxes and equity in net income of affiliated companies</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Tax (expense) benefit</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign currency contracts | Reclassification out of Accumulated Other Comprehensive Loss | Gains (Losses) on Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification out of Accumulated Other Comprehensive Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="num">(0.7)<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods and services sold</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_TreasuryLockMember', window );">Forward treasury locks | Reclassification out of Accumulated Other Comprehensive Loss | Gains (Losses) on Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification out of Accumulated Other Comprehensive Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">$ (0.1)<span></span>
</td>
<td class="num">$ (0.1)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActuarialGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActuarialGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(7)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(7)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_TreasuryLockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_TreasuryLockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932985807760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity - Change in Shareholders' Equity (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning of period</a></td>
<td class="nump">$ 2,684.9<span></span>
</td>
<td class="nump">$ 2,335.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Balance (in shares)</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 140.0<span></span>
</td>
<td class="nump">173.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Activity related to stock-based compensation</a></td>
<td class="nump">$ 11.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Share purchased under share repurchase program (in shares)</a></td>
<td class="nump">183,360<span></span>
</td>
<td class="nump">390,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Shares purchased under share repurchase program</a></td>
<td class="num">$ (60.1)<span></span>
</td>
<td class="num">$ (147.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Dividends declared</a></td>
<td class="num">(14.2)<span></span>
</td>
<td class="num">(13.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">14.6<span></span>
</td>
<td class="num">(22.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, end of period</a></td>
<td class="nump">$ 2,776.2<span></span>
</td>
<td class="nump">$ 2,326.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Balance (in shares)</a></td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares)</a></td>
<td class="nump">75,300,000<span></span>
</td>
<td class="nump">75,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning of period</a></td>
<td class="nump">$ 18.8<span></span>
</td>
<td class="nump">$ 18.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares)</a></td>
<td class="nump">75,300,000<span></span>
</td>
<td class="nump">75,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, end of period</a></td>
<td class="nump">$ 18.8<span></span>
</td>
<td class="nump">$ 18.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Capital in Excess of Par Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning of period</a></td>
<td class="nump">232.2<span></span>
</td>
<td class="nump">249.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Activity related to stock-based compensation</a></td>
<td class="num">(50.8)<span></span>
</td>
<td class="num">(29.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, end of period</a></td>
<td class="nump">181.4<span></span>
</td>
<td class="nump">219.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember', window );">Treasury Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning of period</a></td>
<td class="num">$ (370.9)<span></span>
</td>
<td class="num">$ (229.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Balance (in shares)</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Activity related to stock -based compensation (in shares)</a></td>
<td class="num">(300,000)<span></span>
</td>
<td class="num">(300,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Activity related to stock-based compensation</a></td>
<td class="nump">$ 61.8<span></span>
</td>
<td class="nump">$ 29.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Share purchased under share repurchase program (in shares)</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Shares purchased under share repurchase program</a></td>
<td class="num">$ (60.1)<span></span>
</td>
<td class="num">$ (147.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, end of period</a></td>
<td class="num">$ (369.2)<span></span>
</td>
<td class="num">$ (347.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Balance (in shares)</a></td>
<td class="nump">1,100,000<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning of period</a></td>
<td class="nump">$ 2,987.8<span></span>
</td>
<td class="nump">$ 2,456.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">140.0<span></span>
</td>
<td class="nump">173.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Dividends declared</a></td>
<td class="num">(14.2)<span></span>
</td>
<td class="num">(13.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, end of period</a></td>
<td class="nump">3,113.6<span></span>
</td>
<td class="nump">2,617.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated other comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning of period</a></td>
<td class="num">(183.0)<span></span>
</td>
<td class="num">(159.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">14.6<span></span>
</td>
<td class="num">(22.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, end of period</a></td>
<td class="num">$ (168.4)<span></span>
</td>
<td class="num">$ (182.4)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932989459184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity - Supplemental Equity Information (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Dividends declared per share (in dollars per share)</a></td>
<td class="nump">$ 0.19<span></span>
</td>
<td class="nump">$ 0.18<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932984189792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for issuance under the 2016 Plan (in shares)</a></td>
<td class="nump">1,444,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock options, granted (in shares)</a></td>
<td class="nump">105,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Stock options, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 306.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Stock options, weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 108.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Stock volatility</a></td>
<td class="nump">29.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 8.5<span></span>
</td>
<td class="nump">$ 5.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Share Unit (PSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">37,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 306.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Share Unit (PSUs) | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wst_ShareBasedCompensationArrangementByShareBasedPaymentAwardActualPayoutPercentage', window );">Target award percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Share Unit (PSUs) | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wst_ShareBasedCompensationArrangementByShareBasedPaymentAwardActualPayoutPercentage', window );">Target award percentage</a></td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">4,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 306.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wst_ShareBasedCompensationArrangementByShareBasedPaymentAwardActualPayoutPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Actual Payout, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wst_ShareBasedCompensationArrangementByShareBasedPaymentAwardActualPayoutPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932984141792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Benefit Plans - Schedule of Components of Net Periodic Benefit Cost (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on assets</a></td>
<td class="num">(0.3)<span></span>
</td>
<td class="num">(2.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Recognized actuarial losses (gains)</a></td>
<td class="num">(0.4)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1', window );">Settlements</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">U.S. plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost</a></td>
<td class="num">(0.3)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on assets</a></td>
<td class="num">(0.3)<span></span>
</td>
<td class="num">(2.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Recognized actuarial losses (gains)</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1', window );">Settlements</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension benefits | U.S. plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension benefits | International plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other retirement benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Recognized actuarial losses (gains)</a></td>
<td class="num">(0.5)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1', window );">Settlements</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost</a></td>
<td class="num">(0.4)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other retirement benefits | U.S. plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost</a></td>
<td class="num">(0.4)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other retirement benefits | International plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActuarialGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActuarialGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(7)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(7)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139933082801344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Benefit Plans - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1', window );">Settlements</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1', window );">Settlements</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(7)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(7)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932989391792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Expense (Income) - Schedule of Other (Income) Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairments</a></td>
<td class="nump">$ 11.3<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Loss (gain) on oil hedges</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="num">(2.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Contingent consideration</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange transaction losses (gains)</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="num">(1.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other items</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wst_OtherIncomeExpense', window );">Total other expense (income)</a></td>
<td class="nump">$ 12.9<span></span>
</td>
<td class="num">$ (3.1)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wst_OtherIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of other income and expense items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wst_OtherIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932985900464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Expense (Income) - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfInvestmentHoldingsLineItems', window );"><strong>Summary of Investment Holdings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.3<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Derivative instruments not designated as hedging instruments, gain (loss), net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
<td class="nump">$ 2.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=wst_ProprietaryProductsMember', window );">Proprietary Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfInvestmentHoldingsLineItems', window );"><strong>Summary of Investment Holdings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=wst_The2020RestructuringPlanMember', window );">2020 Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfInvestmentHoldingsLineItems', window );"><strong>Summary of Investment Holdings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wst_RestructuringAndRelatedActivitiesPeriodOfImplementation', window );">Restructuring and related activities, period of implementation</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=wst_The2020RestructuringPlanMember', window );">2020 Restructuring Plan | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfInvestmentHoldingsLineItems', window );"><strong>Summary of Investment Holdings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Restructuring and related cost, expected cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOnFutureEarningsAmount', window );">Effect on future earnings, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=wst_The2020RestructuringPlanMember', window );">2020 Restructuring Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfInvestmentHoldingsLineItems', window );"><strong>Summary of Investment Holdings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Restructuring and related cost, expected cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOnFutureEarningsAmount', window );">Effect on future earnings, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOnFutureEarningsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The quantified amount of the future effect on earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOnFutureEarningsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfInvestmentHoldingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfInvestmentHoldingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wst_RestructuringAndRelatedActivitiesPeriodOfImplementation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring and Related Activities, Period of Implementation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wst_RestructuringAndRelatedActivitiesPeriodOfImplementation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=wst_ProprietaryProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=wst_ProprietaryProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=wst_The2020RestructuringPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=wst_The2020RestructuringPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932984390512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Expense (Income) - Schedule of Restructuring and Related Charges (Details) - 2020 Restructuring Plan<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance, December 31, 2022</a></td>
<td class="nump">$ 25.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Charges</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="num">(0.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance, March 31, 2023</a></td>
<td class="nump">24.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=wst_A2020RestructuringPlanMember', window );">Severance and benefits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance, December 31, 2022</a></td>
<td class="nump">10.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Charges</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="num">(0.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance, March 31, 2023</a></td>
<td class="nump">9.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=wst_A2020RestructuringPlanMember', window );">Asset-related charges</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance, December 31, 2022</a></td>
<td class="nump">15.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Charges</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance, March 31, 2023</a></td>
<td class="nump">$ 15.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=wst_A2020RestructuringPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=wst_A2020RestructuringPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932985659600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 23.6<span></span>
</td>
<td class="nump">$ 21.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">14.90%<span></span>
</td>
<td class="nump">11.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount', window );">Tax benefit associated with stock-based compensation</a></td>
<td class="nump">$ 11.6<span></span>
</td>
<td class="nump">$ 8.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Tax benefit of state tax valuation allowance</a></td>
<td class="nump">$ 5.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126970579&amp;loc=d3e23163-113944<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932987796736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932985540304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Sales by Product Group (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net sales</a></td>
<td class="nump">$ 716.6<span></span>
</td>
<td class="nump">$ 720.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Intersegment sales elimination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net sales</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=wst_ProprietaryProductsMember', window );">Proprietary Products | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net sales</a></td>
<td class="nump">583.1<span></span>
</td>
<td class="nump">601.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=wst_ContractManufacturedProductsMember', window );">Contract-Manufactured Products | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net sales</a></td>
<td class="nump">$ 133.5<span></span>
</td>
<td class="nump">$ 118.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=wst_ProprietaryProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=wst_ProprietaryProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=wst_ContractManufacturedProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=wst_ContractManufacturedProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139932984493808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Segment Financial Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating profit</a></td>
<td class="nump">$ 155.3<span></span>
</td>
<td class="nump">$ 189.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="num">(8.5)<span></span>
</td>
<td class="num">(5.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges', window );">Asset impairment for planned sale of plant</a></td>
<td class="nump">11.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Interest (income) expense, net</a></td>
<td class="num">(2.6)<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income taxes and equity in net income of affiliated companies</a></td>
<td class="nump">157.9<span></span>
</td>
<td class="nump">187.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairments</a></td>
<td class="nump">11.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating profit</a></td>
<td class="nump">188.1<span></span>
</td>
<td class="nump">212.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate and Unallocated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating profit</a></td>
<td class="num">(32.8)<span></span>
</td>
<td class="num">(22.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="num">(8.5)<span></span>
</td>
<td class="num">(5.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Corporate general costs</a></td>
<td class="num">(14.7)<span></span>
</td>
<td class="num">(17.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges', window );">Asset impairment for planned sale of plant</a></td>
<td class="num">(9.4)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquisition-related intangible assets</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=wst_ProprietaryProductsMember', window );">Proprietary Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairments</a></td>
<td class="nump">9.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=wst_ProprietaryProductsMember', window );">Proprietary Products | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating profit</a></td>
<td class="nump">170.7<span></span>
</td>
<td class="nump">193.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=wst_ContractManufacturedProductsMember', window );">Contract-Manufactured Products | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating profit</a></td>
<td class="nump">$ 17.4<span></span>
</td>
<td class="nump">$ 19.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=wst_ProprietaryProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=wst_ProprietaryProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=wst_ContractManufacturedProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=wst_ContractManufacturedProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>wst-20230331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:currency="http://xbrl.sec.gov/currency/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:wst="http://www.westpharma.com/20230331"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="wst-20230331.xsd" xlink:type="simple"/>
    <context id="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id65f0e55c9ce468dab69a4cf20c6ce02_I20230412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
        </entity>
        <period>
            <instant>2023-04-12</instant>
        </period>
    </context>
    <context id="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2af6ba55593d446686e312e0578684c6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5583fe9d33064523a217abe67f6f392d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i00c9b6f38a304d5190000b6168ba7dce_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie3cc75f001344ce095d702cd95b46078_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iae34400f53bb478b90a83802a119f9f9_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">wst:BiologicsCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="icda5c4d11f62428a95249de65f0fefd2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">wst:BiologicsCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie37ebad36b6348b285cca6d19bde1f7b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">wst:GenericsCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i840ac8c485014ee99b6e1a87cfb8a764_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">wst:GenericsCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3f33ea9ddf5f4c6990e93f50d03f03ef_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">wst:PharmaCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia894e91feb4a4bdf8293a2c2963731ab_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">wst:PharmaCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="icca73618ae684d5ea52e3060af4ad383_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">wst:ContractManufacturedCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iaceefe0fe985435aa372154902f65846_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">wst:ContractManufacturedCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i29c510f38fbe49baa6388a40c6f045d8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i27022197520642e3882ce31d9285e029_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie6cdab3f33c048088340a1a1ac085f71_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wst:HighValueProductComponentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0bcd5713f126432fa7b95d333a6687ed_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wst:HighValueProductComponentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4ee7ca1522924116844090df73a38cfc_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wst:HighValueProductDeliveryDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ieb109b3e8b854eef8e2690d97b4deb83_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wst:HighValueProductDeliveryDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8964ed8d404e4ecd8cf51bf7dd57fd72_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wst:StandardPackagingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id4878ca4f0234438bbe2231c100da361_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wst:StandardPackagingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i69658dd90db2466aab6d25979a565ec5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wst:ContractManufacturedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i1a7534f872714dc0b6f41e800f834626_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wst:ContractManufacturedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ieabcd647a4f94d14b6c41f5ed82c736e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0bb4cbfdac1443989f5d65abc02019aa_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i705daa289597485c80cbe6c2a4295b55_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AmericasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6f08de799c8b4bcf84f0b2388b9a1d63_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AmericasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i72821269558f4965b1f01873aa17427e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i068419f0506343b79f1391a7f0d6cc2e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9f79e1cf75c043448cd2aa1afd887c55_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4cfb274b8db44a3e9f441e5bf17fc3ef_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1fc7305b8607421d8a06a356da5a15ed_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib884bebbba5c4e049f608852aff2075d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i73b55d82d73748a38f69bd594560eb79_I20130630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wst:SmartDoseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-06-30</instant>
        </period>
    </context>
    <context id="i3f009365e828466d98af8bbc2bce4411_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wst:SmartDoseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i866c5a8fb2f748d0b77d31bceb45da81_I20230228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
        </entity>
        <period>
            <instant>2023-02-28</instant>
        </period>
    </context>
    <context id="iecf3cc3f4a2e4356986ecea0d53b720d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">wst:TermLoanDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i820fab327f6443ae978dfa28318d48f4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">wst:TermLoanDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id38fa53f753e49438df00d22e5b777e6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">wst:SeniorBNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9a8404bd9ab74326a8394ec3e7f36919_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">wst:SeniorBNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i85a6072962d04208ae531a2b2fbfef0e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">wst:SeniorCNotesDue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib2b66dd4040640348f96693d6e7be1d5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">wst:SeniorCNotesDue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id48d782f5bfb4fe6a7905309804dadd4_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">wst:RevolvingCreditFacilityDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i98cb2924a74a4bcbb3d3520ea87d52f0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">wst:RevolvingCreditFacilityDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if46b82c9c68b443482333077a49f48e9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:SGD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i82f3bc098630498582401da701e7b138_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:SGD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i09563dd08c64439c84993944fccfc6db_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ifdb1000004bd47589080d94726e76022_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5f005fe228a0408495ca4180dcc39feb_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9728ffcf312e4ac4bdb6aae4a7b23a44_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PositionAxis">us-gaap:LongMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if6ea04af1eff40db88226330d1e25200_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PositionAxis">us-gaap:ShortMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="icdd3e55c2a7a4212801e02cabd651cfc_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PositionAxis">us-gaap:LongMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i63dca94e686c450eb00428ac82177d9d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PositionAxis">us-gaap:ShortMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if2a16112236a46548494c875fa25e7c6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:SGD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PositionAxis">us-gaap:LongMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i049f03d104874040b8a9e20dca208dd8_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:SGD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PositionAxis">us-gaap:ShortMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i86cd8c4c0adb4f0bb284e66a3b57f3be_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i949b0ebb4cdd40e8a2bfd21565e1e3e0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3dbbddaad3d544529fc30c5aa103c052_D20171101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0a775eaad7ab4fb2b9ed736aefbf5955_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i024bb3a09a8d4ff89a1465c610f13094_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic2b6751140ae4a8a905c7349d2d7fab8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">wst:OtherExpenseIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i512c05fc14444680a4b01af74b3b7f07_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">wst:OtherExpenseIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie403ae300c3c4982a693b55e66f3705f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ifeb72d8b516e4addb0181e1f85261c85_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0ed146d13e5f4eb2a012abb762cc10f0_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">wst:OtherExpenseIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i88d56264e84240aaa4c3afb58fcf626e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">wst:OtherExpenseIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i550fe20240f54b029e378c9bf7ce6f5d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">wst:NetSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i89d9d14f5ff4438cafe884c5b0d2718f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">wst:NetSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2aaae598465a460fb7b809258de6e1a5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3800bdd574354a39a20ce84a4092c158_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia5c0ef7c3e0147a483d139e864147374_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:TreasuryLockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5d9e67f88dce43dd8855ccc2dbc02a22_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:TreasuryLockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9c377e143e9d48d0ae6ce22294a8da16_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia9abb09cb5a64fc0b766d1350855b2db_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3e6599d390d0401bba4ccd616c8136c8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">wst:OtherExpenseIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2f6ac6dfc13d492b82ae66056c8cdfa7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">wst:OtherExpenseIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i014caa55d11343438f2b721d5b51d6c8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iab874b4cf2374c38a4cc92deabe110c7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if7f2039fc421408da2abf39c8fa7f3e1_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">wst:NetSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if0856bab3e85491fb635e56eda1444de_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">wst:NetSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i143f14fa720c48e8a013cf77a4efde31_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i067a51880daf4861907b0950720d904c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if5d4916f585e4d42bfc35a013fb84cdf_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ibca67bb324884ac1a4bd92682b0eef05_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if7e54bd1a6644a0e8981abafbc1190e8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CommodityOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">wst:OtherExpenseIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i03f4edf339b2471dac58f1cdbd5df6a5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CommodityOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">wst:OtherExpenseIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i97dea892f5984be0a0fd08b4eee5ed4a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0ee1aea1aac947e59b4311a420cdabdf_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8472e48bf22848d09276489a66c9e03e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ief4d8a0c3b5e40789e9de34c75e432bf_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6d4597dfd1ba407789166d3d2ab3a1c6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id11dee14a78441cf8e6ce24a522f88c7_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i74d73afd5be44336b5735abe19adc044_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5f682024fc3e4a7a9e5d718533d31677_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i270bac59038e42c6a92535138d33ff29_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie6fbf09378a54c02a5743d72f4ef99da_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommodityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i11a99f1a1d3645feb7815067a68cd81f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommodityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia53ac927db8b457d821c732f6d7f4f61_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommodityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i520386d8aa8046dc8b6ed7c632c7c7f9_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommodityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie176087c2e0f4f9aaf6886e4438cdcf1_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i20dc5476975c412a9dfc88d9c2216dee_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0e410a2ff35b4d57982b319abc1e1768_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i89f31e1b854b43c68d198cca6624635e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="idecab62008c846caa537823da6bf68cf_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3d38876b8687498fb75a9d1921176e0b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i53b64dbcb5d24234b5920850cfdbdd10_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5022b45891414a1794bd141aad661062_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idd5224d49fab426a864b9ef841b2bd25_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib7fc7fba1d244cd09a928fc5c9b89075_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0e31f6f4b77a4341b3844eaafe791605_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3855c26361a747a6a2063f8669213b1d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommodityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iba6b68a438dd4a579b4713432d302e3d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommodityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie8ff7bccbad64151ab6ea9014d5cc59f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommodityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id1b304b4749d406ba788dcf08bc89106_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommodityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if1036a3de1ea4f318261a593515df52b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9dd9da2fad4544178dd80a8db1ca4501_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie68882e1ec5c418487d91aaacd73759d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i564b193142034a3dad5d2192d388c8df_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib0a2e4816674455e8c1653b4d67a05eb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i526f045cc6ae4ef9aebfa54634f321c7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4b4825baaa3d4e808f9edc322c950ac0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6a916ac5970f44c4ae05918807b57f65_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6339e7f0f9e847638d0b1e918478a17b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibe54e8c2da3440aebf4d2616a05e64c2_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i797411f0d816497e9411895884b514e7_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia8b0a91f9e20469aa04a865d19bf4454_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia80d875680634e70a48cb73ff07b85e4_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i1a6e09ceadea4cf28bdd80365b649ab0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i60c9aeeca640474289ca4b0da5cf3a7d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic60c39b0c368406f8cd641a4d764ddc1_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic5cd3bf0b3e6469e9da46a298c4c805d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6630ce4dbb7747e8858856ea430b90ab_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4fca80d6c8df481687a29bccfb487856_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8c6c1d8c2b4f4a0b89ca2e9a9ddd447c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3a3f5a8af8064476820608f696c42e1d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i936367d439194b7fbc90a34743134e4f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0df22a14170c4331a1256c9f757e5090_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie71d1ab95f7344af96897b0090a0e58d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia67d15eb184042d897c6efc17a13b799_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i111ee7c976334a21a8a888af218b7e87_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6421c8aef05242b2af4fa57c824c4efa_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1a6c194a67cd4b14b2fe810f1803d2fa_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i15d499d767e34686aa1263510f1d36a3_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i43311d97b8684c7d99964d6c9ce008f6_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i90887b06cf074badac168937eaf76a7d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i83a0a64e641241259400ffb042bd9b69_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2a7ae72bcc2f46119331a447f5c3150d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i8d0c261740c340ebb7fdb92c09b03f4e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8e3c4dec591644f5b67d216f6b423622_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:TreasuryLockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6588c22fb7d242729097d46bc107e464_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:TreasuryLockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6c7ca8ad39694e71b583c7ef4a4b1e4d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i840ed86b8d83428dae98a9709644d509_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie947ff5eae324b458a796759ec01b073_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i051025edf9d84083b951a5c2120b859e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i594dfb15b16f4f3b94b3e4c667ae6f31_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id0cbe79b5a944e7ea8c8155a043cfb0c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5974879a41634c43937d0fdc678376ef_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2e4f2583d5104db2b4d1e647dc99032f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i516dc67ea1934343bbf9ab9c724c74fe_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2ad958aa230d4452800e1a411e50a1da_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8c00de3c1e304a8ba1d6c714fc5be20a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i353cb27834c543849553e5d0b7bbf5c1_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ica8dcddf1bfb4c518886c671739fd284_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2b66fb1404f0411794600214ad5981bc_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if8c8c941591f438a9e38e52390bd7143_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9ca2730fabca4305a997b6e33c1c770e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8b96f9bbddfb400fb15bf48690acfac4_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i24c88cbf61274655b654ef8032885498_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic9824a1206b949e9a0e697dab83ac7c1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i18b4fa445330470da5ef68248c88e734_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i32ef532505b441b1806a8f09cd91cd70_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i32bd0566d819471cba804ab5cc28ab44_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie8e072fd9e914a71afd49e2d9a5e79c6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i083cbb87646e4c8ba193971c93fd6efe_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie4063d23292b47168eedc6bfb33a3fbd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia5fc6b2b23e84ec4bc5d35849e3156f6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i48e325bcbc074931a2dd945f8078f5f8_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2b1173baba244d369e85b0aaae78c105_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i83dbf680868b48b9b005cf05def0fad3_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ibb84c364648d488ba64727ae4d194a34_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9ea1399aa8514b6fb5e425e47f1f53b4_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5cea666f1a3e4fca9565501a1a97da9f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if9485a9306be43498daef6ad2c76774a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iaac3fbfd1951416da909602aa595a831_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i15f25764805440459934b22b2c76b3b4_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib6b03745b52d4c23b5f91243d9f4d0c7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="icea6ecda38c04a1980ef2da02b46df03_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i18f818cb77b7453cbd94313211a8df44_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i209901cc4ed54159a25df88bd1b8faee_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ida333f1205fc4fcfb7b85636d28c908d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="idbcc67097f9240329c190bf9487f2480_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i05073a750c324193a92113cb4a636965_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i42e6f528867c45a7b7da2f9fe313486e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i13c26150d9794fafb5581ccf36e02580_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia68ac2f16d2949e69b481796f2242932_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i28fde86f84534f35b341997ed553fd3b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3ad6bf31a752453bb990cc27c2ba0854_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7cb4b2a7f3bc479997ddd2c09c37cf63_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8343aec575e3454988060e5f6ce66a0d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i577299ca8e5a4684b6ab0d6a77f3cabe_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7fe28b57298646bca10b9de129f3bac3_D20221201-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">wst:The2020RestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i966f8dcfe0c8437bb80311fd4f44d03d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">wst:The2020RestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i173c567741e44c9180c9525060447224_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">wst:The2020RestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i23c5432999954af5a1ded50a2d12617d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">wst:The2020RestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i00f636ccc7fe4a40bff18a2475aee5fb_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">wst:The2020RestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ief1173cf0c9c47e8a1b90da1b941c509_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">wst:A2020RestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i320c37f388f0402ebe72c6e91de76520_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">wst:A2020RestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i741e48b8c43549918dae0d3e9f2835dc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">wst:A2020RestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie5751a6a227b4cd09e42603236f7ce4b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">wst:A2020RestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib58ff9d1a085489cb685ece3967cd85c_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">wst:A2020RestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic32e88fe332446cd865cf4708f70ecbd_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">wst:A2020RestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5dddcfaad27c4e2bb489c4f35ed023eb_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">wst:A2020RestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic23b01e75b1e4bc5a81f42b0e6c8108b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">wst:A2020RestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7fa2298580b64ebfb1db3e0ca8424d94_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">wst:A2020RestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3b6114e84e5644b6b9435baa1eba9515_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wst:ProprietaryProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i776c2fc9c0314d5dbc1af6c8aa146ea9_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wst:ProprietaryProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5ec1bf24d76645649ff514efc6f320dd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wst:ProprietaryProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iedc77d2ee3884279ae4e3b4f74b210ca_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wst:ContractManufacturedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i379b3e02ffff4f65b6f70a4e51167f3b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wst:ContractManufacturedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i237555183941451e8d5f239492f90b93_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i959bea7c7da543dfaa998842a57cfc20_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic8cd20fa40094f43a596ebe943a0379a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i92736af48f534f498e235c076ae54733_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i934ac1f9eaf94ecfb00d07b8084f9292_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="icac424a9ffb64141aa0d33bcd8b4fcfb_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000105770</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="sgd">
        <measure>iso4217:SGD</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="jpy">
        <measure>iso4217:JPY</measure>
    </unit>
    <unit id="bbl">
        <measure>utr:bbl</measure>
    </unit>
    <unit id="usdPerBbl">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>wst:bbl</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>wst:segment</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80L2ZyYWc6YzIyMDgxZTYzYWE4NDY1Yjk0ZTFmNDEyYjc5ODM3YmIvdGFibGU6M2E1MmU1YmE2YjBkNDczYmFhOTU5Y2QzYmFkNTU2YmEvdGFibGVyYW5nZTozYTUyZTViYTZiMGQ0NzNiYWE5NTljZDNiYWQ1NTZiYV8yLTEtMS0xLTgyNzgy_be108184-0a70-49d6-b7de-b267537e1b35">0000105770</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80L2ZyYWc6YzIyMDgxZTYzYWE4NDY1Yjk0ZTFmNDEyYjc5ODM3YmIvdGFibGU6M2E1MmU1YmE2YjBkNDczYmFhOTU5Y2QzYmFkNTU2YmEvdGFibGVyYW5nZTozYTUyZTViYTZiMGQ0NzNiYWE5NTljZDNiYWQ1NTZiYV8zLTItMS0xLTgyNzgy_4e0a1c7f-9abe-4909-a067-5cd0c92d70a9">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80L2ZyYWc6YzIyMDgxZTYzYWE4NDY1Yjk0ZTFmNDEyYjc5ODM3YmIvdGFibGU6M2E1MmU1YmE2YjBkNDczYmFhOTU5Y2QzYmFkNTU2YmEvdGFibGVyYW5nZTozYTUyZTViYTZiMGQ0NzNiYWE5NTljZDNiYWQ1NTZiYV80LTEtMS0xLTgyNzgy_3a34db12-e630-41a1-a1be-b131e5914414">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80L2ZyYWc6YzIyMDgxZTYzYWE4NDY1Yjk0ZTFmNDEyYjc5ODM3YmIvdGFibGU6M2E1MmU1YmE2YjBkNDczYmFhOTU5Y2QzYmFkNTU2YmEvdGFibGVyYW5nZTozYTUyZTViYTZiMGQ0NzNiYWE5NTljZDNiYWQ1NTZiYV81LTEtMS0xLTgyNzgy_3f0d5e8d-3539-4cee-bc64-b60bb4b9967c">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80L2ZyYWc6YzIyMDgxZTYzYWE4NDY1Yjk0ZTFmNDEyYjc5ODM3YmIvdGFibGU6M2E1MmU1YmE2YjBkNDczYmFhOTU5Y2QzYmFkNTU2YmEvdGFibGVyYW5nZTozYTUyZTViYTZiMGQ0NzNiYWE5NTljZDNiYWQ1NTZiYV82LTEtMS0xLTgyNzgy_8b2faeb3-8b47-4b76-9ac0-01af7e35f583">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xL2ZyYWc6MTQ1NzAyMDg4MzdlNDQ2N2JkNjY3YWNlMzFlNGExZmUvdGV4dHJlZ2lvbjoxNDU3MDIwODgzN2U0NDY3YmQ2NjdhY2UzMWU0YTFmZV8xMw_181cc52a-082e-44bb-992f-da891c33af98">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xL2ZyYWc6MTQ1NzAyMDg4MzdlNDQ2N2JkNjY3YWNlMzFlNGExZmUvdGFibGU6MDVhYzM5NDc4ZTU2NDkzMWIzNmM0MTE5OWMyNTQzNmYvdGFibGVyYW5nZTowNWFjMzk0NzhlNTY0OTMxYjM2YzQxMTk5YzI1NDM2Zl8wLTAtMS0xLTgyNzgy_851c526c-d115-4940-8841-24b2c776e10b">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xL2ZyYWc6MTQ1NzAyMDg4MzdlNDQ2N2JkNjY3YWNlMzFlNGExZmUvdGV4dHJlZ2lvbjoxNDU3MDIwODgzN2U0NDY3YmQ2NjdhY2UzMWU0YTFmZV82MA_209ca534-5f97-4552-b00d-22dc0ffd2e7a">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xL2ZyYWc6MTQ1NzAyMDg4MzdlNDQ2N2JkNjY3YWNlMzFlNGExZmUvdGFibGU6MWJmOWNjNjMxMjcwNGRhYTlmZDgyZDk0ODFiYmY3MmUvdGFibGVyYW5nZToxYmY5Y2M2MzEyNzA0ZGFhOWZkODJkOTQ4MWJiZjcyZV8wLTAtMS0xLTgyNzgy_c2b68058-0b74-4ab9-856c-9a574ca7b02e">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xL2ZyYWc6MTQ1NzAyMDg4MzdlNDQ2N2JkNjY3YWNlMzFlNGExZmUvdGV4dHJlZ2lvbjoxNDU3MDIwODgzN2U0NDY3YmQ2NjdhY2UzMWU0YTFmZV8xMzc_b04eba54-c9d0-4f58-b198-b797317b96fd">1-8036</dei:EntityFileNumber>
    <dei:EntityFileNumber
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xL2ZyYWc6MTQ1NzAyMDg4MzdlNDQ2N2JkNjY3YWNlMzFlNGExZmUvdGV4dHJlZ2lvbjoxNDU3MDIwODgzN2U0NDY3YmQ2NjdhY2UzMWU0YTFmZV8xMzc_f8c11bef-6230-4cbe-8263-6bc053de0c51">1-8036</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xL2ZyYWc6MTQ1NzAyMDg4MzdlNDQ2N2JkNjY3YWNlMzFlNGExZmUvdGV4dHJlZ2lvbjoxNDU3MDIwODgzN2U0NDY3YmQ2NjdhY2UzMWU0YTFmZV8xNDI_4646003a-819d-4835-8425-9ff9aa79235d">WEST PHARMACEUTICAL SERVICES, INC.</dei:EntityRegistrantName>
    <dei:EntityRegistrantName
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xL2ZyYWc6MTQ1NzAyMDg4MzdlNDQ2N2JkNjY3YWNlMzFlNGExZmUvdGV4dHJlZ2lvbjoxNDU3MDIwODgzN2U0NDY3YmQ2NjdhY2UzMWU0YTFmZV8xNDI_77161ff7-98b3-4c44-8770-36529d1d770a">WEST PHARMACEUTICAL SERVICES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xL2ZyYWc6MTQ1NzAyMDg4MzdlNDQ2N2JkNjY3YWNlMzFlNGExZmUvdGFibGU6ZDUxMzE1OTMxNjBjNDFkZWJlZjFiYzNkNWExZjVhNGYvdGFibGVyYW5nZTpkNTEzMTU5MzE2MGM0MWRlYmVmMWJjM2Q1YTFmNWE0Zl8wLTEtMS0xLTgyNzgy_80998e2e-4641-465c-ac01-1358abb464c9">PA</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xL2ZyYWc6MTQ1NzAyMDg4MzdlNDQ2N2JkNjY3YWNlMzFlNGExZmUvdGFibGU6ZDUxMzE1OTMxNjBjNDFkZWJlZjFiYzNkNWExZjVhNGYvdGFibGVyYW5nZTpkNTEzMTU5MzE2MGM0MWRlYmVmMWJjM2Q1YTFmNWE0Zl8wLTYtMS0xLTgyNzgy_f260fdd9-dab7-487c-adb7-bec47ec8f400">23-1210010</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xL2ZyYWc6MTQ1NzAyMDg4MzdlNDQ2N2JkNjY3YWNlMzFlNGExZmUvdGFibGU6ZDUxMzE1OTMxNjBjNDFkZWJlZjFiYzNkNWExZjVhNGYvdGFibGVyYW5nZTpkNTEzMTU5MzE2MGM0MWRlYmVmMWJjM2Q1YTFmNWE0Zl8zLTEtMS0xLTgyNzgyL3RleHRyZWdpb246ZDJkZDA5YzIzM2JiNDc2ZGE0MmE2NDdiOGNiOTJlNDJfNA_bb631f17-7ecd-4cf8-a086-75533af20df8">530 Herman O. West Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xL2ZyYWc6MTQ1NzAyMDg4MzdlNDQ2N2JkNjY3YWNlMzFlNGExZmUvdGFibGU6ZDUxMzE1OTMxNjBjNDFkZWJlZjFiYzNkNWExZjVhNGYvdGFibGVyYW5nZTpkNTEzMTU5MzE2MGM0MWRlYmVmMWJjM2Q1YTFmNWE0Zl8zLTEtMS0xLTgyNzgyL3RleHRyZWdpb246ZDJkZDA5YzIzM2JiNDc2ZGE0MmE2NDdiOGNiOTJlNDJfOA_6ee063f2-e06a-43e9-bbf3-471863c94147">Exton</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xL2ZyYWc6MTQ1NzAyMDg4MzdlNDQ2N2JkNjY3YWNlMzFlNGExZmUvdGFibGU6ZDUxMzE1OTMxNjBjNDFkZWJlZjFiYzNkNWExZjVhNGYvdGFibGVyYW5nZTpkNTEzMTU5MzE2MGM0MWRlYmVmMWJjM2Q1YTFmNWE0Zl8zLTEtMS0xLTgyNzgyL3RleHRyZWdpb246ZDJkZDA5YzIzM2JiNDc2ZGE0MmE2NDdiOGNiOTJlNDJfMTI_5d2ee00e-f9c4-45dc-89d6-c5e532ee3acc">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xL2ZyYWc6MTQ1NzAyMDg4MzdlNDQ2N2JkNjY3YWNlMzFlNGExZmUvdGFibGU6ZDUxMzE1OTMxNjBjNDFkZWJlZjFiYzNkNWExZjVhNGYvdGFibGVyYW5nZTpkNTEzMTU5MzE2MGM0MWRlYmVmMWJjM2Q1YTFmNWE0Zl8zLTYtMS0xLTgyNzgy_5c47f0f5-1b46-412f-8a5f-36ec5d5a1cbb">19341-0645</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xL2ZyYWc6MTQ1NzAyMDg4MzdlNDQ2N2JkNjY3YWNlMzFlNGExZmUvdGV4dHJlZ2lvbjoxNDU3MDIwODgzN2U0NDY3YmQ2NjdhY2UzMWU0YTFmZV8yNTU_844816c7-975f-4b21-943a-652a4ef96567">610</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xL2ZyYWc6MTQ1NzAyMDg4MzdlNDQ2N2JkNjY3YWNlMzFlNGExZmUvdGV4dHJlZ2lvbjoxNDU3MDIwODgzN2U0NDY3YmQ2NjdhY2UzMWU0YTFmZV8yNTg_65866845-790f-415f-b0de-ebea54a8f649">594-2900</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xL2ZyYWc6MTQ1NzAyMDg4MzdlNDQ2N2JkNjY3YWNlMzFlNGExZmUvdGFibGU6ZDJiMzMwYjM3MjdjNDY4ZDk5OWUzNmEzMWFkYzUzYzYvdGFibGVyYW5nZTpkMmIzMzBiMzcyN2M0NjhkOTk5ZTM2YTMxYWRjNTNjNl8xLTAtMS0xLTgyNzgy_e50c2c6a-55a7-4090-a562-570532b6c584">Common Stock, par value $0.25 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xL2ZyYWc6MTQ1NzAyMDg4MzdlNDQ2N2JkNjY3YWNlMzFlNGExZmUvdGFibGU6ZDJiMzMwYjM3MjdjNDY4ZDk5OWUzNmEzMWFkYzUzYzYvdGFibGVyYW5nZTpkMmIzMzBiMzcyN2M0NjhkOTk5ZTM2YTMxYWRjNTNjNl8xLTEtMS0xLTgyNzgy_d91335b3-ca3d-48b5-b8f4-6fe0cfa41354">WST</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xL2ZyYWc6MTQ1NzAyMDg4MzdlNDQ2N2JkNjY3YWNlMzFlNGExZmUvdGFibGU6ZDJiMzMwYjM3MjdjNDY4ZDk5OWUzNmEzMWFkYzUzYzYvdGFibGVyYW5nZTpkMmIzMzBiMzcyN2M0NjhkOTk5ZTM2YTMxYWRjNTNjNl8xLTItMS0xLTgyNzgy_490ef85b-76c7-4146-850e-e5b183a0cb96">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xL2ZyYWc6MTQ1NzAyMDg4MzdlNDQ2N2JkNjY3YWNlMzFlNGExZmUvdGV4dHJlZ2lvbjoxNDU3MDIwODgzN2U0NDY3YmQ2NjdhY2UzMWU0YTFmZV82Nzg_0dbb2c42-1465-48c9-9441-b71f7a4ab379">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityCurrentReportingStatus
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xL2ZyYWc6MTQ1NzAyMDg4MzdlNDQ2N2JkNjY3YWNlMzFlNGExZmUvdGV4dHJlZ2lvbjoxNDU3MDIwODgzN2U0NDY3YmQ2NjdhY2UzMWU0YTFmZV82Nzg_948db9a8-4fdf-41d2-b0af-d766b6f8b85c">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xL2ZyYWc6MTQ1NzAyMDg4MzdlNDQ2N2JkNjY3YWNlMzFlNGExZmUvdGV4dHJlZ2lvbjoxNDU3MDIwODgzN2U0NDY3YmQ2NjdhY2UzMWU0YTFmZV8xMDA3_0c6284da-0133-4fa8-8922-0f402d814207">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityInteractiveDataCurrent
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xL2ZyYWc6MTQ1NzAyMDg4MzdlNDQ2N2JkNjY3YWNlMzFlNGExZmUvdGV4dHJlZ2lvbjoxNDU3MDIwODgzN2U0NDY3YmQ2NjdhY2UzMWU0YTFmZV8xMDA3_4252b5dc-397d-4d59-88cd-8b593d045751">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xL2ZyYWc6MTQ1NzAyMDg4MzdlNDQ2N2JkNjY3YWNlMzFlNGExZmUvdGFibGU6NmZiNzk4OWM0MTUxNGEyM2E0NjdlZGQ2ZTM4MjhhZTMvdGFibGVyYW5nZTo2ZmI3OTg5YzQxNTE0YTIzYTQ2N2VkZDZlMzgyOGFlM18wLTAtMS0xLTgyNzgy_2993c655-7138-4075-9f38-c5d9d3342843">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xL2ZyYWc6MTQ1NzAyMDg4MzdlNDQ2N2JkNjY3YWNlMzFlNGExZmUvdGFibGU6NmZiNzk4OWM0MTUxNGEyM2E0NjdlZGQ2ZTM4MjhhZTMvdGFibGVyYW5nZTo2ZmI3OTg5YzQxNTE0YTIzYTQ2N2VkZDZlMzgyOGFlM18xLTQtMS0xLTgyNzgy_9275abe8-7ca5-4699-a360-45e98f5f5351">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xL2ZyYWc6MTQ1NzAyMDg4MzdlNDQ2N2JkNjY3YWNlMzFlNGExZmUvdGFibGU6NmZiNzk4OWM0MTUxNGEyM2E0NjdlZGQ2ZTM4MjhhZTMvdGFibGVyYW5nZTo2ZmI3OTg5YzQxNTE0YTIzYTQ2N2VkZDZlMzgyOGFlM18yLTQtMS0xLTgyNzgy_59bba59b-1108-468b-9b14-84ceb40ba2e3">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xL2ZyYWc6MTQ1NzAyMDg4MzdlNDQ2N2JkNjY3YWNlMzFlNGExZmUvdGV4dHJlZ2lvbjoxNDU3MDIwODgzN2U0NDY3YmQ2NjdhY2UzMWU0YTFmZV8xODQx_85f0816a-7062-483f-93a1-3827c748444a">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="id65f0e55c9ce468dab69a4cf20c6ce02_I20230412"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xL2ZyYWc6MTQ1NzAyMDg4MzdlNDQ2N2JkNjY3YWNlMzFlNGExZmUvdGV4dHJlZ2lvbjoxNDU3MDIwODgzN2U0NDY3YmQ2NjdhY2UzMWU0YTFmZV8xNzg3_2fa1f345-2426-40e7-9ffe-bc6320ba1151"
      unitRef="shares">74242584</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfMi0xLTEtMS04Mjc4Mg_e184e5c5-25a1-40f8-864f-b93a56f4851a"
      unitRef="usd">716600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfMi0zLTEtMS04Mjc4Mg_9451859e-784b-48fd-bfc0-d1f69301a635"
      unitRef="usd">720000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfMy0xLTEtMS04Mjc4Mg_f6d7884c-b39e-4001-ba70-e459ae4cd048"
      unitRef="usd">445300000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfMy0zLTEtMS04Mjc4Mg_77bfb2b1-3dc4-43a3-b2e0-e3f4e631b2d8"
      unitRef="usd">435400000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfNC0xLTEtMS04Mjc4Mg_7dfd7742-405e-4bbf-8bbd-ccc34e882024"
      unitRef="usd">271300000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfNC0zLTEtMS04Mjc4Mg_c5e0515c-f3d4-4dba-bc74-1e3642742580"
      unitRef="usd">284600000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfNS0xLTEtMS04Mjc4Mg_4cc763af-1457-4d76-9ecc-24c3096aa718"
      unitRef="usd">17100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfNS0zLTEtMS04Mjc4Mg_600af603-3bff-4f89-b774-900a8ea4f67b"
      unitRef="usd">14600000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfNi0xLTEtMS04Mjc4Mg_28d38d5f-081f-48bb-ad41-c6230a188218"
      unitRef="usd">86000000.0</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfNi0zLTEtMS04Mjc4Mg_29fa1977-86f0-4f7c-bc5a-e66c08d5887c"
      unitRef="usd">83400000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <wst:OtherIncomeExpense
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfNy0xLTEtMS04Mjc4Mg_94957656-ff35-434d-a874-581ad39f0853"
      unitRef="usd">-12900000</wst:OtherIncomeExpense>
    <wst:OtherIncomeExpense
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfNy0zLTEtMS04Mjc4Mg_265e42b9-aa52-4d09-997d-4562af34e004"
      unitRef="usd">3100000</wst:OtherIncomeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfOC0xLTEtMS04Mjc4Mg_1a0bedaa-b026-46b8-8d93-e629d91dd486"
      unitRef="usd">155300000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfOC0zLTEtMS04Mjc4Mg_dc2d4d90-6208-4412-97e2-e945d5237402"
      unitRef="usd">189700000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfOS0xLTEtMS04Mjc4Mg_1d4d3bc1-a8ce-4fd5-b773-2aea4cf748b9"
      unitRef="usd">2200000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfOS0zLTEtMS04Mjc4Mg_64a41286-430b-44b1-85ff-5dc18288cebe"
      unitRef="usd">2200000</us-gaap:InterestExpense>
    <us-gaap:InvestmentIncomeNet
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfMTAtMS0xLTEtODI3ODI_79bbc097-1861-4078-849f-37e2d6e10633"
      unitRef="usd">4800000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfMTAtMy0xLTEtODI3ODI_abea9ac7-fd02-4be7-bba2-6db5b203bf8a"
      unitRef="usd">300000</us-gaap:InvestmentIncomeNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfMTItMS0xLTEtODI3ODI_27aab035-14fa-4622-8330-d5191fb8b601"
      unitRef="usd">157900000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfMTItMy0xLTEtODI3ODI_3f4ec394-d75b-44ad-9842-7afce28c29d5"
      unitRef="usd">187800000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfMTMtMS0xLTEtODI3ODI_926e1ebb-79d5-4493-a40d-195ed579fa00"
      unitRef="usd">23600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfMTMtMy0xLTEtODI3ODI_d8948721-3f85-4a5f-988b-4e3c5cbdda9b"
      unitRef="usd">21200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfMTQtMS0xLTEtODI3ODI_2edc27fa-cd12-44d6-b082-b6ec76098149"
      unitRef="usd">5700000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfMTQtMy0xLTEtODI3ODI_a1ec3984-9d4f-4369-97a9-8f34148068af"
      unitRef="usd">7200000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfMTUtMS0xLTEtODI3ODI_705e8955-590c-4b2b-936f-2758c2b1492b"
      unitRef="usd">140000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfMTUtMy0xLTEtODI3ODI_cbb963c9-630c-4947-8ce3-2a160fc1bb48"
      unitRef="usd">173800000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfMTgtMS0xLTEtODI3ODI_9b1ac7df-9b7f-4f0d-a3cc-875087c8edb7"
      unitRef="usdPerShare">1.88</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfMTgtMy0xLTEtODI3ODI_f419e28c-cb8c-4ab7-8c46-8116760aa970"
      unitRef="usdPerShare">2.34</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfMTktMS0xLTEtODI3ODI_24496375-e97b-4b05-b14d-4f1b8d7af1da"
      unitRef="usdPerShare">1.85</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfMTktMy0xLTEtODI3ODI_3662c576-2322-4733-bef2-c2e61c9e33cd"
      unitRef="usdPerShare">2.29</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfMjItMS0xLTEtODI3ODI_cb01958b-91bc-4fcb-931b-e67c79ea3ca3"
      unitRef="shares">74500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfMjItMy0xLTEtODI3ODI_f87f444b-59a4-46f0-a9ef-6d341980e779"
      unitRef="shares">74400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfMjMtMS0xLTEtODI3ODI_bbe1ef08-e382-4bad-a9ff-7d77ed27209c"
      unitRef="shares">75700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8xOS9mcmFnOmJiNzI0NDM3MmViMTQ1MzdiYjFlZTJjZGUyNGJjZjkwL3RhYmxlOjE0YTA4MjQwMGRiMDRlYzVhMjg5YzYxNTg4MjE3ZDY5L3RhYmxlcmFuZ2U6MTRhMDgyNDAwZGIwNGVjNWEyODljNjE1ODgyMTdkNjlfMjMtMy0xLTEtODI3ODI_b3b45b70-60e3-42ec-adc1-ed614eceebae"
      unitRef="shares">76000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yMi9mcmFnOjRmYjc5NjVjNGNlNTRlN2JhNzY5ODNhZjJjYmZlZGNlL3RhYmxlOmU1ODQ5OTBhZjE1OTQ5MDE4YzllZmNlNjIyYzU1MmEzL3RhYmxlcmFuZ2U6ZTU4NDk5MGFmMTU5NDkwMThjOWVmY2U2MjJjNTUyYTNfMi0xLTEtMS04Mjc4Mg_f9525929-bca2-4a47-913c-cdebda39e35f"
      unitRef="usd">140000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yMi9mcmFnOjRmYjc5NjVjNGNlNTRlN2JhNzY5ODNhZjJjYmZlZGNlL3RhYmxlOmU1ODQ5OTBhZjE1OTQ5MDE4YzllZmNlNjIyYzU1MmEzL3RhYmxlcmFuZ2U6ZTU4NDk5MGFmMTU5NDkwMThjOWVmY2U2MjJjNTUyYTNfMi0zLTEtMS04Mjc4Mg_141108f4-ac3d-4548-bf81-4a6c31cec9e4"
      unitRef="usd">173800000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yMi9mcmFnOjRmYjc5NjVjNGNlNTRlN2JhNzY5ODNhZjJjYmZlZGNlL3RhYmxlOmU1ODQ5OTBhZjE1OTQ5MDE4YzllZmNlNjIyYzU1MmEzL3RhYmxlcmFuZ2U6ZTU4NDk5MGFmMTU5NDkwMThjOWVmY2U2MjJjNTUyYTNfNC0wLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOmE1ODAzMzM1MTUyZTRiNzk5ODE1ZTIyMjIzYTk0YzEyXzI3NDg3NzkwNjk1MTc_f88e4e91-b066-4165-b04d-6c7c59893504"
      unitRef="usd">200000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yMi9mcmFnOjRmYjc5NjVjNGNlNTRlN2JhNzY5ODNhZjJjYmZlZGNlL3RhYmxlOmU1ODQ5OTBhZjE1OTQ5MDE4YzllZmNlNjIyYzU1MmEzL3RhYmxlcmFuZ2U6ZTU4NDk5MGFmMTU5NDkwMThjOWVmY2U2MjJjNTUyYTNfNC0wLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOmE1ODAzMzM1MTUyZTRiNzk5ODE1ZTIyMjIzYTk0YzEyXzI3NDg3NzkwNjk1Mjg_775aa3b0-0f6a-4d38-9461-ff3954212c94"
      unitRef="usd">1000000.0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yMi9mcmFnOjRmYjc5NjVjNGNlNTRlN2JhNzY5ODNhZjJjYmZlZGNlL3RhYmxlOmU1ODQ5OTBhZjE1OTQ5MDE4YzllZmNlNjIyYzU1MmEzL3RhYmxlcmFuZ2U6ZTU4NDk5MGFmMTU5NDkwMThjOWVmY2U2MjJjNTUyYTNfNC0xLTEtMS04Mjc4Mg_a311905c-01de-4196-b505-220f8d8a0fda"
      unitRef="usd">15300000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yMi9mcmFnOjRmYjc5NjVjNGNlNTRlN2JhNzY5ODNhZjJjYmZlZGNlL3RhYmxlOmU1ODQ5OTBhZjE1OTQ5MDE4YzllZmNlNjIyYzU1MmEzL3RhYmxlcmFuZ2U6ZTU4NDk5MGFmMTU5NDkwMThjOWVmY2U2MjJjNTUyYTNfNC0zLTEtMS04Mjc4Mg_bd417d4b-e7c2-4309-b000-485da0fe339e"
      unitRef="usd">-22100000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yMi9mcmFnOjRmYjc5NjVjNGNlNTRlN2JhNzY5ODNhZjJjYmZlZGNlL3RhYmxlOmU1ODQ5OTBhZjE1OTQ5MDE4YzllZmNlNjIyYzU1MmEzL3RhYmxlcmFuZ2U6ZTU4NDk5MGFmMTU5NDkwMThjOWVmY2U2MjJjNTUyYTNfNS0wLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOjliNjZjMjEyNmM2NDRkNGNiOWQ2YzVkMDJiNTUyZWZiXzg1_89ad8e0a-d17a-4b96-a7df-24e90ae75937"
      unitRef="usd">200000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yMi9mcmFnOjRmYjc5NjVjNGNlNTRlN2JhNzY5ODNhZjJjYmZlZGNlL3RhYmxlOmU1ODQ5OTBhZjE1OTQ5MDE4YzllZmNlNjIyYzU1MmEzL3RhYmxlcmFuZ2U6ZTU4NDk5MGFmMTU5NDkwMThjOWVmY2U2MjJjNTUyYTNfNS0wLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOjliNjZjMjEyNmM2NDRkNGNiOWQ2YzVkMDJiNTUyZWZiXzky_ce113bb8-4645-4b14-acfe-bc76541f245a"
      unitRef="usd">-300000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yMi9mcmFnOjRmYjc5NjVjNGNlNTRlN2JhNzY5ODNhZjJjYmZlZGNlL3RhYmxlOmU1ODQ5OTBhZjE1OTQ5MDE4YzllZmNlNjIyYzU1MmEzL3RhYmxlcmFuZ2U6ZTU4NDk5MGFmMTU5NDkwMThjOWVmY2U2MjJjNTUyYTNfNS0xLTEtMS04Mjc4Mg_7d379b08-90d5-434d-b984-66d032c742c6"
      unitRef="usd">500000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yMi9mcmFnOjRmYjc5NjVjNGNlNTRlN2JhNzY5ODNhZjJjYmZlZGNlL3RhYmxlOmU1ODQ5OTBhZjE1OTQ5MDE4YzllZmNlNjIyYzU1MmEzL3RhYmxlcmFuZ2U6ZTU4NDk5MGFmMTU5NDkwMThjOWVmY2U2MjJjNTUyYTNfNS0zLTEtMS04Mjc4Mg_cfd3ac24-c178-4b6f-b50f-e763561a06dd"
      unitRef="usd">-900000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yMi9mcmFnOjRmYjc5NjVjNGNlNTRlN2JhNzY5ODNhZjJjYmZlZGNlL3RhYmxlOmU1ODQ5OTBhZjE1OTQ5MDE4YzllZmNlNjIyYzU1MmEzL3RhYmxlcmFuZ2U6ZTU4NDk5MGFmMTU5NDkwMThjOWVmY2U2MjJjNTUyYTNfNy0wLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOjg0YjA0MGNmNDNkZjQ0MzhiNDk4OTIwZmE4M2RkNGUwXzQz_fe23029f-f12a-4258-aa53-5166fc882eba"
      unitRef="usd">-100000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yMi9mcmFnOjRmYjc5NjVjNGNlNTRlN2JhNzY5ODNhZjJjYmZlZGNlL3RhYmxlOmU1ODQ5OTBhZjE1OTQ5MDE4YzllZmNlNjIyYzU1MmEzL3RhYmxlcmFuZ2U6ZTU4NDk5MGFmMTU5NDkwMThjOWVmY2U2MjJjNTUyYTNfNy0wLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOjg0YjA0MGNmNDNkZjQ0MzhiNDk4OTIwZmE4M2RkNGUwXzUw_6e6d2dbf-e445-4848-a15f-ffd38190226a"
      unitRef="usd">-800000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yMi9mcmFnOjRmYjc5NjVjNGNlNTRlN2JhNzY5ODNhZjJjYmZlZGNlL3RhYmxlOmU1ODQ5OTBhZjE1OTQ5MDE4YzllZmNlNjIyYzU1MmEzL3RhYmxlcmFuZ2U6ZTU4NDk5MGFmMTU5NDkwMThjOWVmY2U2MjJjNTUyYTNfNy0xLTEtMS04Mjc4Mg_51c52b76-921a-4b16-a2bc-bb2c19490391"
      unitRef="usd">-200000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yMi9mcmFnOjRmYjc5NjVjNGNlNTRlN2JhNzY5ODNhZjJjYmZlZGNlL3RhYmxlOmU1ODQ5OTBhZjE1OTQ5MDE4YzllZmNlNjIyYzU1MmEzL3RhYmxlcmFuZ2U6ZTU4NDk5MGFmMTU5NDkwMThjOWVmY2U2MjJjNTUyYTNfNy0zLTEtMS04Mjc4Mg_c867c8f8-0d4d-4834-95a6-2758b38d923b"
      unitRef="usd">-1600000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yMi9mcmFnOjRmYjc5NjVjNGNlNTRlN2JhNzY5ODNhZjJjYmZlZGNlL3RhYmxlOmU1ODQ5OTBhZjE1OTQ5MDE4YzllZmNlNjIyYzU1MmEzL3RhYmxlcmFuZ2U6ZTU4NDk5MGFmMTU5NDkwMThjOWVmY2U2MjJjNTUyYTNfOC0xLTEtMS04Mjc4Mg_96f952fe-6c15-4b70-b992-196fb67466f2"
      unitRef="usd">14600000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yMi9mcmFnOjRmYjc5NjVjNGNlNTRlN2JhNzY5ODNhZjJjYmZlZGNlL3RhYmxlOmU1ODQ5OTBhZjE1OTQ5MDE4YzllZmNlNjIyYzU1MmEzL3RhYmxlcmFuZ2U6ZTU4NDk5MGFmMTU5NDkwMThjOWVmY2U2MjJjNTUyYTNfOC0zLTEtMS04Mjc4Mg_95a6a69a-bcec-4aab-9c70-1bfb8d9856c2"
      unitRef="usd">-22800000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yMi9mcmFnOjRmYjc5NjVjNGNlNTRlN2JhNzY5ODNhZjJjYmZlZGNlL3RhYmxlOmU1ODQ5OTBhZjE1OTQ5MDE4YzllZmNlNjIyYzU1MmEzL3RhYmxlcmFuZ2U6ZTU4NDk5MGFmMTU5NDkwMThjOWVmY2U2MjJjNTUyYTNfOS0xLTEtMS04Mjc4Mg_8f3e4c63-584a-48b9-8145-372a8fa19f62"
      unitRef="usd">154600000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yMi9mcmFnOjRmYjc5NjVjNGNlNTRlN2JhNzY5ODNhZjJjYmZlZGNlL3RhYmxlOmU1ODQ5OTBhZjE1OTQ5MDE4YzllZmNlNjIyYzU1MmEzL3RhYmxlcmFuZ2U6ZTU4NDk5MGFmMTU5NDkwMThjOWVmY2U2MjJjNTUyYTNfOS0zLTEtMS04Mjc4Mg_15a70692-e8ca-4c58-8494-8d131b309e8c"
      unitRef="usd">151000000.0</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMy0xLTEtMS04Mjc4Mg_86b37227-64c1-4d55-bf40-4e20b1956c42"
      unitRef="usd">886300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMy0zLTEtMS04Mjc4Mg_b07cec91-2408-484f-a58d-a12b49747ce2"
      unitRef="usd">894300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNC0xLTEtMS04Mjc4Mg_c98d91d2-f1b3-4ccf-a2f3-77ff59a0466b"
      unitRef="usd">513400000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNC0zLTEtMS04Mjc4Mg_f93cbd55-2235-41bf-839a-d3054fa80565"
      unitRef="usd">507400000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNS0xLTEtMS04Mjc4Mg_3079db6f-c751-4be6-9380-20cb84a885ff"
      unitRef="usd">447000000.0</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNS0zLTEtMS04Mjc4Mg_fec4d473-fc89-4c9a-9f15-efe6ea5ac361"
      unitRef="usd">414800000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNi0xLTEtMS04Mjc4Mg_4ae2545d-b523-46a3-9602-bdd9b348b00a"
      unitRef="usd">90500000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNi0zLTEtMS04Mjc4Mg_ce8a5d4d-80ab-4a9c-9141-c1aa59299fe9"
      unitRef="usd">103000000.0</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNy0xLTEtMS04Mjc4Mg_feb60313-e114-4e8b-a066-91259c70bfa6"
      unitRef="usd">1937200000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNy0zLTEtMS04Mjc4Mg_80304108-58e9-4649-89e8-43b10516ad39"
      unitRef="usd">1919500000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfOC0xLTEtMS04Mjc4Mg_e0121d40-f1c0-4d69-9a59-60ce6ea75605"
      unitRef="usd">2478900000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfOC0zLTEtMS04Mjc4Mg_8d078082-0190-44f4-a75b-6e93c1934f5e"
      unitRef="usd">2386600000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfOS0xLTEtMS04Mjc4Mg_0c64f7b7-d868-420d-97e8-2346f211b7cc"
      unitRef="usd">1263700000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfOS0zLTEtMS04Mjc4Mg_5f51c58f-11a9-4bd0-ad66-71ec1f43c832"
      unitRef="usd">1228300000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMTAtMS0xLTEtODI3ODI_7ffd6abf-eaec-4ac0-93e5-805e0d1cc068"
      unitRef="usd">1215200000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMTAtMy0xLTEtODI3ODI_3ede6d77-4112-4b74-9678-9ed45bd4f725"
      unitRef="usd">1158300000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMTEtMS0xLTEtODI3ODI_22de5108-296f-4342-8c86-9d283be6a380"
      unitRef="usd">101100000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMTEtMy0xLTEtODI3ODI_2f1c7f4b-44db-4d50-af85-94371c31b8b0"
      unitRef="usd">104400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMTItMS0xLTEtODI3ODI_110d20cb-a602-4249-b92d-026361bfcc24"
      unitRef="usd">208800000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMTItMy0xLTEtODI3ODI_f309d9f7-993a-4171-a80b-f848ed437873"
      unitRef="usd">204900000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:Goodwill
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMTMtMS0xLTEtODI3ODI_1d38a526-0cbb-49be-8ef7-dd60b32fe0c2"
      unitRef="usd">107800000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMTMtMy0xLTEtODI3ODI_6dc0e946-3052-4660-875f-47e2b62d18fd"
      unitRef="usd">107300000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMTQtMS0xLTEtODI3ODI_6a82602a-1005-4fd4-be74-c0ff485679e8"
      unitRef="usd">17800000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMTQtMy0xLTEtODI3ODI_51833dbc-8dc3-404a-93ab-852763975496"
      unitRef="usd">18400000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMTUtMS0xLTEtODI3ODI_9f4b0f38-de2b-4667-b53f-82ee14da11d2"
      unitRef="usd">99000000.0</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMTUtMy0xLTEtODI3ODI_36ff4437-b4eb-4e28-91fb-75fb1e627fb2"
      unitRef="usd">65600000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMTctMS0xLTEtODI3ODI_c56a844c-1798-445c-b772-4575d772351e"
      unitRef="usd">36700000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMTctMy0xLTEtODI3ODI_31b99201-efa2-4409-8d38-a34d4ffb28ce"
      unitRef="usd">38400000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMTgtMS0xLTEtODI3ODI_74946ab4-ff72-4c68-863c-bfbb16ebe172"
      unitRef="usd">3723600000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMTgtMy0xLTEtODI3ODI_e62440e5-98cf-4774-8bb4-4ea9108acdf0"
      unitRef="usd">3616800000</us-gaap:Assets>
    <wst:NotesPayableAndOtherDebtCurrent
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMjItMS0xLTEtODI3ODI_ecfa3f6f-796a-4b15-992d-edacf7047156"
      unitRef="usd">2200000</wst:NotesPayableAndOtherDebtCurrent>
    <wst:NotesPayableAndOtherDebtCurrent
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMjItMy0xLTEtODI3ODI_719ddaa4-6175-46cb-a08a-c019ad7e5ed5"
      unitRef="usd">2200000</wst:NotesPayableAndOtherDebtCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMjMtMS0xLTEtODI3ODI_17843e1f-1009-4b55-8e4f-0159184cc434"
      unitRef="usd">233800000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMjMtMy0xLTEtODI3ODI_21485563-9e59-4926-bc1f-69685986e244"
      unitRef="usd">215400000</us-gaap:AccountsPayableCurrent>
    <wst:AccruedSalariesWagesAndBenefitsCurrent
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMjUtMS0xLTEtODI3ODI_b8b911fa-8575-4094-8769-545537f11e36"
      unitRef="usd">65700000</wst:AccruedSalariesWagesAndBenefitsCurrent>
    <wst:AccruedSalariesWagesAndBenefitsCurrent
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMjUtMy0xLTEtODI3ODI_c72ff569-6e6b-4bcc-a61e-bc3705a03e58"
      unitRef="usd">76800000</wst:AccruedSalariesWagesAndBenefitsCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMjYtMS0xLTEtODI3ODI_781463a6-725d-4b99-8f2b-69b0903c3046"
      unitRef="usd">59000000.0</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMjYtMy0xLTEtODI3ODI_ca856412-b818-47e0-99dd-4264296594b9"
      unitRef="usd">24800000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMjctMS0xLTEtODI3ODI_01bef3ac-1923-435d-8f60-1659e2a2c284"
      unitRef="usd">16200000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMjctMy0xLTEtODI3ODI_e1fd0ac6-43fe-4fa7-b6a1-b2c3402bef37"
      unitRef="usd">16000000.0</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMjgtMS0xLTEtODI3ODI_47015a15-e6c7-4fd9-ae4d-a9c9c600128e"
      unitRef="usd">158000000.0</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMjgtMy0xLTEtODI3ODI_9073d580-1868-4bd3-b9cd-8896a202b6be"
      unitRef="usd">183800000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMjktMS0xLTEtODI3ODI_0d0edbaf-3268-4bc2-8644-46e53a1915fa"
      unitRef="usd">534900000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMjktMy0xLTEtODI3ODI_652179cc-3cc0-46ad-8a15-2baa3d7b0b47"
      unitRef="usd">519000000.0</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMzAtMS0xLTEtODI3ODI_89008558-fa1e-4501-afed-7f34c9f3cabe"
      unitRef="usd">206100000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMzAtMy0xLTEtODI3ODI_f70a89f3-6df7-4395-9feb-8d35655565a3"
      unitRef="usd">206700000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMzEtMS0xLTEtODI3ODI_67b09a46-0f14-40ab-9365-ef3526fc7c99"
      unitRef="usd">14500000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMzEtMy0xLTEtODI3ODI_5ceedb35-a94c-4a49-9623-cb7989bae2c1"
      unitRef="usd">14300000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMzItMS0xLTEtODI3ODI_cfa484cf-962d-4469-8b0a-43beea59648c"
      unitRef="usd">27200000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMzItMy0xLTEtODI3ODI_103f5c1f-38bc-4cd7-a6c5-681ada889345"
      unitRef="usd">28200000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMzMtMS0xLTEtODI3ODI_b6cc5136-1325-4faf-ad8c-dc766099ead9"
      unitRef="usd">89900000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMzMtMy0xLTEtODI3ODI_4f520b9f-65df-4b6f-a2df-09b619542fea"
      unitRef="usd">93000000.0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMzQtMS0xLTEtODI3ODI_c5e2ceb7-acfb-4474-87d6-0f71d5bd7f64"
      unitRef="usd">19000000.0</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>
    <us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMzQtMy0xLTEtODI3ODI_f1898add-1d62-439f-8ea5-fdab2af95abb"
      unitRef="usd">19100000</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMzUtMS0xLTEtODI3ODI_e8f86602-8cad-4a9c-899d-14ce4575ea03"
      unitRef="usd">55800000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMzUtMy0xLTEtODI3ODI_3daa90cc-de9e-4db1-b72e-e54e95be910f"
      unitRef="usd">51600000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMzYtMS0xLTEtODI3ODI_1b78c298-881f-4640-8eb8-113522c47830"
      unitRef="usd">947400000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMzYtMy0xLTEtODI3ODI_cf2b8b3f-5294-4d84-9e5a-1f6380467980"
      unitRef="usd">931900000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMzgtMS0xLTEtODI3ODI_89ab87de-91d0-402e-a9bb-4f62b6f0526b"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfMzgtMy0xLTEtODI3ODI_9b83b822-1c66-4e2c-91b4-f2b261bc0a20"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDEtMC0xLTEtODI3ODIvdGV4dHJlZ2lvbjozOWI4ZGNmYTk4ZTg0YjNkYjE2YjRhYjg0ZTZmNjYzOV8yMg_02dd9c68-0815-4244-9a8a-59d1ac7d2ce7"
      unitRef="shares">3000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDEtMC0xLTEtODI3ODIvdGV4dHJlZ2lvbjozOWI4ZGNmYTk4ZTg0YjNkYjE2YjRhYjg0ZTZmNjYzOV8yMg_736ee117-de20-4afc-bb21-b662bfedf0a6"
      unitRef="shares">3000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDEtMC0xLTEtODI3ODIvdGV4dHJlZ2lvbjozOWI4ZGNmYTk4ZTg0YjNkYjE2YjRhYjg0ZTZmNjYzOV80NA_0ba96407-f485-4d42-a3fa-3fd45e6bc007"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDEtMC0xLTEtODI3ODIvdGV4dHJlZ2lvbjozOWI4ZGNmYTk4ZTg0YjNkYjE2YjRhYjg0ZTZmNjYzOV80NA_7e721fb7-5f7b-4acd-b1e1-f938efa2e505"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDEtMC0xLTEtODI3ODIvdGV4dHJlZ2lvbjozOWI4ZGNmYTk4ZTg0YjNkYjE2YjRhYjg0ZTZmNjYzOV80NA_dc603ca1-6341-4e8c-a67f-52c9a54c2af7"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDEtMC0xLTEtODI3ODIvdGV4dHJlZ2lvbjozOWI4ZGNmYTk4ZTg0YjNkYjE2YjRhYjg0ZTZmNjYzOV80NA_f62302e9-7a5d-4488-aff9-fa23bb8d2422"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDEtMS0xLTEtODI3ODI_4bee5c56-17d8-4fbb-bf3f-50b5c4a96259"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDEtMy0xLTEtODI3ODI_c08bf99a-af2a-4d69-ab27-17721f1384d6"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDItMC0xLTEtODI3ODIvdGV4dHJlZ2lvbjo4YzM0ZDZlMjg3NzM0YTk1YWRhMGNkOGVjZDZjZDBiMV8yOA_64d869ee-0bfc-4637-964c-62a4e75c1ec2"
      unitRef="usdPerShare">0.25</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDItMC0xLTEtODI3ODIvdGV4dHJlZ2lvbjo4YzM0ZDZlMjg3NzM0YTk1YWRhMGNkOGVjZDZjZDBiMV8yOA_ef79cd3b-90f5-40bb-a7f5-05f6b48b616e"
      unitRef="usdPerShare">0.25</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDItMC0xLTEtODI3ODIvdGV4dHJlZ2lvbjo4YzM0ZDZlMjg3NzM0YTk1YWRhMGNkOGVjZDZjZDBiMV80Mg_41483808-6527-460e-b30e-c66952bc840d"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDItMC0xLTEtODI3ODIvdGV4dHJlZ2lvbjo4YzM0ZDZlMjg3NzM0YTk1YWRhMGNkOGVjZDZjZDBiMV80Mg_9039baaf-7577-4180-a714-5862345d4055"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDItMC0xLTEtODI3ODIvdGV4dHJlZ2lvbjo4YzM0ZDZlMjg3NzM0YTk1YWRhMGNkOGVjZDZjZDBiMV83OQ_d44b4452-b692-41cb-9ac5-884bdfd02d86"
      unitRef="shares">75300000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDItMC0xLTEtODI3ODIvdGV4dHJlZ2lvbjo4YzM0ZDZlMjg3NzM0YTk1YWRhMGNkOGVjZDZjZDBiMV83OQ_deed5bb7-add2-4add-b3ff-c215f184406b"
      unitRef="shares">75300000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDItMC0xLTEtODI3ODIvdGV4dHJlZ2lvbjo4YzM0ZDZlMjg3NzM0YTk1YWRhMGNkOGVjZDZjZDBiMV8xMjA_4765f3f9-4c84-46b8-9b4b-38e4992fedd8"
      unitRef="shares">74200000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDItMC0xLTEtODI3ODIvdGV4dHJlZ2lvbjo4YzM0ZDZlMjg3NzM0YTk1YWRhMGNkOGVjZDZjZDBiMV8xMjc_674195a4-44da-4bbf-80c1-9712451a9ae8"
      unitRef="shares">74100000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDItMS0xLTEtODI3ODI_5ef2a619-b95a-41be-b801-5198c517142e"
      unitRef="usd">18800000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDItMy0xLTEtODI3ODI_3475699e-f0e2-4f1c-b7d4-00e0fac3dfbf"
      unitRef="usd">18800000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDMtMS0xLTEtODI3ODI_4cf91c4a-c871-4336-bce2-28fb6bf8a787"
      unitRef="usd">181400000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDMtMy0xLTEtODI3ODI_161ccb2d-4635-4763-a1fa-dfb2f46c21ce"
      unitRef="usd">232200000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDQtMS0xLTEtODI3ODI_15a239d4-2571-47c6-aa79-1a419e943b8a"
      unitRef="usd">3113600000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDQtMy0xLTEtODI3ODI_72324ce9-b87e-499a-bd68-a176ad4f3ca3"
      unitRef="usd">2987800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDUtMS0xLTEtODI3ODI_315427ee-0adc-415a-992e-6a4c806331ed"
      unitRef="usd">-168400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDUtMy0xLTEtODI3ODI_edac1d32-8013-490d-871c-b805b27dd44a"
      unitRef="usd">-183000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDYtMC0xLTEtODI3ODIvdGV4dHJlZ2lvbjo2ZjdiYmM1NmFlNzM0NjY5YTg1MGM3NTg3NTVjODA4NF8yOQ_b0235866-b7b7-4392-a24b-77fce11fc644"
      unitRef="shares">1100000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDYtMC0xLTEtODI3ODIvdGV4dHJlZ2lvbjo2ZjdiYmM1NmFlNzM0NjY5YTg1MGM3NTg3NTVjODA4NF8zNg_4e421ccc-961f-4e37-a568-10c6136ee7d6"
      unitRef="shares">1200000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonValue
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDYtMS0xLTEtODI3ODI_a5535321-2bd0-45d8-aee7-c8b5bc3a88a4"
      unitRef="usd">369200000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDYtMy0xLTEtODI3ODI_012e50fe-7774-4f36-a321-a7b9627aae5f"
      unitRef="usd">370900000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:StockholdersEquity
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDctMS0xLTEtODI3ODI_92f1a375-355a-4307-8e37-e38134d8970e"
      unitRef="usd">2776200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDctMy0xLTEtODI3ODI_83d30692-05e2-4329-ade5-e39e54c31871"
      unitRef="usd">2684900000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDgtMS0xLTEtODI3ODI_cf67fbcf-46f2-4c76-8f8d-ff8fa05fdace"
      unitRef="usd">3723600000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yNS9mcmFnOmU3MDliNWY5OGI2NTQ3MzBiYmMzOTllMjgwMGIwZmFlL3RhYmxlOjkxYjVhMTgwZjQ0MTRkNzk4ODlhOWYxODk4MmI0N2I2L3RhYmxlcmFuZ2U6OTFiNWExODBmNDQxNGQ3OTg4OWE5ZjE4OTgyYjQ3YjZfNDgtMy0xLTEtODI3ODI_ad96a924-3e0e-4ba7-a246-9d60deb97c9b"
      unitRef="usd">3616800000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMy0xLTEtMS04Mjc4Mg_53a12c26-88a0-41d6-9f84-14d79f192cd9"
      unitRef="usd">140000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMy0zLTEtMS04Mjc4Mg_3f56d4f9-48a3-4b0f-972d-16f0a73b5e9c"
      unitRef="usd">173800000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfNS0xLTEtMS04Mjc4Mg_28bafc5c-beeb-454b-8f6d-6f4793d5c44b"
      unitRef="usd">30700000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfNS0zLTEtMS04Mjc4Mg_7e4f7e4e-5036-4bdb-9049-d94c00347861"
      unitRef="usd">28700000</us-gaap:Depreciation>
    <us-gaap:AdjustmentForAmortization
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfNi0xLTEtMS04Mjc4Mg_dab655c8-2588-4255-82d6-a35e08bf5276"
      unitRef="usd">900000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfNi0zLTEtMS04Mjc4Mg_acdfa388-9f1f-4e17-9809-aad0d2d2c3d4"
      unitRef="usd">900000</us-gaap:AdjustmentForAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfNy0xLTEtMS04Mjc4Mg_243526d1-06d6-44f2-99cf-e1b1b23c01c6"
      unitRef="usd">8500000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfNy0zLTEtMS04Mjc4Mg_b96d4a3f-2db3-4546-b62a-df36161eb4e8"
      unitRef="usd">5500000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMTAtMS0xLTEtODI3ODI_b76b5962-5907-48e8-a3d6-f59a3dfb6cbf"
      unitRef="usd">-11300000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMTAtMy0xLTEtODI3ODI_79a6e4c3-cd8d-4d2e-a2fb-7675eb9f1a58"
      unitRef="usd">0</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMTItMS0xLTEtODI3ODI_c319f0f5-2a2f-415c-bb40-6074742377ff"
      unitRef="usd">6500000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMTItMy0xLTEtODI3ODI_5dc724dd-4f72-4518-b5c1-dae6c0db47a1"
      unitRef="usd">7500000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMTMtMS0xLTEtODI3ODI_45c9d2d0-c5f9-4562-88a9-c8848068886e"
      unitRef="usd">46800000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMTMtMy0xLTEtODI3ODI_d1ad2a4b-a502-48b8-9f63-638d820ac40e"
      unitRef="usd">50200000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMTQtMS0xLTEtODI3ODI_b7390dc5-2805-4582-ae47-730cedbc379d"
      unitRef="usd">138100000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMTQtMy0xLTEtODI3ODI_1d33c3eb-2e99-46c9-80c6-633bbd8c1b34"
      unitRef="usd">151200000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMTctMS0xLTEtODI3ODI_53de721a-9ab3-464b-ac40-1b15176efd2c"
      unitRef="usd">82100000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMTctMy0xLTEtODI3ODI_43696e78-5dbb-4463-a9b2-999db4da8308"
      unitRef="usd">65800000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMjMtMS0xLTEtODI3ODI_a23db7d0-7166-4ca8-a4cd-c003fb3d36ae"
      unitRef="usd">0</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMjMtMy0xLTEtODI3ODI_611c6850-b67d-467a-b7c8-5b726f55632f"
      unitRef="usd">2500000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMjQtMS0xLTEtODI3ODI_c08a8d1a-54d1-4736-b725-44bc0803a325"
      unitRef="usd">-82100000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMjQtMy0xLTEtODI3ODI_ec06b186-5119-45dd-add7-4adfff121ac8"
      unitRef="usd">-68300000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfOtherLongTermDebt
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMzAtMS0xLTEtODI3ODI_4851980c-3e1e-424f-bd6e-025cd13b4fb4"
      unitRef="usd">600000</us-gaap:RepaymentsOfOtherLongTermDebt>
    <us-gaap:RepaymentsOfOtherLongTermDebt
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMzAtMy0xLTEtODI3ODI_e6368fe7-c46e-4e6a-8ba6-5c54d5272bae"
      unitRef="usd">600000</us-gaap:RepaymentsOfOtherLongTermDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMzEtMS0xLTEtODI3ODI_947ce76c-f6ee-4692-9481-e37f0404565c"
      unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMzEtMy0xLTEtODI3ODI_e0f7f75a-930a-4d4b-ae27-9fdc315ebc9a"
      unitRef="usd">1100000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMzItMS0xLTEtODI3ODI_fd13875d-7b13-4f5b-8aae-2061346addef"
      unitRef="usd">14100000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMzItMy0xLTEtODI3ODI_134d2961-624e-4aef-9a54-692ce1432060"
      unitRef="usd">13400000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMzMtMS0xLTEtODI3ODI_9ed84fe0-b81b-44fa-874f-11e767778d91"
      unitRef="usd">13500000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMzMtMy0xLTEtODI3ODI_6ac4bd61-22a2-45ec-ae80-be1a59d2b2d4"
      unitRef="usd">6300000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMzQtMS0xLTEtODI3ODI_96bae1c9-9735-43ca-820f-20c1f6a941b1"
      unitRef="usd">1800000</us-gaap:ProceedsFromOtherEquity>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMzQtMy0xLTEtODI3ODI_0d39c5a0-f777-4a55-afe4-2f8a1c913308"
      unitRef="usd">2000000.0</us-gaap:ProceedsFromOtherEquity>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMzUtMS0xLTEtODI3ODI_a4f3668d-aa9a-4be5-b675-07c0fd7a3be0"
      unitRef="usd">60100000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMzUtMy0xLTEtODI3ODI_3e80c0e3-dbf2-47e4-b61f-9741ebfed0de"
      unitRef="usd">147100000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMzYtMS0xLTEtODI3ODI_ce94de5c-9576-41bb-beb6-0b58723ec712"
      unitRef="usd">11500000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMzYtMy0xLTEtODI3ODI_50d3669e-246b-4d9c-acf6-9f90906cb5cc"
      unitRef="usd">18800000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMzctMS0xLTEtODI3ODI_3ced26f8-b2d9-46b2-baf1-c0366d4358d2"
      unitRef="usd">-71000000.0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMzctMy0xLTEtODI3ODI_3e0f25f8-1a22-403a-95a4-6f94992cae7f"
      unitRef="usd">-172700000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMzgtMS0xLTEtODI3ODI_b3ebe803-751a-43f0-b64b-11a528f7f55b"
      unitRef="usd">7000000.0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMzgtMy0xLTEtODI3ODI_d902db61-b257-4012-8493-661d707d2493"
      unitRef="usd">-5100000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMzktMS0xLTEtODI3ODI_a4775cf5-bdbb-48d7-9fcf-b4a58369415d"
      unitRef="usd">-8000000.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfMzktMy0xLTEtODI3ODI_84c1c40a-0919-4b46-8ee6-de69cf5a9057"
      unitRef="usd">-94900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfNDEtMS0xLTEtODI3ODI_064ea7ef-db20-406a-9873-00ace72c3308"
      unitRef="usd">894300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i00c9b6f38a304d5190000b6168ba7dce_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfNDEtMy0xLTEtODI3ODI_fd1eb3e8-48aa-4bf6-b44e-b1ccea027f9d"
      unitRef="usd">762600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfNDItMS0xLTEtODI3ODI_70185352-31a9-4b55-8028-500a570a50a5"
      unitRef="usd">886300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie3cc75f001344ce095d702cd95b46078_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8yOC9mcmFnOmI4ODVlNTE1ZTljYTRkMDViMmE0YWE5M2U2Mjk5ZTc0L3RhYmxlOmI2MmJkZTVmNzkxNDRkMjQ5ZmMzNzY2N2YxOTUwOGQwL3RhYmxlcmFuZ2U6YjYyYmRlNWY3OTE0NGQyNDlmYzM3NjY3ZjE5NTA4ZDBfNDItMy0xLTEtODI3ODI_730872e6-cf67-445d-9c9d-638aab1b1da0"
      unitRef="usd">667700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8zNC9mcmFnOmY1NTQ1ZTI5ODI5MDRmNjE5NzYzMmVlOTI2NzRmOTY4L3RleHRyZWdpb246ZjU1NDVlMjk4MjkwNGY2MTk3NjMyZWU5MjY3NGY5NjhfMjAxNA_cceccab8-86da-4a3a-af6f-adb22b8763f2">Basis of Presentation and Summary of Significant Accounting Policies&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The condensed consolidated financial statements included in this report are unaudited and have been prepared in accordance with United States (&#x201c;U.S.&#x201d;) generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) for interim financial reporting and U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) regulations. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, these financial statements include all adjustments, which are of a normal recurring nature, necessary for a fair statement of the financial position, results of operations, cash flows and the change in equity for the periods presented. The condensed consolidated financial statements for the three months ended March&#160;31, 2023, should be read in conjunction with the consolidated financial statements and notes thereto of West Pharmaceutical Services, Inc. and its majority-owned subsidiaries (which may be referred to as &#x201c;West,&#x201d; the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us&#x201d; or &#x201c;our&#x201d;) appearing in our Annual Report on Form 10-K for the year ended December&#160;31, 2022 (the &#x201c;&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/105770/000010577023000012/wst-20221231.htm#i8148abfe270d4f15aa2ba9319df722dc_58" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;2022 Annual Report&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;). The results of operations for any interim period are not necessarily indicative of results for the full year.&lt;/span&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8zNC9mcmFnOmY1NTQ1ZTI5ODI5MDRmNjE5NzYzMmVlOTI2NzRmOTY4L3RleHRyZWdpb246ZjU1NDVlMjk4MjkwNGY2MTk3NjMyZWU5MjY3NGY5NjhfMjAyMg_3e2aeeff-ceab-41e6-acfb-f13ca88d2c4a">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The condensed consolidated financial statements included in this report are unaudited and have been prepared in accordance with United States (&#x201c;U.S.&#x201d;) generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) for interim financial reporting and U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) regulations. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, these financial statements include all adjustments, which are of a normal recurring nature, necessary for a fair statement of the financial position, results of operations, cash flows and the change in equity for the periods presented. The condensed consolidated financial statements for the three months ended March&#160;31, 2023, should be read in conjunction with the consolidated financial statements and notes thereto of West Pharmaceutical Services, Inc. and its majority-owned subsidiaries (which may be referred to as &#x201c;West,&#x201d; the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us&#x201d; or &#x201c;our&#x201d;) appearing in our Annual Report on Form 10-K for the year ended December&#160;31, 2022 (the &#x201c;&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/105770/000010577023000012/wst-20221231.htm#i8148abfe270d4f15aa2ba9319df722dc_58" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;2022 Annual Report&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;). The results of operations for any interim period are not necessarily indicative of results for the full year.&lt;/span&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8zNy9mcmFnOmE1NGYzZGQ0NTM0ZDQxMDJhZGRkOTQ3MTg1ZDU0NzEwL3RleHRyZWdpb246YTU0ZjNkZDQ1MzRkNDEwMmFkZGQ5NDcxODVkNTQ3MTBfMTQ1MA_f2ef32b1-23f6-48f2-8c64-90e3c4a937f8">New Accounting Standards&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2022, the Financial Accounting Standards Board ("FASB") issued guidance that seeks to enhance transparency around entities' use of supplier finance programs. The amendment requires the buyer in a supplier finance program to disclose information about the key terms of the program, outstanding confirmed amounts as of the end of the period, a rollforward of such amounts during each annual period, and a description of where in the financial statements outstanding amounts are presented. This guidance is effective for fiscal years beginning after December 15, 2022. We adopted this guidance as of January 1, 2023, on a prospective basis. The adoption did not have a material impact on our financial statements, as supplier finance programs are not material to the Company as of March&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl8zNy9mcmFnOmE1NGYzZGQ0NTM0ZDQxMDJhZGRkOTQ3MTg1ZDU0NzEwL3RleHRyZWdpb246YTU0ZjNkZDQ1MzRkNDEwMmFkZGQ5NDcxODVkNTQ3MTBfMTQ1Mw_62c2aedb-a6f3-4409-8c14-257377a930a3">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2022, the Financial Accounting Standards Board ("FASB") issued guidance that seeks to enhance transparency around entities' use of supplier finance programs. The amendment requires the buyer in a supplier finance program to disclose information about the key terms of the program, outstanding confirmed amounts as of the end of the period, a rollforward of such amounts during each annual period, and a description of where in the financial statements outstanding amounts are presented. This guidance is effective for fiscal years beginning after December 15, 2022. We adopted this guidance as of January 1, 2023, on a prospective basis. The adoption did not have a material impact on our financial statements, as supplier finance programs are not material to the Company as of March&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RleHRyZWdpb246MGQyN2ViN2QyYTg3NDczOWJhYzU3MmY2ZDJhMjVkZDhfMjA1NA_a90aa9bf-71b5-4500-bee5-1ff7b5beb522">Revenue&lt;div style="margin-bottom:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our revenue results from the sale of goods or services and reflects the consideration to which we expect to be entitled in exchange for those goods or services. We record revenue based on a five-step model, in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) 606. Following the identification of a contract with a customer, we identify the performance obligations (goods or services) in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize the revenue when (or as) we satisfy the performance obligations by transferring the promised goods or services to our customers. A good or service is transferred when (or as) the customer obtains control of that good or service. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the approximate percentage of our net sales by market group:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Biologics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34 %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43 %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Generics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;20 %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17 %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharma&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27 %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24 %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract-Manufactured Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19 %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16 %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100 %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100 %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the approximate percentage of our net sales by product category: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;High-Value Product Components&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51 %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56 %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;High-Value Product Delivery Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7 %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Standard Packaging&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23 %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23 %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract-Manufactured Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19 %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16 %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100 %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100 %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the approximate percentage of our net sales by geographic location: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Americas&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44 %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45 %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe, Middle East, Africa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47 %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45 %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asia Pacific&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9 %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100 %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100 %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract Assets and Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our contract assets and liabilities, excluding amounts included in accounts receivable, net:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract assets, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract assets, March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in contract assets - increase (decrease)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income, March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(57.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in deferred income - decrease (increase)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Contract assets are included within other current assets and deferred income is included within other current liabilities and other long-term liabilities. During the three months ended March&#160;31, 2023, $21.3&#160;million of revenue was recognized that was included in deferred income at the beginning of the year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of the performance obligations within our contracts are satisfied within one year or less. Performance obligations satisfied beyond one year include those relating to a nonrefundable customer payment of $20.0 million received in June 2013 in return for the exclusive use of the SmartDose&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; technology platform within a specific therapeutic area. As of March&#160;31, 2023, there was $2.8 million of deferred income related to this payment, of which $0.9 million was included in other current liabilities and $1.9 million was included in other long-term liabilities. The deferred income is being recognized as income on a straight-line basis over the remaining term of the agreement. The agreement does not include a future minimum purchase commitment from the customer.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RleHRyZWdpb246MGQyN2ViN2QyYTg3NDczOWJhYzU3MmY2ZDJhMjVkZDhfMjA1NQ_ee9c52d6-ba69-4e0b-b2dd-9bda645d7ec2">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the approximate percentage of our net sales by market group:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Biologics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34 %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43 %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Generics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;20 %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17 %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharma&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27 %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24 %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract-Manufactured Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19 %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16 %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100 %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100 %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the approximate percentage of our net sales by product category: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;High-Value Product Components&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51 %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56 %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;High-Value Product Delivery Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7 %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Standard Packaging&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23 %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23 %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract-Manufactured Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19 %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16 %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100 %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100 %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the approximate percentage of our net sales by geographic location: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Americas&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44 %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45 %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe, Middle East, Africa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47 %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45 %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asia Pacific&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9 %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100 %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100 %&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iae34400f53bb478b90a83802a119f9f9_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOjdkYzlkYTgwZWJhZTQwZGQ4YWVmZGM1M2Y2MWYwOTNiL3RhYmxlcmFuZ2U6N2RjOWRhODBlYmFlNDBkZDhhZWZkYzUzZjYxZjA5M2JfMi0xLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOjM3N2Q0YWU1MjRlNjQ5YjQ4ZGU5Y2MzOWU2ZDI0NzQ5XzQ_ff50123e-affc-4ee7-8195-036ff90a81d7"
      unitRef="number">0.34</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="icda5c4d11f62428a95249de65f0fefd2_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOjdkYzlkYTgwZWJhZTQwZGQ4YWVmZGM1M2Y2MWYwOTNiL3RhYmxlcmFuZ2U6N2RjOWRhODBlYmFlNDBkZDhhZWZkYzUzZjYxZjA5M2JfMi0zLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOmM5ZWY3MzQ5NTAwZTRmNTk5YmZiZDYyMjA1MzdiY2E5XzQ_331c7d15-70ea-43f1-a165-91e5c9942c8d"
      unitRef="number">0.43</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie37ebad36b6348b285cca6d19bde1f7b_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOjdkYzlkYTgwZWJhZTQwZGQ4YWVmZGM1M2Y2MWYwOTNiL3RhYmxlcmFuZ2U6N2RjOWRhODBlYmFlNDBkZDhhZWZkYzUzZjYxZjA5M2JfMy0xLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOjA4MjViZmYxYjkzYzQ4NjlhOGZkMjM0ODhiYTFmNjBjXzU_244dcd28-06f9-458b-88d6-46abf19e15d2"
      unitRef="number">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i840ac8c485014ee99b6e1a87cfb8a764_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOjdkYzlkYTgwZWJhZTQwZGQ4YWVmZGM1M2Y2MWYwOTNiL3RhYmxlcmFuZ2U6N2RjOWRhODBlYmFlNDBkZDhhZWZkYzUzZjYxZjA5M2JfMy0zLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOjI1ZGYwNGZkM2Q2ZjRjM2U4NGUzODQ4MDE4ZWZjNjZjXzQ_d068a859-42f5-4f80-b22d-4c9c7216319f"
      unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i3f33ea9ddf5f4c6990e93f50d03f03ef_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOjdkYzlkYTgwZWJhZTQwZGQ4YWVmZGM1M2Y2MWYwOTNiL3RhYmxlcmFuZ2U6N2RjOWRhODBlYmFlNDBkZDhhZWZkYzUzZjYxZjA5M2JfNC0xLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOjUzNTdiMzU4N2JlODQ5Y2FhZWNhZDYxMDY1ZDVlMGIzXzQ_ef0ec5b6-2d9b-4efc-bb75-f6fc1be13a19"
      unitRef="number">0.27</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia894e91feb4a4bdf8293a2c2963731ab_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOjdkYzlkYTgwZWJhZTQwZGQ4YWVmZGM1M2Y2MWYwOTNiL3RhYmxlcmFuZ2U6N2RjOWRhODBlYmFlNDBkZDhhZWZkYzUzZjYxZjA5M2JfNC0zLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOmViMTFjYjhjZjFmMjRjNGI5NWI1YTY1MTg0MDlmNGNkXzQ_a3121150-5383-451c-bc94-d1d896b34f5a"
      unitRef="number">0.24</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="icca73618ae684d5ea52e3060af4ad383_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOjdkYzlkYTgwZWJhZTQwZGQ4YWVmZGM1M2Y2MWYwOTNiL3RhYmxlcmFuZ2U6N2RjOWRhODBlYmFlNDBkZDhhZWZkYzUzZjYxZjA5M2JfNS0xLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOmIzNmNiYWY0MDc0NTQ2ZjY4Nzc5MTg4MGY3NzllZTRlXzQ_72276000-acb7-4b6a-89eb-dd484bd1fbf3"
      unitRef="number">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iaceefe0fe985435aa372154902f65846_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOjdkYzlkYTgwZWJhZTQwZGQ4YWVmZGM1M2Y2MWYwOTNiL3RhYmxlcmFuZ2U6N2RjOWRhODBlYmFlNDBkZDhhZWZkYzUzZjYxZjA5M2JfNS0zLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOjY0MzU4NTcxNTdlNTQ0NDliYzBkYmNhMGUzMzI5NTBlXzQ_b85b68e4-65f8-4743-8180-abfc0a63f99b"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i29c510f38fbe49baa6388a40c6f045d8_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOjdkYzlkYTgwZWJhZTQwZGQ4YWVmZGM1M2Y2MWYwOTNiL3RhYmxlcmFuZ2U6N2RjOWRhODBlYmFlNDBkZDhhZWZkYzUzZjYxZjA5M2JfNi0xLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOmUyNTQyNjNjMThjODQ5MzQ4YTk3NWEwODViMjg3YmFjXzQ_30bf9a8b-7cd9-4e02-bf99-a5e912ef7b73"
      unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i27022197520642e3882ce31d9285e029_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOjdkYzlkYTgwZWJhZTQwZGQ4YWVmZGM1M2Y2MWYwOTNiL3RhYmxlcmFuZ2U6N2RjOWRhODBlYmFlNDBkZDhhZWZkYzUzZjYxZjA5M2JfNi0zLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOjZmMzM0MWRmNGEzMTQ5NThiNjQzNzY4MmEyNjAyMDkxXzQ_2852b56a-d0ee-43af-93d6-6023e3760d08"
      unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie6cdab3f33c048088340a1a1ac085f71_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOjZiODI5ZDc3MmFjYzQ4OGI5MTQ3ZDAwNDU0MTFjMTkyL3RhYmxlcmFuZ2U6NmI4MjlkNzcyYWNjNDg4YjkxNDdkMDA0NTQxMWMxOTJfMi0xLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOjhhYjBmNTA5ZTE1NTRmNjg5ZDY2OTUyYzhkOGE3NGZkXzQ_c30cbe30-5f97-41c7-81f1-18ea6632b8ba"
      unitRef="number">0.51</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0bcd5713f126432fa7b95d333a6687ed_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOjZiODI5ZDc3MmFjYzQ4OGI5MTQ3ZDAwNDU0MTFjMTkyL3RhYmxlcmFuZ2U6NmI4MjlkNzcyYWNjNDg4YjkxNDdkMDA0NTQxMWMxOTJfMi0zLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOjlkODA1YTA0OTIyNjRiZWI5ZDM5Y2E0NzAyOGVmZGE1XzQ_a6cf27a5-a754-41ec-8366-8b0a1d34e33e"
      unitRef="number">0.56</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i4ee7ca1522924116844090df73a38cfc_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOjZiODI5ZDc3MmFjYzQ4OGI5MTQ3ZDAwNDU0MTFjMTkyL3RhYmxlcmFuZ2U6NmI4MjlkNzcyYWNjNDg4YjkxNDdkMDA0NTQxMWMxOTJfMy0xLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOjZlNzdhMDI2Zjk1ZDRiODRiZGMyOWQ5MjNkZjQ2OTRhXzQ_eb9ce2b3-815f-4a87-8be1-bb1e3fcd63a2"
      unitRef="number">0.07</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ieb109b3e8b854eef8e2690d97b4deb83_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOjZiODI5ZDc3MmFjYzQ4OGI5MTQ3ZDAwNDU0MTFjMTkyL3RhYmxlcmFuZ2U6NmI4MjlkNzcyYWNjNDg4YjkxNDdkMDA0NTQxMWMxOTJfMy0zLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOmZlYWEwZmI2YjhmZTQ4YWViMTlhNzYzN2ViYTJmZWJlXzQ_0f8151fc-e4f5-402f-847c-a8286a37c9b2"
      unitRef="number">0.05</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i8964ed8d404e4ecd8cf51bf7dd57fd72_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOjZiODI5ZDc3MmFjYzQ4OGI5MTQ3ZDAwNDU0MTFjMTkyL3RhYmxlcmFuZ2U6NmI4MjlkNzcyYWNjNDg4YjkxNDdkMDA0NTQxMWMxOTJfNC0xLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOjdkYWM3NzgxYzdlZjQ2NGE5MWZiYzQyYWI0MWI3ZTZiXzQ_7f61b70e-a97d-4178-a0fc-f202b2f23b13"
      unitRef="number">0.23</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id4878ca4f0234438bbe2231c100da361_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOjZiODI5ZDc3MmFjYzQ4OGI5MTQ3ZDAwNDU0MTFjMTkyL3RhYmxlcmFuZ2U6NmI4MjlkNzcyYWNjNDg4YjkxNDdkMDA0NTQxMWMxOTJfNC0zLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOmMwMzY3MzEyNzlmYjQyN2VhNTZjOTUzYWFiYTJjY2IyXzQ_cb868169-c03a-4455-8464-63b2b2b3b424"
      unitRef="number">0.23</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i69658dd90db2466aab6d25979a565ec5_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOjZiODI5ZDc3MmFjYzQ4OGI5MTQ3ZDAwNDU0MTFjMTkyL3RhYmxlcmFuZ2U6NmI4MjlkNzcyYWNjNDg4YjkxNDdkMDA0NTQxMWMxOTJfNS0xLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOjU0MWQ3OTZiNTk1ZDQ5ZGFhNjQzZmM5MThlM2QwNjBiXzQ_b10312fa-bf11-42c9-abd5-3091fced2182"
      unitRef="number">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i1a7534f872714dc0b6f41e800f834626_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOjZiODI5ZDc3MmFjYzQ4OGI5MTQ3ZDAwNDU0MTFjMTkyL3RhYmxlcmFuZ2U6NmI4MjlkNzcyYWNjNDg4YjkxNDdkMDA0NTQxMWMxOTJfNS0zLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOmZkNmJmMDA0Y2U3OTRiZGJiZjJjYmRiMDEwZWQyNTA3XzQ_fb3e9c21-8403-4fc2-8661-dbed7d7feedc"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ieabcd647a4f94d14b6c41f5ed82c736e_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOjZiODI5ZDc3MmFjYzQ4OGI5MTQ3ZDAwNDU0MTFjMTkyL3RhYmxlcmFuZ2U6NmI4MjlkNzcyYWNjNDg4YjkxNDdkMDA0NTQxMWMxOTJfNi0xLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOjEzNzAwOTAzYzI1ZTRhM2RhNDNjZjYyNDJkMGNiNDA0XzQ_70bed6df-4cd4-4bb0-904a-1d40706b22e6"
      unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0bb4cbfdac1443989f5d65abc02019aa_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOjZiODI5ZDc3MmFjYzQ4OGI5MTQ3ZDAwNDU0MTFjMTkyL3RhYmxlcmFuZ2U6NmI4MjlkNzcyYWNjNDg4YjkxNDdkMDA0NTQxMWMxOTJfNi0zLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOjFlNDhhNzEyNDZiMjQyOTA5MzQ4MmZkZmUxODBmZjc1XzQ_2362cd6a-b27b-4111-818b-ab4036d667a2"
      unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i705daa289597485c80cbe6c2a4295b55_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOjc5ZjMwZTU2NjRhMTRhYjRiZTEyNTA0NjYyZjFlM2VjL3RhYmxlcmFuZ2U6NzlmMzBlNTY2NGExNGFiNGJlMTI1MDQ2NjJmMWUzZWNfMi0xLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOjUwNDgxODI0YjUyMTRkZTJhMTE5MjNlOWE4MTkwZTIwXzQ_55053622-152a-4301-9d76-8d708c96adb0"
      unitRef="number">0.44</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i6f08de799c8b4bcf84f0b2388b9a1d63_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOjc5ZjMwZTU2NjRhMTRhYjRiZTEyNTA0NjYyZjFlM2VjL3RhYmxlcmFuZ2U6NzlmMzBlNTY2NGExNGFiNGJlMTI1MDQ2NjJmMWUzZWNfMi0zLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOjQ5OWYzMzExMTVhNDQ5YTZhZWE4ODcxNTg3OTgzN2VmXzQ_354d5cb8-a32d-4c5b-a01f-62ed7876d3e0"
      unitRef="number">0.45</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i72821269558f4965b1f01873aa17427e_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOjc5ZjMwZTU2NjRhMTRhYjRiZTEyNTA0NjYyZjFlM2VjL3RhYmxlcmFuZ2U6NzlmMzBlNTY2NGExNGFiNGJlMTI1MDQ2NjJmMWUzZWNfMy0xLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOjYwYzVmYTE0NzU5NzQwNThiZDI1ZTI1OTc5OTQxYTMyXzQ_48c865e2-b61a-4b0c-a293-13339b7fadea"
      unitRef="number">0.47</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i068419f0506343b79f1391a7f0d6cc2e_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOjc5ZjMwZTU2NjRhMTRhYjRiZTEyNTA0NjYyZjFlM2VjL3RhYmxlcmFuZ2U6NzlmMzBlNTY2NGExNGFiNGJlMTI1MDQ2NjJmMWUzZWNfMy0zLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOjhlMmExZDUzOGIyYTQ3YWQ4OTQxMGRkMjBhZDc2NjgzXzQ_24d41ead-f0a5-4591-974a-9830be509d07"
      unitRef="number">0.45</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9f79e1cf75c043448cd2aa1afd887c55_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOjc5ZjMwZTU2NjRhMTRhYjRiZTEyNTA0NjYyZjFlM2VjL3RhYmxlcmFuZ2U6NzlmMzBlNTY2NGExNGFiNGJlMTI1MDQ2NjJmMWUzZWNfNC0xLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOjc4MTBmZGZlZTIzZTRlYjY4MjUxMjBhMjY4Y2I1ZmFlXzQ_ed0fde5f-7b7a-4d59-9d8b-1ff0714e5be6"
      unitRef="number">0.09</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i4cfb274b8db44a3e9f441e5bf17fc3ef_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOjc5ZjMwZTU2NjRhMTRhYjRiZTEyNTA0NjYyZjFlM2VjL3RhYmxlcmFuZ2U6NzlmMzBlNTY2NGExNGFiNGJlMTI1MDQ2NjJmMWUzZWNfNC0zLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOmZhZmRjN2UyNjcyYTQ5YjRiNzdlYmM1NWY2M2JiN2ZmXzQ_7026d486-362d-4663-81fa-994bb5505864"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i1fc7305b8607421d8a06a356da5a15ed_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOjc5ZjMwZTU2NjRhMTRhYjRiZTEyNTA0NjYyZjFlM2VjL3RhYmxlcmFuZ2U6NzlmMzBlNTY2NGExNGFiNGJlMTI1MDQ2NjJmMWUzZWNfNS0xLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOmZiZTU4MWViYzMzZTQzYTU5Y2QyYWFhNjc4YmU2ODFhXzQ_c5fd4e2b-9f22-47fe-95c1-82945544a4d4"
      unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib884bebbba5c4e049f608852aff2075d_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOjc5ZjMwZTU2NjRhMTRhYjRiZTEyNTA0NjYyZjFlM2VjL3RhYmxlcmFuZ2U6NzlmMzBlNTY2NGExNGFiNGJlMTI1MDQ2NjJmMWUzZWNfNS0zLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOjZkNDlkNTEwY2QzODQ1OGI5YzdiNjFiMjdlYmQ1MTYyXzQ_10262dda-2786-4fdc-b17c-2dbde172cb4b"
      unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RleHRyZWdpb246MGQyN2ViN2QyYTg3NDczOWJhYzU3MmY2ZDJhMjVkZDhfMjA1OA_80754310-666a-4983-a0c6-ec4d0bdab5f7">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our contract assets and liabilities, excluding amounts included in accounts receivable, net:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract assets, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract assets, March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in contract assets - increase (decrease)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income, March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(57.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in deferred income - decrease (increase)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOmZkMWM2ZWJiY2VhYTRmODJhZGYxYzkyMDQxNjQ5M2RlL3RhYmxlcmFuZ2U6ZmQxYzZlYmJjZWFhNGY4MmFkZjFjOTIwNDE2NDkzZGVfMS0xLTEtMS04Mjc4Mg_5a2acee7-80c3-4521-9675-75f5a19f4c2b"
      unitRef="usd">16300000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOmZkMWM2ZWJiY2VhYTRmODJhZGYxYzkyMDQxNjQ5M2RlL3RhYmxlcmFuZ2U6ZmQxYzZlYmJjZWFhNGY4MmFkZjFjOTIwNDE2NDkzZGVfMi0xLTEtMS04Mjc4Mg_cf8f2b94-5f05-4c63-a472-6ff5824e3969"
      unitRef="usd">19400000</us-gaap:ContractWithCustomerAssetNet>
    <wst:ContractWithCustomerAssetIncreaseDecrease
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOmZkMWM2ZWJiY2VhYTRmODJhZGYxYzkyMDQxNjQ5M2RlL3RhYmxlcmFuZ2U6ZmQxYzZlYmJjZWFhNGY4MmFkZjFjOTIwNDE2NDkzZGVfMy0xLTEtMS04Mjc4Mg_8083e52b-90db-4bf5-b197-570ca9e10af8"
      unitRef="usd">3100000</wst:ContractWithCustomerAssetIncreaseDecrease>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOmZkMWM2ZWJiY2VhYTRmODJhZGYxYzkyMDQxNjQ5M2RlL3RhYmxlcmFuZ2U6ZmQxYzZlYmJjZWFhNGY4MmFkZjFjOTIwNDE2NDkzZGVfNS0xLTEtMS04Mjc4Mg_c94bf854-917d-4764-af25-9d346a2e6e9c"
      unitRef="usd">68200000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOmZkMWM2ZWJiY2VhYTRmODJhZGYxYzkyMDQxNjQ5M2RlL3RhYmxlcmFuZ2U6ZmQxYzZlYmJjZWFhNGY4MmFkZjFjOTIwNDE2NDkzZGVfNi0xLTEtMS04Mjc4Mg_6a5dd5c9-d1fb-4964-bbb2-ea265965e2e7"
      unitRef="usd">57500000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RhYmxlOmZkMWM2ZWJiY2VhYTRmODJhZGYxYzkyMDQxNjQ5M2RlL3RhYmxlcmFuZ2U6ZmQxYzZlYmJjZWFhNGY4MmFkZjFjOTIwNDE2NDkzZGVfNy0xLTEtMS04Mjc4Mg_6e27c77b-1111-4b56-b547-26c6a5a06105"
      unitRef="usd">10700000</us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RleHRyZWdpb246MGQyN2ViN2QyYTg3NDczOWJhYzU3MmY2ZDJhMjVkZDhfMTI0MA_c0999151-af24-497c-98d3-b853c75fb10d"
      unitRef="usd">21300000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i73b55d82d73748a38f69bd594560eb79_I20130630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RleHRyZWdpb246MGQyN2ViN2QyYTg3NDczOWJhYzU3MmY2ZDJhMjVkZDhfMTU1Mw_6d9462d2-d816-4520-b2f0-0a233ca5c03a"
      unitRef="usd">20000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i3f009365e828466d98af8bbc2bce4411_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RleHRyZWdpb246MGQyN2ViN2QyYTg3NDczOWJhYzU3MmY2ZDJhMjVkZDhfMTY5Nw_934277bc-440f-46db-b86b-6f0fe519aef1"
      unitRef="usd">2800000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i3f009365e828466d98af8bbc2bce4411_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RleHRyZWdpb246MGQyN2ViN2QyYTg3NDczOWJhYzU3MmY2ZDJhMjVkZDhfMTc1Mw_49760ebc-487e-4cca-b72c-e9acbb519fee"
      unitRef="usd">900000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i3f009365e828466d98af8bbc2bce4411_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80MC9mcmFnOjBkMjdlYjdkMmE4NzQ3MzliYWM1NzJmNmQyYTI1ZGQ4L3RleHRyZWdpb246MGQyN2ViN2QyYTg3NDczOWJhYzU3MmY2ZDJhMjVkZDhfMTgwMg_a647d14d-b0b9-4b0d-9e24-cb77dbbeb438"
      unitRef="usd">1900000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80My9mcmFnOjk1NGE1OTkxNWE0MDRiMjk5MTAzMDU1OWQ1NmM0YTY5L3RleHRyZWdpb246OTU0YTU5OTE1YTQwNGIyOTkxMDMwNTU5ZDU2YzRhNjlfMTAyNQ_60d4ea1c-cc8f-4a59-9790-5a0e0d3ce4fb">Net Income Per Share&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the shares used in the calculation of basic net income per share to those used for diluted net income per share:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of equity awards, based on the treasury stock method&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares assuming dilution&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2023 and 2022, there were 0.3 million and 0.0 million shares, respectively, from stock-based compensation plans not included in the computation of diluted net income per share because their impact was antidilutive. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2023, the Board of Directors approved a share repurchase program under which we may repurchase up to $1.0&#160;billion in shares of common stock. The share repurchase program does not have an expiration date under which we may repurchase common stock on the open market or in privately-negotiated transactions. The number of shares to be repurchased and the timing of such transactions will depend on a variety of factors, including market conditions.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2023, we purchased 183,360 shares of our common stock under the program at a cost of $60.1 million, or an average price of $327.90 per share. During the three months ended March 31, 2022, we purchased 390,000 shares of our common stock under the program at a cost of $147.1&#160;million, or an average price of $377.23 per share.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80My9mcmFnOjk1NGE1OTkxNWE0MDRiMjk5MTAzMDU1OWQ1NmM0YTY5L3RleHRyZWdpb246OTU0YTU5OTE1YTQwNGIyOTkxMDMwNTU5ZDU2YzRhNjlfMTAyMg_10e8d1ff-57e9-495f-ae8a-0047fcf604e1">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the shares used in the calculation of basic net income per share to those used for diluted net income per share:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of equity awards, based on the treasury stock method&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares assuming dilution&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80My9mcmFnOjk1NGE1OTkxNWE0MDRiMjk5MTAzMDU1OWQ1NmM0YTY5L3RhYmxlOmQwOWFhNjlmOGQ5NTRmMmJhYzlhNjVkOTY0NTZkZTAzL3RhYmxlcmFuZ2U6ZDA5YWE2OWY4ZDk1NGYyYmFjOWE2NWQ5NjQ1NmRlMDNfMi0xLTEtMS04Mjc4Mg_e7734aa1-7406-4930-9ee6-6fa9ed50bfcb"
      unitRef="usd">140000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80My9mcmFnOjk1NGE1OTkxNWE0MDRiMjk5MTAzMDU1OWQ1NmM0YTY5L3RhYmxlOmQwOWFhNjlmOGQ5NTRmMmJhYzlhNjVkOTY0NTZkZTAzL3RhYmxlcmFuZ2U6ZDA5YWE2OWY4ZDk1NGYyYmFjOWE2NWQ5NjQ1NmRlMDNfMi0zLTEtMS04Mjc4Mg_2fb94b74-1923-4f9f-ba4c-aa0aefbc373c"
      unitRef="usd">173800000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80My9mcmFnOjk1NGE1OTkxNWE0MDRiMjk5MTAzMDU1OWQ1NmM0YTY5L3RhYmxlOmQwOWFhNjlmOGQ5NTRmMmJhYzlhNjVkOTY0NTZkZTAzL3RhYmxlcmFuZ2U6ZDA5YWE2OWY4ZDk1NGYyYmFjOWE2NWQ5NjQ1NmRlMDNfMy0xLTEtMS04Mjc4Mg_9f7ee68f-7d29-478e-a939-da05c8bf629a"
      unitRef="shares">74500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80My9mcmFnOjk1NGE1OTkxNWE0MDRiMjk5MTAzMDU1OWQ1NmM0YTY5L3RhYmxlOmQwOWFhNjlmOGQ5NTRmMmJhYzlhNjVkOTY0NTZkZTAzL3RhYmxlcmFuZ2U6ZDA5YWE2OWY4ZDk1NGYyYmFjOWE2NWQ5NjQ1NmRlMDNfMy0zLTEtMS04Mjc4Mg_6fe1730f-f86f-4b9c-ad42-955edabefe5a"
      unitRef="shares">74400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80My9mcmFnOjk1NGE1OTkxNWE0MDRiMjk5MTAzMDU1OWQ1NmM0YTY5L3RhYmxlOmQwOWFhNjlmOGQ5NTRmMmJhYzlhNjVkOTY0NTZkZTAzL3RhYmxlcmFuZ2U6ZDA5YWE2OWY4ZDk1NGYyYmFjOWE2NWQ5NjQ1NmRlMDNfNC0xLTEtMS04Mjc4Mg_d271a299-6946-4106-af8b-1671d4db0796"
      unitRef="shares">1200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80My9mcmFnOjk1NGE1OTkxNWE0MDRiMjk5MTAzMDU1OWQ1NmM0YTY5L3RhYmxlOmQwOWFhNjlmOGQ5NTRmMmJhYzlhNjVkOTY0NTZkZTAzL3RhYmxlcmFuZ2U6ZDA5YWE2OWY4ZDk1NGYyYmFjOWE2NWQ5NjQ1NmRlMDNfNC0zLTEtMS04Mjc4Mg_1c24dea5-b17e-4d09-8ab7-a938ff0f3820"
      unitRef="shares">1600000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80My9mcmFnOjk1NGE1OTkxNWE0MDRiMjk5MTAzMDU1OWQ1NmM0YTY5L3RhYmxlOmQwOWFhNjlmOGQ5NTRmMmJhYzlhNjVkOTY0NTZkZTAzL3RhYmxlcmFuZ2U6ZDA5YWE2OWY4ZDk1NGYyYmFjOWE2NWQ5NjQ1NmRlMDNfNS0xLTEtMS04Mjc4Mg_4da8eef9-f175-455c-a633-cd4da7813a2a"
      unitRef="shares">75700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80My9mcmFnOjk1NGE1OTkxNWE0MDRiMjk5MTAzMDU1OWQ1NmM0YTY5L3RhYmxlOmQwOWFhNjlmOGQ5NTRmMmJhYzlhNjVkOTY0NTZkZTAzL3RhYmxlcmFuZ2U6ZDA5YWE2OWY4ZDk1NGYyYmFjOWE2NWQ5NjQ1NmRlMDNfNS0zLTEtMS04Mjc4Mg_1a9e3d22-a290-4833-8b9a-f53927e30467"
      unitRef="shares">76000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80My9mcmFnOjk1NGE1OTkxNWE0MDRiMjk5MTAzMDU1OWQ1NmM0YTY5L3RleHRyZWdpb246OTU0YTU5OTE1YTQwNGIyOTkxMDMwNTU5ZDU2YzRhNjlfMjE5_175cefcf-167e-4612-aeaa-8abbb4bbb6e1"
      unitRef="shares">300000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80My9mcmFnOjk1NGE1OTkxNWE0MDRiMjk5MTAzMDU1OWQ1NmM0YTY5L3RleHRyZWdpb246OTU0YTU5OTE1YTQwNGIyOTkxMDMwNTU5ZDU2YzRhNjlfMjI2_f6b58491-1e40-4ccc-b5e3-64825b302ed5"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i866c5a8fb2f748d0b77d31bceb45da81_I20230228"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80My9mcmFnOjk1NGE1OTkxNWE0MDRiMjk5MTAzMDU1OWQ1NmM0YTY5L3RleHRyZWdpb246OTU0YTU5OTE1YTQwNGIyOTkxMDMwNTU5ZDU2YzRhNjlfNTQ5NzU1ODE2Njc3_b42f4ee4-79df-4afc-b735-f88a57b098c7"
      unitRef="usd">1000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80My9mcmFnOjk1NGE1OTkxNWE0MDRiMjk5MTAzMDU1OWQ1NmM0YTY5L3RleHRyZWdpb246OTU0YTU5OTE1YTQwNGIyOTkxMDMwNTU5ZDU2YzRhNjlfOTE4_091eaf0b-b54d-4347-b6c6-f8151b47eb07"
      unitRef="shares">183360</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80My9mcmFnOjk1NGE1OTkxNWE0MDRiMjk5MTAzMDU1OWQ1NmM0YTY5L3RleHRyZWdpb246OTU0YTU5OTE1YTQwNGIyOTkxMDMwNTU5ZDU2YzRhNjlfOTc5_89fedffe-7019-4bdb-a3a6-229b8474889b"
      unitRef="usd">60100000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80My9mcmFnOjk1NGE1OTkxNWE0MDRiMjk5MTAzMDU1OWQ1NmM0YTY5L3RleHRyZWdpb246OTU0YTU5OTE1YTQwNGIyOTkxMDMwNTU5ZDU2YzRhNjlfMTAwNg_d7d69ea2-7afb-4693-90b3-f97c57e4e4f6"
      unitRef="usdPerShare">327.90</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80My9mcmFnOjk1NGE1OTkxNWE0MDRiMjk5MTAzMDU1OWQ1NmM0YTY5L3RleHRyZWdpb246OTU0YTU5OTE1YTQwNGIyOTkxMDMwNTU5ZDU2YzRhNjlfODI0NjMzNzIxMTM2Ng_2143b40a-8763-4f0b-9742-4f2bad80ad27"
      unitRef="shares">390000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80My9mcmFnOjk1NGE1OTkxNWE0MDRiMjk5MTAzMDU1OWQ1NmM0YTY5L3RleHRyZWdpb246OTU0YTU5OTE1YTQwNGIyOTkxMDMwNTU5ZDU2YzRhNjlfODI0NjMzNzIxMTM5MA_45572047-82a8-43b7-88cf-72096d690a6a"
      unitRef="usd">147100000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80My9mcmFnOjk1NGE1OTkxNWE0MDRiMjk5MTAzMDU1OWQ1NmM0YTY5L3RleHRyZWdpb246OTU0YTU5OTE1YTQwNGIyOTkxMDMwNTU5ZDU2YzRhNjlfODI0NjMzNzIxMTQxNA_fdf40cab-7736-4c06-b4ac-8673d6207a43"
      unitRef="usdPerShare">377.23</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80Ni9mcmFnOjVjN2IyYWIzOGE0NTQ1ZGRiMDcyOGVmZTdlNzM5ZDQ2L3RleHRyZWdpb246NWM3YjJhYjM4YTQ1NDVkZGIwNzI4ZWZlN2U3MzlkNDZfMTc4_0d1e1707-416d-4417-bc52-72cb9ad4e096">Inventories&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are valued at the lower of cost (on a first-in, first-out basis) and net realizable value. Inventory balances were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.611%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.933%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;414.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80Ni9mcmFnOjVjN2IyYWIzOGE0NTQ1ZGRiMDcyOGVmZTdlNzM5ZDQ2L3RleHRyZWdpb246NWM3YjJhYjM4YTQ1NDVkZGIwNzI4ZWZlN2U3MzlkNDZfMTgx_29df51c5-5350-427f-be25-78f9986d26ff">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are valued at the lower of cost (on a first-in, first-out basis) and net realizable value. Inventory balances were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.611%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.933%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;414.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80Ni9mcmFnOjVjN2IyYWIzOGE0NTQ1ZGRiMDcyOGVmZTdlNzM5ZDQ2L3RhYmxlOmQ3MmQxYWJlNDk0MjQ2NDliZjk4YzBiZDMyZTI0MTdlL3RhYmxlcmFuZ2U6ZDcyZDFhYmU0OTQyNDY0OWJmOThjMGJkMzJlMjQxN2VfMS0xLTEtMS04Mjc4Mg_4ba26184-7a9e-4e6d-bc5e-40a16b55d233"
      unitRef="usd">181000000.0</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80Ni9mcmFnOjVjN2IyYWIzOGE0NTQ1ZGRiMDcyOGVmZTdlNzM5ZDQ2L3RhYmxlOmQ3MmQxYWJlNDk0MjQ2NDliZjk4YzBiZDMyZTI0MTdlL3RhYmxlcmFuZ2U6ZDcyZDFhYmU0OTQyNDY0OWJmOThjMGJkMzJlMjQxN2VfMS0zLTEtMS04Mjc4Mg_7ac4b16d-522a-4368-b9ea-7b0c02d93d84"
      unitRef="usd">170700000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80Ni9mcmFnOjVjN2IyYWIzOGE0NTQ1ZGRiMDcyOGVmZTdlNzM5ZDQ2L3RhYmxlOmQ3MmQxYWJlNDk0MjQ2NDliZjk4YzBiZDMyZTI0MTdlL3RhYmxlcmFuZ2U6ZDcyZDFhYmU0OTQyNDY0OWJmOThjMGJkMzJlMjQxN2VfMi0xLTEtMS04Mjc4Mg_40f814aa-1713-443f-be39-949ffb53266c"
      unitRef="usd">95900000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80Ni9mcmFnOjVjN2IyYWIzOGE0NTQ1ZGRiMDcyOGVmZTdlNzM5ZDQ2L3RhYmxlOmQ3MmQxYWJlNDk0MjQ2NDliZjk4YzBiZDMyZTI0MTdlL3RhYmxlcmFuZ2U6ZDcyZDFhYmU0OTQyNDY0OWJmOThjMGJkMzJlMjQxN2VfMi0zLTEtMS04Mjc4Mg_220a45c6-0364-4f35-822d-84b2db00fd3b"
      unitRef="usd">79000000.0</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80Ni9mcmFnOjVjN2IyYWIzOGE0NTQ1ZGRiMDcyOGVmZTdlNzM5ZDQ2L3RhYmxlOmQ3MmQxYWJlNDk0MjQ2NDliZjk4YzBiZDMyZTI0MTdlL3RhYmxlcmFuZ2U6ZDcyZDFhYmU0OTQyNDY0OWJmOThjMGJkMzJlMjQxN2VfMy0xLTEtMS04Mjc4Mg_23708830-b55e-49ee-9b12-5c0db93561e5"
      unitRef="usd">170100000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80Ni9mcmFnOjVjN2IyYWIzOGE0NTQ1ZGRiMDcyOGVmZTdlNzM5ZDQ2L3RhYmxlOmQ3MmQxYWJlNDk0MjQ2NDliZjk4YzBiZDMyZTI0MTdlL3RhYmxlcmFuZ2U6ZDcyZDFhYmU0OTQyNDY0OWJmOThjMGJkMzJlMjQxN2VfMy0zLTEtMS04Mjc4Mg_cd1a0b1c-4aab-44a7-9a3f-e80adac3e9b9"
      unitRef="usd">165100000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80Ni9mcmFnOjVjN2IyYWIzOGE0NTQ1ZGRiMDcyOGVmZTdlNzM5ZDQ2L3RhYmxlOmQ3MmQxYWJlNDk0MjQ2NDliZjk4YzBiZDMyZTI0MTdlL3RhYmxlcmFuZ2U6ZDcyZDFhYmU0OTQyNDY0OWJmOThjMGJkMzJlMjQxN2VfNC0xLTEtMS04Mjc4Mg_092df6bc-d3b9-4461-a975-dcfa5b87889c"
      unitRef="usd">447000000.0</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80Ni9mcmFnOjVjN2IyYWIzOGE0NTQ1ZGRiMDcyOGVmZTdlNzM5ZDQ2L3RhYmxlOmQ3MmQxYWJlNDk0MjQ2NDliZjk4YzBiZDMyZTI0MTdlL3RhYmxlcmFuZ2U6ZDcyZDFhYmU0OTQyNDY0OWJmOThjMGJkMzJlMjQxN2VfNC0zLTEtMS04Mjc4Mg_bb72bd0c-8f4a-451f-b9d4-13e42e029935"
      unitRef="usd">414800000</us-gaap:InventoryNet>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RleHRyZWdpb246Zjc4MTEwNTVkY2ExNDkxMGE1NTljZTNlM2ViMTE0YWJfMTIwOQ_5d3f9251-66aa-49e5-a6ec-8fa119a85070">LeasesA lease exists when a contract conveys to the customer the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. The definition of a lease embodies two conditions: 1) there is an identified asset in the contract that is land or a depreciable asset (i.e., property, plant, and equipment); and 2) the customer has the right to control the use of the identified asset. Lease payments included in the measurement of the operating lease right-of-use assets and lease liabilities are comprised of fixed payments (including in-substance fixed payments), variable payments that depend on an index or rate, and the exercise price of a lessee option to purchase the underlying asset if the lessee is reasonably certain to exercise.&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.451%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to leases was as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.451%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for new operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023 and December&#160;31, 2022, the weighted average remaining lease term for operating leases was 9.3 years and 9.3 years, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023 and December&#160;31, 2022, the weighted average discount rate was 3.26% and 3.25%, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of operating lease liabilities were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023 (remaining period as of)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed lease interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RleHRyZWdpb246Zjc4MTEwNTVkY2ExNDkxMGE1NTljZTNlM2ViMTE0YWJfMTIwMQ_2e678fc4-2538-4c79-9744-68b7b1b0d0d8">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.451%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOjU2YjIwMTUyN2YzMTQ0ZmY4YTJiZjNkZTc1NzI1N2U2L3RhYmxlcmFuZ2U6NTZiMjAxNTI3ZjMxNDRmZjhhMmJmM2RlNzU3MjU3ZTZfMi0xLTEtMS04Mjc4Mg_d672fc3e-6abd-4142-950b-4b60fb7bc84b"
      unitRef="usd">5900000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOjU2YjIwMTUyN2YzMTQ0ZmY4YTJiZjNkZTc1NzI1N2U2L3RhYmxlcmFuZ2U6NTZiMjAxNTI3ZjMxNDRmZjhhMmJmM2RlNzU3MjU3ZTZfMi0zLTEtMS04Mjc4Mg_2858cf21-f451-41ff-86c5-cf04b6bef0b3"
      unitRef="usd">3300000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOjU2YjIwMTUyN2YzMTQ0ZmY4YTJiZjNkZTc1NzI1N2U2L3RhYmxlcmFuZ2U6NTZiMjAxNTI3ZjMxNDRmZjhhMmJmM2RlNzU3MjU3ZTZfMy0xLTEtMS04Mjc4Mg_9aaba31b-2151-4a82-9aa1-cd6d32be2cfa"
      unitRef="usd">1300000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOjU2YjIwMTUyN2YzMTQ0ZmY4YTJiZjNkZTc1NzI1N2U2L3RhYmxlcmFuZ2U6NTZiMjAxNTI3ZjMxNDRmZjhhMmJmM2RlNzU3MjU3ZTZfMy0zLTEtMS04Mjc4Mg_10c096f6-969b-4b87-86c2-7f931b3ef443"
      unitRef="usd">400000</us-gaap:ShortTermLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOjU2YjIwMTUyN2YzMTQ0ZmY4YTJiZjNkZTc1NzI1N2U2L3RhYmxlcmFuZ2U6NTZiMjAxNTI3ZjMxNDRmZjhhMmJmM2RlNzU3MjU3ZTZfNC0xLTEtMS04Mjc4Mg_3c57084c-0e0f-4f96-a8ea-9eadda20fe88"
      unitRef="usd">1700000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOjU2YjIwMTUyN2YzMTQ0ZmY4YTJiZjNkZTc1NzI1N2U2L3RhYmxlcmFuZ2U6NTZiMjAxNTI3ZjMxNDRmZjhhMmJmM2RlNzU3MjU3ZTZfNC0zLTEtMS04Mjc4Mg_dfe632ce-5a21-4b3e-83a5-021cfd0efeb9"
      unitRef="usd">1400000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOjU2YjIwMTUyN2YzMTQ0ZmY4YTJiZjNkZTc1NzI1N2U2L3RhYmxlcmFuZ2U6NTZiMjAxNTI3ZjMxNDRmZjhhMmJmM2RlNzU3MjU3ZTZfNS0xLTEtMS04Mjc4Mg_a2357a9c-60de-4d27-8fee-b3dfbdf55c02"
      unitRef="usd">8900000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOjU2YjIwMTUyN2YzMTQ0ZmY4YTJiZjNkZTc1NzI1N2U2L3RhYmxlcmFuZ2U6NTZiMjAxNTI3ZjMxNDRmZjhhMmJmM2RlNzU3MjU3ZTZfNS0zLTEtMS04Mjc4Mg_a63b7a36-5531-4f97-a316-9e0f5c9c1035"
      unitRef="usd">5100000</us-gaap:LeaseCost>
    <wst:LesseeLeaseCashFlowAndSupplementalInformationTableTextBlock
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RleHRyZWdpb246Zjc4MTEwNTVkY2ExNDkxMGE1NTljZTNlM2ViMTE0YWJfMTIwNg_995a3aeb-d4be-4cf2-a542-709b8f1beb3f">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to leases was as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.451%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for new operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</wst:LesseeLeaseCashFlowAndSupplementalInformationTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOjc1Y2I0YWYwY2IwZDQ4Y2ViYWM5YjVlZDIwNTNkMzJlL3RhYmxlcmFuZ2U6NzVjYjRhZjBjYjBkNDhjZWJhYzliNWVkMjA1M2QzMmVfMy0xLTEtMS04Mjc4Mg_2c955383-c410-4c57-b4cd-5d788427ee81"
      unitRef="usd">4900000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOjc1Y2I0YWYwY2IwZDQ4Y2ViYWM5YjVlZDIwNTNkMzJlL3RhYmxlcmFuZ2U6NzVjYjRhZjBjYjBkNDhjZWJhYzliNWVkMjA1M2QzMmVfMy00LTEtMS04Mjc4Mg_162a6d0b-42e7-438d-8ea3-d11f8ba97758"
      unitRef="usd">3200000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOjc1Y2I0YWYwY2IwZDQ4Y2ViYWM5YjVlZDIwNTNkMzJlL3RhYmxlcmFuZ2U6NzVjYjRhZjBjYjBkNDhjZWJhYzliNWVkMjA1M2QzMmVfNC0xLTEtMS04Mjc4Mg_ecc3dcab-78ec-4481-8f46-708957665448"
      unitRef="usd">600000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOjc1Y2I0YWYwY2IwZDQ4Y2ViYWM5YjVlZDIwNTNkMzJlL3RhYmxlcmFuZ2U6NzVjYjRhZjBjYjBkNDhjZWJhYzliNWVkMjA1M2QzMmVfNC00LTEtMS04Mjc4Mg_fd094f7d-27db-435d-adc2-3485b9d5ad0a"
      unitRef="usd">9700000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RleHRyZWdpb246Zjc4MTEwNTVkY2ExNDkxMGE1NTljZTNlM2ViMTE0YWJfMTAxOA_2f52e38a-3fc6-4aee-aa1b-61d62e405e0c">P9Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RleHRyZWdpb246Zjc4MTEwNTVkY2ExNDkxMGE1NTljZTNlM2ViMTE0YWJfMTAzMQ_8792dbe1-f6af-4810-8565-054645a38623">P9Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RleHRyZWdpb246Zjc4MTEwNTVkY2ExNDkxMGE1NTljZTNlM2ViMTE0YWJfMTExMw_596ff66c-5d30-4688-b69d-283087d275e3"
      unitRef="number">0.0326</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RleHRyZWdpb246Zjc4MTEwNTVkY2ExNDkxMGE1NTljZTNlM2ViMTE0YWJfMTEyMA_c4990424-0182-46d1-be3f-0e8547633366"
      unitRef="number">0.0325</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RleHRyZWdpb246Zjc4MTEwNTVkY2ExNDkxMGE1NTljZTNlM2ViMTE0YWJfMTIwOA_36aa585e-9ff9-4e09-8ef2-0d805b540066">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of operating lease liabilities were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023 (remaining period as of)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed lease interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOmY3M2MxNTVkMmUyMzQzODg5NjE1OWEzYTA3NzMzN2M4L3RhYmxlcmFuZ2U6ZjczYzE1NWQyZTIzNDM4ODk2MTU5YTNhMDc3MzM3YzhfMi0xLTEtMS04Mjc4Mg_5fd59460-c7ee-4b06-b4bf-d0ad36e800e9"
      unitRef="usd">14500000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOmY3M2MxNTVkMmUyMzQzODg5NjE1OWEzYTA3NzMzN2M4L3RhYmxlcmFuZ2U6ZjczYzE1NWQyZTIzNDM4ODk2MTU5YTNhMDc3MzM3YzhfMi0zLTEtMS04Mjc4Mg_9c515415-632d-448d-95a5-23982e499f35"
      unitRef="usd">19000000.0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOmY3M2MxNTVkMmUyMzQzODg5NjE1OWEzYTA3NzMzN2M4L3RhYmxlcmFuZ2U6ZjczYzE1NWQyZTIzNDM4ODk2MTU5YTNhMDc3MzM3YzhfMy0xLTEtMS04Mjc4Mg_267bfa25-774f-4cff-b346-264058f482bc"
      unitRef="usd">18300000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOmY3M2MxNTVkMmUyMzQzODg5NjE1OWEzYTA3NzMzN2M4L3RhYmxlcmFuZ2U6ZjczYzE1NWQyZTIzNDM4ODk2MTU5YTNhMDc3MzM3YzhfMy0zLTEtMS04Mjc4Mg_fe33f318-ba00-4a26-b7b6-970a6777d81b"
      unitRef="usd">18100000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOmY3M2MxNTVkMmUyMzQzODg5NjE1OWEzYTA3NzMzN2M4L3RhYmxlcmFuZ2U6ZjczYzE1NWQyZTIzNDM4ODk2MTU5YTNhMDc3MzM3YzhfNC0xLTEtMS04Mjc4Mg_b1feb8de-18d5-479c-9208-b2b0419c50d9"
      unitRef="usd">16200000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOmY3M2MxNTVkMmUyMzQzODg5NjE1OWEzYTA3NzMzN2M4L3RhYmxlcmFuZ2U6ZjczYzE1NWQyZTIzNDM4ODk2MTU5YTNhMDc3MzM3YzhfNC0zLTEtMS04Mjc4Mg_059b3916-e1af-4308-9778-45157f92041c"
      unitRef="usd">16000000.0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOmY3M2MxNTVkMmUyMzQzODg5NjE1OWEzYTA3NzMzN2M4L3RhYmxlcmFuZ2U6ZjczYzE1NWQyZTIzNDM4ODk2MTU5YTNhMDc3MzM3YzhfNS0xLTEtMS04Mjc4Mg_4989fdd2-0198-44f2-b1ce-2cec944ce201"
      unitRef="usd">13400000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOmY3M2MxNTVkMmUyMzQzODg5NjE1OWEzYTA3NzMzN2M4L3RhYmxlcmFuZ2U6ZjczYzE1NWQyZTIzNDM4ODk2MTU5YTNhMDc3MzM3YzhfNS0zLTEtMS04Mjc4Mg_55f57f52-26e7-44e3-a7b9-8e742bd44c8f"
      unitRef="usd">13400000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOmY3M2MxNTVkMmUyMzQzODg5NjE1OWEzYTA3NzMzN2M4L3RhYmxlcmFuZ2U6ZjczYzE1NWQyZTIzNDM4ODk2MTU5YTNhMDc3MzM3YzhfNi0xLTEtMS04Mjc4Mg_c907ab5b-f8f8-436a-a33c-8b099977c30f"
      unitRef="usd">9300000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOmY3M2MxNTVkMmUyMzQzODg5NjE1OWEzYTA3NzMzN2M4L3RhYmxlcmFuZ2U6ZjczYzE1NWQyZTIzNDM4ODk2MTU5YTNhMDc3MzM3YzhfNi0zLTEtMS04Mjc4Mg_c661f07e-a204-44c5-b68f-37e0bf20d481"
      unitRef="usd">9400000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <wst:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOmY3M2MxNTVkMmUyMzQzODg5NjE1OWEzYTA3NzMzN2M4L3RhYmxlcmFuZ2U6ZjczYzE1NWQyZTIzNDM4ODk2MTU5YTNhMDc3MzM3YzhfNy0xLTEtMS04Mjc4Mg_e8ab5786-e6b6-484e-b761-54d49a3857b2"
      unitRef="usd">51500000</wst:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOmY3M2MxNTVkMmUyMzQzODg5NjE1OWEzYTA3NzMzN2M4L3RhYmxlcmFuZ2U6ZjczYzE1NWQyZTIzNDM4ODk2MTU5YTNhMDc3MzM3YzhfNy0zLTEtMS04Mjc4Mg_405c5c74-5728-418d-b698-c55c6a5017e9"
      unitRef="usd">50800000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOmY3M2MxNTVkMmUyMzQzODg5NjE1OWEzYTA3NzMzN2M4L3RhYmxlcmFuZ2U6ZjczYzE1NWQyZTIzNDM4ODk2MTU5YTNhMDc3MzM3YzhfOC0xLTEtMS04Mjc4Mg_3920f4a0-ea4a-4b42-ad88-a76f08eb4776"
      unitRef="usd">123200000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOmY3M2MxNTVkMmUyMzQzODg5NjE1OWEzYTA3NzMzN2M4L3RhYmxlcmFuZ2U6ZjczYzE1NWQyZTIzNDM4ODk2MTU5YTNhMDc3MzM3YzhfOC0zLTEtMS04Mjc4Mg_42f2a0c8-b991-4713-b1b9-907bec32c425"
      unitRef="usd">126700000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOmY3M2MxNTVkMmUyMzQzODg5NjE1OWEzYTA3NzMzN2M4L3RhYmxlcmFuZ2U6ZjczYzE1NWQyZTIzNDM4ODk2MTU5YTNhMDc3MzM3YzhfOS0xLTEtMS04Mjc4Mg_8c12840f-1cb4-4ec6-a9a7-f7439a0a0fdb"
      unitRef="usd">17100000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOmY3M2MxNTVkMmUyMzQzODg5NjE1OWEzYTA3NzMzN2M4L3RhYmxlcmFuZ2U6ZjczYzE1NWQyZTIzNDM4ODk2MTU5YTNhMDc3MzM3YzhfOS0zLTEtMS04Mjc4Mg_6de8acb7-2498-4be8-a876-2e5f6b15ef38"
      unitRef="usd">17700000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOmY3M2MxNTVkMmUyMzQzODg5NjE1OWEzYTA3NzMzN2M4L3RhYmxlcmFuZ2U6ZjczYzE1NWQyZTIzNDM4ODk2MTU5YTNhMDc3MzM3YzhfMTAtMS0xLTEtODI3ODI_81aa75a0-5c5f-4b79-951f-d8200c03cc12"
      unitRef="usd">106100000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl80OS9mcmFnOmY3ODExMDU1ZGNhMTQ5MTBhNTU5Y2UzZTNlYjExNGFiL3RhYmxlOmY3M2MxNTVkMmUyMzQzODg5NjE1OWEzYTA3NzMzN2M4L3RhYmxlcmFuZ2U6ZjczYzE1NWQyZTIzNDM4ODk2MTU5YTNhMDc3MzM3YzhfMTAtMy0xLTEtODI3ODI_93f82791-ab0b-4c4f-add1-7c9ae96717af"
      unitRef="usd">109000000.0</us-gaap:OperatingLeaseLiability>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81Mi9mcmFnOmRhNjNhOGU3ZmQxZDRlNWFhOGZhNjM1NzY4Mjg1OTM4L3RleHRyZWdpb246ZGE2M2E4ZTdmZDFkNGU1YWE4ZmE2MzU3NjgyODU5MzhfMTM3Mw_bce24f1c-291c-4e6f-bff1-fed8ebae3009">Affiliated CompaniesAt March&#160;31, 2023 and December&#160;31, 2022, the aggregate carrying amount of our investment in affiliated companies that are accounted for under the equity method was $200.9 million and $197.0 million, respectively, and the aggregate carrying amount of our investment in affiliated companies that are not accounted for under the equity method was $7.9 million and $7.9 million at March&#160;31, 2023 and December&#160;31, 2022, respectively. We have elected to record these investments, for which fair value was not readily determinable, at cost, less impairment, adjusted for subsequent observable price changes. We test these investments for impairment whenever circumstances indicate that the carrying value of the investments may not be recoverable. &lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our purchases from, and royalty payments made to, affiliates totaled $44.2 million for the three months ended March&#160;31, 2023, as compared to $58.5 million for the same period in 2022. As of March&#160;31, 2023 and December&#160;31, 2022, the payable balance due to affiliates was $30.3 million and $31.2 million, respectively. The majority of these transactions related to a distributorship agreement with Daikyo Seiko, LTD ("Daikyo") that allows us to purchase and re-sell Daikyo products. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales to affiliates were $3.3 million for the three months ended March&#160;31, 2023, as compared to $4.0 million for the same period in 2022. As of March&#160;31, 2023 and December&#160;31, 2022, the receivable balance due from affiliates was $2.5 million and $2.2 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Please refer to Note 7, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Affiliated Companies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to the consolidated financial statements in our &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/105770/000010577023000012/wst-20221231.htm#i8148abfe270d4f15aa2ba9319df722dc_58" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;2022 Annual Report&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for additional details.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <us-gaap:EquityMethodInvestments
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81Mi9mcmFnOmRhNjNhOGU3ZmQxZDRlNWFhOGZhNjM1NzY4Mjg1OTM4L3RleHRyZWdpb246ZGE2M2E4ZTdmZDFkNGU1YWE4ZmE2MzU3NjgyODU5MzhfMTcz_054e2fb3-7315-46ca-a922-6653922e08b6"
      unitRef="usd">200900000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81Mi9mcmFnOmRhNjNhOGU3ZmQxZDRlNWFhOGZhNjM1NzY4Mjg1OTM4L3RleHRyZWdpb246ZGE2M2E4ZTdmZDFkNGU1YWE4ZmE2MzU3NjgyODU5MzhfMTgw_60e39e5e-60a8-456a-8ebd-1088bede01f1"
      unitRef="usd">197000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81Mi9mcmFnOmRhNjNhOGU3ZmQxZDRlNWFhOGZhNjM1NzY4Mjg1OTM4L3RleHRyZWdpb246ZGE2M2E4ZTdmZDFkNGU1YWE4ZmE2MzU3NjgyODU5MzhfMzI5_70561c0b-d575-4822-9357-9d363be7ae80"
      unitRef="usd">7900000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81Mi9mcmFnOmRhNjNhOGU3ZmQxZDRlNWFhOGZhNjM1NzY4Mjg1OTM4L3RleHRyZWdpb246ZGE2M2E4ZTdmZDFkNGU1YWE4ZmE2MzU3NjgyODU5MzhfMzM2_ee125f03-2b78-4018-bc08-fe6b2f737691"
      unitRef="usd">7900000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <wst:PurchasesAndRoyaltyPaymentsFromEquityMethodInvestees
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81Mi9mcmFnOmRhNjNhOGU3ZmQxZDRlNWFhOGZhNjM1NzY4Mjg1OTM4L3RleHRyZWdpb246ZGE2M2E4ZTdmZDFkNGU1YWE4ZmE2MzU3NjgyODU5MzhfNzU4_a737ff89-6332-4c0a-9155-c0becbfe2b92"
      unitRef="usd">44200000</wst:PurchasesAndRoyaltyPaymentsFromEquityMethodInvestees>
    <wst:PurchasesAndRoyaltyPaymentsFromEquityMethodInvestees
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81Mi9mcmFnOmRhNjNhOGU3ZmQxZDRlNWFhOGZhNjM1NzY4Mjg1OTM4L3RleHRyZWdpb246ZGE2M2E4ZTdmZDFkNGU1YWE4ZmE2MzU3NjgyODU5MzhfNzkx_5a9b86b2-03ba-426f-9ace-24a3bb169038"
      unitRef="usd">58500000</wst:PurchasesAndRoyaltyPaymentsFromEquityMethodInvestees>
    <us-gaap:DueToAffiliateCurrentAndNoncurrent
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81Mi9mcmFnOmRhNjNhOGU3ZmQxZDRlNWFhOGZhNjM1NzY4Mjg1OTM4L3RleHRyZWdpb246ZGE2M2E4ZTdmZDFkNGU1YWE4ZmE2MzU3NjgyODU5MzhfODgw_5ab30206-e1a8-4101-b91e-8ab231f608e7"
      unitRef="usd">30300000</us-gaap:DueToAffiliateCurrentAndNoncurrent>
    <us-gaap:DueToAffiliateCurrentAndNoncurrent
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81Mi9mcmFnOmRhNjNhOGU3ZmQxZDRlNWFhOGZhNjM1NzY4Mjg1OTM4L3RleHRyZWdpb246ZGE2M2E4ZTdmZDFkNGU1YWE4ZmE2MzU3NjgyODU5MzhfODg3_f99855a7-1c8b-4da5-a982-f373efe4bc87"
      unitRef="usd">31200000</us-gaap:DueToAffiliateCurrentAndNoncurrent>
    <wst:SalesToEquityMethodInvestees
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81Mi9mcmFnOmRhNjNhOGU3ZmQxZDRlNWFhOGZhNjM1NzY4Mjg1OTM4L3RleHRyZWdpb246ZGE2M2E4ZTdmZDFkNGU1YWE4ZmE2MzU3NjgyODU5MzhfMTA3NA_be824b64-7946-453b-be5d-f6377fcb7311"
      unitRef="usd">3300000</wst:SalesToEquityMethodInvestees>
    <wst:SalesToEquityMethodInvestees
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81Mi9mcmFnOmRhNjNhOGU3ZmQxZDRlNWFhOGZhNjM1NzY4Mjg1OTM4L3RleHRyZWdpb246ZGE2M2E4ZTdmZDFkNGU1YWE4ZmE2MzU3NjgyODU5MzhfMTEwNw_b2b27ba2-a8f8-40d6-bf63-ba94146a164a"
      unitRef="usd">4000000.0</wst:SalesToEquityMethodInvestees>
    <us-gaap:DueFromAffiliates
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81Mi9mcmFnOmRhNjNhOGU3ZmQxZDRlNWFhOGZhNjM1NzY4Mjg1OTM4L3RleHRyZWdpb246ZGE2M2E4ZTdmZDFkNGU1YWE4ZmE2MzU3NjgyODU5MzhfMTIwOQ_54f7473c-4a80-48ee-bb58-330e9bd61e53"
      unitRef="usd">2500000</us-gaap:DueFromAffiliates>
    <us-gaap:DueFromAffiliates
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81Mi9mcmFnOmRhNjNhOGU3ZmQxZDRlNWFhOGZhNjM1NzY4Mjg1OTM4L3RleHRyZWdpb246ZGE2M2E4ZTdmZDFkNGU1YWE4ZmE2MzU3NjgyODU5MzhfMTIxNg_7743c64f-dab1-4628-893d-c50cf6f03b3e"
      unitRef="usd">2200000</us-gaap:DueFromAffiliates>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81NS9mcmFnOjQxZTE3ZjI0MTViZjRkM2Q4Mzg1YjllOTA2ZTdkMjJlL3RleHRyZWdpb246NDFlMTdmMjQxNWJmNGQzZDgzODViOWU5MDZlN2QyMmVfMzA1Mg_13115024-ccdf-4c7f-889d-d8a307cba5bc">Debt&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our long-term debt obligations, net of unamortized debt issuance costs and current maturities. The interest rates shown in parentheses are as of March&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.982%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term Loan, due December 31, 2024 (5.87%)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series B notes, due July 5, 2024 (3.82%)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series C notes, due July 5, 2027 (4.02%) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: unamortized debt issuance costs for Term Loan and Series Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Credit Facility&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2023, the borrowing capacity available under our $500.0&#160;million multi-currency revolving credit facility, including outstanding letters of credit of $2.4 million, was $497.6 million. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Term Loan&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2023, we had $82.6 million in borrowings under the Term Loan, of which $2.2 million was classified as current and $80.4 million was classified as long-term. Please refer to Note 9, &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i7bf87d07bb544f48851c48374130181b_58" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Derivative Financial Instruments&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for a discussion of the foreign currency hedge associated with the Term Loan.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the financial covenants in our debt agreements, we are required to maintain established interest coverage ratios and to not exceed established leverage ratios. In addition, the agreements contain other customary covenants, none of which we consider restrictive to our operations. At March&#160;31, 2023, we were in compliance with all of our debt covenants.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Please refer to Note 10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to the consolidated financial statements in our &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/105770/000010577023000012/wst-20221231.htm#i8148abfe270d4f15aa2ba9319df722dc_58" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;2022 Annual Report&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for additional details regarding our debt agreements.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81NS9mcmFnOjQxZTE3ZjI0MTViZjRkM2Q4Mzg1YjllOTA2ZTdkMjJlL3RleHRyZWdpb246NDFlMTdmMjQxNWJmNGQzZDgzODViOWU5MDZlN2QyMmVfMzA2OA_797d8870-4c2b-4573-88dd-445ad740aff2">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our long-term debt obligations, net of unamortized debt issuance costs and current maturities. The interest rates shown in parentheses are as of March&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.982%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term Loan, due December 31, 2024 (5.87%)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series B notes, due July 5, 2024 (3.82%)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series C notes, due July 5, 2027 (4.02%) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: unamortized debt issuance costs for Term Loan and Series Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iecf3cc3f4a2e4356986ecea0d53b720d_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81NS9mcmFnOjQxZTE3ZjI0MTViZjRkM2Q4Mzg1YjllOTA2ZTdkMjJlL3RhYmxlOjM3NzAxY2ExYWFiMTRmNWJhNzc1ZTcxNGI5YmYwZjdmL3RhYmxlcmFuZ2U6Mzc3MDFjYTFhYWIxNGY1YmE3NzVlNzE0YjliZjBmN2ZfNS0wLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOjY3YTcyOGQ0N2E5YzQ0NDJiN2Q3MjRjZjQ5MmI0ZGQ5XzM4_a8a55958-599b-4bcd-85a3-d73875b2efd5"
      unitRef="number">0.0587</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iecf3cc3f4a2e4356986ecea0d53b720d_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81NS9mcmFnOjQxZTE3ZjI0MTViZjRkM2Q4Mzg1YjllOTA2ZTdkMjJlL3RhYmxlOjM3NzAxY2ExYWFiMTRmNWJhNzc1ZTcxNGI5YmYwZjdmL3RhYmxlcmFuZ2U6Mzc3MDFjYTFhYWIxNGY1YmE3NzVlNzE0YjliZjBmN2ZfNS0xLTEtMS04Mjc4Mg_686fd137-cfd9-4ce7-bb69-d0a2bad283f0"
      unitRef="usd">82600000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i820fab327f6443ae978dfa28318d48f4_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81NS9mcmFnOjQxZTE3ZjI0MTViZjRkM2Q4Mzg1YjllOTA2ZTdkMjJlL3RhYmxlOjM3NzAxY2ExYWFiMTRmNWJhNzc1ZTcxNGI5YmYwZjdmL3RhYmxlcmFuZ2U6Mzc3MDFjYTFhYWIxNGY1YmE3NzVlNzE0YjliZjBmN2ZfNS0zLTEtMS04Mjc4Mg_40bcc328-dce5-4d26-adfc-35365fed3b2a"
      unitRef="usd">83200000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id38fa53f753e49438df00d22e5b777e6_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81NS9mcmFnOjQxZTE3ZjI0MTViZjRkM2Q4Mzg1YjllOTA2ZTdkMjJlL3RhYmxlOjM3NzAxY2ExYWFiMTRmNWJhNzc1ZTcxNGI5YmYwZjdmL3RhYmxlcmFuZ2U6Mzc3MDFjYTFhYWIxNGY1YmE3NzVlNzE0YjliZjBmN2ZfNy0wLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOjUxMGI0YzYyZTNkODRiNTBhNmU0ZWMyMWEyNGUzOTA5XzM4_b159483e-9f07-440d-8c22-84f08788f85c"
      unitRef="number">0.0382</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id38fa53f753e49438df00d22e5b777e6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81NS9mcmFnOjQxZTE3ZjI0MTViZjRkM2Q4Mzg1YjllOTA2ZTdkMjJlL3RhYmxlOjM3NzAxY2ExYWFiMTRmNWJhNzc1ZTcxNGI5YmYwZjdmL3RhYmxlcmFuZ2U6Mzc3MDFjYTFhYWIxNGY1YmE3NzVlNzE0YjliZjBmN2ZfNy0xLTEtMS04Mjc4Mg_dcca88b2-4d8e-453d-98dd-74df43cc1431"
      unitRef="usd">53000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i9a8404bd9ab74326a8394ec3e7f36919_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81NS9mcmFnOjQxZTE3ZjI0MTViZjRkM2Q4Mzg1YjllOTA2ZTdkMjJlL3RhYmxlOjM3NzAxY2ExYWFiMTRmNWJhNzc1ZTcxNGI5YmYwZjdmL3RhYmxlcmFuZ2U6Mzc3MDFjYTFhYWIxNGY1YmE3NzVlNzE0YjliZjBmN2ZfNy0zLTEtMS04Mjc4Mg_6584cc31-98ee-4971-ab48-0ef95f10e265"
      unitRef="usd">53000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i85a6072962d04208ae531a2b2fbfef0e_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81NS9mcmFnOjQxZTE3ZjI0MTViZjRkM2Q4Mzg1YjllOTA2ZTdkMjJlL3RhYmxlOjM3NzAxY2ExYWFiMTRmNWJhNzc1ZTcxNGI5YmYwZjdmL3RhYmxlcmFuZ2U6Mzc3MDFjYTFhYWIxNGY1YmE3NzVlNzE0YjliZjBmN2ZfOC0wLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOjczNWQ3Y2ZiNGVhMDRlNmFhNjFhMDg5MWExNjYwZjA3XzM4_c4bec8bd-584f-4322-af76-ec7f240be2c5"
      unitRef="number">0.0402</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i85a6072962d04208ae531a2b2fbfef0e_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81NS9mcmFnOjQxZTE3ZjI0MTViZjRkM2Q4Mzg1YjllOTA2ZTdkMjJlL3RhYmxlOjM3NzAxY2ExYWFiMTRmNWJhNzc1ZTcxNGI5YmYwZjdmL3RhYmxlcmFuZ2U6Mzc3MDFjYTFhYWIxNGY1YmE3NzVlNzE0YjliZjBmN2ZfOC0xLTEtMS04Mjc4Mg_2e3ab626-ba2b-473f-b52c-6d19ee4adb4e"
      unitRef="usd">73000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ib2b66dd4040640348f96693d6e7be1d5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81NS9mcmFnOjQxZTE3ZjI0MTViZjRkM2Q4Mzg1YjllOTA2ZTdkMjJlL3RhYmxlOjM3NzAxY2ExYWFiMTRmNWJhNzc1ZTcxNGI5YmYwZjdmL3RhYmxlcmFuZ2U6Mzc3MDFjYTFhYWIxNGY1YmE3NzVlNzE0YjliZjBmN2ZfOC0zLTEtMS04Mjc4Mg_774763e2-7370-4c12-9227-4e4c83dc64b7"
      unitRef="usd">73000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81NS9mcmFnOjQxZTE3ZjI0MTViZjRkM2Q4Mzg1YjllOTA2ZTdkMjJlL3RhYmxlOjM3NzAxY2ExYWFiMTRmNWJhNzc1ZTcxNGI5YmYwZjdmL3RhYmxlcmFuZ2U6Mzc3MDFjYTFhYWIxNGY1YmE3NzVlNzE0YjliZjBmN2ZfOS0xLTEtMS04Mjc4Mg_4a2d1c02-491f-48a2-b7c8-d44104f4da7c"
      unitRef="usd">208600000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81NS9mcmFnOjQxZTE3ZjI0MTViZjRkM2Q4Mzg1YjllOTA2ZTdkMjJlL3RhYmxlOjM3NzAxY2ExYWFiMTRmNWJhNzc1ZTcxNGI5YmYwZjdmL3RhYmxlcmFuZ2U6Mzc3MDFjYTFhYWIxNGY1YmE3NzVlNzE0YjliZjBmN2ZfOS0zLTEtMS04Mjc4Mg_05fd7139-35b8-415d-8ec5-fe66257015f4"
      unitRef="usd">209200000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81NS9mcmFnOjQxZTE3ZjI0MTViZjRkM2Q4Mzg1YjllOTA2ZTdkMjJlL3RhYmxlOjM3NzAxY2ExYWFiMTRmNWJhNzc1ZTcxNGI5YmYwZjdmL3RhYmxlcmFuZ2U6Mzc3MDFjYTFhYWIxNGY1YmE3NzVlNzE0YjliZjBmN2ZfMTAtMS0xLTEtODI3ODI_12badf4a-453b-4705-9e4d-1f730839c49d"
      unitRef="usd">300000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81NS9mcmFnOjQxZTE3ZjI0MTViZjRkM2Q4Mzg1YjllOTA2ZTdkMjJlL3RhYmxlOjM3NzAxY2ExYWFiMTRmNWJhNzc1ZTcxNGI5YmYwZjdmL3RhYmxlcmFuZ2U6Mzc3MDFjYTFhYWIxNGY1YmE3NzVlNzE0YjliZjBmN2ZfMTAtMy0xLTEtODI3ODI_03cb67a0-fb84-444a-bd8b-dae364213c29"
      unitRef="usd">300000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:LongTermDebt
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81NS9mcmFnOjQxZTE3ZjI0MTViZjRkM2Q4Mzg1YjllOTA2ZTdkMjJlL3RhYmxlOjM3NzAxY2ExYWFiMTRmNWJhNzc1ZTcxNGI5YmYwZjdmL3RhYmxlcmFuZ2U6Mzc3MDFjYTFhYWIxNGY1YmE3NzVlNzE0YjliZjBmN2ZfMTEtMS0xLTEtODI3ODI_04704b9c-ef7e-4469-85ca-66ca455710ea"
      unitRef="usd">208300000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81NS9mcmFnOjQxZTE3ZjI0MTViZjRkM2Q4Mzg1YjllOTA2ZTdkMjJlL3RhYmxlOjM3NzAxY2ExYWFiMTRmNWJhNzc1ZTcxNGI5YmYwZjdmL3RhYmxlcmFuZ2U6Mzc3MDFjYTFhYWIxNGY1YmE3NzVlNzE0YjliZjBmN2ZfMTEtMy0xLTEtODI3ODI_3ced6187-86a5-437e-9898-22a7e5b1d0f5"
      unitRef="usd">208900000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81NS9mcmFnOjQxZTE3ZjI0MTViZjRkM2Q4Mzg1YjllOTA2ZTdkMjJlL3RhYmxlOjM3NzAxY2ExYWFiMTRmNWJhNzc1ZTcxNGI5YmYwZjdmL3RhYmxlcmFuZ2U6Mzc3MDFjYTFhYWIxNGY1YmE3NzVlNzE0YjliZjBmN2ZfMTItMS0xLTEtODI3ODI_c0e8a502-fa0c-403a-87d1-f8a45f15a0fd"
      unitRef="usd">2200000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81NS9mcmFnOjQxZTE3ZjI0MTViZjRkM2Q4Mzg1YjllOTA2ZTdkMjJlL3RhYmxlOjM3NzAxY2ExYWFiMTRmNWJhNzc1ZTcxNGI5YmYwZjdmL3RhYmxlcmFuZ2U6Mzc3MDFjYTFhYWIxNGY1YmE3NzVlNzE0YjliZjBmN2ZfMTItMy0xLTEtODI3ODI_1fa3895a-eb18-40b3-920e-9048fc89605d"
      unitRef="usd">2200000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81NS9mcmFnOjQxZTE3ZjI0MTViZjRkM2Q4Mzg1YjllOTA2ZTdkMjJlL3RhYmxlOjM3NzAxY2ExYWFiMTRmNWJhNzc1ZTcxNGI5YmYwZjdmL3RhYmxlcmFuZ2U6Mzc3MDFjYTFhYWIxNGY1YmE3NzVlNzE0YjliZjBmN2ZfMTMtMS0xLTEtODI3ODI_f504f4f6-320c-443d-b4d3-63a3047f97bd"
      unitRef="usd">206100000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81NS9mcmFnOjQxZTE3ZjI0MTViZjRkM2Q4Mzg1YjllOTA2ZTdkMjJlL3RhYmxlOjM3NzAxY2ExYWFiMTRmNWJhNzc1ZTcxNGI5YmYwZjdmL3RhYmxlcmFuZ2U6Mzc3MDFjYTFhYWIxNGY1YmE3NzVlNzE0YjliZjBmN2ZfMTMtMy0xLTEtODI3ODI_747e787c-7b7b-4fd1-a0f8-434bc42e449b"
      unitRef="usd">206700000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity
      contextRef="id48d782f5bfb4fe6a7905309804dadd4_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81NS9mcmFnOjQxZTE3ZjI0MTViZjRkM2Q4Mzg1YjllOTA2ZTdkMjJlL3RleHRyZWdpb246NDFlMTdmMjQxNWJmNGQzZDgzODViOWU5MDZlN2QyMmVfMjUxOA_7b77db55-3c21-416d-8fbc-695d904a673b"
      unitRef="usd">500000000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <us-gaap:LineOfCredit
      contextRef="i98cb2924a74a4bcbb3d3520ea87d52f0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81NS9mcmFnOjQxZTE3ZjI0MTViZjRkM2Q4Mzg1YjllOTA2ZTdkMjJlL3RleHRyZWdpb246NDFlMTdmMjQxNWJmNGQzZDgzODViOWU5MDZlN2QyMmVfMjYwNg_7f286c43-2827-4a76-9ee2-252cef7c75ac"
      unitRef="usd">2400000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="id48d782f5bfb4fe6a7905309804dadd4_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81NS9mcmFnOjQxZTE3ZjI0MTViZjRkM2Q4Mzg1YjllOTA2ZTdkMjJlL3RleHRyZWdpb246NDFlMTdmMjQxNWJmNGQzZDgzODViOWU5MDZlN2QyMmVfMjYxNA_74465786-6bac-4742-a7e4-d8b9cab281b0"
      unitRef="usd">497600000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iecf3cc3f4a2e4356986ecea0d53b720d_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81NS9mcmFnOjQxZTE3ZjI0MTViZjRkM2Q4Mzg1YjllOTA2ZTdkMjJlL3RleHRyZWdpb246NDFlMTdmMjQxNWJmNGQzZDgzODViOWU5MDZlN2QyMmVfMjY1Mw_df2dbd51-4df9-427b-8fde-fbc8b3b3f982"
      unitRef="usd">82600000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtCurrent
      contextRef="iecf3cc3f4a2e4356986ecea0d53b720d_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81NS9mcmFnOjQxZTE3ZjI0MTViZjRkM2Q4Mzg1YjllOTA2ZTdkMjJlL3RleHRyZWdpb246NDFlMTdmMjQxNWJmNGQzZDgzODViOWU5MDZlN2QyMmVfMjcwMA_91cb1d27-7f34-4366-9630-6bb045967067"
      unitRef="usd">2200000</us-gaap:DebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="iecf3cc3f4a2e4356986ecea0d53b720d_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81NS9mcmFnOjQxZTE3ZjI0MTViZjRkM2Q4Mzg1YjllOTA2ZTdkMjJlL3RleHRyZWdpb246NDFlMTdmMjQxNWJmNGQzZDgzODViOWU5MDZlN2QyMmVfMjczMw_a34a79bb-582f-4fe9-9994-d7aae2bac731"
      unitRef="usd">80400000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RleHRyZWdpb246YjI0ZGFjYzg3YWNmNDkzNTk3NDEwOWFhZGYxY2I0ZmNfNDA2Mw_632b86dc-1066-419e-b429-e14738f9df9f">Derivative Financial Instruments&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our ongoing business operations expose us to various risks, such as fluctuating interest rates, foreign currency exchange rates and increasing commodity prices. To manage these market risks, we periodically enter into derivative financial instruments, such as interest rate swaps, options and foreign exchange contracts for periods consistent with, and for notional amounts equal to or less than, the related underlying exposures. We do not purchase or hold any derivative financial instruments for investment or trading purposes. All derivatives are recorded in our condensed consolidated balance sheet at fair value.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Foreign Exchange Rate Risk&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into forward exchange contracts, designated as fair value hedges, to manage our exposure to fluctuating foreign exchange rates on cross-currency intercompany loans. As of both March&#160;31, 2023 and December&#160;31, 2022, the total amount of these forward exchange contracts was Singapore Dollar (&#x201c;SGD&#x201d;) 601.5 million and $13.4 million.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, we have entered into several foreign currency contracts, designated as cash flow hedges, for periods of up to eighteen months, intended to hedge the currency risk associated with a portion of our forecasted transactions denominated in foreign currencies. As of March&#160;31, 2023, we had outstanding foreign currency contracts to purchase and sell certain pairs of currencies, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.421%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.459%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sell&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;USD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;EUR&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;EUR&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Yen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,629.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;SGD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, we entered into a cross-currency swap for $90&#160;million, which we designated as a hedge of our net investment in Daikyo. As of March&#160;31, 2023, the notional amount of the cross-currency swap was &#xa5;9.0&#160;billion ($82.6&#160;million) and the swap termination date is December 31, 2024. Under the cross-currency swap, we receive floating interest rate payments based on USD compounded SOFR plus a margin, in return for paying floating interest rate payments based on Japanese Yen (&#x201c;Yen&#x201d;) Tokyo Overnight Average Rate ("TONAR") plus a margin. In addition, we receive periodic fixed payments of USD in return for paying fixed principal payments of Yen.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Commodity Price Risk&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Many of our proprietary products are made from synthetic elastomers, which are derived from the petroleum refining process. We purchase the majority of our elastomers via long-term supply contracts, some of which contain clauses that provide for surcharges related to fluctuations in crude oil prices. The following economic hedges did not qualify for hedge accounting treatment since they did not meet the highly effective requirement at inception.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From November 2017 through March 2023, we purchased several series of call options for a total of 903,932 barrels of crude oil to mitigate our exposure to such oil-based surcharges and protect operating cash flows with regards to a portion of our forecasted elastomer purchases. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, we had outstanding contracts to purchase 250,742 barrels of crude oil from March 2023 to December 2024, at a weighted-average strike price of 104.21 per barrel.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Effects of Derivative Instruments on Financial Position and Results of Operations&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Please refer to Note 10, &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i7bf87d07bb544f48851c48374130181b_61" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Fair Value Measurements&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for the balance sheet location and fair values of our derivative instruments as of March&#160;31, 2023 and December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the effects of derivative instruments designated as fair value hedges on the condensed consolidated statements of income:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.662%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.062%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount of Gain (Loss) Recognized in Income for the&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Location on Statement of Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair Value Hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedged item (intercompany loan)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense (income)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative designated as hedging instrument &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense (income)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount excluded from effectiveness testing&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense (income)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize in earnings the initial value of forward point components on a straight-line basis over the life of the fair value hedge. The amounts recognized in earnings, pre-tax, for forward point components for the three months ended March&#160;31, 2023 and 2022 were $1.2 million and $0.8 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the effects of derivative instruments designated as fair value, cash flow, and net investment hedges on other comprehensive income (&#x201c;OCI&#x201d;) and earnings, net of tax:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.867%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.867%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:44pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount of (Loss) Gain Recognized in OCI for the&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount of (Gain) Loss Reclassified from Accumulated OCI into Income for the&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Location of (Gain) Loss Reclassified from Accumulated OCI into Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair Value Hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency hedge contracts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense (income)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash Flow Hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency hedge contracts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency hedge contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of goods and services sold&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward treasury locks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net Investment Hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense (income)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to the above table which summarizes the effects of derivative instruments designated as fair value hedges within the other expense (income) line in our condensed consolidated statements of income for the three months ended March&#160;31, 2023 and 2022. The following table summarizes the effects of derivative instruments designated as cash flow and net investment hedges by line item in our condensed consolidated statements of income:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of goods and services sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the effects of derivative instruments not designated as hedges on the condensed consolidated statements of income:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount of Gain (Loss) Recognized in Income for the&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Location on Statement of Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commodity call options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense (income) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2023 and 2022, there was no material ineffectiveness related to our hedges.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:DerivativeNotionalAmount
      contextRef="if46b82c9c68b443482333077a49f48e9_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RleHRyZWdpb246YjI0ZGFjYzg3YWNmNDkzNTk3NDEwOWFhZGYxY2I0ZmNfOTgx_8558b8ea-902d-4da5-90c3-2c61a1b96f71"
      unitRef="sgd">601500000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i82f3bc098630498582401da701e7b138_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RleHRyZWdpb246YjI0ZGFjYzg3YWNmNDkzNTk3NDEwOWFhZGYxY2I0ZmNfOTgx_c09d2157-0f6d-42aa-b67b-4a88dbd44823"
      unitRef="sgd">601500000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i09563dd08c64439c84993944fccfc6db_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RleHRyZWdpb246YjI0ZGFjYzg3YWNmNDkzNTk3NDEwOWFhZGYxY2I0ZmNfOTg4_3bf245c8-1dfd-4d9e-93d4-0128e8b7d745"
      unitRef="usd">13400000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ifdb1000004bd47589080d94726e76022_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RleHRyZWdpb246YjI0ZGFjYzg3YWNmNDkzNTk3NDEwOWFhZGYxY2I0ZmNfOTg4_d45f5f4a-4cb3-4c93-88b1-4e834c88b98b"
      unitRef="usd">13400000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeTermOfContract
      contextRef="i5f005fe228a0408495ca4180dcc39feb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RleHRyZWdpb246YjI0ZGFjYzg3YWNmNDkzNTk3NDEwOWFhZGYxY2I0ZmNfMTExNg_9889f86e-1405-474f-a687-3308ef278247">P18M</us-gaap:DerivativeTermOfContract>
    <us-gaap:ScheduleOfDerivativeInstrumentsTextBlock
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RleHRyZWdpb246YjI0ZGFjYzg3YWNmNDkzNTk3NDEwOWFhZGYxY2I0ZmNfNDA2OA_c494e45c-2ac5-4969-b1f2-262510992814">As of March&#160;31, 2023, we had outstanding foreign currency contracts to purchase and sell certain pairs of currencies, as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.421%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.459%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sell&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;USD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;EUR&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;EUR&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Yen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,629.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;SGD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDerivativeInstrumentsTextBlock>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i9728ffcf312e4ac4bdb6aae4a7b23a44_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOmIzOGJhOGRkYTc5YjRlY2Q4M2UzYmM0OWM3NmM0NTg0L3RhYmxlcmFuZ2U6YjM4YmE4ZGRhNzliNGVjZDgzZTNiYzQ5Yzc2YzQ1ODRfMi0xLTEtMS04Mjc4Mg_8655445a-c2e8-4575-9632-2b0208975af7"
      unitRef="eur">8200000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="if6ea04af1eff40db88226330d1e25200_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOmIzOGJhOGRkYTc5YjRlY2Q4M2UzYmM0OWM3NmM0NTg0L3RhYmxlcmFuZ2U6YjM4YmE4ZGRhNzliNGVjZDgzZTNiYzQ5Yzc2YzQ1ODRfMi0zLTEtMS04Mjc4Mg_d145f952-c688-4924-9232-f60b7e39fab2"
      unitRef="usd">8500000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="if6ea04af1eff40db88226330d1e25200_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOmIzOGJhOGRkYTc5YjRlY2Q4M2UzYmM0OWM3NmM0NTg0L3RhYmxlcmFuZ2U6YjM4YmE4ZGRhNzliNGVjZDgzZTNiYzQ5Yzc2YzQ1ODRfMi00LTEtMS04Mjc4Mg_c9c0f48e-f129-4f10-b6ea-b7ecccc39865"
      unitRef="eur">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="icdd3e55c2a7a4212801e02cabd651cfc_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOmIzOGJhOGRkYTc5YjRlY2Q4M2UzYmM0OWM3NmM0NTg0L3RhYmxlcmFuZ2U6YjM4YmE4ZGRhNzliNGVjZDgzZTNiYzQ5Yzc2YzQ1ODRfMy0xLTEtMS04Mjc4Mg_bfad8536-75e9-4111-8cab-3b0f8d41973c"
      unitRef="jpy">5629600000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i63dca94e686c450eb00428ac82177d9d_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOmIzOGJhOGRkYTc5YjRlY2Q4M2UzYmM0OWM3NmM0NTg0L3RhYmxlcmFuZ2U6YjM4YmE4ZGRhNzliNGVjZDgzZTNiYzQ5Yzc2YzQ1ODRfMy0zLTEtMS04Mjc4Mg_ba84a109-5027-4dee-a996-0ea7062cd837"
      unitRef="usd">30200000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i63dca94e686c450eb00428ac82177d9d_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOmIzOGJhOGRkYTc5YjRlY2Q4M2UzYmM0OWM3NmM0NTg0L3RhYmxlcmFuZ2U6YjM4YmE4ZGRhNzliNGVjZDgzZTNiYzQ5Yzc2YzQ1ODRfMy00LTEtMS04Mjc4Mg_da5585de-49df-44f3-99e3-da28ec7bde69"
      unitRef="eur">12500000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="if2a16112236a46548494c875fa25e7c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOmIzOGJhOGRkYTc5YjRlY2Q4M2UzYmM0OWM3NmM0NTg0L3RhYmxlcmFuZ2U6YjM4YmE4ZGRhNzliNGVjZDgzZTNiYzQ5Yzc2YzQ1ODRfNC0xLTEtMS04Mjc4Mg_e7d4fd7b-69a4-45c3-89c5-3a9328b30f6d"
      unitRef="sgd">67900000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i049f03d104874040b8a9e20dca208dd8_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOmIzOGJhOGRkYTc5YjRlY2Q4M2UzYmM0OWM3NmM0NTg0L3RhYmxlcmFuZ2U6YjM4YmE4ZGRhNzliNGVjZDgzZTNiYzQ5Yzc2YzQ1ODRfNC0zLTEtMS04Mjc4Mg_18e7c603-ae47-4b85-a19a-b8522046b11b"
      unitRef="usd">24900000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i049f03d104874040b8a9e20dca208dd8_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOmIzOGJhOGRkYTc5YjRlY2Q4M2UzYmM0OWM3NmM0NTg0L3RhYmxlcmFuZ2U6YjM4YmE4ZGRhNzliNGVjZDgzZTNiYzQ5Yzc2YzQ1ODRfNC00LTEtMS04Mjc4Mg_3bc2e30f-c02c-4486-b371-717e36cc0c29"
      unitRef="eur">23800000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i86cd8c4c0adb4f0bb284e66a3b57f3be_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RleHRyZWdpb246YjI0ZGFjYzg3YWNmNDkzNTk3NDEwOWFhZGYxY2I0ZmNfMTQyOQ_f935624c-e26c-413d-98a8-edc4b7326fb1"
      unitRef="usd">90000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i949b0ebb4cdd40e8a2bfd21565e1e3e0_I20230331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RleHRyZWdpb246YjI0ZGFjYzg3YWNmNDkzNTk3NDEwOWFhZGYxY2I0ZmNfNzE0NjgyNTU4NTA1MA_cb2ec46e-6327-45e7-a056-9b85e3567111"
      unitRef="jpy">9000000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i949b0ebb4cdd40e8a2bfd21565e1e3e0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RleHRyZWdpb246YjI0ZGFjYzg3YWNmNDkzNTk3NDEwOWFhZGYxY2I0ZmNfNzE0NjgyNTU4NTA1OQ_008bd9f9-ccf4-4dea-9378-c10d1402a262"
      unitRef="usd">82600000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNonmonetaryNotionalAmountVolume
      contextRef="i3dbbddaad3d544529fc30c5aa103c052_D20171101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RleHRyZWdpb246YjI0ZGFjYzg3YWNmNDkzNTk3NDEwOWFhZGYxY2I0ZmNfMjQzOA_7cc5289e-01d5-417a-881b-c0d963b9e423"
      unitRef="bbl">903932</us-gaap:DerivativeNonmonetaryNotionalAmountVolume>
    <us-gaap:DerivativeNonmonetaryNotionalAmountVolume
      contextRef="i0a775eaad7ab4fb2b9ed736aefbf5955_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RleHRyZWdpb246YjI0ZGFjYzg3YWNmNDkzNTk3NDEwOWFhZGYxY2I0ZmNfNzE0NjgyNTU4NTAwMw_c97eb90e-3511-472e-a601-ef1868c709d3"
      unitRef="bbl">250742</us-gaap:DerivativeNonmonetaryNotionalAmountVolume>
    <us-gaap:DerivativeAveragePriceRiskOptionStrikePrice
      contextRef="i024bb3a09a8d4ff89a1465c610f13094_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RleHRyZWdpb246YjI0ZGFjYzg3YWNmNDkzNTk3NDEwOWFhZGYxY2I0ZmNfNzE0NjgyNTU4NTAyOQ_e7593a19-79a9-4bb9-bfbe-3b603198a333"
      unitRef="usdPerBbl">104.21</us-gaap:DerivativeAveragePriceRiskOptionStrikePrice>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RleHRyZWdpb246YjI0ZGFjYzg3YWNmNDkzNTk3NDEwOWFhZGYxY2I0ZmNfNDA1NA_66165338-9626-4f0f-a7c7-8c38a56a5fdb">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the effects of derivative instruments designated as fair value hedges on the condensed consolidated statements of income:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.662%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.062%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount of Gain (Loss) Recognized in Income for the&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Location on Statement of Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair Value Hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hedged item (intercompany loan)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense (income)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative designated as hedging instrument &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense (income)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount excluded from effectiveness testing&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense (income)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the effects of derivative instruments designated as fair value, cash flow, and net investment hedges on other comprehensive income (&#x201c;OCI&#x201d;) and earnings, net of tax:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.867%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.867%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:44pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount of (Loss) Gain Recognized in OCI for the&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount of (Gain) Loss Reclassified from Accumulated OCI into Income for the&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Location of (Gain) Loss Reclassified from Accumulated OCI into Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair Value Hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency hedge contracts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense (income)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash Flow Hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency hedge contracts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency hedge contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of goods and services sold&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward treasury locks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net Investment Hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense (income)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to the above table which summarizes the effects of derivative instruments designated as fair value hedges within the other expense (income) line in our condensed consolidated statements of income for the three months ended March&#160;31, 2023 and 2022. The following table summarizes the effects of derivative instruments designated as cash flow and net investment hedges by line item in our condensed consolidated statements of income:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of goods and services sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="ic2b6751140ae4a8a905c7349d2d7fab8_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOmRjNDhhZDAzZWE5MjQ5NGViODRiZWUyNjM2ZWExODg5L3RhYmxlcmFuZ2U6ZGM0OGFkMDNlYTkyNDk0ZWI4NGJlZTI2MzZlYTE4ODlfNC0xLTEtMS04Mjc4Mg_3113ef85-fcb1-4cb5-9023-ae5d4879121c"
      unitRef="usd">-2500000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="i512c05fc14444680a4b01af74b3b7f07_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOmRjNDhhZDAzZWE5MjQ5NGViODRiZWUyNjM2ZWExODg5L3RhYmxlcmFuZ2U6ZGM0OGFkMDNlYTkyNDk0ZWI4NGJlZTI2MzZlYTE4ODlfNC0zLTEtMS04Mjc4Mg_4019e1f6-7d7d-4a45-a88f-791ad78a15b8"
      unitRef="usd">9600000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="ic2b6751140ae4a8a905c7349d2d7fab8_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOmRjNDhhZDAzZWE5MjQ5NGViODRiZWUyNjM2ZWExODg5L3RhYmxlcmFuZ2U6ZGM0OGFkMDNlYTkyNDk0ZWI4NGJlZTI2MzZlYTE4ODlfNS0xLTEtMS04Mjc4Mg_f7a7ccbd-f75f-42a7-af76-22f4447d4087"
      unitRef="usd">2500000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i512c05fc14444680a4b01af74b3b7f07_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOmRjNDhhZDAzZWE5MjQ5NGViODRiZWUyNjM2ZWExODg5L3RhYmxlcmFuZ2U6ZGM0OGFkMDNlYTkyNDk0ZWI4NGJlZTI2MzZlYTE4ODlfNS0zLTEtMS04Mjc4Mg_e0fd7d49-fdf4-43e6-8998-8fd2742e3194"
      unitRef="usd">-9600000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet
      contextRef="ic2b6751140ae4a8a905c7349d2d7fab8_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOmRjNDhhZDAzZWE5MjQ5NGViODRiZWUyNjM2ZWExODg5L3RhYmxlcmFuZ2U6ZGM0OGFkMDNlYTkyNDk0ZWI4NGJlZTI2MzZlYTE4ODlfNi0xLTEtMS04Mjc4Mg_63c5f7f7-584f-4d53-9ba6-15caf916a258"
      unitRef="usd">-1200000</us-gaap:GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet>
    <us-gaap:GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet
      contextRef="i512c05fc14444680a4b01af74b3b7f07_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOmRjNDhhZDAzZWE5MjQ5NGViODRiZWUyNjM2ZWExODg5L3RhYmxlcmFuZ2U6ZGM0OGFkMDNlYTkyNDk0ZWI4NGJlZTI2MzZlYTE4ODlfNi0zLTEtMS04Mjc4Mg_0defc768-0a7c-4c97-81bf-02c8e917dc51"
      unitRef="usd">-800000</us-gaap:GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet>
    <us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOmRjNDhhZDAzZWE5MjQ5NGViODRiZWUyNjM2ZWExODg5L3RhYmxlcmFuZ2U6ZGM0OGFkMDNlYTkyNDk0ZWI4NGJlZTI2MzZlYTE4ODlfNy0xLTEtMS04Mjc4Mg_29d80df4-fe1b-49cd-9790-f4b33fe4c5ca"
      unitRef="usd">-1200000</us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings>
    <us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOmRjNDhhZDAzZWE5MjQ5NGViODRiZWUyNjM2ZWExODg5L3RhYmxlcmFuZ2U6ZGM0OGFkMDNlYTkyNDk0ZWI4NGJlZTI2MzZlYTE4ODlfNy0zLTEtMS04Mjc4Mg_0a856096-32d6-4dd5-a66f-32fa23bed914"
      unitRef="usd">-800000</us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="ie403ae300c3c4982a693b55e66f3705f_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RleHRyZWdpb246YjI0ZGFjYzg3YWNmNDkzNTk3NDEwOWFhZGYxY2I0ZmNfMzM3OA_40ccf493-a989-45cf-a22a-ef1eab6fa100"
      unitRef="usd">1200000</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="ifeb72d8b516e4addb0181e1f85261c85_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RleHRyZWdpb246YjI0ZGFjYzg3YWNmNDkzNTk3NDEwOWFhZGYxY2I0ZmNfMzM4Ng_f5359b44-f1ab-4355-9f25-1edf9fbc6640"
      unitRef="usd">800000</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i0ed146d13e5f4eb2a012abb762cc10f0_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfNC0xLTEtMS04Mjc4Mg_08f58a79-d3f1-4fb0-9f39-98d0a948c2b5"
      unitRef="usd">200000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i88d56264e84240aaa4c3afb58fcf626e_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfNC0zLTEtMS04Mjc4Mg_503448c0-730c-4648-accf-2010f55fe6b6"
      unitRef="usd">-1200000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="i0ed146d13e5f4eb2a012abb762cc10f0_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfNC01LTEtMS04Mjc4Mg_b686ed0a-f53b-4c4b-a3ab-b2fd9ad9b3c4"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="i88d56264e84240aaa4c3afb58fcf626e_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfNC03LTEtMS04Mjc4Mg_46846f48-f8ec-4b43-aa42-7d90b1f3ba36"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="ie403ae300c3c4982a693b55e66f3705f_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfNS0xLTEtMS04Mjc4Mg_4642a2bd-b327-4e28-96cf-5dd16f408bdc"
      unitRef="usd">200000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="ifeb72d8b516e4addb0181e1f85261c85_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfNS0zLTEtMS04Mjc4Mg_b6ec0617-6985-4145-b9ee-e117da588486"
      unitRef="usd">-1200000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="ie403ae300c3c4982a693b55e66f3705f_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfNS01LTEtMS04Mjc4Mg_57d07179-d6ca-45b0-a331-2f153df1ef59"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="ifeb72d8b516e4addb0181e1f85261c85_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfNS03LTEtMS04Mjc4Mg_a77bc723-a09f-458f-bf27-d57e6a71941d"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i550fe20240f54b029e378c9bf7ce6f5d_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfNy0xLTEtMS04Mjc4Mg_430a6b4d-9d37-4567-a046-b01072bb52cb"
      unitRef="usd">-100000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i89d9d14f5ff4438cafe884c5b0d2718f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfNy0zLTEtMS04Mjc4Mg_6e7f628e-70bd-4af0-b212-d87070dc9f11"
      unitRef="usd">400000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax
      contextRef="i550fe20240f54b029e378c9bf7ce6f5d_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfNy01LTEtMS04Mjc4Mg_2307b764-09f6-46f1-95a9-198289e70f97"
      unitRef="usd">-700000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax
      contextRef="i89d9d14f5ff4438cafe884c5b0d2718f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfNy03LTEtMS04Mjc4Mg_21e38a62-b133-4f7f-8cd0-6ef011d4e912"
      unitRef="usd">300000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i2aaae598465a460fb7b809258de6e1a5_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfOC0xLTEtMS04Mjc4Mg_dc38dc22-bd92-48ac-903e-a480e2f22c94"
      unitRef="usd">-1000000.0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i3800bdd574354a39a20ce84a4092c158_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfOC0zLTEtMS04Mjc4Mg_ac6398a5-8ddd-4591-a473-a3f5c45a15cc"
      unitRef="usd">-1100000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax
      contextRef="i2aaae598465a460fb7b809258de6e1a5_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfOC01LTEtMS04Mjc4Mg_da97a9e1-9c48-4dc5-a54a-ed61c036cc99"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax
      contextRef="i3800bdd574354a39a20ce84a4092c158_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfOC03LTEtMS04Mjc4Mg_3f704894-43ff-498e-a8e2-8febc5e554f8"
      unitRef="usd">-500000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="ia5c0ef7c3e0147a483d139e864147374_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfMTAtMS0xLTEtODI3ODI_780568d9-e5ed-464e-a6c0-2239757b0f1a"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i5d9e67f88dce43dd8855ccc2dbc02a22_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfMTAtMy0xLTEtODI3ODI_7d6c6fa2-f5bc-4c38-b4a8-b2ef5a1f67b1"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax
      contextRef="ia5c0ef7c3e0147a483d139e864147374_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfMTAtNS0xLTEtODI3ODI_c8000b26-03df-42cf-a61a-c2ec1abd51a9"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax
      contextRef="i5d9e67f88dce43dd8855ccc2dbc02a22_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfMTAtNy0xLTEtODI3ODI_7b79ac7b-8249-4493-95cb-d240c0b41342"
      unitRef="usd">-100000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i9c377e143e9d48d0ae6ce22294a8da16_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfMTEtMS0xLTEtODI3ODI_f7182003-6501-4420-8871-fceb796e5b37"
      unitRef="usd">-1100000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="ia9abb09cb5a64fc0b766d1350855b2db_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfMTEtMy0xLTEtODI3ODI_a4491a13-4d51-4aed-ad27-cd0daa8afa2e"
      unitRef="usd">-700000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax
      contextRef="i9c377e143e9d48d0ae6ce22294a8da16_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfMTEtNS0xLTEtODI3ODI_3eae0e68-1392-4d42-a82b-eb0e91d04af1"
      unitRef="usd">-700000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax
      contextRef="ia9abb09cb5a64fc0b766d1350855b2db_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfMTEtNy0xLTEtODI3ODI_e3a6e9f1-16b1-489a-b427-73dd0c46a1a7"
      unitRef="usd">-300000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i3e6599d390d0401bba4ccd616c8136c8_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfMTQtMS0xLTEtODI3ODI_38c7d386-adef-4ad8-83b3-c52a7cd0ceda"
      unitRef="usd">1700000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i2f6ac6dfc13d492b82ae66056c8cdfa7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfMTQtMy0xLTEtODI3ODI_0b3235e7-e376-4d8f-b904-5ef230950449"
      unitRef="usd">3300000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="i3e6599d390d0401bba4ccd616c8136c8_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfMTQtNS0xLTEtODI3ODI_752bd04f-a1e2-4dba-936f-8dcf98aac5d0"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="i2f6ac6dfc13d492b82ae66056c8cdfa7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfMTQtNy0xLTEtODI3ODI_248a3ce8-c441-440c-af4a-369a1f50fcaa"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i014caa55d11343438f2b721d5b51d6c8_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfMTUtMS0xLTEtODI3ODI_83808c73-eaff-4746-ae4f-f467b1763158"
      unitRef="usd">1700000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="iab874b4cf2374c38a4cc92deabe110c7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfMTUtMy0xLTEtODI3ODI_38b84cea-36c1-4ca8-80bd-d04ec35ed9ea"
      unitRef="usd">3300000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="i014caa55d11343438f2b721d5b51d6c8_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfMTUtNS0xLTEtODI3ODI_38874bde-ab58-4bec-a998-27d9d35404eb"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="iab874b4cf2374c38a4cc92deabe110c7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOjUwZjdjZjRiZTAyMjQ4MjRhYWFjYjE1NTc0NTk1YTYwL3RhYmxlcmFuZ2U6NTBmN2NmNGJlMDIyNDgyNGFhYWNiMTU1NzQ1OTVhNjBfMTUtNy0xLTEtODI3ODI_8951d6ed-9ffa-4b4d-bd34-1c00d6565954"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="if7f2039fc421408da2abf39c8fa7f3e1_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOmMyMzZhOGE2YmVjZjRhYzE4NzYxNWI2MTg3ZThlMjk0L3RhYmxlcmFuZ2U6YzIzNmE4YTZiZWNmNGFjMTg3NjE1YjYxODdlOGUyOTRfMi0xLTEtMS04Mjc4Mg_08279cc5-4197-49ec-82d6-4d268898aa70"
      unitRef="usd">700000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="if0856bab3e85491fb635e56eda1444de_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOmMyMzZhOGE2YmVjZjRhYzE4NzYxNWI2MTg3ZThlMjk0L3RhYmxlcmFuZ2U6YzIzNmE4YTZiZWNmNGFjMTg3NjE1YjYxODdlOGUyOTRfMi0zLTEtMS04Mjc4Mg_55d38a51-1527-4239-9246-0d3cf3a4fd10"
      unitRef="usd">-300000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="i143f14fa720c48e8a013cf77a4efde31_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOmMyMzZhOGE2YmVjZjRhYzE4NzYxNWI2MTg3ZThlMjk0L3RhYmxlcmFuZ2U6YzIzNmE4YTZiZWNmNGFjMTg3NjE1YjYxODdlOGUyOTRfMy0xLTEtMS04Mjc4Mg_6c4a6a94-5097-438a-8526-13c52ca6f931"
      unitRef="usd">0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="i067a51880daf4861907b0950720d904c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOmMyMzZhOGE2YmVjZjRhYzE4NzYxNWI2MTg3ZThlMjk0L3RhYmxlcmFuZ2U6YzIzNmE4YTZiZWNmNGFjMTg3NjE1YjYxODdlOGUyOTRfMy0zLTEtMS04Mjc4Mg_e9fbdd45-21fa-495c-b532-0dcc9aec5858"
      unitRef="usd">500000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="if5d4916f585e4d42bfc35a013fb84cdf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOmMyMzZhOGE2YmVjZjRhYzE4NzYxNWI2MTg3ZThlMjk0L3RhYmxlcmFuZ2U6YzIzNmE4YTZiZWNmNGFjMTg3NjE1YjYxODdlOGUyOTRfNC0xLTEtMS04Mjc4Mg_e68dda3d-3119-4e31-849c-6ae40d3d7415"
      unitRef="usd">0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="ibca67bb324884ac1a4bd92682b0eef05_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOmMyMzZhOGE2YmVjZjRhYzE4NzYxNWI2MTg3ZThlMjk0L3RhYmxlcmFuZ2U6YzIzNmE4YTZiZWNmNGFjMTg3NjE1YjYxODdlOGUyOTRfNC0zLTEtMS04Mjc4Mg_a38f5c6e-4e68-4492-8441-2c82237a8926"
      unitRef="usd">100000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RleHRyZWdpb246YjI0ZGFjYzg3YWNmNDkzNTk3NDEwOWFhZGYxY2I0ZmNfNDA1NQ_ed78bd07-7b6f-4983-bb2b-9aabf3105363">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the effects of derivative instruments not designated as hedges on the condensed consolidated statements of income:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount of Gain (Loss) Recognized in Income for the&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Location on Statement of Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commodity call options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense (income) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="if7e54bd1a6644a0e8981abafbc1190e8_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOmY0ZmIzMmNiZmViZjQyNThhOTNkMTZjZGNmMTRjNmZlL3RhYmxlcmFuZ2U6ZjRmYjMyY2JmZWJmNDI1OGE5M2QxNmNkY2YxNGM2ZmVfMy0xLTEtMS04Mjc4Mg_358d0443-f4eb-4ad7-9905-49fb1cec7f52"
      unitRef="usd">-600000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i03f4edf339b2471dac58f1cdbd5df6a5_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOmY0ZmIzMmNiZmViZjQyNThhOTNkMTZjZGNmMTRjNmZlL3RhYmxlcmFuZ2U6ZjRmYjMyY2JmZWJmNDI1OGE5M2QxNmNkY2YxNGM2ZmVfMy0zLTEtMS04Mjc4Mg_bcc18245-d3f3-493e-a58e-53e5710a9b97"
      unitRef="usd">2800000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i97dea892f5984be0a0fd08b4eee5ed4a_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOmY0ZmIzMmNiZmViZjQyNThhOTNkMTZjZGNmMTRjNmZlL3RhYmxlcmFuZ2U6ZjRmYjMyY2JmZWJmNDI1OGE5M2QxNmNkY2YxNGM2ZmVfNC0xLTEtMS04Mjc4Mg_43ee6d43-befd-48e9-8446-e55e173f6890"
      unitRef="usd">-600000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i0ee1aea1aac947e59b4311a420cdabdf_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl81OC9mcmFnOmIyNGRhY2M4N2FjZjQ5MzU5NzQxMDlhYWRmMWNiNGZjL3RhYmxlOmY0ZmIzMmNiZmViZjQyNThhOTNkMTZjZGNmMTRjNmZlL3RhYmxlcmFuZ2U6ZjRmYjMyY2JmZWJmNDI1OGE5M2QxNmNkY2YxNGM2ZmVfNC0zLTEtMS04Mjc4Mg_d75650c3-29c2-437b-986f-8cca307bfa62"
      unitRef="usd">2800000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RleHRyZWdpb246M2E2NWEyYmZhYTFiNDU3OGI0ZjgyMDg2MTQ5ZjcyYzNfMzA5Mw_e301c673-2609-41e5-8046-59d86ec26dc0">Fair Value Measurements&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The following fair value hierarchy classifies the inputs to valuation techniques used to measure fair value into one of three levels:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: Unadjusted quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: Unobservable inputs that reflect the reporting entity&#x2019;s own assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the assets and liabilities recorded at fair value on a recurring basis:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.726%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basis of Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commodity call options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.726%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basis of Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commodity call options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred compensation assets are included within other noncurrent assets and are valued using a market approach based on quoted market prices in an active market. The fair value of our foreign currency contracts, included within other current and other noncurrent assets, as well as other current and other long-term liabilities, is valued using an income approach based on quoted forward foreign exchange rates and spot rates at the reporting date. The fair value of the cross-currency swap, included within other noncurrent assets, is valued using a market approach. Please refer to Note 9, &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i7bf87d07bb544f48851c48374130181b_58" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Derivative Financial Instruments&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for further discussion of our derivatives. The fair value of our commodity call options, included within other current and other noncurrent assets, is valued using a market approach. The fair value of the contingent consideration liability, within current and long-term liabilities, related to the SmartDose&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; technology platform (the &#x201c;SmartDose&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; contingent consideration&#x201d;) was initially determined using a probability-weighted income approach, and is revalued at each reporting date or more frequently if circumstances dictate. Changes in the fair value of this obligation are recorded as income or expense within other expense (income) in our condensed consolidated statements of income. The fair value of deferred compensation liabilities is based on quoted prices of the underlying employees&#x2019; investment selections and is included within other long-term liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We believe that the carrying amounts of our cash and cash equivalents and accounts receivable approximate their fair values due to their near-term maturities. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of long-term debt is based on quoted market prices for debt issuances with similar terms and maturities and is classified as Level 2 within the fair value hierarchy. At March&#160;31, 2023, the estimated fair value of long-term debt was $201.2 million compared to a carrying amount of $206.1 million. At December&#160;31, 2022, the estimated fair value of long-term debt was $201.8 million and the carrying amount was $206.7 million.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RleHRyZWdpb246M2E2NWEyYmZhYTFiNDU3OGI0ZjgyMDg2MTQ5ZjcyYzNfMzEwNA_3bbc138a-f7dc-4662-ae1a-f08a42449208">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the assets and liabilities recorded at fair value on a recurring basis:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.726%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basis of Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commodity call options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.726%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basis of Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commodity call options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:DeferredCompensationPlanAssets
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfMy0xLTEtMS04Mjc4Mg_d3781a45-3ba8-44aa-be5b-b9a15f2f33b0"
      unitRef="usd">10400000</us-gaap:DeferredCompensationPlanAssets>
    <us-gaap:DeferredCompensationPlanAssets
      contextRef="i8472e48bf22848d09276489a66c9e03e_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfMy0zLTEtMS04Mjc4Mg_4608f50d-7acd-4d89-ba4b-8c102213c2b8"
      unitRef="usd">10400000</us-gaap:DeferredCompensationPlanAssets>
    <us-gaap:DeferredCompensationPlanAssets
      contextRef="ief4d8a0c3b5e40789e9de34c75e432bf_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfMy01LTEtMS04Mjc4Mg_b75a29c2-38de-4121-84a9-0528b0346be8"
      unitRef="usd">0</us-gaap:DeferredCompensationPlanAssets>
    <us-gaap:DeferredCompensationPlanAssets
      contextRef="i6d4597dfd1ba407789166d3d2ab3a1c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfMy03LTEtMS04Mjc4Mg_6b1b3165-7548-42d9-942e-3c7bbf22c141"
      unitRef="usd">0</us-gaap:DeferredCompensationPlanAssets>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfNC0xLTEtMS04Mjc4Mg_1f5748b8-ce1b-4675-91b7-e9a65decda00"
      unitRef="usd">3500000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i8472e48bf22848d09276489a66c9e03e_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfNC0zLTEtMS04Mjc4Mg_1f05ef8a-261c-4d97-8fb0-e413996613a7"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="ief4d8a0c3b5e40789e9de34c75e432bf_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfNC01LTEtMS04Mjc4Mg_0ced4885-313d-41ee-8704-43cfc3437156"
      unitRef="usd">3500000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i6d4597dfd1ba407789166d3d2ab3a1c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfNC03LTEtMS04Mjc4Mg_c70baf74-8d3f-480b-ae4e-4649bfc93b05"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:DerivativeAssets
      contextRef="id11dee14a78441cf8e6ce24a522f88c7_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfNS0xLTEtMS04Mjc4Mg_f3880ba2-64d5-4515-a3bd-2119c40cc558"
      unitRef="usd">14600000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i74d73afd5be44336b5735abe19adc044_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfNS0zLTEtMS04Mjc4Mg_2c433e32-083a-44fe-afa8-2e34626a314a"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i5f682024fc3e4a7a9e5d718533d31677_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfNS01LTEtMS04Mjc4Mg_e7be2a07-3808-4869-8873-384db56b526c"
      unitRef="usd">14600000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i270bac59038e42c6a92535138d33ff29_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfNS03LTEtMS04Mjc4Mg_62548d37-009f-4b0a-b92e-b3c6d1b4cc88"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ie6fbf09378a54c02a5743d72f4ef99da_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfNi0xLTEtMS04Mjc4Mg_03b3fd53-2c1c-4235-8d45-8289d0ab7a4f"
      unitRef="usd">900000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i11a99f1a1d3645feb7815067a68cd81f_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfNi0zLTEtMS04Mjc4Mg_0f413f41-85e7-436c-a25d-00ad4efa95df"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ia53ac927db8b457d821c732f6d7f4f61_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfNi01LTEtMS04Mjc4Mg_4441152b-cfbd-4a09-8f76-7f7bf684b66a"
      unitRef="usd">900000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i520386d8aa8046dc8b6ed7c632c7c7f9_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfNi03LTEtMS04Mjc4Mg_9cb5f730-32d9-4f50-85e9-80a79e8044d6"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfNy0xLTEtMS04Mjc4Mg_f34eccd8-ec1b-4568-9290-5fd94a2a08d2"
      unitRef="usd">29400000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8472e48bf22848d09276489a66c9e03e_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfNy0zLTEtMS04Mjc4Mg_1d3ff5e0-f8ea-4c5c-a0a0-19d4401241b3"
      unitRef="usd">10400000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ief4d8a0c3b5e40789e9de34c75e432bf_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfNy01LTEtMS04Mjc4Mg_0847cf99-fd4e-4f4d-b12a-c6ff042fcfd8"
      unitRef="usd">19000000.0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6d4597dfd1ba407789166d3d2ab3a1c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfNy03LTEtMS04Mjc4Mg_a863cb22-ca64-4f5b-b232-579e5ebb84ef"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfOS0xLTEtMS04Mjc4Mg_eb6b1f42-fa64-45a9-a5cb-2df60690903a"
      unitRef="usd">4500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i8472e48bf22848d09276489a66c9e03e_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfOS0zLTEtMS04Mjc4Mg_27ad4d43-62e6-4d05-9837-b7c1c1f76ddd"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ief4d8a0c3b5e40789e9de34c75e432bf_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfOS01LTEtMS04Mjc4Mg_59761665-59b4-46b3-a06b-65ccd7633f23"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i6d4597dfd1ba407789166d3d2ab3a1c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfOS03LTEtMS04Mjc4Mg_0ef5b8de-4aa8-46bf-b09f-7df542f8f3a5"
      unitRef="usd">4500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfMTAtMS0xLTEtODI3ODI_c27a21d8-378e-4e68-9b5a-7e92af9caf57"
      unitRef="usd">10600000</us-gaap:OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent>
    <us-gaap:OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent
      contextRef="i8472e48bf22848d09276489a66c9e03e_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfMTAtMy0xLTEtODI3ODI_ddaeff50-8f12-4ca2-9b88-9bdad1d67a87"
      unitRef="usd">10600000</us-gaap:OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent>
    <us-gaap:OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent
      contextRef="ief4d8a0c3b5e40789e9de34c75e432bf_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfMTAtNS0xLTEtODI3ODI_bc94f0ba-abf3-4ae7-b4f8-ec36aa6dd713"
      unitRef="usd">0</us-gaap:OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent>
    <us-gaap:OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent
      contextRef="i6d4597dfd1ba407789166d3d2ab3a1c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfMTAtNy0xLTEtODI3ODI_4117c766-bf0b-44a1-a871-8b43918c6a77"
      unitRef="usd">0</us-gaap:OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="ie176087c2e0f4f9aaf6886e4438cdcf1_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfMTItMS0xLTEtODI3ODI_1c2d36e1-dbe9-40c7-b651-6a0296286ecb"
      unitRef="usd">2400000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i20dc5476975c412a9dfc88d9c2216dee_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfMTItMy0xLTEtODI3ODI_46fab7e6-7809-4f71-b3c2-6bf5ebff0258"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i0e410a2ff35b4d57982b319abc1e1768_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfMTItNS0xLTEtODI3ODI_6d3510ab-1210-4f17-ad9e-dad8efee79c0"
      unitRef="usd">2400000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i89f31e1b854b43c68d198cca6624635e_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfMTItNy0xLTEtODI3ODI_bd27644a-a511-4847-9677-1f0646d1aeea"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfMTMtMS0xLTEtODI3ODI_053ff08a-dd1d-4952-b3b3-125c16c373ff"
      unitRef="usd">17500000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i8472e48bf22848d09276489a66c9e03e_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfMTMtMy0xLTEtODI3ODI_ad7d327e-fc26-4283-8a2e-9f5407565b08"
      unitRef="usd">10600000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ief4d8a0c3b5e40789e9de34c75e432bf_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfMTMtNS0xLTEtODI3ODI_6eccea95-5f5c-4e1d-ac89-2fcf32e9d1f0"
      unitRef="usd">2400000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i6d4597dfd1ba407789166d3d2ab3a1c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjZlYjBjZTljN2U5ZTRiOTA5YjliNGM1ZWRlZTM5MjM3L3RhYmxlcmFuZ2U6NmViMGNlOWM3ZTllNGI5MDliOWI0YzVlZGVlMzkyMzdfMTMtNy0xLTEtODI3ODI_b5e76e4b-132f-4ec3-8d13-661c4aa6f51d"
      unitRef="usd">4500000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:DeferredCompensationPlanAssets
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfMy0xLTEtMS04Mjc4Mg_c7f880c7-484a-463f-a96a-b0127cc18766"
      unitRef="usd">12500000</us-gaap:DeferredCompensationPlanAssets>
    <us-gaap:DeferredCompensationPlanAssets
      contextRef="idecab62008c846caa537823da6bf68cf_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfMy0zLTEtMS04Mjc4Mg_f58c8df2-2678-4df4-8efa-ec654b088ce7"
      unitRef="usd">12500000</us-gaap:DeferredCompensationPlanAssets>
    <us-gaap:DeferredCompensationPlanAssets
      contextRef="i3d38876b8687498fb75a9d1921176e0b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfMy01LTEtMS04Mjc4Mg_fdbc18c2-e4db-4809-89df-51cd8ce15bbf"
      unitRef="usd">0</us-gaap:DeferredCompensationPlanAssets>
    <us-gaap:DeferredCompensationPlanAssets
      contextRef="i53b64dbcb5d24234b5920850cfdbdd10_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfMy03LTEtMS04Mjc4Mg_d61efa7d-3f59-4db1-9dc6-7d7f52d2aa4b"
      unitRef="usd">0</us-gaap:DeferredCompensationPlanAssets>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfNC0xLTEtMS04Mjc4Mg_568480c4-a717-4642-a6d8-4746181f40df"
      unitRef="usd">4500000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="idecab62008c846caa537823da6bf68cf_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfNC0zLTEtMS04Mjc4Mg_ea2d104b-2488-4441-ab9e-3722d37083c5"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i3d38876b8687498fb75a9d1921176e0b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfNC01LTEtMS04Mjc4Mg_3723f069-cb8f-434c-a1de-4c3d9969c035"
      unitRef="usd">4500000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i53b64dbcb5d24234b5920850cfdbdd10_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfNC03LTEtMS04Mjc4Mg_d299e424-ee75-4aa8-8f88-4772450a19fc"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:DerivativeAssets
      contextRef="i5022b45891414a1794bd141aad661062_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfNS0xLTEtMS04Mjc4Mg_f7e9eba0-269f-4788-adf3-8ef8d2ce23f0"
      unitRef="usd">13900000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="idd5224d49fab426a864b9ef841b2bd25_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfNS0zLTEtMS04Mjc4Mg_201e1de6-cc79-42fa-ae8c-dff3949eb6f6"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ib7fc7fba1d244cd09a928fc5c9b89075_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfNS01LTEtMS04Mjc4Mg_11e035f1-98c0-401b-ad16-b717b9afa337"
      unitRef="usd">13900000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i0e31f6f4b77a4341b3844eaafe791605_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfNS03LTEtMS04Mjc4Mg_2d402e71-74c0-4b6e-922f-f95ce354cad4"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i3855c26361a747a6a2063f8669213b1d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfNi0xLTEtMS04Mjc4Mg_11989bd3-3031-4b15-802f-7bb0e349387d"
      unitRef="usd">1200000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="iba6b68a438dd4a579b4713432d302e3d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfNi0zLTEtMS04Mjc4Mg_be15e10b-55fd-4570-85a6-0833084e945a"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ie8ff7bccbad64151ab6ea9014d5cc59f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfNi01LTEtMS04Mjc4Mg_16444611-bd14-4e27-ac07-07f648c5935d"
      unitRef="usd">1200000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="id1b304b4749d406ba788dcf08bc89106_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfNi03LTEtMS04Mjc4Mg_8609e82b-7a0e-477a-aa7f-01761d26f647"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfNy0xLTEtMS04Mjc4Mg_30c4d3e6-d02d-427b-8ad5-f810b33dd26a"
      unitRef="usd">32100000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="idecab62008c846caa537823da6bf68cf_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfNy0zLTEtMS04Mjc4Mg_4d65fb11-2121-439d-b1d7-767e1e7d1fd2"
      unitRef="usd">12500000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3d38876b8687498fb75a9d1921176e0b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfNy01LTEtMS04Mjc4Mg_fc96809f-1653-463f-a142-72fbef37e7ef"
      unitRef="usd">19600000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i53b64dbcb5d24234b5920850cfdbdd10_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfNy03LTEtMS04Mjc4Mg_2f19a633-5f65-4a42-9536-d7ddc5baeb2c"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfOS0xLTEtMS04Mjc4Mg_c8ecf23b-86b1-45f4-9b13-9b25199b682b"
      unitRef="usd">4700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="idecab62008c846caa537823da6bf68cf_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfOS0zLTEtMS04Mjc4Mg_5ad006d3-8930-4a96-bf8d-f95edc6aea04"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i3d38876b8687498fb75a9d1921176e0b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfOS01LTEtMS04Mjc4Mg_8bd63cdf-53dc-44d8-97ec-88afefcdb635"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i53b64dbcb5d24234b5920850cfdbdd10_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfOS03LTEtMS04Mjc4Mg_a33cc124-a582-49f5-8e7d-4392b48c7ff6"
      unitRef="usd">4700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfMTAtMS0xLTEtODI3ODI_97550988-e3cb-4ad5-b1ab-20be0a224aaa"
      unitRef="usd">12700000</us-gaap:OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent>
    <us-gaap:OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent
      contextRef="idecab62008c846caa537823da6bf68cf_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfMTAtMy0xLTEtODI3ODI_2a2d07ab-b4a5-43b8-9b4e-de5f8a471629"
      unitRef="usd">12700000</us-gaap:OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent>
    <us-gaap:OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent
      contextRef="i3d38876b8687498fb75a9d1921176e0b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfMTAtNS0xLTEtODI3ODI_ce6ae26a-85d7-43af-b053-967dc77f7a13"
      unitRef="usd">0</us-gaap:OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent>
    <us-gaap:OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent
      contextRef="i53b64dbcb5d24234b5920850cfdbdd10_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfMTAtNy0xLTEtODI3ODI_6394329c-f199-4406-914c-95bd4f8f0b05"
      unitRef="usd">0</us-gaap:OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="if1036a3de1ea4f318261a593515df52b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfMTEtMS0xLTEtODI3ODI_4e87dec9-7330-42c5-93d0-3cc7dddbda98"
      unitRef="usd">1400000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i9dd9da2fad4544178dd80a8db1ca4501_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfMTEtMy0xLTEtODI3ODI_ae3d6c84-c794-4cee-bd6f-a9a0840515a9"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="ie68882e1ec5c418487d91aaacd73759d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfMTEtNS0xLTEtODI3ODI_ec221539-8c98-4322-9bd5-0196d5b4cd5a"
      unitRef="usd">1400000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i564b193142034a3dad5d2192d388c8df_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfMTEtNy0xLTEtODI3ODI_36fdbefa-279d-4e76-8cb3-61254c7aff56"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfMTItMS0xLTEtODI3ODI_c1f08cb6-94a2-4f20-aece-018cae33e826"
      unitRef="usd">18800000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="idecab62008c846caa537823da6bf68cf_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfMTItMy0xLTEtODI3ODI_808bbb62-be47-486d-8aeb-5a37eec4e800"
      unitRef="usd">12700000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i3d38876b8687498fb75a9d1921176e0b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfMTItNS0xLTEtODI3ODI_e009f915-e91b-40f0-af91-75df6bfaefe3"
      unitRef="usd">1400000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i53b64dbcb5d24234b5920850cfdbdd10_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RhYmxlOjlmYTE1MDFhZjk3MjRiMDZiM2U1ZTQwZTYwMzQxNDQ3L3RhYmxlcmFuZ2U6OWZhMTUwMWFmOTcyNGIwNmIzZTVlNDBlNjAzNDE0NDdfMTItNy0xLTEtODI3ODI_18f0c705-7c76-4892-89bd-59d0d80fc9b5"
      unitRef="usd">4700000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LongTermDebtFairValue
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RleHRyZWdpb246M2E2NWEyYmZhYTFiNDU3OGI0ZjgyMDg2MTQ5ZjcyYzNfMjk2MQ_7131a07d-e506-4733-b3b1-1c098edd33fb"
      unitRef="usd">201200000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RleHRyZWdpb246M2E2NWEyYmZhYTFiNDU3OGI0ZjgyMDg2MTQ5ZjcyYzNfMjk5Nw_3ca98cf0-9081-493d-8eca-616f7b77dc16"
      unitRef="usd">206100000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtFairValue
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RleHRyZWdpb246M2E2NWEyYmZhYTFiNDU3OGI0ZjgyMDg2MTQ5ZjcyYzNfMzA1NQ_c2bf7fca-c1ae-4b74-99bd-622716bde44b"
      unitRef="usd">201800000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82MS9mcmFnOjNhNjVhMmJmYWExYjQ1NzhiNGY4MjA4NjE0OWY3MmMzL3RleHRyZWdpb246M2E2NWEyYmZhYTFiNDU3OGI0ZjgyMDg2MTQ5ZjcyYzNfMzA4Ng_248c52cc-99a1-418c-84e8-d9e93329c33b"
      unitRef="usd">206700000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:ComprehensiveIncomeNoteTextBlock
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RleHRyZWdpb246MTMzYTc0MjA3OWQ0NGNmOGFkNGJhNTc3MGVmNzA0YWJfNjMw_dff65dd8-2fd5-4aac-a3f2-4ae741dda98a">Accumulated Other Comprehensive Loss&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the three months ended March&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.746%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.726%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.291%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.878%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Losses) gains on&lt;br/&gt;derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in equity affiliate investment AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Defined benefit&lt;br/&gt;pension and other &lt;br/&gt;postretirement plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign &lt;br/&gt;currency &lt;br/&gt;translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(175.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(183.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified out from accumulated other comprehensive income (loss)  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss), net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(160.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(168.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the three months ended March&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.746%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.726%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.291%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.878%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Losses) gains on&lt;br/&gt;derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in equity affiliate investment AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Defined benefit&lt;br/&gt;pension and other &lt;br/&gt;postretirement plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign &lt;br/&gt;currency &lt;br/&gt;translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(128.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(159.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive (loss) income before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified out from accumulated other comprehensive (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive (loss) income, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(150.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(182.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the reclassifications out of accumulated other comprehensive loss is presented in the following table: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:35pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Location on Statement of Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Detail of components&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Losses) gains on derivatives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of goods and services sold&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward treasury locks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total before tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of defined benefit pension and other postretirement plans:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actuarial gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total before tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax (expense) benefit &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total reclassifications for the period, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) These components are included in the computation of net periodic benefit cost. Please refer to Note 14, &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i7bf87d07bb544f48851c48374130181b_73" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Benefit Plans&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for additional details.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RleHRyZWdpb246MTMzYTc0MjA3OWQ0NGNmOGFkNGJhNTc3MGVmNzA0YWJfNjU4_1948ca4f-bc7f-499f-bdf2-e248f5369868">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the three months ended March&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.746%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.726%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.291%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.878%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Losses) gains on&lt;br/&gt;derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in equity affiliate investment AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Defined benefit&lt;br/&gt;pension and other &lt;br/&gt;postretirement plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign &lt;br/&gt;currency &lt;br/&gt;translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(175.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(183.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified out from accumulated other comprehensive income (loss)  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss), net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(160.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(168.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the three months ended March&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.746%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.726%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.291%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.878%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Losses) gains on&lt;br/&gt;derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in equity affiliate investment AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Defined benefit&lt;br/&gt;pension and other &lt;br/&gt;postretirement plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign &lt;br/&gt;currency &lt;br/&gt;translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(128.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(159.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive (loss) income before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified out from accumulated other comprehensive (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive (loss) income, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(150.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(182.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquity
      contextRef="ib0a2e4816674455e8c1653b4d67a05eb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjNjNTRjM2QyNmZhYjQyZWViMDc2YTM0NDdjNjE0Zjc5L3RhYmxlcmFuZ2U6M2M1NGMzZDI2ZmFiNDJlZWIwNzZhMzQ0N2M2MTRmNzlfMS0xLTEtMS04Mjc4Mg_9dfaa790-fb8c-4635-a3f1-4784993fc058"
      unitRef="usd">200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i526f045cc6ae4ef9aebfa54634f321c7_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjNjNTRjM2QyNmZhYjQyZWViMDc2YTM0NDdjNjE0Zjc5L3RhYmxlcmFuZ2U6M2M1NGMzZDI2ZmFiNDJlZWIwNzZhMzQ0N2M2MTRmNzlfMS0zLTEtMS04Mjc4Mg_ec49b96d-ee08-468a-be7b-409e84783c73"
      unitRef="usd">1600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4b4825baaa3d4e808f9edc322c950ac0_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjNjNTRjM2QyNmZhYjQyZWViMDc2YTM0NDdjNjE0Zjc5L3RhYmxlcmFuZ2U6M2M1NGMzZDI2ZmFiNDJlZWIwNzZhMzQ0N2M2MTRmNzlfMS01LTEtMS04Mjc4Mg_90a45975-3704-4337-bc9b-69062cc9f3c9"
      unitRef="usd">-9400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6a916ac5970f44c4ae05918807b57f65_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjNjNTRjM2QyNmZhYjQyZWViMDc2YTM0NDdjNjE0Zjc5L3RhYmxlcmFuZ2U6M2M1NGMzZDI2ZmFiNDJlZWIwNzZhMzQ0N2M2MTRmNzlfMS03LTEtMS04Mjc4Mg_7e330016-1ca4-4a97-8810-b50f45dfff70"
      unitRef="usd">-175400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6339e7f0f9e847638d0b1e918478a17b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjNjNTRjM2QyNmZhYjQyZWViMDc2YTM0NDdjNjE0Zjc5L3RhYmxlcmFuZ2U6M2M1NGMzZDI2ZmFiNDJlZWIwNzZhMzQ0N2M2MTRmNzlfMS05LTEtMS04Mjc4Mg_419447f0-63ea-408a-9cb1-63c58d5de05a"
      unitRef="usd">-183000000.0</us-gaap:StockholdersEquity>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="ibe54e8c2da3440aebf4d2616a05e64c2_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjNjNTRjM2QyNmZhYjQyZWViMDc2YTM0NDdjNjE0Zjc5L3RhYmxlcmFuZ2U6M2M1NGMzZDI2ZmFiNDJlZWIwNzZhMzQ0N2M2MTRmNzlfMi0xLTEtMS04Mjc4Mg_dd4a31b3-7b72-4477-bb21-6d6f69045db0"
      unitRef="usd">-900000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i797411f0d816497e9411895884b514e7_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjNjNTRjM2QyNmZhYjQyZWViMDc2YTM0NDdjNjE0Zjc5L3RhYmxlcmFuZ2U6M2M1NGMzZDI2ZmFiNDJlZWIwNzZhMzQ0N2M2MTRmNzlfMi0zLTEtMS04Mjc4Mg_5e5c872a-35a9-4fa8-8d62-1c7a5c144a0b"
      unitRef="usd">0</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="ia8b0a91f9e20469aa04a865d19bf4454_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjNjNTRjM2QyNmZhYjQyZWViMDc2YTM0NDdjNjE0Zjc5L3RhYmxlcmFuZ2U6M2M1NGMzZDI2ZmFiNDJlZWIwNzZhMzQ0N2M2MTRmNzlfMi01LTEtMS04Mjc4Mg_805700b5-0350-4ccb-b1ed-be1f2ab2ccb1"
      unitRef="usd">-200000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="ia80d875680634e70a48cb73ff07b85e4_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjNjNTRjM2QyNmZhYjQyZWViMDc2YTM0NDdjNjE0Zjc5L3RhYmxlcmFuZ2U6M2M1NGMzZDI2ZmFiNDJlZWIwNzZhMzQ0N2M2MTRmNzlfMi03LTEtMS04Mjc4Mg_832f0680-7978-4a82-9b5d-8dc3342794e6"
      unitRef="usd">15300000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjNjNTRjM2QyNmZhYjQyZWViMDc2YTM0NDdjNjE0Zjc5L3RhYmxlcmFuZ2U6M2M1NGMzZDI2ZmFiNDJlZWIwNzZhMzQ0N2M2MTRmNzlfMi05LTEtMS04Mjc4Mg_6ef0dc28-1268-4e69-bb5d-a128515b2608"
      unitRef="usd">14200000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="ibe54e8c2da3440aebf4d2616a05e64c2_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjNjNTRjM2QyNmZhYjQyZWViMDc2YTM0NDdjNjE0Zjc5L3RhYmxlcmFuZ2U6M2M1NGMzZDI2ZmFiNDJlZWIwNzZhMzQ0N2M2MTRmNzlfMy0xLTEtMS04Mjc4Mg_b57c46db-cea8-4a14-98ca-6ad8029bc604"
      unitRef="usd">-700000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="i797411f0d816497e9411895884b514e7_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjNjNTRjM2QyNmZhYjQyZWViMDc2YTM0NDdjNjE0Zjc5L3RhYmxlcmFuZ2U6M2M1NGMzZDI2ZmFiNDJlZWIwNzZhMzQ0N2M2MTRmNzlfMy0zLTEtMS04Mjc4Mg_f6e9d9e7-b02d-45a7-aca0-f347ffad2026"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="ia8b0a91f9e20469aa04a865d19bf4454_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjNjNTRjM2QyNmZhYjQyZWViMDc2YTM0NDdjNjE0Zjc5L3RhYmxlcmFuZ2U6M2M1NGMzZDI2ZmFiNDJlZWIwNzZhMzQ0N2M2MTRmNzlfMy01LTEtMS04Mjc4Mg_4dde5a40-c72c-4699-8451-f7d37cd112e1"
      unitRef="usd">300000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="ia80d875680634e70a48cb73ff07b85e4_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjNjNTRjM2QyNmZhYjQyZWViMDc2YTM0NDdjNjE0Zjc5L3RhYmxlcmFuZ2U6M2M1NGMzZDI2ZmFiNDJlZWIwNzZhMzQ0N2M2MTRmNzlfMy03LTEtMS04Mjc4Mg_7c7f2616-8a44-4a17-946b-972a0c6c6b67"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjNjNTRjM2QyNmZhYjQyZWViMDc2YTM0NDdjNjE0Zjc5L3RhYmxlcmFuZ2U6M2M1NGMzZDI2ZmFiNDJlZWIwNzZhMzQ0N2M2MTRmNzlfMy05LTEtMS04Mjc4Mg_4859b982-1481-49cd-b2d3-9f2ca5645de8"
      unitRef="usd">-400000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ibe54e8c2da3440aebf4d2616a05e64c2_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjNjNTRjM2QyNmZhYjQyZWViMDc2YTM0NDdjNjE0Zjc5L3RhYmxlcmFuZ2U6M2M1NGMzZDI2ZmFiNDJlZWIwNzZhMzQ0N2M2MTRmNzlfNC0xLTEtMS04Mjc4Mg_de7fa52c-8f72-4131-b71b-fd1024e24706"
      unitRef="usd">-200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i797411f0d816497e9411895884b514e7_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjNjNTRjM2QyNmZhYjQyZWViMDc2YTM0NDdjNjE0Zjc5L3RhYmxlcmFuZ2U6M2M1NGMzZDI2ZmFiNDJlZWIwNzZhMzQ0N2M2MTRmNzlfNC0zLTEtMS04Mjc4Mg_bf0aaef6-0d00-479f-856d-bdfd8fa02942"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ia8b0a91f9e20469aa04a865d19bf4454_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjNjNTRjM2QyNmZhYjQyZWViMDc2YTM0NDdjNjE0Zjc5L3RhYmxlcmFuZ2U6M2M1NGMzZDI2ZmFiNDJlZWIwNzZhMzQ0N2M2MTRmNzlfNC01LTEtMS04Mjc4Mg_8c79f3ca-0761-41e8-8566-d1ef75857682"
      unitRef="usd">-500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ia80d875680634e70a48cb73ff07b85e4_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjNjNTRjM2QyNmZhYjQyZWViMDc2YTM0NDdjNjE0Zjc5L3RhYmxlcmFuZ2U6M2M1NGMzZDI2ZmFiNDJlZWIwNzZhMzQ0N2M2MTRmNzlfNC03LTEtMS04Mjc4Mg_caeb04e2-c45a-473e-9ff9-bbff2fb084bc"
      unitRef="usd">15300000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjNjNTRjM2QyNmZhYjQyZWViMDc2YTM0NDdjNjE0Zjc5L3RhYmxlcmFuZ2U6M2M1NGMzZDI2ZmFiNDJlZWIwNzZhMzQ0N2M2MTRmNzlfNC05LTEtMS04Mjc4Mg_dc531131-cb7a-497d-8b91-b524f5953f64"
      unitRef="usd">14600000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity
      contextRef="i1a6e09ceadea4cf28bdd80365b649ab0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjNjNTRjM2QyNmZhYjQyZWViMDc2YTM0NDdjNjE0Zjc5L3RhYmxlcmFuZ2U6M2M1NGMzZDI2ZmFiNDJlZWIwNzZhMzQ0N2M2MTRmNzlfNS0xLTEtMS04Mjc4Mg_c86b7d46-27d4-4f29-8f11-004db01eef44"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i60c9aeeca640474289ca4b0da5cf3a7d_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjNjNTRjM2QyNmZhYjQyZWViMDc2YTM0NDdjNjE0Zjc5L3RhYmxlcmFuZ2U6M2M1NGMzZDI2ZmFiNDJlZWIwNzZhMzQ0N2M2MTRmNzlfNS0zLTEtMS04Mjc4Mg_c983b3b1-cf51-41ad-9de8-0d6d0ca9dd1b"
      unitRef="usd">1600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic60c39b0c368406f8cd641a4d764ddc1_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjNjNTRjM2QyNmZhYjQyZWViMDc2YTM0NDdjNjE0Zjc5L3RhYmxlcmFuZ2U6M2M1NGMzZDI2ZmFiNDJlZWIwNzZhMzQ0N2M2MTRmNzlfNS01LTEtMS04Mjc4Mg_6532b558-9f1e-4912-b020-c9dddd705b56"
      unitRef="usd">-9900000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic5cd3bf0b3e6469e9da46a298c4c805d_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjNjNTRjM2QyNmZhYjQyZWViMDc2YTM0NDdjNjE0Zjc5L3RhYmxlcmFuZ2U6M2M1NGMzZDI2ZmFiNDJlZWIwNzZhMzQ0N2M2MTRmNzlfNS03LTEtMS04Mjc4Mg_6837d7b6-89c8-4d55-9c75-c67a3caf433f"
      unitRef="usd">-160100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6630ce4dbb7747e8858856ea430b90ab_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjNjNTRjM2QyNmZhYjQyZWViMDc2YTM0NDdjNjE0Zjc5L3RhYmxlcmFuZ2U6M2M1NGMzZDI2ZmFiNDJlZWIwNzZhMzQ0N2M2MTRmNzlfNS05LTEtMS04Mjc4Mg_ec349eff-217e-4fe4-8597-4d4997e427bb"
      unitRef="usd">-168400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4fca80d6c8df481687a29bccfb487856_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjAzMjIzNDRiZWFmZTQ4NGZiODQyMDEyOTVjMjUxNzU5L3RhYmxlcmFuZ2U6MDMyMjM0NGJlYWZlNDg0ZmI4NDIwMTI5NWMyNTE3NTlfMS0xLTEtMS04Mjc4Mg_39bac2de-30d2-44e3-b064-835d83c01269"
      unitRef="usd">-1200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8c6c1d8c2b4f4a0b89ca2e9a9ddd447c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjAzMjIzNDRiZWFmZTQ4NGZiODQyMDEyOTVjMjUxNzU5L3RhYmxlcmFuZ2U6MDMyMjM0NGJlYWZlNDg0ZmI4NDIwMTI5NWMyNTE3NTlfMS0zLTEtMS04Mjc4Mg_07cad67a-296c-4107-8b78-7f6439cdd591"
      unitRef="usd">1500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3a3f5a8af8064476820608f696c42e1d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjAzMjIzNDRiZWFmZTQ4NGZiODQyMDEyOTVjMjUxNzU5L3RhYmxlcmFuZ2U6MDMyMjM0NGJlYWZlNDg0ZmI4NDIwMTI5NWMyNTE3NTlfMS01LTEtMS04Mjc4Mg_68ecc4cf-1b8f-468e-b1fb-16ebe45b0062"
      unitRef="usd">-31800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i936367d439194b7fbc90a34743134e4f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjAzMjIzNDRiZWFmZTQ4NGZiODQyMDEyOTVjMjUxNzU5L3RhYmxlcmFuZ2U6MDMyMjM0NGJlYWZlNDg0ZmI4NDIwMTI5NWMyNTE3NTlfMS03LTEtMS04Mjc4Mg_98c76629-bb80-436d-ad86-889b1bbf23d4"
      unitRef="usd">-128100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0df22a14170c4331a1256c9f757e5090_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjAzMjIzNDRiZWFmZTQ4NGZiODQyMDEyOTVjMjUxNzU5L3RhYmxlcmFuZ2U6MDMyMjM0NGJlYWZlNDg0ZmI4NDIwMTI5NWMyNTE3NTlfMS05LTEtMS04Mjc4Mg_ef6bcf67-b0fb-4fdf-a618-aa59707d3247"
      unitRef="usd">-159600000</us-gaap:StockholdersEquity>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="ie71d1ab95f7344af96897b0090a0e58d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjAzMjIzNDRiZWFmZTQ4NGZiODQyMDEyOTVjMjUxNzU5L3RhYmxlcmFuZ2U6MDMyMjM0NGJlYWZlNDg0ZmI4NDIwMTI5NWMyNTE3NTlfMi0xLTEtMS04Mjc4Mg_89f8a170-393e-4a22-9a37-9003d1480d2d"
      unitRef="usd">-1900000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="ia67d15eb184042d897c6efc17a13b799_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjAzMjIzNDRiZWFmZTQ4NGZiODQyMDEyOTVjMjUxNzU5L3RhYmxlcmFuZ2U6MDMyMjM0NGJlYWZlNDg0ZmI4NDIwMTI5NWMyNTE3NTlfMi0zLTEtMS04Mjc4Mg_9c19a062-c24d-48dc-b58d-dea226b5e970"
      unitRef="usd">0</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i111ee7c976334a21a8a888af218b7e87_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjAzMjIzNDRiZWFmZTQ4NGZiODQyMDEyOTVjMjUxNzU5L3RhYmxlcmFuZ2U6MDMyMjM0NGJlYWZlNDg0ZmI4NDIwMTI5NWMyNTE3NTlfMi01LTEtMS04Mjc4Mg_a72d286e-02ad-4355-bdfa-63ae38bb13ba"
      unitRef="usd">400000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i6421c8aef05242b2af4fa57c824c4efa_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjAzMjIzNDRiZWFmZTQ4NGZiODQyMDEyOTVjMjUxNzU5L3RhYmxlcmFuZ2U6MDMyMjM0NGJlYWZlNDg0ZmI4NDIwMTI5NWMyNTE3NTlfMi03LTEtMS04Mjc4Mg_de013afc-b9bf-4180-bf95-cfe950c286d9"
      unitRef="usd">-22100000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjAzMjIzNDRiZWFmZTQ4NGZiODQyMDEyOTVjMjUxNzU5L3RhYmxlcmFuZ2U6MDMyMjM0NGJlYWZlNDg0ZmI4NDIwMTI5NWMyNTE3NTlfMi05LTEtMS04Mjc4Mg_18e84c48-bd58-471e-9180-98c324caf0f5"
      unitRef="usd">-23600000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="ie71d1ab95f7344af96897b0090a0e58d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjAzMjIzNDRiZWFmZTQ4NGZiODQyMDEyOTVjMjUxNzU5L3RhYmxlcmFuZ2U6MDMyMjM0NGJlYWZlNDg0ZmI4NDIwMTI5NWMyNTE3NTlfMy0xLTEtMS04Mjc4Mg_9750ea6a-774e-4da2-8fac-20b80e17500d"
      unitRef="usd">-300000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="ia67d15eb184042d897c6efc17a13b799_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjAzMjIzNDRiZWFmZTQ4NGZiODQyMDEyOTVjMjUxNzU5L3RhYmxlcmFuZ2U6MDMyMjM0NGJlYWZlNDg0ZmI4NDIwMTI5NWMyNTE3NTlfMy0zLTEtMS04Mjc4Mg_49016e02-fd5b-4b2b-969e-8f30d1c10cfa"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="i111ee7c976334a21a8a888af218b7e87_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjAzMjIzNDRiZWFmZTQ4NGZiODQyMDEyOTVjMjUxNzU5L3RhYmxlcmFuZ2U6MDMyMjM0NGJlYWZlNDg0ZmI4NDIwMTI5NWMyNTE3NTlfMy01LTEtMS04Mjc4Mg_b52934f8-efb9-4fdc-b44e-22e27c853357"
      unitRef="usd">-500000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="i6421c8aef05242b2af4fa57c824c4efa_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjAzMjIzNDRiZWFmZTQ4NGZiODQyMDEyOTVjMjUxNzU5L3RhYmxlcmFuZ2U6MDMyMjM0NGJlYWZlNDg0ZmI4NDIwMTI5NWMyNTE3NTlfMy03LTEtMS04Mjc4Mg_efca7060-3042-4a96-a7c7-a587630feed8"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjAzMjIzNDRiZWFmZTQ4NGZiODQyMDEyOTVjMjUxNzU5L3RhYmxlcmFuZ2U6MDMyMjM0NGJlYWZlNDg0ZmI4NDIwMTI5NWMyNTE3NTlfMy05LTEtMS04Mjc4Mg_5fafb3af-0a06-4b6c-a6f9-4f7f90cc2534"
      unitRef="usd">-800000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ie71d1ab95f7344af96897b0090a0e58d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjAzMjIzNDRiZWFmZTQ4NGZiODQyMDEyOTVjMjUxNzU5L3RhYmxlcmFuZ2U6MDMyMjM0NGJlYWZlNDg0ZmI4NDIwMTI5NWMyNTE3NTlfNC0xLTEtMS04Mjc4Mg_2cbc5763-f14e-4561-820f-65fa9c02108b"
      unitRef="usd">-1600000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ia67d15eb184042d897c6efc17a13b799_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjAzMjIzNDRiZWFmZTQ4NGZiODQyMDEyOTVjMjUxNzU5L3RhYmxlcmFuZ2U6MDMyMjM0NGJlYWZlNDg0ZmI4NDIwMTI5NWMyNTE3NTlfNC0zLTEtMS04Mjc4Mg_fd427319-8bd5-4365-929e-f84ccee9e09e"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i111ee7c976334a21a8a888af218b7e87_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjAzMjIzNDRiZWFmZTQ4NGZiODQyMDEyOTVjMjUxNzU5L3RhYmxlcmFuZ2U6MDMyMjM0NGJlYWZlNDg0ZmI4NDIwMTI5NWMyNTE3NTlfNC01LTEtMS04Mjc4Mg_59a17e9a-82ff-49ef-8455-0c1f4edb8e3d"
      unitRef="usd">900000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i6421c8aef05242b2af4fa57c824c4efa_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjAzMjIzNDRiZWFmZTQ4NGZiODQyMDEyOTVjMjUxNzU5L3RhYmxlcmFuZ2U6MDMyMjM0NGJlYWZlNDg0ZmI4NDIwMTI5NWMyNTE3NTlfNC03LTEtMS04Mjc4Mg_1d577540-95c5-419d-bb69-0c5df24ae60c"
      unitRef="usd">-22100000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjAzMjIzNDRiZWFmZTQ4NGZiODQyMDEyOTVjMjUxNzU5L3RhYmxlcmFuZ2U6MDMyMjM0NGJlYWZlNDg0ZmI4NDIwMTI5NWMyNTE3NTlfNC05LTEtMS04Mjc4Mg_986f3c4a-2d7f-4143-bdd4-45663ae71699"
      unitRef="usd">-22800000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity
      contextRef="i1a6c194a67cd4b14b2fe810f1803d2fa_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjAzMjIzNDRiZWFmZTQ4NGZiODQyMDEyOTVjMjUxNzU5L3RhYmxlcmFuZ2U6MDMyMjM0NGJlYWZlNDg0ZmI4NDIwMTI5NWMyNTE3NTlfNS0xLTEtMS04Mjc4Mg_681fdb55-2489-4074-b3e4-f508e2cb4644"
      unitRef="usd">-2800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i15d499d767e34686aa1263510f1d36a3_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjAzMjIzNDRiZWFmZTQ4NGZiODQyMDEyOTVjMjUxNzU5L3RhYmxlcmFuZ2U6MDMyMjM0NGJlYWZlNDg0ZmI4NDIwMTI5NWMyNTE3NTlfNS0zLTEtMS04Mjc4Mg_583842be-fa2f-40ea-9d38-1891756a2551"
      unitRef="usd">1500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i43311d97b8684c7d99964d6c9ce008f6_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjAzMjIzNDRiZWFmZTQ4NGZiODQyMDEyOTVjMjUxNzU5L3RhYmxlcmFuZ2U6MDMyMjM0NGJlYWZlNDg0ZmI4NDIwMTI5NWMyNTE3NTlfNS01LTEtMS04Mjc4Mg_329ef849-a43d-4af9-b017-5bebfc10e6f6"
      unitRef="usd">-30900000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i90887b06cf074badac168937eaf76a7d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjAzMjIzNDRiZWFmZTQ4NGZiODQyMDEyOTVjMjUxNzU5L3RhYmxlcmFuZ2U6MDMyMjM0NGJlYWZlNDg0ZmI4NDIwMTI5NWMyNTE3NTlfNS03LTEtMS04Mjc4Mg_d1560c4e-2bbf-41ab-8ff0-7cd35578c195"
      unitRef="usd">-150200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i83a0a64e641241259400ffb042bd9b69_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOjAzMjIzNDRiZWFmZTQ4NGZiODQyMDEyOTVjMjUxNzU5L3RhYmxlcmFuZ2U6MDMyMjM0NGJlYWZlNDg0ZmI4NDIwMTI5NWMyNTE3NTlfNS05LTEtMS04Mjc4Mg_0b184b4a-3a7b-47c3-b88f-b8cf2075a58f"
      unitRef="usd">-182400000</us-gaap:StockholdersEquity>
    <us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RleHRyZWdpb246MTMzYTc0MjA3OWQ0NGNmOGFkNGJhNTc3MGVmNzA0YWJfNjU5_af5c8e34-2690-498d-af77-f9bebd57eb1d">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the reclassifications out of accumulated other comprehensive loss is presented in the following table: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:35pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Location on Statement of Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Detail of components&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Losses) gains on derivatives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of goods and services sold&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward treasury locks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total before tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of defined benefit pension and other postretirement plans:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actuarial gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total before tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax (expense) benefit &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total reclassifications for the period, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) These components are included in the computation of net periodic benefit cost. Please refer to Note 14, &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i7bf87d07bb544f48851c48374130181b_73" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Benefit Plans&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for additional details.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2a7ae72bcc2f46119331a447f5c3150d_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOmEzNzE3ZTAyNDM3YTQxZTE5MDEyYjNjYjBhMjczMTRkL3RhYmxlcmFuZ2U6YTM3MTdlMDI0MzdhNDFlMTkwMTJiM2NiMGEyNzMxNGRfMy0yLTEtMS04Mjc4Mg_39a5f41e-d603-4b90-9aca-48a138735bca"
      unitRef="usd">-700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8d0c261740c340ebb7fdb92c09b03f4e_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOmEzNzE3ZTAyNDM3YTQxZTE5MDEyYjNjYjBhMjczMTRkL3RhYmxlcmFuZ2U6YTM3MTdlMDI0MzdhNDFlMTkwMTJiM2NiMGEyNzMxNGRfMy00LTEtMS04Mjc4Mg_6281c888-c6ed-440e-a503-91b44f3b7e53"
      unitRef="usd">300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i2a7ae72bcc2f46119331a447f5c3150d_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOmEzNzE3ZTAyNDM3YTQxZTE5MDEyYjNjYjBhMjczMTRkL3RhYmxlcmFuZ2U6YTM3MTdlMDI0MzdhNDFlMTkwMTJiM2NiMGEyNzMxNGRfNC0yLTEtMS04Mjc4Mg_508b95a9-5ec9-4aa4-bc61-2aa6875ad7fb"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i8d0c261740c340ebb7fdb92c09b03f4e_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOmEzNzE3ZTAyNDM3YTQxZTE5MDEyYjNjYjBhMjczMTRkL3RhYmxlcmFuZ2U6YTM3MTdlMDI0MzdhNDFlMTkwMTJiM2NiMGEyNzMxNGRfNC00LTEtMS04Mjc4Mg_3748c1e7-afee-43a5-be7f-22eb908c1f3e"
      unitRef="usd">500000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:InterestExpense
      contextRef="i8e3c4dec591644f5b67d216f6b423622_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOmEzNzE3ZTAyNDM3YTQxZTE5MDEyYjNjYjBhMjczMTRkL3RhYmxlcmFuZ2U6YTM3MTdlMDI0MzdhNDFlMTkwMTJiM2NiMGEyNzMxNGRfNi0yLTEtMS04Mjc4Mg_5488087e-f4f3-447e-bf9c-d2551828e05c"
      unitRef="usd">100000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i6588c22fb7d242729097d46bc107e464_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOmEzNzE3ZTAyNDM3YTQxZTE5MDEyYjNjYjBhMjczMTRkL3RhYmxlcmFuZ2U6YTM3MTdlMDI0MzdhNDFlMTkwMTJiM2NiMGEyNzMxNGRfNi00LTEtMS04Mjc4Mg_b42af8cb-e200-40e5-8e7c-603086e0d904"
      unitRef="usd">100000</us-gaap:InterestExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i6c7ca8ad39694e71b583c7ef4a4b1e4d_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOmEzNzE3ZTAyNDM3YTQxZTE5MDEyYjNjYjBhMjczMTRkL3RhYmxlcmFuZ2U6YTM3MTdlMDI0MzdhNDFlMTkwMTJiM2NiMGEyNzMxNGRfNy0yLTEtMS04Mjc4Mg_7b577a87-656d-4a57-abb4-90805fba008c"
      unitRef="usd">-800000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i840ed86b8d83428dae98a9709644d509_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOmEzNzE3ZTAyNDM3YTQxZTE5MDEyYjNjYjBhMjczMTRkL3RhYmxlcmFuZ2U6YTM3MTdlMDI0MzdhNDFlMTkwMTJiM2NiMGEyNzMxNGRfNy00LTEtMS04Mjc4Mg_773e441c-6e08-4ba0-8111-4b91619a5a5d"
      unitRef="usd">-300000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6c7ca8ad39694e71b583c7ef4a4b1e4d_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOmEzNzE3ZTAyNDM3YTQxZTE5MDEyYjNjYjBhMjczMTRkL3RhYmxlcmFuZ2U6YTM3MTdlMDI0MzdhNDFlMTkwMTJiM2NiMGEyNzMxNGRfOC0yLTEtMS04Mjc4Mg_06c0a9cc-d56d-45a4-8e5a-a0621310fb97"
      unitRef="usd">-100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i840ed86b8d83428dae98a9709644d509_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOmEzNzE3ZTAyNDM3YTQxZTE5MDEyYjNjYjBhMjczMTRkL3RhYmxlcmFuZ2U6YTM3MTdlMDI0MzdhNDFlMTkwMTJiM2NiMGEyNzMxNGRfOC00LTEtMS04Mjc4Mg_503eab72-79d4-4fa7-87dd-85ccca965794"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i6c7ca8ad39694e71b583c7ef4a4b1e4d_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOmEzNzE3ZTAyNDM3YTQxZTE5MDEyYjNjYjBhMjczMTRkL3RhYmxlcmFuZ2U6YTM3MTdlMDI0MzdhNDFlMTkwMTJiM2NiMGEyNzMxNGRfOS0yLTEtMS04Mjc4Mg_6acda5f0-2dc6-418f-8617-97b3639fc2c0"
      unitRef="usd">-700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i840ed86b8d83428dae98a9709644d509_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOmEzNzE3ZTAyNDM3YTQxZTE5MDEyYjNjYjBhMjczMTRkL3RhYmxlcmFuZ2U6YTM3MTdlMDI0MzdhNDFlMTkwMTJiM2NiMGEyNzMxNGRfOS00LTEtMS04Mjc4Mg_fa67e9bd-4c81-4c8a-bb70-99632419fd0c"
      unitRef="usd">-300000</us-gaap:NetIncomeLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="ie947ff5eae324b458a796759ec01b073_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOmEzNzE3ZTAyNDM3YTQxZTE5MDEyYjNjYjBhMjczMTRkL3RhYmxlcmFuZ2U6YTM3MTdlMDI0MzdhNDFlMTkwMTJiM2NiMGEyNzMxNGRfMTItMi0xLTEtODI3ODI_149c59da-0c9b-446f-b86c-6394b2ab4548"
      unitRef="usd">400000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="i051025edf9d84083b951a5c2120b859e_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOmEzNzE3ZTAyNDM3YTQxZTE5MDEyYjNjYjBhMjczMTRkL3RhYmxlcmFuZ2U6YTM3MTdlMDI0MzdhNDFlMTkwMTJiM2NiMGEyNzMxNGRfMTItNC0xLTEtODI3ODI_f4c3e5b2-3fa6-4c19-abf7-7b13b29fc6fe"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="ie947ff5eae324b458a796759ec01b073_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOmEzNzE3ZTAyNDM3YTQxZTE5MDEyYjNjYjBhMjczMTRkL3RhYmxlcmFuZ2U6YTM3MTdlMDI0MzdhNDFlMTkwMTJiM2NiMGEyNzMxNGRfMTMtMi0xLTEtODI3ODI_72aed061-dde5-49f4-88c7-c05f273bba5e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="i051025edf9d84083b951a5c2120b859e_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOmEzNzE3ZTAyNDM3YTQxZTE5MDEyYjNjYjBhMjczMTRkL3RhYmxlcmFuZ2U6YTM3MTdlMDI0MzdhNDFlMTkwMTJiM2NiMGEyNzMxNGRfMTMtNC0xLTEtODI3ODI_f8fb1a4b-5148-4431-9df8-0279e6da2582"
      unitRef="usd">-600000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ie947ff5eae324b458a796759ec01b073_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOmEzNzE3ZTAyNDM3YTQxZTE5MDEyYjNjYjBhMjczMTRkL3RhYmxlcmFuZ2U6YTM3MTdlMDI0MzdhNDFlMTkwMTJiM2NiMGEyNzMxNGRfMTQtMi0xLTEtODI3ODI_dbce5bf1-475b-41ce-8436-5c8460f02a31"
      unitRef="usd">400000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i051025edf9d84083b951a5c2120b859e_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOmEzNzE3ZTAyNDM3YTQxZTE5MDEyYjNjYjBhMjczMTRkL3RhYmxlcmFuZ2U6YTM3MTdlMDI0MzdhNDFlMTkwMTJiM2NiMGEyNzMxNGRfMTQtNC0xLTEtODI3ODI_24ef0965-701e-4fbf-b7bb-bad0704ec44e"
      unitRef="usd">-600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie947ff5eae324b458a796759ec01b073_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOmEzNzE3ZTAyNDM3YTQxZTE5MDEyYjNjYjBhMjczMTRkL3RhYmxlcmFuZ2U6YTM3MTdlMDI0MzdhNDFlMTkwMTJiM2NiMGEyNzMxNGRfMTUtMi0xLTEtODI3ODI_eb58725e-6fda-4625-a1ca-2f473f21e8ed"
      unitRef="usd">100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i051025edf9d84083b951a5c2120b859e_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOmEzNzE3ZTAyNDM3YTQxZTE5MDEyYjNjYjBhMjczMTRkL3RhYmxlcmFuZ2U6YTM3MTdlMDI0MzdhNDFlMTkwMTJiM2NiMGEyNzMxNGRfMTUtNC0xLTEtODI3ODI_4b913ac8-c6dc-49a3-a340-ea72afb4b722"
      unitRef="usd">-100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="ie947ff5eae324b458a796759ec01b073_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOmEzNzE3ZTAyNDM3YTQxZTE5MDEyYjNjYjBhMjczMTRkL3RhYmxlcmFuZ2U6YTM3MTdlMDI0MzdhNDFlMTkwMTJiM2NiMGEyNzMxNGRfMTYtMi0xLTEtODI3ODI_2ee76e44-3c28-4dc2-a2a0-5826dc05ee44"
      unitRef="usd">300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i051025edf9d84083b951a5c2120b859e_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOmEzNzE3ZTAyNDM3YTQxZTE5MDEyYjNjYjBhMjczMTRkL3RhYmxlcmFuZ2U6YTM3MTdlMDI0MzdhNDFlMTkwMTJiM2NiMGEyNzMxNGRfMTYtNC0xLTEtODI3ODI_4e5c2737-64a4-45e1-b9c5-6e1d82b91d61"
      unitRef="usd">-500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i594dfb15b16f4f3b94b3e4c667ae6f31_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOmEzNzE3ZTAyNDM3YTQxZTE5MDEyYjNjYjBhMjczMTRkL3RhYmxlcmFuZ2U6YTM3MTdlMDI0MzdhNDFlMTkwMTJiM2NiMGEyNzMxNGRfMTctMi0xLTEtODI3ODI_d007806c-1187-4f4c-be38-ba09e2844f1d"
      unitRef="usd">-400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id0cbe79b5a944e7ea8c8155a043cfb0c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82NC9mcmFnOjEzM2E3NDIwNzlkNDRjZjhhZDRiYTU3NzBlZjcwNGFiL3RhYmxlOmEzNzE3ZTAyNDM3YTQxZTE5MDEyYjNjYjBhMjczMTRkL3RhYmxlcmFuZ2U6YTM3MTdlMDI0MzdhNDFlMTkwMTJiM2NiMGEyNzMxNGRfMTctNC0xLTEtODI3ODI_d069c28d-7ce2-4c18-877f-890a2e2ea061"
      unitRef="usd">-800000</us-gaap:NetIncomeLoss>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RleHRyZWdpb246NDNkNTgwZGQ3ZWRmNGY2M2IyNzY4ZmEzYzlkNzg4ZTZfMjAw_10fbc855-88d8-44b2-b7f6-e4efc4af9b82">Shareholders&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; Equity&lt;/span&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in shareholders&#x2019; equity for the three months ended March&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.895%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.728%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.886%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.728%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.390%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:30pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common Shares Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capital in Excess of Par Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of Treasury Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Treasury Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Retained earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(370.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,987.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(183.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,684.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Activity related to stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares purchased under share repurchase program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividends declared ($0.19 per share)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(369.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,113.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(168.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,776.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in shareholders&#x2019; equity for the three months ended March&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.895%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.728%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.886%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.728%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.390%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common Shares Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capital in Excess of Par Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of Treasury Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Treasury Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Retained earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(229.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,456.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(159.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,335.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Activity related to stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares purchased under share repurchase program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(147.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(147.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividends declared ($0.18 per share)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive loss, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(347.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,617.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(182.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,326.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityTableTextBlock
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RleHRyZWdpb246NDNkNTgwZGQ3ZWRmNGY2M2IyNzY4ZmEzYzlkNzg4ZTZfMjA0_f9b1c01d-d6c8-45f9-9450-58ad9deac587">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in shareholders&#x2019; equity for the three months ended March&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.895%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.728%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.886%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.728%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.390%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:30pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common Shares Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capital in Excess of Par Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of Treasury Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Treasury Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Retained earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(370.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,987.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(183.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,684.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Activity related to stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares purchased under share repurchase program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividends declared ($0.19 per share)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(369.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,113.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(168.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,776.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in shareholders&#x2019; equity for the three months ended March&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.895%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.728%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.886%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.728%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.390%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common Shares Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capital in Excess of Par Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of Treasury Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Treasury Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Retained earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(229.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,456.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(159.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,335.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Activity related to stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares purchased under share repurchase program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(147.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(147.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividends declared ($0.18 per share)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive loss, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(347.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,617.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(182.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,326.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityTableTextBlock>
    <us-gaap:SharesIssued
      contextRef="i5974879a41634c43937d0fdc678376ef_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfMi0xLTEtMS04Mjc4Mg_e4f9af0f-2dce-4c4e-8b14-4be1ddc1f48f"
      unitRef="shares">75300000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i5974879a41634c43937d0fdc678376ef_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfMi0zLTEtMS04Mjc4Mg_04b75f33-4140-4b9f-a4d7-bf1af8b978a0"
      unitRef="usd">18800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2e4f2583d5104db2b4d1e647dc99032f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfMi01LTEtMS04Mjc4Mg_18bbc905-700a-453a-8465-1ff600d118b8"
      unitRef="usd">232200000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i516dc67ea1934343bbf9ab9c724c74fe_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfMi03LTEtMS04Mjc4Mg_1a13fc3a-e693-41a6-bd17-318c20e4947f"
      unitRef="shares">1200000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="i516dc67ea1934343bbf9ab9c724c74fe_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfMi05LTEtMS04Mjc4Mg_8d1f688b-ab1e-4d32-bc41-6e0137447fa8"
      unitRef="usd">-370900000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2ad958aa230d4452800e1a411e50a1da_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfMi0xMS0xLTEtODI3ODI_f192a78e-8109-4121-8219-c748cb5bba52"
      unitRef="usd">2987800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6339e7f0f9e847638d0b1e918478a17b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfMi0xMy0xLTEtODI3ODI_d9a49660-b07b-444c-a615-c7229495cae3"
      unitRef="usd">-183000000.0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5583fe9d33064523a217abe67f6f392d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfMi0xNS0xLTEtODI3ODI_3a579f72-336f-49a6-857d-f12168a0af9f"
      unitRef="usd">2684900000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i8c00de3c1e304a8ba1d6c714fc5be20a_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfMy0xMS0xLTEtODI3ODI_765c42a3-c540-4f64-b7d4-f433c955397e"
      unitRef="usd">140000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfMy0xNS0xLTEtODI3ODI_b2ff9db7-9fe9-457b-8df3-02811c01321f"
      unitRef="usd">140000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i353cb27834c543849553e5d0b7bbf5c1_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfNC01LTEtMS04Mjc4Mg_eb021fee-392f-4f06-9cfd-ddf111cbb63b"
      unitRef="usd">-50800000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ica8dcddf1bfb4c518886c671739fd284_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfNC03LTEtMS04Mjc4Mg_8525a3f4-bdc1-41de-a10d-d6bd9db7e705"
      unitRef="shares">-300000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ica8dcddf1bfb4c518886c671739fd284_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfNC05LTEtMS04Mjc4Mg_684daec1-f8de-497c-8c43-1e7d7dc3c32e"
      unitRef="usd">61800000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfNC0xNS0xLTEtODI3ODI_8e339fcf-ea81-4627-bacf-c94bd840f66b"
      unitRef="usd">11000000.0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ica8dcddf1bfb4c518886c671739fd284_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfNS03LTEtMS04Mjc4Mg_77346de3-4ef6-4534-902b-c5bdb397b5b6"
      unitRef="shares">200000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ica8dcddf1bfb4c518886c671739fd284_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfNS05LTEtMS04Mjc4Mg_2b7505fa-df1c-43b7-8eec-8f8baa66e90d"
      unitRef="usd">60100000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfNS0xNS0xLTEtODI3ODI_bb526302-8725-49a4-9e67-fd3d3c315497"
      unitRef="usd">60100000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfNi0wLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOjFhOTljNTU5MDMzNTQ4MjViODA2NTdhNzgxZDAxMzBjXzI0_de04a3a0-82cf-45b0-8718-8b07f7888d72"
      unitRef="usdPerShare">0.19</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="i8c00de3c1e304a8ba1d6c714fc5be20a_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfNi0xMS0xLTEtODI3ODI_8128eeb7-53b0-4b83-9ec1-571a85d9791b"
      unitRef="usd">14200000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfNi0xNS0xLTEtODI3ODI_f75f420e-24d7-443e-b4a8-97a9aa3dccdb"
      unitRef="usd">14200000</us-gaap:DividendsCommonStockCash>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i2b66fb1404f0411794600214ad5981bc_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfNy0xMy0xLTEtODI3ODI_6f2defa5-6d14-482f-8fc2-742cf2113000"
      unitRef="usd">14600000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfNy0xNS0xLTEtODI3ODI_606a7a47-75b8-4207-a234-89b995958d5e"
      unitRef="usd">14600000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:SharesIssued
      contextRef="if8c8c941591f438a9e38e52390bd7143_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfOC0xLTEtMS04Mjc4Mg_c62a8dc3-edef-4d81-a486-37e520d2439f"
      unitRef="shares">75300000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="if8c8c941591f438a9e38e52390bd7143_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfOC0zLTEtMS04Mjc4Mg_0b664d42-7c5b-4e01-8111-4f8dffb9c04a"
      unitRef="usd">18800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9ca2730fabca4305a997b6e33c1c770e_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfOC01LTEtMS04Mjc4Mg_70dc814b-d6e2-451f-988a-4f9f517b4d35"
      unitRef="usd">181400000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i8b96f9bbddfb400fb15bf48690acfac4_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfOC03LTEtMS04Mjc4Mg_4a93fac1-70cb-4f0a-a3f1-1b75b3b2dd38"
      unitRef="shares">1100000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="i8b96f9bbddfb400fb15bf48690acfac4_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfOC05LTEtMS04Mjc4Mg_a7d2047c-8c1d-4135-825c-12ee5b8b138d"
      unitRef="usd">-369200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i24c88cbf61274655b654ef8032885498_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfOC0xMS0xLTEtODI3ODI_7afa6ae1-3959-49f3-a003-7834637fdf98"
      unitRef="usd">3113600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6630ce4dbb7747e8858856ea430b90ab_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfOC0xMy0xLTEtODI3ODI_597f8659-01e3-4bf3-a869-f9c71570f679"
      unitRef="usd">-168400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmZhNjcxMTc5YzhjYjQ0NTNiNDU1MDIyYzE1MDMyZDI5L3RhYmxlcmFuZ2U6ZmE2NzExNzljOGNiNDQ1M2I0NTUwMjJjMTUwMzJkMjlfOC0xNS0xLTEtODI3ODI_25aba86d-ef25-4b43-b81e-33decfa0cea3"
      unitRef="usd">2776200000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="ic9824a1206b949e9a0e697dab83ac7c1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfMi0xLTEtMS04Mjc4Mg_3b33d79c-38c1-4d6e-9097-634f866db7d9"
      unitRef="shares">75300000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="ic9824a1206b949e9a0e697dab83ac7c1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfMi0zLTEtMS04Mjc4Mg_cf4fb4f4-80f9-4133-9391-ee574e09ba73"
      unitRef="usd">18800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i18b4fa445330470da5ef68248c88e734_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfMi01LTEtMS04Mjc4Mg_eda24a2d-2364-431d-bd1d-212ab0f2a28d"
      unitRef="usd">249000000.0</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i32ef532505b441b1806a8f09cd91cd70_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfMi03LTEtMS04Mjc4Mg_dbd576bf-0b48-4003-8361-f436c7d75aea"
      unitRef="shares">1100000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="i32ef532505b441b1806a8f09cd91cd70_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfMi05LTEtMS04Mjc4Mg_a37754f1-c64b-4067-9355-f34de1627d7d"
      unitRef="usd">-229500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i32bd0566d819471cba804ab5cc28ab44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfMi0xMS0xLTEtODI3ODI_ac946b65-fd6b-4995-a486-14e10bcf046f"
      unitRef="usd">2456700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0df22a14170c4331a1256c9f757e5090_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfMi0xMy0xLTEtODI3ODI_ff553eb2-d25d-46d4-9625-f2ab2c1e40f3"
      unitRef="usd">-159600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i00c9b6f38a304d5190000b6168ba7dce_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfMi0xNS0xLTEtODI3ODI_05c775b1-f962-4ae2-a656-f638b277e25b"
      unitRef="usd">2335400000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ie8e072fd9e914a71afd49e2d9a5e79c6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfMy0xMS0xLTEtODI3ODI_d98224a6-3894-4cf1-beec-e54147c9e7b0"
      unitRef="usd">173800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfMy0xNS0xLTEtODI3ODI_0d873fb6-ad04-43eb-82a9-d20a7f72a89d"
      unitRef="usd">173800000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i083cbb87646e4c8ba193971c93fd6efe_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfNC01LTEtMS04Mjc4Mg_ab7fb7c5-faac-4a1c-b268-39eab4bf7e0b"
      unitRef="usd">-29100000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ie4063d23292b47168eedc6bfb33a3fbd_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfNC03LTEtMS04Mjc4Mg_df518dc8-278f-4091-8ac3-4dc5e183e140"
      unitRef="shares">-300000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ie4063d23292b47168eedc6bfb33a3fbd_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfNC05LTEtMS04Mjc4Mg_f6eec225-3f84-411c-bcf4-75d849babfff"
      unitRef="usd">29200000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfNC0xNS0xLTEtODI3ODI_136ffd71-8d5b-4ae6-afb8-b65ccf7ba915"
      unitRef="usd">100000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ie4063d23292b47168eedc6bfb33a3fbd_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfNS03LTEtMS04Mjc4Mg_09dc199f-41f4-4dce-8822-aa92a415a7d4"
      unitRef="shares">400000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ie4063d23292b47168eedc6bfb33a3fbd_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfNS05LTEtMS04Mjc4Mg_d9361e75-f8d6-4d9a-9962-3fccb1381696"
      unitRef="usd">147100000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfNS0xNS0xLTEtODI3ODI_f4b181c7-5309-4f75-9b55-8c6c86ffa6c4"
      unitRef="usd">147100000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfNi0wLTEtMS04Mjc4Mi90ZXh0cmVnaW9uOmJiM2E3ZTQ2ODkxMDQ4YzliNWY4ODJlNjE1M2FmNzQ3XzI0_732895b0-4557-44bf-a191-40a483f9783f"
      unitRef="usdPerShare">0.18</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="ie8e072fd9e914a71afd49e2d9a5e79c6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfNi0xMS0xLTEtODI3ODI_72800444-729c-4db3-8502-74c5d62369d1"
      unitRef="usd">13200000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfNi0xNS0xLTEtODI3ODI_64066806-f003-462e-877d-44cb9b1d85af"
      unitRef="usd">13200000</us-gaap:DividendsCommonStockCash>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ia5fc6b2b23e84ec4bc5d35849e3156f6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfNy0xMy0xLTEtODI3ODI_e750d152-a549-44b1-b075-d865ed9604df"
      unitRef="usd">-22800000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfNy0xNS0xLTEtODI3ODI_aae94223-f29e-4124-932e-6d501b7128ec"
      unitRef="usd">-22800000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:SharesIssued
      contextRef="i48e325bcbc074931a2dd945f8078f5f8_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfOC0xLTEtMS04Mjc4Mg_751fc33a-b537-4362-93b5-c47755036542"
      unitRef="shares">75300000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i48e325bcbc074931a2dd945f8078f5f8_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfOC0zLTEtMS04Mjc4Mg_a2a7bb52-98dc-4b91-90dd-11689866496c"
      unitRef="usd">18800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2b1173baba244d369e85b0aaae78c105_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfOC01LTEtMS04Mjc4Mg_d094cb82-bbbe-4b80-8b30-41d8bbdaf8a9"
      unitRef="usd">219900000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i83dbf680868b48b9b005cf05def0fad3_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfOC03LTEtMS04Mjc4Mg_c2d8b229-845e-425d-abda-7aaf5631cec6"
      unitRef="shares">1200000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="i83dbf680868b48b9b005cf05def0fad3_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfOC05LTEtMS04Mjc4Mg_72cd26fe-74f0-4778-86ea-98397df88a55"
      unitRef="usd">-347400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibb84c364648d488ba64727ae4d194a34_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfOC0xMS0xLTEtODI3ODI_48665b25-c378-4465-a3e5-3a6419a9a512"
      unitRef="usd">2617300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i83a0a64e641241259400ffb042bd9b69_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfOC0xMy0xLTEtODI3ODI_adf1eeb3-4278-4da7-8640-fd25f5e4eb7d"
      unitRef="usd">-182400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie3cc75f001344ce095d702cd95b46078_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl82Ny9mcmFnOjQzZDU4MGRkN2VkZjRmNjNiMjc2OGZhM2M5ZDc4OGU2L3RhYmxlOmQ1ZDlmMGE1MzdjYzQ2ZjQ5MGI2YTUyZmRlOGZkYWJlL3RhYmxlcmFuZ2U6ZDVkOWYwYTUzN2NjNDZmNDkwYjZhNTJmZGU4ZmRhYmVfOC0xNS0xLTEtODI3ODI_1f7092e9-1559-48ae-b447-6e37ee503e8f"
      unitRef="usd">2326200000</us-gaap:StockholdersEquity>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83MC9mcmFnOmIxODkxNjY4MTM4MDRlMWY4MDAwNDA0NmFkYjJhMWU5L3RleHRyZWdpb246YjE4OTE2NjgxMzgwNGUxZjgwMDA0MDQ2YWRiMmExZTlfMjQ4MA_e92ab1d5-db21-44c8-b7d0-14a5a22e93e0">Stock-Based Compensation&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The West Pharmaceutical Services, Inc. 2016 Omnibus Incentive Compensation Plan (the &#x201c;2016 Plan&#x201d;) provides for the granting of stock options, stock appreciation rights, restricted stock awards and performance awards to employees and non-employee directors. A committee of the Board of Directors determines the terms and conditions of awards to be granted. Vesting requirements vary by award. At March&#160;31, 2023, there were 1,444,472 shares remaining in the 2016 Plan for future grants.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2023, we granted 105,244 stock options at a weighted average exercise price of $306.68 per share based on the grant-date fair value of our stock to employees under the 2016 Plan. The weighted average grant date fair value of options granted was $108.80 per share as determined by the Black-Scholes option valuation model using the following weighted average assumptions: a risk-free interest rate of 4.1%; expected life of 5.7 years based on prior experience; stock volatility of 29.8% based on historical data; and a dividend yield of 0.3%. Stock option expense is recognized over the vesting period, net of forfeitures.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2023, we granted 37,397 stock-settled performance share unit ("PSU") awards at a weighted average grant-date fair value of $306.68 per share to eligible employees. These awards are earned based on the Company's performance against pre-established targets, including annual growth rate of revenue and return on invested capital, over a specified performance period. Depending on the achievement of the targets, recipients of stock-settled PSU awards are entitled to receive a certain numbers of shares of common stock. Shares earned under PSU awards may vary from 0% to 200% of an employee's targeted award. The fair value of stock-settled PSU awards is based on the market price of our stock at the grant date and is recognized as expense over the performance period, adjusted for estimated target outcomes and net of forfeitures.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2023, we granted 4,284 stock-settled restricted share unit (&#x201c;RSU&#x201d;) awards at a weighted average grant-date fair value of $306.68 per share to eligible employees. These awards are earned over a specified performance period. The fair value of stock-settled RSU awards is based on the market price of our stock at the grant date and is recognized as expense over the vesting period, net of forfeitures. &lt;/span&gt;&lt;/div&gt;Stock-based compensation expense was $8.5 million and $5.5 million for the three months ended March&#160;31, 2023 and 2022, respectively.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i2af6ba55593d446686e312e0578684c6_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83MC9mcmFnOmIxODkxNjY4MTM4MDRlMWY4MDAwNDA0NmFkYjJhMWU5L3RleHRyZWdpb246YjE4OTE2NjgxMzgwNGUxZjgwMDA0MDQ2YWRiMmExZTlfNDUw_ca116094-6b55-4e06-8042-8ff7d7c767a9"
      unitRef="shares">1444472</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83MC9mcmFnOmIxODkxNjY4MTM4MDRlMWY4MDAwNDA0NmFkYjJhMWU5L3RleHRyZWdpb246YjE4OTE2NjgxMzgwNGUxZjgwMDA0MDQ2YWRiMmExZTlfNTM2_6302f4fc-56dd-4b07-b336-d4e25a3c11d9"
      unitRef="shares">105244</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83MC9mcmFnOmIxODkxNjY4MTM4MDRlMWY4MDAwNDA0NmFkYjJhMWU5L3RleHRyZWdpb246YjE4OTE2NjgxMzgwNGUxZjgwMDA0MDQ2YWRiMmExZTlfNTkz_b687a182-71f3-4405-92dd-55d5fd5744dd"
      unitRef="usdPerShare">306.68</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83MC9mcmFnOmIxODkxNjY4MTM4MDRlMWY4MDAwNDA0NmFkYjJhMWU5L3RleHRyZWdpb246YjE4OTE2NjgxMzgwNGUxZjgwMDA0MDQ2YWRiMmExZTlfNzU0_30c91cbd-d60d-444f-8d2e-620ced0c2c7e"
      unitRef="usdPerShare">108.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83MC9mcmFnOmIxODkxNjY4MTM4MDRlMWY4MDAwNDA0NmFkYjJhMWU5L3RleHRyZWdpb246YjE4OTE2NjgxMzgwNGUxZjgwMDA0MDQ2YWRiMmExZTlfOTA0_37d22183-0c6f-4404-8722-15ba8e7725ef"
      unitRef="number">0.041</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83MC9mcmFnOmIxODkxNjY4MTM4MDRlMWY4MDAwNDA0NmFkYjJhMWU5L3RleHRyZWdpb246YjE4OTE2NjgxMzgwNGUxZjgwMDA0MDQ2YWRiMmExZTlfOTI1_8a74d675-1bad-45b9-8b32-26e23ed3abb6">P5Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83MC9mcmFnOmIxODkxNjY4MTM4MDRlMWY4MDAwNDA0NmFkYjJhMWU5L3RleHRyZWdpb246YjE4OTE2NjgxMzgwNGUxZjgwMDA0MDQ2YWRiMmExZTlfOTgx_4650a3e6-1fc2-4276-b6cd-5947d9a490ff"
      unitRef="number">0.298</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83MC9mcmFnOmIxODkxNjY4MTM4MDRlMWY4MDAwNDA0NmFkYjJhMWU5L3RleHRyZWdpb246YjE4OTE2NjgxMzgwNGUxZjgwMDA0MDQ2YWRiMmExZTlfMTAzNA_119daef5-2834-4212-b13b-8311364fae8d"
      unitRef="number">0.003</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i9ea1399aa8514b6fb5e425e47f1f53b4_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83MC9mcmFnOmIxODkxNjY4MTM4MDRlMWY4MDAwNDA0NmFkYjJhMWU5L3RleHRyZWdpb246YjE4OTE2NjgxMzgwNGUxZjgwMDA0MDQ2YWRiMmExZTlfODI0NjMzNzIxMDg2MQ_5c9db2e7-c4b1-434c-a87f-79f4dd863bf0"
      unitRef="shares">37397</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i9ea1399aa8514b6fb5e425e47f1f53b4_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83MC9mcmFnOmIxODkxNjY4MTM4MDRlMWY4MDAwNDA0NmFkYjJhMWU5L3RleHRyZWdpb246YjE4OTE2NjgxMzgwNGUxZjgwMDA0MDQ2YWRiMmExZTlfODI0NjMzNzIxMDg2NQ_2f231cc4-0c58-44b4-8514-51d74debd9ff"
      unitRef="usdPerShare">306.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <wst:ShareBasedCompensationArrangementByShareBasedPaymentAwardActualPayoutPercentage
      contextRef="i5cea666f1a3e4fca9565501a1a97da9f_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83MC9mcmFnOmIxODkxNjY4MTM4MDRlMWY4MDAwNDA0NmFkYjJhMWU5L3RleHRyZWdpb246YjE4OTE2NjgxMzgwNGUxZjgwMDA0MDQ2YWRiMmExZTlfMTcxMw_de4c912c-c509-4d57-bc8a-4cbc5f27d138"
      unitRef="number">0</wst:ShareBasedCompensationArrangementByShareBasedPaymentAwardActualPayoutPercentage>
    <wst:ShareBasedCompensationArrangementByShareBasedPaymentAwardActualPayoutPercentage
      contextRef="if9485a9306be43498daef6ad2c76774a_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83MC9mcmFnOmIxODkxNjY4MTM4MDRlMWY4MDAwNDA0NmFkYjJhMWU5L3RleHRyZWdpb246YjE4OTE2NjgxMzgwNGUxZjgwMDA0MDQ2YWRiMmExZTlfMTcxOQ_bd445061-a7b2-452f-85a5-46b3d39a665e"
      unitRef="number">2</wst:ShareBasedCompensationArrangementByShareBasedPaymentAwardActualPayoutPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="iaac3fbfd1951416da909602aa595a831_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83MC9mcmFnOmIxODkxNjY4MTM4MDRlMWY4MDAwNDA0NmFkYjJhMWU5L3RleHRyZWdpb246YjE4OTE2NjgxMzgwNGUxZjgwMDA0MDQ2YWRiMmExZTlfMjAwOQ_45bc67ba-5773-4c68-b668-d6fe4157101c"
      unitRef="shares">4284</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iaac3fbfd1951416da909602aa595a831_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83MC9mcmFnOmIxODkxNjY4MTM4MDRlMWY4MDAwNDA0NmFkYjJhMWU5L3RleHRyZWdpb246YjE4OTE2NjgxMzgwNGUxZjgwMDA0MDQ2YWRiMmExZTlfMjExMA_0bcbd86d-4779-4353-852d-38f80d637e2f"
      unitRef="usdPerShare">306.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83MC9mcmFnOmIxODkxNjY4MTM4MDRlMWY4MDAwNDA0NmFkYjJhMWU5L3RleHRyZWdpb246YjE4OTE2NjgxMzgwNGUxZjgwMDA0MDQ2YWRiMmExZTlfMjQyMw_6f0de80e-03e6-4683-bd17-f698dfd92603"
      unitRef="usd">8500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83MC9mcmFnOmIxODkxNjY4MTM4MDRlMWY4MDAwNDA0NmFkYjJhMWU5L3RleHRyZWdpb246YjE4OTE2NjgxMzgwNGUxZjgwMDA0MDQ2YWRiMmExZTlfMjQzMA_1b804cda-8a9c-443f-a9f1-b34567784df3"
      unitRef="usd">5500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RleHRyZWdpb246YWNjMzlmMTg3MGJhNDM4YWJlZjYwZDY0ZTcyODllNTNfNDQ1_bb822ad4-ba3a-43b1-a097-631aade8a7a4">Benefit Plans&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of net periodic benefit cost for the three months ended March&#160;31 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.975%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.975%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.018%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pension benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other retirement benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized actuarial losses (gains)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.975%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.975%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.018%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pension benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other retirement benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. plans&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:0.641%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:0.641%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2022, we recorded a pension settlement charge of $0.6&#160;million within other nonoperating expense (income), as we determined that normal-course lump-sum payments for our U.S. qualified defined benefit pension plan exceeded the threshold for settlement accounting under U.S. GAAP for the year.&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:0.801%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:ScheduleOfNetBenefitCostsTableTextBlock
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RleHRyZWdpb246YWNjMzlmMTg3MGJhNDM4YWJlZjYwZDY0ZTcyODllNTNfNDQ3_678415b3-9a7b-4c69-9378-883190f24e93">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of net periodic benefit cost for the three months ended March&#160;31 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.975%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.975%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.018%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pension benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other retirement benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized actuarial losses (gains)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.975%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.975%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.018%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pension benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other retirement benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. plans&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetBenefitCostsTableTextBlock>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i15f25764805440459934b22b2c76b3b4_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfMi0xLTEtMS04Mjc4Mg_4cb8cb54-9625-444c-85fd-7638d2878788"
      unitRef="usd">300000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ib6b03745b52d4c23b5f91243d9f4d0c7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfMi0zLTEtMS04Mjc4Mg_ca242102-93ab-46d6-91a7-3fd59c46a24a"
      unitRef="usd">400000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="icea6ecda38c04a1980ef2da02b46df03_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfMi01LTEtMS04Mjc4Mg_7b39c620-b113-4de0-8d66-aa24d8098839"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i18f818cb77b7453cbd94313211a8df44_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfMi03LTEtMS04Mjc4Mg_a09a2b8a-9a49-4133-b799-8a3b2d29e80e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfMi05LTEtMS04Mjc4Mg_d0524a63-5059-41f3-b13c-0edb9d5a29f9"
      unitRef="usd">300000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfMi0xMS0xLTEtODI3ODI_9c8c324f-b6ba-4c04-ae30-d524f5e13c75"
      unitRef="usd">400000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i15f25764805440459934b22b2c76b3b4_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfMy0xLTEtMS04Mjc4Mg_24b55727-d9e7-4357-ae1a-2f2192117f80"
      unitRef="usd">600000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ib6b03745b52d4c23b5f91243d9f4d0c7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfMy0zLTEtMS04Mjc4Mg_e62c5f7b-98ef-4a9a-98dd-a753935480bf"
      unitRef="usd">1600000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="icea6ecda38c04a1980ef2da02b46df03_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfMy01LTEtMS04Mjc4Mg_f1ef031c-1d2b-455d-abe5-e3c7c29052d0"
      unitRef="usd">100000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i18f818cb77b7453cbd94313211a8df44_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfMy03LTEtMS04Mjc4Mg_18c36f4b-d9e1-47fe-a83c-0ca0a2897999"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfMy05LTEtMS04Mjc4Mg_20b0ace6-1557-499e-b285-ea25e3622534"
      unitRef="usd">700000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfMy0xMS0xLTEtODI3ODI_b672792f-aa5e-4f05-bd9f-b66af9a99a6f"
      unitRef="usd">1600000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i15f25764805440459934b22b2c76b3b4_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfNC0xLTEtMS04Mjc4Mg_7b6c3711-37d7-49f7-a676-6504336eff12"
      unitRef="usd">300000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="ib6b03745b52d4c23b5f91243d9f4d0c7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfNC0zLTEtMS04Mjc4Mg_1a948a04-9fbd-43c8-b2c5-8eedaadbf31f"
      unitRef="usd">2200000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="icea6ecda38c04a1980ef2da02b46df03_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfNC01LTEtMS04Mjc4Mg_783f6b3d-3d72-420a-982a-7bd73402663a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i18f818cb77b7453cbd94313211a8df44_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfNC03LTEtMS04Mjc4Mg_7f896060-5a2d-4f8c-a135-5ce442439fc1"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfNC05LTEtMS04Mjc4Mg_33fd44b6-7ba3-4f98-b9df-3c2b95757359"
      unitRef="usd">300000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfNC0xMS0xLTEtODI3ODI_d71d4d10-2676-4aa2-ab10-90279aea1710"
      unitRef="usd">2200000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="i15f25764805440459934b22b2c76b3b4_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfNy0xLTEtMS04Mjc4Mg_8daef805-abbe-4186-92c4-f597e4d85d7b"
      unitRef="usd">-100000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="ib6b03745b52d4c23b5f91243d9f4d0c7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfNy0zLTEtMS04Mjc4Mg_cb1def65-75d0-4888-9ac1-8dce2d21f685"
      unitRef="usd">-400000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="icea6ecda38c04a1980ef2da02b46df03_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfNy01LTEtMS04Mjc4Mg_b345277b-e5d0-4f8e-88a3-8f34a1007e78"
      unitRef="usd">500000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="i18f818cb77b7453cbd94313211a8df44_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfNy03LTEtMS04Mjc4Mg_86aea262-5fca-4cd2-8be5-5de1367d8f23"
      unitRef="usd">400000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfNy05LTEtMS04Mjc4Mg_20093da7-fb81-4a2f-8e67-c2392636cf44"
      unitRef="usd">400000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfNy0xMS0xLTEtODI3ODI_fe403cc7-3f3b-465c-9611-b70369afb9c7"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="i15f25764805440459934b22b2c76b3b4_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfOS0xLTEtMS04Mjc4Mg_b2e97a4e-7316-4d58-8a64-664ab4325b92"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="ib6b03745b52d4c23b5f91243d9f4d0c7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfOS0zLTEtMS04Mjc4Mg_806bc5e6-83b2-4e30-b01d-293462fdd691"
      unitRef="usd">-600000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="icea6ecda38c04a1980ef2da02b46df03_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfOS01LTEtMS04Mjc4Mg_e941cc96-ad60-4c6d-89fc-8b76dc69099b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="i18f818cb77b7453cbd94313211a8df44_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfOS03LTEtMS04Mjc4Mg_f29a7e06-0f5e-4bfb-a4e6-c3411507bde9"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfOS05LTEtMS04Mjc4Mg_401bc75b-26b5-4b70-b051-3a07df7aeef3"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfOS0xMS0xLTEtODI3ODI_4aacaabb-a059-45fd-b839-d52648ba930d"
      unitRef="usd">-600000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i15f25764805440459934b22b2c76b3b4_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfMTAtMS0xLTEtODI3ODI_b01b57fe-58db-466e-aaf7-993fbafc722f"
      unitRef="usd">700000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ib6b03745b52d4c23b5f91243d9f4d0c7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfMTAtMy0xLTEtODI3ODI_9b2984e5-26f2-4d4b-a84c-b5fe07fd9419"
      unitRef="usd">800000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="icea6ecda38c04a1980ef2da02b46df03_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfMTAtNS0xLTEtODI3ODI_8227c716-4c93-4dc9-9bc0-530c068f6a44"
      unitRef="usd">-400000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i18f818cb77b7453cbd94313211a8df44_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfMTAtNy0xLTEtODI3ODI_fd420fc4-adb7-43f9-ba0a-236efad2d928"
      unitRef="usd">-400000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfMTAtOS0xLTEtODI3ODI_0bcb30fe-52da-41fd-8647-23b01069dc11"
      unitRef="usd">300000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjMzMzZhYmNmZDFiOTRiNThiMzE3ZTIyYmFiN2M5MTRkL3RhYmxlcmFuZ2U6MzMzNmFiY2ZkMWI5NGI1OGIzMTdlMjJiYWI3YzkxNGRfMTAtMTEtMS0xLTgyNzgy_5ee3d6df-206b-4b01-be5b-9f1605d78fab"
      unitRef="usd">400000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i209901cc4ed54159a25df88bd1b8faee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjEwY2EyMzI2ZjQwOTQ2ODJiMzZlMGQzMGM2MjczOWYxL3RhYmxlcmFuZ2U6MTBjYTIzMjZmNDA5NDY4MmIzNmUwZDMwYzYyNzM5ZjFfMi0xLTEtMS04Mjc4Mg_ed4f8f1e-b12a-4480-a3b6-24f1a3dffead"
      unitRef="usd">100000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ida333f1205fc4fcfb7b85636d28c908d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjEwY2EyMzI2ZjQwOTQ2ODJiMzZlMGQzMGM2MjczOWYxL3RhYmxlcmFuZ2U6MTBjYTIzMjZmNDA5NDY4MmIzNmUwZDMwYzYyNzM5ZjFfMi0zLTEtMS04Mjc4Mg_734c0732-e8be-4b71-b45f-259ecfa7c559"
      unitRef="usd">400000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="idbcc67097f9240329c190bf9487f2480_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjEwY2EyMzI2ZjQwOTQ2ODJiMzZlMGQzMGM2MjczOWYxL3RhYmxlcmFuZ2U6MTBjYTIzMjZmNDA5NDY4MmIzNmUwZDMwYzYyNzM5ZjFfMi01LTEtMS04Mjc4Mg_19cba568-99b7-476d-98b7-071249602446"
      unitRef="usd">-400000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i05073a750c324193a92113cb4a636965_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjEwY2EyMzI2ZjQwOTQ2ODJiMzZlMGQzMGM2MjczOWYxL3RhYmxlcmFuZ2U6MTBjYTIzMjZmNDA5NDY4MmIzNmUwZDMwYzYyNzM5ZjFfMi03LTEtMS04Mjc4Mg_a86cabb8-fc1d-4917-bf50-8b910a628cd3"
      unitRef="usd">-400000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i42e6f528867c45a7b7da2f9fe313486e_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjEwY2EyMzI2ZjQwOTQ2ODJiMzZlMGQzMGM2MjczOWYxL3RhYmxlcmFuZ2U6MTBjYTIzMjZmNDA5NDY4MmIzNmUwZDMwYzYyNzM5ZjFfMi05LTEtMS04Mjc4Mg_7969fd60-a496-45ef-a0e8-0a11473e322d"
      unitRef="usd">-300000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i13c26150d9794fafb5581ccf36e02580_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjEwY2EyMzI2ZjQwOTQ2ODJiMzZlMGQzMGM2MjczOWYxL3RhYmxlcmFuZ2U6MTBjYTIzMjZmNDA5NDY4MmIzNmUwZDMwYzYyNzM5ZjFfMi0xMS0xLTEtODI3ODI_5ab9d5c6-cd70-4ee7-b6b7-ee6cd03b63ae"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ia68ac2f16d2949e69b481796f2242932_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjEwY2EyMzI2ZjQwOTQ2ODJiMzZlMGQzMGM2MjczOWYxL3RhYmxlcmFuZ2U6MTBjYTIzMjZmNDA5NDY4MmIzNmUwZDMwYzYyNzM5ZjFfMy0xLTEtMS04Mjc4Mg_73d27d33-13b0-4e60-8212-49553ca645aa"
      unitRef="usd">600000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i28fde86f84534f35b341997ed553fd3b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjEwY2EyMzI2ZjQwOTQ2ODJiMzZlMGQzMGM2MjczOWYxL3RhYmxlcmFuZ2U6MTBjYTIzMjZmNDA5NDY4MmIzNmUwZDMwYzYyNzM5ZjFfMy0zLTEtMS04Mjc4Mg_d6c5472d-3f67-482a-9518-ba80340a774a"
      unitRef="usd">400000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i3ad6bf31a752453bb990cc27c2ba0854_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjEwY2EyMzI2ZjQwOTQ2ODJiMzZlMGQzMGM2MjczOWYxL3RhYmxlcmFuZ2U6MTBjYTIzMjZmNDA5NDY4MmIzNmUwZDMwYzYyNzM5ZjFfMy01LTEtMS04Mjc4Mg_6766814b-9a1b-4357-a85d-6bc57638a17f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i7cb4b2a7f3bc479997ddd2c09c37cf63_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjEwY2EyMzI2ZjQwOTQ2ODJiMzZlMGQzMGM2MjczOWYxL3RhYmxlcmFuZ2U6MTBjYTIzMjZmNDA5NDY4MmIzNmUwZDMwYzYyNzM5ZjFfMy03LTEtMS04Mjc4Mg_0c4784f6-0a67-417e-8f95-6155f178a6bf"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i8343aec575e3454988060e5f6ce66a0d_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjEwY2EyMzI2ZjQwOTQ2ODJiMzZlMGQzMGM2MjczOWYxL3RhYmxlcmFuZ2U6MTBjYTIzMjZmNDA5NDY4MmIzNmUwZDMwYzYyNzM5ZjFfMy05LTEtMS04Mjc4Mg_40fabdd5-2251-4773-9e6f-adef6039c482"
      unitRef="usd">600000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i577299ca8e5a4684b6ab0d6a77f3cabe_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjEwY2EyMzI2ZjQwOTQ2ODJiMzZlMGQzMGM2MjczOWYxL3RhYmxlcmFuZ2U6MTBjYTIzMjZmNDA5NDY4MmIzNmUwZDMwYzYyNzM5ZjFfMy0xMS0xLTEtODI3ODI_f8ab62e5-0fe3-4852-94ec-ac86b168a211"
      unitRef="usd">400000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i15f25764805440459934b22b2c76b3b4_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjEwY2EyMzI2ZjQwOTQ2ODJiMzZlMGQzMGM2MjczOWYxL3RhYmxlcmFuZ2U6MTBjYTIzMjZmNDA5NDY4MmIzNmUwZDMwYzYyNzM5ZjFfNC0xLTEtMS04Mjc4Mg_f919ee3e-40a1-4919-ac47-62bc34dd66cb"
      unitRef="usd">700000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ib6b03745b52d4c23b5f91243d9f4d0c7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjEwY2EyMzI2ZjQwOTQ2ODJiMzZlMGQzMGM2MjczOWYxL3RhYmxlcmFuZ2U6MTBjYTIzMjZmNDA5NDY4MmIzNmUwZDMwYzYyNzM5ZjFfNC0zLTEtMS04Mjc4Mg_f4b58f37-5840-43ba-936a-85233127716d"
      unitRef="usd">800000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="icea6ecda38c04a1980ef2da02b46df03_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjEwY2EyMzI2ZjQwOTQ2ODJiMzZlMGQzMGM2MjczOWYxL3RhYmxlcmFuZ2U6MTBjYTIzMjZmNDA5NDY4MmIzNmUwZDMwYzYyNzM5ZjFfNC01LTEtMS04Mjc4Mg_b487369b-1879-4efb-a3e0-3f0ab6a7434f"
      unitRef="usd">-400000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i18f818cb77b7453cbd94313211a8df44_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjEwY2EyMzI2ZjQwOTQ2ODJiMzZlMGQzMGM2MjczOWYxL3RhYmxlcmFuZ2U6MTBjYTIzMjZmNDA5NDY4MmIzNmUwZDMwYzYyNzM5ZjFfNC03LTEtMS04Mjc4Mg_8ba8a9be-affc-41b1-8748-c22aa0fc51e1"
      unitRef="usd">-400000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjEwY2EyMzI2ZjQwOTQ2ODJiMzZlMGQzMGM2MjczOWYxL3RhYmxlcmFuZ2U6MTBjYTIzMjZmNDA5NDY4MmIzNmUwZDMwYzYyNzM5ZjFfNC05LTEtMS04Mjc4Mg_e3bc37d8-fd75-4236-8be1-156dfb6cb630"
      unitRef="usd">300000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RhYmxlOjEwY2EyMzI2ZjQwOTQ2ODJiMzZlMGQzMGM2MjczOWYxL3RhYmxlcmFuZ2U6MTBjYTIzMjZmNDA5NDY4MmIzNmUwZDMwYzYyNzM5ZjFfNC0xMS0xLTEtODI3ODI_69594514-9e0f-4a4a-8bce-8ae54f422a5b"
      unitRef="usd">400000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="ib6b03745b52d4c23b5f91243d9f4d0c7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83My9mcmFnOmFjYzM5ZjE4NzBiYTQzOGFiZWY2MGQ2NGU3Mjg5ZTUzL3RleHRyZWdpb246YWNjMzlmMTg3MGJhNDM4YWJlZjYwZDY0ZTcyODllNTNfMTk3_096abd0a-c478-4a5d-b8fa-2a388b40a8e3"
      unitRef="usd">-600000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RleHRyZWdpb246ZWUxYzI1YTM0ZTc5NGFhY2I4ZjE0MTY5OTg4ZWRjNDlfMTM0Mg_49242b1f-a532-4e40-8435-5403a7f541d0">Other Expense (Income) &lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other expense (income) consists of:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset impairments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss (gain) on oil hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange transaction losses (gains)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other expense (income)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restructuring and Related Charges&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2022, the Company approved a restructuring plan to adjust our operating cost base to better respond to the macroeconomic factors influencing our business. These changes are expected to be implemented over a period of up to twelve months from the date of approval. The plan is expected to require restructuring and related charges of approximately $25&#160;million to $27&#160;million, with annualized savings in the range of $22.0&#160;million to $24.0&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table presents activity related to our restructuring obligations related to our 2022 restructuring plan:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.210%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Severance&lt;br/&gt;and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-related charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Asset Impairments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2023, in preparation for the sale of one of the Company&#x2019;s manufacturing facilities within the Proprietary Products segment, the Company recorded an impairment expense of $9.4&#160;million within other expense (income) and a corresponding reduction to the disposal group net assets to its fair value less cost to sell. The transaction is expected to close during the second quarter of 2023.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contingent Consideration&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration represents changes in the fair value of the SmartDose&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; contingent consideration. Please refer to Note 10, &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i7bf87d07bb544f48851c48374130181b_61" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Fair Value Measurements&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for additional details.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Oil Hedges&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2023 and 2022, we recorded a loss of $0.6&#160;million and a gain of $2.8&#160;million, respectively, related to oil hedges. Please refer to Note 9, &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i7bf87d07bb544f48851c48374130181b_58" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Derivative Financial Instruments&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for further discussion of our hedging activity.&lt;/span&gt;&lt;/div&gt;</us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock>
    <wst:ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RleHRyZWdpb246ZWUxYzI1YTM0ZTc5NGFhY2I4ZjE0MTY5OTg4ZWRjNDlfMTM1Mg_7a3ea384-1461-4fda-8452-385bb8b0b940">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other expense (income) consists of:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset impairments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss (gain) on oil hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange transaction losses (gains)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other expense (income)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</wst:ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock>
    <us-gaap:AssetImpairmentCharges
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RhYmxlOmJkNTczYmE0MTgwNDQyZWI5MjFkNTBhMzcyYzlhN2FhL3RhYmxlcmFuZ2U6YmQ1NzNiYTQxODA0NDJlYjkyMWQ1MGEzNzJjOWE3YWFfMy0xLTEtMS04Mjc4Mg_9e1bcd67-d4b3-47df-b93f-07b38c10b286"
      unitRef="usd">11300000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RhYmxlOmJkNTczYmE0MTgwNDQyZWI5MjFkNTBhMzcyYzlhN2FhL3RhYmxlcmFuZ2U6YmQ1NzNiYTQxODA0NDJlYjkyMWQ1MGEzNzJjOWE3YWFfMy0zLTEtMS04Mjc4Mg_c45e8437-133c-4423-a209-c052206d546a"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RhYmxlOmJkNTczYmE0MTgwNDQyZWI5MjFkNTBhMzcyYzlhN2FhL3RhYmxlcmFuZ2U6YmQ1NzNiYTQxODA0NDJlYjkyMWQ1MGEzNzJjOWE3YWFfNC0xLTEtMS04Mjc4Mg_ca7521d9-53cd-4f2c-879f-832d02c787f1"
      unitRef="usd">-600000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RhYmxlOmJkNTczYmE0MTgwNDQyZWI5MjFkNTBhMzcyYzlhN2FhL3RhYmxlcmFuZ2U6YmQ1NzNiYTQxODA0NDJlYjkyMWQ1MGEzNzJjOWE3YWFfNC0zLTEtMS04Mjc4Mg_77173b00-4c63-4917-92ac-2a796ddff0f4"
      unitRef="usd">2800000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RhYmxlOmJkNTczYmE0MTgwNDQyZWI5MjFkNTBhMzcyYzlhN2FhL3RhYmxlcmFuZ2U6YmQ1NzNiYTQxODA0NDJlYjkyMWQ1MGEzNzJjOWE3YWFfOC0xLTEtMS04Mjc4Mg_7c6a994c-8d75-4652-9d32-5b5d148dfeb8"
      unitRef="usd">300000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RhYmxlOmJkNTczYmE0MTgwNDQyZWI5MjFkNTBhMzcyYzlhN2FhL3RhYmxlcmFuZ2U6YmQ1NzNiYTQxODA0NDJlYjkyMWQ1MGEzNzJjOWE3YWFfOC0zLTEtMS04Mjc4Mg_37c47b7d-23a5-4891-80e9-b3210acb0ff5"
      unitRef="usd">800000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RhYmxlOmJkNTczYmE0MTgwNDQyZWI5MjFkNTBhMzcyYzlhN2FhL3RhYmxlcmFuZ2U6YmQ1NzNiYTQxODA0NDJlYjkyMWQ1MGEzNzJjOWE3YWFfOS0xLTEtMS04Mjc4Mg_bb60a190-c804-4722-aaca-9d11cccbf940"
      unitRef="usd">-900000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RhYmxlOmJkNTczYmE0MTgwNDQyZWI5MjFkNTBhMzcyYzlhN2FhL3RhYmxlcmFuZ2U6YmQ1NzNiYTQxODA0NDJlYjkyMWQ1MGEzNzJjOWE3YWFfOS0zLTEtMS04Mjc4Mg_96b09350-e90d-4e84-9008-ad6f72cce03a"
      unitRef="usd">1100000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RhYmxlOmJkNTczYmE0MTgwNDQyZWI5MjFkNTBhMzcyYzlhN2FhL3RhYmxlcmFuZ2U6YmQ1NzNiYTQxODA0NDJlYjkyMWQ1MGEzNzJjOWE3YWFfMTAtMS0xLTEtODI3ODI_01bfc122-1e16-44cf-a447-86c22a5f4dd8"
      unitRef="usd">200000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RhYmxlOmJkNTczYmE0MTgwNDQyZWI5MjFkNTBhMzcyYzlhN2FhL3RhYmxlcmFuZ2U6YmQ1NzNiYTQxODA0NDJlYjkyMWQ1MGEzNzJjOWE3YWFfMTAtMy0xLTEtODI3ODI_fd2f65ac-b58a-4b43-b2f2-94cfac080042"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <wst:OtherIncomeExpense
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RhYmxlOmJkNTczYmE0MTgwNDQyZWI5MjFkNTBhMzcyYzlhN2FhL3RhYmxlcmFuZ2U6YmQ1NzNiYTQxODA0NDJlYjkyMWQ1MGEzNzJjOWE3YWFfMTEtMS0xLTEtODI3ODI_85a77d71-d8da-473b-81bd-bb4a7fdd3316"
      unitRef="usd">-12900000</wst:OtherIncomeExpense>
    <wst:OtherIncomeExpense
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RhYmxlOmJkNTczYmE0MTgwNDQyZWI5MjFkNTBhMzcyYzlhN2FhL3RhYmxlcmFuZ2U6YmQ1NzNiYTQxODA0NDJlYjkyMWQ1MGEzNzJjOWE3YWFfMTEtMy0xLTEtODI3ODI_e013efe1-ecb7-40d4-8b0d-3737b4b935e3"
      unitRef="usd">3100000</wst:OtherIncomeExpense>
    <wst:RestructuringAndRelatedActivitiesPeriodOfImplementation
      contextRef="i7fe28b57298646bca10b9de129f3bac3_D20221201-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RleHRyZWdpb246ZWUxYzI1YTM0ZTc5NGFhY2I4ZjE0MTY5OTg4ZWRjNDlfMzc5_735b2c5b-d525-467a-b5f2-b43ee0ce43db">P12M</wst:RestructuringAndRelatedActivitiesPeriodOfImplementation>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="i966f8dcfe0c8437bb80311fd4f44d03d_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RleHRyZWdpb246ZWUxYzI1YTM0ZTc5NGFhY2I4ZjE0MTY5OTg4ZWRjNDlfNDY5_0bb3c1fb-7980-4490-b5a8-d83b1c2e9d88"
      unitRef="usd">25000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="i173c567741e44c9180c9525060447224_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RleHRyZWdpb246ZWUxYzI1YTM0ZTc5NGFhY2I4ZjE0MTY5OTg4ZWRjNDlfNDc1_4ef8c3b2-9bef-4c5c-aa84-5849326bc7e2"
      unitRef="usd">27000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:EffectOnFutureEarningsAmount
      contextRef="i23c5432999954af5a1ded50a2d12617d_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RleHRyZWdpb246ZWUxYzI1YTM0ZTc5NGFhY2I4ZjE0MTY5OTg4ZWRjNDlfNTE5_d6e39a30-11c3-4625-8e13-573c8eb1f26a"
      unitRef="usd">22000000</us-gaap:EffectOnFutureEarningsAmount>
    <us-gaap:EffectOnFutureEarningsAmount
      contextRef="i00f636ccc7fe4a40bff18a2475aee5fb_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RleHRyZWdpb246ZWUxYzI1YTM0ZTc5NGFhY2I4ZjE0MTY5OTg4ZWRjNDlfNTI1_ec497130-4f17-49d8-919c-2bab33864b31"
      unitRef="usd">24000000</us-gaap:EffectOnFutureEarningsAmount>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RleHRyZWdpb246ZWUxYzI1YTM0ZTc5NGFhY2I4ZjE0MTY5OTg4ZWRjNDlfMTM0Ng_d1fbd74d-6231-423b-94d2-ebbc33120f03">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table presents activity related to our restructuring obligations related to our 2022 restructuring plan:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.210%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Severance&lt;br/&gt;and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-related charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="ief1173cf0c9c47e8a1b90da1b941c509_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RhYmxlOjA5OWZiMTg2MDY2OTRkZThiNzkyZjEwMjIxNjg0ZmY5L3RhYmxlcmFuZ2U6MDk5ZmIxODYwNjY5NGRlOGI3OTJmMTAyMjE2ODRmZjlfMS0xLTEtMS04Mjc4Mg_85291e6e-2a93-4633-bc7f-51c0fcf797c1"
      unitRef="usd">10100000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i320c37f388f0402ebe72c6e91de76520_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RhYmxlOjA5OWZiMTg2MDY2OTRkZThiNzkyZjEwMjIxNjg0ZmY5L3RhYmxlcmFuZ2U6MDk5ZmIxODYwNjY5NGRlOGI3OTJmMTAyMjE2ODRmZjlfMS01LTEtMS04Mjc4Mg_8e03f7b5-8e44-4ddd-9cb2-b2bf0212cb75"
      unitRef="usd">15300000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i741e48b8c43549918dae0d3e9f2835dc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RhYmxlOjA5OWZiMTg2MDY2OTRkZThiNzkyZjEwMjIxNjg0ZmY5L3RhYmxlcmFuZ2U6MDk5ZmIxODYwNjY5NGRlOGI3OTJmMTAyMjE2ODRmZjlfMS03LTEtMS04Mjc4Mg_2c6b16be-4ebf-4ab9-8355-321c8a293935"
      unitRef="usd">25400000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges
      contextRef="ie5751a6a227b4cd09e42603236f7ce4b_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RhYmxlOjA5OWZiMTg2MDY2OTRkZThiNzkyZjEwMjIxNjg0ZmY5L3RhYmxlcmFuZ2U6MDk5ZmIxODYwNjY5NGRlOGI3OTJmMTAyMjE2ODRmZjlfMi0xLTEtMS04Mjc4Mg_0f524709-7436-4554-a7c4-e16540a27390"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ib58ff9d1a085489cb685ece3967cd85c_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RhYmxlOjA5OWZiMTg2MDY2OTRkZThiNzkyZjEwMjIxNjg0ZmY5L3RhYmxlcmFuZ2U6MDk5ZmIxODYwNjY5NGRlOGI3OTJmMTAyMjE2ODRmZjlfMi01LTEtMS04Mjc4Mg_08397f9e-ea07-42d2-ae50-a71348a6e325"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ic32e88fe332446cd865cf4708f70ecbd_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RhYmxlOjA5OWZiMTg2MDY2OTRkZThiNzkyZjEwMjIxNjg0ZmY5L3RhYmxlcmFuZ2U6MDk5ZmIxODYwNjY5NGRlOGI3OTJmMTAyMjE2ODRmZjlfMi03LTEtMS04Mjc4Mg_9329948c-7585-443f-80a9-ef8e00d4188e"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring
      contextRef="ie5751a6a227b4cd09e42603236f7ce4b_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RhYmxlOjA5OWZiMTg2MDY2OTRkZThiNzkyZjEwMjIxNjg0ZmY5L3RhYmxlcmFuZ2U6MDk5ZmIxODYwNjY5NGRlOGI3OTJmMTAyMjE2ODRmZjlfMy0xLTEtMS04Mjc4Mg_181daef0-9ff3-4354-829e-a9a97cf5ca53"
      unitRef="usd">700000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="ib58ff9d1a085489cb685ece3967cd85c_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RhYmxlOjA5OWZiMTg2MDY2OTRkZThiNzkyZjEwMjIxNjg0ZmY5L3RhYmxlcmFuZ2U6MDk5ZmIxODYwNjY5NGRlOGI3OTJmMTAyMjE2ODRmZjlfMy01LTEtMS04Mjc4Mg_d49ff4ee-1a57-41ff-ac4b-0a9fdb6dd23d"
      unitRef="usd">0</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="ic32e88fe332446cd865cf4708f70ecbd_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RhYmxlOjA5OWZiMTg2MDY2OTRkZThiNzkyZjEwMjIxNjg0ZmY5L3RhYmxlcmFuZ2U6MDk5ZmIxODYwNjY5NGRlOGI3OTJmMTAyMjE2ODRmZjlfMy03LTEtMS04Mjc4Mg_ea828c53-1fee-4971-a85d-9f4ba2ecd92a"
      unitRef="usd">700000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve
      contextRef="i5dddcfaad27c4e2bb489c4f35ed023eb_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RhYmxlOjA5OWZiMTg2MDY2OTRkZThiNzkyZjEwMjIxNjg0ZmY5L3RhYmxlcmFuZ2U6MDk5ZmIxODYwNjY5NGRlOGI3OTJmMTAyMjE2ODRmZjlfNS0xLTEtMS04Mjc4Mg_e3fc54b0-2415-46ae-9a07-91f49bab7dc5"
      unitRef="usd">9400000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ic23b01e75b1e4bc5a81f42b0e6c8108b_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RhYmxlOjA5OWZiMTg2MDY2OTRkZThiNzkyZjEwMjIxNjg0ZmY5L3RhYmxlcmFuZ2U6MDk5ZmIxODYwNjY5NGRlOGI3OTJmMTAyMjE2ODRmZjlfNS01LTEtMS04Mjc4Mg_575f9bbe-ce39-41c8-bb43-7a46430a64d9"
      unitRef="usd">15300000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i7fa2298580b64ebfb1db3e0ca8424d94_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RhYmxlOjA5OWZiMTg2MDY2OTRkZThiNzkyZjEwMjIxNjg0ZmY5L3RhYmxlcmFuZ2U6MDk5ZmIxODYwNjY5NGRlOGI3OTJmMTAyMjE2ODRmZjlfNS03LTEtMS04Mjc4Mg_bc96a100-01d9-4e0d-9851-fcacc3d44177"
      unitRef="usd">24700000</us-gaap:RestructuringReserve>
    <us-gaap:AssetImpairmentCharges
      contextRef="i3b6114e84e5644b6b9435baa1eba9515_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RleHRyZWdpb246ZWUxYzI1YTM0ZTc5NGFhY2I4ZjE0MTY5OTg4ZWRjNDlfODI0NjMzNzIxMzg3NQ_e879862c-4661-4ef5-adc5-fbfeb2525184"
      unitRef="usd">9400000</us-gaap:AssetImpairmentCharges>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RleHRyZWdpb246ZWUxYzI1YTM0ZTc5NGFhY2I4ZjE0MTY5OTg4ZWRjNDlfODI0NjMzNzIxMjA0NQ_ca7521d9-53cd-4f2c-879f-832d02c787f1"
      unitRef="usd">-600000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83Ni9mcmFnOmVlMWMyNWEzNGU3OTRhYWNiOGYxNDE2OTk4OGVkYzQ5L3RleHRyZWdpb246ZWUxYzI1YTM0ZTc5NGFhY2I4ZjE0MTY5OTg4ZWRjNDlfODI0NjMzNzIxMjA1Mw_77173b00-4c63-4917-92ac-2a796ddff0f4"
      unitRef="usd">2800000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83OS9mcmFnOjY5MDBmYmNjYzllNTQyNjU5Y2UyNzBkNTc5NjkzOGY1L3RleHRyZWdpb246NjkwMGZiY2NjOWU1NDI2NTljZTI3MGQ1Nzk2OTM4ZjVfNzE1_8d348e78-4612-4d6c-aff9-37b1e5d0b555">Income Taxes&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tax provision for interim periods is determined using the estimated annual effective consolidated tax rate, based on the current estimate of full-year earnings before taxes, adjusted for the impact of discrete quarterly items.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes was $23.6 million and $21.2 million for the three months ended March&#160;31, 2023 and 2022, respectively, and the effective tax rate was 14.9% and 11.3%, respectively. During the three months ended March&#160;31, 2023 and 2022, we recorded a tax benefit of $11.6&#160;million and $8.9&#160;million, respectively, associated with stock-based compensation. The increase in the effective tax rate is primarily due to a shift in the geographic earnings mix and a $5.9&#160;million tax benefit recorded as a result of a state tax valuation allowance reversal in the three months ended March 31, 2022 that was not repeated in 2023. This was offset by an increase in the tax benefit related to stock-based compensation for the three months ended March&#160;31, 2023, as compared to the same period in 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83OS9mcmFnOjY5MDBmYmNjYzllNTQyNjU5Y2UyNzBkNTc5NjkzOGY1L3RleHRyZWdpb246NjkwMGZiY2NjOWU1NDI2NTljZTI3MGQ1Nzk2OTM4ZjVfMjk2_926e1ebb-79d5-4493-a40d-195ed579fa00"
      unitRef="usd">23600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83OS9mcmFnOjY5MDBmYmNjYzllNTQyNjU5Y2UyNzBkNTc5NjkzOGY1L3RleHRyZWdpb246NjkwMGZiY2NjOWU1NDI2NTljZTI3MGQ1Nzk2OTM4ZjVfMzAz_d8948721-3f85-4a5f-988b-4e3c5cbdda9b"
      unitRef="usd">21200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83OS9mcmFnOjY5MDBmYmNjYzllNTQyNjU5Y2UyNzBkNTc5NjkzOGY1L3RleHRyZWdpb246NjkwMGZiY2NjOWU1NDI2NTljZTI3MGQ1Nzk2OTM4ZjVfMzcz_23105ba5-2ee4-40ae-a74c-374bb9558a48"
      unitRef="number">0.149</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83OS9mcmFnOjY5MDBmYmNjYzllNTQyNjU5Y2UyNzBkNTc5NjkzOGY1L3RleHRyZWdpb246NjkwMGZiY2NjOWU1NDI2NTljZTI3MGQ1Nzk2OTM4ZjVfMzgw_2ccecf90-d1e8-4786-aaba-121339538d37"
      unitRef="number">0.113</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83OS9mcmFnOjY5MDBmYmNjYzllNTQyNjU5Y2UyNzBkNTc5NjkzOGY1L3RleHRyZWdpb246NjkwMGZiY2NjOWU1NDI2NTljZTI3MGQ1Nzk2OTM4ZjVfODI0NjMzNzIwOTA0Nw_8ef4fb6d-0c70-40a7-b5a9-1c01fea08655"
      unitRef="usd">-11600000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83OS9mcmFnOjY5MDBmYmNjYzllNTQyNjU5Y2UyNzBkNTc5NjkzOGY1L3RleHRyZWdpb246NjkwMGZiY2NjOWU1NDI2NTljZTI3MGQ1Nzk2OTM4ZjVfNDU5_5b3ae0e4-5f12-434a-a667-914093f06e6c"
      unitRef="usd">-8900000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl83OS9mcmFnOjY5MDBmYmNjYzllNTQyNjU5Y2UyNzBkNTc5NjkzOGY1L3RleHRyZWdpb246NjkwMGZiY2NjOWU1NDI2NTljZTI3MGQ1Nzk2OTM4ZjVfODI0NjMzNzIwOTkwOA_f69a58b5-562b-4225-9310-e022a7cca3fb"
      unitRef="usd">-5900000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84Mi9mcmFnOmM3NTczZGRkMTUxNTQ5NjM5OGZlOGIyMmU0ODBkODNjL3RleHRyZWdpb246Yzc1NzNkZGQxNTE1NDk2Mzk4ZmU4YjIyZTQ4MGQ4M2NfNjg3_02652471-d635-46a9-8615-d127870659d5">Commitments and Contingencies&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we are involved in product liability matters and other legal proceedings and claims generally incidental to our normal business activities. We accrue for loss contingencies when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. While the outcome of current proceedings cannot be accurately predicted, we believe their ultimate resolution should not have a material adverse effect on our business, financial condition, results of operations or liquidity.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no significant changes to the commitments and contingencies included in our &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/105770/000010577023000012/wst-20221231.htm#i8148abfe270d4f15aa2ba9319df722dc_58" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;2022 Annual Report&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RleHRyZWdpb246NTc5MjcyZTI5NDUyNDU2NzlmNGZlNGRmZDA4YjBhMGNfMjUxNw_87bb340b-10fe-43d4-9b07-cfa81f7c6879">Segment Information&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our business operations are organized into two reportable segments, Proprietary Products and Contract-Manufactured Products. Our Proprietary Products reportable segment offers proprietary packaging, containment solutions and drug delivery products, along with analytical lab services and other integrated services and solutions, primarily to biologic, generic and pharmaceutical drug customers. Our Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Chief Operating Decision Maker ("CODM") evaluates the performance of our segments based upon, among other things, segment net sales and operating profit. Segment operating profit excludes general corporate costs, which include executive and director compensation, stock-based compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments. Also excluded are items that the CODM considers not representative of ongoing operations. Such items are referred to as other unallocated items and generally include restructuring and related charges, certain asset impairments and other specifically-identified income or expense items. The segment operating profit metric is what the CODM uses in evaluating our results of operations and the financial measure that provides a valuable insight into our overall performance and financial position.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents information about our reportable segments, reconciled to consolidated totals:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.901%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net sales:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proprietary Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;583.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;601.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract-Manufactured Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intersegment sales elimination&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consolidated net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;716.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;720.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The intersegment sales elimination, which is required for the presentation of consolidated net sales, represents the elimination of components sold between our segments.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides summarized financial information for our segments:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proprietary Products&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract-Manufactured Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total business segment operating profit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate and Unallocated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate general costs &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unallocated Items:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset impairment for planned sale of plant &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of acquisition-related intangible assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Corporate and Unallocated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consolidated operating profit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (income) expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income before income taxes and equity in net income of affiliated companies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) Corporate general costs includes executive and director compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2) During the three months ended March&#160;31, 2023, in preparation for the sale of one of the Company&#x2019;s manufacturing facilities within the Proprietary Products segment, the Company recorded an impairment expense of $9.4&#160;million within other expense (income) and a corresponding reduction to the disposal group net assets to its fair value less cost to sell. The transaction is expected to close during the second quarter of 2023.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3) During the three months ended March&#160;31, 2023 and 2022, we recorded $0.2&#160;million of amortization expense within operating profit associated with an intangible asset acquired during the second quarter of 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Please refer to Note 15, &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i7bf87d07bb544f48851c48374130181b_76" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Other Expense (Income)&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for further discussion of certain unallocated items referenced above.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RleHRyZWdpb246NTc5MjcyZTI5NDUyNDU2NzlmNGZlNGRmZDA4YjBhMGNfNzk_2c043096-ae10-4896-b114-ffd0abb3e9b8"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RleHRyZWdpb246NTc5MjcyZTI5NDUyNDU2NzlmNGZlNGRmZDA4YjBhMGNfMjUwNg_fedc0235-4e93-487e-a02a-f407f0e50e93">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents information about our reportable segments, reconciled to consolidated totals:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.901%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net sales:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proprietary Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;583.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;601.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract-Manufactured Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intersegment sales elimination&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consolidated net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;716.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;720.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:Revenues
      contextRef="i776c2fc9c0314d5dbc1af6c8aa146ea9_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOjEzMjk0YjUxNzJlMjRkYTViZjdiZWYyMDFiNTc1MDhiL3RhYmxlcmFuZ2U6MTMyOTRiNTE3MmUyNGRhNWJmN2JlZjIwMWI1NzUwOGJfMy0yLTEtMS04Mjc4Mg_46c5573b-8fa8-4471-9e53-2c454ed24bc9"
      unitRef="usd">583100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5ec1bf24d76645649ff514efc6f320dd_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOjEzMjk0YjUxNzJlMjRkYTViZjdiZWYyMDFiNTc1MDhiL3RhYmxlcmFuZ2U6MTMyOTRiNTE3MmUyNGRhNWJmN2JlZjIwMWI1NzUwOGJfMy00LTEtMS04Mjc4Mg_8957fe5d-a707-48f9-9bc4-d6fb3aa6b391"
      unitRef="usd">601300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iedc77d2ee3884279ae4e3b4f74b210ca_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOjEzMjk0YjUxNzJlMjRkYTViZjdiZWYyMDFiNTc1MDhiL3RhYmxlcmFuZ2U6MTMyOTRiNTE3MmUyNGRhNWJmN2JlZjIwMWI1NzUwOGJfNC0yLTEtMS04Mjc4Mg_13f9b5a6-eaea-453a-b024-880dc0447504"
      unitRef="usd">133500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i379b3e02ffff4f65b6f70a4e51167f3b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOjEzMjk0YjUxNzJlMjRkYTViZjdiZWYyMDFiNTc1MDhiL3RhYmxlcmFuZ2U6MTMyOTRiNTE3MmUyNGRhNWJmN2JlZjIwMWI1NzUwOGJfNC00LTEtMS04Mjc4Mg_fe214a54-fc65-4b75-977b-0216829926d9"
      unitRef="usd">118700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i237555183941451e8d5f239492f90b93_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOjEzMjk0YjUxNzJlMjRkYTViZjdiZWYyMDFiNTc1MDhiL3RhYmxlcmFuZ2U6MTMyOTRiNTE3MmUyNGRhNWJmN2JlZjIwMWI1NzUwOGJfNS0yLTEtMS04Mjc4Mg_217680a7-deba-4981-a06d-35a5b077071b"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i959bea7c7da543dfaa998842a57cfc20_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOjEzMjk0YjUxNzJlMjRkYTViZjdiZWYyMDFiNTc1MDhiL3RhYmxlcmFuZ2U6MTMyOTRiNTE3MmUyNGRhNWJmN2JlZjIwMWI1NzUwOGJfNS00LTEtMS04Mjc4Mg_5e3341a4-f0b4-4ffb-9c30-92eec58d08a9"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOjEzMjk0YjUxNzJlMjRkYTViZjdiZWYyMDFiNTc1MDhiL3RhYmxlcmFuZ2U6MTMyOTRiNTE3MmUyNGRhNWJmN2JlZjIwMWI1NzUwOGJfNi0yLTEtMS04Mjc4Mg_260b976d-b96c-4849-b62f-a3a400deffdb"
      unitRef="usd">716600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOjEzMjk0YjUxNzJlMjRkYTViZjdiZWYyMDFiNTc1MDhiL3RhYmxlcmFuZ2U6MTMyOTRiNTE3MmUyNGRhNWJmN2JlZjIwMWI1NzUwOGJfNi00LTEtMS04Mjc4Mg_630cdf7b-dd96-4da2-9380-6faa31c51f81"
      unitRef="usd">720000000.0</us-gaap:Revenues>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RleHRyZWdpb246NTc5MjcyZTI5NDUyNDU2NzlmNGZlNGRmZDA4YjBhMGNfMjUxNQ_9759e32d-7397-4d4a-a792-007748853ba4">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides summarized financial information for our segments:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proprietary Products&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract-Manufactured Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total business segment operating profit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate and Unallocated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate general costs &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unallocated Items:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset impairment for planned sale of plant &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of acquisition-related intangible assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Corporate and Unallocated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consolidated operating profit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (income) expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income before income taxes and equity in net income of affiliated companies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) Corporate general costs includes executive and director compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2) During the three months ended March&#160;31, 2023, in preparation for the sale of one of the Company&#x2019;s manufacturing facilities within the Proprietary Products segment, the Company recorded an impairment expense of $9.4&#160;million within other expense (income) and a corresponding reduction to the disposal group net assets to its fair value less cost to sell. The transaction is expected to close during the second quarter of 2023.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3) During the three months ended March&#160;31, 2023 and 2022, we recorded $0.2&#160;million of amortization expense within operating profit associated with an intangible asset acquired during the second quarter of 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Please refer to Note 15, &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i7bf87d07bb544f48851c48374130181b_76" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Other Expense (Income)&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for further discussion of certain unallocated items referenced above.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:OperatingIncomeLoss
      contextRef="i776c2fc9c0314d5dbc1af6c8aa146ea9_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOmFiMTU3MTBmNjQ5OTRjYzViNGU3MjgyZDVmZjQ1MGIwL3RhYmxlcmFuZ2U6YWIxNTcxMGY2NDk5NGNjNWI0ZTcyODJkNWZmNDUwYjBfMi0xLTEtMS04Mjc4Mg_092274bb-0d9e-40d0-89c7-df0ca67957f4"
      unitRef="usd">170700000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5ec1bf24d76645649ff514efc6f320dd_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOmFiMTU3MTBmNjQ5OTRjYzViNGU3MjgyZDVmZjQ1MGIwL3RhYmxlcmFuZ2U6YWIxNTcxMGY2NDk5NGNjNWI0ZTcyODJkNWZmNDUwYjBfMi0zLTEtMS04Mjc4Mg_e3c7fe62-99e8-49e7-abd5-13b5a006e5f3"
      unitRef="usd">193400000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iedc77d2ee3884279ae4e3b4f74b210ca_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOmFiMTU3MTBmNjQ5OTRjYzViNGU3MjgyZDVmZjQ1MGIwL3RhYmxlcmFuZ2U6YWIxNTcxMGY2NDk5NGNjNWI0ZTcyODJkNWZmNDUwYjBfMy0xLTEtMS04Mjc4Mg_e86b6cf1-9f9d-4e1b-93b7-86a3a2044ff5"
      unitRef="usd">17400000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i379b3e02ffff4f65b6f70a4e51167f3b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOmFiMTU3MTBmNjQ5OTRjYzViNGU3MjgyZDVmZjQ1MGIwL3RhYmxlcmFuZ2U6YWIxNTcxMGY2NDk5NGNjNWI0ZTcyODJkNWZmNDUwYjBfMy0zLTEtMS04Mjc4Mg_6d038868-8636-4d86-9b47-d152251cad66"
      unitRef="usd">19100000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic8cd20fa40094f43a596ebe943a0379a_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOmFiMTU3MTBmNjQ5OTRjYzViNGU3MjgyZDVmZjQ1MGIwL3RhYmxlcmFuZ2U6YWIxNTcxMGY2NDk5NGNjNWI0ZTcyODJkNWZmNDUwYjBfNC0xLTEtMS04Mjc4Mg_462c9c1c-9391-4dbb-a1a2-77df5755c640"
      unitRef="usd">188100000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i92736af48f534f498e235c076ae54733_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOmFiMTU3MTBmNjQ5OTRjYzViNGU3MjgyZDVmZjQ1MGIwL3RhYmxlcmFuZ2U6YWIxNTcxMGY2NDk5NGNjNWI0ZTcyODJkNWZmNDUwYjBfNC0zLTEtMS04Mjc4Mg_20bc2311-5594-4a37-a482-8b3ba85c0957"
      unitRef="usd">212500000</us-gaap:OperatingIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="i934ac1f9eaf94ecfb00d07b8084f9292_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOmFiMTU3MTBmNjQ5OTRjYzViNGU3MjgyZDVmZjQ1MGIwL3RhYmxlcmFuZ2U6YWIxNTcxMGY2NDk5NGNjNWI0ZTcyODJkNWZmNDUwYjBfNi0xLTEtMS04Mjc4Mg_56270b36-ff19-44c1-a484-7ae0daa054c8"
      unitRef="usd">8500000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="icac424a9ffb64141aa0d33bcd8b4fcfb_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOmFiMTU3MTBmNjQ5OTRjYzViNGU3MjgyZDVmZjQ1MGIwL3RhYmxlcmFuZ2U6YWIxNTcxMGY2NDk5NGNjNWI0ZTcyODJkNWZmNDUwYjBfNi0zLTEtMS04Mjc4Mg_e0853562-a3a0-4dac-8c3b-864ee2b2f1ac"
      unitRef="usd">5500000</us-gaap:ShareBasedCompensation>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i934ac1f9eaf94ecfb00d07b8084f9292_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOmFiMTU3MTBmNjQ5OTRjYzViNGU3MjgyZDVmZjQ1MGIwL3RhYmxlcmFuZ2U6YWIxNTcxMGY2NDk5NGNjNWI0ZTcyODJkNWZmNDUwYjBfNy0xLTEtMS04Mjc4Mg_4f7a110c-0156-4e4a-ad60-598a6309b160"
      unitRef="usd">14700000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="icac424a9ffb64141aa0d33bcd8b4fcfb_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOmFiMTU3MTBmNjQ5OTRjYzViNGU3MjgyZDVmZjQ1MGIwL3RhYmxlcmFuZ2U6YWIxNTcxMGY2NDk5NGNjNWI0ZTcyODJkNWZmNDUwYjBfNy0zLTEtMS04Mjc4Mg_1cb818ab-5fbe-4534-9c7a-eb77c332710a"
      unitRef="usd">17100000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i934ac1f9eaf94ecfb00d07b8084f9292_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOmFiMTU3MTBmNjQ5OTRjYzViNGU3MjgyZDVmZjQ1MGIwL3RhYmxlcmFuZ2U6YWIxNTcxMGY2NDk5NGNjNWI0ZTcyODJkNWZmNDUwYjBfOS0xLTEtMS04Mjc4Mg_2914896c-a175-4566-af3a-3cc5e372a979"
      unitRef="usd">9400000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="icac424a9ffb64141aa0d33bcd8b4fcfb_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOmFiMTU3MTBmNjQ5OTRjYzViNGU3MjgyZDVmZjQ1MGIwL3RhYmxlcmFuZ2U6YWIxNTcxMGY2NDk5NGNjNWI0ZTcyODJkNWZmNDUwYjBfOS0zLTEtMS04Mjc4Mg_91b9372d-f7cc-4340-a1fa-8e28871d560e"
      unitRef="usd">0</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i934ac1f9eaf94ecfb00d07b8084f9292_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOmFiMTU3MTBmNjQ5OTRjYzViNGU3MjgyZDVmZjQ1MGIwL3RhYmxlcmFuZ2U6YWIxNTcxMGY2NDk5NGNjNWI0ZTcyODJkNWZmNDUwYjBfMTAtMS0xLTEtODI3ODI_214f9428-99c2-4a99-a159-6ffcf21dda57"
      unitRef="usd">200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="icac424a9ffb64141aa0d33bcd8b4fcfb_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOmFiMTU3MTBmNjQ5OTRjYzViNGU3MjgyZDVmZjQ1MGIwL3RhYmxlcmFuZ2U6YWIxNTcxMGY2NDk5NGNjNWI0ZTcyODJkNWZmNDUwYjBfMTAtMy0xLTEtODI3ODI_13fc18ea-7120-4d2f-9ad3-868d71d612f9"
      unitRef="usd">200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:OperatingIncomeLoss
      contextRef="i934ac1f9eaf94ecfb00d07b8084f9292_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOmFiMTU3MTBmNjQ5OTRjYzViNGU3MjgyZDVmZjQ1MGIwL3RhYmxlcmFuZ2U6YWIxNTcxMGY2NDk5NGNjNWI0ZTcyODJkNWZmNDUwYjBfMTItMS0xLTEtODI3ODI_1e3ae784-9034-487b-b629-db9632ce4edf"
      unitRef="usd">-32800000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="icac424a9ffb64141aa0d33bcd8b4fcfb_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOmFiMTU3MTBmNjQ5OTRjYzViNGU3MjgyZDVmZjQ1MGIwL3RhYmxlcmFuZ2U6YWIxNTcxMGY2NDk5NGNjNWI0ZTcyODJkNWZmNDUwYjBfMTItMy0xLTEtODI3ODI_e52d7198-7ab6-4f8c-9cf4-430a782cefb3"
      unitRef="usd">-22800000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOmFiMTU3MTBmNjQ5OTRjYzViNGU3MjgyZDVmZjQ1MGIwL3RhYmxlcmFuZ2U6YWIxNTcxMGY2NDk5NGNjNWI0ZTcyODJkNWZmNDUwYjBfMTMtMS0xLTEtODI3ODI_08035860-8947-4575-8a5d-c3271b966315"
      unitRef="usd">155300000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOmFiMTU3MTBmNjQ5OTRjYzViNGU3MjgyZDVmZjQ1MGIwL3RhYmxlcmFuZ2U6YWIxNTcxMGY2NDk5NGNjNWI0ZTcyODJkNWZmNDUwYjBfMTMtMy0xLTEtODI3ODI_94f97c79-0853-4fcc-b969-e4f8c379f813"
      unitRef="usd">189700000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOmFiMTU3MTBmNjQ5OTRjYzViNGU3MjgyZDVmZjQ1MGIwL3RhYmxlcmFuZ2U6YWIxNTcxMGY2NDk5NGNjNWI0ZTcyODJkNWZmNDUwYjBfMTQtMS0xLTEtODI3ODI_efc1c2ca-e56c-409f-b8b6-6f5e42e4ac4b"
      unitRef="usd">2600000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOmFiMTU3MTBmNjQ5OTRjYzViNGU3MjgyZDVmZjQ1MGIwL3RhYmxlcmFuZ2U6YWIxNTcxMGY2NDk5NGNjNWI0ZTcyODJkNWZmNDUwYjBfMTQtMy0xLTEtODI3ODI_cf43b475-e599-46a1-b547-f32d50656450"
      unitRef="usd">-1900000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOmFiMTU3MTBmNjQ5OTRjYzViNGU3MjgyZDVmZjQ1MGIwL3RhYmxlcmFuZ2U6YWIxNTcxMGY2NDk5NGNjNWI0ZTcyODJkNWZmNDUwYjBfMTUtMS0xLTEtODI3ODI_8eae5704-ad0a-48fa-99a0-9d586bbf27f4"
      unitRef="usd">157900000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="iba2c76d7f250449686cbbd3af4eca291_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RhYmxlOmFiMTU3MTBmNjQ5OTRjYzViNGU3MjgyZDVmZjQ1MGIwL3RhYmxlcmFuZ2U6YWIxNTcxMGY2NDk5NGNjNWI0ZTcyODJkNWZmNDUwYjBfMTUtMy0xLTEtODI3ODI_28be210c-b8be-4739-8bad-06017a94c4b7"
      unitRef="usd">187800000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:AssetImpairmentCharges
      contextRef="i3b6114e84e5644b6b9435baa1eba9515_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RleHRyZWdpb246NTc5MjcyZTI5NDUyNDU2NzlmNGZlNGRmZDA4YjBhMGNfODI0NjMzNzIxMjU0OQ_e879862c-4661-4ef5-adc5-fbfeb2525184"
      unitRef="usd">9400000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i934ac1f9eaf94ecfb00d07b8084f9292_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RleHRyZWdpb246NTc5MjcyZTI5NDUyNDU2NzlmNGZlNGRmZDA4YjBhMGNfMjc0ODc3OTA3NTIyMg_24c11a05-4326-4590-97c6-148fb25d0438"
      unitRef="usd">200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="icac424a9ffb64141aa0d33bcd8b4fcfb_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdiZjg3ZDA3YmI1NDRmNDg4NTFjNDgzNzQxMzAxODFiL3NlYzo3YmY4N2QwN2JiNTQ0ZjQ4ODUxYzQ4Mzc0MTMwMTgxYl84NS9mcmFnOjU3OTI3MmUyOTQ1MjQ1Njc5ZjRmZTRkZmQwOGIwYTBjL3RleHRyZWdpb246NTc5MjcyZTI5NDUyNDU2NzlmNGZlNGRmZDA4YjBhMGNfMjc0ODc3OTA3NTIyMg_e335bca0-fdc1-4047-b870-d7cffe80e7ff"
      unitRef="usd">200000</us-gaap:AmortizationOfIntangibleAssets>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>82
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( $*!FU8'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " !"@9M66&[:H.\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9)1
M2\,P$,>_BN2]O30=BJ'+BV-/"H(#Q;>0W+9@TX3DI-VWMZU;A^@'\#%W__SN
M=W"-B=*$A,\I1$SD,-\,ONVR-''-CD11 F1S1*]S.2:ZL;D/R6L:G^D 49L/
M?4 0G-^"1])6DX8)6,2%R%1CC30)-85TQENSX.-G:F>8-8 M>NPH0U56P-0T
M,9Z&MH$K8((1)I^_"V@7XES]$SMW@)V30W9+JN_[LJ_GW+A#!6]/CR_SNH7K
M,NG.X/@K.TFGB&MVF?Q:/VQV6Z8$%W7!5X6XVPDN^;U<B??)]8??5=@'Z_;N
M'QM?!%4#O^Y"?0%02P,$%     @ 0H&;5IE<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M" !"@9M68\8;T=8%  #2'@  &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;+6977/:.!B%_XJ&W=FK$"P92-(ES!"7;)E-4AIH.]V=O5!L 9[:%I5E"/]^
M7QFPDZS\PGK*3>*O<]!C6=*1U%M+]3U="*')<QPEZ75CH?7R7:N5^@L1\_1<
M+D4"=V92Q5S#J9JWTJ42/,A%<=1BCM-MQ3Q,&OU>?FVL^CV9Z2A,Q%B1-(MC
MKC8W(I+KZP9M["\\AO.%-A=:_=Z2S\5$Z,_+L8*S5N$2A+%(TE F1(G9=6-
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MX[JZ?&7\84?%GV$LU-PTS#_ 02\@',1+GMBK%C>L!CU%\&%E\&%X;ME7Y$)
M16)XN$TUWBD"$"L#$,.SR[ZG?37"3_(E;O(QTY!I$S. 6HE_4K39O8>M6R=W
M,ULJJ_Y%F[59Y[+=:ZULC&4(8D>M&'G0HRI(>Z,D$,_D3V&O1MS*<<SDNG-Q
M80U[N+AN799AA^%993]<WH:I2;7?! 0U;)GS@%VS25G3I5;04\0?MXP_+IY:
MBC7.EZ2W<-':PQXPJUK$Q65U&<L(Y.*!Y2WC;MFZFA*W^V2M1UQ4E[&,/RX>
M5@8 &&PA(V[M8PX85/:JN.[_@K5>[!J: 2_?3$V);Q8EMQN(Q=5BPW:0;U.V
MRL>WN[WWW(R7*8G$#*3.^05T>&J[@;H]T7*9[T$^2:UEG!\N! ^$,@_ _9F4
M>G]B?J#8QN[_"U!+ P04    " !"@9M656)]!^,$  ![$@  &    'AL+W=O
M<FMS:&5E=',O<VAE970R+GAM;*V876_B.!2&_XK%CE:MU.;#"21T :D%9A9I
M2ZO2[ERL]L(E!JQ)8L8VT/GW:R<A"8FQ6FU[4>+DG)/GV,=^'0\.E/W@&XP%
M>$OBE \[&R&V-[;-EQN<(&[1+4[EDQ5E"1*RR=8VWS*,HLPIB6WH.#T[023M
MC ;9O4<V&M"=B$F*'QG@NR1![-<=CNEAV'$[QQM/9+T1ZH8]&FS1&B^P>-D^
M,MFRRR@127#*"4T!PZMAY]:]&4.H'#*+OPD^\-HU4*F\4OI#-6;1L.,H(ASC
MI5 AD/S9XS&.8Q5)<OPL@G;*=RK'^O4Q^M<L>9G,*^)X3./O)!*;82?L@ BO
MT"X63_3P)RX2ZJIX2QKS[#\X%+9.!RQW7-"D<)8$"4GS7_16=$3-0<;1.\#"
M 38=_#,.7N'@98GF9%E:$R30:,#H 3!E+:.IBZQO,F^9#4G5,"X$DT^)]!.C
M\<-\,ITOIA,@KQ8/?\TFM\^RL7B6/_?3^?,"/'P%L_GXX7X*+E[FMR^3F7Q^
M":[!RV("+KY< KY!#'- 4G!/XE@.#;\"7^K-@2TDJ'J=O2R@[G(H> ;* _<T
M%1L.IFF$HU-_6R989@F/6=Y!8\![Q"S@N5< .M#3\(S?[PX-.%[9Z5X6SSL3
M;Y8N:8+!0B"!Y900X)_;5RZ8+.E_=9V5!_/UP=0\O^%;M,3#CIS('+,][HQ^
M_\WM.7_H,OVD8"=Y^V7>OBGZ:"Z7)8YBK"V)W+67N:K%9S\*W)[5&]C[.GYN
M%=2MH%/:G%!U2ZJND6I,N0!T!=:41AR@- (J;[*41<UI'.E8\X!AC<+WNY;7
M8-58>5W+U]/V2MJ>D?8;HYR#+:,K(G1HO=9+8>"VT#16H5_K[!.TH$0+C&A/
MLF 06VZR/HSP7FK$5I6W#C-H ;B!Y38H-49G(<,2,C1"+J1BD'1]!=8XQ0S%
M&2R*Y-)*U!14H@+PFU1)KB_3/'JWQA0V:S1L88>>Y3NU/U>?0[_,H6_,X4%L
M,#M2@@N2+2>7.MI^NP>AU6_PMHVN/>L,HNM4PN*8(;=8=6>Z-A1K$>*$K]N>
M2#JSL&\%9Q!KVN<:$6>IP'*5$\>NU"*Z[:EBP2:@V>@4#U9X\'UX^0!KZ6![
M['PK;.)IK)Q:+Y_R52KF&L7B*&.O6.XF<0$)!'K#^2J*?^Z(^*5V BD^YJ#6
M6;1:D9A(Z8N O+5%*='/M.+MI\41M*I79Q8&M3XXS:[2*M<L5K,R'V-Y^.V1
M]UJJI;-RSQ9()5RN6;FF_[>'VPIUW:U-JP)>8Q6<A:]TS#4+V1P;"[O7$GK7
M=YIDO=:>P0V\LT-?Z9@;&/=G%1J0BUB^P[W14AH%\:-;L\^*=IIU)8RN61GO
M$"=+I28@HG&,&*^2UVI+$:Y?[WTK;*T];2MH>6<V06ZE@*Y9 B<DWJGZ_@!N
M7X?;;>*VK>1*WM?CPDH,H6.LJ._9YZ3D17NIBFM\_&J2']9<R,52RJ2VP*!1
M8S]:8)\5[;03*KF%9KFM"BS/7CM,L"VE@6\UATEO]9X]%JSD%YKEMUYB)N"V
MN ;M1;2PJN\;@^9.UJY]QB>8K;/3#2Z7\%TJ\F_=\FYY@G*;G1LT[M^Y-^/\
M'*0*DQ_+R"_9-4DYB/%*AG2L0 *Q_*0C;PBZS0X+7JD0-,DN-QA%F"D#^7Q%
MJ3@VU O*\Z;1?U!+ P04    " !"@9M6U2YVWI0#  "^"@  &    'AL+W=O
M<FMS:&5E=',O<VAE970S+GAM;*U6VV[;.!#]%4(;+&*@U=6W9&T!OA4U4#M!
MG'0?BC[0$FUK*Y$J2=OIWW=(*:IL,VH7R(M$4C-'Y\R0PQD<&?\F=H1(])RE
M5 RMG93YK>.(:$<R+&R6$PI?-HQG6,*4;QV1<X)C[92ECN^Z72?#";7"@5Z[
MY^& [66:4'+/D=AG&>8_QB1EQZ'E62\+#\EV)]6"$PYRO"4K(I_R>PXSIT*)
MDXQ0D3"*.-D,K9%W._%<Y: M/B?D*&ICI*2L&?NF)O-X:+F*$4E))!4$AM>!
M3$B:*B3@\;T$M:I_*L?Z^ 7]@Q8/8M98D E+_TUBN1M:?0O%9(/WJ7Q@QX^D
M%-11>!%+A7ZB8VGK6BC:"\FRTAD89 DMWOBY#$3- 7#,#G[IX)\[M%]Q"$J'
M0 LMF&E94RQQ..#LB+BR!C0UT+'1WJ FH2J-*\GA:P)^,IS<+:>SY6HV13!:
MW7V:3T>/,%D]PFLQ6SZNT-T'^+2X?YA]!+OYYQF:+V$^0]=/R]'3= [6+?0>
M/:VFZ/JJA:Y00M$B25/(D1@X$BBJ'SE126=<T/%?H1.@!:-R)]",QB0^]7=
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MR[W6KI$JF%\:J;WV2B7QW%\WJ]M(?F*@;;P1W<M*UKED69J=%,7.^8%P:IU
M1OA6-T@"(KBGLK@TJ]6J"1OIUN-L?:R:,]UA_((I.CNX$K<)%2@E&X!T[1X4
M*5XT2\5$LESW&VLFH7O1PQTTF(0K _B^84R^3-0/JI8U_ E02P,$%     @
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MR)@K[58.(88&GD,'QK;N4>/0[+=,2$YEP:G6N_X.91G.S'G39I4Y._] 5NC
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MM0*4\%IEW=ZC3*;'$)I3N\4.Y5GJ3.N@";!?$YR/'NAVHZOB5DXW6N4\*67
MA!VX*0F.89*9V35UP+'2W8ZW-X,2B/Q*X!M7NF7'7U[W%)$*MY#@/0R@6=@P
M0'N;ZH/U18\I!(YQDAORS&J7ABZ*BP;)$/DE0TO#;=.W C39'Z6I.9+9[)+,
M^7PT&G1"])LZH4FO!S R7MY9'TK9[&P/I>:C]]'ZGP$^$_Y8U$*IV+5:& :I
MJC/>OE]O#R3;-J^H'YB4K&H^;BA94:X-U/=KQN3K@7[KW?^7P^)_4$L#!!0
M   ( $*!FU8K=Q0S' ,  %\*   8    >&PO=V]R:W-H965T<R]S:&5E=#8N
M>&ULK99K;]HP%(;_BI5-4RMUY,:U@T@4J%JIHZBTVX=I'TPX$*M)G-D.M/OU
MLYV0D9)RF<8'XLLY;Y[WQ$[<75/VS , @5ZB,.8](Q BN31-[@<085ZC"<1R
M9D%9A(7LLJ7)$P9XKI.BT'0LJVE&F,2&U]5C$^9U:2I"$L.$(9Y&$6:O5Q#2
M=<^PC<W  UD&0@V87C?!2YB">$HF3/;,0F5.(H@YH3%BL.@9??MR8%LJ04=\
M([#F6VVDK,PH?5:=VWG/L!01A. +)8'E904#"$.E)#E^Y:)&<4^5N-W>J%]K
M\]+,#',8T/ [F8N@9[0--(<%3D/Q0-<WD!MJ*#V?AES_HW46V^H8R$^YH%&>
M+ DB$F=7_)(78BO!KK^3X.0)SK$);I[@:J,9F;8UQ )[74;7B*EHJ:8:NC8Z
M6[HAL7J,4\'D+)%YPAO<CX>C\70T1+(UO;^['?8?9>>J?]<?#T9H>C,:/4[1
MV=.X_S2\E3/GZ&R"&<0B $%\')ZCS^@C,A$/Y"COFD(R*673S^]_E=W?>>?^
M7S&K(=>^0([EN!7I@_WI0_"+=*><;LI*%.5PBG(X6L]]1V\JL "Y2@6B"W1-
M8AS[!(=H0CG1J^Y'?\8%DVOO9Y753+M>K:TVY"5/L \]0^XX#FP%AO?I@]VT
MOE09_T]BI3*X11G<?>K>1.XE8 SF2"Y __DB?[P(IR*@C/R6$V<DSD?/JTJ1
MZ3>TOGJ5K#S7TK^NN=IV>3BN9*!>&*C_DP'">7H8OKX#]19[7T0)N%$ -_X)
M6+YYN<#QG,3+0]2-@]3[(DK4S8*ZN9=Z0*-([HH<.<$,K7"8@B:=TS#$C*,$
M6$9="9WI=[:1:D[C#?>!H!)ZJT!OG8!^\OIN[932L:S*%7Y,9,E!NW#0/MW!
M<0N\O</4:KA5\$<$EM@[!7OG=/83UGIGEZON5!FH"K3W&+"MOQ].:Z^%1WEJ
MXBE[W9C  OF4BT/DN>HVD6U7D5<%.E7DYM;77QV]Y"=U26*.0EC(3*O6DA(L
M.\UD'4$3?2"842&/%[H9R!,@,!4@YQ>4BDU'G3&*,Z7W!U!+ P04    " !"
M@9M6ZLJ=' (&   V&   &    'AL+W=O<FMS:&5E=',O<VAE970W+GAM;*U9
M;7/:.!#^*QJN<].;*6 +L$V.,)- .NU,\S*EN7X6M@!=;8M* I+[];>RB6V0
MK*8SX4.PS>[ZV=='4B8'+G[(#:4*/65I+B\[&Z6V%_V^C#<T([+'MS2'7U9<
M9$3!K5CWY590DA1*6=K'GA?T,\+RSG12/'L0TPG?J93E]$$@N<LR(IZO:<H/
MEQV_\_+@*UMOE'[0GTZV9$T75#UN'P3<]2LK"<MH+AG/D:"KR\Z5?S'#8ZU0
M2/S#Z$$VKI%V9<GY#WWS.;GL>!H136FLM D"7WLZHVFJ+0&.GT>CG>J=6K%Y
M_6+]8^$\.+,DDLYX^ITE:G/9B3HHH2NR2]57?OA$CPZ-M+V8I[+XBPY'6:^#
MXIU4/#LJ X*,Y>4W>3H&HJ$ =NP*^*B SQ6&+0J#H\*@<+1$5K@U)XI,)X(?
MD-#28$U?%+$IM,$;ENLT+I2 7QGHJ>GL_FY^<[>XF2.X6MQ_^3R_^@8WBV_P
M=7MS]VV![C^BV=7B$_KXY?[[ KU_O+MZG'\&F;]0%STNYNC]N[_0.\1R=,O2
M%#(C)WT%P+3Y?GP$<5V"P"T@!NB6YVHCT4V>T.14OP\.55[A%Z^NL=/@+1$]
M-/ _(.SA@07/[/7JV %G4 5Y4-@;M 69R U:0<=(M!(\0]"$@BB6K\LJ9HI1
M>6$+6VEV:#>K._Q";DE,+SO0PI**/>U,__S##[R_;3Z_D;&3" RK" Q=UJ=W
M,)!8'O.,VMPL=<-"5\^=_=0?>I/^OHF^E F:,N&@%U52)[!&%:R1,S%7R;_0
M8C"5E$2*PUB*>1ZSE**\PJN?Z[M8YW K^)Y!B:+E\^N3.'K+)+Z1L9-H!56T
M F<2YQ2,QHSH^6MSM-2.&BD:>+WP+(^F$(X:0B? P@I8Z 1VE7&AV'^MP$+C
MG5YO?(;++7,"*ZI@14Y8"\7C'UU-,@F"4@+FE:T0(^/U46]T!M&4&35D3B".
M*XAC=^2DU)6>;0D311O8L(V-]_I^;W &KA0:->-GA^9[-35Y3G#W:D,%RGG>
M+9J/*9K)#[H9K0SC&2B[@1%"FU38%D2_0:*^$^EL0_(UE9H%B8ZH1"1/4,K(
MDJ7%8+ B]DTLPZ QTHZ0+6(CKX=;,.,:,_[E2'[54+-BQV9-#**>?X[=(C;R
M6['7?.K_'J&R?$_E:V:Q_Z:,^E;63J-0<ZKO)M49V3)%4D2?8+0D3.U$2[*&
M9@5%N.>-FY_SS%ET@E$;W_HUX?I.ABI[NKV)1XXI<@0V,H'AU@ZNJ<UW<UO5
M#3L]K:&/;25EA6P2VJ^#:]$)HL9(/76BID$__*VV6+&<P'KF%6WAY-??;HLW
MLG8:A9IU?3?M?J5;\ERNZ?@*I3Q?=Q45&6SNEO:B,WFUZ_6"\YS]0NH4;,V_
MOIN YP *,2EWD"@*JP1IIV#?1:]'@"9-=_W&1#[=2-4DC-TD/&>:'(#-7H)J
M@X<MM.H/#3JPB@UZPQ:,-?UB-_T^"!Y3FARK7K8LNQ Y$)'8\9L<"[C.%P\6
MJ:"M:7'-P]C-PS?9-N7/E):XT78GX@U@1]N4Y( _5X(M=ZIM8XTM#&LL(8Y"
MS>IIH6!<4S!VDMMTL2'0O!7<!.U@[RZ0U(]A(U6[(?A:D,R*?6 9@YY9-18Q
M?QBVEG;-G]C-GT<7:K )6G&!Z$M"%'E"!Z8V&YXF,$3M\;?P)*R.C=*QB45M
M=(IK.L5N.C5HRS;RK;A-INV&1N0M7.N'N&V[AFNVQ6ZVO5FM:*ST>*9/<;%V
M1K#LA%Q EVIWK(@# _'YWA);>'746B<UK6+W]E('.:&QH+J>68FP6. 7%_3G
MCNU)VCH:0S/01G^:F\_N>-@;>XU/FQ<U+6(W+>K%P0=]J)'N=#4;X!%1:$G7
M+,_UKY :V HPGEA]LNQ6 >_YEM B%@:XC3-QS9G8S9FO\40SEMN'L7&@%$6!
MZ8,I%@2AT0']Q@EL1L6Z.)B6,+YWN2J/+:NGU>'W57'D>_;\VK^8E4?8M9GR
M1/V6"$B.1"E=@4FO%T))B?*0NKQ1?%N<\RZY4CPK+C>4P%#6 O#[BG/U<J-?
M4/VK8/H_4$L#!!0    ( $*!FU;1,[XIKP0  &$+   8    >&PO=V]R:W-H
M965T<R]S:&5E=#@N>&ULM5;?;]LV$/Y7#BI09(!CV7*:98EMP$FSK1@*&/&R
M/@Q[H*63Q50B59**X_]^=Z0D.X7C80]]L2F2]]W==S]XTZTV7VV!Z."E*I6=
M185S]74<V[3 2MBAKE'12:Y-)1Q]FDUL:X,B\T)5&2>CT65<":FB^=3O+<U\
MJAM72H5+ [:I*F%VMUCJ[2P:1]W&@]P4CC?B^;06&URA>ZR7AK[B'B63%2HK
MM0*#^2Q:C*]O+_B^O_"7Q*T]6 -[LM;Z*W]\RF;1B W"$E/'"(+^GO$.RY*!
MR(QO+6;4JV3!PW6'_JOWG7Q9"XMWNOPB,U?,HJL(,LQ%4[H'O?T=6W\^,%ZJ
M2^M_81ON7OX20=I8IZM6F"RHI K_XJ7EX4#@:O2&0-(*)-[NH,A;^5$X,9\:
MO07#MPF-%]Y5+TW&2<5!63E#IY+DW/Q66&E!Y[ T:%$Y$;A2&:Q"F/AL)3=*
MYC(5RL$B376CG%0;6.I2IA+M-'9D">/%::OU-FA-WM Z@<]:N<+"O<HP>RT?
MDP>]&TGGQFUR$O"S,$.8C >0C)+)";Q)3\O$XTW>P#OB)?R]6%MG*(W^.>9P
MP+LXCL>E=6UKD>(LJIEH\XS1_/V[\>7HYH2U%[VU%Z?0?U@0?[Q6. YR#7\6
M"*FF[% 6,UY9DLB$HX]<*J%2*4JP=!VI0S@+4J5E0[E$"W %01JLM7$@#$*C
M1)-)%F7C"O&,L$940)&HZ=S+"++-9(2+5("N@$?E!5:LP<+9^W=723*Z>1RN
MAGXYOOD)-JC0B++<L3#6'G_O86W()%F7WTG#;XO%LH>@IDK*'1I9';@53&<0
MMM=+K3!MC'3,&._=OZ2%4!N$.UU5TOH.V6E9W=_U^ 8W3>DIM4-/Z0Z%.4>5
MO<7M6I2>@_ @T)Z K;#4Y@SU3J+>Z HZ,H_%80#KAN0TV:FTZZ("Q!)DTJ:E
MM@W%F>SZUDAF?KV#GI4AW*%Q](Z06'AMNGS*M78$AZ\P%%]A]@]#+Y1JR*"C
M*7(RW)T1!^FQIXBBI"OIR.DA?.+\0M"U5&P>96XE%#U?K&/ 1Q9/9JCG0F1/
MU-I;QK:%3 N?J 0F6K^((HJXX210PI'# U"8HK5<5YPV G(AS5X!"[-A>]VU
MMI(I'!"6I4?*EQF]YB8DQ !280O(Z5D.2<72;5H10QPA%U3Q 8E)G7D2N4R9
MB?];HAV4*PPB5.$!0'X @-HW4=#U[P&EGVY*R@X$'C38'()_:E1XR7W$7-#^
M'SK9+\X<R_<-.LT<?$'K8%D(XCG%QE%S*JG S+,D?@<4X'3HY23)5^))4]WM
MSO56D0[;K*W,I#!<B&<A<)78!4-S-)Q=I(,JIBU&5C5HR]&;W.Y3W=9"[?JC
M=GN+W^\TMML@]MH]W9B^PD5=4TESFA!)= "+4 $/H?T16SR\P'AT_D<? &X"
M+?$?*:>J-9J.^P3.#JP,.Z\1.\TA_D<S*^2GVO6M+22/3W'N"ETB2U^\&?'/
MDQEC='"=I7E#Q<+F#H^]DO'!V%.AV?CASH)OP6$"ZG?[^7$1QJ;]]3!\4@)N
M)%E>8DZBH^'/'R(P8: +'T[7?HA::T<CF5\6E)IH^ *=<XOJ/EA!/U7/_P50
M2P,$%     @ 0H&;5F@CXI29 P  (0@  !@   !X;"]W;W)K<VAE971S+W-H
M965T.2YX;6R=5FV/VS8,_BN$!ZP=$,2)DVN+:Q(@N>ZP%NAPN*SKAZ$?%(N.
MA;,EEY*;YM^/E!TW!9(#M@]WU@OY\.%#B<KBX.C)EX@!OM>5]<ND#*&Y35.?
MEU@K/W8-6MXI'-4J\)3VJ6\(E8Y.=95FD\FKM%;&)JM%7'N@U<*UH3(6'PA\
M6]>*CANLW&&93)/3PJ/9ET$6TM6B47O<8OC4/!#/T@%%FQJM-\X"8;%,UM/;
MS5SLH\'?!@_^; R2R<ZY)YF\U\MD(H2PPCP(@N+/-[S#JA(@IO&UQTR&D.)X
M/CZAW\?<.9>=\GCGJL]&AW*9O$E 8Z':*CRZPQ_8YW,C>+FK?/P/A\[V]3R!
MO/7!U;TS,ZB-[;[J>Z_#F<.;R16'K'?((N\N4&3Y3@6U6I [ (DUH\D@IAJ]
MF9RQ4I1M(-XU[!=6?[)NZSQWK0W&[F$;E-6*M%^D@='%)LU[I$V'E%U!FL%'
M9T/IX7>K4?_LGS*K@5IVHK;)G@7\J&@,L^D(LDDV>P9O-J0ZBWBS*WB7TH1/
MC58!@:=P5RJ[1S#V7) ',C8W387PSWKG _$I^G))FR[T_')HN5FWOE$Y+A.^
M.A[I&R:K7W^9OIJ\?2:Q^9#8_#GT_U3#_X<$CYBC#=41UMHU ?79UGL+6^2U
M>H<DI<I&$$J$>V,5*Z>JRX ;QQ]XF=ROMYOD-S#>MXRZ;XUF+V0$%< C/GD(
M#M"6W2HIRS(2VOP(BAA5\UXPP:!_ :U'< 6WEZ:I#',I(@.$AMR>5.W'\!?S
M4MQ1-/\%;BE?6\/5B'1W[9%=N/;J*H PT<;GE?-R2KJ&&#O+CKM=1'G"(P2D
MV@L16>A=1\ 67I(7%7)G"T,UYZMJ4<:#&AR8W."+9)P>,2-RE?3?@T@6,\S+
MP56W))BH9,W:E@4?'!E+<8OR.9DF,F7G0XD4#[F$*(8B,3DN(0KB.=6!($DN
M?'(M%U^$-/Y'L7B,18&QOP+S9%B?,^81%7G8X=Y8&\$*U@;>\5&*9V5Z$Z]V
M-H;/7);^7(6?D#M=/BA.BX[0MP(64\K$TOJF#\I]V9SJ*T"2JS8:K M0*C90
MW#,YN&1J:KZ(03!<2Q<5&$G<J\<H:B'  R*?"Q'SSC&R/?:DN7MQ14[M:WSI
MFJ=G;;M&VL?'R4.\+5T''U:']V_=M?T?YMWCR=%890\5%NPZ&;^^28"Z!ZF;
M!-?$1V#G C\I<5CR&XXD!KQ?.!=.$PDP_"I8_0M02P,$%     @ 0H&;5DIL
MO(I\!@  =A   !D   !X;"]W;W)K<VAE971S+W-H965T,3 N>&ULQ5A;;^,V
M%OXKA)LM$L"Q9=FY-),$<#+3RV('&TRV[<.B#[1T++$CD2I)C<?[Z_<[I*0X
MSJT/!?H0F9=S#K]S)W.Y,?:S*XF\^%I7VEV-2N^;B^G49275TDU,0QH[:V-K
MZ3&UQ=0UEF0>F.IJFB;)Z;262H^N+\/:G;V^-*VOE*8[*UQ;U])N;Z@RFZO1
M;-0O?%)%Z7EA>GW9R(+NR?_<W%G,IH.47-6DG3):6%I?C9:SBYL%TP>"7Q1M
MW,Y8L"8K8S[SY*?\:I0P(*HH\RQ!XN<+W5)5L2# ^*.3.1J.9,;=<2_]^Z [
M=%E)1[>F^E7EOKP:G8]$3FO95OZ3V?Q(G3XG+"\SE0M?L8FTB[.1R%KG3=TQ
M T&M=/R57SL[[#"<)R\PI!U#&G#'@P+*]]++ZTMK-L(R-:3Q(*@:N %.:7;*
MO;?85>#SUY_H"^F6+J<>PGAIFG6,-Y$Q?8%Q+CX:[4LG/NB<\L?\4X 8D*0]
MDIOT58$?I9V(^6PLTB2=OR)O/F@V#_+FKVLFUM;4XA98+2( UO6EN UV)2O^
MNURYL/[;<P:(\A?/R^=LN7"-S.AJA'1P9+_0Z/K;;V:GR;M7T"\&](O7I+_F
MES_%*/[=6B1-' ,>@M1%4_B2A),5";,6A3&Y$P9)"O@J(R>DSCG7.&E<(,T,
M$C G*T,2>2,VI<I*L2%!7QM0\=(*$^V5KR@72F,C*Z4N8'I(]J5Q]/2@B?B5
M<67&Y@-,SJY<<*J*-5+UV'EJ1&URJL8L5F9,+75&T8M+S%L<JPMQ[X%;6AQQ
M:W*U5EE$>_CM-^=IFKQ;WM^&T>S=D3A-3B?B>U.A&C$GJPCU(&;@@ETDJ[T3
M,+)+1;)CUKQCV ;NAFRHC8S+K"I5!"E.'#[1^8BUZ&P:A(]1/SQ9I#6%=2QJ
M)V.Y:BQ8QD("*'"]L,_&?PW#D_.B>S-3:/6_*+,W_J8D& QH)7!N.$2\<F^H
MN-I&2&NRMC=F@QA3[,>GL06P!E'9FQ(QL Q4.T1"N0>1$/((55"E3UVS\F@Y
M+NJ&L@FO^5+Z?8$3\9^2 W'PMUQ5#!()J[L(EPTP?U4U6QF:9MA .V*!C%:C
M,7*Z!&W1MSYC7EC3-A>0;(D>E<%0N_B3BAME*E.HS(GY0OQ#+.;X_$":+"^E
M"6:S,WSN2@G#BI3'*1/VE>KXH]3M&H.6[7!G3=YR2LZ^8\Y3_B3)\/TK=6SB
M48*CKC!V^X:>/Z+M'?\B*X10!Q(JU(W1X>R3&="=,-QGZ-Y3A32W6PQB@+ 1
M3O#7I[.XD]EG6;!.*=LO?/YV Q5D"BL;E$$1<A.I\(:-EC6[73JQ"*' *GYH
M+2Y68_%1Y3FP?) .V;E<,YE8G/542Z<D&X&+DPB*)7N*#8UMZ1SY6+__I>1*
M5<HKX'U.\7@!0P%P,1][$?)!1/4@8LSUO&ISYI<U5URN*[P2J[V,9=AQ72'U
MA4\8L\$NQ.$![]>JJKA:'#U@C0>-X?>,ZA62N6O[J3B ZR;SIY2X'*#I]+<#
M.'FR$+>QR>"(?0V.&2"NJ&@\ASG%T1%DSR<SG-F5%I"@D#P/XO#T?)(>/:7=
M@W%X<C8Y.=H!DC]F )#^>''80V(@LV1RMJ^DD)8>#,MM!P(-8I,K)H3J1P[:
M/TFY-WAW/!H$Q-W*Z.*86]#N_D2\;X=Z[D-@US&P*03V8RN,Q4$Z@\\Z/W/*
M##U%NH=ND\?ZS&N[X;.O"$CXV!4A[36#"(6=Q);X?LCA7,O?C55^V^^\U)UZ
M,^R$>#1R;&UJQU(ZRN>^@22' >Y>D/G NJ*M83/VK)U.W7W'4B7#S00]3PIM
M-.Y4+6H:I]_0PAJYK=DUT.,@32;)8,*82=$^_VQQ0IK,YCRQA&JGNWL5Q<1T
MH!2MH]X<]\AM_YY!X#)ZMG@G/&6EYF:$V@Y4K%>ON!0.=[A073@<9$.MQQA&
MDFC.CD7N.YOIHF</TLGYKM?W/1ELP&[G.PKBLU-WS+3Q$GF03+X;).P'QNOA
M>S![D_6%V.80>B9[5L3NVHG6*)-WPXV4WPG\PCOF"S=?5<%CT+VZ2Q2_?X._
M^;S.$[) ZK#*\=!A*G(#+;3Q0]#@PMMR'^,7GJK;6C0MK,YE P!JY0/7<'OO
M VCRW#MCNO,6!$T17KQ\34*-CL_"875X5"_C6_*!/+[(X?J"KU@5K<&*DG4R
M$C:^<N/$FR:\+%?& U 8EB3Q6& "[*^-\?V$#QC^U7#]?U!+ P04    " !"
M@9M6,(:54ET$  !J"@  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6RE
M5MMNVT80_94!:Q0MH%"4*$N.*PFPXP3-0P(C;IN'H@\K<B@NO.0RNTO)^ON>
M75(7M[8;HP^B>)DY<^;,S.[.M]K<VY+9T4.E:KN(2N>:R^'09B57PL:ZX1I?
M"FTJX?!HUD/;&!9Y<*K4<)PDTV$E9!TMY^'=K5G.=>N4K/G6D&VK2IC=-2N]
M742C:/_BBUR7SK\8+N>-6/,=N]^;6X.GX0$EEQ775NJ:#!>+Z&IT>3WQ]L'@
M#\E;>W)//I.5UO?^X6.^B!)/B!5GSB,(_&WX'2OE@4#C6X\9'4)ZQ]/[/?J'
MD#MR60G+[[3Z*G-7+J*+B'(N1*O<%[W]E?M\SCU>II4-5]IVMFD24=9:IZO>
M&0PJ67?_XJ'7X<3AXCF'<>\P#KR[0('EC7!B.3=Z2\9; \W?A%2#-\C)VA?E
MSAE\E?!SR\^H^\<ZTQ73+1NZ*X7A^= !V7\?9CW*=8<R?@8EI4^Z=J6E]W7.
M^6/_(1@=:(WWM*['+P)^$B:F=#2@<3).7\!+#VFF 2]]!N^],+6LU_:8)/UY
MM;+.H"O^>BK?#F[R-)R?E$O;B(P7$4;!LMEPM/SQA]$T^>4%LI,#V<E+Z-]=
MD]>CT&\E4Z$51A%JD!,KQ1BM3->95&S)X;/UAI9:RSG).KS*A,I:)<(8Z<)/
M@<RH!K[L\!O@!S=R&@[:<N>.-8-RJ5J'^Z?,+\'',#]J'OH)02NI%(+9GT/]
M_65,GX\ 9S2:)''B_V=I?$%?P^S!5VS88"DA6%7@VJ>"M<@Z4><^Y=DD/O>7
M"=UX8E@1B(L"2X1/C+^UTNU(;(7)[2!,>TZZT\!AR;.MV1%&,KNGBI%G3J-X
MC-_TWPSZT,)BM?-Q@PQ>O]EY/*/9%.QO6A.*X,&##%4G P<9, %9>1@! OT@
MP\#;0^BMOR1QNI<J&'A-]L\=@0&J:QL.2Y_:#:@PNNHR>--E!Z6POMNNMHT2
MM:5:!Z%5FY]T ,Q:=^B EXI**\X$RN_]I"%984X<;07$J)W,>]5C]"9]X)5I
ML16$%$-F=*VAO0]Q(]&73ANX-8W1&Z]M'\!PTT(<\"=\61M140O-#&U+"<VV
M4%+L3JW:QC?FV0CRK'IYY+$[BD.[>%WB,"//!LHU=PJ5J#0R(GYHI.F$R87C
M_V!R&FG?67Z#A9VYAY@8&#!KC-P 2^W>U+S63@JO-=8JU"GL9;8C6;?5"K&0
M0)\*DER=LLY#5X0&DZ$+O6D+8J=8V'"4PD8&%J'9!6V$D8PY@'4A0@T&?4-X
MC)XIUHQ<]F1>T\D#K\J1X.@B':33Y*08NC6/9>H4]>#[(@@'EIFV86C/IDD\
MVK?]P"N(JNS'$$IF'*S2\2Q^FQS;]%6LQ_]@G;Y-!DGROUB/)K/OHCV;Q1C_
M(^VG]I?AR?Y?L5F'4XY%K+9VW5'@\/9PD+KJS@]'\^X4AK37$DVAN(!K$L_.
M(S+=R:9[<+H)IXF5=CB;A-L2AT$VW@#?"ZW=_L$'.!POEW\#4$L#!!0    (
M $*!FU8L0$41H0(  +D%   9    >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM
M;(5474_;,!3]*U<9FIC$FH^FM'1M)0I#XP$)@38>ICVXR4UCX=B9[;2P7[]K
M)PV=5+J7V->^Y_A<.^?.MDH_FQ+1PDLEI)D'I;7U- Q-5F+%S$#5*&FG4+IB
MED*]#DVMD>4>5(DPB:+SL&)<!HN97[O7BYEJK. 2[S68IJJ8?EVB4-MY$ >[
MA0>^+JU;"!>SFJWQ$>WW^EY3%/8L.:]0&JXD:"SFP64\7:8NWR?\X+@U>W-P
ME:R4>G;!;3X/(B<(!6;6,3 :-GB%0C@BDO&[XPSZ(QUP?[YCO_&U4RTK9O!*
MB2>>VW(>3 +(L6"-L ]J^PV[>D:.+U/"^"]LV]QA$D#6&*NJ#DP**B[;D;UT
M][ 'F$3O )(.D'C=[4%>Y36S;#'3:@O:91.;F_A2/9K$<>D>Y=%JVN6$LXM;
MN4%IE>9H9J$E0K<<9AUXV8*3=\!#N%/2E@:^RASS?_$A">G5)#LUR^0HX1W3
M QC&9Y!$R? (W["O;NCYAO^I[A6NN<F$,HU&^'FY,E;3[_#K4,4M87J8T%ED
M:FJ6X3P@#QC4&PP6'S_$Y]&7(W+37FYZC/U_CW$4?%C:'B/LSQG=PX:)!G-@
M%FR)0.Y$#:J 3!D+I\XP4'!M[&<NS[H9F=I9@)M/P&0.DGH&-0+!_["5Z/@&
M\';G*R:8S.@T8D9@!@HEZ!@SA=,3X))^9R'(F<1&[YZ5_N&O,<-J14I<\,"V
M]*];U)P) R<03^)!Y,9Q-!C#$]G=T=1:T2$&+D:#"QA?4,8-EYPLD<-:J=SX
M]!CB\Q%]3R!-QYXDC=/!! Z]6KAGIPKUVC<-0Q?32-LZJU_M^])E:\>W]+:I
M46%K+@T(+ A*JD<!Z+91M(%5M3?G2EFRNI^6U%M1NP3:+Y2RN\ =T'?KQ5]0
M2P,$%     @ 0H&;5G*NDKK_!   #@P  !D   !X;"]W;W)K<VAE971S+W-H
M965T,3,N>&ULI5?;;N,V$/T5PLT6,>#(EGS)91,#R>X6+;!!@R3=HBCZ0$NT
M1:PD:DDJCO^^9T:7V$[6+=H'2Z0XES-G9DCZ<FWL5Y<JY<5SGA7NJI=Z7UX,
MARY.52Y=8$I58&5I;"X]IG8U=*55,F&E/!M&H]%LF$M=].:7_.W.SB]-Y3-=
MJ#LK7)7GTFYN5&;65[VPUWZXUZO4TX?A_+*4*_6@_&_EG<5LV%E)=*X*ITTA
MK%I>]:[#BYL)R;/ %ZW6;FLL*)*%,5]I\DMRU1L1()6IV),%B=>3^J"RC P!
MQK?&9J]S28K;X];Z3QP[8EE(ISZ8['>=^/2J=]83B5K**O/W9OVS:N*9DKW8
M9(Z?8EW+AA".*^=-WB@#0:Z+^BV?&QZV%,Y&WU&(&H6(<=>.&.5'Z>7\TIJU
ML"0-:S3@4%D;X'1!27GP%JL:>G[^62$D=SGTL$5?AG&C=U/K1=_1&XM;4_C4
MB4]%HI)=_2$P=$"B%LA-=-#@K;2!&(<#$8VB\0%[XRZP,=L;'PQ,_'F]<-XB
M]W^]%6-M8O*V">J'"U?*6%WU4/!.V2?5F__X0S@;O3\ <-(!G!RR?H#Y@WIO
MHZJ-78N,WD(]:^>=6*<*92]B)(H8H,&3VCCAC?"I:JI+69Y8JEY:86F4(7VL
M8,LLA4Y4X?52JT24%MN!]9N!*#-9^($P5JAOE2[1IUY@CX _"&B3D*)'^PI=
M $^<RF*E6  .'"Q:25T9B$?X01?I0G.70DNV4>0+DVCDT*\95L(2[D*$?4)G
M8=H)66S#D\YA'X-'CJ^-VZ?2DRP0)X(A)@K4Q5HN,M7H'.M !8/7\9%*%V#_
M/<^C_BY_J73_R"$-]X$&@M,F2KDAZP[ XZQ".[41Y%BNK&)N&QL$#\P5JX8D
M]GEBEB?DAZTZQEBO9@A19^ -+$I+E.2EU4YQ=I;ZF3+:.C^NO9-I79RX"GTC
MBUCMB?4'XDG:FKE.E0D&IXKX+3@GV!6>B6N 536+A%X]*QMK"MGJ6+7)!FH*
MC/,/]LK*HEP@Q/3!D,TVA*I);LU#HX6LXBARI@"@C8B1.JG92.NI+C"*VQ2,
M%3[;)@%>O-=42<C@TF0XH5!>CZF%Y>WM31P?44IRG654@7W>H^@1B5_W\A$;
MY\61F ;G>(Z#L7A(C?4G7ME\6R+$RBB8B"\MESMKI_A-Q*/Q,MLU>\9FIT$H
M'JJRS+@R(!-+EXHET -E?4[71V8&\A-B(ZLWPS7"_,^1?B GI=1)W>:YJ?Y%
MR;XJPXLMQCK8@&1-OE_;#J%.&AXC<?]&H9L%I;MVOK/'%+@-['?*=B\<@?P9
MGN>@^IIK L=/G';G#Q?L1Q5C"T)_-U^C 4>XYH.>>O@)#N 0T0+%BR/.-:%X
M%0_Q?X[,;Y2T=9MVLP',N%+Q'27;!/\?5:)=3"GB#F3/8''VCFU@-'VW[_%6
M^LK6],#S(?9>=<Q^T;S WD'[!P+=*B@>';^PUYP;DOSWD9QP$DSI=1Z,2'8B
MPC.PA4=(TZD(9R@+/'AU)L(Q>H8?F)XRL^?41712R"62(J8A#$Y'P9D((RJI
M,)HA_Y^QDUP(G9<5T5='JPO(*[3<<7@:X+BAUVE_IR-WRRD<S0"+WH3VK=O!
M<.N.AD-CQ3=1)SA']76M^]I==J_K.]Z+>'U3!KTK7> \4TNHCH+3::\^!]J)
M-R7?^!;&XX3B88H+N[(D@/6E,;Z=D(/N+\#\;U!+ P04    " !"@9M6@C+\
M^7T$   B"P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6RM5FUOVS80
M_BL'+1@VP)-LV4[2S#;@)"W68=F"I&L_#/M 26>+#46J)&77_WYWE"T[KTBQ
M?K$EDO?</?<<3S=9&WOG2D0/7RNEW30JO:_/DL3E)5;"Q:9&33L+8ROAZ=4N
M$U=;%$4PJE22]OO'226DCF:3L'9M9Q/3>"4U7EMP354)NSE'9=;3:!#M%F[D
MLO2\D,PFM5CB+?J_ZVM+;TF'4L@*M9-&@\7%-)H/SLY'?#X<^"AQ[0Z>@9ED
MQMSQR_MB&O4Y(%28>T80]+?""U2*@2B,+UO,J'/)AH?/._1W@3MQR83#"Z,^
MR<*7T^@T@@(7HE'^QJQ_PRV?,>/E1KGP"^OV[/@X@KQQWE1;8XJ@DKK]%U^W
M>3@P..T_8Y!N#=(0=^LH1'DIO)A-K%F#Y=.$Q@^!:K"FX*1F46Z]I5U)=GXV
M7RRDDL)C 1>FJH66Z":))V3>3_(MRGF+DCZ#,H0KHWWIX*TNL+AOGU!$75CI
M+JSS]$7 *V%C& YZD/;3X0MXPX[F,. -G\%[^Z61?@-7Z$M3P'N]0N>IM+P#
MH0OXW4CMX2.]-Q8=_#//G+=4+_\^E8G6T>AI1WR'SEPM<IQ&=$D<VA5&LQ]_
M&!SW?WV!QJBC,7H)_=5J?3O*W /E/"^[I(?$7&*.589VMYKVP)<(8KFTN"0
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M/[1\@/87AC*S?6$'W5@\^P]02P,$%     @ 0H&;5CW>4V;3!   TPH  !D
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MXNN_^"/8G%^YC6S .8Z_3I5$YM "W!];G%G*'[1!_0[V[+]02P,$%     @
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M:'^!\!.K5N[0OE 6KP!N6.*=BVM:@-\+A0FU$PK0W>)F?P-02P,$%     @
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MAQT>/P[) /NM]W*<I "GYW3]#U!+ P04    " !"@9M6W<Q/\:@'  "%$P
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M-^48HM%M,V8?90UW>*WT7A5KV+,YX"TJHQZQC&,?1@LJ?1786&1:;DKK P%
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MX,,!Z-Z*2+M'1+&=U#&*$21P031(8$8.0C/J^"&@02W3&$.<8N-L73&+FJ+
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M%$I .FZL"Z0<4VM4FVLQE7(KU1W3BMD06&GP/-HHD.]RX#+Z(I3TR42#I7A
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M:&>7SDWI)M@FGE56-N#D$R]+C!IV\@*>RR='?R,.AL/KQ3]02P,$%     @
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MM7:4AF%:TK,,C2>@\UQKMUMX!=U#;_$/4$L#!!0    ( $*!FU8 O(SV[ (
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M=X#:!=!^H91]F[@"_1],^A=02P,$%     @ 0H&;5JK'*Q2Q @  P@4  !D
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MO=+64V\GX">A.S#HM\'K>8,=>(/*]X'#&SSN>]UCD0;P 8.%3!<P8=)(*]'
MF31^K$RF$7Z?S$F<"/7'MJCDB^YO7Y2+;&26PL>3!E6107V+C?'K5_UA[VB'
M2_N52_N[T,<S*MH@BQ%4",1:XF0*TTQK3/U[F%(ZV&JSS>J=N-NMGAA>AK+B
M1U5:VK!"B$0 U ",I5!R%,/"$K^TQ"\M :M@F1$ %98+/-5K##YJ2_T$ED)J
MMT:A2&EH@S"$%U,S,2-HDE BXYCJV[1@QKJ5MU<E[-?9&9Q_O7;_AQV/_@_@
M]:M#K^\=P6^8PD%[Z+WK#&'0HY=]C][.WI_!\&WG'7C[?!AT#F%';@ZJW!P\
M.3?G88CL/ET^P$+J6%]LA)JREE#((^Z#3L17"4+SS9?IY9N6"]FYT"E%>6M6
M=UJT/:LW$18!YM19KOZB9<N_J S()L"U]<':>EFS/D!#"1<6 Y<ORB/<BC@C
M:E!AH?..@8@' 3E&4G1E5"P#IT+$L5B$(21<=GD$DT1EJ>4G[YD<S8_*4-*O
MT5>+E$P+2+ ,#Q'.X=]$&G&C#<%'Y0NW']#?K%R'0<O([L$&J9C4?/#@@KWX
MYKSXX+P8Y6=:F%"8BQ8U82Q%>@^Q$FD+]H#IM =-XE>KR"?>+=EEEN<%6W4"
M;(8M*IK0.K#0)+P6,%L? "N"A'=^G+&[H59)D2]:($5#&41C&;9/=.\1M1]
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MS0V]EE [ YIOE+*'CEN@?W\M_@502P,$%     @ 0H&;5@E]IN4P!0  BPX
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MP18E+RNL=2EK4+B8>F?LY#RV]]V%KR6N]<XWV$CF4M[9S:=\Z@76(128&8O
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M:'9'92_0^4)*L]E8 ]O_!F9_ 5!+ P04    " !"@9M6];$/W48#   N"
M&0   'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6RU5FUOTS 0_BNG,$VMA)(T
M[<:TM976#<0^ -6ZP0?$!S>Y-A:.'6QG'?QZSLY+N]%52(@/=?QR]]SS^.QS
MQQNEOYL<T<)C(:29!+FUY7D4F33'@IE0E2AI9:5TP2P-]3HRI4:6>:="1$D<
MGT8%XS*8COW<7$_'JK*"2YQK,%51,/USAD)M)L$@:"=N^3JW;B*:CDNVQ@7:
M^W*N:11U*!DO4!JN)&A<38++P?ELY.R]P6>.&[/3!Z=DJ=1W-[C))D'L"*'
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MJ7B#TG E0>-F'EUGT^78V7N#?SCNS=$[N$S62OUPFT_5/$H=(1186H? :'G
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M&JA'ZUOTNKP[7J:75S!6;,F$)AP6&(JI\""J\E8K.T:NBIMD+@T:M6AF^"4
MRD[ YPLI3=6Q">IOB_@/4$L#!!0    ( $*!FU9;/;*T5@,  )P-   9
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M;F[E_@W4@B:6+Y5<NU^RK^<&'DFWVLBR!F,&)1/5/_U2&W$$0)YN0%0#HH>
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M&BRU7;/ ZQ,H.P&?KZ4TAXX-T%S(5M\ 4$L#!!0    ( $*!FU8V<"E)*@0
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M;B90=Q.N!&!^S9C<=]0"326_^!]02P,$%     @ 0H&;5M!/])Z* @  T@8
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ML@FEA1;"+NU>E%XH]B06:TFNI,2[;U])=DP"3FAA;VS]S#F>;^11VBC]:$H
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M^P"WOU7*'B>^[?M;/OL+4$L#!!0    ( $*!FU:7)?>460,  .\+   9
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M'ACGF"T]\PWZM@A^4OFY+_T$S_@)R8,4)M/DO4@A/;?W,>8Z\. 4^'W0"?A
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MUNW5NKT"SS?IOL^Y8#NY*07ZXT$:H'L!&?]3)ZY$&^C15*[=\BV)86+)9.+
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MH"B/QF5#\75QNIQQI<^JQ>4*R!R$&:#[%YRKIX8YL-9_4"2_ 5!+ P04
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MG U03!9XD\H/;/N&5( FN;Z(I:+XB[:5['B HHV0+*L&@P590LO_^+%R1&,
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M&90K;;HG%(?RPOX3V<K3#G:((VVZ0Q07\^QDS&TB3_;N1%81'8-B6)Z5L_S
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MK![?CK#6?N6H9[XK-9"HA;1%2U*M5IWOB>_W?EL_=1VQ;^L>8(IVFAH.HFE
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MP:)Z]HKM<BBVRU.Q771.^AT'Z*8SEUTCE\X=O9M!XV: )G9K=VNS.["9W9;
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MJ_[Y!-*G..D//6RI5>:WA:8&"\Q/AYA_?&E90Z&I@YFH+@+O4YSW)Y66->9
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M+R(]EJ][WJ5"I''Y\8$S*=P* _G[0YJ*GU^*-TB;-X:W_P-02P,$%     @
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M_-Q.?B/Y+COZ<L>EY$EVN:4DI$(;J-_7G,O'&]U!>7IJ^3]02P,$%     @
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MIORA&"+.(I92FP7%V*!J@;>/OI )JS(!'H9V#P<[6($3UI7.ZGH)<)H021=
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MX]$Q#KH.NR-<K&K\^"V5Q6'VQPK7+6CG@-]72MG=Q07H%WC^%U!+ P04
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MCT3]5R0,PJA#S_CY\/" G*@U,W)\T1-\$[120$'V3:6B()]-"8I,I38*#%.
M[X%Y%/;M(V+)E8%*?^^RMDX]Z$YM7_8+O:0Y##U\FS6H-7C9RQ?].'C;Y<N1
MR/9<&K0N#0ZQ9W@S&.X<Z#Q"-3AQ8'L'K;,@]=>[XNN(>#>B%[<Q>YK.6TWG
M!S5-FWMI5F])I["##'^[ 4<BVRLV;HN-_]\QC8_ITI'(]EQ*6I>2?SFFR1^/
M:?*,8^KOW-P5J(5K:)KD<B5,?0VVJVW/O'2MXM'Z"'MIW?I^T]2-&"^Y!<.-
MXS!'RJ"7X-%3=7.K)T8N77^828/=Q@U+_!X 90/P^5Q*LYW8!.T71O8+4$L#
M!!0    ( $*!FU8LH+A#(P,   <)   9    >&PO=V]R:W-H965T<R]S:&5E
M=#8T+GAM;*V6WV_:,!#'_Q4KJZ96&DE(6GYT$ EHIU5:M:I=MX=I#R8YB%7'
M9K:![K_?.0X9A33;PUX@MN^^_MS%OLMH*]63S@$,>2ZXT&,O-V9U&00ZS:&@
MVI<K$+BRD*J@!H=J&>B5 IJ53@4/HC#L!05EPDM&Y=R=2D9R;3@3<*>(7A<%
M5;^FP.5V['6]W<0]6^;&3@3):$67\ #F<76G<!34*ADK0&@F!5&P&'N3[N5L
M:.U+@Z\,MGKOF=A(YE(^V<%--O9""P0<4F,5*/YM8 :<6R'$^%EI>O66UG'_
M>:?^H8P=8YE3#3/)O[',Y&-OX)$,%G3-S;W<?H0JG@NKETJNRU^RK6Q#CZ1K
M;611.2-!P83[I\]5'O8<4*?9(:H<HD.'\U<<XLHA+@-U9&585]309*3DEBAK
MC6KVH<Q-Z8W1,&'?XH-1N,K0SR2?30Z*7#_CJ=! 3F]$*@LX(QWR@.<E6W,@
M<D&<4;U86U^!H8QK:_[X<$5.3\[("6&"W#+.\1WI46 0T6X4I!7.U.%$K^#$
MY%8*DVMR+3+(7OH'&%H=7[2+;QJU"MY2Y9.X^XY$810W\,S^W3UJP8GK=,>E
M7MR:;I=(0D6VRZ4FWR=S;12>ZA]-67.JY\VJ]J9?ZA5-8>SA5=:@-N E;]]T
M>^'[II#_D]B+!)S7"3AO4T\F6F-I8L6*,H7%P#2>$2?1*R5L&=HDW:Z/;V^S
M'X4SZN\9A;7%"[2+&NVB%>V3U)J<+K'RG1$L,))Q@E=@"8V(3FJPO[O?.R \
MMNE$_J 9LE=#]EHA9W@]F%ABYDB*-XQEH*BMATV,O0;&PRPVV;R"V*\1^ZV(
M6%ZQ> H"SVE.$97@L1::NK+-,<E0I5F?-5'W&XB&!]3'-IVNWVW&'M38@U9L
M=S69@:+QA0^.MPS]Z(#+&5W\_4P.:ZAA*]07:2@GLD2#7=EEK@XW40Z/;TYT
ME+UCHTY\E+U@KZ<4H)9EJ]5XZ-;"N/);S];=?%(VL8/Y*79YUY3_R+A/!"RN
M2SP%A,,")4._CXE3KNVZ@9&KLG/-I<$^6#[F^*4"RAK@^D)*LQO8#>IOG^0W
M4$L#!!0    ( $*!FU8IE@ "@ 0  ,D9   9    >&PO=V]R:W-H965T<R]S
M:&5E=#8U+GAM;+6976^C.!2&_XK%C%:ME F8?+:;1&I+1U-INUNUFMV+U5ZX
M<))8 W;&-DE7VA^_-A "&6I-9MR;!(//:\Z#?>"%V8Z++W(-H-!+EC(Y]]9*
M;2Y]7\9KR(CL\PTP?63)14:4;HJ5+S<"2%($9:D?!L'8SPAEWF)6['L0BQG/
M54H9/ @D\RPCXM]K2/EN[F%OO^.1KM;*[/ 7LPU9P1.HSYL'H5M^K9+0#)BD
MG"$!R[EWA2\C?&$"BAY_4MC)QC8RJ3QS_L4T[I*Y%Y@S@A1B922(_MO"#:2I
M4=+G\;42]>HQ36!S>Z_^L4A>)_-,)-SP]"^:J/7<FWHH@27)4_7(=Y^@2FAD
M]&*>RN(7[<J^DPL/Q;E4/*N"]1EDE)7_Y*4"T0C0.MT!8140?F_ H H8' <,
M7PD85@'#@DR92L$A(HHL9H+OD#"]M9K9*& 6T3I]RLQU?U)"'Z4Z3BW^4&L0
MZ/9%SR,)Z.R.Q3R#<_0!_4Z$(.::H+,(%*&I-'L_/T7H[/TY>H\H0_<T3?6U
MDS-?Z3,Q>GY<C7I=CAJ^,BI&]YRIM42W+(&D(_[&'C^PQ/N:0(TAW&.X#JV"
M$<1]-, ]% 9AV'4^]O![(NKP04=X]/WAH26;07U1!X7>X!6]IW(1([Y$=VP+
M4NF%JM GGB:4K23Z^S?=']TIR.0_7=>N%!]VBYM"="DW)(:YIRN-!+$%;_'+
M.SP.?NT"YU(L<B36@CJLH0YMZHLK*749IMF&4&%X=DY[J\2IZ$JQ<2%FZO=V
M@7%?3Z]M$TG9:=+H%-0]6GF.ZCQ'UCPC$'1;KGS*I!)YD2QB7.EZ*NF*$04)
M(A*M(5GI^=3LU4,K?:M!9RF7\KR'&*@N2-;Q3X54BDT;^7\(^N,C2*-O2(;]
M:3>F<8UI;,7T(/A&4%T9]3K3VTD>=\\(J\JIR;H4BQR)M>A-:GJ3MZQ0$Y=0
M78I%CL1:4*<UU.G/5RBKQ*GHIM\LOHO^\&CM.1JP1>2B)G)A):+OIP%Z!%.?
M8I4+4ZT>4L*ZN%B%3N7B4BQR)-8"B(/#\V'PEBNU4G?$U:E:Y$JM3;;QY(VM
MD[,]+PE+M(]*RYNK,4-44= WU(V^'?/$X-<+.P5#GQC'U G;/B .458\-G>B
MM<:>C-:16AMM>$ ;_LBZ1_]IS\)HEF>=]*R:)T]5EVJ1*[4VSX.?P&]J*+!3
M1^%4+7*EUB9[,!78[BI>+P(QEZJ'0#OS>-_L9.O4<E1JH^:3\NCHANYJQ#:Q
M@SW!=G]RNUQJ(H@SM,PU-D! !#/3L(=(QG/63<FIYZC46I3"8TJ.1FQ3.K@3
M;+<GE@I(7EZM@$[-BE.UR)5:F^?!K^ W-2S8J6-QJA:Y4FN3/9@6;'<M/U\!
MG5J:2JVUMB?':_LM/ T^F!IL=S4_5@&=&IQ*K?G:*3PV?JY&+"GYC7?<&8A5
M\:U ZDFA\RW?\]9[Z^\15\5;^*/]-^8[1?'N_"!3?N2X)V)%F40I++5DT)_H
M22#*[P9E0_%-\2;]F2O%LV)S#20!83KHXTO.U;YA!JB_WBS^!U!+ P04
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MXBBZ)AUE N>IW]NH/)6#X4S 1B$]=!U5SVO@\I#A.3YN;%G3&K=!\K2G#>S
M?.LWREID8JE8!T(S*9"".L.K^7*]</[>X3N#@SY9(Y=)(>6C,^ZJ#$=.$' H
MC6.@]K>'&^#<$5D9OT=./(5TP-/UD?V+S]WF4E --Y+_8)5I,_P1HPIJ.G"S
ME8>O,.9SY?A*R;7_HD/P7<08E8,VLAO!5D''1/C3I[$.)X#X)4 \ F*O.P3R
M*F^IH7FJY $IYVW9W,*GZM%6'!/N4G9&V5-F<2;?06-+;-"="!?L*O4>/5"E
MJ"L7>G,+AC*NWZ;$V' .1,J1>AVHXQ>H$W0OA6DU^BPJJ/[%$RMSTAH?M:[C
MBX3W5,U0,G^'XBA.D [*+_ F4PT2SYO\IP9;Z*4R3#3HYZK01MF.^74N[<"V
M.,_FIFBI>UI"ANV8:%![P/GK5_/KZ-,%K8M)Z^(2>_XP= 4H)&L[$4XM+3@<
M2Z'/B0UT5Y[.3>@^CU.R/U5 3KJG ]7X&=&HE(,PH9&FW6D,5Z'[_KJ'&;8W
MU#"A$8?:0J/9!QM7A;D(AI&][\5"&MO9?MG:IP24<[#GM93F:+@ T^.4_P%0
M2P,$%     @ 0H&;5G"FH;1] P  KPX  !D   !X;"]W;W)K<VAE971S+W-H
M965T-CDN>&ULS5=-;]LX$/TKA%H4*=!:7['L9&T!C=/=#=!T@QCM'A9[8*2Q
M350B59**6V!_?(>4K$A>56T*'7*Q2&KF\<V;$<U9[(7\I'8 FGS),ZZ6SD[K
MXMQU5;*#G*J)*(#CFXV0.=4XE5M7%1)H:IWRS T\+W)SRK@3+^S:C8P7HM09
MXW CB2KSG,JO%Y")_=+QG</"+=ONM%EPXT5!M[ &_:&XD3AS&Y24Y< 5$YQ(
MV"R=-_[YR@^-@[7XR&"O6F-B0KD3XI.97*5+QS.,((-$&PB*CWM80989).3Q
MN09UFCV-8WM\0/_=!H_!W%$%*Y']S5*]6SISAZ2PH66F;\7^3Z@#FAJ\1&3*
M_I)];>LY)"F5%GGMC QRQJLG_5(+T7) G'Z'H'8(CAU.O^,0U@Y6.;=B9L.Z
MI)K&"RGV1!IK1#,#JXWUQF@8-VE<:XEO&?KI> U;3(HF5[PJ"2/M:[*F&2AR
M]Y7<2)&6B29_2%$6Y.02-&69>HDF']:7Y.3Y2_*<,$ZN69:AIUJX&CD99#>I
M][^H]@^^LW](K@77.T7>\A32KK^+L30!!8> +H)!P&LJ)R3T7Y' "\(>/JN?
M=P\&Z(2-OJ'%"W^@[RT40FK&MZ]PF B>,+3<DBL-.4'ER5\%2&K>&\DW3).3
M=T*AT!LI<G( T8*L4&61L91J2,D_[W WBZ'^[9.^HG;:3\T<$.>JH DL'3P!
M%,A[<.(7S_S(^ZU/MY' .BJ>-BJ>#J''[_$\4Z8F^Z*L7"/K:DZM^WCF1Y-H
MX=ZWZ5=6L[95X#4V'5;3AM5TD-45UR!5G1M+CT#&\".UGU$?U4&\QR9D)+!.
MZ%$3>O1TRSH:4\61P#HJSAH59[]>UI7KM%6PWE%)#UET^,P;/O-!/IBC0C(\
MXV5S\BOR7RN)=<9Z^0Y"/S8K(X%U5#AK5#A[NK5]-J:*(X%U5/2]AYN%]^O5
M7?O.6\4[G8<3_ZC$>\PBSY^$_77NMVX]_B WS(F6>(5\?4UYN<%!*3$YCZ[Y
MX5T>FZZQT+J:! ^:!$^W[FMN8RDY$EI7R8<[GS]X&?I!Y8?_NZ_X83B9'E=^
MCYD_G\R.*M]M7?USD%O;$2F2B)+KZM+<K#9=UQO;:QRM7YANS+84#S!5*X=7
MXBWCBF2P04AO,L-_'%EU1]5$B\(V&'="8[MBASOL*$$: WR_$4(?)F:#ID>-
MOP%02P,$%     @ 0H&;5O\.6CX4!0  L!D  !D   !X;"]W;W)K<VAE971S
M+W-H965T-S N>&ULM5G;;N,V$/T50ET4";"^D+[)J6T@<;IH@ 8-$J1]*/K
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M?],T,%HET")&4C-M"1(FHH4RA=F*/FDGL''3'O^Z.FAUVVC?A7>LJC_K"H6
MW KA3O!84/T#5+P!/5YL CM)-\RI!:<IM*K3A49 GZD14*,:H2FT:B@*C8#<
M&N$H^8KJW;]^QMP/^E%'"B6!W$K"ELC@/W"< G9CG[REGZ$L4*$LT&<J"]2H
MLF@*K1J*0EF@CRL+5)<,<-2MM3^;V;A7.@55BH6R0&YE,>=,"1RHUBUFFZ4>
M;(1N'*=GL/,I)V];0VC5F!3B!8T^,X.=RNCD4#2$5@U%H8Z06QT=E<%^_>W=
MJ%Z?+5;CFGSKE-Y]1T2LDD\"4HO'#5/IZ^+\:O[9X3)YV;YW_0I>S-./!P5,
M^BWC%HL591*$9*DA]4G3)TNDGP?2B>)Q\H;]B2O%HV2X)GA!A#'0]Y><J]W$
M/"#_2#/['U!+ P04    " !"@9M6**BG8FX#  #&%@  #0   'AL+W-T>6QE
M<RYX;6S=6-%NVC 4_94H7:=6FAI"1B K(&U(E29M4Z7V86^5(0Y8<IS,,1WT
M<?^RMWW%/F5?,M\X)$!]*>O#!@LJL>_)/??<ZQOBM%^H):<W,TJ5LTBY* ;N
M3*G\C><5DQE-27&1Y51H),ED2I2>RJE7Y)*2N "GE'OM5BOT4L*$.^R+>7J5
MJL*99'.A!FY4FQQS>A\/7#]\[3J&;I3%=.#>G;W\,L_4Y0O'G$]>G9RT+EIW
MYY?;R%D%G;N>E;BS!S%*BY&&FZ2-NJ?4=/=*<U>>*'7/HNFTEG2*N4765-8\
M88(X=UOV='Y^1ZI; SO+V_7MM+^^_4#;H<&>6()N>Q_-%SM45]1>U=C#?I*)
MIK\#UQAT;))2YY[P@3LBG(TE Z^$I(POC;D-ADG&,^DH?6-I,3Y8B@<#^V8&
M]US%DS*1R3*VB6"^Q]7E6\!J!@(9Y[7 MFL,PWY.E*)27.E)>7%I? 0YU?AV
MF6N%4TF6?KOC-@[E20<99S*FL@[CNRO3L,]I G(DF\[@K++< U"I+-6#F)%I
M)DBI8>51#33MA')^ S](GY,-[D6RMJIE'XIZJ 550T-C)L"_SF:XUVG#9_$Z
M.;O/U+NY3D>4<^@5>BUIPA;E?)'4 C!V'V<G><Z7;SF;BI2:Y/<...R3E9\S
MRR1[T-&@52;:0*7KW%.IV&3=\E62_)8NU*J=%@FNN7V$FO]NG:=44$GXNFC=
M^X=<Y6<K#KK_2G+YJ[(MV*JQVF4<NLC.,8@,CT'D4?1D[QA$1H<O,C@"C=6.
M^=!%^L<@LGV0(KUJ3[FV<=W8MM96!UX/!NXG>!7A35!G/&=<,5'-9BR.J7BT
M>]7TBHSU2_H&O[X^I@F9<W5;@P.W&7^D,9NG47W5-12BNJH9?X#T]%9X]6ZB
M8S$1TP6-1]543L?ET-$#';4ZP&$;N2H/.X+Y&,R. (;%P11@/L8+B_,_Y=-#
M\S$8IJUG17JH3P_U,5XV9%1^L#AVGT@?]DRC* C"$*OH:&15,,+J%H;P9V?#
MM($'%@<B_5FM\=7&.V1W'V!KNJM#L$SQ3L0RQ6L-B+UNX!%%]M7&XH 'M@I8
M[T!\>QSH*;M/$,"J8MJP.QA'H@A#H!?M/1J&2'5"^-C7![M+@B"*[ A@=@5!
M@"%P-^((I@ T8$@0E,_!K>>1MWI.><U_KH>_ 5!+ P04    " !"@9M6EXJ[
M',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6
M!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV
M)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O
M@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=
MI7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    (
M $*!FU8N].]A=P4  -\M   /    >&PO=V]R:V)O;VLN>&ULQ9I+4^-&$(#_
MRI0OV1R(L5[L4D"5P9!0!8;"%#FF!JEM3ZTTX\R,@-U?ORW)WHR(Z,JEXY/U
MLORY->JOYW'R:NS79V.^BK>JU.YTM/9^<SP>NWP-E72_F0UH/+,TMI(>=^UJ
M[#869.'6 +XJQ]'A83:NI-*CLY/=O>[M.-PQ'G*OC,:#S8$G!:_NG_/-KGA1
M3CVK4OEOIZ-VNX21J)16E?H.Q>GH<"3<VKS^8:SZ;K27Y2*WIBQ/1Y/NQ!-8
MK_)_'5XTD(_RV;5'O'Q^D AR.LH.\89+99UOKVCO+Y'Q!?#B;J_VYDJ5'NQ,
M>OC=FGJC]*JY#?Z+<? WVCCL/KL@'MO_$D:S7*H<9B:O*]"^BZ.%L@'4;JTV
M;B2TK.!T=&%>P#;_!W_@NNC^FT>H(%+V6.$)>UVT>(PH=_/9Y7QQ.1.XM;B[
MN9Y-'W%G\8@?MY?S #(B(*,]0OX5!9 Q 1GO$S(.(!,",MD+Y/GT9CJ_N!0!
M9$I IGN$[#WNC(#,]OFXDP#RB( \XH4\ETXY89;BWH+#2]LKA-2%6-15)0/(
MSP3D9U[(.=IBFN>FUAX3LEAXY).V< '=%X+N"R_= [R KB',UH=4NC[D#I87
MUSHW%8A[L&*QEK;'1JJ$V277&D/E4>@0/KL))8X)LSEN0+H^#66(";,BIGAA
MJ?#'"W%AJHW4[R)%B6'";(89//N0A<K_$V8!S,"J%]D4;^)*::ES)4ML]<[;
M]ILA)F6 ";,"KJ2RXDF6-8A;;&>UA>8+O2=*Y?X)<_+'G%I7==DVMSN_QFS1
M-#H+:] .0QMB4ME_PIS^VQ2V-F4!UOTB+O^NL<L0LE&Y?\*<_!?>Y%\/T*+;
M-Q8CUUX4EL64#2)F&YR#AJ7RXKZ4.FQW$:6!B%D#75N[?&NB!>)39ZM?0SJR
M*\%LA*T\'^5;+_=&E!<B[JZ#J2KEV^31%F<7IBV% !-?'Y(21,0LB 6LFBLP
M#W=??_<:4+Z(F'U!EKF]#D-$^2)B]L6VE!2?'B7^L.N]$I0H(F91#-64@Y"4
M)B)F303%Y2 ;I8F(61-=E3F$%5-VB)GMT)1T@U"4'6)F.Y"U77\LA])$S*R)
M#VJ[73A#3'+,B;M'0=5X_6A2[HBYW3%0XPVV3,HB,;=%PF)JD(Z21\PLC^&J
M:A"3<DG,[)*!*F&0D5))S*R2G8</Q&[K 7*STJJC#3$IJ\3_S\@38C;UH)7Y
MMCJ\4;*96 D'E"G+),R6(3%[*2BAO),P>V>XR)F!EZKL-<V$TD["WCL)JIPA
M.$HV";-LMF7.@6@W\'$[/PQ)3G PJ^8]I'1K<56:UVUW(,2D9),PR^8=YI^@
M5NM&XM,7L'(5#LXDE'429NO\Q+R5OK:8(*'M9]UMD!*[J"$F99V$>ZAK8&!U
MN&E2WDF8O=/6X_C$C5X=>+"5Z KT(4S*.PFS=[:8%Q8*K(:N9-[.XO_D#.<(
M*>^D[+T;JB,1SK>FE'?2O?9WPGG"E!)/RBP>&C,-,2D%I<P*HC&S$).24,HL
MH8]ZCP=BZAR$$Q@I.<_.+*&/,=O>1HA)22AEEA#=R>V]Z92$TGW.M_3?=,I"
MZ1[F6YITOY9Z!2+L5J24A5+NJ9=AS$6]V9383,-%()2%,F8+?31#M-5EB$E9
M*&.V4']L \.(]RSJ$IIB#K%#3,I"&;.%WF/.I;5=MF_#&6)2%LJ8+?3!6,PN
MK"$F9:&,V4(?8G9A#3$I"V7,%B*CV5_N1:[W8K90.'$X6+1GE'RR/8R[!>]/
MB$G))^.6SR#F0I88T^=OX?K#C))/QBV?8<SMT:MP<1\EGZ-6/N/V8G=V4F!N
MTU#,\2<<'L]EF=];T7QTZZ22M%GLL*S+\@*/W>D;(XO=^N3=VNJS'U!+ P04
M    " !"@9M6VW:P<3$"  ")*0  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QSS=I+;J- %(7AK5@L(+CNBZ059]233*-L #GEAV(;1-%*LONVG(%]
M4 ]Z$G%&J$!<_M$' AY?\J$=]]VI[/9]67P>#Z>RJG;CV/^JZ[+>Y6-;[KH^
MG\Y'-MUP;,?S<MC6?;M^;[>YEN4RZN%V1O7T>#MS\?K5Y_^9V&TV^W7^W:W_
M'/-I_,?@^J,;WLLNY[%:O+;#-H^KJOX\7'>7^K))=^?)U>+Y;54-SV^IJN<.
M$@B2^8,4@G3^((,@FS_((<CG#PH(BOF#&@AJY@^ZAZ#[^8,>(.AA_J"T1!F7
M!$D3K FT3LAU(O Z(=B)0.R$9"<"LQ.BG0C43LAV(G [(=R)0.Z$="<"NQ/B
MG0CT%M1;"/06U%L(]);)PS:!WH)Z"X'>@GH+@=Z">@N!WH)Z"X'>@GH+@=Z"
M>@N!WH)Z"X'>BGHK@=Z*>BN!WHIZ*X'>.GE90J"WHMY*H+>BWDJ@MZ+>2J"W
MHMY*H+>BWDJ@MZ+>2J"WH=Y&H+>AWD:@MZ'>1J"WH=Y&H+=-7G83Z&VHMQ'H
M;:BW$>AMJ+<1Z&VHMQ'H;:BW$>CMJ+<3Z.VHMQ/H[:BW$^CMJ+<3Z.VHMQ/H
M[9./E01Z.^KM!'H[ZNT$>COJ[01Z.^KM!'H'ZAT$>@?J'01Z!^H=!'H'ZAT$
M>@?J'01Z!^H=!'K'Y&<3 KT#]0X"O0/U#@*] _4. KT;U+OY2;W+^'7(Y=KS
MO<;K_R35X_G<?+W\9?F]$^\7S07G^K:B//T%4$L#!!0    ( $*!FU:DR,-W
M^@$  +0H   3    6T-O;G1E;G1?5'EP97-=+GAM;,W:RT[#,! %T%^ILD6-
MZR</T6Z +;#@!TPRI5&3V+)=*'^/DP(2""I0D;B;1JWMN1./=%8]OWOV%"?;
MKNWCO%BEY,\8B]6*.AM+YZG/*TL7.IORU_# O*W6]H&8F,T,JUR?J$_3--0H
M%N>7M+2;-DVNMOGGV+A^7@1J8S&YV&T<LN:%];YM*IOR.GOLZT\IT]>$,I\<
M]\15X^-1WE"P+Q.&E>\#7L_=/%((34V36QO2M>WR+K9M64S/+<5R?XDO>G3+
M95-1[:I-EX^4T0>R=5P1I:XM=T6/]B>G?,.T^^0'YX]E]@7FG;?!^9@G%NCW
M<6\C&4Y/?2Y$(37[7_$],9<^^/UHF'9-]0^S\_4^N; >YQ'9^#C\CC_.^+W^
M+_L0('U(D#X42!\:I \#TL<Q2!\G('V<@O3!9RB-H(C*44CE**9R%%0YBJH<
MA56.XBI'@96CR"I09!4HL@H4606*K )%5H$BJT"15:#(*E!D%2BR2A19)8JL
M$D56B2*K1)%5HL@J4625*+)*%%DEBJP*15:%(JM"D56AR*I09%4HLBH4616*
MK I%5H4BJT:15:/(JE%DU2BR:A19-8JL&D56C2*K1I%5H\AJ4&0U*+(:%%D-
MBJP&15:#(JM!D=6@R&I09#4HLA[_IZSWSJW_.'Y\EIUM^K=\-OY9<?$"4$L!
M A0#%     @ 0H&;5@=!36*!    L0   !               ( !     &1O
M8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !"@9M66&[:H.\    K @  $0
M            @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " !"
M@9M6F5R<(Q &  "<)P  $P              @ '- 0  >&PO=&AE;64O=&AE
M;64Q+GAM;%!+ 0(4 Q0    ( $*!FU9CQAO1U@4  -(>   8
M  " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " !"
M@9M656)]!^,$  ![$@  &               @($:#@  >&PO=V]R:W-H965T
M<R]S:&5E=#(N>&UL4$L! A0#%     @ 0H&;5M4N=MZ4 P  O@H  !@
M         ("!,Q,  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0
M   ( $*!FU9FV@B7_@(  '@'   8              " @?T6  !X;"]W;W)K
M<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " !"@9M6BE7,#H '  #Q(
M&               @($Q&@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L!
M A0#%     @ 0H&;5BMW%#,< P  7PH  !@              ("!YR$  'AL
M+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( $*!FU;JRIT< @8
M #88   8              " @3DE  !X;"]W;W)K<VAE971S+W-H965T-RYX
M;6Q02P$"% ,4    " !"@9M6T3.^*:\$  !A"P  &               @(%Q
M*P  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ 0H&;5F@C
MXI29 P  (0@  !@              ("!5C   'AL+W=O<FMS:&5E=',O<VAE
M970Y+GAM;%!+ 0(4 Q0    ( $*!FU9*;+R*? 8  '80   9
M  " @24T  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @
M0H&;5C"&E5)=!   :@H  !D              ("!V#H  'AL+W=O<FMS:&5E
M=',O<VAE970Q,2YX;6Q02P$"% ,4    " !"@9M6+$!%$:$"  "Y!0  &0
M            @(%L/P  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4
M Q0    ( $*!FU9RKI*Z_P0   X,   9              " @41"  !X;"]W
M;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ 0H&;5H(R_/E]!
M(@L  !D              ("!>D<  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX
M;6Q02P$"% ,4    " !"@9M6/=Y39M,$  #3"@  &0              @($N
M3   >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( $*!FU9"
M!:7P20H  (\=   9              " @3A1  !X;"]W;W)K<VAE971S+W-H
M965T,38N>&UL4$L! A0#%     @ 0H&;5EF^5#1?!P  8Q4  !D
M     ("!N%L  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( $*!FU;G< JDA04  ,<,   9              "
M@<5V  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ 0H&;
M5BP_ZV^C P  FP@  !D              ("!@7P  'AL+W=O<FMS:&5E=',O
M<VAE970R,RYX;6Q02P$"% ,4    " !"@9M6*R,O0%<#  !:!P  &0
M        @(%;@   >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0
M   ( $*!FU;=S$_QJ <  (43   9              " @>F#  !X;"]W;W)K
M<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ 0H&;5D>Q/4L*!@  R X
M !D              ("!R(L  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q0
M2P$"% ,4    " !"@9M6+1XX(O8#  #T"0  &0              @($)D@
M>&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( $*!FU8 O(SV
M[ (  &P&   9              " @3:6  !X;"]W;W)K<VAE971S+W-H965T
M,C@N>&UL4$L! A0#%     @ 0H&;5JK'*Q2Q @  P@4  !D
M ("!69D  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " !"
M@9M66KZ#G-8#  "#"0  &0              @(%!G   >&PO=V]R:W-H965T
M<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( $*!FU:\!R=[+@,  !,'   9
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M970S-2YX;6Q02P$"% ,4    " !"@9M6];$/W48#   N"   &0
M    @($0MP  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    (
M $*!FU80HGV08 ,  -T'   9              " @8VZ  !X;"]W;W)K<VAE
M971S+W-H965T,S<N>&UL4$L! A0#%     @ 0H&;5KR_TF>N!0  APT  !D
M             ("!)+X  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"
M% ,4    " !"@9M68\L*7Z4%  #**@  &0              @($)Q   >&PO
M=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( $*!FU;0J/GKZ0(
M &<(   9              " @>7)  !X;"]W;W)K<VAE971S+W-H965T-# N
M>&UL4$L! A0#%     @ 0H&;5EL]LK16 P  G T  !D              ("!
M!<T  'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " !"@9M6
M-G I22H$  #5#P  &0              @(&2T   >&PO=V]R:W-H965T<R]S
M:&5E=#0R+GAM;%!+ 0(4 Q0    ( $*!FU;03_2>B@(  -(&   9
M      " @?/4  !X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%
M  @ 0H&;5O+)T^&A @  ; <  !D              ("!M-<  'AL+W=O<FMS
M:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    " !"@9M6747WZ<<"  #F!@
M&0              @(&,V@  >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+
M 0(4 Q0    ( $*!FU9QVW0K0 (  /$%   9              " @8K=  !X
M;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ 0H&;5I<E]Y19
M P  [PL  !D              ("! >   'AL+W=O<FMS:&5E=',O<VAE970T
M-RYX;6Q02P$"% ,4    " !"@9M6C>-H>W4#  #E"P  &0
M@(&1XP  >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( $*!
MFU84Y_:,(@0  #L3   9              " @3WG  !X;"]W;W)K<VAE971S
M+W-H965T-#DN>&UL4$L! A0#%     @ 0H&;5AX6&/*5 P  K!   !D
M         ("!ENL  'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4
M    " !"@9M6[^.V[EP&   0.P  &0              @(%B[P  >&PO=V]R
M:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( $*!FU:0%R-E-@4  &TL
M   9              " @?7U  !X;"]W;W)K<VAE971S+W-H965T-3(N>&UL
M4$L! A0#%     @ 0H&;5FAL86<9!P  YC$  !D              ("!8OL
M 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    " !"@9M6#D">
M'RL#   S#   &0              @(&R @$ >&PO=V]R:W-H965T<R]S:&5E
M=#4T+GAM;%!+ 0(4 Q0    ( $*!FU8)-3 S?@<  #T\   9
M  " @10& 0!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @
M0H&;5MUDG[%1 @  S04  !D              ("!R0T! 'AL+W=O<FMS:&5E
M=',O<VAE970U-BYX;6Q02P$"% ,4    " !"@9M6:(.)1#@&  !))0  &0
M            @(%1$ $ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4
M Q0    ( $*!FU9X76B"EP4  ,0>   9              " @< 6 0!X;"]W
M;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ 0H&;5J>JH!6J!@
M"R8  !D              ("!CAP! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX
M;6Q02P$"% ,4    " !"@9M6J]N5WV<"  #,!0  &0              @(%O
M(P$ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( $*!FU8M
M\?O0%@4  -L:   9              " @0TF 0!X;"]W;W)K<VAE971S+W-H
M965T-C$N>&UL4$L! A0#%     @ 0H&;5M=5X::Y!0  UB4  !D
M     ("!6BL! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( $*!FU;57:4PU (  .4'   9              "
M@<L_ 0!X;"]W;W)K<VAE971S+W-H965T-C<N>&UL4$L! A0#%     @ 0H&;
M5@[P"*LD @  J 0  !D              ("!UD(! 'AL+W=O<FMS:&5E=',O
M<VAE970V."YX;6Q02P$"% ,4    " !"@9M6<*:AM'T#  "O#@  &0
M        @($Q10$ >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0
M   ( $*!FU;_#EH^% 4  + 9   9              " @>5( 0!X;"]W;W)K
M<VAE971S+W-H965T-S N>&UL4$L! A0#%     @ 0H&;5BBHIV)N P  QA8
M  T              ( !,$X! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !"
M@9M6EXJ[',     3 @  "P              @ ')40$ 7W)E;',O+G)E;'-0
M2P$"% ,4    " !"@9M6+O3O87<%  #?+0  #P              @ &R4@$
M>&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ 0H&;5MMVL'$Q @  B2D  !H
M             ( !5E@! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!
M A0#%     @ 0H&;5J3(PW?Z 0  M"@  !,              ( !OUH! %M#
G;VYT96YT7U1Y<&5S72YX;6Q02P4&     $X 3@!9%0  ZEP!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>227</ContextCount>
  <ElementCount>279</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>76</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITEDParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - New Accounting Standards</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/NewAccountingStandards</Role>
      <ShortName>New Accounting Standards</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Net Income Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/NetIncomePerShare</Role>
      <ShortName>Net Income Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Affiliated Companies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/AffiliatedCompanies</Role>
      <ShortName>Affiliated Companies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Derivative Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/DerivativeFinancialInstruments</Role>
      <ShortName>Derivative Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Accumulated Other Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/AccumulatedOtherComprehensiveLoss</Role>
      <ShortName>Accumulated Other Comprehensive Loss</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/BenefitPlans</Role>
      <ShortName>Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Other Expense (Income)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/OtherExpenseIncome</Role>
      <ShortName>Other Expense (Income)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/RevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.westpharma.com/role/Revenue</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Net Income Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/NetIncomePerShareTables</Role>
      <ShortName>Net Income Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.westpharma.com/role/NetIncomePerShare</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.westpharma.com/role/Inventories</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.westpharma.com/role/Leases</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.westpharma.com/role/Debt</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Derivative Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/DerivativeFinancialInstrumentsTables</Role>
      <ShortName>Derivative Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.westpharma.com/role/DerivativeFinancialInstruments</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.westpharma.com/role/FairValueMeasurements</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Accumulated Other Comprehensive Loss (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossTables</Role>
      <ShortName>Accumulated Other Comprehensive Loss (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.westpharma.com/role/AccumulatedOtherComprehensiveLoss</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Shareholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/ShareholdersEquityTables</Role>
      <ShortName>Shareholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.westpharma.com/role/ShareholdersEquity</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Benefit Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/BenefitPlansTables</Role>
      <ShortName>Benefit Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.westpharma.com/role/BenefitPlans</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Other Expense (Income) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/OtherExpenseIncomeTables</Role>
      <ShortName>Other Expense (Income) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.westpharma.com/role/OtherExpenseIncome</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.westpharma.com/role/SegmentInformation</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Revenue - Revenue Recognition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/RevenueRevenueRecognitionDetails</Role>
      <ShortName>Revenue - Revenue Recognition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Revenue - Contracts and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/RevenueContractsandLiabilitiesDetails</Role>
      <ShortName>Revenue - Contracts and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Revenue - Contracts and Liabilities, Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails</Role>
      <ShortName>Revenue - Contracts and Liabilities, Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Net Income Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/NetIncomePerShareDetails</Role>
      <ShortName>Net Income Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.westpharma.com/role/NetIncomePerShareTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/InventoriesDetails</Role>
      <ShortName>Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.westpharma.com/role/InventoriesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Leases - Lease Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/LeasesLeaseCostDetails</Role>
      <ShortName>Leases - Lease Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Leases - Lease Cash Flow and Supplemental Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/LeasesLeaseCashFlowandSupplementalInformationDetails</Role>
      <ShortName>Leases - Lease Cash Flow and Supplemental Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Leases - Lease Weighted Average (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/LeasesLeaseWeightedAverageDetails</Role>
      <ShortName>Leases - Lease Weighted Average (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Maturities of Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Affiliated Companies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/AffiliatedCompaniesDetails</Role>
      <ShortName>Affiliated Companies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.westpharma.com/role/AffiliatedCompanies</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Debt - Long-term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/DebtLongtermDebtDetails</Role>
      <ShortName>Debt - Long-term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Debt - Credit Facility (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/DebtCreditFacilityDetails</Role>
      <ShortName>Debt - Credit Facility (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Derivative Financial Instruments - Foreign Exchange Rate Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails</Role>
      <ShortName>Derivative Financial Instruments - Foreign Exchange Rate Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Derivative Financial Instruments - Foreign Currency Contracts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignCurrencyContractsDetails</Role>
      <ShortName>Derivative Financial Instruments - Foreign Currency Contracts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Derivative Financial Instruments - Effects of Derivative Instruments on OCI and Earnings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails</Role>
      <ShortName>Derivative Financial Instruments - Effects of Derivative Instruments on OCI and Earnings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Derivative Financial Instruments - Derivative Instruments Not Designated as Hedges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails</Role>
      <ShortName>Derivative Financial Instruments - Derivative Instruments Not Designated as Hedges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Fair Value Measurements - Assets and Liabilities Recorded at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Assets and Liabilities Recorded at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Fair Value Measurements - Other Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/FairValueMeasurementsOtherFinancialInstrumentsDetails</Role>
      <ShortName>Fair Value Measurements - Other Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails</Role>
      <ShortName>Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Accumulated Other Comprehensive Loss - Other Comprehensive Loss Reclassifications (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails</Role>
      <ShortName>Accumulated Other Comprehensive Loss - Other Comprehensive Loss Reclassifications (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Shareholders' Equity - Change in Shareholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails</Role>
      <ShortName>Shareholders' Equity - Change in Shareholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Shareholders' Equity - Supplemental Equity Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/ShareholdersEquitySupplementalEquityInformationDetails</Role>
      <ShortName>Shareholders' Equity - Supplemental Equity Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/StockBasedCompensationDetails</Role>
      <ShortName>Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.westpharma.com/role/StockBasedCompensation</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - Benefit Plans - Schedule of Components of Net Periodic Benefit Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails</Role>
      <ShortName>Benefit Plans - Schedule of Components of Net Periodic Benefit Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - Benefit Plans - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/BenefitPlansNarrativeDetails</Role>
      <ShortName>Benefit Plans - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - Other Expense (Income) - Schedule of Other (Income) Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/OtherExpenseIncomeScheduleofOtherIncomeExpenseDetails</Role>
      <ShortName>Other Expense (Income) - Schedule of Other (Income) Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.westpharma.com/role/OtherExpenseIncomeTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - Other Expense (Income) - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/OtherExpenseIncomeNarrativeDetails</Role>
      <ShortName>Other Expense (Income) - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.westpharma.com/role/OtherExpenseIncomeTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - Other Expense (Income) - Schedule of Restructuring and Related Charges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/OtherExpenseIncomeScheduleofRestructuringandRelatedChargesDetails</Role>
      <ShortName>Other Expense (Income) - Schedule of Restructuring and Related Charges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.westpharma.com/role/OtherExpenseIncomeTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>0000067 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.westpharma.com/role/IncomeTaxes</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>0000068 - Disclosure - Segment Information - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/SegmentInformationNarrativeDetails</Role>
      <ShortName>Segment Information - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>0000069 - Disclosure - Segment Information - Sales by Product Group (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/SegmentInformationSalesbyProductGroupDetails</Role>
      <ShortName>Segment Information - Sales by Product Group (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="wst-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>0000070 - Disclosure - Segment Information - Segment Financial Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails</Role>
      <ShortName>Segment Information - Segment Financial Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept DueToAffiliateCurrentAndNoncurrent in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. wst-20230331.htm 4</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept DueFromAffiliates in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. wst-20230331.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="wst-20230331.htm">wst-20230331.htm</File>
    <File>ex311q12023.htm</File>
    <File>ex312q12023.htm</File>
    <File>ex321q12023.htm</File>
    <File>ex322q12023.htm</File>
    <File>wst-20230331.xsd</File>
    <File>wst-20230331_cal.xml</File>
    <File>wst-20230331_def.xml</File>
    <File>wst-20230331_lab.xml</File>
    <File>wst-20230331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="772">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="33">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>88
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "wst-20230331.htm": {
   "axisCustom": 0,
   "axisStandard": 25,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 772,
    "http://xbrl.sec.gov/dei/2022": 33
   },
   "contextCount": 227,
   "dts": {
    "calculationLink": {
     "local": [
      "wst-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "wst-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "wst-20230331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "wst-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "wst-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "wst-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 473,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 5
   },
   "keyCustom": 11,
   "keyStandard": 268,
   "memberCustom": 18,
   "memberStandard": 55,
   "nsprefix": "wst",
   "nsuri": "http://www.westpharma.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.westpharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Revenue",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.westpharma.com/role/Revenue",
     "shortName": "Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Net Income Per Share",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.westpharma.com/role/NetIncomePerShare",
     "shortName": "Net Income Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Inventories",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.westpharma.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.westpharma.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Affiliated Companies",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.westpharma.com/role/AffiliatedCompanies",
     "shortName": "Affiliated Companies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Debt",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.westpharma.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Derivative Financial Instruments",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.westpharma.com/role/DerivativeFinancialInstruments",
     "shortName": "Derivative Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.westpharma.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Accumulated Other Comprehensive Loss",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLoss",
     "shortName": "Accumulated Other Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Shareholders' Equity",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.westpharma.com/role/ShareholdersEquity",
     "shortName": "Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:GrossProfit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Stock-Based Compensation",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.westpharma.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Benefit Plans",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.westpharma.com/role/BenefitPlans",
     "shortName": "Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Other Expense (Income)",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.westpharma.com/role/OtherExpenseIncome",
     "shortName": "Other Expense (Income)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.westpharma.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://www.westpharma.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Segment Information",
     "menuCat": "Notes",
     "order": "25",
     "role": "http://www.westpharma.com/role/SegmentInformation",
     "shortName": "Segment Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "26",
     "role": "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Revenue (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.westpharma.com/role/RevenueTables",
     "shortName": "Revenue (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Net Income Per Share (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.westpharma.com/role/NetIncomePerShareTables",
     "shortName": "Net Income Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Inventories (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.westpharma.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.westpharma.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Debt (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.westpharma.com/role/DebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Derivative Financial Instruments (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTables",
     "shortName": "Derivative Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.westpharma.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Accumulated Other Comprehensive Loss (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossTables",
     "shortName": "Accumulated Other Comprehensive Loss (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Shareholders' Equity (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://www.westpharma.com/role/ShareholdersEquityTables",
     "shortName": "Shareholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Benefit Plans (Tables)",
     "menuCat": "Tables",
     "order": "36",
     "role": "http://www.westpharma.com/role/BenefitPlansTables",
     "shortName": "Benefit Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "wst:ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Other Expense (Income) (Tables)",
     "menuCat": "Tables",
     "order": "37",
     "role": "http://www.westpharma.com/role/OtherExpenseIncomeTables",
     "shortName": "Other Expense (Income) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "wst:ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Segment Information (Tables)",
     "menuCat": "Tables",
     "order": "38",
     "role": "http://www.westpharma.com/role/SegmentInformationTables",
     "shortName": "Segment Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i29c510f38fbe49baa6388a40c6f045d8_D20230101-20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Revenue - Revenue Recognition (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails",
     "shortName": "Revenue - Revenue Recognition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i29c510f38fbe49baa6388a40c6f045d8_D20230101-20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) (Parenthetical)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITEDParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i5583fe9d33064523a217abe67f6f392d_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Revenue - Contracts and Liabilities (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.westpharma.com/role/RevenueContractsandLiabilitiesDetails",
     "shortName": "Revenue - Contracts and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i5583fe9d33064523a217abe67f6f392d_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Revenue - Contracts and Liabilities, Narrative (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails",
     "shortName": "Revenue - Contracts and Liabilities, Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Net Income Per Share (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.westpharma.com/role/NetIncomePerShareDetails",
     "shortName": "Net Income Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i2af6ba55593d446686e312e0578684c6_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Inventories (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.westpharma.com/role/InventoriesDetails",
     "shortName": "Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i2af6ba55593d446686e312e0578684c6_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Leases - Lease Cost (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.westpharma.com/role/LeasesLeaseCostDetails",
     "shortName": "Leases - Lease Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "wst:LesseeLeaseCashFlowAndSupplementalInformationTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Leases - Lease Cash Flow and Supplemental Information (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.westpharma.com/role/LeasesLeaseCashFlowandSupplementalInformationDetails",
     "shortName": "Leases - Lease Cash Flow and Supplemental Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "wst:LesseeLeaseCashFlowAndSupplementalInformationTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i2af6ba55593d446686e312e0578684c6_I20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Leases - Lease Weighted Average (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.westpharma.com/role/LeasesLeaseWeightedAverageDetails",
     "shortName": "Leases - Lease Weighted Average (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i2af6ba55593d446686e312e0578684c6_I20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i2af6ba55593d446686e312e0578684c6_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails",
     "shortName": "Leases - Maturities of Operating Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i2af6ba55593d446686e312e0578684c6_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i2af6ba55593d446686e312e0578684c6_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Affiliated Companies (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.westpharma.com/role/AffiliatedCompaniesDetails",
     "shortName": "Affiliated Companies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i2af6ba55593d446686e312e0578684c6_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i2af6ba55593d446686e312e0578684c6_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Debt - Long-term Debt (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.westpharma.com/role/DebtLongtermDebtDetails",
     "shortName": "Debt - Long-term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i2af6ba55593d446686e312e0578684c6_I20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:UnamortizedDebtIssuanceExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i2af6ba55593d446686e312e0578684c6_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i2af6ba55593d446686e312e0578684c6_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i2af6ba55593d446686e312e0578684c6_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Debt - Credit Facility (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.westpharma.com/role/DebtCreditFacilityDetails",
     "shortName": "Debt - Credit Facility (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "id48d782f5bfb4fe6a7905309804dadd4_I20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "ie403ae300c3c4982a693b55e66f3705f_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Derivative Financial Instruments - Foreign Exchange Rate Risk (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails",
     "shortName": "Derivative Financial Instruments - Foreign Exchange Rate Risk (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "ie403ae300c3c4982a693b55e66f3705f_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i9728ffcf312e4ac4bdb6aae4a7b23a44_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Derivative Financial Instruments - Foreign Currency Contracts (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignCurrencyContractsDetails",
     "shortName": "Derivative Financial Instruments - Foreign Currency Contracts (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i9728ffcf312e4ac4bdb6aae4a7b23a44_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Derivative Financial Instruments - Effects of Derivative Instruments on OCI and Earnings (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails",
     "shortName": "Derivative Financial Instruments - Effects of Derivative Instruments on OCI and Earnings (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "wst:ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Derivative Financial Instruments - Derivative Instruments Not Designated as Hedges (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails",
     "shortName": "Derivative Financial Instruments - Derivative Instruments Not Designated as Hedges (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i97dea892f5984be0a0fd08b4eee5ed4a_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i2af6ba55593d446686e312e0578684c6_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCompensationPlanAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Fair Value Measurements - Assets and Liabilities Recorded at Fair Value (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails",
     "shortName": "Fair Value Measurements - Assets and Liabilities Recorded at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i2af6ba55593d446686e312e0578684c6_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCompensationPlanAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i2af6ba55593d446686e312e0578684c6_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Fair Value Measurements - Other Financial Instruments (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.westpharma.com/role/FairValueMeasurementsOtherFinancialInstrumentsDetails",
     "shortName": "Fair Value Measurements - Other Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i2af6ba55593d446686e312e0578684c6_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i5583fe9d33064523a217abe67f6f392d_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Income (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails",
     "shortName": "Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Accumulated Other Comprehensive Loss - Other Comprehensive Loss Reclassifications (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails",
     "shortName": "Accumulated Other Comprehensive Loss - Other Comprehensive Loss Reclassifications (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i594dfb15b16f4f3b94b3e4c667ae6f31_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i5583fe9d33064523a217abe67f6f392d_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Shareholders' Equity - Change in Shareholders' Equity (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails",
     "shortName": "Shareholders' Equity - Change in Shareholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i2af6ba55593d446686e312e0578684c6_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i2af6ba55593d446686e312e0578684c6_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Shareholders' Equity - Supplemental Equity Information (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.westpharma.com/role/ShareholdersEquitySupplementalEquityInformationDetails",
     "shortName": "Shareholders' Equity - Supplemental Equity Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i2af6ba55593d446686e312e0578684c6_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Stock-Based Compensation (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.westpharma.com/role/StockBasedCompensationDetails",
     "shortName": "Stock-Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i2af6ba55593d446686e312e0578684c6_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - Benefit Plans - Schedule of Components of Net Periodic Benefit Cost (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails",
     "shortName": "Benefit Plans - Schedule of Components of Net Periodic Benefit Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - Benefit Plans - Narrative (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.westpharma.com/role/BenefitPlansNarrativeDetails",
     "shortName": "Benefit Plans - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "wst:ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetImpairmentCharges",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - Other Expense (Income) - Schedule of Other (Income) Expense (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofOtherIncomeExpenseDetails",
     "shortName": "Other Expense (Income) - Schedule of Other (Income) Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "wst:ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "wst:ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetImpairmentCharges",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - Other Expense (Income) - Narrative (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.westpharma.com/role/OtherExpenseIncomeNarrativeDetails",
     "shortName": "Other Expense (Income) - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i7fe28b57298646bca10b9de129f3bac3_D20221201-20221231",
      "decimals": null,
      "lang": "en-US",
      "name": "wst:RestructuringAndRelatedActivitiesPeriodOfImplementation",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i741e48b8c43549918dae0d3e9f2835dc_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - Other Expense (Income) - Schedule of Restructuring and Related Charges (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofRestructuringandRelatedChargesDetails",
     "shortName": "Other Expense (Income) - Schedule of Restructuring and Related Charges (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i741e48b8c43549918dae0d3e9f2835dc_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000067 - Disclosure - Income Taxes (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.westpharma.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": "3",
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000068 - Disclosure - Segment Information - Narrative (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://www.westpharma.com/role/SegmentInformationNarrativeDetails",
     "shortName": "Segment Information - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000069 - Disclosure - Segment Information - Sales by Product Group (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://www.westpharma.com/role/SegmentInformationSalesbyProductGroupDetails",
     "shortName": "Segment Information - Sales by Product Group (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000070 - Disclosure - Segment Information - Segment Financial Information (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails",
     "shortName": "Segment Information - Segment Financial Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:NonoperatingIncomeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - New Accounting Standards",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.westpharma.com/role/NewAccountingStandards",
     "shortName": "New Accounting Standards",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wst-20230331.htm",
      "contextRef": "i12f0467718f24f99a41d0cdad469d8ee_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 76,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S. plans"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AllCurrenciesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Currencies [Domain]",
        "terseLabel": "All Currencies [Domain]"
       }
      }
     },
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignCurrencyContractsDetails",
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_JPY": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Japan, Yen",
        "terseLabel": "Japan, Yen"
       }
      }
     },
     "localname": "JPY",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignCurrencyContractsDetails",
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_SGD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Singapore, Dollars",
        "terseLabel": "SGD"
       }
      }
     },
     "localname": "SGD",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignCurrencyContractsDetails",
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_USD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "United States of America, Dollars",
        "terseLabel": "EUR"
       }
      }
     },
     "localname": "USD",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignCurrencyContractsDetails",
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.westpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.westpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.westpharma.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.westpharma.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.westpharma.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.westpharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r752"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.westpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r753"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.westpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.westpharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.westpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.westpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.westpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.westpharma.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.westpharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.westpharma.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.westpharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.westpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.westpharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.westpharma.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.westpharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r754"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.westpharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.westpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.westpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.westpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.westpharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.westpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r749"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of each class"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.westpharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r751"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.westpharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.westpharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_AmericasMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Americas [Member]",
        "terseLabel": "Americas"
       }
      }
     },
     "localname": "AmericasMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_AsiaPacificMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asia Pacific [Member]",
        "terseLabel": "Asia Pacific"
       }
      }
     },
     "localname": "AsiaPacificMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r231",
      "r273",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r291",
      "r295",
      "r351",
      "r352",
      "r353",
      "r354",
      "r356",
      "r357",
      "r359",
      "r361",
      "r362",
      "r788",
      "r789"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.westpharma.com/role/SegmentInformationSalesbyProductGroupDetails",
      "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r231",
      "r273",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r291",
      "r295",
      "r351",
      "r352",
      "r353",
      "r354",
      "r356",
      "r357",
      "r359",
      "r361",
      "r362",
      "r788",
      "r789"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.westpharma.com/role/SegmentInformationSalesbyProductGroupDetails",
      "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]",
        "terseLabel": "Currency [Axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignCurrencyContractsDetails",
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r301",
      "r726",
      "r792",
      "r822"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r347",
      "r348",
      "r349",
      "r350",
      "r504",
      "r661",
      "r677",
      "r699",
      "r700",
      "r722",
      "r741",
      "r748",
      "r790",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.westpharma.com/role/OtherExpenseIncomeNarrativeDetails",
      "http://www.westpharma.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r347",
      "r348",
      "r349",
      "r350",
      "r504",
      "r661",
      "r677",
      "r699",
      "r700",
      "r722",
      "r741",
      "r748",
      "r790",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.westpharma.com/role/OtherExpenseIncomeNarrativeDetails",
      "http://www.westpharma.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r301",
      "r726",
      "r792",
      "r822"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r297",
      "r662",
      "r724",
      "r746",
      "r785",
      "r786",
      "r792",
      "r821"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails",
      "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r297",
      "r662",
      "r724",
      "r746",
      "r785",
      "r786",
      "r792",
      "r821"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails",
      "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r347",
      "r348",
      "r349",
      "r350",
      "r452",
      "r504",
      "r533",
      "r534",
      "r535",
      "r637",
      "r661",
      "r677",
      "r699",
      "r700",
      "r722",
      "r741",
      "r748",
      "r783",
      "r790",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.westpharma.com/role/OtherExpenseIncomeNarrativeDetails",
      "http://www.westpharma.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r347",
      "r348",
      "r349",
      "r350",
      "r452",
      "r504",
      "r533",
      "r534",
      "r535",
      "r637",
      "r661",
      "r677",
      "r699",
      "r700",
      "r722",
      "r741",
      "r748",
      "r783",
      "r790",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.westpharma.com/role/OtherExpenseIncomeNarrativeDetails",
      "http://www.westpharma.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r298",
      "r299",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r725",
      "r747",
      "r792"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r298",
      "r299",
      "r687",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r725",
      "r747",
      "r792"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r14",
      "r745"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r303",
      "r304"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r1",
      "r157",
      "r168"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "auth_ref": [
      "r27",
      "r32",
      "r121",
      "r759",
      "r760",
      "r761"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "terseLabel": "Defined benefit pension and other postretirement plans",
        "verboseLabel": "Amortization of Defined Benefit Pension And Other Postretirement Plans"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails",
      "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r80",
      "r188"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "auth_ref": [
      "r209",
      "r216",
      "r217",
      "r568",
      "r707",
      "r759"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "terseLabel": "(Losses) gains on derivatives",
        "verboseLabel": "Gains (Losses) on Derivatives"
       }
      }
     },
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails",
      "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r204",
      "r205",
      "r206",
      "r209",
      "r216",
      "r217",
      "r759"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]",
        "terseLabel": "Change in equity affiliate investment AOCI"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r30",
      "r31",
      "r32",
      "r197",
      "r672",
      "r682",
      "r685"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r215",
      "r216",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r29",
      "r32",
      "r121",
      "r627",
      "r678",
      "r679",
      "r759",
      "r760",
      "r761",
      "r770",
      "r771",
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated other comprehensive loss",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails",
      "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r26",
      "r32",
      "r121",
      "r216",
      "r217",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r759"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r6",
      "r745"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Capital in excess of par value"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r541",
      "r542",
      "r543",
      "r770",
      "r771",
      "r772",
      "r806"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Capital in Excess of Par Value"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentForAmortization": {
     "auth_ref": [
      "r52",
      "r76"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.",
        "label": "Amortization",
        "terseLabel": "Amortization"
       }
      }
     },
     "localname": "AdjustmentForAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r537"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r52",
      "r74",
      "r76"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "negatedLabel": "Amortization of acquisition-related intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive options excluded from computation of diluted net income per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/NetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r52",
      "r77"
     ],
     "calculation": {
      "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofOtherIncomeExpenseDetails": {
       "order": 5.0,
       "parentTag": "wst_OtherIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Asset impairments"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/OtherExpenseIncomeNarrativeDetails",
      "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofOtherIncomeExpenseDetails",
      "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r156",
      "r167",
      "r191",
      "r228",
      "r281",
      "r287",
      "r293",
      "r310",
      "r351",
      "r352",
      "r354",
      "r355",
      "r356",
      "r358",
      "r360",
      "r362",
      "r363",
      "r566",
      "r569",
      "r594",
      "r745",
      "r788",
      "r789",
      "r812"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r184",
      "r200",
      "r228",
      "r310",
      "r351",
      "r352",
      "r354",
      "r355",
      "r356",
      "r358",
      "r360",
      "r362",
      "r363",
      "r566",
      "r569",
      "r594",
      "r745",
      "r788",
      "r789",
      "r812"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r147"
     ],
     "calculation": {
      "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r565",
      "r765"
     ],
     "calculation": {
      "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofOtherIncomeExpenseDetails": {
       "order": 3.0,
       "parentTag": "wst_OtherIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofOtherIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r116",
      "r117",
      "r564"
     ],
     "calculation": {
      "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r54",
      "r186",
      "r701"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r49",
      "r54",
      "r55"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, including cash equivalents at end of period",
        "periodStartLabel": "Cash, including cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r49",
      "r150"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash Flow Hedges"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": {
     "auth_ref": [
      "r143"
     ],
     "calculation": {
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.",
        "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments",
        "negatedTerseLabel": "Change in unrealized gain (loss) on fair value hedging instruments"
       }
      }
     },
     "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1": {
     "auth_ref": [
      "r143"
     ],
     "calculation": {
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.",
        "label": "Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge",
        "negatedTerseLabel": "Derivative (gain) loss on hedged item, fair value hedges"
       }
      }
     },
     "localname": "ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r23",
      "r161",
      "r173"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r85",
      "r345",
      "r346",
      "r689",
      "r787"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "verboseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommodityMember": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading in a derivative instrument whose primary underlying risk is tied to commodity prices.",
        "label": "Commodity [Member]",
        "terseLabel": "Commodity call options"
       }
      }
     },
     "localname": "CommodityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommodityOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option contract in which the underlying asset is a commodity.",
        "label": "Commodity Option [Member]",
        "terseLabel": "Commodity call options"
       }
      }
     },
     "localname": "CommodityOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Dividends declared per share (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/ShareholdersEquitySupplementalEquityInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r770",
      "r771",
      "r806"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r5",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r5",
      "r745"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, par value $0.25 per share; 200.0 million shares authorized; shares issued: 75.3\u00a0million in 2023 and 2022; shares outstanding: 74.2\u00a0million and 74.1 million"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r33",
      "r212",
      "r214",
      "r221",
      "r668",
      "r674"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "auth_ref": [
      "r43",
      "r220",
      "r667",
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLoss"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r60",
      "r61",
      "r148",
      "r149",
      "r301",
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r60",
      "r61",
      "r148",
      "r149",
      "r301",
      "r686",
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r60",
      "r61",
      "r148",
      "r149",
      "r301",
      "r688",
      "r823"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r60",
      "r61",
      "r148",
      "r149",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r60",
      "r61",
      "r148",
      "r149",
      "r301",
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r791"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Schedule of Change in Contract With Customer, Asset and Liability"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/RevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r410",
      "r412",
      "r423"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "periodEndLabel": "Contract assets, March\u00a031, 2023",
        "periodStartLabel": "Contract assets, December 31, 2022"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/RevenueContractsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r410",
      "r411",
      "r423"
     ],
     "calculation": {
      "http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "negatedPeriodEndLabel": "Deferred income, March\u00a031, 2023",
        "negatedPeriodStartLabel": "Deferred income, December 31, 2022",
        "totalLabel": "Deferred income"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/RevenueContractsandLiabilitiesDetails",
      "http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized": {
     "auth_ref": [
      "r723"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized arising from contract liability from change in timeframe for performance obligation to be satisfied.",
        "label": "Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized",
        "terseLabel": "Change in deferred income - decrease (increase)"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/RevenueContractsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r410",
      "r411",
      "r423"
     ],
     "calculation": {
      "http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ContractWithCustomerLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred income, current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r410",
      "r411",
      "r423"
     ],
     "calculation": {
      "http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ContractWithCustomerLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred income, noncurrent"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r424"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Revenue recognized that was included in the deferred income balance"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r67",
      "r286",
      "r287",
      "r288",
      "r289",
      "r295",
      "r776"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Corporate and Unallocated"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r38",
      "r662"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "negatedTerseLabel": "Cost of goods and services sold",
        "verboseLabel": "Cost of goods and services sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails",
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of goods and services sold"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DebtCreditFacilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DebtCreditFacilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CrossCurrencyInterestRateContractMember": {
     "auth_ref": [
      "r793",
      "r805"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to interest rates and foreign exchange rates.",
        "label": "Cross Currency Interest Rate Contract [Member]",
        "terseLabel": "Cross Currency Interest Rate Contract"
       }
      }
     },
     "localname": "CrossCurrencyInterestRateContractMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignCurrencyContractsDetails",
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrencySwapMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Swap involving the exchange of principal and interest in one currency for another currency.",
        "label": "Currency Swap [Member]",
        "terseLabel": "Cross-currency swap"
       }
      }
     },
     "localname": "CurrencySwapMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails",
      "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r57",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtCurrent": {
     "auth_ref": [
      "r192"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of debt and lease obligation, classified as current.",
        "label": "Debt, Current",
        "terseLabel": "Long-term debt, current"
       }
      }
     },
     "localname": "DebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DebtCreditFacilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r87",
      "r226",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r380",
      "r387",
      "r388",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "verboseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r2",
      "r158",
      "r166",
      "r391"
     ],
     "calculation": {
      "http://www.westpharma.com/role/DebtLongtermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Long-term debt, gross"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DebtCreditFacilityDetails",
      "http://www.westpharma.com/role/DebtLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r20",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Debt instrument, stated interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DebtLongtermDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DebtLongtermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r21",
      "r92",
      "r95",
      "r96",
      "r97",
      "r151",
      "r152",
      "r154",
      "r165",
      "r231",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r370",
      "r376",
      "r377",
      "r378",
      "r379",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r389",
      "r610",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r768"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DebtLongtermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 7.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer).",
        "label": "Deferred Compensation Liability, Classified, Noncurrent",
        "verboseLabel": "Deferred compensation benefits"
       }
      }
     },
     "localname": "DeferredCompensationLiabilityClassifiedNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationPlanAssets": {
     "auth_ref": [
      "r757"
     ],
     "calculation": {
      "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of assets held under deferred compensation agreements.",
        "label": "Deferred Compensation Plan Assets",
        "terseLabel": "Deferred compensation assets"
       }
      }
     },
     "localname": "DeferredCompensationPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r545",
      "r546"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r545",
      "r546"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanActuarialGainLoss": {
     "auth_ref": [
      "r436"
     ],
     "calculation": {
      "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.",
        "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)",
        "negatedTerseLabel": "Recognized actuarial losses (gains)",
        "verboseLabel": "Actuarial gains"
       }
      }
     },
     "localname": "DefinedBenefitPlanActuarialGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails",
      "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": {
     "auth_ref": [
      "r429",
      "r467",
      "r492",
      "r733",
      "r734"
     ],
     "calculation": {
      "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets",
        "negatedLabel": "Expected return on assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanInterestCost": {
     "auth_ref": [
      "r429",
      "r434",
      "r466",
      "r491",
      "r733",
      "r734"
     ],
     "calculation": {
      "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.",
        "label": "Defined Benefit Plan, Interest Cost",
        "terseLabel": "Interest cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanInterestCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": {
     "auth_ref": [
      "r464",
      "r489",
      "r733",
      "r734"
     ],
     "calculation": {
      "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)",
        "totalLabel": "Net periodic benefit cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1": {
     "auth_ref": [
      "r430",
      "r471",
      "r496"
     ],
     "calculation": {
      "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement",
        "negatedTerseLabel": "Settlements",
        "terseLabel": "Settlements"
       }
      }
     },
     "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails",
      "http://www.westpharma.com/role/BenefitPlansNarrativeDetails",
      "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanServiceCost": {
     "auth_ref": [
      "r432",
      "r465",
      "r490",
      "r733",
      "r734"
     ],
     "calculation": {
      "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Service Cost",
        "terseLabel": "Service cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanServiceCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]",
        "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]"
       }
      }
     },
     "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r106",
      "r107",
      "r108",
      "r109",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures and provisions pertaining to defined benefit pension plans or other postretirement defined benefit plans. The arrangements are generally based on terms and conditions stipulated by the entity, and which contain a promise by the employer to pay certain amounts or awards at designated future dates, including a period after retirement, upon compliance with stipulated requirements. Excludes disclosures pertaining to defined contribution plans.",
        "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]",
        "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/BenefitPlansNarrativeDetails",
      "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]",
        "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/BenefitPlansNarrativeDetails",
      "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r52",
      "r78"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r201",
      "r202",
      "r593",
      "r706"
     ],
     "calculation": {
      "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "terseLabel": "Commodity call options"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAveragePriceRiskOptionStrikePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average strike price on the group of price risk option contracts such as put options or call options.",
        "label": "Derivative, Average Price Risk Option Strike Price",
        "terseLabel": "Derivative, average price risk option strike price"
       }
      }
     },
     "localname": "DerivativeAveragePriceRiskOptionStrikePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails"
     ],
     "xbrltype": "perUnitItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract Type [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails",
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails",
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails",
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignCurrencyContractsDetails",
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings": {
     "auth_ref": [
      "r578",
      "r802"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from excluded component of derivative hedge, recognized in earnings. Excludes recognition under systematic and rational method.",
        "label": "Derivative, Excluded Component, Gain (Loss), Recognized in Earnings",
        "terseLabel": "Derivative, forward point components, gain (loss), recognized in earnings"
       }
      }
     },
     "localname": "DerivativeExcludedComponentGainLossRecognizedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r131",
      "r132",
      "r136",
      "r138",
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails",
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails",
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails",
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignCurrencyContractsDetails",
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r146",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "verboseLabel": "Derivative Financial Instruments"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DerivativeFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r129",
      "r131",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails",
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignCurrencyContractsDetails",
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": {
     "auth_ref": [
      "r129",
      "r131",
      "r136",
      "r138",
      "r142",
      "r145",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table]",
        "terseLabel": "Derivative Instruments, Gain (Loss) by Hedging Relationship, by Income Statement Location, by Derivative Instrument Risk [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails",
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments, Gain (Loss) [Line Items]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails",
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": {
     "auth_ref": [
      "r135",
      "r803"
     ],
     "calculation": {
      "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofOtherIncomeExpenseDetails": {
       "order": 1.0,
       "parentTag": "wst_OtherIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net",
        "negatedTerseLabel": "Loss (gain) on oil hedges",
        "terseLabel": "Derivative instruments not designated as hedging instruments, gain (loss), net"
       }
      }
     },
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails",
      "http://www.westpharma.com/role/OtherExpenseIncomeNarrativeDetails",
      "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofOtherIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignCurrencyContractsDetails",
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNonmonetaryNotionalAmountVolume": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal volume used to calculate payments on a derivative instrument.",
        "label": "Derivative, Nonmonetary Notional Amount, Volume",
        "terseLabel": "Derivative, nonmonetary notional amount, volume"
       }
      }
     },
     "localname": "DerivativeNonmonetaryNotionalAmountVolume",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails"
     ],
     "xbrltype": "volumeItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r800",
      "r801"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Derivative, notional amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignCurrencyContractsDetails",
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r123",
      "r124",
      "r125",
      "r129",
      "r130",
      "r133",
      "r136",
      "r140",
      "r141",
      "r145",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignCurrencyContractsDetails",
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeTermOfContract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Term of Contract",
        "terseLabel": "Derivative contract term"
       }
      }
     },
     "localname": "DerivativeTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignCurrencyContractsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails",
      "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r422",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails",
      "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r792"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/RevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r510",
      "r538",
      "r539",
      "r540",
      "r544",
      "r742"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "verboseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsCommonStockCash": {
     "auth_ref": [
      "r98"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.",
        "label": "Dividends, Common Stock, Cash",
        "negatedTerseLabel": "Dividends declared"
       }
      }
     },
     "localname": "DividendsCommonStockCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticPlanMember": {
     "auth_ref": [
      "r794",
      "r795",
      "r796"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Domestic Plan [Member]",
        "terseLabel": "Domestic Plan"
       }
      }
     },
     "localname": "DomesticPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DueFromAffiliates": {
     "auth_ref": [
      "r155",
      "r175",
      "r629"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an unclassified balance sheet, amount of receivables due from an entity that is affiliated with the reporting entity by means of direct or indirect ownership.",
        "label": "Due from Affiliates",
        "terseLabel": "Amount receivable from affiliates"
       }
      }
     },
     "localname": "DueFromAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/AffiliatedCompaniesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToAffiliateCurrentAndNoncurrent": {
     "auth_ref": [
      "r155",
      "r160",
      "r174",
      "r178",
      "r630"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payable due to an entity that is affiliated with the reporting entity by means of direct or indirect ownership.",
        "label": "Due to Affiliate",
        "terseLabel": "Amount due and payable to affiliates"
       }
      }
     },
     "localname": "DueToAffiliateCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/AffiliatedCompaniesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EMEAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regions of Europe, Middle East and Africa.",
        "label": "EMEA [Member]",
        "terseLabel": "Europe, Middle East, Africa"
       }
      }
     },
     "localname": "EMEAMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]",
        "verboseLabel": "Net income per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r222",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r252",
      "r254",
      "r259",
      "r260",
      "r261",
      "r265",
      "r584",
      "r585",
      "r669",
      "r675",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r222",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r254",
      "r259",
      "r260",
      "r261",
      "r265",
      "r584",
      "r585",
      "r669",
      "r675",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r262",
      "r263",
      "r264",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Net Income Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/NetIncomePerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r602"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rates on cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectOnFutureEarningsAmount": {
     "auth_ref": [
      "r83"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The quantified amount of the future effect on earnings.",
        "label": "Effect on Future Earnings, Amount",
        "terseLabel": "Effect on future earnings, amount"
       }
      }
     },
     "localname": "EffectOnFutureEarningsAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/OtherExpenseIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": {
     "auth_ref": [
      "r798",
      "r799"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount",
        "negatedTerseLabel": "Tax benefit associated with stock-based compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeSeveranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Employee Severance [Member]",
        "terseLabel": "Severance and benefits"
       }
      }
     },
     "localname": "EmployeeSeveranceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofRestructuringandRelatedChargesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]",
        "verboseLabel": "Equity:"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r91",
      "r180",
      "r215",
      "r216",
      "r217",
      "r232",
      "r233",
      "r234",
      "r238",
      "r246",
      "r248",
      "r267",
      "r312",
      "r409",
      "r541",
      "r542",
      "r543",
      "r552",
      "r553",
      "r583",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r627",
      "r678",
      "r679",
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails",
      "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails",
      "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r70",
      "r282",
      "r756"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Carrying amount, equity-method investments"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/AffiliatedCompaniesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments and Joint Ventures [Abstract]",
        "terseLabel": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.",
        "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]",
        "terseLabel": "Affiliated Companies"
       }
      }
     },
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/AffiliatedCompanies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r309"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "terseLabel": "Carrying amount, investments not accounted for under the equity method"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/AffiliatedCompaniesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r589",
      "r590",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r378",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r590",
      "r634",
      "r635",
      "r636",
      "r718",
      "r719",
      "r731",
      "r732",
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueHedgingMember": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk.",
        "label": "Fair Value Hedging [Member]",
        "terseLabel": "Fair Value Hedges"
       }
      }
     },
     "localname": "FairValueHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails",
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r378",
      "r455",
      "r460",
      "r590",
      "r634",
      "r731",
      "r732",
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r378",
      "r455",
      "r460",
      "r590",
      "r635",
      "r718",
      "r719",
      "r731",
      "r732",
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r378",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r590",
      "r636",
      "r718",
      "r719",
      "r731",
      "r732",
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r378",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r634",
      "r635",
      "r636",
      "r718",
      "r719",
      "r731",
      "r732",
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r307",
      "r308",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r389",
      "r406",
      "r580",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r711",
      "r777",
      "r778",
      "r779",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.",
        "label": "Foreign Currency Contract, Asset, Fair Value Disclosure",
        "terseLabel": "Foreign currency contracts"
       }
      }
     },
     "localname": "ForeignCurrencyContractAssetFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.",
        "label": "Foreign Currency Contracts, Liability, Fair Value Disclosure",
        "terseLabel": "Foreign currency contracts and swaps"
       }
      }
     },
     "localname": "ForeignCurrencyContractsLiabilityFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r598",
      "r599",
      "r600",
      "r601"
     ],
     "calculation": {
      "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofOtherIncomeExpenseDetails": {
       "order": 4.0,
       "parentTag": "wst_OtherIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "negatedTerseLabel": "Foreign exchange transaction losses (gains)"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofOtherIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r706",
      "r731",
      "r743"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "terseLabel": "Foreign currency hedge contracts",
        "verboseLabel": "Foreign currency contracts"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails",
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails",
      "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignExchangeForwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.",
        "label": "Foreign Exchange Forward [Member]",
        "terseLabel": "Foreign Exchange Forward"
       }
      }
     },
     "localname": "ForeignExchangeForwardMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignCurrencyContractsDetails",
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignPlanMember": {
     "auth_ref": [
      "r794",
      "r795",
      "r796"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Foreign Plan [Member]",
        "terseLabel": "International plans"
       }
      }
     },
     "localname": "ForeignPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForwardContractsMember": {
     "auth_ref": [
      "r804"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts negotiated between two parties to purchase and sell a specific quantity of a financial instrument, foreign currency, or commodity at a price specified at origination of the contract, with delivery and settlement at a specified future date.",
        "label": "Forward Contracts [Member]",
        "terseLabel": "Forward Contracts"
       }
      }
     },
     "localname": "ForwardContractsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet": {
     "auth_ref": [
      "r144",
      "r573"
     ],
     "calculation": {
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net gain (loss) relating to components of the gain (loss) on the fair value hedging instrument excluded from the assessment of fair value hedge effectiveness. Recognized in earnings.",
        "label": "Gain (Loss) from Components Excluded from Assessment of Fair Value Hedge Effectiveness, Net",
        "negatedTerseLabel": "Derivative (gain) loss on amount excluded from effectiveness testing, fair value hedges"
       }
      }
     },
     "localname": "GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": {
     "auth_ref": [
      "r131"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.",
        "label": "Gain (Loss) on Derivative Instruments, Net, Pretax",
        "terseLabel": "Gain (loss) on derivative instruments, net, pretax"
       }
      }
     },
     "localname": "GainLossOnDerivativeInstrumentsNetPretax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings": {
     "auth_ref": [
      "r134"
     ],
     "calculation": {
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total amount of gain (loss) derived from fair value hedges recognized in earnings in the period.",
        "label": "Gain (Loss) on Fair Value Hedges Recognized in Earnings",
        "negatedTotalLabel": "Derivative (gain) loss recognized in income, fair value hedges"
       }
      }
     },
     "localname": "GainLossOnFairValueHedgesRecognizedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges": {
     "auth_ref": [
      "r766"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.",
        "label": "Gain (Loss) on Sale of Assets and Asset Impairment Charges",
        "negatedLabel": "Asset impairments",
        "negatedNetLabel": "Asset impairment for planned sale of plant"
       }
      }
     },
     "localname": "GainLossOnSalesOfAssetsAndAssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED",
      "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r39"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "negatedTerseLabel": "Corporate general costs"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeographicConcentrationRiskMember": {
     "auth_ref": [
      "r59",
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).",
        "label": "Geographic Concentration Risk [Member]",
        "terseLabel": "Geographic Concentration Risk"
       }
      }
     },
     "localname": "GeographicConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r189",
      "r324",
      "r666",
      "r712",
      "r745",
      "r781",
      "r782"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r37",
      "r228",
      "r281",
      "r286",
      "r292",
      "r295",
      "r310",
      "r351",
      "r352",
      "r354",
      "r355",
      "r356",
      "r358",
      "r360",
      "r362",
      "r363",
      "r594",
      "r710",
      "r788"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r129",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails",
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignCurrencyContractsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails",
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignCurrencyContractsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails",
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignCurrencyContractsDetails",
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r281",
      "r286",
      "r292",
      "r295",
      "r710"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before income taxes and equity in net income of affiliated companies"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails",
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
      "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r35",
      "r52",
      "r70",
      "r162",
      "r176",
      "r278"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedTerseLabel": "Equity in net income of affiliated companies"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r334",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails",
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails",
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r229",
      "r549",
      "r550",
      "r551",
      "r557",
      "r559",
      "r561",
      "r562",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r230",
      "r247",
      "r248",
      "r279",
      "r547",
      "r558",
      "r560",
      "r676"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Tax (expense) benefit",
        "verboseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails",
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
      "http://www.westpharma.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r799"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "negatedTerseLabel": "Tax benefit of state tax valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "negatedLabel": "Changes in assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "verboseLabel": "Changes in the Components of Accumulated Other Comprehensive Loss, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails",
      "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r255",
      "r256",
      "r257",
      "r261",
      "r509"
     ],
     "calculation": {
      "http://www.westpharma.com/role/NetIncomePerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "terseLabel": "Dilutive effect of equity awards, based on the treasury stock method (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/NetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r73",
      "r75"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r153",
      "r164",
      "r218",
      "r275",
      "r609"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails",
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseMember": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing interest expense.",
        "label": "Interest Expense [Member]",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntersegmentEliminationMember": {
     "auth_ref": [
      "r273",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r291",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eliminating entries used in operating segment consolidation.",
        "label": "Intersegment Eliminations [Member]",
        "terseLabel": "Intersegment sales elimination"
       }
      }
     },
     "localname": "IntersegmentEliminationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/SegmentInformationSalesbyProductGroupDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r71",
      "r703"
     ],
     "calculation": {
      "http://www.westpharma.com/role/InventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r198",
      "r702",
      "r745"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.westpharma.com/role/InventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "totalLabel": "Total inventories",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.westpharma.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r71",
      "r705"
     ],
     "calculation": {
      "http://www.westpharma.com/role/InventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r71",
      "r704"
     ],
     "calculation": {
      "http://www.westpharma.com/role/InventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNet": {
     "auth_ref": [
      "r40",
      "r42"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.",
        "label": "Investment Income, Net",
        "negatedTerseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": {
     "auth_ref": [
      "r758"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.",
        "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures",
        "terseLabel": "Investments in affiliated companies"
       }
      }
     },
     "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r623",
      "r744"
     ],
     "calculation": {
      "http://www.westpharma.com/role/LeasesLeaseCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/LeasesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r810"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Lease, Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r811"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Lessee, Operating Lease, Liability, Maturity"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r624"
     ],
     "calculation": {
      "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Operating leases liabilities payments due"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r624"
     ],
     "calculation": {
      "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": 8.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r624"
     ],
     "calculation": {
      "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "Year one"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r624"
     ],
     "calculation": {
      "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": 7.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "Year five"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r624"
     ],
     "calculation": {
      "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "Year four"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r624"
     ],
     "calculation": {
      "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "Year three"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r624"
     ],
     "calculation": {
      "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "Year two"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r811"
     ],
     "calculation": {
      "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "Remainder of fiscal year"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r624"
     ],
     "calculation": {
      "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed lease interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DebtCreditFacilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r17",
      "r228",
      "r310",
      "r351",
      "r352",
      "r354",
      "r355",
      "r356",
      "r358",
      "r360",
      "r362",
      "r363",
      "r567",
      "r569",
      "r570",
      "r594",
      "r709",
      "r788",
      "r812",
      "r813"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r10",
      "r159",
      "r171",
      "r745",
      "r769",
      "r780",
      "r807"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r19",
      "r185",
      "r228",
      "r310",
      "r351",
      "r352",
      "r354",
      "r355",
      "r356",
      "r358",
      "r360",
      "r362",
      "r363",
      "r567",
      "r569",
      "r570",
      "r594",
      "r745",
      "r788",
      "r812",
      "r813"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r147"
     ],
     "calculation": {
      "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities, Fair Value Disclosure",
        "totalLabel": "Total liabilities at fair value"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r2",
      "r158",
      "r166"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-Term Line of Credit",
        "terseLabel": "Long-term line of credit"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DebtCreditFacilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": {
     "auth_ref": [
      "r15"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Current Borrowing Capacity",
        "terseLabel": "Line of credit facility, current borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityCurrentBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DebtCreditFacilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DebtCreditFacilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "auth_ref": [
      "r15"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "terseLabel": "Line of credit facility, unused commitment level"
       }
      }
     },
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DebtCreditFacilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r15",
      "r768"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]",
        "terseLabel": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DebtCreditFacilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates an ownership position in, or purchase of, a security.",
        "label": "Long [Member]",
        "terseLabel": "Long"
       }
      }
     },
     "localname": "LongMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignCurrencyContractsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r2",
      "r158",
      "r169",
      "r377",
      "r392",
      "r718",
      "r719"
     ],
     "calculation": {
      "http://www.westpharma.com/role/DebtLongtermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.westpharma.com/role/DebtLongtermDebtDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "totalLabel": "Total debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DebtLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.westpharma.com/role/DebtLongtermDebtDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-Term Debt, Current Maturities",
        "terseLabel": "Less: current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DebtLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-Term Debt, Fair Value",
        "verboseLabel": "Long-term debt, fair value"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/FairValueMeasurementsOtherFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r193"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.westpharma.com/role/DebtLongtermDebtDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt",
        "verboseLabel": "Long-term debt, net"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.westpharma.com/role/DebtCreditFacilityDetails",
      "http://www.westpharma.com/role/DebtLongtermDebtDetails",
      "http://www.westpharma.com/role/FairValueMeasurementsOtherFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DebtCreditFacilityDetails",
      "http://www.westpharma.com/role/DebtLongtermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r21",
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DebtCreditFacilityDetails",
      "http://www.westpharma.com/role/DebtLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r224"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r224"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r49",
      "r50",
      "r53"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r36",
      "r53",
      "r163",
      "r177",
      "r183",
      "r210",
      "r213",
      "r217",
      "r228",
      "r237",
      "r241",
      "r242",
      "r243",
      "r244",
      "r247",
      "r248",
      "r258",
      "r281",
      "r286",
      "r292",
      "r295",
      "r310",
      "r351",
      "r352",
      "r354",
      "r355",
      "r356",
      "r358",
      "r360",
      "r362",
      "r363",
      "r585",
      "r594",
      "r710",
      "r788"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income",
        "totalLabel": "Net income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails",
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED",
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED",
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
      "http://www.westpharma.com/role/NetIncomePerShareDetails",
      "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetInvestmentHedgingMember": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedges of a net investment in a foreign operation.",
        "label": "Net Investment Hedging [Member]",
        "terseLabel": "Net Investment Hedges"
       }
      }
     },
     "localname": "NetInvestmentHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails",
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignCurrencyContractsDetails",
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update and Change in Accounting Principle [Abstract]",
        "terseLabel": "New Accounting Pronouncements and Changes in Accounting Principles [Abstract]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r181",
      "r235",
      "r236",
      "r239",
      "r240",
      "r249",
      "r250",
      "r251",
      "r305",
      "r306",
      "r313",
      "r314",
      "r554",
      "r555",
      "r556",
      "r582",
      "r586",
      "r587",
      "r588",
      "r595",
      "r596",
      "r597",
      "r611",
      "r612",
      "r626",
      "r628",
      "r663",
      "r664",
      "r665",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
        "verboseLabel": "New Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/NewAccountingStandards"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not Designated as Hedging Instrument"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "negatedTerseLabel": "Interest (income) expense, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r775"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent": {
     "auth_ref": [
      "r32",
      "r34"
     ],
     "calculation": {
      "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent.",
        "label": "OCI, before Reclassifications, Net of Tax, Attributable to Parent",
        "terseLabel": "Other comprehensive income (loss) before reclassifications"
       }
      }
     },
     "localname": "OciBeforeReclassificationsNetOfTaxAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r281",
      "r286",
      "r292",
      "r295",
      "r710"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      },
      "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Operating profit",
        "totalLabel": "Operating profit"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
      "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r616",
      "r744"
     ],
     "calculation": {
      "http://www.westpharma.com/role/LeasesLeaseCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/LeasesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r614"
     ],
     "calculation": {
      "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r614"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r614"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r615",
      "r619"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/LeasesLeaseCashFlowandSupplementalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r613"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r622",
      "r744"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/LeasesLeaseWeightedAverageDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r621",
      "r744"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/LeasesLeaseWeightedAverageDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/SegmentInformationSalesbyProductGroupDetails",
      "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OptionMember": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific commodity, or financial or equity instrument, at a specified price during a specified period (an American option) or at a specified date (a European option) which were purchased or otherwise acquired, excluding options written (for which a premium was received).",
        "label": "Options Held [Member]",
        "terseLabel": "Options Held"
       }
      }
     },
     "localname": "OptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r199",
      "r745"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r190"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other noncurrent assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r28",
      "r30",
      "r118",
      "r120"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent",
        "negatedLabel": "Defined benefit pension and other postretirement plan adjustments, net of tax of $(0.2) and $0.3"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent": {
     "auth_ref": [
      "r118",
      "r119",
      "r120"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax, Attributable to Parent",
        "negatedTerseLabel": "Defined benefit pension and other postretirement plan adjustments, tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITEDParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r118",
      "r119",
      "r120"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation adjustments, net of tax of $0.2 and $1.0"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent": {
     "auth_ref": [
      "r118",
      "r119",
      "r120"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation adjustments, tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITEDParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": {
     "auth_ref": [
      "r207"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent",
        "terseLabel": "Net loss on derivatives, net of tax of $(0.1) and $(0.8)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent": {
     "auth_ref": [
      "r208"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax, Parent",
        "terseLabel": "Net loss on derivatives, tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITEDParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r203",
      "r207",
      "r571",
      "r572",
      "r579"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Cash flow hedges, amount of gain (loss) recognized in OCI"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax": {
     "auth_ref": [
      "r574"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from discontinuance of cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Reclassification for Discontinuance, before Tax",
        "negatedTerseLabel": "Cash flow hedges, amount of (gain) loss reclassified from accumulated OCI into income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r575"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Fair value and net investment hedges, amount of gain (loss) recognized in OCI"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [
      "r576"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax",
        "negatedTerseLabel": "Fair value and net investment hedges, amount of (gain) loss reclassified from accumulated OCI into income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss), net of tax:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r211",
      "r214"
     ],
     "calculation": {
      "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive income (loss), net of tax",
        "totalLabel": "Other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails",
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED",
      "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the liabilities, classified as other, for deferred compensation arrangements payable after one year or the operating cycle, if longer.",
        "label": "Other Deferred Compensation Arrangements, Liability, Classified, Noncurrent",
        "terseLabel": "Deferred compensation liabilities"
       }
      }
     },
     "localname": "OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]",
        "terseLabel": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": {
     "auth_ref": [
      "r102",
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.",
        "label": "Other Income and Other Expense Disclosure [Text Block]",
        "verboseLabel": "Other Expense (Income)"
       }
      }
     },
     "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/OtherExpenseIncome"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r18",
      "r745"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Other non-cash items, net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofOtherIncomeExpenseDetails": {
       "order": 2.0,
       "parentTag": "wst_OtherIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "negatedTerseLabel": "Other items"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofOtherIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": {
     "auth_ref": [
      "r104",
      "r427",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r476",
      "r477",
      "r479",
      "r482",
      "r485",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r501",
      "r502",
      "r503",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.",
        "label": "Other Postretirement Benefits Plan [Member]",
        "terseLabel": "Other retirement benefits"
       }
      }
     },
     "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherRestructuringMember": {
     "auth_ref": [
      "r713",
      "r714",
      "r715",
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring and related activities classified as other.",
        "label": "Other Restructuring [Member]",
        "terseLabel": "Asset-related charges"
       }
      }
     },
     "localname": "OtherRestructuringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofRestructuringandRelatedChargesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r762",
      "r763"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other, net"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Shares purchased under share repurchase program"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRestructuring": {
     "auth_ref": [
      "r337",
      "r764"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.",
        "label": "Payments for Restructuring",
        "negatedTerseLabel": "Cash payments"
       }
      }
     },
     "localname": "PaymentsForRestructuring",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofRestructuringandRelatedChargesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedTerseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividendsCommonStock": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.",
        "label": "Payments of Ordinary Dividends, Common Stock",
        "negatedLabel": "Dividend payments"
       }
      }
     },
     "localname": "PaymentsOfDividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r223"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedTerseLabel": "Shares repurchased for employee tax withholdings"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Capital expenditures"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r452",
      "r454",
      "r460",
      "r478",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r499",
      "r500",
      "r501",
      "r506",
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "verboseLabel": "Benefit Plans"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/BenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": {
     "auth_ref": [
      "r3",
      "r427",
      "r428",
      "r451",
      "r733"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.",
        "label": "Liability, Defined Benefit Plan, Noncurrent",
        "terseLabel": "Pension and other postretirement benefits"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionPlansDefinedBenefitMember": {
     "auth_ref": [
      "r103",
      "r427",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r476",
      "r477",
      "r479",
      "r482",
      "r485",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r501",
      "r502",
      "r505",
      "r733",
      "r734",
      "r738",
      "r739",
      "r740"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.",
        "label": "Pension Plan [Member]",
        "terseLabel": "Pension benefits"
       }
      }
     },
     "localname": "PensionPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/BenefitPlansNarrativeDetails",
      "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance Share Unit (PSUs)"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PositionAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by position taken for a security.",
        "label": "Position [Axis]",
        "terseLabel": "Position [Axis]"
       }
      }
     },
     "localname": "PositionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignCurrencyContractsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PositionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates position taken for a security.",
        "label": "Position [Domain]",
        "terseLabel": "Position [Domain]"
       }
      }
     },
     "localname": "PositionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignCurrencyContractsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r4",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r4",
      "r745"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, 3.0\u00a0million shares authorized; 0 shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r45",
      "r113"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from stock-based compensation awards"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromOtherEquity": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from the issuance of equity classified as other.",
        "label": "Proceeds from Other Equity",
        "terseLabel": "Employee stock purchase plan contributions"
       }
      }
     },
     "localname": "ProceedsFromOtherEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductConcentrationRiskMember": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.",
        "label": "Product Concentration Risk [Member]",
        "terseLabel": "Product Concentration Risk"
       }
      }
     },
     "localname": "ProductConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r79",
      "r187"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r81",
      "r172",
      "r671",
      "r745"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Loss [Line Items]"
       }
      }
     },
     "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": {
     "auth_ref": [
      "r32",
      "r34"
     ],
     "calculation": {
      "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.",
        "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent",
        "negatedLabel": "Amounts reclassified out from accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]",
        "terseLabel": "Schedule of Reclassification out of Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": {
     "auth_ref": [
      "r64",
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]",
        "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/SegmentInformationSalesbyProductGroupDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfOtherLongTermDebt": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for the payment of debt classified as other, maturing after one year or the operating cycle, if longer.",
        "label": "Repayments of Other Long-Term Debt",
        "negatedLabel": "Repayments of long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfOtherLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r115",
      "r179",
      "r820"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCost1": {
     "auth_ref": [
      "r336",
      "r339",
      "r342",
      "r344"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Expected Cost",
        "verboseLabel": "Restructuring and related cost, expected cost"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostExpectedCost1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/OtherExpenseIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r52",
      "r340",
      "r342",
      "r784"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Charges"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofRestructuringandRelatedChargesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r336",
      "r337",
      "r342",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofRestructuringandRelatedChargesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofRestructuringandRelatedChargesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by individual restructuring plan.",
        "label": "Restructuring Plan [Axis]",
        "terseLabel": "Restructuring Plan [Axis]"
       }
      }
     },
     "localname": "RestructuringPlanAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/OtherExpenseIncomeNarrativeDetails",
      "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofRestructuringandRelatedChargesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the individual restructuring plans.",
        "label": "Restructuring Plan [Domain]",
        "terseLabel": "Restructuring Plan [Domain]"
       }
      }
     },
     "localname": "RestructuringPlanDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/OtherExpenseIncomeNarrativeDetails",
      "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofRestructuringandRelatedChargesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r337",
      "r341"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "periodEndLabel": "Balance, March 31, 2023",
        "periodStartLabel": "Balance, December 31, 2022"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofRestructuringandRelatedChargesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Restructuring Reserve [Roll Forward]",
        "terseLabel": "Restructuring Reserve [Roll Forward]"
       }
      }
     },
     "localname": "RestructuringReserveRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofRestructuringandRelatedChargesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r7",
      "r98",
      "r170",
      "r681",
      "r685",
      "r745"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r180",
      "r232",
      "r233",
      "r234",
      "r238",
      "r246",
      "r248",
      "r312",
      "r541",
      "r542",
      "r543",
      "r552",
      "r553",
      "r583",
      "r678",
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationAxis": {
     "auth_ref": [
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r479",
      "r482",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r794",
      "r795",
      "r796"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Axis]",
        "terseLabel": "Retirement Plan Sponsor Location [Axis]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationDomain": {
     "auth_ref": [
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r479",
      "r482",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r794",
      "r795",
      "r796"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Domain]",
        "terseLabel": "Retirement Plan Sponsor Location [Domain]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r103",
      "r104",
      "r427",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r476",
      "r477",
      "r479",
      "r482",
      "r485",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r501",
      "r502",
      "r503",
      "r505",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]",
        "terseLabel": "Retirement Plan Type [Axis]"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/BenefitPlansNarrativeDetails",
      "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r103",
      "r104",
      "r427",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r476",
      "r477",
      "r479",
      "r482",
      "r485",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r501",
      "r502",
      "r503",
      "r505",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type [Domain]"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/BenefitPlansNarrativeDetails",
      "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r272",
      "r273",
      "r285",
      "r290",
      "r291",
      "r297",
      "r298",
      "r301",
      "r421",
      "r422",
      "r662"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Net sales"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails",
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r425",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/Revenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r219",
      "r228",
      "r272",
      "r273",
      "r285",
      "r290",
      "r291",
      "r297",
      "r298",
      "r301",
      "r310",
      "r351",
      "r352",
      "r354",
      "r355",
      "r356",
      "r358",
      "r360",
      "r362",
      "r363",
      "r594",
      "r670",
      "r788"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Net sales"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/SegmentInformationSalesbyProductGroupDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r620",
      "r744"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for new operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/LeasesLeaseCashFlowandSupplementalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r301",
      "r774"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue Benchmark"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r32",
      "r808",
      "r809"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Components of Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Schedule of Long-term Debt Obligations, Net of Current Maturities"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r131",
      "r136",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Effects of Derivative Instruments on Other Comprehensive Income ('OCI') and Earnings"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": {
     "auth_ref": [
      "r123",
      "r124",
      "r125",
      "r129",
      "r130",
      "r133",
      "r136",
      "r140",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Schedule of Derivative Instruments [Table Text Block]",
        "terseLabel": "Schedule of Foreign Currency Contracts"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r773"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Basic to Diluted Net Income Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/NetIncomePerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "terseLabel": "Schedule of Sales by Significant Product Group"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r589",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Assets and Liabilities Measured at Fair Value"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r0",
      "r11",
      "r12",
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.",
        "label": "Schedule of Net Benefit Costs [Table Text Block]",
        "terseLabel": "Schedule of Components of Net Periodic Benefit Cost"
       }
      }
     },
     "localname": "ScheduleOfNetBenefitCostsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/BenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r135",
      "r803"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.",
        "label": "Derivatives Not Designated as Hedging Instruments [Table Text Block]",
        "terseLabel": "Schedule of Derivatives Not Designated as Hedging Instruments"
       }
      }
     },
     "localname": "ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r336",
      "r337",
      "r338",
      "r339",
      "r342",
      "r343",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofRestructuringandRelatedChargesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "auth_ref": [
      "r82",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "terseLabel": "Schedule of Restructuring Reserve"
       }
      }
     },
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/OtherExpenseIncomeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r62",
      "r63",
      "r65",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r62",
      "r63",
      "r65",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r507",
      "r508",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r88",
      "r89",
      "r90",
      "r92",
      "r93",
      "r94",
      "r95",
      "r96",
      "r97",
      "r98",
      "r194",
      "r195",
      "r196",
      "r268",
      "r393",
      "r394",
      "r395",
      "r397",
      "r401",
      "r406",
      "r408",
      "r722",
      "r755",
      "r767"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.",
        "label": "Schedule of Stockholders Equity [Table Text Block]",
        "terseLabel": "Schedule of Stockholders Equity"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/ShareholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r269",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r295",
      "r301",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r339",
      "r344",
      "r712",
      "r821"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segment [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/OtherExpenseIncomeNarrativeDetails",
      "http://www.westpharma.com/role/SegmentInformationSalesbyProductGroupDetails",
      "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r269",
      "r270",
      "r271",
      "r281",
      "r284",
      "r289",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r300",
      "r301",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "verboseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/SegmentInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]",
        "terseLabel": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/SegmentInformationSalesbyProductGroupDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "negatedTerseLabel": "Stock-based compensation expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED",
      "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Stock volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for issuance under the 2016 Plan (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r797"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Stock options, granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Stock options, weighted average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Stock options, weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates the sale of a borrowed security or written option.",
        "label": "Short [Member]",
        "terseLabel": "Short"
       }
      }
     },
     "localname": "ShortMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignCurrencyContractsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r617",
      "r744"
     ],
     "calculation": {
      "http://www.westpharma.com/role/LeasesLeaseCostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-Term Lease, Cost",
        "terseLabel": "Short-term lease cost"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/LeasesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r56",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "verboseLabel": "Basis of Presentation and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r182",
      "r269",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r295",
      "r301",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r335",
      "r339",
      "r344",
      "r712",
      "r821"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/OtherExpenseIncomeNarrativeDetails",
      "http://www.westpharma.com/role/SegmentInformationSalesbyProductGroupDetails",
      "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r24",
      "r91",
      "r180",
      "r215",
      "r216",
      "r217",
      "r232",
      "r233",
      "r234",
      "r238",
      "r246",
      "r248",
      "r267",
      "r312",
      "r409",
      "r541",
      "r542",
      "r543",
      "r552",
      "r553",
      "r583",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r627",
      "r678",
      "r679",
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails",
      "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails",
      "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r4",
      "r5",
      "r91",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Activity related to stock -based compensation (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r4",
      "r5",
      "r98",
      "r111"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Activity related to stock-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock repurchase program, authorized repurchase amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/NetIncomePerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r5",
      "r8",
      "r9",
      "r69",
      "r745",
      "r769",
      "r780",
      "r807"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance, end of period",
        "periodStartLabel": "Balance, beginning of period",
        "totalLabel": "Total Equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails",
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r101",
      "r227",
      "r394",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r407",
      "r409",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Shareholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/ShareholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SummaryOfInvestmentHoldingsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Summary of Investment Holdings [Line Items]",
        "terseLabel": "Summary of Investment Holdings [Line Items]"
       }
      }
     },
     "localname": "SummaryOfInvestmentHoldingsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/OtherExpenseIncomeNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SummaryOfInvestmentHoldingsTable": {
     "auth_ref": [
      "r824"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The summary of investment holding table is used for any listing of investment in a summary form. Table lists the 50 largest investments and any other investment the value of which exceeded 1 percent of net asset value of the registrant as of the close of the period.",
        "label": "Summary of Investment Holdings [Table]",
        "terseLabel": "Summary of Investment Holdings [Table]"
       }
      }
     },
     "localname": "SummaryOfInvestmentHoldingsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/OtherExpenseIncomeNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r307",
      "r308",
      "r389",
      "r406",
      "r580",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r777",
      "r778",
      "r779",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryLockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customized agreement that fixes the yield or price on a specified treasury security for a specific period.",
        "label": "Treasury Lock [Member]",
        "terseLabel": "Forward treasury locks"
       }
      }
     },
     "localname": "TreasuryLockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails",
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.",
        "label": "Treasury Stock Acquired, Average Cost Per Share",
        "terseLabel": "Stock repurchase program, average price per share (in dollars per share)"
       }
      }
     },
     "localname": "TreasuryStockAcquiredAverageCostPerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/NetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TreasuryStockCommonMember": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockCommonMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonShares": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Shares",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)",
        "terseLabel": "Treasury stock, at cost (in shares)"
       }
      }
     },
     "localname": "TreasuryStockCommonShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical",
      "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockCommonValue": {
     "auth_ref": [
      "r25",
      "r99",
      "r100"
     ],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Value",
        "negatedTerseLabel": "Treasury stock, at cost (1.1\u00a0million and 1.2 million shares)"
       }
      }
     },
     "localname": "TreasuryStockCommonValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r5",
      "r91",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "terseLabel": "Share purchased under share repurchase program (in shares)",
        "verboseLabel": "Stock repurchase program, shares purchased (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/NetIncomePerShareDetails",
      "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r91",
      "r98",
      "r99"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Shares purchased under share repurchase program",
        "terseLabel": "Stock purchase program, cost of shares purchased"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/NetIncomePerShareDetails",
      "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r336",
      "r337",
      "r342",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofRestructuringandRelatedChargesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnamortizedDebtIssuanceExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.westpharma.com/role/DebtLongtermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.",
        "label": "Unamortized Debt Issuance Expense",
        "terseLabel": "Less: unamortized debt issuance costs for Term Loan and Series Notes"
       }
      }
     },
     "localname": "UnamortizedDebtIssuanceExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/DebtLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r618",
      "r744"
     ],
     "calculation": {
      "http://www.westpharma.com/role/LeasesLeaseCostDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/LeasesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r253",
      "r261"
     ],
     "calculation": {
      "http://www.westpharma.com/role/NetIncomePerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Weighted average shares assuming dilution (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
      "http://www.westpharma.com/role/NetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r252",
      "r261"
     ],
     "calculation": {
      "http://www.westpharma.com/role/NetIncomePerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average common shares outstanding (in shares)",
        "verboseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
      "http://www.westpharma.com/role/NetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "verboseLabel": "Weighted average shares outstanding:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "wst_A2020RestructuringPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Restructuring Plan [Member]",
        "label": "2020 Restructuring Plan [Member]",
        "terseLabel": "2020 Restructuring Plan"
       }
      }
     },
     "localname": "A2020RestructuringPlanMember",
     "nsuri": "http://www.westpharma.com/20230331",
     "presentation": [
      "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofRestructuringandRelatedChargesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "wst_AccruedSalariesWagesAndBenefitsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Salaries, Wages, and Benefits, Current",
        "label": "Accrued Salaries, Wages, and Benefits, Current",
        "terseLabel": "Accrued salaries, wages and benefits"
       }
      }
     },
     "localname": "AccruedSalariesWagesAndBenefitsCurrent",
     "nsuri": "http://www.westpharma.com/20230331",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "wst_BiologicsCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biologics Customers [Member]",
        "label": "Biologics Customers [Member]",
        "terseLabel": "Biologics"
       }
      }
     },
     "localname": "BiologicsCustomersMember",
     "nsuri": "http://www.westpharma.com/20230331",
     "presentation": [
      "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "wst_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Paid for Amounts Included in the Measurement of Lease Liabilities [Abstract]",
        "label": "Cash Paid for Amounts Included in the Measurement of Lease Liabilities [Abstract]",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:"
       }
      }
     },
     "localname": "CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract",
     "nsuri": "http://www.westpharma.com/20230331",
     "presentation": [
      "http://www.westpharma.com/role/LeasesLeaseCashFlowandSupplementalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "wst_ContractManufacturedCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract-Manufactured Customers [Member]",
        "label": "Contract-Manufactured Customers [Member]",
        "terseLabel": "Contract-Manufactured Products"
       }
      }
     },
     "localname": "ContractManufacturedCustomersMember",
     "nsuri": "http://www.westpharma.com/20230331",
     "presentation": [
      "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "wst_ContractManufacturedProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract Manufactured Products [Member]",
        "label": "Contract Manufactured Products [Member]",
        "terseLabel": "Contract-Manufactured Products",
        "verboseLabel": "Contract-Manufactured Products"
       }
      }
     },
     "localname": "ContractManufacturedProductsMember",
     "nsuri": "http://www.westpharma.com/20230331",
     "presentation": [
      "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails",
      "http://www.westpharma.com/role/SegmentInformationSalesbyProductGroupDetails",
      "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "wst_ContractWithCustomerAssetIncreaseDecrease": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Asset, Increase (Decrease)",
        "label": "Contract With Customer, Asset, Increase (Decrease)",
        "terseLabel": "Change in contract assets - increase (decrease)"
       }
      }
     },
     "localname": "ContractWithCustomerAssetIncreaseDecrease",
     "nsuri": "http://www.westpharma.com/20230331",
     "presentation": [
      "http://www.westpharma.com/role/RevenueContractsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "wst_ContractWithCustomerAssetRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Asset [Roll Forward]",
        "label": "Contract With Customer, Asset [Roll Forward]",
        "terseLabel": "Contract With Customer, Asset [Roll Forward]"
       }
      }
     },
     "localname": "ContractWithCustomerAssetRollForward",
     "nsuri": "http://www.westpharma.com/20230331",
     "presentation": [
      "http://www.westpharma.com/role/RevenueContractsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "wst_ContractWithCustomerLiabilityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability [Roll Forward]",
        "label": "Contract With Customer, Liability [Roll Forward]",
        "terseLabel": "Contract With Customer, Liability [Roll Forward]"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRollForward",
     "nsuri": "http://www.westpharma.com/20230331",
     "presentation": [
      "http://www.westpharma.com/role/RevenueContractsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "wst_GenericsCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generics Customers [Member]",
        "label": "Generics Customers [Member]",
        "terseLabel": "Generics"
       }
      }
     },
     "localname": "GenericsCustomersMember",
     "nsuri": "http://www.westpharma.com/20230331",
     "presentation": [
      "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "wst_HighValueProductComponentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "High-Value Product Components [Member]",
        "label": "High-Value Product Components [Member]",
        "terseLabel": "High-Value Product Components"
       }
      }
     },
     "localname": "HighValueProductComponentsMember",
     "nsuri": "http://www.westpharma.com/20230331",
     "presentation": [
      "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "wst_HighValueProductDeliveryDevicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "High-Value Product Delivery Devices [Member]",
        "label": "High-Value Product Delivery Devices [Member]",
        "terseLabel": "High-Value Product Delivery Devices"
       }
      }
     },
     "localname": "HighValueProductDeliveryDevicesMember",
     "nsuri": "http://www.westpharma.com/20230331",
     "presentation": [
      "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "wst_LesseeLeaseCashFlowAndSupplementalInformationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Lease Cash Flow And Supplemental Information",
        "label": "Lessee, Lease Cash Flow And Supplemental Information [Table Text Block]",
        "terseLabel": "Schedule of Cash Flow and Supplemental Information"
       }
      }
     },
     "localname": "LesseeLeaseCashFlowAndSupplementalInformationTableTextBlock",
     "nsuri": "http://www.westpharma.com/20230331",
     "presentation": [
      "http://www.westpharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "wst_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
        "label": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://www.westpharma.com/20230331",
     "presentation": [
      "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "wst_NetSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Sales [Member]",
        "label": "Net Sales [Member]",
        "terseLabel": "Net sales"
       }
      }
     },
     "localname": "NetSalesMember",
     "nsuri": "http://www.westpharma.com/20230331",
     "presentation": [
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "wst_NotesPayableAndOtherDebtCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes Payable and Other Debt, Current",
        "label": "Notes Payable and Other Debt, Current",
        "terseLabel": "Notes payable and other current debt"
       }
      }
     },
     "localname": "NotesPayableAndOtherDebtCurrent",
     "nsuri": "http://www.westpharma.com/20230331",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "wst_OtherExpenseIncomeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Expense (Income)",
        "label": "Other Expense (Income) [Member]",
        "terseLabel": "Other expense (income)"
       }
      }
     },
     "localname": "OtherExpenseIncomeMember",
     "nsuri": "http://www.westpharma.com/20230331",
     "presentation": [
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails",
      "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "wst_OtherFinancialInstrumentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Financial Instruments [Abstract]",
        "label": "Other Financial Instruments [Abstract]",
        "terseLabel": "Other Financial Instruments [Abstract]"
       }
      }
     },
     "localname": "OtherFinancialInstrumentsAbstract",
     "nsuri": "http://www.westpharma.com/20230331",
     "presentation": [
      "http://www.westpharma.com/role/FairValueMeasurementsOtherFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "wst_OtherIncomeExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      },
      "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofOtherIncomeExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of other income and expense items that are associated with the entity's normal revenue producing operation.",
        "label": "Other Income (Expense)",
        "negatedLabel": "Other expense (income)",
        "negatedTotalLabel": "Total other expense (income)"
       }
      }
     },
     "localname": "OtherIncomeExpense",
     "nsuri": "http://www.westpharma.com/20230331",
     "presentation": [
      "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
      "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofOtherIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "wst_PharmaCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharma Customers [Member]",
        "label": "Pharma Customers [Member]",
        "terseLabel": "Pharma"
       }
      }
     },
     "localname": "PharmaCustomersMember",
     "nsuri": "http://www.westpharma.com/20230331",
     "presentation": [
      "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "wst_ProprietaryProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proprietary Products",
        "label": "Proprietary Products [Member]",
        "terseLabel": "Proprietary Products"
       }
      }
     },
     "localname": "ProprietaryProductsMember",
     "nsuri": "http://www.westpharma.com/20230331",
     "presentation": [
      "http://www.westpharma.com/role/OtherExpenseIncomeNarrativeDetails",
      "http://www.westpharma.com/role/SegmentInformationSalesbyProductGroupDetails",
      "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "wst_PurchasesAndRoyaltyPaymentsFromEquityMethodInvestees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchases and Royalty Payments from Equity Method Investees",
        "label": "Purchases and Royalty Payments from Equity Method Investees",
        "terseLabel": "Purchases and royalty payments made to affiliates"
       }
      }
     },
     "localname": "PurchasesAndRoyaltyPaymentsFromEquityMethodInvestees",
     "nsuri": "http://www.westpharma.com/20230331",
     "presentation": [
      "http://www.westpharma.com/role/AffiliatedCompaniesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "wst_RestructuringAndRelatedActivitiesPeriodOfImplementation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring and Related Activities, Period of Implementation",
        "label": "Restructuring and Related Activities, Period of Implementation",
        "terseLabel": "Restructuring and related activities, period of implementation"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesPeriodOfImplementation",
     "nsuri": "http://www.westpharma.com/20230331",
     "presentation": [
      "http://www.westpharma.com/role/OtherExpenseIncomeNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "wst_RevolvingCreditFacilityDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revolving Credit Facility, Due 2024 [Member]",
        "label": "Revolving Credit Facility, Due 2024 [Member]",
        "terseLabel": "Revolving Credit Facility, Due 2024"
       }
      }
     },
     "localname": "RevolvingCreditFacilityDue2024Member",
     "nsuri": "http://www.westpharma.com/20230331",
     "presentation": [
      "http://www.westpharma.com/role/DebtCreditFacilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "wst_SalesToEquityMethodInvestees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales to Equity Method Investees",
        "label": "Sales to Equity Method Investees",
        "terseLabel": "Sales to affiliates"
       }
      }
     },
     "localname": "SalesToEquityMethodInvestees",
     "nsuri": "http://www.westpharma.com/20230331",
     "presentation": [
      "http://www.westpharma.com/role/AffiliatedCompaniesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "wst_ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Other Income and Expense, by Component [Table Text Block]",
        "label": "Schedule Of Other Income And Expense, By Component [Table Text Block]",
        "terseLabel": "Schedule of Other Expense (Income)"
       }
      }
     },
     "localname": "ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock",
     "nsuri": "http://www.westpharma.com/20230331",
     "presentation": [
      "http://www.westpharma.com/role/OtherExpenseIncomeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "wst_SeniorBNotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior B Notes Due 2024 [Member]",
        "label": "Senior B Notes Due 2024 [Member]",
        "terseLabel": "Series B notes, due July 5, 2024 (3.82%)"
       }
      }
     },
     "localname": "SeniorBNotesDue2024Member",
     "nsuri": "http://www.westpharma.com/20230331",
     "presentation": [
      "http://www.westpharma.com/role/DebtLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "wst_SeniorCNotesDue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior C Notes Due 2027 [Member]",
        "label": "Senior C Notes Due 2027 [Member]",
        "terseLabel": "Series C notes, due July 5, 2027 (4.02%)"
       }
      }
     },
     "localname": "SeniorCNotesDue2027Member",
     "nsuri": "http://www.westpharma.com/20230331",
     "presentation": [
      "http://www.westpharma.com/role/DebtLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "wst_ShareBasedCompensationArrangementByShareBasedPaymentAwardActualPayoutPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Actual Payout, Percentage",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Actual Payout, Percentage",
        "terseLabel": "Target award percentage"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardActualPayoutPercentage",
     "nsuri": "http://www.westpharma.com/20230331",
     "presentation": [
      "http://www.westpharma.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "wst_SmartDoseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Smart Dose [Member]",
        "label": "Smart Dose [Member]",
        "terseLabel": "Smart Dose"
       }
      }
     },
     "localname": "SmartDoseMember",
     "nsuri": "http://www.westpharma.com/20230331",
     "presentation": [
      "http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "wst_StandardPackagingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Standard Packaging [Member]",
        "label": "Standard Packaging [Member]",
        "terseLabel": "Standard Packaging"
       }
      }
     },
     "localname": "StandardPackagingMember",
     "nsuri": "http://www.westpharma.com/20230331",
     "presentation": [
      "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "wst_TermLoanDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan Due 2024 [Member]",
        "label": "Term Loan Due 2024 [Member]",
        "terseLabel": "Term Loan, due December 31, 2024 (5.87%)",
        "verboseLabel": "Term Loan Due 2024"
       }
      }
     },
     "localname": "TermLoanDue2024Member",
     "nsuri": "http://www.westpharma.com/20230331",
     "presentation": [
      "http://www.westpharma.com/role/DebtCreditFacilityDetails",
      "http://www.westpharma.com/role/DebtLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "wst_The2020RestructuringPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The 2020 Restructuring Plan",
        "label": "The 2020 Restructuring Plan [Member]",
        "terseLabel": "2020 Restructuring Plan"
       }
      }
     },
     "localname": "The2020RestructuringPlanMember",
     "nsuri": "http://www.westpharma.com/20230331",
     "presentation": [
      "http://www.westpharma.com/role/OtherExpenseIncomeNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "610",
   "URI": "https://asc.fasb.org/topic&trid=49130413",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "720",
   "URI": "https://asc.fasb.org/topic&trid=2122503",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "83",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126929950&loc=d3e34841-113949",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(i)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(iii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624186-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5629052-113961",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "https://asc.fasb.org/topic&trid=2229140",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.3)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04.12(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(21))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "https://asc.fasb.org/topic&trid=2122394",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i),(j),(k)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "https://asc.fasb.org/topic&trid=2196965",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1731-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "220",
   "URI": "https://asc.fasb.org/topic&trid=2134417",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577181&loc=SL110061172-113977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=d3e56071-112765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8475-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r749": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r751": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r752": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r753": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r754": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "740",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126970579&loc=d3e23163-113944",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998890-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(6)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r815": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r816": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r817": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r818": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r819": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r820": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r821": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r822": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r823": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r824": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r825": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r826": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r827": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r828": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r829": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r830": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r831": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>89
<FILENAME>0000105770-23-000023-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000105770-23-000023-xbrl.zip
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ML*SO&I9W5H1=1%2U*39,U[+1J!L?Z@E-2S<%HGU,0Q*4W"HZ$//2"17(+@R
MC2<TY1W#)LBY*_!B9^DIJ/N1P#?9'_@N6?AF)DT9J8J#2VF*Q%#/$!:_(\%#
M$O$ TJTN=V=[$:AH",+T54XYMF7X^-@/D05Y9TV<,*>?+G'$>)F*Q[U'U1K
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M,L4M)VRN@PBVLKMG4! "[*5;L$DN;PCC;O3I<4_!&0QIHOA@##9(M8/8P*Q
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MRJS2;YO\ASWSBVMSN*F/6:._ %!+ P04    " !"@9M6A=FL_0 $  #:#0
M#P   &5X,S(R<3$R,#(S+FAT;=57:V_;-A3]OE]QJV!I DC6P\[#CQIP9 ?Q
MD,:IK2SMIX$1J8B(1*H4%<?[];N4[#R0=$.Q=7 -0[!T[R7/.3R\M ;OQK,P
M^G(Y@53G&5Q>G9Q/0[ <U[UNAZX[CL9P%GT\AT[+\R%21)1<<RE(YKJ3"PNL
M5.NBY[K+Y;*U;+>DNG6CN6N&ZKB9E"5K44VMX< \P2LC=/C+X)WCP%C&5<Z$
MAE@QHAF%JN3B%JXI*^_ <=99H2Q6BM^F&@(O:,.U5'?\GC1QS77&AIMQ!FYS
M/W#K208WDJZ& \KO@=,/%C\(8B_I= /:I=W.\>'AS>%QQPO(D4=9FQ!*__ 1
MI(OI34VI5QG[8.5<."DS\_>.@D+WEYSJM.=[WJ]6G3<<)%)HG$QA<?.S&>/5
M2)H]:(=D_%;T:CY64[H)QS*3JK?CU9^^B3@)R7FVZKV/>,Y*N&!+F,N<B/=V
MB6O@E$SQI$DL^9\,,2&\^G:YQHOC9%RP#7X_,* GG\^F)],(VD$K>(GX;:PQ
M*LN4]4V>/ZSJ_Q8FG,RCZ>DT'$73V07N@OGB:G01030#_QBN6HM6V(+%)*RC
M?OO VWI"HP6,QK/+:#)^P6;#H>L=PNQTZUE$9Q-8C.8GHXO)PIE]/I]\@5$8
M(7+L!]YK!_^=X_XY]N/(==XD-Q402R%8;!HJ++E.0:<,/E5$H>+9"N:LD$H#
M!D^ERL'WG$\@$[AFI8;+E*B<Q*S2/"89+)BZYS$K;9B*N 5[9J#=G>,@\/JA
MS LB5O6=W]^'1*IZG@)12PI,4.R^'XF*T]T=_]#KMWV[[K8VD!(2GF'T$=N"
MQ97" P!%((+"Y"%.B;AEV*?SG)>EX8%?DTFQJ4/*%$/ S]$TG#9@$*X-)TP)
MHBC\UH(3KNZ8UC9.)#CB_!TYP:5B):=H0QO"E+,$3KD@(N9(VX"8(1%B)"QA
MEB18H(Q(9LHU<QOPF>8)_B@J558$EUK+YQM[O01F8]>L"96%.9.>IV^2S,Y9
MC[\@ZH8(5CJSAXRM8!1K$S'.M#%.D.7!<?\G,.*>OP\1\EG[+:DR-%^,XF5F
MH1\77[&O%5?,G+:E(?HDVQ[9!UPM_V"/[C^*\V251YNL%?*[[4ZC<UZ[#W7J
M]LU:_@Q:!8U67. ^RFO?F5VL"692?%ISWPA)N-G&!?K7:&:;,,DRP#*<'.V+
M@0)%+.VZ*GFT-0Y(Z[]9M<$QJ\H:R>63UU]ZO/4?]\+MD;Q?GT64Q;)AWJO0
M,LID6</=G<Y1OZRO;W21K8!O#;<6V+_JL5OO&VLXQFU6MV 8%8IGS>D6'#6G
MVW?AWR!__BY0R.9-J*=8AM+<LU=O!YNJ&ZFUS'O>4PFY*656Z6^7?,>?Z1?7
MYJVG?O\:_@502P,$%     @ 0H&;5A,JDY%4Q $  M 6 !    !W<W0M,C R
M,S S,S$N:'1M['UI5QM)L^;W^RLTO#-WNL_IPKDO=+_,P2"[Z6L)&X1]X8M/
MKE!82%Q)8.#73V1) K/9+ *I1-G=&*FVK(R()YZ(S(S\Z_^='K9K)Z'7S[N=
M?R_@1;10^W_+?_VO+/OOMYL?:FM==WP8.H/::B^80?"U[_E@O_;%A_ZW6NQU
M#VM?NKUO^8G)LN*:U>[162_?VQ_4""+TVL'>DJ&,$1)MIE5$&;/198I:E$F'
M++;2:6'M'WM+,3!BO>49Y4AF+!H/%QB2>69QE%)SC=T??DG:J*1'TEK.6&1*
M<>R8HI)ABK#"-CUV?P!O!V_8Z2_EIX.L']R_%_8'@Z.E-V^^?_^^")\7][HG
M;_)..^^$],9O!CW3Z<=N[] ,H$?>$(1YAE1&\<+H/L?];,^8HXO[1-.WB]W>
MWIO1 ;B$D-')5Q[VG1:G8:WUF]/4L/$=3VVO[?.+<]/'XDR"D'@S/'CQ\$'O
MRCU_/%>_@:/C$UWWN#/HG5V]Z?AU1P=_;.G2]_[@:FM#?W"T;Z ?%EWW,)U*
M$;WL!1_RV^\-!Z[<%SKVVYU-IF_286OZX<>^R']R?M[I#TS'79[?SV_K9#@7
MO_GOQH<MMQ\.37;]JGYO<%-^\.65EI_>:/H5"::C%[U]W.N%CKNKNT='K]P=
MU/'VU_R9+A*4(9+ARYOTNXQ@^;/^&IYQ^=2[SL7TAR<7IR^U36?OWPNADVUO
M+8 I!>.7_SH, U-+=\C"_QSG)_]>6.UV!@ 06>OL"+K7#3_]>V$03@=O"B5_
ML_P?__$??PWR03LL@Y)E8TWZZ\WPN[_>#.]LN_YL^2^?G]3Z@[-V^/>"S_M'
M;7.VU.EV CP_/UU*)X;>\-?<^] I?H7C30"I7NZ&CS\=;(;X[X4<DXB8D!*K
M2%C4VC#LD?/&,Z&]"N'K6M$4C'!VJ=T=<Y@>'?*E>@?:=[8*;],S[?6.#Z?_
M%<X6:KF'6WOZ^<RN=4\^D,V3'=HX]@?UD]WW^F#CP.>[!WMT=VV%[ARNX^;:
MYF%S;8\U6^\.X-_SYOFGT\;YRNG&VKO\ VVV=\Z[<-X.:Y)/WYODG[S9^H1V
M#SZQC;7MTYWS3ZQQ[E"CU?C>:.V=[K05^D!VSW:^.+%SOG[66-L[W6WMG.]\
MJ;/FV@[>.?B&=EOOX'GULYT#QS?6&JD-)_[]N]R^WQ8-4L>-PVV\<U@G.P=O
MOS77W/G.X;O]C=8VWR&?TN_?FJUM L='UWR&9_'.;JM[OM/:/MMM?<YW6KMY
MX_TGU#QOYO!<WFRU#W;7TN^?<!..[7Q69Q]:]4%C"YU^:.V=-<_WSK[:@)'"
MBF7(2$!][45FI0^9)4)R*@.VE"\L(_B#$9<2_?7FBE"?4\:KA64.WN5]9]H[
MP?3J';\&?JX2\Z_$?/ZAM7Y5S"P@@YV,F38V@)B1S@P2,N,.)**)E\CHA>4,
MT"M+QO]B,AY3F$LAOX-O^I6(?R5B=,.2*1 X;T& 05"P9&QP9C (VV** [ R
MQC!;6$Y"F)I\/\+]N[Z2\+TDC&]*."+/@_) O:G.F L@7"=89@6REEFMA70+
MRY]>TGY70+B^$'#;["W4AG0(;GLZ6(KY:?!9-.U^A=B_%#:Y(6QE233!TDQ9
M!G&6E0*PVP'%Q";*0'GDBBXL%]U[0]YOKG*P7H@A<=S0OX4Y)J:\U"^8.&A$
MK6#.2P/@B_]>Z.>'1^U$RXOO]GM)87XDB8NG?0]W>'/U%L/'7SYSU(1^][A7
M?"J"B*61$@X5XS%*.+Y1*)C@^%/NT^>8AUZM:%"X-:)<7?^OJYSF^L7+XZ^N
MWOVHP*_Q)XA:>H-$2 I0!<' ?^/K+H]=--/_<"HMO.S5(^//XX>\N=)1M_:;
M%SRBP+G3+C"AO+$"^LY%@IQP 9&OZT5W,8A)IM]=PS!O,.H!!E3CXD:C(_?K
M@>-./GS]/@3 H7_Q9H?!](][87DD@.+@^!;C8^//Z1XW[G=<://5"T81VM+V
MUMI][G5%.M80)X67D7#$F!9*.&L]-9$%9XC&A5:3L5:36=1J<G^M)D_1ZA]E
M "1A*PGOHB\@ZH1W^/'4 NC,H-M[I+AN7)^^7 N=[F'>N>VV]U6I*[=X<[7U
MO](68J*PAG.NJ6=,@+8$BDD 42JAF!,C6YX-);EJRS_*_6&V?*4'.'BT&+2G
M% G&"34@28A6A(PB4HA1BAX@F,Q:#Y!QU/3D'D 0BUEX664 M#W'.C73"BR4
M-=*[4/0 GKT>P!/K@4"=D^#4$*8,""[2'$)3XKSFE@DDU5 '9L\*R,2LP 1X
M<X0BI\#II;(:&445(@9C'>'O%+C0"/["7B+ZPX\>'G9ZU,Y=/FB$0PN/\#D<
M'8Y3C'+M2ZM=X'\I0Y<2I)MY_]O;L[= "?</3>_;RFD.KGM\YI9IA_YF. F=
MX] ,HUO^]>;6)SVM 2D3>O79J\?]01?\P8V3G]J*?F^PU# 'W=[X"?WA@X%"
M+[W-N^WN7N[Z%\=^\;0WUX0PJ_STPI-WCE/#[V!G1_#K@_D4! 3<,8]Q%(01
M930G3/N0.' ,T9,I\*G*,LIO&2_%<:_Y.1FL\51801F$^HH[9X3'VOJ H[05
MRL^#+K\/G920F3N0OZ+*BB'CE&.*(\Q"T,!@ S9*NFB5D8)5L%RI<DE0F49*
M@]'>1QXAY-8:!4TC1Q[1B&B(%2K/@RI_+";.S#4F&Z59T#@&RPRS/BJBJ2&.
M:$$EQ<96F%PI<BD0&5BQI (K$X1BG@?#2:!((!,9L&=%2X#(/Y-@FI_5,V[0
M,)WC"/]"'.SO*\_*@DJ,SRZ$&% ,6G%&N3%4$LR91B0*KI@H 3Y7:CW3:CT5
MM";:<8PB5=$&IJTQ@BIE&'(B(L:]*@%:5]HULZ!)9!K^TY(3)!C0 *6("Q1[
M310/B.@2@&:E73.+74$X;VS* #C$%%**,F0P_'5(\2AQN;'KIG _]KK^V TF
M'K!,7<43,1F]W$9O*_1.<A<NJ<G?^=[^9],^#A?O?WC4[4!#YS(/@*SS7&(:
M,1&,DFBDU=Q32HT02@9?;LBLE'K:2CT5I&8A2&<P)T03AK%0C"&-?)344.6B
MJY#Z.71J+;3SD] [6POIO)F/XDH)U\%BI"T-RBH.6AY5( (T6TO+?+"C;%<%
MUY5FEPZSE18L>.498H$%YP&G.;91>J GT4M28?9L*-<336MK8#K>]/Q'X[Z9
MO;RS-X\H[9F2RAD6X::,465M((1BAQ'RAHIIS.NO=+G\NCP57!9:<.4]D Q+
MF!#&6.$)UU(;+GAPO,+EN=#EVP9D1F?/9=X#&\DIBTH2B9EWR(K(<% (1469
M(&487ZO4>J;5>CHY:F.=%TP"]]#,8V:%8SAR(-;$22JFL4ZV4NMYP<Q40\#9
MZ(W#P&JUTI%[P4'C$ "E-J;"S/E0KJD@ET3<&T.4!F[)%'<*.1N$(X81S2TO
M \],K@AB@D%(Y[\/W;V>.=K/G6D/A9D.KQ3U%\S,IY F:TB7??$JIB&(B)0/
M4FNG++,N*A:1)50IJPWVH@Q)VDJ59TZ5IX/*1!%,A.9<1:8%MS@BK"0U!DM&
M9!GXY"]4>2S8>J.^4JGR'*,R$HIA'1%'@C)JI8Z8:FQD1%XX1T+Y4;E2Y5>"
MRCI*';"+DCO$*&/*>0*(;*)72KI2<.6IZ]=]&$X_-Q^-@S=TKT2;IP+,S$5+
M)+/*6\8,#3HRA@.W$<OHQFLJ9QN8*VV>16V>"C;CZ"1%W"J!@"%CKPP2AG+A
M#3>8CR945M@\#_HU%;2T2C$;K+6IU$U 3$>!E.+$Q$B0Y"6?L%OIU[3Q2U++
MN5?$2RJ9,E1%H:WGFG&! D1-J;X:IA!#H5E3JU],UCA,O=?MA\D+[;+*&P8[
M%QF]?)W'5WFC$2%-!0^**":$U\I$9:TCU@7@1_CEJCV64 X3K#FIA'#<**"H
M$>S!(RNEIQB$8!GW1HWE0(B:K7J#-&TU0M0$>B"X2)VCD1D2&# 9K41PP2#/
MJ94$^=G5Q#&$?^AV]@:A=[@6[. 2X),VMN#;#UW363L.\!*L+#I)4#26$AD%
M8]0$+96/ABB*E6<JLI>K@UINB4RN+JL'/VDXC9+3P#2C( ^$/"$0QDHIPPO6
MYIV\1+9")^_VWC:[@] OEYUHHQABUFMC):-$&$4U"XX&&:G06)?93EY:*I.S
M%<4-Q,9$"^(1(TB9P"DV!!RLC2&B4'Y;6?U!*K(DMF*)!9:9EE\@P1 %-Z*%
MT-2+(&W GI??5EY.*A/T*T YI2*1VVA9#,)(C3A%6B'F#4BKS+8"\7RW?9)W
M]E9[P>>#=\;E;6AYR5R,<C:M,C4RU5%SUE)/.4'!*.DYB6CV!72U]Z_F/CZ$
M <AN(P[/F53:9<Y5(C)A%7':"66!GC-%**5(2L-T9"K,,.M(D?OJ:+?+H5#&
M>U\N;;U?>[K@UZ 33\P@/PGKT+V]X]2LE$>[JG3ONKWOIN?'4[>?89[VI*#Z
M<J.9O;LWAKGHN0<4,@?$I]8!S N*F%9<$8:P-Q)A\,:8JME%E5>H0I-##J2Y
MH-XCY5)<KYUB6D/$PJ)ST0EO2RGVBYUV*K'?Y3"\Q4D<*51EDBN-%/*:20+<
M6P!$E=)AS*O8)\?MTR8V/ 9"E(&@"VR=.\,PB-XYJF,H4X7_>\LIY'N=^JG;
M-YV],!+;/ [2:DE4C"ZF_;F8<6#75A@#OTI+J&$S'+8]MT7_'7Q:*;T6^J )
MQ4#J51T9'PA^I3\Z]U*E)A6 /*.ZWKL-'[O]_.;KI]!H=KW6!=\-QS?W[1GS
MW?KVYH/Y;A0!,-!$'&)DR%NE"!$0-'D<"$33)8BB;Q?GUGZW-Y&Y795)OJ@'
M>1::Y[RG:2M68J0!2R$*HCE$G+%><)RJDLV\DL^[ICP_>#_%V/_YN#.+.G[A
M% Z.SNYT"A=M?X!3@%#8&<U"VA:7<10L!$C E9V"&TJO2S#OX!F=0F62I368
MJ\R'&"PP)H0*PP1G$ 8RIR2/AO @7W)3W\HIE-$I_"RI.BLZGB8I(^HQ8DJF
M\66KC X$ ;H3I+R?X6QV!>0S >1E4'(@*5XYYI#Q-JWWMT0!=1&&6BXCM<-9
M+:A*X@Z5JO_>Y)T/W7[_[=E(F3=#N]#Z_GY^=%7=FF&PWCD)_4&Z<'3VRRK\
M:@]:.NZB=1!Z#UJS";9X45[J.2-0-+&,LV;: H^VS*6)/D$98J,G.!7RPX&&
M&4ZS5#HZVSHZ.1REWEKOC?'4<\8XT=%1Y+@Q&%&'>%$'&$L\/Z,B&T=)I9YW
M% 3+#+_LYN[6MF\D XX'O27X_L&) &2DY %40AIPK998';R$>"E$&[DNU7+W
MV5&)*17A(,Q::I VRK,8E388HEXG,(J8(CW# V.S(<&))^V.^_YCZ+W]P5I]
M?@+]]..)37C)GAET>]<->IS=NW#!MQOUC>O3EVNATSW,.[?=-LT$_ 5.7+GZ
MS=6&_PI.'+%"<HP92B.R$(LB[B1EVA,OH[%EVH-NO>.ZA^%BX?^'KOLA<DS=
MN#'8#[WZZ1%<&(8GSR.J<$R &L14EI(QH9!A%F$3);/4RHADB=9$SYY$IU/'
MEB%J D7(4<>T(D;HM"X9 NI()8BZ1#;ZU-#BG<E[Q68D]PLK2FG ,5A)O+(<
M"X!D[\%\%0XX*DX$=HJ7R(!+)NZI6#<*'FB?QS3PR((E!F%BK)6". =,$)7<
MNG^9,;UG2#Y%IS&OZCX5=%/*<T$$"XH1()W&,$=-M%Q%%^'[,E0>K-2]E.H^
M%73G',5BO1:*'(@XT8%*Y;2-T@41>9DJ8,V$NC]5YU9-?_]=N_M]PFGI7UIA
M,PR*NDUS">G::^ PD<>8-OAR)@:EF.,6>2*Q*E/-PDK'9U_'IX+C!)A*X%HQ
MP0T3*%II%=*$*Q]$P&;^TN[3I"V7)>GZ@XUX'YV:4=LJ)9Q3A9!-.XTRRIFA
MVA#D@*T;!OKN,%<5G%>J/B>H;KA# :@X#0BG?<(4]9CJH 2#CU2RN4/U5J\8
M/SH#)9S8SDWETK/IC,EX'82,2GD7&/5>*<Z=<\2G[<(,(7,'J96>36<O!$>E
M#)C1H%.Q)&2"<($0HIE1WF!1<CR;76E/!56,-M8B[2PW@D6'K!1I'($C0!<+
MV%)R5)E=:4_%MFD07&M/-?*((6RM8<YY@853F,*/DMOV+9,X1_,WM[Z;HRI;
M_IA9M:5$-1*%<<)'AZEGFEA%P(L)Q$'%G8^F3/-7*CTOAYY/9]P?,V<,YQYC
MRN"OBL1*@CVW'/ORX_F,BWPZA,TJR2QSD5#)'%7)@VOB@[$!8^3*#FTS+O*I
M6'F4$>2HHV,$,P1!&#$VIFIVX,DB#;A$5CXKXS_3F90'096PQM*@.-,X6D%Y
MX") 5,T8\V6:MC(K<IS.CF2,1LS ^ AR3 5E$*8NIGJT(?I Y\8>'SZN4$JS
M1$(:CI5"WD2F!-9(6J0Y2ENQ:,3<O)CERXMS.MZ20\B'1>2*!^89L=%1GDPT
M6L4@^ILWZQPO31T%8O-HH=89(:VEA"G%C,,F;4%"A"(6A1!1F6:SSZ!(I\1I
M P<I8B,$8P8%I14VUD3K, !P*%/D.F-YDEN20]W#PZZ'+KO7(LI[/_Q7!5::
MW8Z_J+$RC["$:&3!1TJU)4QB;QQ7$3MO/?=1F+F!I4J'7T2'IS/:*WTP2I.8
MYB7:@ R*'BG+0@@\>&9*A,.S),OIX%$(V 2#C7&:@7_5EE$,9 G"5&^L+],<
MZEF2Y53L4C%) E,V$J+2+ Q-I&!* UUR.B!:@CW=+E;FO#V[7*0#=S0]MW_V
M(9R$]ATK>=8[1\>#?G$&GKQHGZ7&3H@L[4OOJ(68$TFE@_:!,B?A(X4(]'5(
MBY1$6L(S#GXO>FP-2 O$A87PU!-CJ<%E*!$Z"6G1DDC+8^S!L3$C%6/8157,
M1V.&$Q*5<K($TLH[IN-RT[XDN(\>O9\5J4CF)371<QL8HU18+BE/8Y#:>(=F
M>4..YY!*Y11O41$>A4JK5J.C::,6HP/W$BM.J:=8R#(8[@LXQ5>-(D0B:QS7
MB*K B!-&$TXYILI3&B/1KT-%?N6)7[6*!!%M1)I*93A+*QW2FC(O260A:NU-
M"53DEU(9Y[9*(A*,C=81&^RI8#R5&E*8IU%4H9Q7N S1SJ1$4CG^6_3#<&J<
M)M);91F77A'L)"51>!E9%+@$^E$NQU\R_. $_+WPRAB%F/!.61&\=((2)YV,
ME==_Y?H1L!1(24<" KS0QD @H40HZH)X%\N '[\2R>.6B\^*@-)6(YQ)H25W
M#!.C?71*>>T(P<*'*CD]80,NM[:@P# R)$;*+?-<:D4LQ=I8AY.EEV"WFG+1
M@7)KB]*1@EY8Q9EEU GEL5;.&2$(2_.E7X>VO!PY*+>V^.",%00AY103:2T4
ME8I0;X0%TN#B[.[T7I[ <'(;M%-/E9+"*J$DTRI:R8$[8$TP^(& [.N0UO,.
MDTY.6IQ:P;QUEGO""&66:X(41RYZZSU&KT-:SSM,.D%IP<TLXTICAIG!4J?9
MM0P;XX7 2) 22&MFLM>3DXKWG!#FF8[&,B*,$LSJ$!7#EEA/^.N22N44;U$1
M*Z.3T1H,*,N<1]IHHJ+C3ENED2R#BI0J/"HABJ! <121V;3&D )V4,58,"8&
MJ;% KT1%YG"8=(+4.E6#(X(*;"231AB"!(U*""#7U&)? A69C33V!($=@E"A
MP&"5]\QPJ2V3J4P'\1210%^32"K'?XM^!!6CM,Y9H.@,<VRL"$8CS#QWCNM7
MDKN8MV'2"<8.X.<1 ]!@VC,DK)&I]F=$RCJ(\I!X'?HQ;\.DD]./B!$5AOJ
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ME*CFS.S3DNF7I9%:,HPC\L _F99!PR>EN5+,<LR"G&MQOSB9F;Z\C8)P0V,
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M)"G#NYKF!;1S7TP+6 ==N591:0.Z&(YU]L:*,RF ?]6:>95!!H=M!,R70C!
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MCDX8[.?%DK"CM"3LN7WTL+T7KC?T?U]\A%N=U,^7<,\_B#%)<>0=7I<[.&W
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M,V59<\ 82CA/YH(Q#(>)7ME4F(=DFY^!2IQ QZ=)@\/XJAFJE1(/6C#:6DF
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M*6H*_ ZTKUH\]$A_L'US=AOB06G.,ZZ1RY@E-M-4Q(Q(KARQP.)(416O])M
M5;O>55@V<\F]"LN>A&77N"T(0POJ="9HPC+-9*9<2"M_ *>BP]:RHBHO??J0
M9;42\E;^.SYE;&"\0-1)!]_WN,</@J'0];Y[;-OA4;N-EZ*5,ZL0<SV,?1D'
MU8X"Z/Z^Z86E>^SG_OCAM1>^1RF25K<C]WP:29DG ;\U_=P])8<T;SSZME><
M;5/[&57^&'I;"0 G&_Z3ZXRY;GH=Z*W^^'&%5ETP9U0QYWLPY[V;<U<L-D[Z
MF&DK4VU\Y#-#G<N4Y$A)IX*W$ICSHIK47+\9&M.I(&C.(>B)47L%0<\#0=>"
M]\BP3O.*,V?A!S,V!>],9 IC(04R1LLT?6Z15ONR5L-3/X6(M;Q]/ @W-IA_
M0"[G)\'X/'J!AW? W/F(YZ:I(YVLO,2#O,2WF]..D@.GDF=!2YLQBWAF,?-
M6;%57IJ(O2F(*I]\AO<71E&>X:H*WEX;O#TW!:[@[9'P=GW1G1#$<2DR0@G)
MF*0TLR&2S)$@L-.!4N>+"EM/7JL[97B;68I<C6!5(UBO9P3K2_$A^)J!5IF]
M,!S#ZM>ZQX/^P'2*]YC$@-9\#2158V_5V%NY4B*WCKW-^6*&.VGR$..>>YKJ
M&%I7ALC:/#ZTH;<1"[K<W[C$UZO9XVKJUSV(\\'-*C?.(JRYLIG&UF4LNC2-
M%=LL".FD#H8Z0Q>6)5M\<EY@]@:P*CM^SBF:E1T_JQU?'P52,C+&;,8!@3.6
MMBLU.L1,>,JP5BA(J0L[KD:!JE&@QXP"W0LLKR9'AJ]Q/;Y]:D*U[$#[4H1I
M),<;>%M![8.@]F:]&FL##A&I+%"5*N8:#U ;8R:]E,$329!V +6W+>%^4J[Q
MR>94HEHW%8+, %6K$&12"'*-K%EJ&;<290(%FC$27&:\PUGP H,,0[ &N(<4
MDUXZ.&,(4CJB-WL-+LN95<<^9\>^&1BP6/C7YR?+?Q4_AOA@>V^6+[!B?'!\
MNQ],V(54)?;EG1])SF\KA)IQPY)/9VE[X4YW '<?=)/7\ZET6^J-3K%&L*@.
M%?..Z;C<M*&E\$51WV3QSM<</4L2:,Q1MY\G&%WJA;89Y"?AS^^Y'^R/O? /
M5XV@$EU>8BRT /SAG9?,2G_2JUWQX\_4VL)C2QN5]$A:RQF+3"F.'5-4,@R1
MA\+V*R$+XXOV+\9VCX <9+87S+?,1'C!)=/^;L[Z"V^N],-AWLE^[/3K_75G
MK\3XF%[1XTXI;KB4#T $[I?=-'1@0(JZPP+*2^ T0R^=!8TTL]NXVGXO<<!_
M_5J"<F&YE6 AE59+%:.3E?SUQBS?IAT_D\J$=%7>JJNK&\VU>G.KOE:#W[8V
M/JROK;3@PU8+_FG4FZVMVL8[.-3XN%G_&\Y;_UROK3?A<[WVVW9S97MM'<[^
M_8;I3\?NOJ2MNSX"63XT+AP79*BV%7HGN0O]/VKK';=8;-JP=6S[N<]-[\?R
M=M-M^6]YIP:W;:="XK?U9N%>+I&Q8(O0MK8YZH>E\2]_CMU3WBF>4%STYZ'I
M[0$>C."4']T@BH6J#P]?(L4B&J+%B#&,GCPZO%@<ND9]A\<D6B28W7D8+>([
MC_WLMI@L*D8>==N?'Q/H<5?^LK'TOK<M#\FYFSV6:>+(+P;^]7U>:L@N9NJU
M6N"60JT!Y^WW:W7P5K[@G@W3<_LUBO]X]ID.KT=%?LC /:"(QHSK3\IT3^J-
M[S.):*YZCKR.>40EG"98%?RKBF15!?^N).W/&ODH:7^P>;ASX'CSX/-!\WVS
MW6QMMN'Z_>;Y#M]8:^[O'OQSL'.XV]Z%8Q=)^\-MO+'VB6^TWL+Q.MYH?>*-
MM3K;.6^W=P_A'@?K9SOGV[AQ6#^_GK3?;6VSYMHWWGC_[K#1VN;P.[1I_V#C
MR^?#';)-&O"\9FO[;*?5C(U\F+#_80_OJ#GAFNC,.D,R9IC,-*8N<SY8;Z@.
ME,>JWE\%9164O9IZ?V6!LO-K4(89QDA%EAE'?<8X4YF-"@.H"4>Q"TX'5I7[
MFPW26\+]/38&^Z%72^,YO; ?.OW\Y&+KVM_:8+Z__U%L_-&-:1^SQZV2^76O
MS!Y\/F&5S 37G54KRQY@/3\,:HUN\?_9>].FMI*L7?2O*'C[W%L5X:1R'EQ]
MN($-=E.G)#P(T^*+(T>0T,"11&'X]7?EEH2QA,TD8 ,[NNV2I3WDM)Y\ULHU
MH'S]:T)6Z22^\3$6TKO!$/[9K_GCX3#V_6EM/(2G=8N3HIH-G>-IR8>+8I;_
M\Z_'U$4*4'A[$1,F^_FT,V^G?6E^[\KZ>4^:]MN'P;#X;CP>MMUQ<;30''RP
M<$]I"GH]"3;0>(M/?F #;8/W_GN ?>]+W^Z:X^U>]EY:/ZN?U0D\ZW2O^:G=
M.#N$=F^2O>;6:;VS==9J'N+6V>;I?\^V&(P;@]]/&IU#N-Y_35I''@U!#DN)
M.)$"/O& I%=>&&T8\,&5-7Q)E8SB;.PF2W3I'+-:HL]_B7;VORHEK&4.(YRD
M13PPC0R7!*7$C."44&\R^[U$C9\[.;^%6^MS<DTMV:8Q:=YZ/UPJGZ _;J=*
M2)<II/,&,LL(,5AXA$F( /U&(B>P0 "]20=M<2HR#(E55OJZD%49UT<M;S:"
M#L.G"@V>$!K,VYA<X$0%[E!4GB+.L $BB#'B6@2 @LB8 ;6.TE5RAWII58'8
M>S<@E5,%WH@)O@LU-ZGI7,L%G@OM%W2(06%^.AJ,QL,X;@\+]^ :C..O=>-'
MK;SZ,V2;=G-:N?H#]&%4H=;R4.OS%8I&I]MN=/8Z]<[F::-7IS!&A]"']O;N
M1]HZ^W)8W\CC  K([E[[OV?[Y*LV%J8?6Q2( LW" 0.R.3<X!8T8VZB$8>IR
MY??WQ]!^;[C-5HOQZ2S&P].O/A+"G-.(2RY@,9)\W),B<K!L!"> 7,+FQ;C(
MQFMWT'.?;K:,I[(!5"SV'D5P7J=5@2GCL$8&!Q BQ@-RN0:PE $S &!.O<Q"
MM)@<IT1%?ZN\.(_IQW#W7;:2^'N4^'F]U2>87D\Y\D3!WNEDRE:L!&JL9$(2
MBV4(6>+OG$>V2J-3_@8_E2NK<_&9LW7V+ZD!I@=XQ#]%A.^CJ_HWW "R@]M;
M.SIXUQV<_">&_?C>MOOYR_4<<?LI^JX=C=H)IB6W/6\&%>[?&/=/KU*V]G&K
MLX[K[QLP-HU#Z"^NGQVTX9E\N[EULM?;Y'6:%;"=D_^>?3S[FB+,/34))4)!
M\Z="(VL%0X)(F;S6-+I"V;K$V#G1_,MM8:_6Y%-;DSLG7V64@08'U(5G X#F
ML":)@"4*#$<3 RM#%FMRT<?S]Q=YT/V<MH5\\%5)X>VD<-X&((@7U"F)#"79
MJDLDLM1YY!SUQ'"#F2$_L>J6YR"K.M%^2B?:E; _E+ OJ/]:*J^31CCDXEB:
M<62$E8@JH1W3P5#FLG.8++.P/P,%];F'/=REI,#=XNG*A\5E/'C)8%M96Y<+
MM]N+/H-&YK#:%)'T)!]2*HR<,101^,%)Q4%[ICFH]A*\O9VYM30QM4L\@GEN
M>%!^;E8AP]*189Z(9=9EI;'(^9BK6EN'C =X("XYH&%:2$\+_\%?F2_*#0K/
M@*8]P90L;R\A:$M-IXQ_S*C\DE,>+&. RKU7/29WO61SFFU,U>YSD]UGT>]'
M)Q:YEPP)S2WBVAFD"1>(*6IULL0DF7FI6 (Q7;K$/(UL,!5V5MCYB+&^%78N
M#3L7LLL(J[ $)3YJ#]CIA4::&XYT((PXA@U\G['SL@C;YX6=)27X5;6 JEK
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M$IY$3W^]&?QD$=UN4Z@6T5-<1#$IXP-SR. D$,= !:V"3U@ D'#M))$1%"U
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MDY,N::NTRO!#[IY,I7(0*K&<+HL?5'*Z)#F=+P4CB?<NEW:23""N)$.6)(N
M'M#$I:?$YUK5C-Z]%DSY7(&>#D_X%,<VUT:J13OL0P^>35;W$E.#V9AO3H=\
MW?OCWG$WNZ#D2E6^/:[L<\N#IL4D[T18R@RH+%1D"J&\1-8J@XCEQ$3#F=-V
M98V](H3=/1-D960HL40OBT14$OW $CU'-A3P".ZC04ZKB'CV079!:F <2MK
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MF;7*&4F5M5$D$%*%+ZF0\2A"^B+J<$Y*;4T24-_%U/J2Z_$LBQ\4D',PZ,)
MCB8S4E'PY2&27Z -AB9BF1*(B>Q;SK!".A/IR#1A/&BC<'9*>:647)I;2FEJ
M<2W10ON297]9M*.2_7N6_3DVHEF &3,489']UADUR(8H0/9-%-PSHA7)L@\
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M@Z"*NGP(5QIY?6GNO7F-U]JCT3%H8!%Z/*HR3SZ"I\!VRO.P-9V&MWD6*J^
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M8N0TR1&.R2*M>$*$1 6K0.E@2(%J=ZX\5)DMRBOTR^<BE="72>CG(Q^LYRX
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M-]TB,<-CTIFSQCF=:1&X%JC,E@"Z(.KY/9E2G '!Z'WI;C>W:./L4V^[V>)
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M@Y,92Z8IJ9V/GPN2,KK@5E\<YYQ3\1H1$Q:^"HH*J(N3I3_^X<F3<?G+0K=
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M0A#>H$ 2\$@#@.*<HRA:*H7)\5-1K:P)M;H8A/$S0*E4^9NJ\N%'5 %5?J;
MUWZ;*?6W5>67X&+U3'G<$@>HW*#]&,: :X'W1 *V^KFW:0CW?8C#-!A"AWW<
M=C!PA<?/9_A[E-HQ?(K_Q/YQ_!3]8+\/_0\5^-\$_!>-"#)2Y95RB.1\BMP)
MB9S@"E'I85^P6!(LLI?9ZF*0[)VL",MQ^[S]QG+N8?:#]]/=':T>7+R)6#QA
MJMEA_.Y0<P)R!SO,8'P 2KT_AEVF_X-CSOS6TQY=<>\%3Y[B 9-?NX/^/AK'
M8>_B[ZNUC>-AX29T$.%/S@77&Q2YX&+.!7<9=WY5^U=IT>H2^"G :@PM^39^
MW3_NH3 8H^GSGSHVW=ZCK;F%Z^M?/3;&$$&R?LJ!6"J/C X,.2V85R(Y@L/*
M&B4_/9F>>N_D;)_#R<C73FSA%38=?EA2=EQ\=]%];'Y!PR5Y^;D(@MS/BQ&>
ME[\XC7:X^A >EH_EI=>SG<$0ENVLPT??]];:X'QS'9U+^07/O0F&C&;[[ODE
M_<FPU08@\'$$\OWA)\_\?JN+IX.,$K-;IU,%+1H NQW&+ER9$6)0LS58 \.8
M8-<H'/S\5/YJ1_:TEY$'^G$3<%#,"1$T#8HIKBW321H7A.%"XNB4R>HG85@R
M?"?ULX* RR!@A]1/OLI@N*2!HJ")S,XI&#E ;(0M9<Q;D>M>Y;R*JY=XL<^D
M?^($.A'MOXYA%>5)R_\8QO'QL)^'OUC=A4_I"*ZL'8_B;,E_!GD<;\!"FPGL
M4F51KHIK"..?1X-1NTA'/%GL_\0_,[M!;/42]U,'BEY^P$K&0,7_O)=V7Q-#
M:N/H#_KPLOW3VA&T/"_T&1+8VN@H%L']>9R']B@>0S<R:MC5VOHHC_^EFWN^
M> +C-Y%DEC V3(JHJ>825I6V23OGJ?.1<T*69$BJ)/DR26Z)QLE7PS@%/<$C
MSG%"7 8'^[AT2":<HB#&QD1 DE?USP49EL3\UEP(1-['![ P@'A.@?Y5OO;D
MH.T/RK=*WDY8<+58+E\L/L,^<+V\P\)BT2HB[KU%3E&/HK'>.5@M*0+ X=5+
M<AK,%LL\J?NU"E*Z5=(8]'VU4'ZU4/9/ZOM?K>0J$!Z0P\[D#%T!F0C*@G=*
M!>>BXTROK)&;+Y2?:*.9%5^B[[J8&>@%O6+RS/SKH-CJ8*+SOHCR'EF#+1KN
M&<#&75",8>S9=J%7%.^;$@^[#\INQK+)2\__60L#6+/]P?B<!]M:.L[E(:%'
M_7;ON%<[.H9],UM^H0&]]KBX*PT'O>*Y,TX\I[A<&B-W+85ENN,K"I1@D:B<
M1\#\KQ^#9Z?Z#?Y^BW6C0?=X_/-;%N)%'DDSTG,C=^'OW-I"#)5+6@6L *PX
M3UQK03S7H$6 ND T<5\Y6YG==##\?NRQ'Y$#!G0(*B]T\+7MGMC3T<H?/VJ(
MH!Y>'/3Y\?KIJ*1TFU$QLT$I'OBZ/88I\%=SUF*V *4&D]#@UZ"3Q>&$F/[;
MEK=QM8-A!OG_N7H&%>C(A98) INA/)<<^?<?=NVRU?$ AKW+PT,;@W&L\=<3
M$CTUN-YOO.:F'68L&X%>__D V'QIHC)/9QO4(6F\WR3;S<-OC=U-7-_XU*YW
M#D6]N7Y6W]@AV[L?2:-7QRV@K?,;U'9S!^>D"MO-3=)JPGO?;YWFY]0WZB<-
M^'YO8X>VSCX=-#I=V*#63QL?OTH<>+3$(^\UT%Z;<S,I@Y&P..+ @#$D-^$7
M@+PQK.=M/@3NJ [!1IJ * O'55+!P%)TL" EGH_B;,1Q;6NRV\"HUXIA7S1,
M7VIHO@S;YW:"Z;1=U:;[C@/^[ ]B..[&[32_PM[ =NK7^V&CG;>/4*Y8X$=8
M=4"+"(XZD)204!%HD?G_V7O7IC:296WTKRB\UGMB)L+%U/WB6<<G&&-[,[$D
MQC:V7_A"U!6$=6%+PAA^_<GJEKA(XB(0((E>>X^-D;J[NBKSJ<RLS"=%0C9J
MBS"&9?-)8I[9&<9J@9_C].':@N!L2W5\,[=FRE9+/R]T/P=F"ANM,&1LRQ^W
M2A$%",Y&E2\:.@T-KR-0A>*RTCG,L<+B\ASN":6H3/WZFRFJLC3UPE7WIZK[
MTY2[5]V?'G?BER&YY;=KR]FK=E4SO/&+:_15=:Q:5(UNG%LO58U>5:/WU(DN
MC:(B#X3OO]U^?W'BT/=SN(9I=)].M@JNQ%9[Z^,GT=C^W*ZW<_RY!;_[]F-K
M>P<WMG=_[,(])M+H-M;%SO?W=.O[#M_=R,_>.=UI?SC<@M\UOL.]#O/S/K?J
M&U/:;NWO1:48MY8@Q;$$AXUA9&*42"9K8A#8)9])&/BT@^X%K<:;$Y%T!645
ME(US6%KJE0PJ48$Y-U)+[UQ@-O'H+37D%@[+"LKF"F5G8U!&DS/<*8Z(H0S!
M5I.0L]PC:[&-R7FFF <H4VS*4?]20=D*&+U+V,SL>_&/?,0*H\JMW/,A)^#%
M,$+8/1[T![:37^=:OX7>/B-W*_9>HJJ[:^&UG+?'-A9'J[9>+EJCH";>2D7\
MOK]UL69%++]"X%D0>+(FPR0%MJ-.2 5J$%<Z(FN80<%BX;5+DAK[ZJWB4PKR
M9@3@F;7EL8W)N_*+5Q!P&P3,W<BJ(. 1(6#<"),I@H6%$TI:)L2= ?LK<(J,
M$#%8%U,4)03,R+&U<!"P D;8_+H@#6^!\O>+U)CB'LU.B)W!&V2>HY:DI#S(
MQZTYL1[>,_JB#"/^[W$N++$GMA?ZK_/I;<PE'F6=5ZY6/NZ=PC"[_D>M'0<'
MW7!G2H3[\\HL.V3/W6HK&+=R^J!MO2NL[!*LUP>#7M,=%^?;V]U1#D8,_Y3)
MU^N]7J[)S3]6SO0L.#[1%VY_+U!%8+<U2!HN$2=8HIQLC(A4)/#@L#(RY[=.
M<K7<SY5>H,!?I=J/:8U5JOW4JCUNHA%/>8@VD^[E&H> #=+6J>RJZ91P8IKB
MK-IRX55[!6RP50B$#2-@MM\_;N=$NB+)#>1E#G&PQV* 6798?JHXV3"U=<)7
MKC!X%@R>Y,+CP<(J)8,24;E[N  W63*&/-A65FG"+,UNLG@X>\EC-*U;LDA:
M!2+/&VFK0&0^(#)AR%D36: 4P6)AQ#7@AW;&HB28H2JRO$, B,B'IVXL.(@L
MJ!TXV0SP<EW,;66.SU,2,3/K45'%G.'AG"$A__',ULQZ9] ,P]C?E^CAG7(5
M[?M?9;'MAUZW#;[G$7B;>7"3A3WK16NW):E_?NI"G\/W8@^,%A^33SD<!"ZD
M)(!!T=KL1SK'X3\922Z3G^1'.J]^SF+SS-O5(TA):OZ* 9W%7O<%"\@FW4O2
M"<T-021RG'D4/'(B,B2YIL(Q3&,064#P2!XF!:64@=<U^.,H^KQ&K=/793EY
M$9Y'9>C>PQ+%3K\LQP(<[ERI4;\HVKI8R8+.XX8ZK)H#><I,/'!=LU=KMH\R
M05VNUK>7!&:M-D-EX[/!^6:G]B&ZWK'MG5[0V-3^ZMI>R-.PT>S!U'9[\&I'
M1[UNYBJRPTGHQ?-J?OADOV?;M:)8><AN<I))NDXO?^OX*->[S<)GH:7TPNKD
M:%)<!YRI$QAQ/CHNP#\:\5E0JJ_HL9ZHT,SB\/E\)/^4PUT_'AQT<V?/4"HJ
MN1N>FQ>FKC >T3B#^V6ZS4//]ARG@*B1(V5"+AQ.H+J*"92TMD(Y;+17.3QX
MG5'IA@#?O$B-2N>Y4GFE2EZ):Z7LG&;BP/Z,H'*U^.NH69;+UX(=Q%O$\/*3
M1N=Z74 (^%[O!VA[-_.XP<.:/^%>K5/4B?O=0;/D\NF!II7O,F3<*#N9YQ<8
MO@I(N+L\ZE#L8X6UU&P/&?KZQS"PR_>JG<"4@ 3#*$))R_'3]IJQI+=+ME#
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MI2JP= =#25:!I84RE"JLG15K)WL=<*--"H$B3 P@+$\4.>(CHCYZP[F/%!/
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M>&J5Y2"Y&I.(J;<N2$%\\M6!_\) TNF$D^"2#5HPB92( $F$$*1AZ1!S..G
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M"#1\K?;UG$=Z"JX4NU\/+BJH/5K=*60KM2-[6I)\.)N).>!I7[]L%+20V;J
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M7CIMS4(W5]J9>EZ+M^EL<5:(5URSR,"D:X5 @L?^2>F!<3:#6HED:01Z.!+
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MB*T_B"VBC@DGLG3&98,2'DHF,%749(6< SRQ6-6Q.X>SF1 KDT* D GS)A/
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M^L/1;G[5[\?A\U[\,PW^Z80T_+/?C0^[LMP=":[VBQE=6E+CK726R!0L >>
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M>RQ!)Z[TWU$\GJ_G*US.JI0O6MAB[_5HIS/N-;R[_5K@O_<,;) V.D*#]01
ME8X=*A E+'CN<!G!%*U\MFE'30Y^,)Q+):-<IIAM1&/:"&\E<S)PQJDWR, +
MGX9=B7/KR=A2.+K]XEN.SA!$DIX3@18WVMG,$N>S)MHSX;G-0>6T/BG_JZ=
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MU7@X%>NIW^WVC_)OEXC8#H?C@V9[7P D#SK#KRAE):"376;9GAED @>JOI:
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MH99/@-/O\V3EIBQ?6'L>UIX];M%8.B^B1)HYBG@N,^HP"8@"ADN:0I"&+*3
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M_NN9)A572)#I&\ "Q#)R=48^HCX"/VD.LLR[L+#]6KX)EY&% ,K(0@!E9"&
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M4<XE,*X4/H',T$GAZ-W\,:>%BW\=%\_:'"8'"W/MD1):(,Y90AI;@V+2$>/
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M$S(V,*2E#J#-24*367J&73DM;ODFO"HCGT)D>9-E.7]\^0V<#G?(4%IMN;0
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MV1L\SUZK/.1HK^-!/8+Y-NV0^LW"^#$8PQ,_BA^=6WX_)4X+"EUMO;KC>D^
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M/<F$9/)3+3^)!R_B2E!5_;>$85GQ(QQ?<[_,55GB+>(UP"6&"*5M.,1*VG=
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M:APNWH2P1'UOHL7A8GQG)GZL@0( 6&8#E">@/49PG*V;)QV#8+XS'R4<2)!
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ME4^AO5O/-.$$8#;X(&I!KH NOUU[IIPS5XWD\HY8;*HZ:[;737S<$'D+V5-
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MBBB2NU%(+LN/1O'7>0X>9M<0U^*XQ('-<648.2D,LO\C(I5HS'H!R\4/R6]
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MY%\M49 "=^;P:GIM "@@!$!28*0PYI 8DS(827OF2CO(7H=N/]:6N1]<XD@
M@,>OH884>K+ZW[>#.7&-Z)=!C[1'BJ])GC7L!@7VG>\@%T&W'8LF=1[_S?BP
M%"X<$A>(60B)._*%Y9W)B%KFK>+!%&%SH>]".1$/#;"Y,*8WH"),#@Q1">H
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MWM?&0GW&UWA3AN1NR:9#$V.&$X?38]P3+6O]O:[AX(NSR,$0 AOELU"ZL @
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M=^\8=5"WM)[X LK&FWA(,FKJ'U(SDZD5)6R3^=0& 71HR1H E_!7U)^OO D
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M* NC.UXLUQT_#CQK!O]@P<M?_S]02P,$%     @ 0H&;5H[][0]K#@  .*4
M !    !W<W0M,C R,S S,S$N>'-D[5W?<]HZ%G[O7Z'E9;LSE_ C:=-DFNZ0
MA-QF)B&9D-[>?>H(6P9-C<25Y"3\]RO)-AAD(\LAO>R:/C1@ZWQ'.M^1+)TC
MF<__?IF&X DQCBDY:W0.V@V B$=]3,9GC6^/5\U/C7]_>??N\S^:S3_/'V[
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MMJUKK-*WD6T#[]-/=7I$)1F81S@*77A>%;,29BSB$WGP/D:HD\6--(ZK[8L
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M47/=,QO,55^^#_'KVU;0AIS]KD'PV[BB9Q!%!_">J>21HU4&EFK&U6'0;)<
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M:Y3( 0)C]8Z,(P1."S*"C!-!$(MMG6IW^?3/6:L'RK+U.[J8!/(&)F62MKZ
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M1UOYWQLB_?=O;DCJ)_KRX-X.VV2*19CFGR8A3L[ILW'Q2YC757S @SL][/J
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M,EA.4N$88VI>&+<'S/&YUT/CLW'5U8%AJRC<7:;[B_F\UH&N BV?T+[<#.7
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M=MNFD_WZIZSO?'[&Y=O9E3CGXBP:%QAYC."]YZ"4J&-B30%F$QD!/)/X6[L
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M_Q%(3Y :+970(5]Z.T_AU3I#YU593?VH@USO&?^A9=(^9@ETQ-<DT%RW.2%
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MZ'!WET8.Z^PV8DM<P!I9AV4#.@*S&T.$ V]DHECCMBUIX]38)0<*GQ>H'Y/
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MIY')P!^B >&N/1 $BV,]U,?$ :H]:NY'GO8]'.YNJ][D>8M9$B>1CB%/L66
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M#O(T(.1N1!T*Q)')>HW=-R,G6 EZU9Z&KUR0UD>;36'8-M4<L $LX=C<!:Y
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M-R(J0S*.%?6Z4?/H^]*,I&W7D]T:'6WT2NN(TL@_S!O59UP<R6$<M,?FCH!
MG^'*XPQ9<+>=TST_DXN.,R3'W7'<FQB8BG51WGY1U;V]<WSU6%5F\SA+:$2)
M2#3,<D[LC6 $&8HS*&04QSD7+%?:*\OJ?A^71E8VT^-?@&B% P^+JCE;-1-J
M;F2'1H)[(+V+)QS"UHV(SD1L9,*QTD$K'K#R78%.0O KLY_ILNC)AN.?__0X
M$J%2FQ[H8=JLI<=5W$M(VO/HN*F8;6;;M\57-6/&L&&&'V"*L;%PLCR&+!<2
M1IH+&>N<:8+&2,&\$N#2F*-)^:N-8./D7E[C[D@<(Z(Y-JL,R;7\M@_XT9(M
M/T5OXB3+Z^XO,KGR4W"&)E7>:V<8P7U02YN2[Z9:?"VDDB]__%;;G%-=LE9C
M4XEE\;59M&99(B3E&8%*I1RBE&#($Z$@UHE*DAQC0IF/_[%[UUZD-H&/LO6+
M$C9/YF/=9EW3*YD!6POM1W@>X^!&=>.@.S+)66";!*0KL6V8YHO?6I1_ FOA
MP?5IF+WIS1^Q0,3FT?&DE.8/R%,R&]#"^?NT=2J]69SDD1",0RXX@@A%'!))
M,TC3#&E%1203Y>>[>; ?GPDTC>/F^YUMV78^SN%;M VL_INT05!-O$W;9-8<
M9WNVA\$(&[1-'\^V1=M3LV^3MO_PP @I(6SF<<,H-XMY(0R?;/R,,=-YS@7,
MN*UB&2?&:DFIAAG!>4X)CIAT*FMWNJM+VWIM) 4K40>[&O< [,8&86 ;F1(&
M(N8?FW42C%#Q6L<[FC:&ZZ3">W%=I]\86AQ[(?[XI![,-W-GME;&-+FMV/WU
MX_)N4=E\N]=-#8-XIKE D3![G#2E B(M$:08)U @A0T$D<R95RTMQWXOC40:
ML4&UEAL\M()? ;86??O/;0D(W[K:;D/B>$L5'NBQ;Z@:C#<B@YL5QANIP74_
ML /J<'O!%*PBMUNO$]?F]H)BOTJWW^O#>.MI=82W1HWKA2BZ<^XV59;9;WW4
M7]CWZ^6R*OCCLHE"7]RPYFY%:BXQMP[16AM&4SR&)%4:4I(D&:4H(TBNBANX
M<=K9,CE-PMU:!V,;3<U@-74-.M7,W%L\+H']; #;RA&Q:')$B)T<$5VP7%OX
MQH\$SQ]?-WJ<9LRFRE[\I Q-,TC7'U^]V]RZM0I= 7NTM-"V2(VAU2VU[*%Y
MJU@X;@V&<2#6/5^>2?DX&'Q/F3I<P^?F(/RP*.\7I5JRZL>'A16%S5OF^=MB
M_GAO3ZXHIDI+F-A#*T02 FF$,IC*E,=$QX;&\; 4@B=ZOC3[<R/X%2@WHIM_
MM[)W!N<5^-J(/S1AWZGQ<./645 >F4.W =Z2&JS$[@S/*_"W?H#/2)GG"%;P
MC'>G^GVFA'6.<!S/-^?:P# 2^QNK"LN)S<VD=;2:29PPUM234*F&*,^,8<G2
M&.9*QHRF"<ZD5[C=7@^71DHK <'<2FALP-ISQ[N/H1O!G(7,R$2R!J7S2WC5
MAXHW6QS5/! K[+<_Z>P_JM[367[\P8''8>K6>A1TM8N83'(FHPBF,4DA2M,F
M\%Y 8W/$A$B2F4VCUZ'7=NN7-HL[X3QK/QT&SO%H:B@<8Q] M7*%+/'4JW*H
MPZ2=MJ<],CJDUM[!T,&'!FX='LTFY%KK8EZPI>HV+->E-&M]YY8[BS-,A5F"
MH>#,[!EX3"&C2D%.\R3))*$L\DM7=K++2YO1K94#Y*-J?/L?V(_5#I^MU/!T
MRW& W7%K$!3,L?<$CPUH:W$#&OW.,(2R]D]W.*V9[PS GGWO_F:8%&B;M, T
MS6@2&XM>1(F B$D$"<XTS!EB,8V8EGEV7@ZT0<F!ITN"UN6766>A.B]/EV^^
MY2!@C4P9AS)UC9(<^208(R7K>J:$QB?5/96NZ]PDQ+9$Y:_LOQ;5JMY2W62/
M4EQIG-,,9@QG$$F60<;L466.:<2U2!%R*AQWN/E+,RQ6PGDEX3J"7/^</Q^/
MD2>Z*Q1>Q6"/:WQ&&=@#C4Y6 /:X0MNE7WN>\INDK0$@?LS^X^8_9PKQA(@X
M@38O.$01QY!SLRW@G$5(Q4D4YTXA2-N-7MJ$_ _VP$H;Y%*ZS<4=@/IGX%"U
M1YYW#AH[3[E#*O84%%L]WDZVU4^;R;;3W"13[) "JXEU\&]#[^MT42KY4I7F
M'\L;,Q[O2O-UJWK9G-D2GN <2;/AID0;LSBED&0HATC13"?<6,V9\+NDZ^ON
MTJ;@2K8!Q]\G<'6]; N%UN@W;(V@H),46%&OP!J^L.?D;J@$NTKK[6SB^S,7
MQ?<OS9S>&D8?;Q?5-U;)5='25>XR&B<*JTA!A>+4D 7BD,9Q!+'93NL,)SG#
M7C67#W=S:7312;FNU^MY$'<$2S>J.!^AD2EB#YP1LL#U@Q"($8YT,BD3]"OZ
ME %./#W8<%#&"I&V.I JZ\;9:!W$^VKM6+AUBDQR1&,A#"D0*2!"F8:,QPRF
MD8XSFD<D8;G?$9NW#)=W]+92H?&R7.D >$O6OB?YWD/B;(:,!_/XEDF+[[;P
MVPD%-O(WSD&=!D&ME6'@A3-@//N?VJ89!L\!,V=@0\/XKZ\TF@T(?CM??+,%
M,-6>1^:BLJ5=%C;RY]%F/WRI]*)27]CW&1<)TCQ1D$69V6-E/(;45F/"'%%"
M!:9$DI7[^A=WZVD$49UF^*Y7^Y<I#C%M8+TVZH [JT]]U?E.6K?H%[?,!MA;
MO_5=U_<]M_>/K]Z!HEPN.E]W/Q(>X[MPH^GG&N9IB/QDO<JK-JV"U;*IEJVN
MP+[S_*("NZI>F;76*FN]YL.1_HA#$6A9&$/"21>.$2%^NK2,V57XQ>>#6FZE
M@;=BK2LR-[T_%?*ZE)9C(LS3*,,9E,*ZN<;&1"=2YI AQKA A&OFE?(OO(@7
MM]U?9YQH7''*II+8NF;"_@)TVU1G;^*F[ *TN"V;J$?S2[/@A%MD!H[_^6O,
M^*/Z_$M,ZRFQ*8S1KC._-"/;/=*M)WMKC_U&)EMDSAN+"=:8@0)>S!)S'L ^
M*\R9/9V1W_\EJW?W4]=59>9+4^^H?OEC\TR7L^W:GC(U__EB>C5RV,/F#V;"
M=1[$"4449;F",>(8HLBN+D)*&*6)BA3-L=GZ>+E>CR#DI2TRC:3 BCK4B7N,
MD71;+)Y[?$9>+GR&9EC:_I&P"YG^/[2(TY<1& GD@^4(QNKKK,"83ZK)=EW>
MFI7$X%:8-VYMR2BS>UGGZ+RI%KI8VD7'!A1W+WY9O%J4]6)>R"9KP;HRFHH8
M4S9GN" :VZU$#*E,%,P-SRN681VE7@F"1Y+STJA^%:RSUK,YP%AIVE1=:PXP
M-NEQ6VT[R[,]QUHULER ;:7/*88WTE?BN(8\_]B/O(P\_[ /C7@::U#"QDX%
ME_(YHK#&@OI(/-=HW0U-#+15 L,N@9T9RC5*HR@3D$3<NIGH!!+!<TAB%)$L
MCN,TYCX+S9%^+FVAV"WQ8N4<N#<XAJL;-0= :V1J'0+4@$PXO3 $RV]SN)>)
ML];TJKJ?BZ;_\7,SS*P<6JQMW'VY6J:9=3V#6L767S4WC)!% B9IELF<$()Y
M-BRIS'YGET8+&UG73E;G'!STXNSJ.!(&O=%]1/:!"\\3+F $S_]RH*MG2OER
M7.GC65YZWAE<"F+W+-404^=FJ7B:QYI$D&AB-JTL0I GL80D47F"4*P3X>6R
M>KRK2^.-0W<:_J4=CN'JQA1AT!J9)PX 9>V*\'ZLI]$(5Y;A6$=3EV$XH?"!
ML@NGWAA&$;]49D?3[FUF24IU)'(%4XESB!*)(3&D ",=Q2DG9K_!(Y]R,%MM
M>Y' !/5>&M%LYF,CF]_<WP;,;;(/A&'DV=TB<-./@/=4/J!KH+F[W?*DD_6
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MDPW35&YL9\M[63YMH>#W=G +UG$ )P+S@ZJ^JD^+^;R+CI]E-$N27"C(XDQ
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MNJ]G4:1DG#,!4Q%KFX<XARR6"<QSK,UF'%.=#*V3X"3 I:V(VSD)V[J .QJ
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MJXVSH=AO?PI;#G>M;5VM*DS*-]:B#V8W\@H&WL@<=;"SW)P!@U\#Y0CER%Q
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M]G7IX@6&L2TN  '+D"%%(B @5"N0,D$I%7&&A5?AN5&MG1W!ULY&]NM2:6X
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M$H'K^?%A3/6FV+*[NXU=#UAQ._U%_5"K1U7>HBYP#D6J2 9T1A' B@M S6^
MBA7*6)JD,/6JM-#7V-PXZ;FM]A*ZMK:^8O848NG%V8V$0J$W,O,,!\Z;;%P0
M"<0PO4U-2BLN3A]SB=-G!A9SNG]8KI^4^FI>N;$14<W2AFC*4@(!S%(%,$D(
M((PQ&UT$4:+R)$G]BCF=;V=NM+$WKU3]X6JE=.%=N*D#4C>:" #4V/?BM871
M :SP"Y$+,(0JW=31RK2EF_I=/2G==.'Q@0N)_9%L-:>E4DN($0)<JQ1@)"G@
M5&H J;)'W9*DV.M6_.C]<QOW!_,&K@^.X'-<$@P'9>Q5@#L>_M/^>:]#S?1'
M;Y]V<C_OVLE\WO'8L*'KH&9M3U&K+Z:(D8RU)""."37S>@H!HS@&G @N4L:S
M+/;:$_@T/K=![Z@17UUS#.,%K[YQ(XVQ$!^94<*"[4TZ0U +Q$A>34]*5T-
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M:#.-W:^;?HC6!_.GZAZW@X#10!^9R4_BA2O+2[7Q"O*6\3=EX)T(=W(P"+5
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M-+*6WD0-=J_[L!MP3N. 2;##FKZV)CZQ<7#[]-C&Y4-#28/O&DTT)60,4\B
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M>>N^JGF@O;I_G$DWYZOJGN[&US_@Z?NHNW^UNXJ,19:GYIHB*\R*%RD@"@M
M,*$DDTPA[!0#?_CRN2WR1C93<VO5GZQU'3)+#X<G$&/[-@XP&"-$XX+6H;P:
MAZ^>UI]Q0:DS3\:E9T8(N?@[-7<*VY?Z2+4_7NHC/A*D$$"DJ5[&!.: "24!
MX4*PM$@RPE&PL(O+,LQMM1\>3&T""#JM H9J]$R6'8&,/ 4C\XP+XJ->$-P
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MR.:_^N?5LUBN']_^P;_J[XG\1+?RK5)2;Z,Y0WD."PZ27"4 %[D"-$88Y/K
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MK4?JSU]I)5_IT>MF9'*]J;^J]U5ECO"U#*]>]L^T<MV;SH+UJ66!4RYBG@A
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MN(PODQ1K2\ARBE9+"U8;PG\PDO9!5UUE%$+S5/R1X?*CK]\)*F[H4&DAVT&
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MJ:$2A@"IZLC=E]0HL&1BBG50HZC%>]:"RT@F5O*0G50NI4X:^]TGI=^#T:Y
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M5FDM%K@\F^;7XQ#'D_'R^QT6#5IM=*SC6=%1])/(S@H;(+F,QG'$8EN7TAU
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M%O$P(+*9GUZO(<EC,3D:8"F16+ATX,G5!HQ&4SAOL806\>F#!/3G>1ZOT_L
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MV>>:"0Y79C$+63MI*! F$>4A.W#*T[)QWL08&2/.&N#C]EM[!$4;%<Z:R',
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M6!/_P.M&.BA=9^9!R#:#$L:!0XS @HG$N'6XVW3!XSGON6%\AXBYNP6TT,4
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M\%R"<R0JJ1(BF8ID4NL^G1,&C(^0HC](S?L-&#]$YAT@YTU8_/7KY>R?]YE
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MV]RR2_J&[=H68+/3H@Z+\+&69^3,B.%(_'N)BJ./OISCX?\@HGMY/VN'I'W
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M_S-<7N,3'&K&N%48(1J=R$7@&7P0$G(F.<>8/5.#; \XB,IQRY0[ &DK#7:
MT7ONQ.KPO4HD0Z+D CT**RPQ$/5R+&^ (#."9<8YG:/CS:>$[2!GW,KBT5R\
M$W32&[R6QV;#2>UE7=7C7Y!(*/(A3S5ZE4&A,>!U%N"TTH4GS;)H/95D'[K&
M+30>#7 MM-1/[?HODV^3C-.\N%/S4>?_7.0@>?1$OW6U^-%36$XN;P2M'-+-
M'3F+S;<!/$'+7D#S/P/0FFBC'W"=O.W*)LP>,Q2OR9_U44 ,M>\OH_$JN:":
M)S?/L<F,LY\!J^=4;@>6^MZ;MY7>:$442Z4E*)-<W2Z8 <F)C9&30ZMTZS#D
MX$S#SY=J.$3L33>7-4TT8,"2;-$0W')'41V!PU! X3J89)A'V\MFYI\UTW"(
M"CH!TM/OVEQ)9$$+,$F3;T!RJF(1D I*8W.*C+>VDJ?E&?A/GF@X1"%]+UA\
MW';W\?KKU]4@AG"Y^IUWTS*C_ZA^K&73X5X?&JSO\' VAVD]S *Y$X:#D2+2
M124]A#J#D#EET9/CY'3KI'3;UL,[@<Q-</,GSI<2_Z7V"M='F^("!3$NU'2O
M)5>0<PAH+$21 T.9!8^M']+VH:N'MHZCD+"CGZ.-$CKND5X6Z3U\=3[A8MKY
M\UK=/_L3W>B:^66R2)<S,E_XOMS]Y@=<EK?69ZU5DBE6JOX,/Y;C0&[ Z!2S
MEHP9).'(PL6L('!OR(F*P@2FA"VM7R1/H[AA!_76M,:K^;PVJB^_^?K'[=]9
MT_&J>ANKFE%GK JZ"'"&(A<5G01')PA8X73D,' ;6K^K-2-^Y(UVY\/LCF[N
M,ZJ_@U>/%>7TEY?MI]:D: ):"-J2""O=7I@(=?,0_:\G";<>HW./@&YZN\\)
M@H=-"$=KI ,X'2^X6[:GN8Z*^R/<K _*SIK"&0>MN '%R87Q@H3KA0^1(>;H
MF]<$#,#'N. ^ 5;;7NS&U'$'."?G>ADM3M.J#&+3AI:BTY'^%YBH%:Z6:PC1
MFKK--]0:5\5MZV$93Y R\E4Z.D9F[176 >X^4' QGR3RAI8AQ=^GDZO%AX]_
MWW2EE1Q*%8MA*M5W*0,^"@_<.Q*0MRZGUNC;2=#(C5V]8;"=\D9$XF)^=?&A
M2G!I1U32-@N&8#T2T8)[B$4B^3V1)?J%)S;V01S]U#MHHW^[1=J]#W;3*CB"
M@WB\Y'N RV;!3Q:1,U] RU(K6%D$HE]#= YU77^:RUZYL7T ,Z8A/$%9#]5]
MA.1&5OCOD^GDR_67->$\*+0Y5L.*HOJ:'GPAKU,;-#8K8W3>:U[F,RJ_]]&1
ME7Z,RF8MY#>VXL/W.X0SDY3ATD*,3(%2C#BGT *,")%K293C7J_^SRG^[D?'
M,1#-%'^T_#KP39^UB4^9Q-]N&J&S2;PD8X'Y.CH(92"1$<?6B1Q%\F06F[=H
MGDSUN*UW?3Q:G5GW+QGM?US7P[U6U^+5MS"YK.+_=3;_&_VW5Q?%.(;,UDDV
MLI:NT-%W6D=@*4J?HBVL^?"RH7CI_ VB,29;'8F6 'G)!^7]U^6N@R73BW?3
M5>?110E<>ZX8\9S(E6:)@U<B@4298_0JE-1\!WI3#CI_%.GT4)P.AI=P%)ZT
MT%O9_R^<?/[K"O.K;S@/G_'M=YRGR0+_G$\27@11=$#M2$MU'UY! \Z' A@,
MN:/)Y%Q:;RDX(WLC^UR='Z*18/023M@IDEG^X2_A"G\-D_FR2^Q"^L"5KO5:
MRM=])APA6L9!VMJ9F+T0PTPD.A^+XTZ$Z/VDC0BGEWS:;CA^M5A<?UG)ZL-D
M\8]?YXB;%58?2#(7@N"O40= 599/( :\X0Q*LM;YQ- VWTXY.%/CCKAXJ2=J
M$,CT<H;B\P*)^PBD;MM*JP[/+_Q">YM\-IX<8[I#R!E6X 46B!BR"DYJ)IMO
M[AB,FW%G;O1P:L8'22_'I=7]L9'$?\XNZ<=<UMZA>H/D%')8KA*WR=2EHP*<
M2!$B<T$%@\5$W[/1V<[6N.-#>CA '<'F9SU)F^Z3I4"<35E[$H/D4H.R=;U?
MB0R<4I))XV(1K:N)!V=JW)DH/^,I.AHR+_D,;5H.%U?SZ^6+S7+8PJ>_PG3[
M0Z>QK"!%@)!332A;H<'[H$ ZIH,TA6Z;LY= -^)MW.$O+_5$#0F@?Z&#]?R3
MC(G",BD9!)]J@;!1$"F(!!:+8\5SKTHWSF!KYD<>=O,O<C;;8G#$P_O/Q=7Q
M0GN5KJ[K/K$?L^LKDDNJ2/N,%\6@*L0\2,85*([$NHB9 M5L0HA"*/9@$,^C
M#M\!R!IY/L](!V-L_79@EUY=+O\.YNUR6&^[OU!"8V%>@]:*@8HI0S"6#FS@
M3'I9"F+K9^O]*!MY*M#(-_H VNMW4,)KG&*97-7^E<6F2'!6;O?-SLH?>+6R
M0).T_LNUQ?KX40JG?K'1L(6FC+<:QT ?F6*^2]JKZ6K)V)_TZ3E>3>:K W#G
M;]SVP]\VN2=1(M;Q]$HA@DI>UE5!!D+6:!,&YW3KFZ45[2=/,CV1CE65:RE.
ME\@1BJI+(I2LZ2$501I,)@EGL;2>[->$\)%',XR!WT?#4\\.@ X\C@\W7%5V
M;AJX17&11<F!)$C>DF<)8I01 F/&,Y=24:UG#&ZGY&7C\@A(/-Y'>JI^ND39
MNM^5:Q$"YXX"3E^SZ2Z"KS.D?$@RH*:3G%IW9#Q%R[A(:Z'G9Z%SA- [ ,^?
M=3KP;+HZ6_<.Y*8=BDMD=;&.SG2J5!*LUJXG\"@\YTR7]JMGGJ.I-S =H_E'
M(PX:JJ$#6#UWBV]CD?@I(3 +2C,!2B0-7E@/TA59LM;%-D\Y'D'FN"T @X!O
M:&5U@,?[<OM(T>1B-O^M_F=5<=48H$RA6"DA,[((*I-?ZS(+@%PZ:\E2A#S
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MN$;IDH4J,34?"G#ZK+<!$^+G1<=!T^ .454/N+LW]DISBK690,A,*5",Z*;
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M4$L! A0#%     @ 0H&;5@W/+$Q#!P  )"(   \              ( !
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M%@ 0              "  3P7  !W<W0M,C R,S S,S$N:'1M4$L! A0#%
M  @ 0H&;5H[][0]K#@  .*4  !               ( !OML! '=S="TR,#(S
M,#,S,2YX<V102P$"% ,4    " !"@9M6H?%^:,$B  "&2P$ %
M    @ %7Z@$ =W-T+3(P,C,P,S,Q7V-A;"YX;6Q02P$"% ,4    " !"@9M6
M@W9O!D!)   ./P, %               @ %*#0( =W-T+3(P,C,P,S,Q7V1E
M9BYX;6Q02P$"% ,4    " !"@9M6(9 L./#:  "XTP@ %
M@ &\5@( =W-T+3(P,C,P,S,Q7VQA8BYX;6Q02P$"% ,4    " !"@9M6OHAC
M6>>'  !?! 8 %               @ '>,0, =W-T+3(P,C,P,S,Q7W!R92YX
8;6Q02P4&      H "@!X @  ][D#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
